[
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Circulation"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "AHA/ACC/HFSA CLINICAL PRACTICE GUIDELINE"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "2022 AHA/ACC/HFSA Guideline for the"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Management of Heart Failure: A Report of the"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "AHA Scientific Statements"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "American College of Cardiology/American Heart"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Association Joint Committee on Clinical Practice"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Guidelines"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Writing Committee Members*"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Paul A. Heidenreich, MD, MS, FACC, FAHA, FHFSA, Chair†; Biykem Bozkurt, MD, PhD, FACC, FAHA, FHFSA, Vice Chair†;"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "David Aguilar, MD, MSc, FAHA†; Larry A. Allen, MD, MHS, FACC, FAHA, FHFSA†; Joni J. Byun†; Monica M. Colvin, MD, MS, FAHA†;"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Anita Deswal, MD, MPH, FACC, FAHA, FHFSA‡; Mark H. Drazner, MD, MSc, FACC, FAHA, FHFSA†;"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Shannon M. Dunlay, MD, MS, FAHA, FHFSA†; Linda R. Evers, JD†; James C. Fang, MD, FACC, FAHA, FHFSA†;"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Savitri E. Fedson, MD, MA†; Gregg C. Fonarow, MD, FACC, FAHA, FHFSA§; Salim S. Hayek, MD, FACC†;"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Adrian F. Hernandez, MD, MHS‡; Prateeti Khazanie, MD, MPH, FHFSA†; Michelle M. Kittleson, MD, PhD†;"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Christopher S. Lee, PhD, RN, FAHA, FHFSA†; Mark S. Link, MD†; Carmelo A. Milano, MD†; Lorraine C. Nnacheta, DrPH, MPH†;"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Alexander T. Sandhu, MD, MS†; Lynne Warner Stevenson, MD, FACC, FAHA, FHFSA†; Orly Vardeny, PharmD, MS, FAHA, FHFSA‖;"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Amanda R. Vest, MBBS, MPH, FHFSA‖; Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA†"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "AIM: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces the “2013 ACCF/AHA Guideline"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "for the Management of Heart Failure” and the “2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "for the Management of Heart Failure.” The 2022 guideline is intended to provide patient-centric recommendations for"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "clinicians to prevent, diagnose, and manage patients with heart failure."
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "METHODS: A comprehensive literature search was conducted from May 2020 to December 2020, encompassing studies,"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "reviews, and other evidence conducted on human subjects that were published in English from MEDLINE (PubMed),"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "EMBASE, the Cochrane Collaboration, the Agency for Healthcare Research and Quality, and other relevant databases."
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Additional relevant clinical trials and research studies, published through September 2021, were also considered. This"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "guideline was harmonized with other American Heart Association/American College of Cardiology guidelines published"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "through December 2021."
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "STRUCTURE: Heart failure remains a leading cause of morbidity and mortality globally. The 2022 heart failure guideline provides"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "recommendations based on contemporary evidence for the treatment of these patients. The recommendations present an"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "evidence-based approach to managing patients with heart failure, with the intent to improve quality of care and align with"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "patients’ interests. Many recommendations from the earlier heart failure guidelines have been updated with new evidence,"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "and new recommendations have been created when supported by published data. Value statements are provided for certain"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "treatments with high-quality published economic analyses."
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "*Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry may apply; see Appendix 1"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "for detailed information. †ACC/AHA Representative. ‡ACC/AHA Joint Committee on Clinical Practice Guidelines Liaison. §ACC/AHA Task Force on Performance"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Measures Representative. ‖HFSA Representative."
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "ACC/AHA Joint Committee on Clinical Practice Guidelines Members, see page e986."
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "The American Heart Association requests that this document be cited as follows: Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A,"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC,"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–e1032. doi: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "© 2022 by the American Heart Association, Inc., the American College of Cardiology Foundation, and the Heart Failure Society of America."
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Circulation is available at www.ahajournals.org/journal/circ"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e895"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 1,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "e896 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Key Words: AHA Scientific Statements ◼ heart failure ◼ heart failure with reduced ejection fraction ◼ heart failure with preserved ejection fraction"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "◼ heart failure with mildly reduced ejection fraction ◼ systolic heart failure ◼ heart failure rehabilitation ◼ cardiac failure ◼ chronic heart failure"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "◼ acute decompensated heart failure ◼ cardiogenic shock ◼ beta blockers ◼ mineralocorticoid receptor antagonists ◼ ACE inhibitors"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "◼ angiotensin and neprilysin receptor antagonist ◼ sacubitril valsartan ◼ angiotensin receptor antagonist ◼ sodium glucose co-transporter 2"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "◼ SGLT2 inhibitors ◼ cardiac amyloidosis ◼ atrial fibrillation ◼ congestive heart failure ◼ guideline-directed medical therapy"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "◼ diabetes ◼ cardiomyopathy ◼ valvular heart disease ◼ mitral regurgitation ◼ cardiomyopathy in pregnancy ◼ reduced ejection fraction"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "◼ right heart pressure ◼ palliative care ◼ cardio-oncology ◼ social determinants of health"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "TABLE OF CONTENTS 7.1. Nonpharmacological Interventions ..........e923"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.1.1. Self-Care Support in HF .............e923"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Abstract .............................................................e895"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.1.2. Dietary Sodium Restriction ..........e925"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Top 10 Take-Home Messages ............................e897"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.1.3. Management of Stage C HF:"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Preamble ...........................................................e898"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Activity, Exercise Prescription,"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "1. Introduction ...................................................e899"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "and Cardiac Rehabilitation ...........e926"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "1.1. Methodology and Evidence Review .........e899"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.2. Diuretics and Decongestion Strategies"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "1.2. Organization of the Writing Committee ....e899"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "in Patients With HF ................................e927"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "1.3. Document Review and Approval .............e899"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3. Pharmacological Treatment for HFrEF .......e928"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "1.4. Scope of the Guideline ...........................e899"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.1. Renin-Angiotensin System Inhibition"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "1.5. Class of Recommendation and"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "With ACEi or ARB or ARNi ..........e928"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Level of Evidence ...................................e900"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.2. Beta Blockers .............................e931"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "1.6. Abbreviations .........................................e900"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.3. Mineralocorticoid Receptor"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "2. Definition of HF .............................................e901"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Antagonists (MRAs) ....................e931"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "2.1. Stages of HF .........................................e901"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.4. Sodium-Glucose Cotransporter"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "2.2. Classification of HF by Left Ventricular"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "2 Inhibitors .................................e932"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Ejection Fraction (LVEF).........................e901"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.5. Hydralazine and Isosorbide"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "2.3. Diagnostic Algorithm for Classification"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Dinitrate .....................................e933"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "of HF According to LVEF .......................e905"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.6. Other Drug Treatment .................e934"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "3. Epidemiology and Causes of HF .....................e906"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.7. Drugs of Unproven Value or"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "3.1. Epidemiology of HF ...............................e906"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "That May Worsen HF ..................e935"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "3.2. Cause of HF ..........................................e907"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.8. GDMT Dosing: Sequencing"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4. Initial and Serial Evaluation .............................e908"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "and Uptitration ............................e937"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4.1. Clinical Assessment: History and"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.9. Additional Medical Therapies .......e939"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Physical Examination .............................e908"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.9.1. Management of Stage C"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4.1.1. Initial Laboratory and"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "HF: Ivabradine ...............e939"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Electrocardiographic Testing .......e910"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.9.2. Pharmacological"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4.2. Use of Biomarkers for Prevention, Initial"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Treatment for Stage C"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Diagnosis, and Risk Stratification ............e911"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "HFrEF (Digoxin) ............e940"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4.3. Genetic Evaluation and Testing ...............e912"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7.3.9.3. Pharmacological"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4.4. Evaluation With Cardiac Imaging.............e913 Treatment for Stage C"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4.5. Invasive Evaluation .................................e915"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "HFrEF: Soluble Guanylyl"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4.6. Wearables and Remote Monitoring Cyclase Stimulators .......e941"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "(Including Telemonitoring and Device 7.4. Device and Interventional Therapies"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Monitoring) ............................................e916 for HFrEF ..............................................e941"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4.7. Exercise and Functional Capacity 7.4.1. ICDs and CRTs ...........................e941"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Testing ..................................................e917 7.4.2. Other Implantable Electrical"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "4.8. Initial and Serial Evaluation: Clinical Interventions ...............................e945"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Assessment: HF Risk Scoring ................e918 7.4.3. Revascularization for CAD ...........e945"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "5. Stage A (Patients at Risk for HF) ...................e919 7.5. Valvular Heart Disease ...........................e946"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "5.1. Patients at Risk for HF (Stage A: 7.6. Heart Failure With Mildly Reduced"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Primary Prevention) ................................e919 EF (HFmrEF) and Improved EF"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "6. Stage B (Patients With Pre-HF) ......................e921 (HFimpHF) ............................................e948"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "6.1. Management of Stage B: Preventing 7.6.1. HF With Mildly Reduced"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "the Syndrome of Clinical HF in Ejection Fraction .........................e948"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Patients With Pre-HF .............................e921 7.6.2. HF With Improved Ejection"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "7. Stage C HF ...................................................e923 Fraction ......................................e949"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 2,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e897"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "7.7. Preserved EF (HFpEF) ..........................e949 Appendix 3"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "7.7.1. HF With Preserved Ejection Appendix for Tables 3 and 4. Suggested"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Fraction ......................................e949 Thresholds for Structural Heart Disease and"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "7.8. Cardiac Amyloidosis ...............................e952 Evidence of Increased Filling Pressures ..............e1032"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "7.8.1. Diagnosis of Cardiac Amyloidosis ....e952"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "7.8.2. Treatment of Cardiac Amyloidosis ....e954"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "TOP 10 TAKE-HOME MESSAGES"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "8. Stage D (Advanced) HF .................................e955"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "8.1. Specialty Referral for Advanced HF ........e955 1. Guideline-directed medical therapy (GDMT) for"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "8.2. Nonpharmacological Management: heart failure (HF) with reduced ejection fraction"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Advanced HF ........................................e956 (HFrEF) now includes 4 medication classes that"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "8.3. Inotropic Support ...................................e957 include sodium-glucose cotransporter-2 inhibitors"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "8.4. Mechanical Circulatory Support ..............e958 (SGLT2i)."
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "8.5. Cardiac Transplantation ..........................e960 2. SGLT2i have a Class of Recommendation 2a"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "9. Patients Hospitalized With Acute in HF with mildly reduced ejection fraction"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Decompensated HF .......................................e960 (HFmrEF). Weaker recommendations (Class of"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "9.1. Assessment of Patients Hospitalized Recommendation 2b) are made for ARNi, ACEi,"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "With Decompensated HF .......................e960 ARB, MRA, and beta blockers in this population."
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "9.2. Maintenance or Optimization of 3. New recommendations for HFpEF are made for"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "GDMT During Hospitalization .................e962 SGLT2i (Class of Recommendation 2a), MRAs"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "9.3. Diuretics in Hospitalized Patients: (Class of Recommendation 2b), and ARNi (Class"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Decongestion Strategy...........................e963 of Recommendation 2b). Several prior recommen-"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "9.4a. Parenteral Vasodilation Therapy in dations have been renewed including treatment of"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Patients Hospitalized With HF ................e964 hypertension (Class of Recommendation 1), treat-"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "9.4b. VTE Prophylaxis in Hospitalized ment of atrial fibrillation (Class of Recommendation"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Patients .................................................e965 2a), use of ARBs (Class of Recommendation 2b),"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "9.5. Evaluation and Management of and avoidance of routine use of nitrates or phospho-"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Cardiogenic Shock .................................e965 diesterase-5 inhibitors (Class of Recommendation"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "9.6. Integration of Care: Transitions and 3: No Benefit)."
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Team-Based Approaches .......................e967 4. Improved LVEF is used to refer to those patients"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "10. Comorbidities in Patients With HF ................e969 with previous HFrEF who now have an LVEF"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "10.1. Management of Comorbidities in >40%. These patients should continue their HFrEF"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Patients With HF ...............................e969 treatment."
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "10.2. Management of AF in HF...................e972 5. Value statements were created for select rec-"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "11. Special Populations ......................................e973 ommendations where high-quality, cost-effec-"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "11.1. Disparities and Vulnerable tiveness studies of the intervention have been"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Populations .......................................e973 published."
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "11.2. Cardio-Oncology................................e975 6. Amyloid heart disease has new recommendations"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "11.3. HF and Pregnancy .............................e978 for treatment including screening for serum and"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "12. Quality Metrics and Reporting ......................e980 urine monoclonal light chains, bone scintigraphy,"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "12.1. Performance Measurement ................e980 genetic sequencing, tetramer stabilizer therapy, and"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "13. Goals of Care ..............................................e980 anticoagulation."
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "13.1. Palliative and Supportive Care, Shared 7. Evidence supporting increased filling pressures is"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Decision-Making, and End-of-Life ........e980 important for the diagnosis of HF if the LVEF is"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "14. Recommendation for Patient-Reported >40%. Evidence for increased filling pressures can"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Outcomes and Evidence Gaps and be obtained from noninvasive (eg, natriuretic pep-"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Future Research Directions ..........................e986 tide, diastolic function on imaging) or invasive test-"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "14.1. Patient-Reported Outcomes ...............e986 ing (eg, hemodynamic measurement)."
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "14.2. Evidence Gaps and Future 8. Patients with advanced HF who wish to prolong"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Research Directions ...........................e986 survival should be referred to a team specializing"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "References .........................................................e987 in HF. A HF specialty team reviews HF manage-"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Appendix 1 ment, assesses suitability for advanced HF thera-"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Author Relationships With Industry and pies, and uses palliative care including palliative"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Other Entities (Relevant) ...................................e1026 inotropes where consistent with the patient’s"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Appendix 2 goals of care."
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Reviewer Relationships With Industry and Other 9. Primary prevention is important for those at risk"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Entities (Comprehensive) ..................................e1029 for HF (stage A) or pre-HF (stage B). Stages of"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 3,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "e898 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "HF were revised to emphasize the new terminolo- response to evolving technologies and other factors to op-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "gies of “at risk” for HF for stage A and pre-HF for timally facilitate dissemination of information to health care"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "stage B. professionals at the point of care."
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "10. Recommendations are provided for select patients Numerous modifications to the guidelines have been"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "with HF and iron deficiency, anemia, hypertension, implemented to make them shorter and enhance “user"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "sleep disorders, type 2 diabetes, atrial fibrillation, friendliness.” Guidelines are written and presented in a"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "coronary artery disease, and malignancy. modular, “knowledge chunk” format in which each chunk"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "includes a table of recommendations, a brief synopsis, rec-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "ommendation-specific supportive text and, when appro-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "PREAMBLE"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "priate, flow diagrams or additional tables. Hyperlinked"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Since 1980, the American College of Cardiology (ACC) references are provided for each modular knowledge"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "and American Heart Association (AHA) have translated chunk to facilitate quick access and review.In recognition"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "scientific evidence into clinical practice guidelines with of the importance of cost–value considerations, in certain"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "recommendations to improve cardiovascular health. guidelines, when appropriate and feasible, an assessment"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "These guidelines, which are based on systematic meth- of value for a drug, device, or intervention may be per-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "ods to evaluate and classify evidence, provide a founda- formed in accordance with the ACC/AHA methodology.3"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "tion for the delivery of quality cardiovascular care. The To ensure that guideline recommendations remain cur-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "ACC and AHA sponsor the development and publication rent, new data will be reviewed on an ongoing basis by"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "of clinical practice guidelines without commercial sup- the writing committee and staff. Going forward, targeted"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "port, and members volunteer their time to the writing and sections/knowledge chunks will be revised dynamically"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "review efforts. Guidelines are official policy of the ACC after publication and timely peer review of potentially"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "and AHA. For some guidelines, the ACC and AHA part- practice-changing science. The previous designations of"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "ner with other organizations. “full revision” and “focused update” will be phased out."
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "For additional information and policies on guideline devel-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "opment, readers may consult the ACC/AHA guideline"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Intended Use"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "methodology manual4 and other methodology articles.5–7"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Clinical practice guidelines provide recommenda-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "tions applicable to patients with or at risk of developing"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Selection of Writing Committee Members"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "cardiovascular disease (CVD). The focus is on medical"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "practice in the United States, but these guidelines are rel- The Joint Committee strives to ensure that the guide-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "evant to patients throughout the world. Although guide- line writing committee contains requisite content exper-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "lines may be used to inform regulatory or payer decisions, tise and is representative of the broader cardiovascular"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "the intent is to improve quality of care and align with pa- community by selection of experts across a spectrum of"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "tients’ interests. Guidelines are intended to define prac- backgrounds, representing different geographic regions,"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "tices meeting the needs of patients in most, but not all, sexes, races, ethnicities, intellectual perspectives/biases,"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "circumstances and should not replace clinical judgment. and clinical practice settings. Organizations and profes-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "sional societies with related interests and expertise are"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "invited to participate as partners or collaborators."
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Clinical Implementation"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Management, in accordance with guideline recommenda-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Relationships With Industry and Other Entities"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "tions, is effective only when followed by both practitioners"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "and patients. Adherence to recommendations can be The ACC and AHA have rigorous policies and methods"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "enhanced by shared decision-making between clinicians to ensure that documents are developed without bias or"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "and patients, with patient engagement in selecting inter- improper influence. The complete policy on relationships"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "ventions on the basis of individual values, preferences, with industry and other entities (RWI) can be found online."
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "and associated conditions and comorbidities. Appendix 1 of the guideline lists writing committee mem-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "bers’ relevant RWI; for the purposes of full transparency,"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "their comprehensive disclosure information is available in"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Methodology and Modernization a Supplemental Appendix. Comprehensive disclosure in-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "The ACC/AHA Joint Committee on Clinical Practice Guide- formation for the Joint Committee is also available online."
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "lines (Joint Committee) continuously reviews, updates, and"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "modifies guideline methodology on the basis of published"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Evidence Review and Evidence Review"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "standards from organizations, including the National Acad-"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Committees"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "emy of Medicine (formerly, the Institute of Medicine),1,2 and"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "on the basis of internal reevaluation. Similarly, presentation In developing recommendations, the writing committee"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "and delivery of guidelines are reevaluated and modified in uses evidence-based methodologies that are based on"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 4,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e899"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "all available data.4,5 Literature searches focus on ran- onists; ACE-inhibitors, angiotensin and neprilysin recep-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "domized controlled trials (RCTs) but also include regis- tor antagonist; sacubitril valsartan; angiotensin receptor"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "tries, nonrandomized comparative and descriptive stud- antagonist; Sodium glucose co-transporter 2 or SGLT2"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "ies, case series, cohort studies, systematic reviews, and inhibitors; cardiac amyloidosis; atrial fibrillation; conges-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "expert opinion. Only key references are cited. tive heart failure; guideline-directed medical therapy;"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "An independent evidence review committee is com- HFrEF; diabetes mellitus; cardiomyopathy; cardiac"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "missioned when there are ≥1 questions deemed of amyloidosis; valvular heart disease; mitral regurgitation;"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "utmost clinical importance and merit formal systematic cardiomyopathy in pregnancy; reduced ejection fraction;"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "review to determine which patients are most likely to ben- right heart pressure; palliative care."
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "efit from a drug, device, or treatment strategy, and to what Additional relevant studies, published through Sep-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "degree. Criteria for commissioning an evidence review tember 2021 during the guideline writing process, were"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "committee and formal systematic review include absence also considered by the writing committee and added to"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "of a current authoritative systematic review, feasibility of the evidence tables when appropriate. This guideline was"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "defining the benefit and risk in a time frame consistent harmonized with other ACC/AHA guidelines published"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "with the writing of a guideline, relevance to a substantial through December 2021.The final evidence tables are"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "number of patients, and likelihood that the findings can included in the Online Data Supplement and summarize"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "be translated into actionable recommendations. Evidence the evidence used by the writing committee to formulate"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "review committee members may include methodologists, recommendations. References selected and published"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "epidemiologists, clinicians, and biostatisticians. Recom- in the present document are representative and not all-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "mendations developed by the writing committee on the inclusive."
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "basis of the systematic review are marked “SR.”"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "1.2. Organization of the Writing Committee"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "Guideline-Directed Medical Therapy"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "The writing committee consisted of cardiologists, HF"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "The term guideline-directed medical therapy (GDMT) specialists, internists, interventionalists, an electro-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "encompasses clinical evaluation, diagnostic testing, and physiologist, surgeons, a pharmacist, an advanced"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "both pharmacological and procedural treatments. For nurse practitioner, and 2 lay/patient representatives."
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "these and all recommended drug treatment regimens, the The writing committee included representatives from"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "reader should confirm dosage with product insert material the ACC, AHA, and Heart Failure Society of America"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "and evaluate for contraindications and interactions. Rec- (HFSA). Appendix 1 of the present document lists writ-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "ommendations are limited to drugs, devices, and treat- ing committee members’ relevant RWI. For the purpos-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "ments approved for clinical use in the United States. es of full transparency, the writing committee members’"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "Joshua A. Beckman, MD, MS, FAHA, FACC comprehensive disclosure information is available in a"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "Chair, ACC/AHA Joint Committee on Clinical Supplemental Appendix."
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "Practice Guidelines"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "1.3. Document Review and Approval"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "1. INTRODUCTION This document was reviewed by 2 official reviewers nom-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "inated by the AHA; 1 official reviewer nominated by the"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "1.1. Methodology and Evidence Review"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "ACC; 2 official reviewers from the HFSA; 1 official Joint"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "The recommendations listed in this guideline are, Committee on Clinical Practice Guidelines reviewer; and"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "whenever possible, evidence based. An initial exten- 32 individual content reviewers. Reviewers’ RWI informa-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "sive evidence review, which included literature derived tion was distributed to the writing committee and is pub-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "from research involving human subjects, published in lished in this document (Appendix 2).This document was"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "English, and indexed in MEDLINE (through PubMed), approved for publication by the governing bodies of the"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "EMBASE, the Cochrane Collaboration, the Agency for ACC, AHA, and HFSA."
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "Healthcare Research and Quality, and other selected"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "databases relevant to this guideline, was conducted"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "1.4. Scope of the Guideline"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "from May 2020 to December 2020. Key search words"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "included but were not limited to the following: heart The purpose of the “2022 AHA/ACC/HFSA Guideline"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "failure; heart failure with reduced ejection fraction; heart for the Management of Heart Failure” (2022 HF guide-"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "failure with preserved ejection fraction; heart failure with line) is to provide an update and to consolidate the “2013"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "mildly reduced ejection fraction; systolic heart failure; ACCF/AHA Guideline for the Management of Heart"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "heart failure rehabilitation; cardiac failure; chronic heart Failure”1 for adults and the “2017 ACC/AHA/HFSA"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "failure; acute decompensated heart failure; cardiogenic Focused Update of the 2013 ACCF/AHA Guideline for"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "shock; beta blockers; mineralocorticoid receptor antag- the Management of Heart Failure”2 into a new document."
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 5,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "e900 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "Related ACC/AHA guidelines include recommendations 1.6. Abbreviations"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "relevant to HF and, in such cases, the HF guideline re-"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "fers to these documents. For example, the 2019 primary Abbreviation Meaning/Phrase"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "prevention of cardiovascular disease guideline3 includes ACEi angiotensin-converting enzyme inhibitors"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "recommendations that will be useful in preventing HF, ACS acute coronary syndrome"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "and the 2021 valvular heart disease guideline4 provides"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "ARNi angiotensin receptor-neprilysin inhibitors"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "recommendations for mitral valve (MV) clipping in mitral"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "ARB angiotensin (II) receptor blockers"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "regurgitation (MR)."
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "AF atrial fibrillation"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "AL-CM immunoglobulin light chain amyloid cardiomyopathy"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "Areas of focus include:"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "ATTR-CM transthyretin amyloid cardiomyopathy"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "• Prevention of HF. ATTRv variant transthyretin amyloidosis"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "• Management strategies in stage C HF, including: ATTRwt wild-type transthyretin amyloidosis"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "◦ New treatment strategies in HF, including"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "BNP B-type natriuretic peptide"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "sodium-glucose cotransporter-2 inhibitors"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "CABG coronary artery bypass graft"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "(SGLT2i) and angiotensin receptor-neprilysin"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "inhibitors (ARNi). CAD coronary artery disease"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "◦ Management of HF and atrial fibrillation (AF), CCM cardiac contractility modulation"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "including ablation of AF. CHF congestive heart failure"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "◦ Management of HF and secondary MR, includ- CKD chronic kidney disease"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "ing MV transcatheter edge-to-edge repair."
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "CMR cardiovascular magnetic resonance"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "• Specific management strategies, including:"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "COVID-19 coronavirus disease 2019"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "◦ Cardiac amyloidosis."
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "◦ Cardio-oncology. CPET cardiopulmonary exercise test"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "• Implantable devices. CRT cardiac resynchronization therapy"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "• Left ventricular assist device (LVAD) use in stage D CRT-D cardiac resynchronization therapy with defibrillation"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "HF. CRT-P cardiac resynchronization therapy with pacemaker"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "The intended primary target audience consists of"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "CT computed tomography"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "clinicians who are involved in the care of patients with"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "CVD cardiovascular disease"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "HF. Recommendations are stated in reference to the"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "CVP central venous pressure"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "patients and their condition. The focus is to provide the"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "most up-to-date evidence to inform the clinician during DOAC direct-acting oral anticoagulants"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "shared decision-making with the patient. Although the DPP-4 dipeptidyl peptidase-4"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "present document is not intended to be a procedural- ECG electrocardiogram"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "based manual of recommendations that outlines the"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "EF ejection fraction"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "best practice for HF, there are certain practices that"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "eGFR estimated glomerular filtration rate"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "clinicians might use that are associated with improved"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "FDA US Food and Drug Administration"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "clinical outcomes."
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "In developing the 2022 HF guideline, the writing com- FLC free light chain"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "mittee reviewed previously published guidelines and GDMT guideline-directed medical therapy"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "related statements. Table 1 contains a list of these guide- HF heart failure"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "lines and statements deemed pertinent to this writing"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "HFimpEF heart failure with improved ejection fraction"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "effort and is intended for use as a resource, thus obviating"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "HFmrEF heart failure with mildly reduced ejection fraction"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "the need to repeat existing guideline recommendations."
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "HFpEF heart failure with preserved ejection fraction"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "HFrEF heart failure with reduced ejection fraction"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "1.5. Class of Recommendation and Level of"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "ICD implantable cardioverter-defibrillator"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "Evidence"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "IFE immunofixation electrophoresis"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "The Class of Recommendation (COR) indicates the LBBB left bundle branch block"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "strength of recommendation, encompassing the estimat-"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "LV left ventricular"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "ed magnitude and certainty of benefit in proportion to"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "LVAD left ventricular assist device"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "risk. The Level of Evidence (LOE) rates the quality of sci-"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "LVEDV left ventricular end-diastolic volume"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "entific evidence supporting the intervention on the basis"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "LVEF left ventricular ejection fraction"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "of the type, quantity, and consistency of data from clinical"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "trials and other sources (Table 2).1 LVH left ventricular hypertrophy"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 6,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 6,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Abbreviation": "ACEi",
                "Meaning/Phrase": "angiotensin-converting enzyme inhibitors"
            },
            {
                "Abbreviation": "ACS",
                "Meaning/Phrase": "acute coronary syndrome"
            },
            {
                "Abbreviation": "ARNi",
                "Meaning/Phrase": "angiotensin receptor-neprilysin inhibitors"
            },
            {
                "Abbreviation": "ARB",
                "Meaning/Phrase": "angiotensin (II) receptor blockers"
            },
            {
                "Abbreviation": "AF",
                "Meaning/Phrase": "atrial fibrillation"
            },
            {
                "Abbreviation": "AL-CM",
                "Meaning/Phrase": "immunoglobulin light chain amyloid cardiomyopathy"
            },
            {
                "Abbreviation": "ATTR-CM",
                "Meaning/Phrase": "transthyretin amyloid cardiomyopathy"
            },
            {
                "Abbreviation": "ATTRv",
                "Meaning/Phrase": "variant transthyretin amyloidosis"
            },
            {
                "Abbreviation": "ATTRwt",
                "Meaning/Phrase": "wild-type transthyretin amyloidosis"
            },
            {
                "Abbreviation": "BNP",
                "Meaning/Phrase": "B-type natriuretic peptide"
            },
            {
                "Abbreviation": "CABG",
                "Meaning/Phrase": "coronary artery bypass graft"
            },
            {
                "Abbreviation": "CAD",
                "Meaning/Phrase": "coronary artery disease"
            },
            {
                "Abbreviation": "CCM",
                "Meaning/Phrase": "cardiac contractility modulation"
            },
            {
                "Abbreviation": "CHF",
                "Meaning/Phrase": "congestive heart failure"
            },
            {
                "Abbreviation": "CKD",
                "Meaning/Phrase": "chronic kidney disease"
            },
            {
                "Abbreviation": "CMR",
                "Meaning/Phrase": "cardiovascular magnetic resonance"
            },
            {
                "Abbreviation": "COVID-19",
                "Meaning/Phrase": "coronavirus disease 2019"
            },
            {
                "Abbreviation": "CPET",
                "Meaning/Phrase": "cardiopulmonary exercise test"
            },
            {
                "Abbreviation": "CRT",
                "Meaning/Phrase": "cardiac resynchronization therapy"
            },
            {
                "Abbreviation": "CRT-D",
                "Meaning/Phrase": "cardiac resynchronization therapy with defibrillation"
            },
            {
                "Abbreviation": "CRT-P",
                "Meaning/Phrase": "cardiac resynchronization therapy with pacemaker"
            },
            {
                "Abbreviation": "CT",
                "Meaning/Phrase": "computed tomography"
            },
            {
                "Abbreviation": "CVD",
                "Meaning/Phrase": "cardiovascular disease"
            },
            {
                "Abbreviation": "CVP",
                "Meaning/Phrase": "central venous pressure"
            },
            {
                "Abbreviation": "DOAC",
                "Meaning/Phrase": "direct-acting oral anticoagulants"
            },
            {
                "Abbreviation": "DPP-4",
                "Meaning/Phrase": "dipeptidyl peptidase-4"
            },
            {
                "Abbreviation": "ECG",
                "Meaning/Phrase": "electrocardiogram"
            },
            {
                "Abbreviation": "EF",
                "Meaning/Phrase": "ejection fraction"
            },
            {
                "Abbreviation": "eGFR",
                "Meaning/Phrase": "estimated glomerular filtration rate"
            },
            {
                "Abbreviation": "FDA",
                "Meaning/Phrase": "US Food and Drug Administration"
            },
            {
                "Abbreviation": "FLC",
                "Meaning/Phrase": "free light chain"
            },
            {
                "Abbreviation": "GDMT",
                "Meaning/Phrase": "guideline-directed medical therapy"
            },
            {
                "Abbreviation": "HF",
                "Meaning/Phrase": "heart failure"
            },
            {
                "Abbreviation": "HFimpEF",
                "Meaning/Phrase": "heart failure with improved ejection fraction"
            },
            {
                "Abbreviation": "HFmrEF",
                "Meaning/Phrase": "heart failure with mildly reduced ejection fraction"
            },
            {
                "Abbreviation": "HFpEF",
                "Meaning/Phrase": "heart failure with preserved ejection fraction"
            },
            {
                "Abbreviation": "HFrEF",
                "Meaning/Phrase": "heart failure with reduced ejection fraction"
            },
            {
                "Abbreviation": "ICD",
                "Meaning/Phrase": "implantable cardioverter-defibrillator"
            },
            {
                "Abbreviation": "IFE",
                "Meaning/Phrase": "immunofixation electrophoresis"
            },
            {
                "Abbreviation": "LBBB",
                "Meaning/Phrase": "left bundle branch block"
            },
            {
                "Abbreviation": "LV",
                "Meaning/Phrase": "left ventricular"
            },
            {
                "Abbreviation": "LVAD",
                "Meaning/Phrase": "left ventricular assist device"
            },
            {
                "Abbreviation": "LVEDV",
                "Meaning/Phrase": "left ventricular end-diastolic volume"
            },
            {
                "Abbreviation": "LVEF",
                "Meaning/Phrase": "left ventricular ejection fraction"
            },
            {
                "Abbreviation": "LVH",
                "Meaning/Phrase": "left ventricular hypertrophy"
            }
        ],
        "conteudo_texto": "ACEi, angiotensin-converting enzyme inhibitors | ACS, acute coronary syndrome | ARNi, angiotensin receptor-neprilysin inhibitors | ARB, angiotensin (II) receptor blockers | AF, atrial fibrillation | AL-CM, immunoglobulin light chain amyloid cardiomyopathy | ATTR-CM, transthyretin amyloid cardiomyopathy | ATTRv, variant transthyretin amyloidosis | ATTRwt, wild-type transthyretin amyloidosis | BNP, B-type natriuretic peptide | CABG, coronary artery bypass graft | CAD, coronary artery disease | CCM, cardiac contractility modulation | CHF, congestive heart failure | CKD, chronic kidney disease | CMR, cardiovascular magnetic resonance | COVID-19, coronavirus disease 2019 | CPET, cardiopulmonary exercise test | CRT, cardiac resynchronization therapy | CRT-D, cardiac resynchronization therapy with defibrillation | CRT-P, cardiac resynchronization therapy with pacemaker | CT, computed tomography | CVD, cardiovascular disease | CVP, central venous pressure | DOAC, direct-acting oral anticoagulants | DPP-4, dipeptidyl peptidase-4 | ECG, electrocardiogram | EF, ejection fraction | eGFR, estimated glomerular filtration rate | FDA, US Food and Drug Administration | FLC, free light chain | GDMT, guideline-directed medical therapy | HF, heart failure | HFimpEF, heart failure with improved ejection fraction | HFmrEF, heart failure with mildly reduced ejection fraction | HFpEF, heart failure with preserved ejection fraction | HFrEF, heart failure with reduced ejection fraction | ICD, implantable cardioverter-defibrillator | IFE, immunofixation electrophoresis | LBBB, left bundle branch block | LV, left ventricular | LVAD, left ventricular assist device | LVEDV, left ventricular end-diastolic volume | LVEF, left ventricular ejection fraction | LVH, left ventricular hypertrophy"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e901"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "sociated with reduced survival.3 Therapeutic interven-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "Abbreviation Meaning/Phrase"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "tions in each stage aim to modify risk factors (stage"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "MCS mechanical circulatory support"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "A), treat risk and structural heart disease to prevent"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "MI myocardial infarction"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "HF (stage B), and reduce symptoms, morbidity, and"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "MR mitral regurgitation"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "mortality (stages C and D). To address the evolving"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "MRA mineralocorticoid receptor antagonist role of biomarkers and structural changes for recogni-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "MV mitral valve tion of patients who are at risk of developing HF, who"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "NSAID nonsteroidal anti-inflammatory drug are potential candidates for targeted treatment strat-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "NSVT nonsustained ventricular tachycardia egies for the prevention of HF, and to enhance the"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "understanding and adoption of these classifications,"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "NT-proBNP N-terminal prohormone of B-type natriuretic peptide"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "the writing committee proposed the terminologies"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "NYHA New York Heart Association"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "listed in Table 3 for the stages of HF. For thresholds"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "QALY quality-adjusted life year"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "of cardiac structural, functional changes, elevated fill-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "QOL quality of life"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "ing pressures, and biomarker elevations, refer to Ap-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "PA pulmonary artery"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "pendix 3."
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "PCWP pulmonary capillary wedge pressure"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "PET positron emission tomography New York Heart Association (NYHA)"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "PPAR-γ peroxisome proliferator-activated receptor gamma"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "Classification"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "PUFA polyunsaturated fatty acid"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "The NYHA classification is used to characterize symp-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "RA right atrial"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "toms and functional capacity of patients with symp-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "RASS renin-angiotensin-aldosterone system"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "tomatic (stage C) HF or advanced HF (stage D). It is"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "RAASi renin-angiotensin-aldosterone system inhibitors"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "a subjective assessment by a clinician and can change"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "RCT randomized controlled trial over time. Although reproducibility and validity can be"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "RV right ventricular limited,4,5 the NYHA functional classification is an inde-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "SCD sudden cardiac death pendent predictor of mortality,6,7 and it is widely used in"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "SGLT2i sodium-glucose cotransporter-2 inhibitors clinical practice to determine the eligibility of patients for"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "SPECT single photon emission CT treatment strategies. Clinicians specify NYHA classifica-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "tion at baseline after the initial diagnosis and after treat- 99mTc-PYP technetium pyrophosphate"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "ment through the continuum of care of a patient with"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "TEER transcatheter mitral edge-to-edge repair"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "HF. Although a patient with symptomatic HF (stage C)"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "TTE transthoracic echocardiogram"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "may become asymptomatic with treatment (NYHA class"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "VA ventricular arrhythmia I), that patient will still be categorized as stage C HF. Pa-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "VF ventricular fibrillation"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "tients with stage C HF can be classified according to the"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "VHD valvular heart disease trajectory of their symptoms (Figure 2)."
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "VO oxygen consumption/oxygen uptake"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "VT ventricular tachycardia"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "2.2. Classification of HF by Left Ventricular"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "Ejection Fraction (LVEF)"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "2. DEFINITION OF HF"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "LVEF is considered important in the classification of"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "HF Description"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "patients with HF because of differing prognosis and"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "HF is a complex clinical syndrome with symptoms and response to treatments and because most clinical tri-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "signs that result from any structural or functional im- als select patients based on ejection fraction (EF)."
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "pairment of ventricular filling or ejection of blood. The RCTs with evidence of survival benefit in patients with"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "writing committee recognizes that asymptomatic stages HF have mainly enrolled patients with HF with an"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "with structural heart disease or cardiomyopathies are LVEF ≤35% or ≤40%, often labeled HF with reduced"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "not covered under the above definition as having HF. ejection fraction (HFrEF).1 In this guideline, HFrEF is"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "Such asymptomatic stages are considered at-risk for HF defined as LVEF ≤40% (Table 4). HF with preserved"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "(stage A) or pre-HF (stage B), as explained in Section EF (HFpEF) represents at least 50% of the popula-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "2.1, “Stages of HF. ” tion with HF, and its prevalence is increasing.2 HFpEF"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "has been variably classified as LVEF >40%, >45%, or"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "≥50%. Because some of these patients do not have"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "2.1. Stages of HF"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "entirely normal LVEF but also do not have major re-"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "The ACC/AHA stages of HF (Figure 1, Table 3) duction in systolic function, the term preserved EF has"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "emphasize the development and progression of dis- been used. In this guideline, the threshold for HFpEF"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "ease,1,2 and advanced stages and progression are as- is an LVEF ≥50% (Table 4)."
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 7,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 7,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Abbreviation": "MCS",
                "Meaning/Phrase": "mechanical circulatory support"
            },
            {
                "Abbreviation": "MI",
                "Meaning/Phrase": "myocardial infarction"
            },
            {
                "Abbreviation": "MR",
                "Meaning/Phrase": "mitral regurgitation"
            },
            {
                "Abbreviation": "MRA",
                "Meaning/Phrase": "mineralocorticoid receptor antagonist"
            },
            {
                "Abbreviation": "MV",
                "Meaning/Phrase": "mitral valve"
            },
            {
                "Abbreviation": "NSAID",
                "Meaning/Phrase": "nonsteroidal anti-inflammatory drug"
            },
            {
                "Abbreviation": "NSVT",
                "Meaning/Phrase": "nonsustained ventricular tachycardia"
            },
            {
                "Abbreviation": "NT-proBNP",
                "Meaning/Phrase": "N-terminal prohormone of B-type natriuretic peptide"
            },
            {
                "Abbreviation": "NYHA",
                "Meaning/Phrase": "New York Heart Association"
            },
            {
                "Abbreviation": "QALY",
                "Meaning/Phrase": "quality-adjusted life year"
            },
            {
                "Abbreviation": "QOL",
                "Meaning/Phrase": "quality of life"
            },
            {
                "Abbreviation": "PA",
                "Meaning/Phrase": "pulmonary artery"
            },
            {
                "Abbreviation": "PCWP",
                "Meaning/Phrase": "pulmonary capillary wedge pressure"
            },
            {
                "Abbreviation": "PET",
                "Meaning/Phrase": "positron emission tomography"
            },
            {
                "Abbreviation": "PPAR-γ",
                "Meaning/Phrase": "peroxisome proliferator-activated receptor gamma"
            },
            {
                "Abbreviation": "PUFA",
                "Meaning/Phrase": "polyunsaturated fatty acid"
            },
            {
                "Abbreviation": "RA",
                "Meaning/Phrase": "right atrial"
            },
            {
                "Abbreviation": "RASS",
                "Meaning/Phrase": "renin-angiotensin-aldosterone system"
            },
            {
                "Abbreviation": "RAASi",
                "Meaning/Phrase": "renin-angiotensin-aldosterone system inhibitors"
            },
            {
                "Abbreviation": "RCT",
                "Meaning/Phrase": "randomized controlled trial"
            },
            {
                "Abbreviation": "RV",
                "Meaning/Phrase": "right ventricular"
            },
            {
                "Abbreviation": "SCD",
                "Meaning/Phrase": "sudden cardiac death"
            },
            {
                "Abbreviation": "SGLT2i",
                "Meaning/Phrase": "sodium-glucose cotransporter-2 inhibitors"
            },
            {
                "Abbreviation": "SPECT",
                "Meaning/Phrase": "single photon emission CT"
            },
            {
                "Abbreviation": "99mTc-PYP",
                "Meaning/Phrase": "technetium pyrophosphate"
            },
            {
                "Abbreviation": "TEER",
                "Meaning/Phrase": "transcatheter mitral edge-to-edge repair"
            },
            {
                "Abbreviation": "TTE",
                "Meaning/Phrase": "transthoracic echocardiogram"
            },
            {
                "Abbreviation": "VA",
                "Meaning/Phrase": "ventricular arrhythmia"
            },
            {
                "Abbreviation": "VF",
                "Meaning/Phrase": "ventricular fibrillation"
            },
            {
                "Abbreviation": "VHD",
                "Meaning/Phrase": "valvular heart disease"
            },
            {
                "Abbreviation": "VO 2",
                "Meaning/Phrase": "oxygen consumption/oxygen uptake"
            },
            {
                "Abbreviation": "VT",
                "Meaning/Phrase": "ventricular tachycardia"
            }
        ],
        "conteudo_texto": "MCS, mechanical circulatory support | MI, myocardial infarction | MR, mitral regurgitation | MRA, mineralocorticoid receptor antagonist | MV, mitral valve | NSAID, nonsteroidal anti-inflammatory drug | NSVT, nonsustained ventricular tachycardia | NT-proBNP, N-terminal prohormone of B-type natriuretic peptide | NYHA, New York Heart Association | QALY, quality-adjusted life year | QOL, quality of life | PA, pulmonary artery | PCWP, pulmonary capillary wedge pressure | PET, positron emission tomography | PPAR-γ, peroxisome proliferator-activated receptor gamma | PUFA, polyunsaturated fatty acid | RA, right atrial | RASS, renin-angiotensin-aldosterone system | RAASi, renin-angiotensin-aldosterone system inhibitors | RCT, randomized controlled trial | RV, right ventricular | SCD, sudden cardiac death | SGLT2i, sodium-glucose cotransporter-2 inhibitors | SPECT, single photon emission CT | 99mTc-PYP, technetium pyrophosphate | TEER, transcatheter mitral edge-to-edge repair | TTE, transthoracic echocardiogram | VA, ventricular arrhythmia | VF, ventricular fibrillation | VHD, valvular heart disease | VO 2, oxygen consumption/oxygen uptake | VT, ventricular tachycardia"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "e902 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Table 1. Associated Guidelines and Statements"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Publication"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Year"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Title Organization (Reference)"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Guidelines"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery ACCF/AHA 20116"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Hillis et al., “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery” is now replaced and retired by"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization”5"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention ACCF/AHA/SCAI 20117"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Levine et al., “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention,” is now replaced and"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "retired by the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization”5"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2015 ACCF/AHA/SCAI Focused Update Guideline for Percutaneous Coronary Intervention ACCF/AHA/SCAI 20168"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease ACC/AHA 20214"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy ACC/AHA 20209"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease ACC/AHA 20193"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients AHA/ACC/HRS 201910"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "With Atrial Fibrillation"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detec- ACC/AHA/AAPA/ABC/ 201811"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "tion, Evaluation, and Management of High Blood Pressure in Adults ACPM/AGS/AphA/ASH/"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "ASPC/NMA/PCNA"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure ACC/AHA/HFSA 20172"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the ACC/AHA/HFSA 201612"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2013 ACCF/AHA Guideline for the Management of Heart Failure"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of ACC/AHA/AATS/PCNA/ 201413*"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Patients With Stable Ischemic Heart Disease SCAI/STS"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk AHA/ACC 201414"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults AHA/ACC/TOS 201415"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/AphA/ASPC/NLA/PCNA Guideline on the Manage- AHA/ACC/AACVPR/AAPA/ 201916"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "ment of Blood Cholesterol ABC/ACPM/ADA/AGS/"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "AphA/ASPC/NLA/PCNA"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk ACC/AHA 201417"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "in Adults"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk ACC/AHA 201418"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2013 ACCF/AHA Guideline for the Management of Heart Failure ACCF/AHA 20131"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction ACCF/AHA 201319"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm ACCF/AHA/HRS 201220"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Abnormalities"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With ACCF/AHA/ACP/AATS/ 201221"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Stable Ischemic Heart Disease PCNA/SCAI/STS"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update AHA 201122"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atheroscle- AHA/ACCF 201123"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "rotic Vascular Disease: 2011 Update"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults ACCF/AHA 201024"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Part 9: Post–Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscita- AHA 201025"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "tion and Emergency Cardiovascular Care"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High NHLBI 200326"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Blood Pressure"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Statements"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Cardiac Amyloidosis: Evolving Diagnosis and Management AHA 202027"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain AHA 201028"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus AHA/ADA 200729"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Prevention and Control of Influenza CDC 200530"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "AATS indicates American Association for Thoracic Surgery; AACVPR, American Association of Cardiovascular and Pulmonary Rehabilitation; AAPA, American"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Academy of Physician Associates; ABC, Association of Black Cardiologists; ACC, American College of Cardiology; ACCF, American College of Cardiology Founda-"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "tion; ACPM, American College of Preventive Medicine; ADA, American Diabetes Association; AGS, American Geriatrics Society; AHA, American Heart Association;"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "AphA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; CDC, Centers for Disease"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Control and Prevention; ESC, European Society of Cardiology; HFSA, Heart Failure Society of America; HRS, Heart Rhythm Society; NHLBI, National Heart, Lung,"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "and Blood Institute; NICE, National Institute for Health and Care Excellence; NMA, National Medical Association; NLA, National Lipid Association; PCNA, Preventive"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Cardiovascular Nurses Association; SCAI, Society for Cardiovascular Angiography and Interventions; SIHD, stable ischemic heart disease; STS, Society of Thoracic"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Surgeons; TOS, The Obesity Society; and WHF, World Heart Federation."
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "*The full SIHD guideline is from 2012.21 A focused update was published in 2014.13"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 8,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 8,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Title": "Guidelines",
                "Organization": "",
                "Publication Year (Reference)": ""
            },
            {
                "Title": "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery Hillis et al., “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery” is now replaced and retired by the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization”5",
                "Organization": "ACCF/AHA",
                "Publication Year (Reference)": "20116"
            },
            {
                "Title": "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention Levine et al., “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention,” is now replaced and retired by the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization”5",
                "Organization": "ACCF/AHA/SCAI",
                "Publication Year (Reference)": "20117"
            },
            {
                "Title": "2015 ACCF/AHA/SCAI Focused Update Guideline for Percutaneous Coronary Intervention",
                "Organization": "ACCF/AHA/SCAI",
                "Publication Year (Reference)": "20168"
            },
            {
                "Title": "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease",
                "Organization": "ACC/AHA",
                "Publication Year (Reference)": "20214"
            },
            {
                "Title": "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy",
                "Organization": "ACC/AHA",
                "Publication Year (Reference)": "20209"
            },
            {
                "Title": "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease",
                "Organization": "ACC/AHA",
                "Publication Year (Reference)": "20193"
            },
            {
                "Title": "2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation",
                "Organization": "AHA/ACC/HRS",
                "Publication Year (Reference)": "201910"
            },
            {
                "Title": "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detec- tion, Evaluation, and Management of High Blood Pressure in Adults",
                "Organization": "ACC/AHA/AAPA/ABC/ ACPM/AGS/AphA/ASH/ ASPC/NMA/PCNA",
                "Publication Year (Reference)": "201811"
            },
            {
                "Title": "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure",
                "Organization": "ACC/AHA/HFSA",
                "Publication Year (Reference)": "20172"
            },
            {
                "Title": "2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure",
                "Organization": "ACC/AHA/HFSA",
                "Publication Year (Reference)": "201612"
            },
            {
                "Title": "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease",
                "Organization": "ACC/AHA/AATS/PCNA/ SCAI/STS",
                "Publication Year (Reference)": "201413*"
            },
            {
                "Title": "2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk",
                "Organization": "AHA/ACC",
                "Publication Year (Reference)": "201414"
            },
            {
                "Title": "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults",
                "Organization": "AHA/ACC/TOS",
                "Publication Year (Reference)": "201415"
            },
            {
                "Title": "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/AphA/ASPC/NLA/PCNA Guideline on the Manage- ment of Blood Cholesterol",
                "Organization": "AHA/ACC/AACVPR/AAPA/ ABC/ACPM/ADA/AGS/ AphA/ASPC/NLA/PCNA",
                "Publication Year (Reference)": "201916"
            },
            {
                "Title": "2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults",
                "Organization": "ACC/AHA",
                "Publication Year (Reference)": "201417"
            },
            {
                "Title": "2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk",
                "Organization": "ACC/AHA",
                "Publication Year (Reference)": "201418"
            },
            {
                "Title": "2013 ACCF/AHA Guideline for the Management of Heart Failure",
                "Organization": "ACCF/AHA",
                "Publication Year (Reference)": "20131"
            },
            {
                "Title": "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction",
                "Organization": "ACCF/AHA",
                "Publication Year (Reference)": "201319"
            },
            {
                "Title": "2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities",
                "Organization": "ACCF/AHA/HRS",
                "Publication Year (Reference)": "201220"
            },
            {
                "Title": "2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease",
                "Organization": "ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS",
                "Publication Year (Reference)": "201221"
            },
            {
                "Title": "Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update",
                "Organization": "AHA",
                "Publication Year (Reference)": "201122"
            },
            {
                "Title": "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atheroscle- rotic Vascular Disease: 2011 Update",
                "Organization": "AHA/ACCF",
                "Publication Year (Reference)": "201123"
            },
            {
                "Title": "2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults",
                "Organization": "ACCF/AHA",
                "Publication Year (Reference)": "201024"
            },
            {
                "Title": "Part 9: Post–Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscita- tion and Emergency Cardiovascular Care",
                "Organization": "AHA",
                "Publication Year (Reference)": "201025"
            },
            {
                "Title": "Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure",
                "Organization": "NHLBI",
                "Publication Year (Reference)": "200326"
            },
            {
                "Title": "Statements",
                "Organization": "",
                "Publication Year (Reference)": ""
            },
            {
                "Title": "Cardiac Amyloidosis: Evolving Diagnosis and Management",
                "Organization": "AHA",
                "Publication Year (Reference)": "202027"
            },
            {
                "Title": "Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain",
                "Organization": "AHA",
                "Publication Year (Reference)": "201028"
            },
            {
                "Title": "Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus",
                "Organization": "AHA/ADA",
                "Publication Year (Reference)": "200729"
            },
            {
                "Title": "Prevention and Control of Influenza",
                "Organization": "CDC",
                "Publication Year (Reference)": "200530"
            }
        ],
        "conteudo_texto": "Guidelines, ,  | 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery Hillis et al., “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery” is now replaced and retired by the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization”5, ACCF/AHA, 20116 | 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention Levine et al., “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention,” is now replaced and retired by the “2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization”5, ACCF/AHA/SCAI, 20117 | 2015 ACCF/AHA/SCAI Focused Update Guideline for Percutaneous Coronary Intervention, ACCF/AHA/SCAI, 20168 | 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease, ACC/AHA, 20214 | 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy, ACC/AHA, 20209 | 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, ACC/AHA, 20193 | 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation, AHA/ACC/HRS, 201910 | 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detec- tion, Evaluation, and Management of High Blood Pressure in Adults, ACC/AHA/AAPA/ABC/ ACPM/AGS/AphA/ASH/ ASPC/NMA/PCNA, 201811 | 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, ACC/AHA/HFSA, 20172 | 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, ACC/AHA/HFSA, 201612 | 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, ACC/AHA/AATS/PCNA/ SCAI/STS, 201413* | 2013 AHA/ACC Guideline on Lifestyle Management to Reduce Cardiovascular Risk, AHA/ACC, 201414 | 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults, AHA/ACC/TOS, 201415 | 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/AphA/ASPC/NLA/PCNA Guideline on the Manage- ment of Blood Cholesterol, AHA/ACC/AACVPR/AAPA/ ABC/ACPM/ADA/AGS/ AphA/ASPC/NLA/PCNA, 201916 | 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, ACC/AHA, 201417 | 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk, ACC/AHA, 201418 | 2013 ACCF/AHA Guideline for the Management of Heart Failure, ACCF/AHA, 20131 | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, ACCF/AHA, 201319 | 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities, ACCF/AHA/HRS, 201220 | 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS, 201221 | Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update, AHA, 201122 | AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atheroscle- rotic Vascular Disease: 2011 Update, AHA/ACCF, 201123 | 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults, ACCF/AHA, 201024 | Part 9: Post–Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscita- tion and Emergency Cardiovascular Care, AHA, 201025 | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, NHLBI, 200326 | Statements, ,  | Cardiac Amyloidosis: Evolving Diagnosis and Management, AHA, 202027 | Testing of Low-Risk Patients Presenting to the Emergency Department With Chest Pain, AHA, 201028 | Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus, AHA/ADA, 200729 | Prevention and Control of Influenza, CDC, 200530"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e903"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "Table 2. Applying American College of Cardiology/American Heart Association Class of Recommendation and Level of"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care (Updated May 2019)*"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "Patients with HF and an LVEF between the HFrEF or ≥50%, respectively, are necessary for the diagno-"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "and HFpEF range have been termed as “HF with mid- sis of the HFmrEF and HFpEF, the requirements for"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "range EF, ”3,4 or “HF with mildly reduced EF. ”4 Because additional objective measures of cardiac dysfunction"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "of LVEF being lower than normal, these patients are can improve the diagnostic specificity. The signs and"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "classified in this document as HF with mildly reduced symptoms of HF are frequently nonspecific and over-"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "EF (HFmrEF). Patients with HFmrEF are usually in lap with other clinical conditions. Elevated natriuretic"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "a dynamic trajectory to improvement from HFrEF or peptide levels are supportive of the diagnosis, but"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "to deterioration to HFrEF (Figure 3). Therefore, for normal levels do not exclude a diagnosis of HFmrEF"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "patients whose EF falls into this mildly reduced cat- or HFpEF. To improve the specificity of diagnosing"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "egory, 1 EF measurement at 1 time point may not be HFmrEF and HFpEF, the clinical diagnosis of HF in"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "adequate, and the trajectory of LVEF over time and these EF categories should be further supported by"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "the cause is important to evaluate (Figure 3). Further- objective measures. Therefore, the writing commit-"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "more, the diagnosis of HFmrEF and HFpEF can be tee proposes the addition of evidence of spontane-"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "challenging. Although the classic clinical signs and ous (at rest) or provokable (eg, during exercise, fluid"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "symptoms of HF, together with EF of 41% to 49% challenge) increased LV filling pressures (eg, elevated"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 9,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "e904 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Figure 1. ACC/AHA Stages of HF."
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "The ACC/AHA stages of HF are shown. ACC indicates American College of Cardiology; AHA, American Heart Association; CVD, cardiovascular"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "disease; GDMT, guideline-directed medical therapy; and HF, heart failure."
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "natriuretic peptide, noninvasive/invasive hemody- working definition of HF-recovered EF that included a"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "namic measurement) to the classifications of HFm- baseline LVEF ≤40%, a ≥10% increase from baseline"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "rEF and HFpEF (Table 4). LVEF, and a second measurement of LVEF >40%.3"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "The “2013 ACCF/AHA Guideline for the Man- Although associated with better outcomes, improve-"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "agement of Heart Failure”1 has used the HFpEF- ment in LVEF does not mean full myocardial recov-"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "improved terminology for those whose EF improved ery or normalization of LV function. In most patients,"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "from a lower level to EF >40% under the subgroup- cardiac structural abnormalities, such as LV cham-"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "ing of patients with HFpEF. Others have proposed a ber dilatation and ventricular systolic and diastolic"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Table 3. Stages of HF"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Stages Definition and Criteria"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Stage A: At Risk for HF At risk for HF but without symptoms, structural heart disease, or cardiac biomarkers of stretch or injury (eg, patients with"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "hypertension, atherosclerotic CVD, diabetes, metabolic syndrome and obesity, exposure to cardiotoxic agents, genetic"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "variant for cardiomyopathy, or positive family history of cardiomyopathy)."
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Stage B: Pre-HF No symptoms or signs of HF and evidence of 1 of the following:"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Structural heart disease*"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Reduced left or right ventricular systolic function"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Reduced ejection fraction, reduced strain"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Ventricular hypertrophy"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Chamber enlargement"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Wall motion abnormalities"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Valvular heart disease"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Evidence for increased filling pressures*"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "By invasive hemodynamic measurements"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "By noninvasive imaging suggesting elevated filling pressures (eg, Doppler echocardiography)"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Patients with risk factors and"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Increased levels of BNPs* or"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Persistently elevated cardiac troponin"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "in the absence of competing diagnoses resulting in such biomarker elevations such as acute coronary syndrome, CKD,"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "pulmonary embolus, or myopericarditis"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Stage C: Symptomatic HF Structural heart disease with current or previous symptoms of HF."
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Stage D: Advanced HF Marked HF symptoms that interfere with daily life and with recurrent hospitalizations despite attempts to optimize GDMT."
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "BNP indicates B-type natriuretic peptide; CKD, chronic kidney disease; CVD, cardiovascular disease; GDMT, guideline-directed medical therapy; and HF, heart failure."
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "*For thresholds of cardiac structural, functional changes, elevated filling pressures, and biomarker elevations, refer to Appendix 3."
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 10,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 10,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Stages": "Stage A: At Risk for HF",
                "Definition and Criteria": "At risk for HF but without symptoms, structural heart disease, or cardiac biomarkers of stretch or injury (eg, patients with hypertension, atherosclerotic CVD, diabetes, metabolic syndrome and obesity, exposure to cardiotoxic agents, genetic variant for cardiomyopathy, or positive family history of cardiomyopathy)."
            },
            {
                "Stages": "Stage B: Pre-HF",
                "Definition and Criteria": "No symptoms or signs of HF and evidence of 1 of the following:"
            },
            {
                "Stages": "",
                "Definition and Criteria": "Structural heart disease* Reduced left or right ventricular systolic function Reduced ejection fraction, reduced strain Ventricular hypertrophy Chamber enlargement Wall motion abnormalities Valvular heart disease"
            },
            {
                "Stages": "",
                "Definition and Criteria": "Evidence for increased filling pressures* By invasive hemodynamic measurements By noninvasive imaging suggesting elevated filling pressures (eg, Doppler echocardiography)"
            },
            {
                "Stages": "",
                "Definition and Criteria": "Patients with risk factors and Increased levels of BNPs* or Persistently elevated cardiac troponin in the absence of competing diagnoses resulting in such biomarker elevations such as acute coronary syndrome, CKD, pulmonary embolus, or myopericarditis"
            },
            {
                "Stages": "Stage C: Symptomatic HF",
                "Definition and Criteria": "Structural heart disease with current or previous symptoms of HF."
            },
            {
                "Stages": "Stage D: Advanced HF",
                "Definition and Criteria": "Marked HF symptoms that interfere with daily life and with recurrent hospitalizations despite attempts to optimize GDMT."
            }
        ],
        "conteudo_texto": "Stage A: At Risk for HF, At risk for HF but without symptoms, structural heart disease, or cardiac biomarkers of stretch or injury (eg, patients with hypertension, atherosclerotic CVD, diabetes, metabolic syndrome and obesity, exposure to cardiotoxic agents, genetic variant for cardiomyopathy, or positive family history of cardiomyopathy). | Stage B: Pre-HF, No symptoms or signs of HF and evidence of 1 of the following: | , Structural heart disease* Reduced left or right ventricular systolic function Reduced ejection fraction, reduced strain Ventricular hypertrophy Chamber enlargement Wall motion abnormalities Valvular heart disease | , Evidence for increased filling pressures* By invasive hemodynamic measurements By noninvasive imaging suggesting elevated filling pressures (eg, Doppler echocardiography) | , Patients with risk factors and Increased levels of BNPs* or Persistently elevated cardiac troponin in the absence of competing diagnoses resulting in such biomarker elevations such as acute coronary syndrome, CKD, pulmonary embolus, or myopericarditis | Stage C: Symptomatic HF, Structural heart disease with current or previous symptoms of HF. | Stage D: Advanced HF, Marked HF symptoms that interfere with daily life and with recurrent hospitalizations despite attempts to optimize GDMT."
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e905"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "Figure 2. Trajectory of Stage C HF."
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "The trajectory of stage C HF is displayed. Patients whose symptoms and signs of HF are resolved are still stage C and should be treated"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "accordingly. If all HF symptoms, signs, and structural abnormalities resolve, the patient is considered to have HF in remission. HF indicates heart"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "failure; and LV, left ventricular. *Full resolution of structural and functional cardiac abnormalities is uncommon."
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "dysfunction, may persist. Furthermore, changes in 2.3. Diagnostic Algorithm for Classification of"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "LVEF might not be unidirectional; a patient may have HF According to LVEF"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "improvement followed by a decrease in EF or vice"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "Structural and functional alterations of the heart as the"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "versa depending on the underlying cause, duration"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "underlying cause for the clinical presentation support"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "of disease, adherence to the GDMT, or reexposure"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "the diagnosis of HFmrEF and HFpEF1 (Figure 4). The"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "to cardiotoxicity.5 Therefore, the writing committee"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "criteria for diagnosis of HFmrEF and HFpEF require"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "elected not to use “recovered EF” or HFpEF, even"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "evidence of increased LV filling pressures at rest, exer- if subsequent LVEF was >50% but, rather, “HF with"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "cise, or other provocations. The criteria can be fulfilled"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "improved EF” (HFimpEF) as a subgroup of HFrEF to"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "with findings of elevated levels of natriuretic peptides,"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "characterize these patients (Table 4, Figure 3). Impor-"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "echocardiographic diastolic parameters such as an"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "tantly, EF can decrease after withdrawal of pharmaco-"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "E/e′ ≥15 or other evidence of elevated filling pres-"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "logical treatment in many patients who had improved"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "EF to normal range with GDMT.5 Trajectory of LVEF sures, or invasive hemodynamic measurement at rest"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "can be important, and a significant reduction in LVEF or exercise. Evidence of structural heart disease (eg,"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "over time is a poor prognostic factor. LV structural or functional alterations) may be used to"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "further support the diagnosis of HFpEF. Key structural"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "alterations are an increase in left atrial size and volume"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "Table 4. Classification of HF by LVEF (left atrial volume index) and/or an increase in LV mass"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "(LV mass index)."
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "Type of HF According to"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "LVEF Criteria Exercise stress testing with echocardiographic"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "HFrEF (HF with reduced EF) LVEF ≤40% evaluation of diastolic parameters can be helpful if"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "the diagnosis remains uncertain.2,3 Alternatively, or in"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "HFimpEF (HF with improved Previous LVEF ≤40% and a follow-up"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "EF) measurement of LVEF >40% addition, invasive hemodynamics at rest or with exer-"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "HFmrEF (HF with mildly re- LVEF 41%–49% cise, with assessment of filling pressures (pulmonary"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "duced EF) Evidence of spontaneous or provokable capillary wedge pressure or LV end diastolic pressures,"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "increased LV filling pressures (eg, elevated pulmonary artery [PA] pressures, stroke volumes, and"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "natriuretic peptide, noninvasive and invasive"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "cardiac output) can be performed to help further estab-"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "hemodynamic measurement)"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "lish the diagnosis.4"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "HFpEF (HF with preserved LVEF ≥50%"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "The diagnosis of HFpEF is often challenging. A clin-"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "EF) Evidence of spontaneous or provokable"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "increased LV filling pressures (eg, elevated ical composite score to diagnose HFpEF, the H FPEF"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "natriuretic peptide, noninvasive and invasive score,5–7 integrates these predictive variables: obesity,"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "hemodynamic measurement)"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "atrial fibrillation (AF), age >60 years, treatment with"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "Please see Appendix 3 for suggested thresholds for structural heart disease ≥2 antihypertensive medications, echocardiographic"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "and evidence of increased filling pressures. E/e′ ratio >9, and echocardiographic PA systolic pres-"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "HF indicates heart failure; LV, left ventricular; and LVEF, left ventricular ejec-"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "sure >35 mm Hg. A weighted score based on these"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "tion fraction."
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 11,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 11,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Type of HF According to LVEF": "HFrEF (HF with reduced EF)",
                "Criteria": "LVEF ≤40%"
            },
            {
                "Type of HF According to LVEF": "HFimpEF (HF with improved EF)",
                "Criteria": "Previous LVEF ≤40% and a follow-up measurement of LVEF >40%"
            },
            {
                "Type of HF According to LVEF": "HFmrEF (HF with mildly re- duced EF)",
                "Criteria": "LVEF 41%–49% Evidence of spontaneous or provokable increased LV filling pressures (eg, elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement)"
            },
            {
                "Type of HF According to LVEF": "HFpEF (HF with preserved EF)",
                "Criteria": "LVEF ≥50% Evidence of spontaneous or provokable increased LV filling pressures (eg, elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement)"
            }
        ],
        "conteudo_texto": "HFrEF (HF with reduced EF), LVEF ≤40% | HFimpEF (HF with improved EF), Previous LVEF ≤40% and a follow-up measurement of LVEF >40% | HFmrEF (HF with mildly re- duced EF), LVEF 41%–49% Evidence of spontaneous or provokable increased LV filling pressures (eg, elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement) | HFpEF (HF with preserved EF), LVEF ≥50% Evidence of spontaneous or provokable increased LV filling pressures (eg, elevated natriuretic peptide, noninvasive and invasive hemodynamic measurement)"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "e906 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "Figure 3. Classification and Trajectories of HF Based on LVEF."
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "See Appendix 3 for suggested thresholds for laboratory findings. The classification for baseline and subsequent LVEF is shown. Patients with"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "HFrEF who improve their LVEF to >40% are considered to have HFimpEF and should continue HFrEF treatment. HF indicates heart failure;"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "HFimpEF, heart failure with improved ejection fraction; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; and LVEF, left ventricular ejection fraction. *There is limited"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "evidence to guide treatment for patients who improve their LVEF from mildly reduced (41%-49%) to ≥50%. It is unclear whether to treat these"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "patients as HFpEF or HFmrEF."
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "6 variables was used to create the composite score elderly, AF), and diagnostic laboratory tests, ECG, and"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "ranging from 0 to 9. The odds of HFpEF doubled for echocardiography. In the absence of overt noncardiac"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "each 1-unit score increase (odds ratio, 1.98; 95% causes of breathlessness, HFpEF can be suspected"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "CI: 1.74-2.30; P<0.0001), with a c-statistic of 0.841. if there is a normal LVEF, no significant heart valve"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "Scores <2 and ≥6 reflect low and high likelihood, disease or cardiac ischemia, and at least 1 typical risk"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "respectively, for HFpEF. A score between 2 and 5 may factor. The score used functional, morphological, and"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "require further evaluation of hemodynamics with exer- biomarker domains. The points score assigns 2 points"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "cise echocardiogram or cardiac catheterization to con- for a major criterion or 1 point for a minor criterion"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "firm or negate a diagnosis of HFpEF. The use of this within each domain, with a maximum of 2 points for"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "H FPEF score may help to facilitate discrimination of each domain."
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "HFpEF from noncardiac causes of dyspnea and can"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "assist in determination of the need for further diag-"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "3. EPIDEMIOLOGY AND CAUSES OF HF"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "nostic testing in the evaluation of patients with unex-"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "plained exertional dyspnea.6,7 3.1. Epidemiology of HF"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "The European Society of Cardiology has developed"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "Trends in Mortality and Hospitalization for HF"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "a diagnostic algorithm.8 This involves a pretest that"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "assesses for HF symptoms and signs, typical clini- HF is a growing health and economic burden for the"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "cal demographics (obesity, hypertension, diabetes, United States, in large part because of the aging popula-"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 12,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e907"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "Figure 4. Diagnostic Algorithm for HF"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "and EF-Based Classification."
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "The algorithm for a diagnosis of HF and"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "EF-based classification is shown. BNP"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "indicates B-type natriuretic peptide; ECG,"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "electrocardiogram; EF, ejection fraction; HF,"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "heart failure; HFmrEF, heart failure with mildly"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "reduced ejection fraction; HFpEF, heart failure"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "with preserved ejection fraction; HFrEF, heart"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "failure with reduced ejection fraction; LVEF, left"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "ventricular ejection fraction; LV, left ventricular;"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "and NT-proBNP, N-terminal pro-B type"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "natriuretic peptide."
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "tion.1,2 Beginning in 2012, the age-adjusted death rate highest death rate per capita.4 A report examining the"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "per capita for HF increased for the first time in the Unit- US population found age-adjusted mortality rate for"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "ed States.3 A recent US evaluation found total deaths HF to be 92 per 100 000 individuals for non-Hispanic"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "caused by HF have increased from 275 000 in 2009 to Black patients, 87 per 100 000 for non-Hispanic White"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "310 000 in 2014.3 patients, and 53 per 100 000 for Hispanic patients.4"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "US hospitalizations for HF decreased up until 20124; Among Medicare beneficiaries, non-Hispanic Black"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "however, from 2013 to 2017, an increase in HF hospitaliza- beneficiaries had a slightly greater decrease in HF in-"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "tions was observed. In 2017, there were 1.2 million HF hos- cidence (38 cases per 1000 to 26 cases per 1000,"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "pitalizations in the United States among 924 000 patients P=0.009) than non-Hispanic White beneficiaries (36"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "with HF.4 This represents a 26% increase in HF hospitaliza- cases per 1000 to 28 cases per 1000, P=0.003) from"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "tions and number of patients hospitalized with HF. 2011 to 2016.4 Among patients with established HF,"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "Although the absolute number of patients with HF non-Hispanic Black patients experienced a higher rate"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "has partly grown as a result of the increasing number of of HF hospitalization and a lower rate of death com-"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "older adults, the incidence of HF has decreased.5 Among pared with non-Hispanic White patients with HF.8–10"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "US Medicare beneficiaries, HF incidence declined from Hispanic patients with HF have been found to have"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "36 cases per 1000 beneficiaries in 2011 to 27 cases similar8 or higher10 HF hospitalization rates and similar10"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "per 1000 beneficiaries in 2014 and remained stable or lower8 mortality rates compared with non-Hispanic"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "through 2016.5 Divergent trends in the incidence of HF White patients. Asian/Pacific Islander patients with HF"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "have been observed for those with HFrEF (decreasing have had a similar rate of hospitalization as non-His-"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "incidence) and HFpEF (increasing incidence).6,7 Deaths panic White patients but a lower rate of death.8,10 These"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "attributable to cardiomyopathies have been increasing racial and ethnic disparities in outcome, for those with"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "globally because of, in part, increased recognition, diag- HF, warrant studies and health policy changes to ad-"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "nosis, and documentation of specific cardiomyopathies dress health inequity."
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "and cardiotoxicity.2"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "3.2. Cause of HF"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "Racial and Ethnic Disparities in Mortality and"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "In the United States, approximately 115 million peo-"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "Hospitalization for HF"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "ple have hypertension, 100 million have obesity, 92"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "Racial and ethnic disparities in death resulting from HF million have prediabetes, 26 million have diabetes,"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "persist, with non-Hispanic Black patients having the and 125 million have atherosclerotic CVD.1 These are"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 13,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "e908 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Table 5. Other Potential Nonischemic Causes of HF 4. INITIAL AND SERIAL EVALUATION"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Cause Reference 4.1. Clinical Assessment: History and Physical"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Chemotherapy and other cardiotoxic medications 23–25 Examination"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Rheumatologic or autoimmune 26"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Recommendations for Clinical Assessment: History and Physical Ex-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Endocrine or metabolic (thyroid, acromegaly, pheochromocy- 27–31"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "amination toma, diabetes, obesity)"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Familial cardiomyopathy or inherited and genetic heart 32 rized in the Online Data Supplements."
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "disease"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Heart rhythm–related (eg, tachycardia-mediated, PVCs, RV 33"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "1. In patients with HF, vital signs and evidence of"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "pacing)"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "clinical congestion should be assessed at each"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Hypertension 34 1 B-NR encounter to guide overall management, includ-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "ing adjustment of diuretics and other medica-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Infiltrative cardiac disease (eg, amyloid, sarcoid, hemochro- 21,35,36"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "tions.1–6"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "matosis)"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "2. In patients with symptomatic HF, clinical factors"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Myocarditis (infectious, toxin or medication, immunological, 37,38"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "indicating the presence of advanced HF should"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "hypersensitivity) 1 B-NR"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "be sought via the history and physical examina-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Peripartum cardiomyopathy 39 tion.7–12"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Stress cardiomyopathy (Takotsubo) 40,41 3. In patients with cardiomyopathy, a 3-generation"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "family history should be obtained or updated"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Substance abuse (eg, alcohol, cocaine, methamphetamine) 42–44 1 B-NR"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "when assessing the cause of the cardiomyopa-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "HF indicates heart failure; PVC, premature ventricular contraction; and RV, thy to identify possible inherited disease.13,14"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "right ventricular. 4. In patients presenting with HF, a thorough history"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "and physical examination should direct diagnos-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "1 B-NR"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "tic strategies to uncover specific causes that"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "known risk factors with high relative risk and popula- may warrant disease-specific management.15,16"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "tion attributable risk for development of HF. There-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "5. In patients presenting with HF, a thorough"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "fore, a large proportion of the US population can be history and physical examination should be"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "categorized as being at-risk for HF or stage A HF. obtained and performed to identify cardiac and"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "1 C-EO noncardiac disorders, lifestyle and behavioral"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "The common causes of HF include ischemic heart"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "factors, and social determinants of health that"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "disease and myocardial infarction (MI), hypertension, might cause or accelerate the development or"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "and valvular heart disease (VHD). Other causes can progression of HF."
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "include familial or genetic cardiomyopathies; amyloi-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "dosis; cardiotoxicity with cancer or other treatments"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "or substance abuse such as alcohol, cocaine, or meth-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "amphetamine; tachycardia, right ventricular (RV) pac- The history and physical examination remain a cornerstone"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "ing or stress-induced cardiomyopathies; peripartum in the assessment of patients with HF. The history and"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "cardiomyopathy; myocarditis; autoimmune causes, physical examination provide information about the cause"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "sarcoidosis; iron overload, including hemochromato- of an underlying cardiomyopathy, including the possibility"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "sis; and thyroid disease and other endocrine metabol- of an inherited cardiomyopathy as ascertained by a fam-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "ic and nutritional causes (Table 5). Furthermore, with ily history or a condition requiring disease-specific therapy"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "cardiac imaging and biomarkers, myocardial injury or like amyloid heart disease, as well as reasons why a previ-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "cardiac maladaptive structural changes can be de- ously stable patient developed acutely decompensated HF."
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "tected at earlier phases with a higher sensitivity, even A critical component of the history and physical examina-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "in the absence of gross LV dysfunction or symptoms. tion is to assess for clinical congestion (ie, those signs and"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "With the coronavirus disease 2019 (COVID-19) pan- symptoms resulting from elevated cardiac filling pressures)."
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "demic, investigators are gaining better insights into Congestion is a target for medication adjustment and is as-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "infection and inflammation-related myocardial injury sociated with quality of life (QOL) and prognosis. The his-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "and myocarditis. With the increasing ability to detect tory and physical examination also allow for the determina-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "myocardial injury and with an increasing awareness tion of clinical clues that suggest the patient has advanced"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "of cardiotoxicity and injury patterns including inflam- HF, which may warrant referral to an advanced HF center."
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "mation, pre-HF or stage B HF will likely continue to"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "increase. Beyond classifications of EF and staging"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "in HF, clinicians should seek the cause of HF be-"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "cause appropriate treatment may be determined by 1. Clinical congestion can be assessed by various"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "the cause (Table 5). methods, including the presence of jugular venous"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 14,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 14,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Cause": "Chemotherapy and other cardiotoxic medications",
                "Reference": "23–25"
            },
            {
                "Cause": "Rheumatologic or autoimmune",
                "Reference": "26"
            },
            {
                "Cause": "Endocrine or metabolic (thyroid, acromegaly, pheochromocy- toma, diabetes, obesity)",
                "Reference": "27–31"
            },
            {
                "Cause": "Familial cardiomyopathy or inherited and genetic heart disease",
                "Reference": "32"
            },
            {
                "Cause": "Heart rhythm–related (eg, tachycardia-mediated, PVCs, RV pacing)",
                "Reference": "33"
            },
            {
                "Cause": "Hypertension",
                "Reference": "34"
            },
            {
                "Cause": "Infiltrative cardiac disease (eg, amyloid, sarcoid, hemochro- matosis)",
                "Reference": "21,35,36"
            },
            {
                "Cause": "Myocarditis (infectious, toxin or medication, immunological, hypersensitivity)",
                "Reference": "37,38"
            },
            {
                "Cause": "Peripartum cardiomyopathy",
                "Reference": "39"
            },
            {
                "Cause": "Stress cardiomyopathy (Takotsubo)",
                "Reference": "40,41"
            },
            {
                "Cause": "Substance abuse (eg, alcohol, cocaine, methamphetamine)",
                "Reference": "42–44"
            }
        ],
        "conteudo_texto": "Chemotherapy and other cardiotoxic medications, 23–25 | Rheumatologic or autoimmune, 26 | Endocrine or metabolic (thyroid, acromegaly, pheochromocy- toma, diabetes, obesity), 27–31 | Familial cardiomyopathy or inherited and genetic heart disease, 32 | Heart rhythm–related (eg, tachycardia-mediated, PVCs, RV pacing), 33 | Hypertension, 34 | Infiltrative cardiac disease (eg, amyloid, sarcoid, hemochro- matosis), 21,35,36 | Myocarditis (infectious, toxin or medication, immunological, hypersensitivity), 37,38 | Peripartum cardiomyopathy, 39 | Stress cardiomyopathy (Takotsubo), 40,41 | Substance abuse (eg, alcohol, cocaine, methamphetamine), 42–44"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e909"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "distention,17 orthopnea,18 bendopnea,19 a square- care professionals improved the rate of detection"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "wave response to the Valsalva maneuver,20 and leg of a familial process as compared with routine"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "edema.6 On a practical level, clinicians use extent care.14 Furthermore, a family history of cardiomy-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "of clinical congestion to guide titration of pharma- opathy, as determined by a 3-generation pedigree"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "cological treatments, including doses of diuretics. analysis, was associated with findings of gadolin-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "Observational studies have shown that clinical ium enhancement on cardiac magnetic resonance"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "congestion is an important adverse risk factor in imaging (MRI) and increased major adverse car-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "patients with HF.1–6,17 Recently, the PARADIGM-HF diac events.13 The possibility of an inherited car-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "(The Efficacy and Safety of LCZ696 Compared to diomyopathy provides the impetus for cascade"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "Enalapril on Morbidity and Mortality of Patients With screening of undiagnosed family members, thereby"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "Chronic Heart Failure) investigators showed that, potentially avoiding preventable adverse events in"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "in patients with chronic HFrEF, changes in markers affected relatives by implementation of GDMT and"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "of clinical congestion were associated with QOL other management that otherwise would not be"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "as assessed by the Kansas City Cardiomyopathy initiated."
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "Questionnaire and also provided prognostic infor- 4. Certain conditions that cause HF require disease-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "mation independently even of natriuretic peptides specific therapies. For example, in amyloid heart"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "or the MAGGIC (Meta-analysis Global Group in disease, whether on the basis of transthyretin21 or"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "Chronic Heart Failure) risk score.2 These data light chain deposition,22 there are specific treat-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "highlight the ongoing relevance of clinical con- ments that otherwise would not be used in patients"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "gestion ascertained by the history and physical with HF. Hence, expeditious and accurate diag-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "examination. nosis of such conditions is important. Currently,"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "2. Some patients with HF progress to an advanced important delays have been reported in diagnos-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "state, a condition that can be treated with special- ing amyloid heart disease,16 perhaps not unexpect-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "ized interventions such as mechanical circulatory edly given the wide spectrum of possible clinical"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "support (MCS) or cardiac transplantation. Such presentations.15 Similarly, HF attributable to sar-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "patients should be identified before they progress coidosis, hemochromatosis, hypothyroidism, hyper-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "to a state of extremis, at which point they may suc- thyroidism, acromegaly, connective tissue disease,"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "cumb to their illness or suffer complications of tachycardia-induced cardiomyopathy, or high-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "an intervention as a result of their very advanced output HF from an arteriovenous fistula, among"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "state. Several “simple clinical clues” are available others, requires specific therapeutic approaches."
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "to identify advanced HF and should be ascertained Given that the differential diagnosis of HF is broad,"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "via a focused history and physical examination. The the history and physical examination can provide"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "recognition that a patient has advanced HF will clues to narrow the number of causes to consider"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "allow for earlier referral to an advanced HF center, and guide the diagnostic approach to identify such"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "when appropriate, as will be discussed later in this conditions (Table 5)."
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "document (see Section 8, “Specialty Referral for 5. The history and physical examination help to"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "Advanced HF”). identify the cause of a clinical deterioration. To"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "3. Increasingly, familial cardiomyopathy is recognized determine the cause of a clinical deterioration,"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "as a more accurate diagnosis in some patients the clinician assesses for concurrent illness (eg,"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "previously classified as having an idiopathic dilated ongoing myocardial ischemia, pulmonary emboli,"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "cardiomyopathy (DCM). A detailed family history or systemic infection), initiation of a medication"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "may provide the first clue of a genetic basis. A potentially detrimental in the setting of HF (eg,"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "broad array of questions includes whether family nonsteroidal anti-inflammatory drugs [NSAIDs]),"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "members had a weak, enlarged, or thick heart, or or the possibility of chronic RV pacing (eg, a"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "HF; muscular dystrophy; a pacemaker or defibril- newly implanted pacemaker or medications such"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "lator; were on a heart transplant list; or died unex- as amiodarone that leads to bradycardia and"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "pectedly. Periodic updating of the family history in resultant chronic RV pacing), nonadherence to"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "patients with a cardiomyopathy of uncertain origin a medication or dietary regimen, and ongoing"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "may lead to a diagnosis of familial cardiomyopathy substance abuse. In addition, an assessment of"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "in the event that a relative subsequently develops a social determinants of health (eg, housing stabil-"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "cardiomyopathy or a related complication. A 3-gen- ity, food security, available transportation) should"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "eration family pedigree obtained by genetic health be made."
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 15,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "e910 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "4.1.1. Initial Laboratory and Electrocardiographic Table 6. Selected Potential Causes of Elevated Natriuretic"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Testing Peptide Levels50–53"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Recommendations for Initial Laboratory and Electrocardiographic Test- Cardiac"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "ing"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "HF, including RV HF syndromes"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements. ACS"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations Heart muscle disease, including LVH"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "1. For patients presenting with HF, the specific VHD"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "cause of HF should be explored using addi-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "1 B-NR Pericardial disease"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "tional laboratory testing for appropriate man-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "agement.1–8 AF"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "2. For patients who are diagnosed with HF, Myocarditis"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "laboratory evaluation should include com-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Cardiac surgery"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "plete blood count, urinalysis, serum electro-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "1 C-EO lytes, blood urea nitrogen, serum creatinine, Cardioversion"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "glucose, lipid profile, liver function tests, iron"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Toxic-metabolic myocardial insults, including cancer chemotherapy"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "studies, and thyroid-stimulating hormone to"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "optimize management. Noncardiac"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "3. For all patients presenting with HF, a 12-lead Advancing age"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "1 C-EO ECG should be performed at the initial encoun-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Anemia"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "ter to optimize management."
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Renal failure"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Pulmonary: Obstructive sleep apnea, severe pneumonia"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Pulmonary embolism, pulmonary arterial hypertension"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Laboratory evaluation with complete blood count, urinaly-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Critical illness"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "sis, serum electrolytes (including sodium, potassium, cal-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Bacterial sepsis"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "cium, and magnesium), blood urea nitrogen, serum cre-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Severe burns"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "atinine, glucose, fasting lipid profile, liver function tests,"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "iron studies (serum iron, ferritin, transferrin saturation), ACS indicates acute coronary syndromes; AF, atrial fibrillation; HF, heart fail-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "and thyroid-stimulating hormone level and electrocar- ure; LVH, left ventricular hypertrophy; RV, right ventricular; and VHD, valvular"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "heart disease."
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "diography is part of the standard diagnostic evaluation"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "of a patient with HF. In addition to routine assessment, 2. Laboratory evaluation with complete blood count,"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "specific diagnostic testing and evaluation is often neces- urinalysis, serum electrolytes, blood urea nitro-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "sary to identify specific cause and other comorbidities in gen, serum creatinine, glucose, fasting lipid pro-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "patients with HF. file, liver function tests, iron studies (serum iron,"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "ferritin, transferrin saturation), and thyroid-stimu-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "lating hormone levels provides important informa-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "tion regarding patients’ comorbidities, suitability"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "1. Identifying the specific cause of HF is impor- for and adverse effects of treatments, potential"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "tant, because conditions that cause HF may causes or confounders of HF, severity and prog-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "require disease-specific therapies. Depending nosis of HF, and is usually performed on initial"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "on the clinical suspicion, additional diagnostic evaluation. Pertinent laboratory tests are repeated"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "studies are usually required to diagnose specific with changes in clinical condition or treatments"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "causes (Table 6) such as ischemic cardiomy- (eg, to monitor renal function or electrolytes with"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "opathy, cardiac amyloidosis, sarcoidosis, hemo- diuretics)."
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "chromatosis, infectious mechanisms (eg, HIV, 3. Electrocardiography is part of the routine evalua-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "COVID-19, Chagas), hypothyroidism, hyperthy- tion of a patient with HF and provides important"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "roidism, acromegaly, connective tissue disorders, information on rhythm, heart rate, QRS morphol-"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "tachycardia-induced cardiomyopathy, Takotsubo, ogy and duration, cause, and prognosis of HF."
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "peripartum cardiomyopathy, cardiotoxicity with It is repeated when there is a clinical indication,"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "cancer therapies, or substance abuse would such as a suspicion for arrhythmia, ischemia or"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "require specific management in addition to or myocardial injury, conduction, or other cardiac"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "beyond GDMT.1,2,9–15 abnormalities."
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 16,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e911"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "4.2. Use of Biomarkers for Prevention, Initial levels have higher sensitivity than specificity and"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Diagnosis, and Risk Stratification may be more useful for ruling out HF than ruling in"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "HF. Although lower levels of BNP and NT-proBNP"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Recommendations for Use of Biomarkers for Prevention, Initial Diagno- may help exclude the presence of HF, and higher"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "sis, and Risk Stratification levels have high positive predictive value to diag-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "nose HF, increases in both BNP and NT-proBNP"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "levels have been reported in patients with various"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "cardiac and noncardiac causes (Table 6).50–53"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "1. In patients presenting with dyspnea, measure-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "2. and 3. Higher levels of BNP and NT-proBNP are"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "ment of B-type natriuretic peptide (BNP) or"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "1 A N-terminal prohormone of B-type natriuretic associated with a greater risk for adverse short-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "peptide (NT-proBNP) is useful to support a and long-term outcomes in patients with HF, includ-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "diagnosis or exclusion of HF.1–12"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "ing all-cause and cardiovascular death and major"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "2. In patients with chronic HF, measurements of cardiovascular events.11,13–19 Studies have shown"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "1 A BNP or NT-proBNP levels are recommended"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "incremental prognostic value of these biomark-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "for risk stratification.11,13–29"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "ers to standard approaches of CVD risk assess-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "3. In patients hospitalized for HF, measurement"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "1 A of BNP or NT-proBNP levels at admission is ment.11,16 Not all patients may need biomarker"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "recommended to establish prognosis.11,13–19 measurement for prognostication, especially if they"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "4. In patients at risk of developing HF, BNP or already have advanced HF with established poor"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "NT-proBNP–based screening followed by prognosis or persistently elevated levels of bio-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "2a B-R team-based care, including a cardiovascular"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "markers in former settings."
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "specialist, can be useful to prevent the devel-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "opment of LV dysfunction or new-onset HF.30,31 4. The STOP-HF (St Vincent’s Screening to Prevent"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "5. In patients hospitalized for HF, a predischarge Heart Failure) study is a large single-center trial"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "BNP or NT-proBNP level can be useful to of patients at risk of HF, defined by the presence"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "2a B-NR"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "inform the trajectory of the patient and estab-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "of hypertension, diabetes, or known vascular dis-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "lish a postdischarge prognosis.14,17,20–29"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "ease but without established LV systolic dys-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "function or symptomatic HF, who were randomly"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Synopsis assigned to screening with BNP testing or usual"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "care.31 Participants in the intervention group with"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Assays for BNP and NT-proBNP are frequently used"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "BNP levels ≥50 pg/mL underwent echocardiog-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "to establish the presence and severity of HF. In general,"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "raphy and referral to a cardiovascular special-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "BNP and NT-proBNP levels are similar, and either can"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "ist.31 All patients received coaching by a specialist"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "be used in patient care settings as long as their respec-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "nurse who provided education on the importance"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "tive absolute values and cut-points are not used inter-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "of adherence to medication and healthy lifestyle"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "changeably.32–34 Obesity is associated with lower levels of"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "behaviors.31 BNP-based screening reduced the"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "BNP and NT-proBNP thereby reducing their diagnostic"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "composite endpoint of incident asymptomatic LV"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "sensitivity.35,36 A substantial evidence base supports the"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "dysfunction with or without newly diagnosed HF."
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "use of natriuretic peptide biomarkers for excluding HF"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Similarly, accelerated uptitration of renin-angioten-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "as a cause of symptoms in ambulatory and emergency"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "sin-aldosterone system (RAAS) antagonists and"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "department settings. Although a reduction in BNP and"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "beta blockers reduced cardiac events in patients"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "NT-proBNP has been associated with better outcomes,"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "with diabetes and elevated NT-proBNP levels but"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "the evidence for treatment guidance using serial BNP"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "without cardiac disease at baseline.30 Standardized"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "or NT-proBNP measurements remains insufficient.37–39"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "screening for HF remains challenging as a result"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Lastly, a widening array of biomarkers including mark-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "of the heterogeneity of risk factors across different"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "ers of myocardial injury, inflammation, oxidative stress,"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "patient populations. Studies are needed to assess"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "vascular dysfunction, and matrix remodeling have been"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "the cost-effectiveness and risks of such screening,"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "shown to provide incremental prognostic information"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "as well as its impact on QOL and mortality."
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "over natriuretic peptides but remain without evidence of"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "5. Predischarge BNP and NT-proBNP levels are"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "an incremental management benefit.13,40–49"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "strong predictors of the risk of death or hospital"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "readmission for HF.14,17,20–29 Although patients in"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "whom levels of BNP or NT-proBNP decreased with"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "1. Measurement of BNP and NT-proBNP levels in the treatment had better outcomes than those without"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "ambulatory setting for a suspected cardiac cause any changes or with a biomarker rise,14,23,28,29 tar-"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "of dyspnea provides incremental diagnostic value geting a certain threshold, value, or relative change"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "to clinical judgment when the cause of dyspnea is in these biomarker levels during hospitalization"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "unclear and the physical examination equivocal.1–9 has not been shown to be consistently effective in"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "In the emergency setting, BNP and NT-proBNP improving outcomes.37–39 Patients in which GDMT"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 17,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "e912 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Table 7. Examples of Factors Implicating Possible Genetic Cardiomyopathy"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Phenotypic Category Patient or Family Member Phenotypic Finding* Ask Specifically About Family Members* With"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Cardiac morphology Marked LV hypertrophy Any mention of cardiomyopathy, enlarged or weak heart, HF."
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "LV noncompaction Document even if attributed to other causes, such as alcohol or peri-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "partum cardiomyopathy"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Right ventricular thinning or fatty replacement on imaging"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "or biopsy"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Findings on 12-lead ECG Abnormal high or low voltage or conduction, and repolar- Long QT or Brugada syndrome"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "ization, altered RV forces"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Dysrhythmias Frequent NSVT or very frequent PVCs ICD"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Sustained ventricular tachycardia or fibrillation Recurrent syncope"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Sudden death attributed to “massive heart attack” without known CAD"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Unexplained fatal event such as drowning or single-vehicle crash"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Early onset AF “Lone” AF before age 65 y"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Early onset conduction disease Pacemaker before age 65 y"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Extracardiac features Skeletal myopathy Any known skeletal muscle disease, including mention of Duchenne"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Neuropathy and Becker’s, Emory-Dreifuss limb-girdle dystrophy"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Cutaneous stigmata Systemic syndromes:"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Other possible manifestations of systemic syndromes Dysmorphic features"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Mental retardation"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Congenital deafness"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Neurofibromatosis"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Renal failure with neuropathy"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "AF indicates atrial fibrillation; CAD, coronary artery disease; LV, left ventricular; NSVT, nonsustained ventricular tachycardia; PVC, premature ventricular contraction;"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "and RV, right ventricular."
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "*Note that genetic cause is more likely when the person is younger at the onset of events. However, the cardiac morphology and peripheral manifestations of"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "hereditary amyloidosis may present in later life, unlike most other inherited cardiomyopathies."
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "leads to a reduction in BNP and NT-proBNP lev- diagrammed as a family tree pedigree (see Section"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "els represent a population with improved long-term 4.1, “Clinical Assessment: History and Physical Ex-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "outcomes compared with those with persistently amination”). Genetic variants have been implicated in"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "elevated levels despite appropriate treatment.37–39 25% to 40% of patients with DCM with a positive fam-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "BNP and NT-proBNP levels and their change ily history but also in 10% to 30% of patients without"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "could help guide discussions on prognosis as well a recognized family history.3,4 Phenotype and family"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "as adherence to, and optimization of, GDMT. history are important for identifying patients in whom"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "genetic testing is most likely to yield clinically action-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "able information (Table 7). Presentation of DCM with"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "4.3. Genetic Evaluation and Testing"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "conduction disease or ventricular arrhythmias raises"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "concern of sarcoidosis and arrhythmogenic cardio-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Recommendations for Genetic Evaluation and Testing"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa- myopathy, which is of particular concern because of"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements. the risk of sudden death in patients and families.5 No"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations controlled studies have shown clinical benefits of ge-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "1. In first-degree relatives of selected patients netic testing for cardiomyopathy, but genetic testing"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "with genetic or inherited cardiomyopathies, contributes to risk stratification and has implications"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "genetic screening and counseling are recom-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "1 B-NR for treatment, currently most often for decisions re-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "mended to detect cardiac disease and prompt"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "consideration of treatments to decrease HF garding defibrillators for primary prevention of sudden"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "progression and sudden death.1,2 death5 and regarding exercise limitation for hypertro-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "2. In select patients with nonischemic cardio- phic cardiomyopathy and the desmosomal variants."
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "myopathy, referral for genetic counseling and Consultation with a trained counselor before and af-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "2a B-NR testing is reasonable to identify conditions that"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "ter genetic testing helps patients to understand and"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "could guide treatment for patients and family"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "members.3,4 weigh the implications of possible results for their"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "own lives and those of family members, including pos-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "sible discrimination on the basis of genetic informa-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "tion. Unless shown to be free of the genetic variant(s)"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "In patients in whom a genetic or inherited cardiomy- implicated in the proband, first-degree relatives of af-"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "opathy is suspected, a family history should be per- fected probands should undergo periodic screening"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "formed, including at least 3 generations and ideally with echocardiography and electrocardiography."
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 18,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 18,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Phenotypic Category": "Cardiac morphology",
                "Patient or Family Member Phenotypic Finding*": "Marked LV hypertrophy",
                "Ask Specifically About Family Members* With": "Any mention of cardiomyopathy, enlarged or weak heart, HF. Document even if attributed to other causes, such as alcohol or peri- partum cardiomyopathy"
            },
            {
                "Phenotypic Category": "",
                "Patient or Family Member Phenotypic Finding*": "LV noncompaction",
                "Ask Specifically About Family Members* With": ""
            },
            {
                "Phenotypic Category": "",
                "Patient or Family Member Phenotypic Finding*": "Right ventricular thinning or fatty replacement on imaging or biopsy",
                "Ask Specifically About Family Members* With": ""
            },
            {
                "Phenotypic Category": "Findings on 12-lead ECG",
                "Patient or Family Member Phenotypic Finding*": "Abnormal high or low voltage or conduction, and repolar- ization, altered RV forces",
                "Ask Specifically About Family Members* With": "Long QT or Brugada syndrome"
            },
            {
                "Phenotypic Category": "Dysrhythmias",
                "Patient or Family Member Phenotypic Finding*": "Frequent NSVT or very frequent PVCs Sustained ventricular tachycardia or fibrillation",
                "Ask Specifically About Family Members* With": "ICD Recurrent syncope Sudden death attributed to “massive heart attack” without known CAD Unexplained fatal event such as drowning or single-vehicle crash"
            },
            {
                "Phenotypic Category": "",
                "Patient or Family Member Phenotypic Finding*": "Early onset AF",
                "Ask Specifically About Family Members* With": "“Lone” AF before age 65 y"
            },
            {
                "Phenotypic Category": "",
                "Patient or Family Member Phenotypic Finding*": "Early onset conduction disease",
                "Ask Specifically About Family Members* With": "Pacemaker before age 65 y"
            },
            {
                "Phenotypic Category": "Extracardiac features",
                "Patient or Family Member Phenotypic Finding*": "Skeletal myopathy Neuropathy Cutaneous stigmata Other possible manifestations of systemic syndromes",
                "Ask Specifically About Family Members* With": "Any known skeletal muscle disease, including mention of Duchenne and Becker’s, Emory-Dreifuss limb-girdle dystrophy Systemic syndromes: Dysmorphic features Mental retardation Congenital deafness Neurofibromatosis Renal failure with neuropathy"
            }
        ],
        "conteudo_texto": "Cardiac morphology, Marked LV hypertrophy, Any mention of cardiomyopathy, enlarged or weak heart, HF. Document even if attributed to other causes, such as alcohol or peri- partum cardiomyopathy | , LV noncompaction,  | , Right ventricular thinning or fatty replacement on imaging or biopsy,  | Findings on 12-lead ECG, Abnormal high or low voltage or conduction, and repolar- ization, altered RV forces, Long QT or Brugada syndrome | Dysrhythmias, Frequent NSVT or very frequent PVCs Sustained ventricular tachycardia or fibrillation, ICD Recurrent syncope Sudden death attributed to “massive heart attack” without known CAD Unexplained fatal event such as drowning or single-vehicle crash | , Early onset AF, “Lone” AF before age 65 y | , Early onset conduction disease, Pacemaker before age 65 y | Extracardiac features, Skeletal myopathy Neuropathy Cutaneous stigmata Other possible manifestations of systemic syndromes, Any known skeletal muscle disease, including mention of Duchenne and Becker’s, Emory-Dreifuss limb-girdle dystrophy Systemic syndromes: Dysmorphic features Mental retardation Congenital deafness Neurofibromatosis Renal failure with neuropathy"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e913"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "Recommendations for Evaluation With Cardiac Imaging (Continued)"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "1. and 2. Inherited dilated, restrictive, and hypertrophic COR LOE Recommendations"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "cardiomyopathies have been identified, although 1 3. In patients with HF who have had a significant"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "gene variant may cause different phenotypes in the clinical change, or who have received GDMT and"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "are being considered for invasive procedures"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "same family. The most common pathogenic variants"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "1 C-LD or device therapy, repeat measurement of EF,"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "identified are truncations in the large structural protein degree of structural remodeling, and valvular"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "titin, which have been implicated in DCM3–5 and also function are useful to inform therapeutic interven-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "tions.4–7"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "in peripartum or alcoholic cardiomyopathies; however,"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "variants that do not cause disease are also common. 4. In patients for whom echocardiography is"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "inadequate, alternative imaging (eg, cardiac"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "Pathogenic variants in lamin A/C can be associated"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "1 C-LD magnetic resonance [CMR], cardiac computed"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "with conduction block and atrial arrhythmias as well tomography [CT], radionuclide imaging) is rec-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "as ventricular arrhythmias, which may progress more ommended for assessment of LVEF.8–15"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "rapidly than symptoms of HF. Although previously 5. In patients with HF or cardiomyopathy, CMR"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "linked with the phenotype of arrhythmogenic RV car- 2a B-NR can be useful for diagnosis or manage-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "ment.16–23"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "diomyopathy, desmosomal protein variants are now"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "6. In patients with HF, an evaluation for possible"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "recognized to affect the left ventricle also with or with-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "2a B-NR ischemic heart disease can be useful to identify"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "out the right ventricle, and the term arrhythmogenic the cause and guide management.24–27"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "cardiomyopathy is now preferred for the phenotype"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "7. In patients with HF and coronary artery disease"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "of arrhythmias combined with DCM. Filamin-C muta- (CAD) who are candidates for coronary revas-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "tions have been associated with skeletal myopathies cularization, noninvasive stress imaging (stress"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "echocardiography, single-photon emission CT"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "and with isolated cardiomyopathy with ventricular 2b B-NR"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "[SPECT], CMR, or positron emission tomog-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "arrhythmias. The identification of pathogenic variants raphy [PET]) may be considered for detection"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "associated with increased risk of sudden death may of myocardial ischemia to help guide coronary"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "revascularization.28–32"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "trigger consideration of primary prevention implant-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "8. In patients with HF in the absence of: 1) clinical"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "able cardioverter-defibrillators (ICDs) even in patients"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "status change, 2) treatment interventions that"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "who have LVEF >0.35 or <3 months of guideline- 3: No might have had a significant effect on cardiac"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "C-EO"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "recommended therapies.6 Evidence of desmosomal Benefit function, or 3) candidacy for invasive proce-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "dures or device therapy, routine repeat assess-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "cardiac disease carries the additional implication of"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "ment of LV function is not indicated."
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "advice to avoid strenuous exercise, which may accel-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "erate ventricular remodeling.7 Genetic confirmation of"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "symptomatic Fabry’s cardiomyopathy is an indication Synopsis"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "for replacement therapy with the enzyme agalsidase"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "Cardiac imaging has a key role in the initial evaluation"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "beta, and migalastat was recently approved for this"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "of individuals with suspected HF and, when indicated,"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "uncommon cardiomyopathy."
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "in the serial assessment of patients with HF. After a"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "complete history and physical examination, a com-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "prehensive TTE is the most useful initial diagnostic"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "4.4. Evaluation With Cardiac Imaging"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "test given the vast amount of diagnostic and prognos-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "tic information provided. The determination of LVEF"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "Recommendations for Evaluation With Cardiac Imaging"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa- is a fundamental step to classify HF and to guide"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements. evidence-based pharmacological and device-based"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations therapy. In certain situations, the echocardiogram is"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "1. In patients with suspected or new-onset HF, or unable to accurately assess cardiac structure and/or"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "those presenting with acute decompensated function or more information is needed to determine"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "HF, a chest x-ray should be performed to"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "the cause of the cardiac dysfunction. Other imaging"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "1 C-LD assess heart size and pulmonary congestion"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "and to detect alternative cardiac, pulmonary, modalities, such as CMR, SPECT or radionuclide ven-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "and other diseases that may cause or contrib- triculography, PET, or cardiac CT or invasive coronary"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "ute to the patient’s symptoms.1,2"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "angiography, can provide additional and complemen-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "2. In patients with suspected or newly diag- tary information to cardiac ultrasound.11 In general,"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "nosed HF, transthoracic echocardiography"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "cardiac imaging tests, including repeat tests, are per-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "1 C-LD (TTE) should be performed during initial"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "evaluation to assess cardiac structure and formed only when the results have a meaningful im-"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "function.3 pact on clinical care."
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 19,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "e914 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text in LVEF, and valvular function in response to"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "evidence-based medical, revascularization, and"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "1. The chest x-ray is a useful initial diagnostic test for"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "device therapies, and repeat assessment of LVEF"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "the evaluation of patients presenting with signs and"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "and remodeling is appropriate in those who have"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "symptoms of HF because it assesses cardiomeg-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "received treatments that might have had a signifi-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "aly, pulmonary venous congestion, and interstitial or"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "cant effect on cardiac structure and function.4–7,53–59"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "alveolar edema and may reveal alternative causes,"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "Recovery of function appears more common in"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "cardiopulmonary or otherwise, of the patient’s"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "those with LV systolic dysfunction occurring in the"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "symptoms.1,2 Apart from congestion, other findings"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "setting of adverse energetic circumstances (eg,"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "on chest x-ray are associated with HF only in the"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "chronic tachycardia or thyroid disease), dilated car-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "context of clinical presentation. Importantly, cardio-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "diomyopathies associated with immune responses"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "megaly may be absent in acute HF and, although"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "(eg, peripartum cardiomyopathy, acute myocardi-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "cephalization, interstitial edema, and alveolar edema"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "tis, systemic inflammatory responses), or in those"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "are modestly specific for HF, these findings are rel-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "who have undergone revascularization or device-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "atively insensitive.2,33 Considering the limited sensi-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "based therapies.60 Reevaluation of EF (>40 days"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "tivity and specificity, the chest x-ray should not be"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "after MI, >90 days after revascularization, >90"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "used as the only determinant of the specific cause"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "days after GDMT) is useful to determine candidacy"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "or presence of HF."
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "for implantable cardioverter-defibrillator (ICD) or"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "2. TTE provides information regarding cardiac struc-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "cardiac resynchronization therapy (CRT). Finally,"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "ture and function and identifies abnormalities"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "repeat surveillance of LV function is appropriate"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "of myocardium, heart valves, and pericardium."
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "in patients exposed to treatments that potentially"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "Echocardiography reveals structural and functional"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "damage the myocardium, such as chemotherapy."
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "information that predicts subsequent risk.34–40"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "4. If TTE is unable to accurately evaluate cardiac"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "Guidelines provide recommendations for quanti-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "structure and function, additional noninvasive"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "fication of cardiac structure and function, includ- imaging modalities are available to clarify the ini-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "ing LVEF measurements, ventricular dimensions tial diagnosis and to provide information on car-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "and volumes, evaluation of chamber geometry, and diac structure and function. The choice between"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "regional wall motion.41 RV size and function, atrial these modalities depends on availability, local"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "size, and all valves are evaluated for anatomic and expertise, patient characteristics, indication, and"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "flow abnormalities. Guidelines also provide recom- goal of limiting radiation exposure. CMR provides"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "mendations for diastolic function and estimates an accurate and highly reproducible assessment"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "of LV filling and left atrial pressure.42 The tricus- of cardiac volumes, mass, and EF of the left and"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "pid valve regurgitant gradient, coupled with inferior right ventricles.8–10 CMR provides high anatomic"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "vena cava diameter and its response during respi- resolution of all aspects of the heart and surround-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "ration, provides estimates of systolic PA pressure ing structures and is not associated with ioniz-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "and central venous pressure. Indices of myocardial ing radiation, leading to its recommended use in"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "deformation, such as global longitudinal strain, may known or suspected congenital heart diseases.11,61"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "identify subclinical LV systolic dysfunction, which Electrocardiographic-gated cardiac CT can also"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "has been associated with greater risk of developing accurately assess ventricular size, EF, and wall"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "HF or recurrent HF hospitalizations.38,43–46 Given motion abnormalities, but it is accompanied with"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "the widespread availability, lack of ionizing radia- ionizing radiation.13–15 Radionuclide ventriculog-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "tion, and wealth of provided information, echocar- raphy is highly reproducible for measurement of"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "diography is the preferred initial imaging modality LVEF, although it also exposes the patient to ion-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "for evaluation of patients with suspected HF. Point- izing radiation.12"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "of-care cardiac ultrasound is an evolving tool for 5. CMR provides noninvasive characterization of the"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "assessment of cardiac function and assessment of myocardium that may provide insights into HF"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "volume status and pulmonary congestion.47–52 cause.62 Late-gadolinium enhancement, reflect-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "3. Serial echocardiograms to assess changes in ing fibrosis and damaged myocardium, can iden-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "EF, structural remodeling, and valvular function, tify acute and chronic MI.63,64 and identify HF"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "although not recommended routinely in stable caused by CAD65,66 Patterns of late-gadolinium"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "patients, are useful in various situations. In patients enhancement or specific T-1 and T-2 techniques"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "who have an unexplained, significant change can suggest specific infiltrative and inflammatory"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "in clinical status, echocardiography can provide cardiomyopathies, such as myocarditis, sarcoid-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "important information, such as worsening ven- osis, Fabry disease, Chagas disease, noncom-"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "tricular or valvular function. A subset of patients paction, iron overload, and amyloidosis.16,20,22,67"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "may also have reverse remodeling, improvement T-1 mapping techniques allow for measurement"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 20,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e915"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "of interstitial space characteristics and extracel- 4.5. Invasive Evaluation"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "lular volume fraction and provides diagnostic and"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "prognostic information.19,21–23,68–71 The presence Recommendations for Invasive Evaluation"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "of delayed hyperenhancement has been associ-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "ated with worse outcomes and can provide risk"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "stratification.72–77 Although registry data show"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "1. In patients with HF, endomyocardial biopsy"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "that CMR findings commonly impact patient care"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "2a B-NR may be useful when a specific diagnosis is sus-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "management and provide diagnostic information pected that would influence therapy.1,2"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "in patients with suspected myocarditis or cardio-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "2. In selected patients with HF with persistent or"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "myopathy,17,18 a strategy of routine screening with worsening symptoms, signs, diagnostic param-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "CMR in patients with nonischemic cardiomyopathy 2a C-EO eters, and in whom hemodynamics are uncer-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "tain, invasive hemodynamic monitoring can be"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "was not shown to yield more specific HF causes"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "useful to guide management."
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "than a strategy of selective CMR strategy based"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "3. In patients with HF, routine use of invasive"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "on echocardiographic and clinical findings in a 3: No"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "B-R hemodynamic monitoring is not recom-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Benefit"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "recent trial.78 mended.3,4"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "6. HF is often caused by coronary atherosclerosis,79 4. For patients undergoing routine evaluation of"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "and evaluation for ischemic heart disease can help 3: Harm C-LD HF, endomyocardial biopsy should not be per-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "formed because of the risk of complications.5,6"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "in determining the presence of significant coronary"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "artery disease (CAD). Noninvasive stress imag-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "ing with echocardiography or nuclear scintigraphy Synopsis"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "can be helpful in identifying patients likely to have"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Invasive evaluation of patients with HF may provide"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "obstructive CAD.24,25 Invasive or computed tomog-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "important clinical information to determine the cause"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "raphy coronary angiography can detect and char-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "of HF and treatment options. Routine right heart cath-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "acterize extent of CAD.26,27"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "eterization does not provide sufficient information to"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "7. CAD is a leading cause of HF79 and myocardial"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "guide treatment decisions.3,4 However, hemodynamic"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "ischemia may contribute to new or worsening HF"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "evaluation with right heart catheterization and moni-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "symptoms. Noninvasive testing (ie, stress echo-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "toring in the setting of acute respiratory distress, sys-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "cardiography, SPECT, CMR, or PET) may be con-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "temic hypoperfusion including cardiogenic shock, or"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "sidered for detection of myocardial ischemia to"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "when hemodynamics are uncertain, may guide treat-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "help guide coronary revascularization decisions."
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "ment decisions. Coronary angiography may be useful"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Multiple nonrandomized, observational studies"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "in patients who are candidates for revascularization7–9"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "have reported improved survival with revascular-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "(see Section 4.4, “Evaluation with Cardiac Imaging,” for"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "ization in patients with viable but dysfunctional"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "recommendations). Endomyocardial biopsy may be ad-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "myocardium.28,30–32 Despite these observational"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "vantageous in patients with HF in which a histological"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "data, RCTs have not shown that viability imag-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "diagnosis, such as amyloidosis or myocarditis, may in-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "ing improves guidance of revascularization"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "fluence treatment decisions.1,2"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "to a reduction of adverse cardiovascular out-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "comes.80–82 A prespecified viability substudy"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "of the STICH (Surgical Treatment for Ischemic"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Heart Failure) trial showed that the presence of"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "myocardial viability did not determine the long- 1. Endomyocardial biopsy may be useful when seeking"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "term benefit from surgical revascularization in a specific diagnosis that would influence treatment,"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "patients with ischemic cardiomyopathy.81,82 Of and biopsy should thus be considered in patients"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "note, a relatively small number of individuals with rapidly progressive clinical HF or worsening"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "enrolled in the STICH substudy did not have ventricular dysfunction that persists despite appro-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "viability, which may limit the power of the study. priate medical treatment. Endomyocardial biopsy"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Although these data do not support the concept should also be considered in patients suspected"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "of routine viability assessment before revascu- of having acute cardiac rejection status after heart"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "larization, myocardial viability is used as one of transplantation or having myocardial infiltrative"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "the tools to inform decisions regarding revas- processes. A specific example is to determine"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "cularization in patients with high surgical risk or treatment for light chain (AL) amyloidosis or trans-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "with complex medical problems. thyretin amyloidosis.5 Additional indications for"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "8. Repeat noninvasive imaging of cardiac struc- endomyocardial biopsy include patients with rap-"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "ture and function for routine surveillance is rarely idly progressive and unexplained cardiomyopathy"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "appropriate in the absence of a change in clinical and those in whom active myocarditis, especially"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "status or treatment interventions.11,83 giant cell myocarditis, is being considered.1"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 21,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "e916 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "2. Right-heart catherization in patients in Synopsis"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "acute HF. The ESCAPE (Evaluation Study"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "HF is a chronic condition punctuated by periods of insta-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "of Congestive Heart Failure and Pulmonary"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "bility. Despite close longitudinal monitoring via in-person"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Artery Catheterization Effectiveness) trial found"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "visits, event rates remain high, affording a potential role for"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "that routine use of PA catheter monitoring"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "remote monitoring strategies to improve clinical outcomes."
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "for patients with HF did not provide benefit.3"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Strategies tested in randomized trials include an implant-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "However, invasive hemodynamic evaluation or"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "able PA pressure sensor (CardioMEMS), noninvasive tele-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "monitoring can be useful to guide management"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "monitoring, or monitoring via existing implanted electronic"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "in carefully selected patients with acute HF"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "devices (ICDs or CRT-Ds). Results from a single random-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "who have persistent symptoms despite treat-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "ized trial,1–3 and subsequent observational studies,8–10 sup-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "ment. This includes patients whose fluid status,"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "port consideration of an implantable PA sensor in selected"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "perfusion, or systemic or pulmonary vascular"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "patients with HF to reduce the risk of HF hospitalization."
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "resistance is uncertain whose systolic blood"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "In contrast, a recent trial testing a PA pressure sensor did"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "pressure (SBP) remains low, or is associated"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "not meet its primary endpoint.4 Results from previous clini-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "with symptoms, despite initial treatment; whose"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "cal trials do not support the alternative remote monitoring"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "renal function is worsening with therapy; or who"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "strategies (eg, noninvasive telemonitoring or remote moni-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "require parenteral vasoactive agents."
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "toring of physiological parameters such as patient activity,"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "3. There has been no established role for routine"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "thoracic impedance, heart rate) for this purpose.11–18"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "or periodic invasive hemodynamic measure-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "ments in the management of HF. Most drugs"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "used to treat HF are prescribed on the basis Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "of their ability to improve symptoms or survival"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "1. The CHAMPION (CardioMEMS Heart Sensor"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "rather than their effect on hemodynamic vari-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Allows Monitoring of Pressure to Improve Outcomes"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "ables. The initial and target doses of these drugs"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "in NYHA Class III Heart Failure patients) trial"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "are generally selected on the basis of controlled"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "reported a significant 28% reduction of HF-related"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "trial experience rather than changes produced"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "hospitalizations after 6 months in patients random-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "in cardiac output or pulmonary capillary wedge"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "ized to an implanted PA pressure monitor compared"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "pressure.3,4"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "with a control group.1 Patients had to have a HF"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "4. Patients with HF should not undergo routine endo-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "hospitalization in the previous year and be on stable"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "myocardial biopsy because of the risk of complica-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "doses of a beta blocker and angiotensin-converting"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "tions that include perforation, cardiac tamponade,"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "enzyme inhibitor (ACEi) (or angiotensin (II) recep-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "and thrombus formation, as well as limited diag-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "tor blocker [ARB]) if tolerated. The clinical benefit"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "nostic yield.5,6"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "persisted after longer term follow-up and was seen"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "in both subjects with reduced3 and preserved2 LVEF."
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "4.6. Wearables and Remote Monitoring However, CHAMPION was a nonblinded trial, and"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "(Including Telemonitoring and Device there was differential contact of study personnel with"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "patients in the treatment arm, raising methodologi-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Monitoring)"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "cal concerns about the opportunity for bias to have"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Recommendation for Wearables and Remote Monitoring (Including influenced its results.19–21 In the recent GUIDE-HF"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Telemonitoring and Device Monitoring) (Haemodynamic-GUIDEed management of Heart"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendation are summarized"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Failure) study, hemodynamic-guided management"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "in the Online Data Supplements."
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "of patients with NYHA class II to IV heart failure did"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "not significantly reduce the composite endpoint rate"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "1. In selected adult patients with NYHA class of mortality and total HF events.4 The usefulness of"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "III HF and history of a HF hospitalization in"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "the past year or elevated natriuretic peptide noninvasive telemonitoring11,12,22,23 or remote moni-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "levels, on maximally tolerated stable doses of toring of physiological parameters13–18 (eg, patient"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "2b B-R GDMT with optimal device therapy, the use-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "activity, thoracic impedance, heart rate) via implanted"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "fulness of wireless monitoring of PA pressure"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "by an implanted hemodynamic monitor to electrical devices (ICDs or CRT-Ds) to improve clini-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "reduce the risk of subsequent HF hospitaliza- cal outcomes remains uncertain. Further study of"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "tions is uncertain.1–4"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "these approaches is needed before they can be"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "2. In patients with NYHA class III HF with a HF recommended for routine clinical care."
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Value Statement: hospitalization within the previous year, wireless"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "2. Three model-based studies5–7 have evaluated the"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Uncertain Value monitoring of the PA pressure by an implanted"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "(B-NR) hemodynamic monitor provides uncertain cost-effectiveness of wireless PA pressure monitor-"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "value.4–7 ing using data from the CHAMPION-HF1 study of"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 22,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e917"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "the CardioMEMS device. All 3 studies estimated their HF. NYHA class II includes patients who are"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "CardioMEMS implantation and monitoring increased comfortable at rest but have slight symptoms result-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "survival and quality-adjusted life year (QALY) while ing from HF (dyspnea, fatigue, lightheadedness) with"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "increasing costs. Primarily based on differences ordinary activity. NYHA class III includes patients"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "regarding the expected magnitude of clinical benefit, who are comfortable at rest but have symptoms of"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2 analyses5,7estimated the device provided high value HF with less than ordinary activity. NYHA class IV"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "while the third6 estimated intermediate value. These includes patients who are unable to carry out any"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "analyses had several important differences detailed physical activity without symptoms and have symp-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "in the evidence tables, including the model duration, toms at rest. NYHA functional classification has"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "QOL data, cost estimates, and assumptions regarding been widely used in clinical practice, clinical trials,"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "mortality. One analysis6 found the economic value of and clinical practice guidelines to determine candi-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "CardioMEMS implantation was highly dependent on dacy for drug and device therapy. Limitations include"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "its effect on mortality and duration of treatment ben- its ability to be inconsistently assessed from 1 clini-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "efit, both of which remain unclear. Cost-effectiveness cian to another, resulting in poor reproducibility.23"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "studies incorporating data from GUIDE-HF4 have 2. Many CPET variables have been associated with"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "not been published. Additional data regarding clinical prognosis in patients with HF.4,5,12,14,16,24 Peak exer-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "outcomes following CardioMEMS implantation will cise oxygen consumption/oxygen uptake (VO ) is"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "improve estimates of its economic value. often used to risk stratify patients and make deci-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "sions about timing of advanced HF therapies, includ-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "ing heart transplantation and LVAD. In a landmark"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "4.7. Exercise and Functional Capacity Testing article,7 investigators divided patients referred for"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "heart transplantation into groups based on their peak"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "Recommendations for Exercise and Functional Capacity Testing"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "VO .7 Patients with peak VO <14 mL/kg/min were"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa- 2 2"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements. listed for transplant, while those with higher peak VO"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "values were deferred for being too well. Patients with"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "peak VO >14 mL/kg/min who were deferred had"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "1. In patients with HF, assessment and documen- 2"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "tation of NYHA functional classification are 1- and 2-year survival of 94% and 84%, respectively,"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "1 C-LD"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "recommended to determine eligibility for treat- which was similar to survival after heart transplant."
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "ments.1–3"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "As such, the authors proposed peak VO ≤14 mL/"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2. In selected ambulatory patients with HF, kg/min as a cutoff to distinguish patients who may"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "cardiopulmonary exercise testing (CPET) is"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "derive survival benefit from heart transplant.7 Patients"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "1 C-LD recommended to determine appropriateness"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "of advanced treatments (eg, LVAD, heart tolerating beta blockers may have improved survival"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "transplant).4–8 with an equivalent VO compared with patients who"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "3. In ambulatory patients with HF, performing a do not tolerate beta blockers.25,26 For patients on"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2a C-LD CPET or 6-minute walk test is reasonable to beta blockers, a peak VO ≤12 mL/kg/min has been"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "assess functional capacity.4,5,9–16 2"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "suggested as a more appropriate cutoff to consider"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "4. In ambulatory patients with unexplained dys-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "cardiac transplant listing.8"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2a C-LD pnea, CPET is reasonable to evaluate the"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "cause of dyspnea.17,18 3. Objective assessment of exercise capacity with"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "CPET can be useful in the clinical management"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "of patients with HF. Although CPET remains the"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "gold standard measure of exercise capacity, limita-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "Functional impairment and exercise intolerance are com- tions to more widespread use include need for spe-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "mon in HF. CPET and the 6-minute walk test are standard- cial equipment and trained personnel, which leads"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "ized, reliable, and reproducible tests to quantify functional to lack of availability at many hospitals and clinics."
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "capacity.19–22 The NYHA functional classification can be Furthermore, it is not well tolerated by some patients."
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "used to grade the severity of functional limitation based on The 6-minute walk test is an alternative way to mea-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "patient report of symptoms experienced with activity1 and sure exercise capacity that is widely available and"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "is used to define candidates for certain treatments. well tolerated by patients. It entails walking for 6"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "minutes on a measured flat course, and patients are"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "allowed to slow down or stop if needed. A system-"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "atic review of 14 studies found that the 6-minute"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "1. NYHA functional classification is an ordinal, categor- walk test results correlated moderately with peak"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "ical variable (I-IV) that is used to document functional VO levels and were a reliable and valid indicator"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "limitation in patients with cardiac disease, including of functional capacity in patients with HF who did"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "HF.1 In HF, NYHA functional class I includes patients not walk >490 m.8 Distance walked in the 6-minute"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "with no limitations in physical activity resulting from walk test has been associated with prognosis in HF"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 23,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "e918 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "across multiple studies.9–13,15,16,27 A cutoff of <300 Table 8. Selected Multivariable Risk Scores to Predict"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "m roughly correlates to patients with NYHA class III Outcome in HF"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "to IV symptoms and is associated with worse 3-year"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Year"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "survival free of heart transplant (62% versus 82% Risk Score Reference/Link Published"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "for those walking ≥300 m).27 Chronic HF"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "4. Dyspnea is a complex symptom that can reflect"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "All Patients With Chronic HF"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "abnormalities in a number of different systems"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Seattle Heart Failure Model 2 2006"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "and can be influenced by psychological and envi- https://depts.washing-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "ronmental factors. CPET involves having patients ton.edu/shfm/?width"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "=1440&height=900"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "perform a treadmill (or stationary bicycle) exer-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "15"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "cise test, while also performing ventilatory gas"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Heart Failure Survival Score 1 1997"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "exchange measurements.28 CPET enables the"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "comprehensive assessment of multiple physiologi- MAGGIC 3 2013"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "http://www.heartfailure-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "cal measures that can impact exercise capacity and"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "risk.org/"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "contribute to dyspnea. It provides analysis of gas 16"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "exchange and yields measures of oxygen uptake CHARM Risk Score 4 2006"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "(VO ), carbon dioxide output, and ventilation. These"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "2 CORONA Risk Score 5 2009"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "measures can be integrated with standard exercise"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Specific to Chronic HFrEF"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "testing variables, such as heart rate, blood pres-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "PARADIGM-HF 6 2020"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "sure, electrocardiographic findings, and symptoms"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "to provide insights into the physiologic mechanisms HF-ACTION 7 2012"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "underlying a patient’s dyspnea. In particular, CPET GUIDE-IT 8 2019"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "can help to distinguish respiratory versus cardiac Specific to Chronic HFpEF"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "etiologies of dyspnea. If exercise capacity is dimin-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "I-PRESERVE Score 9 2011"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "ished but cardiopulmonary responses are normal,"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "TOPCAT 10 2020"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "other causes of dyspnea, such as metabolic abnor-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Acutely Decompensated HF"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "malities and deconditioning, should be considered."
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "ADHERE Classification and Re- 11 2005"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "gression Tree (CART) Model"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "4.8. Initial and Serial Evaluation: Clinical AHA Get With The Guidelines 12 2010, 2021"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Assessment: HF Risk Scoring Score https://www.mdcalc."
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "com/gwtg-heart-failure-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "risk-score"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Recommendation for Initial and Serial Evaluation: Clinical Assessment: 17"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "HF Risk Scoring"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendation are summarized EFFECT Risk Score 13 2003, 2016"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "in the Online Data Supplements. http://www.ccort.ca/"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Research/CHFRisk-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation Model.aspx"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "1. In ambulatory or hospitalized patients with HF, 18"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "2a B-NR validated multivariable risk scores can be useful ESCAPE Risk Model and 14 2010"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "to estimate subsequent risk of mortality.1–14 Discharge Score"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "ADHERE indicates Acute Decompensated Heart Failure National Registry;"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Synopsis AHA, American Heart Association; ARIC, Atherosclerosis Risk in Communi-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "ties; CHARM, Candesartan in Heart failure-Assessment of Reduction in Mor-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Clinicians should routinely assess a patient’s risk for an tality and morbidity; CORONA, Controlled Rosuvastatin Multinational Trial in"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Heart Failure; EFFECT, Enhanced Feedback for Effective Cardiac Treatment;"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "adverse outcome to guide discussions on prognosis,"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "ESCAPE, Evaluation Study of Congestive Heart Failure and Pulmonary Artery"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "goals of care, and treatment decisions. Several predictive Catheterization Effectiveness; GUIDE-ID, Guiding Evidence-Based Therapy"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "models of outcomes of patients with HF have been de- Using Biomarker Intensified Treatment; HF, heart failure; HFpEF, heart failure"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "with preserved ejection fraction; HF-ACTION, Heart Failure: A Controlled Trial"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "veloped and validated using data from clinical trials, regis-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Investigating Outcomes of Exercise Training MAGGIC Meta-analysis Global"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "tries, and population-based cohorts. The best performing Group in Chronic Heart Failure; I-PRESERVE, Irbesartan in Heart Failure with"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "models have focused on predicting short- and long-term Preserved Ejection Fraction Study; PCP-HF, Pooled Cohort Equations to Pre-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "vent HF; and TOPCAT, Treatment of Preserved Cardiac Function Heart Failure"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "mortality, whereas predictive models for hospitalization or"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "with an Aldosterone Antagonist trial."
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "readmission for HF have generally had poor or modest"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "discrimination. Predictive models may also assess the risk risk stratification may help guide therapeutic decision-"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "of incident HF among the general population and should making, including a more rapid transition to advanced"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "be considered in the prevention of HF. In the course of HF therapies. Several methods objectively assess risk"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "standard evaluation, clinicians should routinely assess the (Table 8), including biomarker testing, as well as various"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "patient’s potential for adverse outcome, because accurate multivariable clinical risk scores, and some that include"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 24,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 24,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Risk Score": "Chronic HF",
                "Reference/Link": "",
                "Year Published": ""
            },
            {
                "Risk Score": "All Patients With Chronic HF",
                "Reference/Link": "",
                "Year Published": ""
            },
            {
                "Risk Score": "Seattle Heart Failure Model",
                "Reference/Link": "2 https://depts.washing- ton.edu/shfm/?width =1440&height=900 15",
                "Year Published": "2006"
            },
            {
                "Risk Score": "Heart Failure Survival Score",
                "Reference/Link": "1",
                "Year Published": "1997"
            },
            {
                "Risk Score": "MAGGIC",
                "Reference/Link": "3 http://www.heartfailure- risk.org/ 16",
                "Year Published": "2013"
            },
            {
                "Risk Score": "CHARM Risk Score",
                "Reference/Link": "4",
                "Year Published": "2006"
            },
            {
                "Risk Score": "CORONA Risk Score",
                "Reference/Link": "5",
                "Year Published": "2009"
            },
            {
                "Risk Score": "Specific to Chronic HFrEF",
                "Reference/Link": "",
                "Year Published": ""
            },
            {
                "Risk Score": "PARADIGM-HF",
                "Reference/Link": "6",
                "Year Published": "2020"
            },
            {
                "Risk Score": "HF-ACTION",
                "Reference/Link": "7",
                "Year Published": "2012"
            },
            {
                "Risk Score": "GUIDE-IT",
                "Reference/Link": "8",
                "Year Published": "2019"
            },
            {
                "Risk Score": "Specific to Chronic HFpEF",
                "Reference/Link": "",
                "Year Published": ""
            },
            {
                "Risk Score": "I-PRESERVE Score",
                "Reference/Link": "9",
                "Year Published": "2011"
            },
            {
                "Risk Score": "TOPCAT",
                "Reference/Link": "10",
                "Year Published": "2020"
            },
            {
                "Risk Score": "Acutely Decompensated HF",
                "Reference/Link": "",
                "Year Published": ""
            },
            {
                "Risk Score": "ADHERE Classification and Re- gression Tree (CART) Model",
                "Reference/Link": "11",
                "Year Published": "2005"
            },
            {
                "Risk Score": "AHA Get With The Guidelines Score",
                "Reference/Link": "12 https://www.mdcalc. com/gwtg-heart-failure- risk-score 17",
                "Year Published": "2010, 2021"
            },
            {
                "Risk Score": "EFFECT Risk Score",
                "Reference/Link": "13 http://www.ccort.ca/ Research/CHFRisk- Model.aspx 18",
                "Year Published": "2003, 2016"
            },
            {
                "Risk Score": "ESCAPE Risk Model and Discharge Score",
                "Reference/Link": "14",
                "Year Published": "2010"
            }
        ],
        "conteudo_texto": "Chronic HF, ,  | All Patients With Chronic HF, ,  | Seattle Heart Failure Model, 2 https://depts.washing- ton.edu/shfm/?width =1440&height=900 15, 2006 | Heart Failure Survival Score, 1, 1997 | MAGGIC, 3 http://www.heartfailure- risk.org/ 16, 2013 | CHARM Risk Score, 4, 2006 | CORONA Risk Score, 5, 2009 | Specific to Chronic HFrEF, ,  | PARADIGM-HF, 6, 2020 | HF-ACTION, 7, 2012 | GUIDE-IT, 8, 2019 | Specific to Chronic HFpEF, ,  | I-PRESERVE Score, 9, 2011 | TOPCAT, 10, 2020 | Acutely Decompensated HF, ,  | ADHERE Classification and Re- gression Tree (CART) Model, 11, 2005 | AHA Get With The Guidelines Score, 12 https://www.mdcalc. com/gwtg-heart-failure- risk-score 17, 2010, 2021 | EFFECT Risk Score, 13 http://www.ccort.ca/ Research/CHFRisk- Model.aspx 18, 2003, 2016 | ESCAPE Risk Model and Discharge Score, 14, 2010"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e919"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "machine learning.1–14 These risk scores are for use in am- ACC primary prevention guidelines provide recommen-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "bulatory, hospitalized patients, and the general population. dations for diet, physical activity, and weight control, all"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "of which have been associated with the risk of HF.28"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text Blood pressure is an important risk factor for HF, and a"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "treatment goal of <130/80 mm Hg is recommended for"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "1. For HF, there are several clinical models to consider"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "those with a CVD risk of ≥10%.29,30 Multiple RCTs have"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "that include the spectrum of HF based on EF and clin-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "found that patients with diabetes and CVD without HF"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "ical setting. For chronic HF, the Seattle Heart Failure"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "have improved survival and reduced HF hospitalizations"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Model,2 the Heart Failure Survival score,1 and the"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "with SGLT2i.31 Patients at risk for HF screened with BNP"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "MAGGIC score3 have commonly been used to provide"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "or NT-proBNP followed by collaborative care, diagnostic"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "estimates of survival. The MAGGIC predictive model"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "evaluation, and treatment in those with elevated levels"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "may be quite useful given its derivation and valida-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "can reduce combined rates of LV systolic dysfunction,"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "tion across multiple clinical trials and cohorts, includ-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "diastolic dysfunction, and HF.22,23 See Figure 5 for COR 1"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "ing more recent studies. For chronic HFrEF, there are"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "and 2a for stage A (at risk for HF) and stage B (pre-HF)."
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "additional models that include other clinical variables,"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "including exercise capacity7 and natriuretic peptide"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "levels.8 Likewise, for chronic HFpEF there are more"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "specific predictive models for that population derived"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "from clinical trial data.9,10 In acute HF, several clinical 1. Elevated systolic and diastolic blood pressure are"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "models may be used to predict short-term survival.11–13 major risk factors for the development of symp-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "tomatic HF.8,9,32 Many trials have shown that hyper-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "tension control reduces the risk of HF.1–7 Although"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "5. STAGE A (PATIENTS AT RISK FOR HF)"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "the magnitude of benefit varies with the patient"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "5.1. Patients at Risk for HF (Stage A: Primary population, target blood pressure reduction, and"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "HF criteria, effective hypertension treatment invari-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Prevention)"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "ably reduces HF events. In the SPRINT (Systolic"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Recommendations for Patients at Risk for HF (Stage A: Primary Blood Pressure Intervention Trial) trial, control to"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Prevention) an SBP goal <120 mm Hg decreased incident"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "HF by 38% and mortality by 23% compared with"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "summarized in the Online Data Supplements."
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "an SBP goal of <140 mm Hg6,7 A meta-analysis"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "showed that blood pressure control was associ-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "1. In patients with hypertension, blood pressure"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "ated with an approximately 40% reduction in HF"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "1 A should be controlled in accordance with GDMT"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "for hypertension to prevent symptomatic HF.1–9 events.5 Therefore, SBP and diastolic blood pres-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "sure should be controlled in accordance with pub-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "2. In patients with type 2 diabetes and either"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "established CVD or at high cardiovascular risk, lished clinical practice guidelines.30"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "1 A"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "SGLT2i should be used to prevent hospitaliza- 2. Multiple RCTs in patients with type 2 diabetes and"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "tions for HF.10–12"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "at risk for, or with established CVD or at high risk for"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "3. In the general population, healthy lifestyle hab- CVD, have shown that SGLT2i prevent HF hospital-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "its such as regular physical activity, maintaining"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "izations compared with placebo.10–12 The benefit for"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "1 B-NR normal weight, healthy dietary patterns, and"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "avoiding smoking are helpful to reduce future reducing HF hospitalizations in these trials predomi-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "risk of HF.13–21 nantly reflects primary prevention of symptomatic HF,"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "4. For patients at risk of developing HF, natriuretic because only approximately 10% to 14% of partici-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "peptide biomarker–based screening followed"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "pants in these trials had HF at baseline. The mecha-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "by team-based care, including a cardiovascular"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "2a B-R specialist optimizing GDMT, can be useful to nisms for the improvement in HF events have not"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "prevent the development of LV dysfunction been clearly elucidated but seem to be independent"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "(systolic or diastolic) or new-onset HF.22,23"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "of glucose lowering. Proposed mechanisms include"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "5. In the general population, validated multivari- reductions in plasma volume, cardiac preload and"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "2a B-NR able risk scores can be useful to estimate sub-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "afterload, alterations in cardiac metabolism, reduced"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "sequent risk of incident HF.24–26"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "arterial stiffness, and interaction with the Na+/H+"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "exchanger.33,34 SGLT2i are generally well tolerated,"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "but these agents have not been evaluated in those"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Healthy lifestyle habits such as maintaining regular phys- with severe renal impairment (estimated glomerular"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "ical activity; normal weight, blood pressure, and blood filtration rate [eGFR] <25 mL/min/1.73 m2).35"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "glucose levels; healthy dietary patterns, and not smok- 3. Greater adherence to healthy lifestyle habits"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "ing reduce primordial risk and have been associated with such as regular physical activity, avoiding obe-"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "a lower lifetime risk of developing HF.13–21,27 The AHA/ sity, maintaining normal blood pressure and"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 25,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "e920 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "Figure 5. Recommendations (Class 1 and 2a) for Patients at Risk of HF (Stage A) and Those With Pre-HF (Stage B)."
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "Colors correspond to COR in Table 2. COR 1 and COR 2a for patients at risk for HF (stage A) and those with pre-HF (stage B) are shown."
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "Management strategies implemented in patients at risk for HF (stage A) should be continued though stage B. ACEi indicates angiotensin-"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; COR, Class of Recommendation; CVD, cardiovascular"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "disease; HF, heart failure; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MI, myocardial infarction; and SGLT2i,"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "sodium glucose cotransporter 2 inhibitor."
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "blood glucose, not smoking, and healthy dietary 4. A large-scale unblinded single-center study"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "patterns have been associated with a lower life- (STOP-HF [The St Vincent’s Screening to Prevent"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "time risk of HF and greater preservation of car- Heart Failure])22 of patients at risk of HF (identi-"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "diac structure.13–16,27 Healthful eating patterns, fied by the presence of hypertension, diabetes, or"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "particularly those that are based more on con- known vascular disease) but without established"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "sumption of foods derived from plants, such as LV systolic dysfunction or symptomatic HF at base-"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "the Mediterranean, whole grain, plant-based line found that screening with BNP testing and"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "diet and the DASH (Dietary Approaches to Stop then intervening on those with levels of ≥50 pg/"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "Hypertension) diet, are inversely associated with mL (performing echocardiography and referral to"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "incident HF and may offer some protection against a cardiovascular specialist) reduced the composite"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "HF development.17–21 endpoint of asymptomatic LV dysfunction (systolic"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 26,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e921"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Table 9. Selected Multivariable Risk Scores to Predict De-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Recommendations for Management of Stage B: Preventing the"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "velopment of Incident HF"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Syndrome of Clinical HF in Patients With Pre-HF (Continued)"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Risk Score Reference Year Published COR LOE Recommendations"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Framingham Heart Failure Risk Score 24 1999 2. In patients with a recent or remote history of"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "MI or ACS, statins should be used to prevent"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Health ABC Heart Failure Score 25 2008 1 A"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "symptomatic HF and adverse cardiovascular"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "ARIC Risk Score 26 2012 events.5–9"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "PCP-HF 29 2019 3. In patients with a recent MI and LVEF ≤40%"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "who are intolerant to ACEi, ARB should be used"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "ARIC indicates Atherosclerosis Risk in Communities; HF, heart failure; and 1 B-R to prevent symptomatic HF and reduce mortal-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "PCP-HF, Pooled Cohort Equations to Prevent HF. ity.10"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "4. In patients with a recent or remote history of MI"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "or diastolic) with or without newly diagnosed HF.22"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "or acute coronary syndrome (ACS) and LVEF"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Similarly, in another small, single-center RCT, 1 B-R ≤40%, evidence-based beta blockers should"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "accelerated uptitration of RAAS antagonists and be used to reduce mortality.11–13"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "beta blockers reduced cardiac events in patients 5. In patients who are at least 40 days post-MI"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "with diabetes and elevated NT-proBNP levels but with LVEF ≤30% and NYHA class I symptoms"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "while receiving GDMT and have reasonable"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "without cardiac disease at baseline.23"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "1 B-R expectation of meaningful survival for >1 year,"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "5. Incident HF may be predicted from different mod- an ICD is recommended for primary prevention"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "els, including those derived from diverse populations of sudden cardiac death (SCD) to reduce total"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "mortality.14"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "(Table 9). The PCP-HF (Pooled Cohort equations"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "6. In patients with LVEF ≤40%, beta blockers"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "to Prevent HF) model provides race- and sex- 1 C-LD"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "should be used to prevent symptomatic HF.12,13"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "specific 10-year risk equations from 7 community-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "7. In patients with LVEF <50%, thiazolidinediones"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "based cohorts with at least 12 years of follow-up.29"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "3: Harm B-R should not be used because they increase the"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Predictors of HF included in the race- and sex-spe- risk of HF, including hospitalizations.15"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "cific models were age, blood pressure (treated or"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "8. In patients with LVEF <50%, nondihydropyri-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "untreated), fasting glucose (treated or untreated), 3: Harm C-LD dine calcium channel blockers with negative"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "body mass index, cholesterol, smoking status, and inotropic effects may be harmful.16,17"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "QRS duration. Models can be applied to the clinical"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "setting of interest, with clinical trial models potentially Synopsis"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "less generalizable to registry- or population-based"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "In general, all recommendations for patients with stage"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "models. In addition, predictive models provide the"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "A HF also apply to those with stage B HF. Stage B (pre-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "average estimate of risk derived from a population,"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "HF) represents a phase of clinically asymptomatic struc-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "and individual risk may vary.36 The integration of risk"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "tural and functional cardiac abnormalities that increases"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "scores into clinical practice have shown improved"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "the risk for symptomatic HF.18–21 Identifying individu-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "outcomes. As data generation increases from elec-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "als with stage B HF provides an opportunity to initiate"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "tronic health records and digital sources, advanced"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "lifestyle modification and pharmacological therapy that"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "methods with machine learning are expected to pro-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "may prevent or delay the transition to symptomatic HF"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "liferate the development of risk prediction models."
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "(stage C/D). Several ACC/AHA clinical practice guide-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Machine learning models are often not externally"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "lines address appropriate management of patients with"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "validated, and their performance may vary based on"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "stage B HF (Table 10). Although multiple studies high-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "the population and clinical setting.37 Patient popula-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "light the increased HF risk associated with asymptomatic"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "tions change over time, and models may need to be"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "LV systolic19,20,22–26 and diastolic dysfunction identified by"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "recalibrated periodically."
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "noninvasive imaging,19,26–30 beneficial pharmacotherapy"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "for asymptomatic LV systolic dysfunction, such as inhibi-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "6. STAGE B (PATIENTS WITH PRE-HF) tors of the renin-angiotensin system and beta blockers,"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "have been predominantly observed in individuals with"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "6.1. Management of Stage B: Preventing the depressed LVEF (LVEF <35%–40%).1–4,11–13 Studies of"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Syndrome of Clinical HF in Patients With Pre-HF specific treatments to alter the onset of HF in the set-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "ting of asymptomatic cardiac dysfunction with preserved"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Recommendations for Management of Stage B: Preventing the"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "LVEF (eg, abnormalities of myocardial deformation or"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Syndrome of Clinical HF in Patients With Pre-HF"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are diastolic dysfunction) have been limited. Several comor-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "summarized in the Online Data Supplements. bid conditions, including diabetes, obesity, and hyperten-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations sion, have been associated with asymptomatic LV dys-"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "function27,28,30,31 and with progression of asymptomatic"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "1. In patients with LVEF ≤40%, ACEi should be"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "1 A used to prevent symptomatic HF and reduce LV dysfunction to symptomatic HF.27 Accordingly, these"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "mortality.1–4 comorbidities are controlled according to current clinical"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 27,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "e922 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Table 10. Other ACC/AHA Clinical Practice Guidelines Addressing Patients With Stage B HF"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Consideration Reference"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Patients with an acute MI who have not developed HF 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction51"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "symptoms treated in accordance with GDMT 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coro-"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "nary Syndromes52"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Coronary revascularization for patients without symptoms of 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Pa-"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "HF in accordance with GDMT tients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "of ST-Elevation Myocardial Infarction53 (This guideline has been replaced by Lawton, 2021.54)"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Management of Patients With Stable Ischemic Heart Disease55"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery56 (This guideline has been"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "replaced by Lawton, 2021.54)"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Valve replacement or repair for patients with hemodynamically 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease.57,58"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "significant valvular stenosis or regurgitation and no symptoms"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "of HF in accordance with GDMT"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Patients with congenital heart disease that may increase the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease59"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "risk for the development of HF"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA,"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "American Heart Association; GDMT, guideline-directed medical therapy; HF, heart failure; MI, myocardial infarction; PCNA, Preventive Cardiovascular Nurses As-"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "sociation; SCAI, Society for Cardiovascular Angiography and Interventions; and STS, The Society of Thoracic Surgeons."
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "practice guidelines. The benefits of mineralocorticoid hospitalization.42 These data support the use of"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "receptor antagonists (MRA) after MI have mostly been statins to prevent symptomatic HF and cardiovas-"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "shown in patients with symptomatic HFrEF.32–34 cular events in patients with acute MI or ACS."
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "ARNi have not been well studied in stage B HF. 3. Two major trials have compared ARB with ACEi after"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "The PARADISE-MI (Prospective ARNi vs. ACE inhibi- MI. The VALIANT (Valsartan in Acute Myocardial"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "tor trial to DetermIne Superiority in reducing heart Infarction) trial, which included approximately 25% of"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "failure Events after Myocardial Infarction) study35 will patients with asymptomatic LV dysfunction, showed"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "report the efficacy and safety of sacubitril/valsartan in that the benefits of valsartan on mortality and other"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "patients after acute MI, with LVEF ≤40 and/or pulmo- adverse cardiovascular outcomes were compa-"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "nary congestion, plus an additional risk-enhancing fac- rable to captopril.10,38 In the OPTIMAAL (Optimal"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "tor, compared with ramipril. Trial in Myocardial Infarction with the Angiotensin"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "II Antagonist Losartan) trial, losartan did not meet"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "the noninferiority criteria for mortality compared with"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "captopril.39 It has been hypothesized that the lower"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "1. ACEi have been shown to impede maladaptive remod- dose of losartan (50 mg daily) in the OPTIMAAL"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "eling after acute MI in patients with reduced LVEF.36,37 trial may have contributed to the greater differ-"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "In survivors of acute MI with asymptomatic LV dys- ence than those seen with valsartan in VALIANT.40"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "function (LVEF <35%–40%), RCTs have shown No clinical trials have specifically evaluated ARB in"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "that ACEi reduced mortality, HF hospitalizations, and patients with asymptomatic reduced LVEF in the"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "progression to severe HF compared with placebo.2,4 absence of previous MI. Although ARB are alterna-"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Similarly, in those individuals with asymptomatic LV tives for patients with ACEi-induced angioedema,"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "dysfunction in the SOLVD (Studies of Left Ventricular caution is advised because some patients have also"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Systolic Dysfunction) prevention trial, which included developed angioedema with ARB."
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "approximately 20% without ischemic heart disease, 4. Current evidence supports the use of beta block-"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "enalapril was associated with reduced HF hospitaliza- ers to improve adverse cardiac remodeling and"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "tion and mortality compared with placebo.1,3 outcomes in patients with asymptomatic reduced"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "2. In multiple RCTs,42 statins have been shown to pre- LVEF after MI. Among patients with a recent MI"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "vent adverse CAD events in patients with an MI, and reduced LVEF, carvedilol reduced maladaptive"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "ACS, and with high cardiovascular risk. These trials remodeling41 and reduced mortality compared with"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "have also shown that statin therapy reduces the placebo.11 Among patients with asymptomatic LV"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "risk of incident HF.5–9 A meta-analysis of 6 RCTs systolic dysfunction in the SOLVD prevention trial"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "of >110 000 patients with an ACS showed that (which included 80% with previous MI) and the"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "intensive statin therapy reduced hospitalizations SAVE (Survival and Ventricular Enlargement) trial,"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "for HF.5 A subsequent, larger collaborative meta- secondary analyses showed that the administra-"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "analysis of up to 17 major primary and secondary tion of beta blockers in addition to ACEi reduced"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "prevention RCTs showed that statins reduced HF mortality and hospitalization.12,13"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 28,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 28,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Consideration": "Patients with an acute MI who have not developed HF symptoms treated in accordance with GDMT",
                "Reference": "2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction51 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coro- nary Syndromes52"
            },
            {
                "Consideration": "Coronary revascularization for patients without symptoms of HF in accordance with GDMT",
                "Reference": "2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Pa- tients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction53 (This guideline has been replaced by Lawton, 2021.54) 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease55 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery56 (This guideline has been replaced by Lawton, 2021.54)"
            },
            {
                "Consideration": "Valve replacement or repair for patients with hemodynamically significant valvular stenosis or regurgitation and no symptoms of HF in accordance with GDMT",
                "Reference": "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease.57,58"
            },
            {
                "Consideration": "Patients with congenital heart disease that may increase the risk for the development of HF",
                "Reference": "2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease59"
            }
        ],
        "conteudo_texto": "Patients with an acute MI who have not developed HF symptoms treated in accordance with GDMT, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction51 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coro- nary Syndromes52 | Coronary revascularization for patients without symptoms of HF in accordance with GDMT, 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Pa- tients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction53 (This guideline has been replaced by Lawton, 2021.54) 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease55 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery56 (This guideline has been replaced by Lawton, 2021.54) | Valve replacement or repair for patients with hemodynamically significant valvular stenosis or regurgitation and no symptoms of HF in accordance with GDMT, 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease.57,58 | Patients with congenital heart disease that may increase the risk for the development of HF, 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease59"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e923"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "5. The Framingham studies have shown a 60% patients with low LVEF, nondihydropyridine calcium"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "increased risk of death in patients with asymptomatic channel blockers may be harmful in this population"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "low LVEF compared with those with normal LVEF, because of their negative inotropic effects."
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "and almost half of these patients remained free"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "of HF before their death.25 MADIT-II (Multicenter"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "Automatic Defibrillator Implantation Trial II) showed 7. STAGE C HF"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "a 31% relative risk reduction in all-cause mortality"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "7.1. Nonpharmacological Interventions"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "in patients with post-MI with LVEF ≤30% receiv-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "ing a prophylactic ICD compared with standard 7.1.1. Self-Care Support in HF"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "of care.14 These findings provided justification for"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "Recommendations for Nonpharmacological Interventions: Self-Care"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "the broad adoption of ICDs for primary prevention Support in HF"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "of SCD in the post-MI setting with reduced LVEF, Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "even in the absence of HF symptoms."
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "6. Although beta blockers have been shown to improve COR LOE Recommendations"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "outcomes in patients with symptomatic HFrEF and 1. Patients with HF should receive care from"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "multidisciplinary teams to facilitate the imple-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "in patients with reduced LVEF after MI,11 few data"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "1 A mentation of GDMT, address potential barriers"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "exist regarding the use of beta blockers in asymp- to self-care, reduce the risk of subsequent"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "tomatic patients with depressed LVEF without a his- rehospitalization for HF, and improve survival.1–4"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "tory of MI. There is evidence to support the role of 2. Patients with HF should receive specific edu-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "beta blockers to prevent adverse LV remodeling in 1 B-R cation and support to facilitate HF self-care in a"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "multidisciplinary manner.2,5–9"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "asymptomatic patients with LV systolic dysfunction,"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "including those with nonischemic cause.43 Also, in 3. In patients with HF, vaccinating against respi-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "2a B-NR ratory illnesses is reasonable to reduce mor-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "a post hoc analysis of the SOLVD prevention trial, tality.10–16"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "which included approximately 20% of participants"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "4. In adults with HF, screening for depression,17,18"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "with nonischemic HF cause, beta blockers were social isolation,19–22 frailty,23,24 and low health"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "2a B-NR"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "associated with a reduction in the risk of death and literacy25,26 as risk factors for poor self-care is"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "reasonable to improve management."
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "in death or hospitalization for symptomatic HF in"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "those patients randomized to enalapril, a finding that"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "was not seen in the placebo group.12 Given the long-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "term benefits of beta blockers to reduce HF hos-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "pitalizations in patients with symptomatic HFrEF,44 Because of the complexity of HF management and"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "beta-blocker therapy is recommended to prevent coordination of other health and social services re-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "symptomatic HF in patients with reduced LVEF. quired, HF care is ideally provided by multidisciplinary"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "7. Thiazolidinediones have been associated with fluid teams27–30 that include cardiologists, nurses, and phar-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "retention and increased rates of HF in RCTs of macists who specialize in HF as well as dieticians,"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "patients with type 2 diabetes who were predominantly mental health clinicians, social workers, primary care"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "free of symptomatic HF at baseline.47–49 In a smaller clinicians, and additional specialists.31–33 Self-care in"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "RCT of patients with more severely symptomatic HF comprises treatment adherence and health main-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "HFrEF, pioglitazone was associated with increased tenance behaviors.34,35 Patients with HF should learn to"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "rates of HF hospitalization compared with placebo.50 take medications as prescribed, restrict sodium intake,"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "In patients with more mild symptoms (NYHA class stay physically active, and get vaccinations.36,37 They"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "I to II) but with depressed LVEF,15 rosiglitazone was also should understand how to monitor for signs and"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "associated with more fluid-related events, includ- symptoms of worsening HF, and what to do in response"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "ing worsening edema and need for increased HF to symptoms when they occur.36,37 Knowledge alone"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "medications.15 Given the evidence, thiazolidinediones is insufficient to improve self-care.38 Patients with HF"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "should be avoided in patients with reduced LVEF. need time and support to gain skills and overcome bar-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "8. Nondihydropiridine calcium channel blockers diltia- riers to effective self-care.37 Measures listed as Class"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "zem and verapamil are myocardial depressants and 1 recommendations for patients in stages A and B are"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "generally not tolerated in HF. In previous studies of recommended where appropriate for patients in stage"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "patients with HF or reduced LVEF after acute MI, dil- C. GDMT, as depicted in Figure 6, should be the main-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "tiazem was associated with increased risk of HF,16,17 stay of pharmacological therapy for HFrEF."
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "although in a smaller study of patients with non-"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "ischemic cardiomyopathy, diltiazem had no impact"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "on mortality.45 Verapamil had no impact on survival"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "or major cardiovascular events after acute MI.46 1. In a meta-analysis of 30 RCTs, multidisciplinary"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "Although not specifically tested in asymptomatic interventions reduced hospital admission and"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 29,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "e924 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "Figure 6. Treatment of HFrEF Stages C and D."
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "Colors correspond to COR in Table 2. Treatment recommendations for patients with HFrEF are displayed. Step 1 medications may be started"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "simultaneously at initial (low) doses recommended for HFrEF. Alternatively, these medications may be started sequentially, with sequence guided"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "by clinical or other factors, without need to achieve target dosing before initiating next medication. Medication doses should be increased to target"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "as tolerated. ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "inhibitor; COR, Class of Recommendation; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; ICD, implantable"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "cardioverter-defibrillator; hydral-nitrates, hydralazine and isosorbide dinitrate; HFrEF, heart failure with reduced ejection fraction; LBBB, left bundle"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "branch block; MCS, mechanical circulatory support; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NSR,"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "normal sinus rhythm; NYHA, New York Heart Association; and SGLT2i, sodium-glucose cotransporter 2 inhibitor. *Participation in investigational"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "studies is appropriate for stage C, NYHA class II and III HF."
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "all-cause mortality.1 In a separate meta-analysis of significantly reduce the risk of HF-related hos-"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "22 RCTs, specialized multidisciplinary team follow- pitalization,2,5–8 all-cause hospitalization,2,8,9 and"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "up was associated with reduced HF hospitalizations all-cause mortality,6,9 as well as improve QOL.5"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "and all-cause hospitalizations.2 In a recent meta- Interventions that aim to improve self-care knowl-"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "analysis of 22 RCTs, multidisciplinary interventions edge and skill,2,5,8 and those that focus on enhanc-"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "that included a pharmacist reduced HF hospitaliza- ing medication adherence9 or reinforce self-care"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "tions.3 In a recent Cochrane systematic review and with structured telephone support,6,7 are effective"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "meta-analysis of 43 RCTs, both case management in patients with HF. There is uncertainty whether"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "(ie, active management of complex patients by case mobile health–delivered educational interven-"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "managers working in integrated care systems) and tions improve self-care in patients with HF.39 In"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "multidisciplinary interventions (ie, coordinated mul- a single RCT involving rural patients with HF, an"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "tidisciplinary health care interventions and commu- educational intervention was shown to improve"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "nications) were shown to reduce all-cause mortality, knowledge and self-care40 but did not significantly"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "all-cause readmission, and readmission for HF.4 decrease the combined endpoint of cardiac death"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "2. Meta-analyses of RCTs have shown that inter- or HF hospitalization.41 In a recent pragmatic trial,"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "ventions focused on improving HF self-care a transitional care services program that included"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 30,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e925"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "self-care education improved discharge prepared- marginal health literacy is common among adults"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "ness, quality of transition, and QOL but did not sig- with HF (ie, 24%) and associated independently"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "nificantly improve clinical outcomes compared with with the risk of mortality and hospitalization.25 Low"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "usual care.42 literacy also is associated with poor HF self-care,"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "3. In propensity-adjusted models, influenza vacci- as most interventions depend on both literacy and"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "nation was associated with a significant reduc- health literacy/numeracy.26"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "tion in all-cause mortality among participants in"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "7.1.2. Dietary Sodium Restriction"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "PARADIGM-HF (Prospective Comparison of ARNi"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "with ACEi to Determine Impact on Global Mortality Recommendation for Dietary Sodium Restriction"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "and Morbidity in Heart Failure).14 In adjusted mod- COR LOE Recommendation"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "els, influenza vaccination was associated with 1. For patients with stage C HF, avoiding exces-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "significant reductions in all-cause mortality and car- 2a C-LD sive sodium intake is reasonable to reduce"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "congestive symptoms.1–6"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "diovascular mortality12 in 1 registry study and was"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "associated with significant reductions in all-cause"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "mortality and the composite of all-cause mortality"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "and cardiovascular hospitalizations in another large"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "Restricting dietary sodium is a common nonpharmaco-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "cohort study.11 In a self-controlled case series study"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "logical treatment for patients with HF symptomatic with"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "of patients with HF, influenza vaccination was asso-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "congestion, but specific recommendations have been"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "ciated with a significantly lower risk of cardiovas-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "based on low-quality evidence.7 Concerns about the qual-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "cular, respiratory, and all-cause hospitalization.43 In"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "ity of data regarding clinical benefits or harm of sodium"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "a meta-analysis of 16 studies of patients with CVD,"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "restriction in patients with HF include the lack of current"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "influenza vaccination was associated with a lower"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "pharmacological therapy, small samples without sufficient"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "risk of all-cause, cardiovascular mortality, and major"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "racial and ethnic diversity, questions about the correct"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "adverse cardiovascular events compared with con-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "threshold for clinical benefit, uncertainty about which sub-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "trol patients.15 In the Cardiovascular Health Study,"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "groups benefit most from sodium restriction,7,8 and seri-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "pneumococcal vaccination was associated with sig-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "ous questions about the validity of several RCTs in this"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "nificant reductions in incident HF, all-cause mortal-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "area.9–11 However, there are promising pilot trials of so-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "ity, and cardiovascular mortality.16 Patients with HF"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "dium restriction in patients with HF3,5,6 The AHA currently are uniquely susceptible to poor outcomes in the"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "recommends a reduction of sodium intake to <2300"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "setting of SARS-CoV-2 infection44–47 and should be"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "mg/d for general cardiovascular health promotion12; how-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "vaccinated against COVID-19.10"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "ever, there are no trials to support this level of restriction"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "4. Many health and social factors are associated with"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "in patients with HF.13 Sodium restriction can result in poor"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "poor HF self-care.36,37 (Table 11) but have also been"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "dietary quality with inadequate macronutrient and mi-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "linked to poor clinical outcomes and fundamen-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "cronutrient intake.14 Nutritional inadequacies have been"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "tally change how education and support must be"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "associated with clinical instability,15–17 but routine supple-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "delivered. Depression is a risk factor for poor self-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "mentation of oral iron,18 thiamine,19 zinc,20 vitamin D,21 or"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "care,40 rehospitalization,17 and all-cause mortality18"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "multivitamins has not proven beneficial.22 The DASH diet"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "among patients with HF. Interventions that focus"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "is rich in antioxidants and potassium, can achieve sodium"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "on improving HF self-care have been reported"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "restriction without compromising nutritional adequacy to be effective among patients with moderate/"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "when accompanied by dietary counseling,5 and may be"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "severe depression with reductions in hospitaliza-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "associated with reduced hospitalizations for HF.23"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "tion and mortality risk.5 Nonrandomized studies"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "have provided evidence of a link between social"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "isolation and mortality in patients with HF19,20 In a"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "recent meta-analysis of 29 cohort studies, frailty"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "was associated with an increased risk of all-cause 1. A registered dietitian- or nurse-coached interven-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "mortality and hospitalization.23 Frailty also has been tion with 2 to 3 g/d sodium restriction improved"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "shown to impair self-care among elderly patients NYHA functional class and leg edema in patients"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "with HF.24 A recent meta-analysis of observational with HFrEF.1 In a nonrandomized study (>2.5 g/d"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "studies revealed social isolation to be common versus <2.5 g/d), lower dietary sodium was associ-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "among adults with HF (ie, 37%) and associated ated with worse all-cause mortality in patients with"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "with a 55% greater risk of HF-related rehospital- HFrEF.2 In small RCTs, aggressive sodium restriction"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "ization.21 Poor social support also has been shown (0.8 g/d) during hospitalization for acute decom-"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "in nonrandomized studies to be associated with pensated HF has not reduced weight, congestion,"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "lower HF self-care.22 A recent meta-analysis of diuretic use, rehospitalization, or all-cause mortality"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "observational studies showed that inadequate/ in patients with HFrEF24 or in patients with HFpEF.25"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 31,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "e926 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Table 11. Potential Barriers to Effective HF Self-Care and Example Interventions"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Potential Barrier Example Screening Tools Example Interventions"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Medical Barriers"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Cognitive impairment48–50 Mini-Cog Home health aide"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Mini-Mental State Examination (MMSE) Home meal deliveries"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Montreal Cognitive Assessment (MoCA) Adult day care"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Geriatric psychiatry referral"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Memory care support groups"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Depression51,52 Hamilton Depression Rating Scale (HAM-D) Psychotherapy"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Beck Depression Inventory-II (BDI-II) Selective serotonin reuptake inhibitors"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Patient Health Questionnaire-9 (PHQ-9) Nurse-led support"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Substance use disorders53 Tobacco, Alcohol, Prescription medication, and other Sub- Referral to social work services and community support partners"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "stance use (TAPS) Referral for addiction psychiatry consultation"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Frailty54 Fried frailty phenotype Cardiac rehabilitation"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Registered dietitian nutritionist evaluation for malnutrition"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Social Barriers"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Financial burden of HF COmprehensive Score for financial Toxicity–Functional As- PharmD referral to review prescription assistance eligibilities"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "treatments55 sessment of Chronic Illness Therapy (COST-FACIT)"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Food insecurity56,57 Hunger Vital Sign, 2 items Determine eligibility for the Supplemental Nutrition Assistance"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "US Household Food Security Survey Module, 6 items Program (SNAP)"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Connect patients with community partners such as food pantries/"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "food banks"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Home meal deliveries"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Registered dietitian nutritionist evaluation for potential malnutrition"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Homelessness or housing Homelessness Screening Clinical Reminder (HSCR) Referral to local housing services"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "insecurity58–60 Connect patients with community housing partners"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Intimate partner violence or Humiliation, Afraid, Rape, Kick (HARK) questionnaire Referral to social work services and community support partners"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "elder abuse61,62 Partner Violence Screen (PVS)"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Woman Abuse Screening Tool (WAST)"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Limited English proficiency or Routinely inquire in which language the patient is most Access to interpreter services covering a wide range of languag-"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "other language barriers63 comfortable conversing es, ideally in person or, alternatively, via video platform"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Printed educational materials in a range of appropriate languages"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Low health literacy64 Short Assessment of Health Literacy (SAHL) Agency for Healthcare Research and Quality (AHRQ) Health Lit-"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Rapid Estimate of Adult Literacy in Medicine–Short Form eracy Universal Precautions Toolkit"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "(REALM-SF) Written education tools provided at sixth grade reading level or"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Brief Health Literacy Screen (BHLS), 3 items below Graphic educational documents"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Social isolation or low social Patient-Reported Outcomes Measurement Information Determine eligibility for home care services"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "support65 System (PROMIS) Social Isolation Short Form Support group referral"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Transport limitations No validated tools currently available. Referral to social work services"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Determine eligibility for insurance or state-based transportation, or"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "reduced-cost public transportation"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Maximize opportunities for telehealth visits and remote monitoring"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "HF indicates heart failure."
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "A recent pilot RCT N=27) showed that providing 7.1.3. Management of Stage C HF: Activity, Exercise"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "patients with 1.5 g/d sodium meals can reduce uri- Prescription, and Cardiac Rehabilitation"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "nary sodium and improve QOL but not improve clini-"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Recommendations for Management of Stage C HF: Activity, Exercise"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "cal outcomes.3 Another recent pilot RCT (N=38) of Prescription, and Cardiac Rehabilitation"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "1.5 versus 2.3 g/d sodium resulted in sodium intake Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "and improvement in BNP levels and QOL in the rized in the Online Data Supplements."
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "1.5 g/d sodium intake arm5; the full trial is due to COR LOE Recommendations"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "be completed in 2022. A third pilot RCT (N=66) of 1. For patients with HF who are able to par-"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "home-delivered 1.5 g/d meals showed favorable but 1 A ticipate, exercise training (or regular physical"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "activity) is recommended to improve functional"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "nonsignificant trends toward improvement in clini-"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "status, exercise performance, and QOL.1–9"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "cal status and readmission rates.6 Moreover, results"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "2. In patients with HF, a cardiac rehabilitation"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "from RCTs have shown that reducing dietary sodium"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "program can be useful to improve functional"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "2a B-NR"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "is difficult to achieve in patients with HF, even with capacity, exercise tolerance, and health-related"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "prepared meals3 or home visits.26 QOL.1,2,5,6,8"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 32,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 32,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Potential Barrier": "Medical Barriers",
                "Example Screening Tools": "",
                "Example Interventions": ""
            },
            {
                "Potential Barrier": "Cognitive impairment48–50",
                "Example Screening Tools": "Mini-Cog Mini-Mental State Examination (MMSE) Montreal Cognitive Assessment (MoCA)",
                "Example Interventions": "Home health aide Home meal deliveries Adult day care Geriatric psychiatry referral Memory care support groups"
            },
            {
                "Potential Barrier": "Depression51,52",
                "Example Screening Tools": "Hamilton Depression Rating Scale (HAM-D) Beck Depression Inventory-II (BDI-II) Patient Health Questionnaire-9 (PHQ-9)",
                "Example Interventions": "Psychotherapy Selective serotonin reuptake inhibitors Nurse-led support"
            },
            {
                "Potential Barrier": "Substance use disorders53",
                "Example Screening Tools": "Tobacco, Alcohol, Prescription medication, and other Sub- stance use (TAPS)",
                "Example Interventions": "Referral to social work services and community support partners Referral for addiction psychiatry consultation"
            },
            {
                "Potential Barrier": "Frailty54",
                "Example Screening Tools": "Fried frailty phenotype",
                "Example Interventions": "Cardiac rehabilitation Registered dietitian nutritionist evaluation for malnutrition"
            },
            {
                "Potential Barrier": "Social Barriers",
                "Example Screening Tools": "",
                "Example Interventions": ""
            },
            {
                "Potential Barrier": "Financial burden of HF treatments55",
                "Example Screening Tools": "COmprehensive Score for financial Toxicity–Functional As- sessment of Chronic Illness Therapy (COST-FACIT)",
                "Example Interventions": "PharmD referral to review prescription assistance eligibilities"
            },
            {
                "Potential Barrier": "Food insecurity56,57",
                "Example Screening Tools": "Hunger Vital Sign, 2 items US Household Food Security Survey Module, 6 items",
                "Example Interventions": "Determine eligibility for the Supplemental Nutrition Assistance Program (SNAP) Connect patients with community partners such as food pantries/ food banks Home meal deliveries Registered dietitian nutritionist evaluation for potential malnutrition"
            },
            {
                "Potential Barrier": "Homelessness or housing insecurity58–60",
                "Example Screening Tools": "Homelessness Screening Clinical Reminder (HSCR)",
                "Example Interventions": "Referral to local housing services Connect patients with community housing partners"
            },
            {
                "Potential Barrier": "Intimate partner violence or elder abuse61,62",
                "Example Screening Tools": "Humiliation, Afraid, Rape, Kick (HARK) questionnaire Partner Violence Screen (PVS) Woman Abuse Screening Tool (WAST)",
                "Example Interventions": "Referral to social work services and community support partners"
            },
            {
                "Potential Barrier": "Limited English proficiency or other language barriers63",
                "Example Screening Tools": "Routinely inquire in which language the patient is most comfortable conversing",
                "Example Interventions": "Access to interpreter services covering a wide range of languag- es, ideally in person or, alternatively, via video platform Printed educational materials in a range of appropriate languages"
            },
            {
                "Potential Barrier": "Low health literacy64",
                "Example Screening Tools": "Short Assessment of Health Literacy (SAHL) Rapid Estimate of Adult Literacy in Medicine–Short Form (REALM-SF) Brief Health Literacy Screen (BHLS), 3 items",
                "Example Interventions": "Agency for Healthcare Research and Quality (AHRQ) Health Lit- eracy Universal Precautions Toolkit Written education tools provided at sixth grade reading level or below Graphic educational documents"
            },
            {
                "Potential Barrier": "Social isolation or low social support65",
                "Example Screening Tools": "Patient-Reported Outcomes Measurement Information System (PROMIS) Social Isolation Short Form",
                "Example Interventions": "Determine eligibility for home care services Support group referral"
            },
            {
                "Potential Barrier": "Transport limitations",
                "Example Screening Tools": "No validated tools currently available.",
                "Example Interventions": "Referral to social work services Determine eligibility for insurance or state-based transportation, or reduced-cost public transportation Maximize opportunities for telehealth visits and remote monitoring"
            }
        ],
        "conteudo_texto": "Medical Barriers, ,  | Cognitive impairment48–50, Mini-Cog Mini-Mental State Examination (MMSE) Montreal Cognitive Assessment (MoCA), Home health aide Home meal deliveries Adult day care Geriatric psychiatry referral Memory care support groups | Depression51,52, Hamilton Depression Rating Scale (HAM-D) Beck Depression Inventory-II (BDI-II) Patient Health Questionnaire-9 (PHQ-9), Psychotherapy Selective serotonin reuptake inhibitors Nurse-led support | Substance use disorders53, Tobacco, Alcohol, Prescription medication, and other Sub- stance use (TAPS), Referral to social work services and community support partners Referral for addiction psychiatry consultation | Frailty54, Fried frailty phenotype, Cardiac rehabilitation Registered dietitian nutritionist evaluation for malnutrition | Social Barriers, ,  | Financial burden of HF treatments55, COmprehensive Score for financial Toxicity–Functional As- sessment of Chronic Illness Therapy (COST-FACIT), PharmD referral to review prescription assistance eligibilities | Food insecurity56,57, Hunger Vital Sign, 2 items US Household Food Security Survey Module, 6 items, Determine eligibility for the Supplemental Nutrition Assistance Program (SNAP) Connect patients with community partners such as food pantries/ food banks Home meal deliveries Registered dietitian nutritionist evaluation for potential malnutrition | Homelessness or housing insecurity58–60, Homelessness Screening Clinical Reminder (HSCR), Referral to local housing services Connect patients with community housing partners | Intimate partner violence or elder abuse61,62, Humiliation, Afraid, Rape, Kick (HARK) questionnaire Partner Violence Screen (PVS) Woman Abuse Screening Tool (WAST), Referral to social work services and community support partners | Limited English proficiency or other language barriers63, Routinely inquire in which language the patient is most comfortable conversing, Access to interpreter services covering a wide range of languag- es, ideally in person or, alternatively, via video platform Printed educational materials in a range of appropriate languages | Low health literacy64, Short Assessment of Health Literacy (SAHL) Rapid Estimate of Adult Literacy in Medicine–Short Form (REALM-SF) Brief Health Literacy Screen (BHLS), 3 items, Agency for Healthcare Research and Quality (AHRQ) Health Lit- eracy Universal Precautions Toolkit Written education tools provided at sixth grade reading level or below Graphic educational documents | Social isolation or low social support65, Patient-Reported Outcomes Measurement Information System (PROMIS) Social Isolation Short Form, Determine eligibility for home care services Support group referral | Transport limitations, No validated tools currently available., Referral to social work services Determine eligibility for insurance or state-based transportation, or reduced-cost public transportation Maximize opportunities for telehealth visits and remote monitoring"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e927"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Synopsis QOL.3,4,6,7,11,16,17 In a diverse population of older"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "patients who were hospitalized for acute decom-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Exercise training in patients with HF is safe and has"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "pensated HF, an early, transitional, tailored, pro-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "numerous benefits. In a major trial of exercise and HF,"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "gressive rehabilitation intervention that included"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "exercise training was associated with a reduction in"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "multiple physical-function domains (strength, bal-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "CVD mortality or hospitalizations in the exercise train-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "ance, mobility, and endurance) initiated during, or"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "ing group after adjustment for risk factors.1 Meta-anal-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "early after hospitalization for HF, and continued"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "yses show that cardiac rehabilitation improves func-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "after discharge, resulted in greater improvement in"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "tional capacity, exercise duration, and health-related"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "physical function than usual care.9"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "QOL. A cardiac rehabilitation program for patients"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "with HF usually includes a medical evaluation, educa-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "tion regarding the importance of medical adherence, 7.2. Diuretics and Decongestion Strategies in"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "dietary recommendations, psychosocial support, and Patients With HF"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "an exercise training and physical activity counseling"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "program. Patients with HF on optimal GDMT, who are Recommendations for Diuretics and Decongestion Strategies in"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Patients With HF"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "in stable medical condition and are able to participate"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "in an exercise program, are candidates for an exercise summarized in the Online Data Supplements."
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "rehabilitation program.10,11"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "1. In patients with HF who have fluid retention,"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text diuretics are recommended to relieve conges-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "1 B-NR"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "tion, improve symptoms, and prevent worsen-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "1. Evidence from RCTs indicates that exercise training ing HF.1–5"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "improves functional status, exercise performance,"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "2. For patients with HF and congestive symptoms,"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "and QOL in patients with HFrEF and HFpEF. In addition of a thiazide (eg, metolazone) to treat-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "HF-ACTION, the largest randomized trial with exer- 1 B-NR ment with a loop diuretic should be reserved"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "for patients who do not respond to moderate-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "cise training in patients with HF,1 2331 patients"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "or high-dose loop diuretics to minimize electro-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "with LVEF ≤35% (NYHA class II and III) were ran- lyte abnormalities.6"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "domized to usual care versus supervised exercise"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "training plus usual care. There were modest reduc-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "tions in all-cause mortality and hospitalization rates"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "that did not reach significance by primary analysis Bumetanide, furosemide, and torsemide inhibit reabsorp-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "but, after prespecified adjustment, were associated tion of sodium or chloride at the loop of Henle, whereas"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "with reductions in cardiovascular mortality or HF thiazide and thiazide-like diuretics act in the distal con-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "hospitalizations.1 Many RCTs of exercise training in voluting tubule and potassium-sparing diuretics (eg, spi-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "HF have been conducted, but the statistical power ronolactone) in the collecting duct.7,8 Loop diuretics are"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "of most was low.2–5,9–13 Meta-analyses suggest that the preferred diuretic agents for use in most patients"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "exercise training is associated with improvement with HF. Thiazide diuretics such as chlorthalidone or"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "in functional capacity, exercise duration, health- hydrochlorothiazide may be considered in patients with"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "related QOL, and reduction in HF hospitalizations hypertension and HF and mild fluid retention. Metola-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "in patients with HFrEF as well as HFpEF.2–6,8,11,14,15 zone or chlorothiazide may be added to loop diuretics in"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Most studies and meta-analyses have not shown patients with refractory edema unresponsive to loop di-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "significant changes in all-cause mortality.2,12,14–22 uretics alone. Diuretics should be prescribed to patients"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "except for a few showing mortality benefit with who have evidence of congestion or fluid retention. In"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "longer follow-up6,7 Other benefits of exercise train- any patient with a history of congestion, maintenance"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "ing include improved endothelial function, blunted diuretics should be considered to avoid recurrent symp-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "catecholamine spillover, increased peripheral oxy- toms. The treatment goal of diuretic use is to eliminate"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "gen extraction, and improvement in peak oxygen clinical evidence of fluid retention, using the lowest dose"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "consumption.2–5,8,10–12,21 possible to maintain euvolemia. With the exception of"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "2. A formal cardiac rehabilitation program usually MRAs, the effects of diuretics on morbidity and mortality"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "includes a medical evaluation, education regard- are uncertain.1–5 As such, diuretics should not be used"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "ing the importance of medical adherence, dietary in isolation but always combined with other GDMT for"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "recommendations, psychosocial support, and an HF that reduces hospitalizations and prolongs survival."
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "exercise training and physical activity counseling Table 12 lists oral diuretics recommended for use in the"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "program. Exercise-based cardiac rehabilitation treatment of chronic HF. Hyponatremia complicates HF"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "has been associated with an improvement in func- management. If reversing potential causes and free wa-"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "tional capacity, exercise tolerance, the rate of over- ter restriction do not improve hyponatremia, vasopressin"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "all and HF-specific hospitalization, and improved antagonists may be helpful in the acute management of"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 33,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "e928 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Table 12. Commonly Used Oral Diuretics in Treatment of natriuresis. However, in a propensity-score"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Congestion for Chronic HF matched analysis in patients with hospitalized HF,"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "the addition of metolazone to loop diuretics was"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Maximum"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Total Daily Duration found to increase the risk for hypokalemia, hypo-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Drug Initial Daily Dose Dose of Action natremia, worsening renal function, and mortality,"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Loop diuretics whereas use of higher doses of loop diuretics was"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Bumetanide 0.5–1.0 mg once or twice 10 mg 4–6 h not found to adversely affect survival.17 Although"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Furosemide 20–40 mg once or twice 600 mg 6–8 h randomized data comparing the 2 diuretic strate-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "gies are limited, the DOSE (Diuretic Optimization"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Torsemide 10–20 mg once 200 mg 12–16 h"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Strategies Evaluation) trial lends support for the"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Thiazide diuretics"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "use of high-dose intravenous loop diuretics.18"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Chlorthiazide 250–500 mg once or 1000 mg 6–12 h"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "twice"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Chlorthalidone 12.5–25 mg once 100 mg 24–72 h 7.3. Pharmacological Treatment* for HFrEF"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Hydrochlorothiazide 25 mg once or twice 200 mg 6–12 h"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "7.3.1. Renin-Angiotensin System Inhibition With"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Indapamide 2.5 mg once 5 mg 36 h"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "ACEi or ARB or ARNi"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Metolazone 2.5 mg once 20 mg 12–24 h"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Recommendations for Renin-Angiotensin System Inhibition With ACEi"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "HF indicates heart failure. or ARB or ARNi"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "summarized in the Online Data Supplements."
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "volume overload to decrease congestion while maintain-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "ing serum sodium. COR LOE Recommendations"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "1. In patients with HFrEF and NYHA class II to III"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "1 A symptoms, the use of ARNi is recommended to"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "reduce morbidity and mortality.1–5"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "1. Controlled trials with diuretics showed their effects 2. In patients with previous or current symptoms"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "of chronic HFrEF, the use of ACEi is beneficial"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "to increase urinary sodium excretion, decrease 1 A"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "to reduce morbidity and mortality when the use"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "physical signs of fluid retention, and improve of ARNi is not feasible.6–13"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "symptoms, QOL, and exercise tolerance.1–5 Recent"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "3. In patients with previous or current symptoms"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "data from the nonrandomized OPTIMIZE-HF of chronic HFrEF who are intolerant to ACEi"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "(Organized Program to Initiate Lifesaving Treatment 1 A because of cough or angioedema and when the"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "use of ARNi is not feasible, the use of ARB is rec-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "in Hospitalized Patients with Heart Failure) regis-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "ommended to reduce morbidity and mortality.14–18"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "try revealed reduced 30-day all-cause mortality"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "4. In patients with previous or current symptoms"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "and hospitalization for HF with diuretic use com-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Value Statement: of chronic HFrEF, in whom ARNi is not feasible,"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "pared with no diuretic use after hospital discharge High Value (A) treatment with an ACEi or ARB provides high"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "for HF.9 The most commonly used loop diuretic economic value.19–25"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "for the treatment of HF is furosemide, but some 5. In patients with chronic symptomatic HFrEF"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "NYHA class II or III who tolerate an ACEi or"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "patients respond more favorably to other agents in 1 B-R"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "ARB, replacement by an ARNi is recommended"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "this category (eg, bumetanide, torsemide), poten- to further reduce morbidity and mortality.1–5"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "tially because of their increased oral bioavailabil-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "6. In patients with chronic symptomatic HFrEF,"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Value Statement:"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "ity.10–12 In outpatients with HF, diuretic therapy is treatment with an ARNi instead of an ACEi pro-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "High Value (A)"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "commonly initiated with low doses, and the dose vides high economic value.26–29"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "is increased until urine output increases and 7. ARNi should not be administered concomi-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "3: Harm B-R tantly with ACEi or within 36 hours of the last"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "weight decreases, generally by 0.5 to 1.0 kg daily."
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "dose of an ACEi.30,31"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Patients may become unresponsive to high doses"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "8. ARNi should not be administered to patients"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "of diuretic drugs if they consume large amounts of 3: Harm C-LD"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "with any history of angioedema.32–35"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "dietary sodium, are taking agents that can block"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "9. ACEi should not be administered to patients"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "the effects of diuretics (eg, NSAIDs), or have sig- 3: Harm C-LD"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "with any history of angioedema.36–39"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "nificant impairment of renal function or perfusion."
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "*See Section 7.2, “Diuretics and Decongestion Strategies in Patients with"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "2. Diuretic resistance can be overcome in several"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "HF,” for diuretic recommendations."
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "ways, including escalation of loop diuretic dose,"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "intravenous administration of diuretics (bolus or"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "continuous infusion),6 or combination of different"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "diuretic classes.13–16 The use of a thiazide or thia- Inhibition of the renin-angiotensin system is recommend-"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "zide-like diuretic (eg, metolazone) in combination ed to reduce morbidity and mortality for patients with"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "with a loop diuretic inhibits compensatory distal HFrEF, and ARNi, ACEi, or ARB are recommended as"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "tubular sodium reabsorption, leading to enhanced first-line therapy.1–18 If patients have chronic symptomatic"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 34,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 34,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Drug": "Loop diuretics",
                "Initial Daily Dose": "",
                "Maximum Total Daily Dose": "",
                "Duration of Action": ""
            },
            {
                "Drug": "Bumetanide",
                "Initial Daily Dose": "0.5–1.0 mg once or twice",
                "Maximum Total Daily Dose": "10 mg",
                "Duration of Action": "4–6 h"
            },
            {
                "Drug": "Furosemide",
                "Initial Daily Dose": "20–40 mg once or twice",
                "Maximum Total Daily Dose": "600 mg",
                "Duration of Action": "6–8 h"
            },
            {
                "Drug": "Torsemide",
                "Initial Daily Dose": "10–20 mg once",
                "Maximum Total Daily Dose": "200 mg",
                "Duration of Action": "12–16 h"
            },
            {
                "Drug": "Thiazide diuretics",
                "Initial Daily Dose": "",
                "Maximum Total Daily Dose": "",
                "Duration of Action": ""
            },
            {
                "Drug": "Chlorthiazide",
                "Initial Daily Dose": "250–500 mg once or twice",
                "Maximum Total Daily Dose": "1000 mg",
                "Duration of Action": "6–12 h"
            },
            {
                "Drug": "Chlorthalidone",
                "Initial Daily Dose": "12.5–25 mg once",
                "Maximum Total Daily Dose": "100 mg",
                "Duration of Action": "24–72 h"
            },
            {
                "Drug": "Hydrochlorothiazide",
                "Initial Daily Dose": "25 mg once or twice",
                "Maximum Total Daily Dose": "200 mg",
                "Duration of Action": "6–12 h"
            },
            {
                "Drug": "Indapamide",
                "Initial Daily Dose": "2.5 mg once",
                "Maximum Total Daily Dose": "5 mg",
                "Duration of Action": "36 h"
            },
            {
                "Drug": "Metolazone",
                "Initial Daily Dose": "2.5 mg once",
                "Maximum Total Daily Dose": "20 mg",
                "Duration of Action": "12–24 h"
            }
        ],
        "conteudo_texto": "Loop diuretics, , ,  | Bumetanide, 0.5–1.0 mg once or twice, 10 mg, 4–6 h | Furosemide, 20–40 mg once or twice, 600 mg, 6–8 h | Torsemide, 10–20 mg once, 200 mg, 12–16 h | Thiazide diuretics, , ,  | Chlorthiazide, 250–500 mg once or twice, 1000 mg, 6–12 h | Chlorthalidone, 12.5–25 mg once, 100 mg, 24–72 h | Hydrochlorothiazide, 25 mg once or twice, 200 mg, 6–12 h | Indapamide, 2.5 mg once, 5 mg, 36 h | Metolazone, 2.5 mg once, 20 mg, 12–24 h"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e929"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "HFrEF with NYHA class II or III symptoms and they toler- function, hyperkalemia, symptomatic hypotension,"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "ate an ACEi or ARB, they should be switched to an ARNi angioedema) when compared with enalapril.3"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "because of improvement in morbidity and mortality.1–5 An Additional outcome analyses suggested reduction"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "ARNi is recommended as de novo treatment in hospital- in all-cause mortality and rehospitalization for HF"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "ized patients with acute HF before discharge given im- but were only hypothesis-generating as exploratory"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "provement in health status, reduction in the prognostic study endpoints. In the open-label TRANSITION"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "biomarker NT-proBNP, and improvement of LV remodel- trial, patients with HFrEF hospitalized with wors-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "ing parameters compared with ACEi/ARB. Although data ening HF were randomized to start ARNi either"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "are limited, the use of an ARNi may be efficacious as before or after discharge.2 Safety outcomes were"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "de novo treatment in patients with symptomatic chronic similar for both arms, suggesting that early initia-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "HFrEF to simplify management. ARB may be used as tion may simplify management (rather than initiat-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "an alternative to ACEi in the setting of intolerable cough, ing and uptitrating ACEi first and then switching to"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "or as alternatives to ACEi and ARNi in patients with a ARNi).2 ARNi should be initiated de novo in patients"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "history of angioedema. If patients are switched from an hospitalized with acute HFrEF before discharge in"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "ACEi to an ARNi or vice versa, there should be at least the absence of contraindications. ARNi may be ini-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "36 hours between ACEi and ARNi doses. tiated de novo in patients with chronic symptom-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "atic HFrEF to simplify management, although data"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "are limited. The PARADISE-MI (Prospective ARNi"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "vs ACE Inhibitor Trial to DetermIne Superiority in"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "1. An ARNi is composed of an ARB and an inhibi- Reducing Heart Failure Events After MI) trial40 will"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "tor of neprilysin, an enzyme that degrades natri- provide information on whether sacubitril-valsartan"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "uretic peptides, bradykinin, adrenomedullin, and will significantly reduce the rate of cardiovascular"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "other vasoactive peptides. In PARADIGM-HF death, HF hospitalization or outpatient HF requir-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "(Prospective Comparison of ARNi with ACEi ing treatment in patients after acute MI, with LVEF"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "to Determine Impact on Global Mortality and ≤40% and/or pulmonary congestion, and 1 of 8"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Morbidity in Heart Failure), an RCT that compared additional risk-enhancing factors like AF, previous"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "the first approved ARNi, sacubitril-valsartan, with MI, diabetes, compared with the ACEi ramipril; and"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "enalapril in symptomatic patients with HFrEF tol- whether the safety and tolerability of sacubitril-val-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "erating an adequate dose of either ACEi or ARB, sartan was comparable to that of ramipril. Thus, at"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "sacubitril-valsartan significantly reduced the com- the present time, the efficacy of ARNi in patients"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "posite endpoint of cardiovascular death or HF with LV dysfunction, and HF in the early post-MI"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "hospitalization by 20% relative to enalapril.1 The period, remains uncertain."
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "benefit was observed to a similar extent for death 2. ACEi reduce morbidity and mortality in HFrEF. RCTs"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "and HF hospitalization and was consistent across clearly establish the benefits of ACE inhibition in"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "prespecified subgroups.1 Use of an ARNi is more patients with mild, moderate, or severe symptoms"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "frequently associated with symptomatic hypoten- of HF and in patients with or without CAD.6–11 Data"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "sion and a comparable incidence of angioedema suggest that there are no differences among avail-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "when compared with enalapril.1 Sacubitril-valsartan able ACEi in their effects on symptoms or survival.12"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "has been approved for patients with symptomatic ACEi should be started at low doses and titrated"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "HF. HF effects and potential off-target effects upward to doses shown to reduce the risk of car-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "may be complex with inhibition of the neprily- diovascular events in clinical trials. ACEi can pro-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "sin enzyme, which has multiple biological targets. duce angioedema and should be given with caution"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Trial data have included ACEi/ARB-naïve patients to patients with low systemic blood pressures, renal"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "before ARNi initiation (53% in the PIONEER-HF insufficiency, or elevated serum potassium (>5.0"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "[Comparison of Sacubitril-Valsartan versus mEq/L). If maximal doses are not tolerated, inter-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Enalapril on Effect on NT-proBNP in Patients mediate doses should be tried; abrupt withdrawal of"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Stabilized from an Acute Heart Failure Episode] ACE inhibition can lead to clinical deterioration and"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "trial and 24% in the TRANSITION [Comparison should be avoided. Although the use of an ARNi"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "of Pre- and Post-discharge Initiation of Sacubitril/ in lieu of an ACEi for HFrEF has been found to be"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Valsartan Therapy in HFrEF Patients After an superior, for those patients for whom ARNi is inap-"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Acute Decompensation Event] trial) and have propriate, continued use of an ACEi for all classes"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "shown similar efficacy and safety in treatment- of HFrEF remains strongly advised."
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "naïve patients.2,3 The PIONEER-HF trial showed 3. ARB have been shown to reduce mortality and"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "that ARNi reduced NT-proBNP levels in patients HF hospitalizations in patients with HFrEF in"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "hospitalized for acute decompensated HF without large RCTs.14–16 Long-term treatment with ARB"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "increased rates of adverse events (worsening renal in patients with HFrEF produces hemodynamic,"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 35,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "e930 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "neurohormonal, and clinical effects consistent therapy using the results of PARADIGM-HF.26–29,41"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "with those expected after interference with the Three high-quality analyses26,28,29 consistently"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "renin-angiotensin system.17,18 Unlike ACEi, ARB found costs per QALY <$60 000, which provides"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "do not inhibit kininase and are associated with a high value according to the benchmarks adopted"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "much lower incidence of cough and angioedema, for the current clinical practice guideline. These"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "although kininase inhibition by ACEi may produce results were robust to the range of sacubitril-val-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "beneficial vasodilatory effects. Patients who are sartan costs currently seen in care. These results"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "intolerant to ACEi because of cough or angio- were sensitive to the estimated mortality reduc-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "edema should be started on an ARB. ARB should tion and duration of treatment effectiveness. ARNi"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "be started at low doses and titrated upward, with an would need to maintain effectiveness beyond the"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "attempt to use doses shown to reduce the risk of PARADIGM-HF study period (mean, 27 months)"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "cardiovascular events in clinical trials. ARB should to be considered high value.29 If clinical benefit"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "be given with caution to patients with low systemic were limited to 27 months, ARNi would be inter-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "blood pressure, renal insufficiency, or elevated mediate value. One additional analysis, based on"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "serum potassium (>5.0 mEq/L). Although ARB are the PIONEER-HF trial, found that inpatient initia-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "alternatives for patients with ACEi-induced angio- tion of ARNi was also high value compared with"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "edema, caution is advised because some patients delayed initiation postdischarge.27"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "have also developed angioedema with ARB. For 7. Oral neprilysin inhibitors, used in combination with"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "those patients for whom an ACEi or ARNi is inap- ACEi, can lead to angioedema, and concomitant"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "propriate, use of an ARB remains advised. use is contraindicated and should be avoided. A"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "4. Several cost-effectiveness analyses consistently medication that represented a neprilysin inhibitor"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "found that ACEi therapy provides high value for and an ACEi—omapatrilat—was studied in hyper-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "patients with chronic HF. A model-based analysis, tension and HF, but its development was termi-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "using generic ACEi costs, found ACEi therapy was nated because of an unacceptable incidence of"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "high value.19 Previous analyses also found ACEi angioedema.30,31 and associated significant mor-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "therapy was high value despite previously higher bidity. This adverse effect was thought to occur"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "ACEi costs.19,21,22,24,25 This includes a trial-based because ACEi and neprilysin break down brady-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "analysis of SOLVD (Studies of Left Ventricular kinin, which can directly or indirectly cause angio-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "Dysfunction) that modeled long-term outcomes.21 edema31,32 An ARNi should not be administered"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "Previous analyses included a range of clinical sce- within 36 hours of switching from or to an ACEi."
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "narios including asymptomatic LV dysfunction24 8. Omapatrilat, a neprilysin inhibitor (as well as an"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "and LV dysfunction after MI,25 with ACEi therapy ACEi and aminopeptidase P inhibitor), was asso-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "providing high value in each. There are limited data ciated with a higher frequency of angioedema"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "on the cost-effectiveness of ARBs from 2 clinical than that seen with enalapril in an RCT of patients"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "trials—a within-trial analysis of Val-HeFT (Valsartan with HFrEF.30 In a very large RCT of hyperten-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "Heart Failure Trial)23 and an analysis of the ELITE sive patients, omapatrilat was associated with a"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "(Evaluation of Losartan in the Elderly) study20— 3-fold increased risk of angioedema compared"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "which both suggested ARB therapy is high value. with enalapril.31 Black patients and patients who"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "The high value of ARB therapy is also supported smoked were particularly at risk. The high inci-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "by its similar efficacy as ACEi therapy and the dence of angioedema ultimately led to cessation"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "low-cost generic availability for both medication of the clinical development of omapatrilat.33,34"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "classes. Because of these observations, angioedema was"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "5. Patients with chronic stable HFrEF who toler- an exclusion criterion in the first large trial assess-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "ate ACEi and ARB should be switched to ARNi. ing ARNi therapy in patients with hypertension35"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "In patients with mild-to-moderate HF who were and then in the large trial that showed clinical ben-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "able to tolerate both a target dose of enalapril (10 efit of ARNi therapy in HFrEF.1 The rates of angio-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "mg twice daily) and then subsequently an ARNi edema were numerically higher in patients treated"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "(sacubitril-valsartan; 200 mg twice daily, with the with ARNi than in patients treated with ACEi in"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "ARB component equivalent to valsartan 160 mg), PARADIGM-HF, although this difference did not"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "hospitalizations and mortality were significantly reach significance.1 ARNi therapy should not be"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "decreased with the valsartan-sacubitril compound administered in patients with a history of angio-"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "compared with enalapril.1 Another RCT and meta- edema because of the concern that it will increase"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "analysis showed improvement in LV remodeling the risk of a recurrence of angioedema."
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "parameters with ARNi compared with enalapril.4,5 9. Angioedema attributable to ACEi is thought to"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "6. Multiple model-based analyses evaluated the eco- result from defective degradation of the vasoactive"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "nomic value of ARNi therapy compared with ACEi peptides bradykinin, des-Arg9-BK (a metabolite"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 36,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e931"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "of bradykinin), and substance P.36,37 ACEi should hospital discharge, provided patients are clinically"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "not be administered to patients with any history of stabilized and do not require intravenous inotropic"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "angioedema, but ARB do not interfere as directly therapy for HF.17 If a contraindication or intoler-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "with bradykinin metabolism and have been associ- ance are noted, they should be documented, and"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "ated with low rates of angioedema.38,39 the patient restarted on beta-blocker therapy in the"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "future, so long as an absolute contraindication is"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "7.3.2. Beta Blockers"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "not present. Even if symptoms or LVEF improve,"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Recommendation for Beta Blockers long-term treatment with beta blockers and use of"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendation are summarized"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "target doses should be maintained to reduce the"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "in the Online Data Supplements."
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "risk of progression in LV dysfunction or major car-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "diovascular events.18,19 Abrupt withdrawal of beta-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "1. In patients with HFrEF, with current or previ-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "blocker therapy can lead to clinical deterioration"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "ous symptoms, use of 1 of the 3 beta blockers"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "proven to reduce mortality (eg, bisoprolol, and should be avoided unless indicated.18"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "1 A"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "carvedilol, sustained-release metoprolol succi- 2. Multiple analyses have shown the high value of"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "nate) is recommended to reduce mortality and"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "beta-blocker therapy among HF patients. A model-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "hospitalizations.1–3"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "based analysis, using generic beta-blocker costs,"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "2. In patients with HFrEF, with current or previous"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Value Statement: found beta-blocker therapy was high value.4 These"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "symptoms, beta-blocker therapy provides high"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "High Value (A) economic value.4–8 results were consistent with earlier model-based"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "cost-effectiveness analyses5–7 and a trial-based"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "economic analysis of the US Carvedilol Heart"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Failure (CHF) Trials Program.8 Each of these stud-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Treatment with beta blockers reduces the risk of death ies also found treatment with a beta blocker was"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "and the combined risk of death or hospitalization in pa- high value despite using previously higher beta-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "tients with HFrEF.1–3 In addition, this treatment can im- blocker costs."
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "prove LVEF, lessen the symptoms of HF, and improve"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "7.3.3. Mineralocorticoid Receptor Antagonists"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "clinical status.1–3,9–11 Clinical trials have shown that"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "(MRAs)"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "beta blockers should be prescribed to all patients when"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "HFrEF is diagnosed, including in-hospital, unless contra- Recommendations for Mineralocorticoid Receptor Antagonists (MRAs)"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "indicated or not tolerated.1–3,9–11 These benefits of beta"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "blockers were observed in patients with or without CAD,"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "and in patients with or without diabetes, older patients,"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "1. In patients with HFrEF and NYHA class II to IV"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "as well as in women and across racial and ethnic groups"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "symptoms, an MRA (spironolactone or eplere-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "but not in patients with AF.1–3,10–12 Even if symptoms do none) is recommended to reduce morbidity and"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "not improve, long-term treatment should be maintained mortality, if eGFR is >30 mL/min/1.73 m2 and"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "1 A serum potassium is <5.0 mEq/L. Careful moni-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "to reduce the risk of major cardiovascular events. Beta"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "toring of potassium, renal function, and diuretic"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "blockers should be initiated at low doses, and every ef- dosing should be performed at initiation and"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "fort should be made to achieve the target doses of the closely monitored thereafter to minimize risk of"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "hyperkalemia and renal insufficiency.1–3"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "beta blockers shown to be effective in major clinical tri-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "als, as tolerated1–3,9,10 (see Section 7.3.8, “GDMT Dosing, Value Statement: 2. In patients with HFrEF and NYHA class II to"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "IV symptoms, MRA therapy provides high eco- Sequencing and Uptitration”). High Value (A)"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "nomic value.4–7"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "3. In patients taking MRA whose serum potas-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text 3: Harm B-NR sium cannot be maintained at <5.5 mEq/L,"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "MRA should be discontinued to avoid life-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "1. Three beta blockers have been shown to be effec- threatening hyperkalemia.8,9"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "tive in reducing the risk of death in patients with"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "HFrEF: bisoprolol, sustained-release metoprolol"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "(succinate), and carvedilol.1–3 The favorable find-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "ings with these 3 agents, however, should not be MRA (also known as aldosterone antagonists or anti-min-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "considered a beta-blocker class effect in HFrEF. eralocorticoids) show consistent improvements in all-cause"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Other beta blockers are not included in this rec- mortality, HF hospitalizations, and SCD across a wide range"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "ommendation for use.13–15 Even when asymptom- of patients with HFrEF.1–3 Patients at risk for renal dysfunc-"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "atic, or when symptoms are mild or improve with tion or hyperkalemia require close monitoring, and eGFR"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "other therapies, beta-blocker therapy is important ≤30 mL/min/1.73 m2 or serum potassium ≥5.0 mEq/L"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "and should not be delayed until symptoms return or are contraindications to MRA initiation.10,11 Because of the"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "disease progression is documented.16 Data show higher selectivity of eplerenone for the aldosterone receptor,"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "that beta blockers can be safely initiated before adverse effects such as gynecomastia and vaginal bleeding"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 37,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "e932 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "are observed less often in patients who take eplerenone of younger patients with fewer multiple chronic"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "than in those who take spironolactone. conditions than seen in the general HFrEF popula-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "tion, safety may be overstated. Observational data"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "have raised concerns about less favorable out-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "comes of MRA use for HFrEF during usual care.8,9"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "1. Clinical trials taken on MRA together—RALES Coadministration of MRA with ACEi or ARB mildly"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "(Randomized Aldactone Evaluation Study)1 ran- increases the risk of hyperkalemia. Hyperkalemia"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "domized highly symptomatic patients with LVEF risk was lower with ARNi in patients with chronic"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "≤35%; EPHESUS (Eplerenone Post–Acute HF in the PARADIGM-HF trial13 but not different in"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Myocardial Infarction Heart Failure Efficacy and patients with HF who were decompensated in the"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Survival Study)2 randomized patients post-MI with PIONEER-HF trial14 when compared with ACEi."
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "LVEF ≤40%; and EMPHASIS-HF (Eplerenone in Diarrhea causing dehydration or loop diuretic ther-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Mild Patients Hospitalization and Survival Study apy interruption, because of worsening renal func-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "in Heart Failure)3 randomized patients with mild tion or hyperkalemia, should be a consideration for"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "symptoms and LVEF ≤30%—suggest a benefit of temporarily holding the MRA. The development of"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "MRA across the spectrum of HFrEF, inclusive of worsening renal function or hyperkalemia is often"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "a wide range of etiologies and disease severities. a reflection of acute clinical change or progressive"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Initiation in the ambulatory or hospital setting is disease, prompting careful evaluation of the entire"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "appropriate.12 The starting dose of spironolactone medical regimen and other causes of hyperkalemia,"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "and eplerenone is 25 mg orally daily, increased to in addition to holding the MRA. The efficacy of the"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "50 mg daily orally after a month; for eGFR 31 to use of potassium binders (eg, patiromer, sodium zir-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "49 mL/min/1.73 m2, dosing should be reduced conium cyclosilicate) to improve outcomes by facili-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "by half. Regular checks of serum potassium levels tating continuation of MRA is uncertain15,16 and is"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "and renal function should be performed accord- addressed in Section 7.3.6, “Other Drug Treatment.”"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "ing to clinical status, approximately 1 week, then 4"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "weeks, then every 6 months after initiating or inten- 7.3.4. Sodium-Glucose Cotransporter 2 Inhibitors"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "sifying MRA, with more frequent testing for clinical"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Recommendation for SGLT2i"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "instability. We elected to remove the 2013 recom- Referenced studies that support the recommendation are summarized"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "mendation “Aldosterone receptor antagonists are in the Online Data Supplements."
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "recommended to reduce morbidity and mortality COR LOE Recommendation"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "following an acute MI in patients who have LVEF of 1. In patients with symptomatic chronic HFrEF,"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "40% or less who develop symptoms of HF or who 1 A SGLT2i are recommended to reduce hospital-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "ization for HF and cardiovascular mortality, irre-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "have a history of diabetes mellitus, unless contrain-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "spective of the presence of type 2 diabetes.1,2"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "dicated” because the new recommendation covers"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Value Statement: 2. In patients with symptomatic chronic HFrEF,"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "the spectrum of symptomatic patients with HF."
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Intermediate Value SGLT2i therapy provides intermediate eco-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "2. The economic value of MRA therapy was assessed (A) nomic value.3,4"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "by both RCTs (RALES5 and EPHESUS6,7) and a"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "model-based analysis.4 The model-based analysis"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "used generic MRA costs and found therapy was"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "high value with a cost per QALY of under $1000.4 Several RCTs in patients with type 2 diabetes and ei-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "The earlier trial-based economic analyses of MRAs ther established CVD or high risk for CVD have shown"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "from RALES and EPHESUS also found MRA ther- that SGLT2i prevent HF hospitalizations compared with"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "apy was high value despite using previously higher placebo.5–7 The overall 31% reduction in HF hospitaliza-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "MRA costs.5–7 tions was noted irrespective of the presence or absence"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "3. Spironolactone and eplerenone are partially of preexisting HF, although only 10% to 14% of par-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "excreted through the kidneys, raising concerns ticipants had HF at baseline. The benefit appears in-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "about safety when eGFR is ≤30 mL/min/1.73 dependent of the glucose-lowering effects.8 Therefore,"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "m2.10,11 Spironolactone and eplerenone decrease several trials were launched to examine the efficacy of"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "renal potassium excretion, raising the risk of SGLT2i on outcomes in patients with HF, irrespective of"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "hyperkalemia, particularly when MRA is initiated the presence of type 2 diabetes. The DAPA-HF (Dapa-"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "at serum potassium ≥5.0 mEq/L and continued gliflozin and Prevention of Adverse Outcomes in Heart"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "≥5.5 mEq/L. The incidence of clinically significant Failure) trial and EMPEROR-Reduced (EMPagliflozin"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "hyperkalemia events was <1% in EPHESUS and outcomE tRial in Patients With chrOnic heaRt Failure"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "EMPHASIS-HF, without a significant difference With Reduced Ejection Fraction) showed the benefit of"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "between eplerenone and placebo.2,3 however, in the SGLT2i (dapagliflozin and empagliflozin, respectively)"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "closely monitored setting of a RCT with enrollment versus placebo on outcomes (median follow-up, 16–18"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 38,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e933"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "months).1,2 Patients enrolled had symptomatic chronic These 2 analyses estimated a cost per QALY below"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "HFrEF (LVEF ≤40%, NYHA class II to IV, and elevated $50 000 with annual dapagliflozin costs of $3240"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "natriuretic peptides) and were already on GDMT. Impor- (43% reduction from main analysis) and $2500"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "tant exclusions were eGFR <20 (EMPEROR-Reduced) (40% reduction from main analysis), respectively.3,4"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "or <30 mL/min/1.73 m2 (DAPA-HF), type 1 diabetes, or A smaller reduction in drug cost would lead to a"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "lower SBP <95 to 100 mm Hg. cost per QALY of under $60 000, the threshold for"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "high value in this guideline."
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text 7.3.5. Hydralazine and Isosorbide Dinitrate"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "1. In the DAPA-HF and EMPEROR-Reduced tri- Recommendations for Hydralazine and Isosorbide Dinitrate"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "als, SGLT2i compared with placebo reduced the"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "composite of cardiovascular death or HF hospi-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "talization by approximately 25%.1,2,9 The benefit in"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "1. For patients self-identified as African American"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "reduction of HF hospitalization was greater (30%)"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "with NYHA class III-IV HFrEF who are receiv-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "in both trials.9 Risk of cardiovascular death was ing optimal medical therapy, the combination"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "1 A"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "significantly lowered (18%) with dapagliflozin, as of hydralazine and isosorbide dinitrate is rec-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "ommended to improve symptoms and reduce"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "was risk of all-cause mortality (17%). Although"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "morbidity and mortality.1,2"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "no significant cardiovascular mortality benefit was"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "2. For patients self-identified as African Ameri-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "observed with empagliflozin in a meta-analysis"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "can with NYHA class III to IV HFrEF who are"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "of DAPA-HF and EMPEROR-Reduced trials, Value Statement: receiving optimal medical therapy with ACEi or"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "SGLT2i therapy was associated with a reduction High Value (B-NR) ARB, beta blockers, and MRA, the combination"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "of hydralazine and isosorbide dinitrate provides"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "in all-cause mortality and cardiovascular death.9"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "high economic value.3"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "The benefits in both trials were seen irrespective"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "3. In patients with current or previous symp-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "of baseline diabetes status. Furthermore, serious tomatic HFrEF who cannot be given first-line"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "renal outcomes were less frequent, and the rate agents, such as ARNi, ACEi, or ARB, because"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "2b C-LD of drug intolerance or renal insufficiency, a"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "of decline in eGFR was slower in patients treated"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "combination of hydralazine and isosorbide dini-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "with SGLT2i.1,2,9 In the SOLOIST-WHF (Effect of trate might be considered to reduce morbidity"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "Sotagliflozin on Cardiovascular Events in Patients and mortality.4,5"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "With Type 2 Diabetes And Worsening Heart Failure)"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "trial, patients with diabetes and HF hospitalization"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "(79%: LVEF, <50%) were enrolled before dis-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "charge or within 3 days of discharge. Sotagliflozin, Two RCTs, V-HeFT I (Vasodilator Heart Failure Trial)"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "a dual inhibitor of sodium-glucose co-transporters and A-HeFT (African-American Heart Failure Trial), es-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "1 and 2, reduced the combined endpoint of car- tablished benefit of the combination of hydralazine-iso-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "diovascular death, HF hospitalization, or urgent sorbide dinitrate in self-identified African Americans.2,4"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "HF visits by 33%10 but has not been approved by A-HeFT was terminated early because of evidence of"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "the US Food and Drug Administration (FDA) as of remarkable benefit, but the result is vulnerable to a small"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "2021. Although SGLT2i increased risk for genital number of events and the exigencies of early cessation"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "infections, they were otherwise well tolerated in the of RCTs.2 The benefit in both trials was seen only at doses"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "trials. As the use of SGLT2i is translated into clini- achieved in those trials that are higher than doses typi-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "cal practice, caution is warranted for euglycemic cally used in clinical practice and with short-acting nitrate"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "ketoacidosis, genital and soft tissue infections, and therapy.2,4 Uptake of this regimen has been modest as a"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "adjustment of diuretics, if needed, to prevent vol- result of the complexity of the medical regimen and the"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "ume depletion.11 array of drug-related adverse effects.5 Even when pre-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "2. Two model-based analyses evaluated the economic scribed, there is marked underusage based on very low"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "value of dapagliflozin therapy compared with usual prescription refill rates. Race-based medical therapy re-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "care based on the results of the DAPA-HF trial.3,4 mains a challenging issue, as well, with ongoing research"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "Both analyses found costs per QALY between now focused on biological hypotheses, particularly ab-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "$60 000 and $90 000, which is consistent with sence of European ancestry, which may be associated"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "intermediate value according to the benchmarks with responsiveness to this combination. There are insuf-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "adopted for the current guideline. The results were ficient data to guide the use of hydralazine-isosorbide"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "most sensitive to the magnitude of cardiovascular dinitrate with ARNi. In patients with HFrEF who cannot"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "mortality reduction, with a ≥8% reduction in cardio- receive first-line agents such as ARNi, ACEi, or ARB, re-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "vascular mortality necessary for a cost per QALY ferral to a HF specialist can provide guidance for further"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "below $150 000 in 1 study.3 There are a wide management because the use of hydralazine and isosor-"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "range of costs currently seen with dapagliflozin. bide dinitrate in these patients is uncertain."
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 39,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "e934 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text 7.3.6. Other Drug Treatment"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "1. In a large-scale trial that compared the vasodila- Recommendations for Other Drug Treatment"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "tor combination with placebo, the use of hydrala-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "zine and isosorbide dinitrate reduced mortality in"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "patients with HF treated with digoxin and diuretics"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "1. In patients with HF class II to IV symptoms,"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "but not an ACEi or beta blocker.4 However, in 2"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "omega-3 polyunsaturated fatty acid (PUFA)"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "other trials that compared the vasodilator combina- 2b B-R supplementation may be reasonable to use as"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "tion with an ACEi, the ACEi produced more favor- adjunctive therapy to reduce mortality and car-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "diovascular hospitalizations.1–4"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "able effects on survival.6,7 A post hoc retrospective"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "analysis of these vasodilator trials showed particu- 2. In patients with HF who experience hyperkale-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "mia (serum potassium level ≥5.5 mEq/L) while"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "lar efficacy of isosorbide dinitrate and hydralazine"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "taking a renin-angiotensin-aldosterone system"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "in the African American cohort.1 In a subsequent inhibitor (RAASi), the effectiveness of potas-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "2b B-R"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "trial, which was limited to patients self-identified sium binders (patiromer, sodium zirconium"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "cyclosilicate) to improve outcomes by facilitat-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "as African American, the addition of a fixed-dose"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "ing continuation of RAASi therapy is uncer-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "combination of hydralazine and isosorbide dini- tain.5,6"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "trate to standard therapy with an ACEi or ARB, a"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "3. In patients with chronic HFrEF without a spe-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "beta blocker, and MRA offered significant benefit.2 cific indication (eg, venous thromboembolism"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "3: No"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "Thus, the combination of hydralazine and isosor- Benefit B-R [VTE], AF, a previous thromboembolic event, or"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "a cardioembolic source), anticoagulation is not"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "bide dinitrate is appropriate for African Americans recommended.7–9"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "with HFrEF who remain symptomatic despite con-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "comitant use of ACEi (or ARB), beta blockers, and"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "MRA. There are insufficient data for concomitant Synopsis"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "use with ARNi."
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "Trials in prevention of CVD, including HF, showed that"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "2. The economic value of hydralazine and isosorbide"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "omega-3 PUFA supplementation results in a 10% to"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "nitrate therapy was assessed by the A-HeFT trial.3"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "20% risk reduction in fatal and nonfatal cardiovascular"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "This analysis found hydralazine and isosorbide"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "events when used with other evidence-based thera-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "dinitrate increased survival and reduced health"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "pies.2,3,10 Hyperkalemia is common in HF and can lead"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "care costs over the 12.8-month trial. Extrapolating"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "to arrhythmias and underuse of GDMT.11,12 Two newer"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "beyond the trial, the analysis found hydralazine and"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "gastrointestinal potassium-binding agents—patiromer"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "isosorbide dinitrate remained high value over a life-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "and sodium zirconium cyclosilicate—have been shown"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "time with a cost per life-year <$60 000 despite"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "to lower potassium levels and enable treatment with a"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "conservative assumptions regarding the durabil-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "RAASi in patients with HF.5,6,13"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "ity of therapy effectiveness and previously higher"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "hydralazine and isosorbide dinitrate costs."
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "3. It is unclear if a benefit of hydralazine-isosorbide"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "dinitrate (suggested in a trial before the use of 1. Supplementation with omega-3 PUFA has been"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "ACEi)4 exists for non–African Americans with evaluated as an adjunctive therapy for CVD and"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "HFrEF. Despite the lack of data with the vaso- HF.14 The GISSI-HF (Effect of n-3 polyunsaturated"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "dilator combination in patients who are intoler- fatty acids in patients with chronic heart failure)"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "ant of ACEi or ARB, especially those with renal trial showed a reduction in death among post-MI"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "insufficiency, the combined use of hydralazine patients taking 1 g of omega-3 PUFA (850–882"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "and isosorbide dinitrate might be considered as mg of eicosapentaenoic acid [EPA] and docosa-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "a therapeutic option in such patients. Although hexaenoic acid [DHA] as ethyl esters in the ratio"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "the potential benefit is unknown and has not of 1:1.2).10 A post hoc subgroup analysis revealed"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "been shown in recent observational datasets,5 in that this reduction in mortality and SCD was con-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "V-HeFT I, the use of hydralazine and isosorbide centrated in the approximately 2000 patients with"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "dinitrate reduced mortality in patients with HF reduced LVEF.10 The GISSI-HF investigators ran-"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "treated with digoxin and diuretics, compared with domized symptomatic patients with HF to 1 g daily"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "placebo.4 If patients are unable to tolerate first- of omega-3 PUFA (850–882 mg of EPA-DHA)"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "line agents, such as ARNi, ACEi, or ARB, because or placebo. Death from any cause was reduced"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "of drug intolerance, hypotension, or renal insuf- from 29% with placebo to 27% in those treated"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "ficiency, referral to a HF specialist can provide with omega-3 PUFA.2 The outcome of death or"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "guidance for further management, and the use admission to hospital for a cardiovascular event"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "of hydralazine and isosorbide dinitrate in these was also significantly reduced. The REDUCE-IT"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "patients might be considered. trial randomized patients with established CVD"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 40,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e935"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "or diabetes with risk factors to 2 g of icosapent difference in the combined outcome of death, isch-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "ethyl (a highly purified EPA) twice daily or placebo emic stroke, intracerebral hemorrhage, MI, or HF"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "and showed a reduced risk for the composite of hospitalization.8 There was a significant increase"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "cardiovascular death, nonfatal MI, nonfatal stroke, in major bleeding with warfarin. A trial of rivaroxa-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "coronary revascularization, or unstable angina.3 In ban in patients with HFrEF, CAD, and normal sinus"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "reported studies, omega-3 PUFA therapy has been rhythm showed no difference in mortality, MI, and"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "well tolerated. Recent studies have reported that stroke compared with placebo.9 Therefore, there is"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "in patients with cardiovascular risk treated with no evidence of benefit for anticoagulation in HF"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "omega-3 fatty acid, there may be a dose-related patients without a specific indication (eg, VTE, AF,"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "risk of AF.3,15,16 a previous thromboembolic event, or a cardioem-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "2. Hyperkalemia is common in HF as a result of bolic source)."
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "the syndrome itself, comorbidities (diabetes,"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "7.3.7. Drugs of Unproven Value or That May Worsen"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "CKD), and use of RAASi, and can increase the"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "HF"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "risk for ventricular arrhythmias and mortality.11"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Hyperkalemia results in dose reductions or dis- Recommendations for Drugs of Unproven Value or Drugs That May"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Worsen HF"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "continuation of RAASi, compromising their cardio-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "renal benefit in HF.12 Two newer gastrointestinal rized in the Online Data Supplements."
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "potassium binders—patiromer (RLY5016) and"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "sodium zirconium cyclosilicate (SZC)—remove"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "1. In patients with HFrEF, dihydropyridine calcium"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "potassium by exchanging cations (calcium for pat- 3: No A channel-blocking drugs are not recommended"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Benefit"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "iromer, and sodium and hydrogen for SZC), lead- treatment for HF.1,2"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "ing to increased fecal excretion. Both agents have 2. In patients with HFrEF, vitamins, nutritional"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "been FDA approved for treatment of hyperkalemia 3: No supplements, and hormonal therapy are not"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "B-R"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Benefit recommended other than to correct specific"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "for patients receiving RAASi. In the PEARL-HF"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "deficiencies.3–9"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "(Evaluation of the efficacy and safety of RLY5016,"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "3. In patients with HFrEF, nondihydropyridine"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "a polymeric potassium binder in patients with"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "3: Harm A calcium channel-blocking drugs are not recom-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "chronic heart failure) trial, patiromer led to lower mended.10–13"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "potassium levels, less hyperkalemia, and a higher 4. In patients with HFrEF, class IC antiarrhythmic"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "proportion of patients able to increase spironolac- 3: Harm A medications and dronedarone may increase the"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "risk of mortality.14–16"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "tone dose to 50 mg daily compared with placebo.5"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "The HARMONIZE (Hyperkalemia Randomized 5. In patients with HFrEF, thiazolidinediones"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "3: Harm A increase the risk of worsening HF symptoms"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Intervention Multidose ZS-9 Maintenance) trial"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "and hospitalizations.17–21"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "included 94 patients (out of 258 total) with HF"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "6. In patients with type 2 diabetes and high"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "(87 of whom entered the double-blind phase).6,13"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "cardiovascular risk, the dipeptidyl pepti-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "The SZC groups achieved lower potassium lev- dase-4 (DPP-4) inhibitors saxagliptin and"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "3: Harm B-R"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "els overall compared with placebo, and a higher alogliptin increase the risk of HF hospitaliza-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "tion and should be avoided in patients with"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "proportion maintained normokalemia (potassium HF.22–24"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "levels, <5.1 mEq/L). Whether patiromer or SZC"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "7. In patients with HFrEF, NSAIDs worsen HF"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "improve clinical outcomes is under investigation. 3: Harm B-NR symptoms and should be avoided or withdrawn"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Adverse effects for the newer potassium bind- whenever possible.25–28"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "ers include hypomagnesemia (for patiromer) and"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "edema (for SZC)."
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "3. In several retrospective analyses, the risk of throm-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "boembolic events was not lower in patients with Although there is strong evidence for benefit with se-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "HF taking warfarin than in patients not treated with lected medications for HFrEF as outlined in Section 7.3,"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "antithrombotic drugs.17–19 The use of warfarin was “Pharmacological Treatment for HF With Reduced Ejec-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "associated with a reduction in major cardiovascular tion Fraction (HFrEF),” there remain several classes of"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "events and death in patients with HF in some stud- medications that have either unproven value or poten-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "ies but not in others.20–22 An RCT that compared tial for harm (Table 13). These recommendations are"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "the outcome of patients with HFrEF assigned not exhaustive but focus on the most relevant and com-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "to aspirin, warfarin, or clopidogrel found that no monly encountered medications in the management of"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "therapy was superior.7 Another trial that compared patients with HFrEF: calcium channel blockers; antiar-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "aspirin with warfarin in patients with reduced LVEF, rhythmic agents; NSAIDs; medications for treatment of"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "sinus rhythm, and no cardioembolic source showed type 2 diabetes including thiazolidinediones and DPP-4"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "no difference in either the primary outcome of inhibitors; and vitamins, hormones, and nutritional sup-"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "death, stroke, or intracerebral hemorrhage, and no plements."
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 41,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "e936 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Table 13. Selected Prescription Medications That May Cause or Exacerbate HF"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Associated With HF"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Exacerbates"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Causes Direct Underlying Magnitude of LOE for HF"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Myocardial Myocardial HF Induction or Induction or"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Drug or Therapeutic Class Toxicity Dysfunction Precipitation Precipitation Possible Mechanism(s) Onset"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "COX, nonselective inhibi- X Major B Prostaglandin inhibition leading to Immediate"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "tors (NSAIDs) sodium and water retention, increased"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "systemic vascular resistance, and blunted"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "COX, selective inhibitors X Major B"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "response to diuretics"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "(COX-2 inhibitors)"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Thiazolidinediones X Major A Possible calcium channel blockade Intermediate"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Saxagliptin X Major A Unknown Intermediate to"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "delayed"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Alogliptin X Major A"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Flecainide X Major A Negative inotrope, proarrhythmic effects Immediate to"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "intermediate"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Disopyramide X Major B"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Sotalol X Major A Proarrhythmic properties, beta blockade Immediate to"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "intermediate"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Dronedarone X Major A Negative inotrope"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Alpha-1 blockers"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Doxazosin X Moderate B Beta-1-receptor stimulation with increas- Intermediate to"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "es in renin and aldosterone delayed"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Diltiazem X Major B Negative inotrope Immediate to"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "intermediate"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Verapamil X Major B"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Nifedipine X Moderate C"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "COX indicates cyclo-oxygenase; HF, heart failure; LOE, Level of Evidence; and NSAID, nonsteroidal anti-inflammatory drug."
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Adapted from Page RL 2nd et al.57 Copyright 2016 American Heart Association Inc."
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text nonrandomized design.32,33 In addition, adverse"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "1. Second-generation dihydropyridine calcium effects and drug-nutraceutical interactions remain"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "channel blockers, including amlodipine and unresolved. There is a lack of evidence of benefit"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "felodipine, have greater selectivity for calcium from vitamin D,3–5 thiamine,34–36 carnitine,37 and"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "channels in vascular smooth muscle cells and taurine38,39 and potential harm from vitamin E.6,7"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "less myocardial depressant activity. By reduc- The largest RCT of coenzyme Q10—Q-SYMBIO"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "ing peripheral vasoconstriction and LV afterload, (Coenzyme Q10 as adjunctive treatment of chronic"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "calcium channel blockers were thought to have heart failure with focus on SYMptoms, BIomarker"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "a potential role in the management of chronic status [Brain-Natriuretic Peptide], and long-term"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "HF. The PRAISE-1 (Prospective Randomized Outcome [hospitalisations/mortality])—showed no"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Amlodipine Survival Evaluation-1) study showed changes in NYHA functional classification at 16"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "a reduction in mortality in the subgroup of weeks, although the incidence of major adverse"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "patients with nonischemic cardiomyopathy who cardiovascular events at 2 years was significantly"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "received amlodipine.1 However, in the PRAISE-2 reduced (hazard ratio, 0.50; 95% CI, 0.32-0.80;"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "(Prospective Randomized Amlodipine Survival P=0.003).8 Despite these findings, concerns about"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Evaluation 2) trial, which enrolled only patients slow recruitment in this trial have tempered enthusi-"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "with nonischemic cardiomyopathy, no survival asm for coenzyme Q10 supplementation in clinical"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "benefit was observed, indicating the limitations practice.9,31 Hormonal therapies have been proposed"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "of conclusions derived from subgroup analyses.29 for the treatment of HF, but trials have shown a neu-"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "However, dihydropyridine calcium channel block- tral effect of testosterone,40,41 growth hormone,30,42"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "ers may be used for treatment of hypertension and thyroid hormone43–45 in HF outcomes."
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "in patients who have elevated blood pressure 3. Nondihydropyridine calcium channel blockers—dil-"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "despite optimization of GDMT. tiazem and verapamil—are myocardial depressants"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "2. Many nutritional supplements and hormonal and generally not well tolerated in HF. Verapamil"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "therapies have been proposed for the treatment had no impact of survival or major cardiac events"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "of HF.3–9,30,31 Ultimately, most studies are limited post-MI, including in those patients with HFrEF"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "by small sample sizes, surrogate endpoints, or after acute MI.10 In patients with nonischemic"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 42,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e937"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "cardiomyopathy, diltiazem had no impact on mor- including only patients with no HF history,23,50 but"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "tality13 but, in HFrEF after acute MI, diltiazem was sitagliptin51,52and linagliptin53–55 did not; these"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "associated with a higher risk of recurrent HF.11,12 findings may have been a result of baseline dif-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "4. In the CAST (Cardiac Arrhythmia Suppression) ferences in the use of metformin, thiazolidinedio-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "trial, patients with asymptomatic ventricular nes, and insulin, which also affect HF risk. The"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "arrhythmias post-MI on the class IC antiarrhyth- FDA recommends discontinuation specifically of"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "mics encainide or flecainide had increased mortal- saxagliptin and alogliptin in patients who develop"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "ity.14 The applicability of CAST to patients without HF,56 and whether the risk of worsening HF is a"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "recent MI or to other class I antiarrhythmic drugs class effect of DPP-4 inhibitors is unclear."
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "is uncertain, but class IC antiarrhythmic agents 7. NSAIDs inhibit the synthesis of renal prosta-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "are generally avoided in patients with structural glandins, which mediate vasodilation in the kid-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "heart disease. In ANDROMEDA (Antiarrhythmic neys and directly inhibit sodium resorption in the"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "Trial with Dronedarone in Moderate to Severe thick ascending loop of Henle and collecting"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "CHF Evaluating Morbidity Decrease Study), for tubule. Hence, NSAIDs can cause sodium and"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "the class III antiarrhythmic dronedarone, patients water retention and blunt the effects of diuret-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "with HFrEF who were hospitalized had increased ics. Several observational cohort studies have"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "mortality.16 In the SWORD (Survival With ORal revealed increased morbidity and mortality in"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "D-sotalol) trial of the class III antiarrhythmic sotalol, patients with HF using either nonselective or"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "patients with HF post-MI had increased mortality.15 selective NSAIDs.25–28"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "However, SWORD was published in 1996, and"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "whether sotalol would be harmful in the current 7.3.8. GDMT Dosing: Sequencing and Uptitration"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "era of GDMT and ICDs is uncertain; sotalol may"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "Recommendations for GDMT Dosing: Sequencing and Uptitration"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "be used for refractory atrial-ventricular arrhyth- Referenced studies that support the recommendations are"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "mias with close monitoring for decompensation. summarized in the Online Data Supplements."
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "Amiodarone46,47 and dofetilide48,49 are the only anti- COR LOE Recommendations"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "arrhythmic agents with neutral effects on mortal- 1. In patients with HFrEF, titration of guideline-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "ity in clinical trials of patients with HFrEF. Class IA directed medication dosing to achieve target"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "doses showed to be efficacious in RCTs is rec-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "antiarrhythmic agents such as quinidine and class 1 A"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "ommended, to reduce cardiovascular mortality"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "IB agents such as mexiletine have not been stud- and HF hospitalizations, unless not well toler-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "ied and may be indicated for the management of ated.1–10"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "refractory ventricular arrhythmias in the context of 2. In patients with HFrEF, titration and optimiza-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "the individual patient’s risk benefit calculus and in tion of guideline-directed medications as"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "frequently as every 1 to 2 weeks depending on"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "conjunction with electrophysiology consultation. 2a C-EO"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "the patient’s symptoms, vital signs, and labora-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "5. Thiazolidinediones increase insulin sensitivity by tory findings can be useful to optimize manage-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "activating nuclear peroxisome proliferator-acti- ment."
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "vated receptor gamma (PPAR-γ). Expressed in"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "virtually all tissues, PPAR-γ also regulates sodium"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "reabsorption in the collecting ducts of the kidney."
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "In observational cohort studies,17 meta-analysis,18 Clinical trials of ACEi, ARB, ARNi, beta blockers, and"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "and clinical trials,19–21 thiazolidinediones have been most other HFrEF medications had therapy initiated at"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "associated with increased incidence of fluid reten- low dose by trial protocol.1–9,11–14 If the initial dose was"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "tion and HF events in those patients with19,21or tolerated, the protocol would then direct the uptitration"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "without18,20a previous history of HF. of medication dose over time to a specified target dose"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "6. DPP-4 is a cell-surface enzyme that deactivates (Table 14), unless not well tolerated. Even if symptoms"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "several peptides include glucose-dependent improved or other indicators of response were shown"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "insulinotropic polypeptide and glucagon-like at lower doses, the medication dose would still be in-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "peptide 1. DPP-4 inhibitors affect glucose reg- creased to the trial-defined target doses. Because"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "ulation through multiple mechanisms, includ- these target doses were the ones that established the"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "ing enhancement of glucose-dependent insulin efficacy and safety of these medications in HFrEF and"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "secretion, slowed gastric emptying, and reduction serve as the basis of the guideline recommendations"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "of postprandial glucagon and of food intake. The (Table 15), use of these target doses is recommended,"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "impact of DPP-4 inhibitors on cardiovascular out- if tolerated.1–9,11–14 Use of all 4 drug classes has been"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "comes in patients with diabetes and high cardio- estimated to reduce all-cause mortality by 73% com-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "vascular risk has been assessed in multiple RCTs. pared with no treatment.15"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "Saxagliptin increased the risk of hospitalization If the target dose cannot be achieved or is not well tol-"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "for HF,22 as did alogliptin in a post hoc analysis erated, then the highest tolerated dose is recommended."
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 43,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "e938 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Table 14. Drugs Commonly Used for HFrEF (Stage C HF)"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Mean Doses Achieved in"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Drug Initial Daily Dose(s) Target Doses(s) Clinical Trials References"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "ACEi"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Captopril 6.25 mg 3 times daily 50 mg 3 times daily 122.7 mg total daily 19"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Enalapril 2.5 mg twice daily 10–20 mg twice daily 16.6 mg total daily 3"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Fosinopril 5–10 mg once daily 40 mg once daily NA …"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Lisinopril 2.5–5 mg once daily 20–40 mg once daily 32.5–35.0 mg total daily 17"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Perindopril 2 mg once daily 8–16 mg once daily NA …"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Quinapril 5 mg twice daily 20 mg twice daily NA …"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Ramipril 1.25–2.5 mg once daily 10 mg once daily NA …"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Trandolapril 1 mg once daily 4 mg once daily NA …"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "ARB"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Candesartan 4–8 mg once daily 32 mg once daily 24 mg total daily 20"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Losartan 25–50 mg once daily 50–150 mg once daily 129 mg total daily 18"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Valsartan 20–40 mg once daily 160 mg twice daily 254 mg total daily 21"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "ARNi"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Sacubitril-valsartan 49 mg sacubitril and 51 mg val- 97 mg sacubitril and 103 mg val- 182 mg sacubitril and 193 mg 22"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "sartan twice daily (therapy may be sartan twice daily valsartan total daily"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "initiated at 24 mg sacubitril and"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "26 mg valsartan twice daily)"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Beta blockers"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Bisoprolol 1.25 mg once daily 10 mg once daily 8.6 mg total daily 1"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Carvedilol 3.125 mg twice daily 25–50 mg twice daily 37 mg total daily 23"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Carvedilol CR 10 mg once daily 80 mg once daily NA …"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Metoprolol succinate extended 12.5–25 mg once daily 200 mg once daily 159 mg total daily 11"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "release (metoprolol CR/XL)"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Mineralocorticoid receptor antagonists"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Spironolactone 12.5–25 mg once daily 25–50 mg once daily 26 mg total daily 6"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Eplerenone 25 mg once daily 50 mg once daily 42.6 mg total daily 13"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "SGLT2i"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Dapagliflozin 10 mg once daily 10 mg once daily 9.8 mg total daily 8"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Empagliflozin 10 mg once daily 10 mg once daily NR 9"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Isosorbide dinitrate and hydralazine"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Fixed dose combination 20 mg isosorbide dinitrate and 40 mg isosorbide dinitrate and 75 90 mg isosorbide dinitrate and 10"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "37.5 mg hydralazine 3 times daily mg hydralazine 3 times daily ∼175 mg hydralazine total daily"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Isosorbide dinitrate and hydrala- 20–30 mg isosorbide dinitrate 120 mg isosorbide dinitrate total NA 24"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "zine and 25–50 mg hydralazine 3–4 daily in divided doses and 300"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "times daily mg hydralazine total daily in di-"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "vided doses"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "I Channel inhibitor"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "f"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Ivabradine 5 mg twice daily 7.5 mg twice daily 12.8 total daily 25–27"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Soluble guanylate cyclase stimulator"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Vericiguat 2.5 mg once daily 10 mg once daily 9.2 mg total daily 28"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Cardiac glycoside"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Digoxin 0.125–0.25 mg daily (modified Individualized variable dose to NA 29,30"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "according to monogram) achieve serum digoxin concentra-"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "tion 0.5–<0.9 ng/mL"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CR, controlled release; CR/XL, controlled release/extended release; HF, heart"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "failure; HFrEF, heart failure with reduced ejection fraction; NA, not applicable; NR, not reported; and SGLT2i, sodium glucose cotransporter 2 inhibitor."
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "There are no direct data showing that use of lower doses lar degree of clinical benefit. In trials that have evaluated"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "of HFrEF medications among patients, where higher target dose response for outcomes, composite event rates were"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "doses could be tolerated, would produce the same or simi- lower with target doses compared with lower dose.16–18"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 44,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 44,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Drug": "ACEi",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Captopril",
                "Initial Daily Dose(s)": "6.25 mg 3 times daily",
                "Target Doses(s)": "50 mg 3 times daily",
                "Mean Doses Achieved in Clinical Trials": "122.7 mg total daily",
                "References": "19"
            },
            {
                "Drug": "Enalapril",
                "Initial Daily Dose(s)": "2.5 mg twice daily",
                "Target Doses(s)": "10–20 mg twice daily",
                "Mean Doses Achieved in Clinical Trials": "16.6 mg total daily",
                "References": "3"
            },
            {
                "Drug": "Fosinopril",
                "Initial Daily Dose(s)": "5–10 mg once daily",
                "Target Doses(s)": "40 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "NA",
                "References": "…"
            },
            {
                "Drug": "Lisinopril",
                "Initial Daily Dose(s)": "2.5–5 mg once daily",
                "Target Doses(s)": "20–40 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "32.5–35.0 mg total daily",
                "References": "17"
            },
            {
                "Drug": "Perindopril",
                "Initial Daily Dose(s)": "2 mg once daily",
                "Target Doses(s)": "8–16 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "NA",
                "References": "…"
            },
            {
                "Drug": "Quinapril",
                "Initial Daily Dose(s)": "5 mg twice daily",
                "Target Doses(s)": "20 mg twice daily",
                "Mean Doses Achieved in Clinical Trials": "NA",
                "References": "…"
            },
            {
                "Drug": "Ramipril",
                "Initial Daily Dose(s)": "1.25–2.5 mg once daily",
                "Target Doses(s)": "10 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "NA",
                "References": "…"
            },
            {
                "Drug": "Trandolapril",
                "Initial Daily Dose(s)": "1 mg once daily",
                "Target Doses(s)": "4 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "NA",
                "References": "…"
            },
            {
                "Drug": "ARB",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Candesartan",
                "Initial Daily Dose(s)": "4–8 mg once daily",
                "Target Doses(s)": "32 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "24 mg total daily",
                "References": "20"
            },
            {
                "Drug": "Losartan",
                "Initial Daily Dose(s)": "25–50 mg once daily",
                "Target Doses(s)": "50–150 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "129 mg total daily",
                "References": "18"
            },
            {
                "Drug": "Valsartan",
                "Initial Daily Dose(s)": "20–40 mg once daily",
                "Target Doses(s)": "160 mg twice daily",
                "Mean Doses Achieved in Clinical Trials": "254 mg total daily",
                "References": "21"
            },
            {
                "Drug": "ARNi",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Sacubitril-valsartan",
                "Initial Daily Dose(s)": "49 mg sacubitril and 51 mg val- sartan twice daily (therapy may be initiated at 24 mg sacubitril and 26 mg valsartan twice daily)",
                "Target Doses(s)": "97 mg sacubitril and 103 mg val- sartan twice daily",
                "Mean Doses Achieved in Clinical Trials": "182 mg sacubitril and 193 mg valsartan total daily",
                "References": "22"
            },
            {
                "Drug": "Beta blockers",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Bisoprolol",
                "Initial Daily Dose(s)": "1.25 mg once daily",
                "Target Doses(s)": "10 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "8.6 mg total daily",
                "References": "1"
            },
            {
                "Drug": "Carvedilol",
                "Initial Daily Dose(s)": "3.125 mg twice daily",
                "Target Doses(s)": "25–50 mg twice daily",
                "Mean Doses Achieved in Clinical Trials": "37 mg total daily",
                "References": "23"
            },
            {
                "Drug": "Carvedilol CR",
                "Initial Daily Dose(s)": "10 mg once daily",
                "Target Doses(s)": "80 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "NA",
                "References": "…"
            },
            {
                "Drug": "Metoprolol succinate extended release (metoprolol CR/XL)",
                "Initial Daily Dose(s)": "12.5–25 mg once daily",
                "Target Doses(s)": "200 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "159 mg total daily",
                "References": "11"
            },
            {
                "Drug": "Mineralocorticoid receptor antagonists",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Spironolactone",
                "Initial Daily Dose(s)": "12.5–25 mg once daily",
                "Target Doses(s)": "25–50 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "26 mg total daily",
                "References": "6"
            },
            {
                "Drug": "Eplerenone",
                "Initial Daily Dose(s)": "25 mg once daily",
                "Target Doses(s)": "50 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "42.6 mg total daily",
                "References": "13"
            },
            {
                "Drug": "SGLT2i",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Dapagliflozin",
                "Initial Daily Dose(s)": "10 mg once daily",
                "Target Doses(s)": "10 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "9.8 mg total daily",
                "References": "8"
            },
            {
                "Drug": "Empagliflozin",
                "Initial Daily Dose(s)": "10 mg once daily",
                "Target Doses(s)": "10 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "NR",
                "References": "9"
            },
            {
                "Drug": "Isosorbide dinitrate and hydralazine",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Fixed dose combination",
                "Initial Daily Dose(s)": "20 mg isosorbide dinitrate and 37.5 mg hydralazine 3 times daily",
                "Target Doses(s)": "40 mg isosorbide dinitrate and 75 mg hydralazine 3 times daily",
                "Mean Doses Achieved in Clinical Trials": "90 mg isosorbide dinitrate and ∼175 mg hydralazine total daily",
                "References": "10"
            },
            {
                "Drug": "Isosorbide dinitrate and hydrala- zine",
                "Initial Daily Dose(s)": "20–30 mg isosorbide dinitrate and 25–50 mg hydralazine 3–4 times daily",
                "Target Doses(s)": "120 mg isosorbide dinitrate total daily in divided doses and 300 mg hydralazine total daily in di- vided doses",
                "Mean Doses Achieved in Clinical Trials": "NA",
                "References": "24"
            },
            {
                "Drug": "I Channel inhibitor f",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Ivabradine",
                "Initial Daily Dose(s)": "5 mg twice daily",
                "Target Doses(s)": "7.5 mg twice daily",
                "Mean Doses Achieved in Clinical Trials": "12.8 total daily",
                "References": "25–27"
            },
            {
                "Drug": "Soluble guanylate cyclase stimulator",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Vericiguat",
                "Initial Daily Dose(s)": "2.5 mg once daily",
                "Target Doses(s)": "10 mg once daily",
                "Mean Doses Achieved in Clinical Trials": "9.2 mg total daily",
                "References": "28"
            },
            {
                "Drug": "Cardiac glycoside",
                "Initial Daily Dose(s)": "",
                "Target Doses(s)": "",
                "Mean Doses Achieved in Clinical Trials": "",
                "References": ""
            },
            {
                "Drug": "Digoxin",
                "Initial Daily Dose(s)": "0.125–0.25 mg daily (modified according to monogram)",
                "Target Doses(s)": "Individualized variable dose to achieve serum digoxin concentra- tion 0.5–<0.9 ng/mL",
                "Mean Doses Achieved in Clinical Trials": "NA",
                "References": "29,30"
            }
        ],
        "conteudo_texto": "ACEi, , , ,  | Captopril, 6.25 mg 3 times daily, 50 mg 3 times daily, 122.7 mg total daily, 19 | Enalapril, 2.5 mg twice daily, 10–20 mg twice daily, 16.6 mg total daily, 3 | Fosinopril, 5–10 mg once daily, 40 mg once daily, NA, … | Lisinopril, 2.5–5 mg once daily, 20–40 mg once daily, 32.5–35.0 mg total daily, 17 | Perindopril, 2 mg once daily, 8–16 mg once daily, NA, … | Quinapril, 5 mg twice daily, 20 mg twice daily, NA, … | Ramipril, 1.25–2.5 mg once daily, 10 mg once daily, NA, … | Trandolapril, 1 mg once daily, 4 mg once daily, NA, … | ARB, , , ,  | Candesartan, 4–8 mg once daily, 32 mg once daily, 24 mg total daily, 20 | Losartan, 25–50 mg once daily, 50–150 mg once daily, 129 mg total daily, 18 | Valsartan, 20–40 mg once daily, 160 mg twice daily, 254 mg total daily, 21 | ARNi, , , ,  | Sacubitril-valsartan, 49 mg sacubitril and 51 mg val- sartan twice daily (therapy may be initiated at 24 mg sacubitril and 26 mg valsartan twice daily), 97 mg sacubitril and 103 mg val- sartan twice daily, 182 mg sacubitril and 193 mg valsartan total daily, 22 | Beta blockers, , , ,  | Bisoprolol, 1.25 mg once daily, 10 mg once daily, 8.6 mg total daily, 1 | Carvedilol, 3.125 mg twice daily, 25–50 mg twice daily, 37 mg total daily, 23 | Carvedilol CR, 10 mg once daily, 80 mg once daily, NA, … | Metoprolol succinate extended release (metoprolol CR/XL), 12.5–25 mg once daily, 200 mg once daily, 159 mg total daily, 11 | Mineralocorticoid receptor antagonists, , , ,  | Spironolactone, 12.5–25 mg once daily, 25–50 mg once daily, 26 mg total daily, 6 | Eplerenone, 25 mg once daily, 50 mg once daily, 42.6 mg total daily, 13 | SGLT2i, , , ,  | Dapagliflozin, 10 mg once daily, 10 mg once daily, 9.8 mg total daily, 8 | Empagliflozin, 10 mg once daily, 10 mg once daily, NR, 9 | Isosorbide dinitrate and hydralazine, , , ,  | Fixed dose combination, 20 mg isosorbide dinitrate and 37.5 mg hydralazine 3 times daily, 40 mg isosorbide dinitrate and 75 mg hydralazine 3 times daily, 90 mg isosorbide dinitrate and ∼175 mg hydralazine total daily, 10 | Isosorbide dinitrate and hydrala- zine, 20–30 mg isosorbide dinitrate and 25–50 mg hydralazine 3–4 times daily, 120 mg isosorbide dinitrate total daily in divided doses and 300 mg hydralazine total daily in di- vided doses, NA, 24 | I Channel inhibitor f, , , ,  | Ivabradine, 5 mg twice daily, 7.5 mg twice daily, 12.8 total daily, 25–27 | Soluble guanylate cyclase stimulator, , , ,  | Vericiguat, 2.5 mg once daily, 10 mg once daily, 9.2 mg total daily, 28 | Cardiac glycoside, , , ,  | Digoxin, 0.125–0.25 mg daily (modified according to monogram), Individualized variable dose to achieve serum digoxin concentra- tion 0.5–<0.9 ng/mL, NA, 29,30"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e939"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Table 15. Benefits of Evidence-Based Therapies for Patients With HFrEF3–6,8,10–14,23,31–42"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Relative Risk Reduction in"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "All-Cause Mortality in NNT to Prevent All-Cause NNT for All-Cause Mortality NNT for All- Cause Mortality"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Evidence-Based Therapy Pivotal RCTs, % Mortality Over Time* (Standardized to 12 mo) (Standardized to 36 mo)"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "ACEi or ARB 17 22 over 42 mo 77 26"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "ARNi† 16 36 over 27 mo 80 27"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Beta blocker 34 28 over 12 mo 28 9"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Mineralocorticoid receptor 30 9 over 24 mo 18 6"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "antagonist"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "SGLT2i 17 43 over 18 mo 63 22"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Hydralazine or nitrate‡ 43 25 over 10 mo 21 7"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "CRT 36 12 over 24 mo 24 8"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "ICD 23 14 over 60 mo 70 23"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor neprilysin inhibitor; CRT, cardiac resyn-"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "chronization therapy; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; NNT, number needed to treat; RCT, randomized"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "controlled trial; and SGLT2i, sodium-glucose cotransporter-2 inhibitor."
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "*Median duration follow-up in the respective clinical trial."
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "†Benefit of ARNi therapy incremental to that achieved with ACEi therapy. For the other medications shown, the benefits are based on comparisons to placebo"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "control."
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "‡Benefit of hydralazine-nitrate therapy was limited to African American patients in this trial."
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text cause of HF, and ability of follow-up. In patients"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "with HFrEF, simultaneous initiation or sequencing,"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "1. The use of these specific medications for HFrEF"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "and order of guideline-directed medications are"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "should involve initiation at low-starting doses,"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "usually individualized according to patient’s symp-"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "uptitration at specified intervals as tolerated, and"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "toms, vital signs, functional status, tolerance, renal"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "achieving-maintaining the target doses shown to"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "function, electrolytes, comorbidities, specific cause"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "be effective in major clinical trials. Every effort"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "of HF, and ability of follow-up, and does not neces-"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "should be made by clinicians to achieve and main-"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "sarily need to be done according to the sequence"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "tain the clinical trial–defined target doses (Table"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "of trial publications and should not be delayed."
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "13) of guideline-directed medications, as long as"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "they are well tolerated by the patient. Patients 7.3.9. Additional Medical Therapies"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "should be monitored for changes in heart rate,"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "7.3.9.1. Management of Stage C HF: Ivabradine"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "blood pressure, electrolytes, renal function, and"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "symptoms during this uptitration period. Planned Recommendation for the Management of Stage C HF: Ivabradine"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendation are summarized"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "uptitration of a HF medication should be delayed"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "in the Online Data Supplements."
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "until any adverse effects observed with lower"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "doses have resolved. When such a strategy is"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "1. For patients with symptomatic (NYHA class II"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "used for dose titration, most patients (approxi-"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "to III) stable chronic HFrEF (LVEF ≤35%) who"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "mately 70%–85%) enrolled in clinical trials who are receiving GDMT, including a beta blocker"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "received these medications were able to tolerate 2a B-R at maximum tolerated dose, and who are in"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "sinus rhythm with a heart rate of ≥70 bpm at short-, intermediate-, and long-term treatment"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "rest, ivabradine can be beneficial to reduce HF"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "with these agents and achieve and maintain hospitalizations and cardiovascular death.1,2"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "the trial defined target dose.1–9,11–14 Repeated"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "attempts at uptitration can result in optimization,"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "even if initial attempts may fail. In patients with"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "HFrEF, beta blockers provide dose-dependent Heart rate is a strong predictor of cardiovascular out-"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "improvements in LVEF, reduction in HF hospi- comes in the general population and in patients with"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "talizations, and reduction in all-cause mortality.17 CVD, including HF. The SHIFT (Ivabradine and Outcomes"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Trials of lower versus higher dose of ACEi and in Chronic Heart Failure) trial tested the hypothesis that"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "ARB have shown lower risk of cardiovascular reducing heart rate in patients with HF improves cardio-"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "death or HF hospitalization with higher doses, vascular outcomes.1 SHIFT demonstrated the efficacy of"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "with similar safety and tolerability.17,18 ivabradine, a sinoatrial node modulator that selectively"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "2. Initiation and titration should be individualized and inhibits the I current, in reducing the composite endpoint"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "f"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "optimized without delay according to patient’s of cardiovascular death or HF hospitalization in patients"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "symptoms, vital signs, functional status, tolerance, with HF. See Figure 7 for a summary of additional medi-"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "renal function, electrolytes, comorbidities, specific cal therapy recommendations."
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 45,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 45,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Evidence-Based Therapy": "ACEi or ARB",
                "Relative Risk Reduction in All-Cause Mortality in Pivotal RCTs, %": "17",
                "NNT to Prevent All-Cause Mortality Over Time*": "22 over 42 mo",
                "NNT for All-Cause Mortality (Standardized to 12 mo)": "77",
                "NNT for All- Cause Mortality (Standardized to 36 mo)": "26"
            },
            {
                "Evidence-Based Therapy": "ARNi†",
                "Relative Risk Reduction in All-Cause Mortality in Pivotal RCTs, %": "16",
                "NNT to Prevent All-Cause Mortality Over Time*": "36 over 27 mo",
                "NNT for All-Cause Mortality (Standardized to 12 mo)": "80",
                "NNT for All- Cause Mortality (Standardized to 36 mo)": "27"
            },
            {
                "Evidence-Based Therapy": "Beta blocker",
                "Relative Risk Reduction in All-Cause Mortality in Pivotal RCTs, %": "34",
                "NNT to Prevent All-Cause Mortality Over Time*": "28 over 12 mo",
                "NNT for All-Cause Mortality (Standardized to 12 mo)": "28",
                "NNT for All- Cause Mortality (Standardized to 36 mo)": "9"
            },
            {
                "Evidence-Based Therapy": "Mineralocorticoid receptor antagonist",
                "Relative Risk Reduction in All-Cause Mortality in Pivotal RCTs, %": "30",
                "NNT to Prevent All-Cause Mortality Over Time*": "9 over 24 mo",
                "NNT for All-Cause Mortality (Standardized to 12 mo)": "18",
                "NNT for All- Cause Mortality (Standardized to 36 mo)": "6"
            },
            {
                "Evidence-Based Therapy": "SGLT2i",
                "Relative Risk Reduction in All-Cause Mortality in Pivotal RCTs, %": "17",
                "NNT to Prevent All-Cause Mortality Over Time*": "43 over 18 mo",
                "NNT for All-Cause Mortality (Standardized to 12 mo)": "63",
                "NNT for All- Cause Mortality (Standardized to 36 mo)": "22"
            },
            {
                "Evidence-Based Therapy": "Hydralazine or nitrate‡",
                "Relative Risk Reduction in All-Cause Mortality in Pivotal RCTs, %": "43",
                "NNT to Prevent All-Cause Mortality Over Time*": "25 over 10 mo",
                "NNT for All-Cause Mortality (Standardized to 12 mo)": "21",
                "NNT for All- Cause Mortality (Standardized to 36 mo)": "7"
            },
            {
                "Evidence-Based Therapy": "CRT",
                "Relative Risk Reduction in All-Cause Mortality in Pivotal RCTs, %": "36",
                "NNT to Prevent All-Cause Mortality Over Time*": "12 over 24 mo",
                "NNT for All-Cause Mortality (Standardized to 12 mo)": "24",
                "NNT for All- Cause Mortality (Standardized to 36 mo)": "8"
            },
            {
                "Evidence-Based Therapy": "ICD",
                "Relative Risk Reduction in All-Cause Mortality in Pivotal RCTs, %": "23",
                "NNT to Prevent All-Cause Mortality Over Time*": "14 over 60 mo",
                "NNT for All-Cause Mortality (Standardized to 12 mo)": "70",
                "NNT for All- Cause Mortality (Standardized to 36 mo)": "23"
            }
        ],
        "conteudo_texto": "ACEi or ARB, 17, 22 over 42 mo, 77, 26 | ARNi†, 16, 36 over 27 mo, 80, 27 | Beta blocker, 34, 28 over 12 mo, 28, 9 | Mineralocorticoid receptor antagonist, 30, 9 over 24 mo, 18, 6 | SGLT2i, 17, 43 over 18 mo, 63, 22 | Hydralazine or nitrate‡, 43, 25 over 10 mo, 21, 7 | CRT, 36, 12 over 24 mo, 24, 8 | ICD, 23, 14 over 60 mo, 70, 23"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "e940 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "7.3.9.2. Pharmacological Treatment for Stage C"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "HFrEF: Digoxin"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "Recommendation for the Pharmacological Treatment for Stage C"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "HFrEF: Digoxin"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendation are summarized"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "in the Online Data Supplements."
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "1. In patients with symptomatic HFrEF despite"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "GDMT (or who are unable to tolerate GDMT),"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "2b B-R"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "digoxin might be considered to decrease hospi-"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "talizations for HF.1,2"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "To date, there has been only 1 large-scale, RCT of digox-"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "in in patients with HF.1 This trial, which predated current"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "GDMT, primarily enrolled patients with NYHA class II to"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "III HF and showed that treatment with digoxin for 2 to 5"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "years had no effect on mortality but modestly reduced"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "the combined risk of death and hospitalization. The trial"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "also found no significant effect on health-related QOL"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "in a subset of the trial patients.3 The effect of digoxin"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "on hospitalizations has been supported by retrospective"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "analyses and meta-analyses.2,4–6 Additionally, observa-"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "tional studies and retrospective analyses have shown"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "improvement in symptoms and exercise tolerance in mild"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "to moderate HF; however, they have mostly shown either"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "lack of mortality benefit or increased mortality associated"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "Figure 7. Additional Medical Therapies for Patients With HFrEF. with digoxin.7 The benefit in patients on current GDMT"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "Colors correspond to COR in Table 2. Recommendations for additional is unclear because most trials preceded current GDMT."
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "medical therapies that may be considered for patients with HF are Thus, use of digoxin requires caution in patients with HF"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "shown. GDMT indicates guideline-directed medical therapy; HF,"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "and is reserved for those who remain symptomatic de-"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "heart failure; HFH, heart failure hospitalization; HFrEF, heart failure"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "spite optimization of GDMT."
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "with reduced ejection fraction; IV, intravenous; LVEF, left ventricular"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "ejection fraction; LVESD, left ventricular end systolic dimension; MV,"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "mitral valve; MR, mitral regurgitation; NP, natriuretic peptide; NSR,"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "normal sinus rhythm; NYHA, New York Heart Association; and RAASi,"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "renin-angiotensin-aldosterone system inhibitors. 1. Digoxin is usually initiated at a low dose because"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "higher doses are rarely required in the management"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "of HF and are potentially detrimental. Two retro-"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "1. Although the primary outcome in SHIFT was a com- spective analyses of large-scale clinical trials have"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "posite of hospitalization and cardiovascular death, shown a linear relationship between mortality and"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "the greatest benefit was a reduction in HF hospi- digoxin serum concentration in patients with AF"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "talization. SHIFT included patients with HFrEF and and at risk for stroke, including those with HF, and"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "LVEF ≤35% who were in sinus rhythm with a resting in patients with HF. The risk of death was indepen-"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "heart rate of ≥70 bpm. Participants were predomi- dently associated with serum digoxin concentration,"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "nantly NYHA class II and III. Participants had been with a significantly higher risk observed in those with"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "hospitalized for HF in the preceding 12 months and concentrations ≥1.2 ng/mL and ≥1.6 ng/mL.8,9 The"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "were on stable GDMT for 4 weeks before initiation benefit of digoxin in patients with HF remains con-"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "of ivabradine therapy.1–4 The target of ivabradine troversial. GDMT is expected to be optimized before"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "is heart rate, and the benefit of ivabradine results considering the addition of digoxin. Clinical worsen-"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "from a reduction in heart rate. However, only 25% ing after withdrawal of digoxin has been shown.10"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "of patients studied in SHIFT were on optimal doses Therapy with digoxin may either be continued in the"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "of beta-blocker therapy. Given the well-proven mor- absence of a contraindication or discontinued with"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "tality benefits of beta-blocker therapy, these agents caution.11 Therapy with digoxin is commonly initi-"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "should be initiated and uptitrated to target doses, ated and maintained at a dose of 0.125 to 0.25 mg"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "as tolerated, before assessing the resting heart rate daily. Low doses (0.125 mg daily or every other day)"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "for consideration of ivabradine initiation.5,6 should be used initially if the patient is >70 years of"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 46,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e941"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "age, has impaired renal function, or has a low lean a higher risk population. Although not statistically"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "body mass. Higher doses (eg, digoxin 0.375 to 0.50 significant, symptomatic hypotension (9.1% versus"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "mg daily) are rarely used or needed in the manage- 7.9%; P=0.12) and syncope (4.0% versus 3.5%;"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "ment of patients with HF. P=0.30) were numerically higher in the vericiguat"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "group versus placebo. There was heterogeneity"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "7.3.9.3. Pharmacological Treatment for Stage C"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "by subgroup analysis, and patients in the highest"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "HFrEF: Soluble Guanylyl Cyclase Stimulators"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "quartile of NT-proBNP subgroup (NT proBNP level"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "Recommendation for Pharmacological Treatment for Stage C HFrEF: >5314 pg/mL) did not have benefit from vericiguat"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "Soluble Guanylyl Cyclase Stimulators"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "when compared with placebo."
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendation are summarized"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "in the Online Data Supplements."
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation 7.4. Device and Interventional Therapies for"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "1. In selected high-risk patients with HFrEF and HFrEF"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "recent worsening of HF already on GDMT,"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "2b B-R an oral soluble guanylate cyclase stimulator 7.4.1. ICDs and CRTs"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "(vericiguat) may be considered to reduce HF"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "hospitalization and cardiovascular death.1 Recommendations for ICDs and CRTs"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "summarized in the Online Data Supplements."
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "In patients with progression of HFrEF despite GDMT, 1. In patients with nonischemic DCM or ischemic"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "heart disease at least 40 days post-MI with"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "there may be a role for novel therapeutic agents. Oral"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "LVEF ≤35% and NYHA class II or III symp-"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "soluble guanylyl cyclase stimulator (eg, vericiguat) di- 1 A toms on chronic GDMT, who have reasonable"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "rectly binds and stimulates sGC and increases cGMP expectation of meaningful survival for >1 year,"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "ICD therapy is recommended for primary pre-"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "production. cGMP has several potentially beneficial"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "vention of SCD to reduce total mortality.1–9"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "effects in patients with HF, including vasodilation, im-"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "2. A transvenous ICD provides high economic"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "provement in endothelial function, as well as decrease"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "value in the primary prevention of SCD"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "in fibrosis and remodeling of the heart.2–7 The VICTORIA particularly when the patient’s risk of death"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "(Vericiguat Global Study in Subjects with Heart Failure Value Statement: caused by ventricular arrythmia is deemed"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "High Value (A) high and the risk of nonarrhythmic death"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "with Reduced Ejection Fraction) trial randomized 5050"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "(either cardiac or noncardiac) is deemed low"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "higher-risk patients with worsening HFrEF to vericiguat based on the patient’s burden of comorbidi-"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "versus placebo.1 ties and functional status.10–15"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "3. In patients at least 40 days post-MI with LVEF"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "≤30% and NYHA class I symptoms while"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text receiving GDMT, who have reasonable expec-"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "1 B-R"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "tation of meaningful survival for >1 year, ICD"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "1. Patients with HFrEF in the VICTORIA trial had LVEF therapy is recommended for primary prevention"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "<45%, NYHA class II to IV, were on GDMT, with of SCD to reduce total mortality.6"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "elevated natriuretic peptides (BNP ≥300 pg/mL 4. For patients who have LVEF ≤35%, sinus rhythm,"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "or NT-proBNP ≥1000 pg/mL if in sinus rhythm; left bundle branch block (LBBB) with a QRS"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "duration ≥150 ms, and NYHA class II, III, or"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "higher cutoffs with AF), and recent HF worsening 1 B-R"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "ambulatory IV symptoms on GDMT, CRT is"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "(hospitalized within 6 months or recently received indicated to reduce total mortality, reduce hospi-"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "intravenous diuretic therapy without hospitaliza- talizations, and improve symptoms and QOL.16–21"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "tion). Patients on long-acting nitrates, with SBP 5. For patients who have LVEF ≤35%, sinus"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "rhythm, LBBB with a QRS duration of ≥150"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "<100 mm Hg, or eGFR <15 mL/min/1.73 m2 were Value Statement:"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "ms, and NYHA class II, III, or ambulatory IV excluded.1 Over a median follow-up of 10.8 months, High Value (B-NR) symptoms on GDMT, CRT implantation pro-"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "the primary outcome, cardiovascular death or HF vides high economic value.22–27"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "hospitalization, occurred in 35.5% with vericiguat 6. For patients who have LVEF ≤35%, sinus"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "compared with 38.5% with placebo (HR, 0.90; rhythm, a non-LBBB pattern with a QRS"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "duration ≥150 ms, and NYHA class II, III, or"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "P=0.019). All-cause mortality occurred in 20.3%"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "2a B-R ambulatory class IV symptoms on GDMT,"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "in the vericiguat group and 21.2% in the placebo CRT can be useful to reduce total mortality,"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "group (HR, 0.95; 95% CI, 0.84-1.07; P=0.38) and reduce hospitalizations, and improve symp-"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "toms and QOL.16–21,28–33"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "composite of any-cause death or HF hospitaliza-"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "7. In patients with high-degree or complete"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "tion was also lower in the vericiguat group versus"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "heart block and LVEF of 36% to 50%, CRT is"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "placebo group (HR, 0.90; 95% CI, 0.83–0.98; 2a B-R reasonable to reduce total mortality, reduce"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "P=0.02). The relative risk reduction of 10% in the hospitalizations, and improve symptoms and"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "QOL.34,35"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "primary outcome was lower than expected, even in"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 47,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "e942 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Recommendations for ICDs and CRTs (Continued)"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations 1. ICDs were first assessed in patients who had"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "8. For patients who have LVEF ≤35%, sinus been resuscitated from a cardiac arrest. In AVID"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "rhythm, LBBB with a QRS duration of 120 (Antiarrhythmics versus Implantable Defibrillators"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "to 149 ms, and NYHA class II, III, or ambu-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "trial), CASH (Cardiac Arrest Study Hamburg),"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "2a B-NR latory IV symptoms on GDMT, CRT can"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "be useful to reduce total mortality, reduce and CIDS (Canadian Implantable Defibrillator"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "hospitalizations, and improve symptoms and StudyS), benefit was observed in those who were"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "QOL.16–21,28–33"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "randomized to ICDs.1–3 Extension of benefit was"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "9. In patients with AF and LVEF ≤35% on GDMT, then shown in other patient populations that"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "CRT can be useful to reduce total mortality,"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "were at perceived risk of SCD. In the first MADIT"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "improve symptoms and QOL, and increase"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "LVEF, if: a) the patient requires ventricular pac- (Multicenter Automated Defibrillator Implantation"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "2a B-NR"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "ing or otherwise meets CRT criteria and b) Trial) trial, patients with previous MI, LVEF ≤35%"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "atrioventricular nodal ablation or pharmacologi-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "with nonsustained VT had a mortality benefit with"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "cal rate control will allow near 100% ventricu-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "lar pacing with CRT.16–21,28–33 ICD.4 Similar populations in MUSTT (Multicenter"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "UnSustained Tachycardia Trial) also showed bene-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "10. For patients on GDMT who have LVEF"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "≤35% and are undergoing placement of fit.5 In MADIT-II (Multicenter Automatic Defibrillator"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "a new or replacement device implantation Implantation Trial II), patients with no arrhyth-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "with anticipated requirement for significant"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "2a B-NR mia qualifier but with previous MIs and LVEF"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "(>40%) ventricular pacing, CRT can be"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "useful to reduce total mortality, reduce ≤30% derived benefit from ICD.6 The DEFINITE"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "hospitalizations, and improve symptoms and (Defibrillators in Non-Ischemic Cardiomyopathy"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "QOL.16–21,28–33"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Treatment Evaluation) study included only non-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "11. In patients with genetic arrhythmogenic car-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "ischemic patients with LVEF ≤35% and frequent"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "diomyopathy with high-risk features of sudden"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "2a B-NR death, with EF ≤45%, implantation of ICD is premature ventricular contractions (PVCs) or non-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "reasonable to decrease sudden death.36,37 sustained ventricular tachycardia (VT).7 There was"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "12. For patients who have LVEF ≤35%, sinus a trend to mortality benefit, but it ultimately did"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "rhythm, a non-LBBB pattern with QRS dura- not achieve significance. In SCD-HEFT (Sudden"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "tion of 120 to 149 ms, and NYHA class III or"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Cardiac Death in Heart Failure Trial), patients with"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "2b B-NR ambulatory class IV on GDMT, CRT may be"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "considered to reduce total mortality, reduce ischemic and nonischemic cardiomyopathy, LVEF"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "hospitalizations, and improve symptoms and ≤35%, and HF class II to III showed benefit with"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "QOL.16–21,28–33"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "an ICD compared with either amiodarone or pla-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "13. For patients who have LVEF ≤30%, ischemic cebo.8 More recently, the DANISH (Defibrillator"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "cause of HF, sinus rhythm, LBBB with a QRS"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "duration ≥150 ms, and NYHA class I symp- Implantation in Patients with Nonischemic Systolic"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "2b B-NR"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "toms on GDMT, CRT may be considered to Heart Failure) trial enrolled patients with nonisch-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "reduce hospitalizations and improve symptoms emic cardiomyopathy and LVEF ≤35% to ICD or"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "and QOL.16–21,28–33"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "standard care.9 There was no reduction in the pri-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "3: No 14. In patients with QRS duration <120 ms, CRT"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "B-R mary endpoint of total mortality, but there was a"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Benefit is not recommended.36–41"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "reduction in SCD risk. In the DANISH trial, 58% of"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "15. For patients with NYHA class I or II symptoms"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "3: No patients in each limb received CRT, possibly miti-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "B-NR and non-LBBB pattern with QRS duration"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Benefit"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "<150 ms, CRT is not recommended.16–21,28–33 gating the benefit of an ICD."
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "16. For patients whose comorbidities or frailty 2. Economic outcomes of ICD implantation for pri-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "limit survival with good functional capacity to mary prevention of SCD were assessed in 3 RCTs"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "3: No"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "C-LD <1 year, ICD and cardiac resynchronization"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Benefit (MADIT-I,13 MADIT-II,15 and SCD-HeFT,12 1 obser-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "therapy with defibrillation (CRT-D) are not indi-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "cated.1–9,16–21 vational study,10 and 3 simulation models,11,14,42 all"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "of which had generally consistent results. All stud-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "ies reported increased survival and life expectancy"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "and higher lifetime costs of medical care with an"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "RCTs have informed the decisions regarding cardiac ICD than without an ICD. The incremental cost-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "implantable devices (ICDs and CRTs) over the past 20 effectiveness ratios were generally <$60 000 per"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "years. In fact, the seminal RCTs for ICDs and CRTs are year of life added by an ICD, which provides high"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "unlikely to be repeated. Subgroup analyses of these tri- value according to the benchmarks adopted for the"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "als have also informed decisions, but these were not the current guideline. The value provided by an ICD"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "primary endpoints of these studies and thus should be was consistently high when life expectancy was"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "interpreted with caution. GDMT is optimized before ICD projected to increase by >1.4 years.14 In contrast,"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "and CRT implantation to assess whether the LVEF im- when survival was not increased by ICD implanta-"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "proves. Figures 8 and 9 summarize device and interven- tion, as in the coronary artery bypass graft (CABG)"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "tional therapy recommendations. Patch trial,43 the ICD did not provide value, because"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 48,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e943"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "Figure 8. Algorithm for CRT Indications in Patients With Cardiomyopathy or HFrEF."
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "Colors correspond to COR in Table 2. Recommendations for cardiac resynchronization therapy (CRT) are displayed. AF indicates atrial fibrillation;"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "Amb, ambulatory; CM, cardiomyopathy; GDMT, guideline-directed medical therapy; HB, heart block; HF, heart failure; HFrEF, heart failure with"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "reduced ejection fraction; LBBB, left bundle branch block; LV, left ventricular; LVEF, left ventricular ejection fraction; NSR, normal sinus rhythm;"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "NYHA, New York Heart Association; and RV, right ventricular."
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "the higher costs were unaccompanied by a gain in with CRT-P and CRT-D. The CARE-HF (Cardiac"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "life expectancy.14 Resynchronization Heart Failure) trial included"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "3. The MADIT-II trial randomized patients with previ- a similar group with NYHA class III to IV, LVEF"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "ous MI and LVEF <30%, without any limitation of ≤35%, QRS >120 ms, and showed a significant"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "HF class, to ICDs or not.6 Thirty-seven percent of reduction in primary and endpoint of death or hos-"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "the patients were in class I congestive heart failure pitalization.18 In the REVERSE (Resynchronization"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "(CHF). Mortality was reduced with an ICD. Reverses Remodeling in Systolic Left Ventricular"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "4. Most of the relevant data for the guidelines of Dysfunction) trial, patients with NYHA class I to II"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "CRT in HF come from seminal trials published and LVEF ≤40% were randomized to CRT-D on for"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "from 2002 to 2010. The first of these was the 1 year and CRT-D off for 1 year or vice versa.19 A"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "MIRACLE (Multicenter InSync Randomized Clinical HF composite endpoint was less common when"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "Evaluation) trial, which took patients with LVEF CRT was activated. MADIT-CRT enrolled NYHA"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "≤35%, moderate to severe HF, and QRS duration class I and II HF with LVEF ≤30% and QRS ≥130"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "≥130 ms.16 There was a benefit in the 6-minute ms and compared CRT-D with ICD.20 The primary"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "walk test, QOL, functional HF classification, and endpoint of death or HF was reduced by CRT-D."
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "LVEF. The COMPANION (Comparison of Medical The RAFT (Resynchronization-Defibrillation for"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "Therapy, Pacing and Defibrillation in Heart Failure) Ambulatory Heart Failure) trial randomized patients"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "trial, which enrolled NYHA class III to IV patients with NYHA class II to III HF, LVEF ≤30%, QRS"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "with QRS ≥120 ms, included 3 arms: GDMT, CRT-D, >120 ms, or paced QRS ≥200 ms and compared"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "and CRT pacemaker (CRT-P).17 The primary end- CRT-D with ICD.21 Again, there was a reduction in"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "point of death or hospitalization was decreased the primary endpoint of death or HF hospitalization."
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 49,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "e944 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "including longer QRS duration, and LBBB versus"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "non-LBBB.28 The most benefit was gained with"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "wider QRS durations and with LBBB. This was"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "true in COMPANION, CARE-HF, MADIT-CRT,"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "REVERSE, and RAFT.17,29–32 A QRS duration >150"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "ms was also a predictor of response, and in those"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "with non-LBBB, a prolonged PR predicted benefit"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "in MADIT-CRT but not in REVERSE.33"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "7. Extension of benefit to those with LVEF between"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "35% and 50% has been seen. In the BLOCK-HF"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "(Biventricular versus Right Ventricular Pacing in"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "Heart Failure) trial, patients with NYHA class I"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "to III HF, LVEF ≤50%, and atrioventricular block"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "randomized to RV pacing or CRT, there was ben-"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "efit to CRT in reduction in the primary outcome of"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "death, urgent HF visit, or 15% increase in LV end"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "systolic volume.34"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "8. In the previously mentioned CRT trials, there was"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "some benefit for those with LBBB and QRS dura-"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "tions between 120 and 149, but not as much ben-"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "efit as those with LBBB ≥150 ms.17,28–32"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "9. Several trials have included patients with AF."
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "In the MUSTIC AF (Multisite Stimulation in"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "Cardiomyopathies),44 RAFT,45 and the SPARE"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "Figure 9. Additional Device Therapies."
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "Colors correspond to COR in Table 2. Recommendations for (Spanish Atrial Fibrillation and Resynchronization)46"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "additional nonpharmaceutical interventions that may be considered trials, there were benefits in patients with AF,"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "for patients with HF are shown. GDMT indicates guideline-directed while in COMPANION,47 AF attenuated the ben-"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "medical therapy; HF, heart failure; HFH, heart failure hospitalization;"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "efit of CRT. In the PAVE (Post AV Nodal Ablation"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "HFrEF, heart failure with reduced ejection fraction; IV, intravenous;"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "Evaluation) study, patients with NYHA class II to III,"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "LVEF, left ventricular ejection fraction; LVESD, left ventricular end"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "systolic dimension; MV, mitral valve; MR, mitral regurgitation; NP, mean LVEF of 46%, and AF undergoing atrioven-"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "natriuretic peptide; NSR, normal sinus rhythm; NYHA, New York tricular node ablation, CRT improved the 6-minute"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "Heart Association; and PASP, pulmonary artery systolic pressure. walk test and LVEF compared with those who were"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "RV paced.35"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "5. The economic value of CRT has been evaluated 10. In patients in whom there is an expected high bur-"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "by 3 RCTs (COMPANION,22 MADIT-CRT,26 and den of ventricular pacing, especially if >40%, CRT"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "REVERSE23), 2 model-based analyses,25,27 and 1 may be used to reduce mortality, reduce hospital-"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "observational study.24 These analyses consistently izations, and improve symptoms and QOL.35,48"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "found CRT increased survival and QOL in addition 11. Identification of specific arrhythmogenic genetic"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "to increasing health care costs. However, the eco- variants such as LMNA/C, desmosomal proteins,"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "nomic value of CRT likely varies as a result of the phospholamban, and Filamin-C carry implications"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "shown variation in treatment effect.26 Among popu- for implantation of ICDs for primary prevention"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "lations with larger expected mortality reduction and of sudden death even in patients who have LVEF"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "improvement in QOL, such as patients with a LBBB >35%, or <3 months of GDMT. Most patients with"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "with QRS duration >150 ms, the cost per QALY is LMNA/C cardiomyopathy will progress to cardiac"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "<$60 000.22,26,27 Among other populations expected transplantation, sometimes precipitated by refrac-"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "to have smaller treatment benefit, the economic tory arrhythmias more than by pump failure.36–38,49"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "value is more uncertain. However, a model-based 12. Subgroup analysis of the CRT RCTs has shown"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "analysis of patients with NYHA class I to II found that patients with LVEFs ≤35%, non-LBBB, and"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "the incremental cost-effectiveness ratio remained QRS duration of 120 to 149 ms and NYHA class"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "<$150 000 per QALY with even small reductions in III to ambulatory class IV did not derive as much"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "all-cause mortality.27 Therefore, CRT likely provides benefit as those with LBBB ≥120 ms.17,28–32"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "at least intermediate value for patients with other 13. The MADIT-CRT trial included NYHA class I (and"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "guideline-indicated recommendations in which CRT class II) patients with ischemic heart disease, LVEF"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "is expected to reduce mortality. ≤30%, and QRS >130 ms.39 Patients with non-"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "6. Subgroup analysis of the previously mentioned tri- ischemic cardiomyopathy were enrolled if they had"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "als has informed us of the predictors of benefit, NYHA class II HF."
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 50,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e945"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "14. Extension of benefit to patients with narrow QRS (CCM), a device-based therapy that involves applying"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "has been attempted but has generally failed. In the relatively high-voltage, long-duration electric signals to"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "RETHINQ (Cardiac Resynchronization Therapy in the RV septal wall during the absolute myocardial refrac-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "Patients with Heart Failure and Narrow QRS) trial, tory period, has been associated with augmentation of"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "patients with QRS duration <130 ms were ran- LV contractile performance. CCM is FDA-approved for"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "domized to CRT or not.40 There was no benefit from patients with NYHA class III with LVEF of 25% to 45%"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "CRT, but subgroup analysis showed there was a who are not candidates for CRT. Four RCTs have shown"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "benefit with QRS durations between 120 and 130 benefits in exercise capacity and QOL but, as of yet, no"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "ms. In the ECHO-CRT (Echocardiography Guided benefits in death or hospitalizations.11–14 Most patients in"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "Cardiac Resynchronization Therapy) trial, patients these trials were class III CHF.3"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "with NYHA class III to IV HF, LVEF ≤35% and a"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "7.4.3. Revascularization for CAD"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "QRS duration ≤130 ms, and mechanical dysyn-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "chrony on echocardiography underwent random- Recommendation for Revascularization for CAD"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendation are summarized"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "ization to CRT.50 There was no benefit to CRT in"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "in the Online Data Supplements."
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "this trial. And in the LESSER-EARTH (Evaluation"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "of Resynchronization Therapy for Heart Failure)"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "1. In selected patients with HF, reduced EF (EF"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "trial, patients with severe LV dysfunction and QRS"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "≤35%), and suitable coronary anatomy, surgical"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "<120 ms derived no benefit from CRT.51 The 1 B-R revascularization plus GDMT is beneficial to"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "NARROW-CRT (Narrow QRS Ischemic Patients improve symptoms, cardiovascular hospitaliza-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "tions, and long-term all-cause mortality.1–8"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "Treated With Cardiac Resynchronization Therapy)"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "was the only trial that showed a benefit in a clinical"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "composite score in patients with an indication for Synopsis"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "an ICD and QRS <120 ms.52"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "CAD is commonly associated with HF, necessitating re-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "15. Subgroup analysis of the CRT trials has shown no"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "vascularization in selected patients with angina or HF"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "benefit for those with LVEF ≤35%, non-LBBB 120"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "symptoms. Data from the STICH Trial showed that, com-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "to 149, and NYHA class I-II HF.17,28–32"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "pared with optimal medical management alone, CABG"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "16. The 1-year survival is a standard inclusion for ICD"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "surgery plus GDMT did not reduce the primary endpoint"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "and CRT trials.1–9,16–21"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "of all-cause mortality at a median of 56 months; how-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "7.4.2. Other Implantable Electrical Interventions ever, at 10 years’ follow-up, CABG+GDMT resulted in"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "Autonomic nervous system modulation is intriguing as a significant reductions in all-cause mortality, cardiovas-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "treatment for HFrEF because of the heightened sym- cular mortality, and death from any cause or cardiovas-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "pathetic response and decreased parasympathetic re- cular hospitalization in patients with LVEF ≤35% and"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "sponse in HF.1 Trials of device stimulation of the vagus ischemic cardiomyopathy.7,8 Furthermore, a retrospective"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "nerve, spinal cord, and baroreceptors have had mixed analysis showed significant reductions in first and recur-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "responses.2 An implantable device that electrically stimu- rent all-cause, cardiovascular, and HF hospitalizations at"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "lates the baroreceptors of the carotid artery has been 10 years in patients receiving CABG+ optimal medical"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "approved by the FDA for the improvement of symptoms therapy compared with optimal medical therapy alone.2"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "in patients with advanced HF who are unsuited for treat- Similar benefits from percutaneous coronary intervention"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "ment with other HF devices including CRT. In a prospec- revascularization, in this cohort, have not yet been shown"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "tive, multicenter, RCT with a total of 408 patients with in an RCT, although the REVIVED-BCIS2 (Study of Ef-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "current or recent NYHA class III HF, LVEF ≤35%, baro- ficacy and Safety of Percutaneous Coronary Intervention"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "receptor stimulation was associated with improvements to Improve Survival in Heart Failure) trial, which com-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "in QOL, exercise capacity, and NT-proBNP levels.3 To pares percutaneous coronary intervention with medical"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "date, there are no mortality or hospitalization rates results therapy in a similar population, is ongoing.9 Recent data"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "available with this device. Although early trials of vagus continue to show a benefit of CABG over percutaneous"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "nerve stimulation were positive, the largest and latest trial coronary intervention in patients with diabetes, CAD, and"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "did not show a reduction in mortality and HF hospital- LV dysfunction and in patients with left main CAD and"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "izations.4 Multisite LV pacing studies initially were prom- moderate or severe LV dysfunction.4,6,10 Figure 9 sum-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "ising.5,6 However, more recent data have not confirmed marizes revascularization and additional device therapy"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "benefit, and the larger phase 2 trial was terminated early recommendations."
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "for low probability of benefit.7 His bundle and left bundle"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "pacing are attractive because they use the intrinsic con-"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "duction system. In observational data, there does appear"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "to be a benefit over RV pacing8; however, comparisons 1. CABG has been shown to improve outcomes"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "to CRT are limited.9,10 Cardiac contractility modulation in patients with left main or left main equivalent"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 51,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "e946 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "disease and HF.1,4,10–14 Long-term follow-up shows tality in patients treated with TEER and GDMT com-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "a reduction in all-cause, cardiovascular, and HF pared with GDMT alone, while MITRA-FR (Multicentre"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "hospitalizations and in all-cause and cardiovascu- Study of Percutaneous Mitral Valve Repair MitraClip"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "lar mortality in patients with LV dysfunction who Device in Patients With Severe Secondary Mitral Re-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "receive CABG and GDMT compared with GDMT gurgitation) showed no benefit of TEER over GDMT in"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "alone.2,7 The long-term survival benefit is greater in reducing death or hospitalization.6 Specifically, trans-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "those with more advanced ischemic cardiomyopa- catheter edge-to-edge MV repair has been shown to be"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "thy (lower EF or 3-vessel disease) and diminishes beneficial in patients with persistent symptoms despite"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "with increasing age.5,7 CABG also improves QOL GDMT, appropriate anatomy on transesophageal echo-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "compared with GDMT alone.3 An RCT of CABG cardiography and with LVEF between 20% and 50%,"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "combined with surgical ventricular remodeling com- LVESD ≤70 mm, and pulmonary artery systolic pressure"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "pared with CABG alone did not show a reduction in ≤70 mm Hg6 (Figure 10). Optimal management of sec-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "death or hospitalization, or improvement in symp- ondary MR may depend on the degree of MR relative"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "toms with surgical ventricular remodeling.15 Surgical to LV remodeling.4,5,14,18–22 Disproportionate MR (MR out"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "ventricular remodeling performed at the time of of proportion to LV remodeling) may respond better to"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "CABG may be useful in patients with intractable HF, procedural interventions that reduce MR, such as CRT,"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "large thrombus, or persistent arrhythmias resulting TEER, and MV surgery. Proportionate MR may respond"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "from well-defined aneurysm or scar, if other thera- to measures that reverse LV remodeling and reduce LV"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "pies are ineffective or contraindicated.15,16 volumes, such as GDMT and CRT."
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Aortic Stenosis"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "7.5. Valvular Heart Disease In patients with symptomatic aortic stenosis, transcath-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "eter and surgical aortic valve repair can improve survival,"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Recommendations for Valvular Heart Disease"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "symptoms, and LV function.15 However, the choice of"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements. transcatheter aortic valve implantation versus surgical"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "aortic valve replacement is based on shared decision-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "making, indications, and assessment of the risk-benefit"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "1. In patients with HF, VHD should be managed in a"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "multidisciplinary manner in accordance with clini- profile.23,24 The benefit of GDMT in nonsevere aortic ste-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "1 B-R"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "cal practice guidelines for VHD to prevent wors- nosis and HFrEF is being evaluated in the TAVR UNLOAD"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "ening of HF and adverse clinical outcomes.1–11"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "(Transcatheter Aortic Valve Replacement to Unload the"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "2. In patients with chronic severe secondary MR Left Ventricle in Patients With Advanced Heart Failure)"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "and HFrEF, optimization of GDMT is recom-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "1 C-LD trial.25 GDMT is usually continued in conjunction with"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "mended before any intervention for secondary"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "MR related to LV dysfunction.3–5,12–14 clinical surveillance and imaging in patients with nonse-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "vere aortic stenosis and reduced EF."
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Synopsis Tricuspid Regurgitation"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "GDMT applies to all patients with HFrEF, irrespective of The severity of secondary tricuspid regurgitation may"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "the presence of VHD. Significant valve disease warrants be dynamic, depending on RV function and pulmonary"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "evaluation by a multidisciplinary team with expertise in hypertension, and management entails focusing on"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "VHD, and management should proceed in accordance underlying causes, such as pulmonary hypertension,"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "with the VHD guidelines.15 RV failure, and HFrEF. Referral to the multidisciplinary"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "team for consideration of intervention might be helpful in"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Mitral Regurgitation"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "patients with refractory tricuspid regurgitation."
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Optimization of GDMT can improve secondary MR as-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "sociated with LV dysfunction and obviate the need for"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "intervention.14,16,17 Therefore, optimizing GDMT and re-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "assessing MR before MV interventions are important. 1. VHD is a significant cause of HF. In patients with"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Patients with persistent severe secondary MR despite HF, management of VHD should be performed by"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "GDMT may benefit from either surgical or transcatheter a multidisciplinary team with expertise in HF and"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "repair, depending on clinical scenario. Thus, patient- VHD, in accordance with the VHD guidelines.15"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "centric conversation with a multidisciplinary cardiovas- Cardiologists with expertise in the management of"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "cular team that includes a cardiologist with expertise HF are integral to the multidisciplinary team and to"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "in HF is essential when considering MV intervention.15 guiding the optimization of GDMT in patients with"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Two RCTs of transcatheter mitral valve edge-to-edge HF and coexisting valve disease. Severe aortic ste-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "repair (TEER) in patients with HFrEF and severe sec- nosis, aortic regurgitation, MR, and tricuspid regur-"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "ondary MR have been performed. The COAPT trial gitation are associated with adverse outcomes and"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "showed significant reduction in HF and all-cause mor- require timely assessment, optimization of medical"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 52,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e947"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "Figure 10. Treatment Approach in Secondary Mitral Regurgitation."
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "Colors correspond to Table 2. AF indicates atrial fibrillation; CABG, coronary artery bypass graft; ERO, effective regurgitant orifice; GDMT,"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "guideline-directed medical therapy; HF, heart failure; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter;"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "MR, mitral regurgitation; MV, mitral valve; PASP, pulmonary artery systolic pressure; RF, regurgitant fraction; RVol, regurgitant volume; and Rx,"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "medication. *Chordal-sparing MV replacement may be reasonable to choose over downsized annuloplasty repair. Adapted from Otto CM, et al.15"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "Copyright 2021 American College of Cardiology Foundation and American Heart Association, Inc."
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "therapies, and consideration of surgical or transcath- severe secondary MR, LVEF between 20% and"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "eter interventions accordingly to prevent worsening 50%, LV end-systolic diameter ≤70 mm, PA systolic"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "of HF and other adverse outcomes.1–10,12–20,22–35 pressure ≤70 mm Hg, and persistent symptoms"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "2. GDMT, including RAAS inhibition, beta blockers, (NYHA class II to IV) while on optimal GDMT,28"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "and biventricular pacing, improves MR and LV and these criteria apply when considering TEER."
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "dimensions in patients with HFrEF and second- A cardiologist with expertise in the management"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "ary MR, particularly MR that is proportionate to LV of HF is integral to shared decision-making for"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "dilatation.1–5,12,13,17 In a small RCT, sacubitril-valsar- valve intervention and should guide optimization of"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "tan resulted in a significant reduction in effective GDMT to ensure that medical options for HF and"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "regurgitant area and in regurgitant volume when secondary MR have been effectively applied for"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "compared with valsartan. The COAPT trial showed an appropriate time period and exhausted before"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "a mortality benefit with TEER in patients with considering intervention."
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 53,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "e948 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "pear to respond to medical therapies similarly to patients"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "with HFrEF. Thus, it may be reasonable to treat these pa-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "tients with GDMT used for treatment of HFrEF. Patients"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "with HFmrEF should have repeat evaluation of LVEF to"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "determine the trajectory of their disease process. Future"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "prospective studies are needed to further clarify treat-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "ment recommendations for patients with HFmrEF. Figure"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "11 summarizes COR 1, 2a, and 2b for HFmrEF."
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "1. EMPEROR-Preserved (Empagliflozin Outcome Trial"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "in Patients with Chronic Heart Failure with Preserved"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Ejection Fraction) showed a significant benefit of"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "the SGLT2i, empagliflozin, in patients with symptom-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "atic HF, with LVEF >40% and elevated natriuretic"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "peptides.1 The 21% reduction in the primary com-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "posite endpoint of time to HF hospitalization or car-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "diovascular death was driven mostly by a significant"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "29% reduction in time to HF hospitalization (nonsig-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "nificant lower cardiovascular death [HR, 0.91; 95%"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Figure 11. Recommendations for Patients With Mildly CI, 0.76–1.0]), with no benefit on all-cause mortality."
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Reduced LVEF (41%–49%). Empagliflozin also resulted in a significant reduction"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Colors correspond to COR in Table 2. Medication recommendations"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "in total HF hospitalizations, decrease in the slope"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "for HFmrEF are displayed. ACEi indicates angiotensin-converting"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "of the eGFR decline, and a modest improvement in"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi,"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "angiotensin receptor-neprilysin inhibitor; HFmrEF, heart failure with QOL at 52 weeks. Of note, the benefit was simi-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "mildly reduced ejection fraction; HFrEF, heart failure with reduced lar irrespective of the presence or absence of dia-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "ejection fraction; LVEF, left ventricular ejection fraction; MRA, betes at baseline. In a subgroup of 1983 patients"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "mineralocorticoid receptor antagonist; and SGLT2i, sodium-glucose with LVEF 41% to 49% in EMPEROR-Preserved,"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "cotransporter 2 inhibitor."
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "empagliflozin, a SGLT2i, reduced the risk of the pri-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "mary composite endpoint of cardiovascular death or"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "7.6. Heart Failure With Mildly Reduced EF"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "hospitalization for HF.1 Although the benefit in the"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "(HFmrEF) and Improved EF (HFimpHF)"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "primary endpoint did not have a significant interac-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "7.6.1. HF With Mildly Reduced Ejection Fraction tion by LVEF subgroups (41%–49%, 50%–<60%,"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "and >60%),1 in a subgroup analysis by EF, there"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Recommendations for HF With Mildly Reduced Ejection Fraction"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa- was a signal for lower benefit on the primary com-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements. posite endpoint, first and recurrent hospitalizations"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations for HF at higher LVEFs >62.5%.10"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "1. In patients with HFmrEF, SGLT2i can be ben- 2. Post hoc and subsets of analyses of HFrEF trials"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "2a B-R eficial in decreasing HF hospitalizations and that included HFmrEF (LVEF 41%–49%) have"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "cardiovascular mortality.1"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "suggested benefit from use of GDMT for HFrEF (ie,"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "2. Among patients with current or previous symp- beta blockers, ARNi, ACEi or ARB, and spironolac-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "tomatic HFmrEF (LVEF, 41%–49%), use of"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "tone).2,3,5–8 The BBmeta-HF (Beta-blockers in Heart"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "evidence-based beta blockers for HFrEF, ARNi,"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "ACEi, or ARB, and MRAs may be considered Failure Collaborative Group) performed a meta-anal-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "2b B-NR"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "to reduce the risk of HF hospitalization and ysis of 11 HF trials; in a subgroup of 575 patients"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "cardiovascular mortality, particularly among"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "with LVEF 40% to 49% in sinus rhythm, beta"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "patients with LVEF on the lower end of this"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "spectrum.2–9 blockers reduced the primary outcome of all-cause"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "and cardiovascular mortality.2 A subgroup analysis"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "of the PARAGON-HF (Prospective Comparison"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "of ARNi with ARB Global Outcomes in HF with"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "There are no prospective RCTs for patients specifically Preserved Ejection Fraction) trial for patients with"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "with HFmrEF (LVEF, 41%–49%). All data for HFmrEF LVEF 45% to 57% (lower range of EFs in the trial)"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "are from post hoc or subsets of analyses from previous suggested benefit of sacubitril-valsartan versus val-"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "HF trials with patients now classified as HFmrEF. LVEF is sartan alone (rate ratio, 0.78; 95% CI, 0.64-0.95).3"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "a spectrum, and among patients with LVEF 41% to 49%, In a subgroup of 1322 patients with LVEF 41% to"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "patients with LVEF on the lower end of this spectrum ap- 49% in a post hoc analysis of pooled data from the"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 54,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e949"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "CHARM (Candesartan in Heart failure-Assessment symptomatic or with LV dysfunction), GDMT should not"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "of Reduction in Mortality and morbidity) trials, can- only be continued but also optimized."
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "desartan reduced risk of cardiovascular death and"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "HF hospitalization, the risk of first HF hospitaliza-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "tion, and the risk of recurrent HF hospitalization.5"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "In a subgroup of 520 patients with LVEF 44% to 1. In an open-label RCT,1 phased withdrawal of HF"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "49% in a post hoc analysis of TOPCAT (Treatment medications in patients with previous DCM—who"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "of Preserved Cardiac Function Heart Failure With were now asymptomatic, whose LVEF had improved"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "an Aldosterone Antagonist), spironolactone reduced from <40% to ≥50%, whose left ventricular end-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "the risk of the primary composite endpoint of car- diastolic volume (LVEDV) had normalized, and who"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "diovascular death, HF hospitalization, or resusci- had an NT-proBNP concentration <250 ng/L—"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "tated sudden death, which was mostly caused by a resulted in relapse of cardiomyopathy and HF"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "reduction in cardiovascular mortality with spirono- in 40% of the patients within 6 months. Relapse"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "lactone and among patients enrolled in North and was defined by at least 1 of these: 1) a reduction"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "South America.6 Spironolactone is preferred among in LVEF by >10% and <50%; 2) an increase in"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "HFmrEF patients with poorly controlled hyperten- LVEDV by >10% and to higher than the normal"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "sion given previous evidence supporting its use range; 3) a 2-fold rise in NT-proBNP concentration"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "for blood pressure management.1 Continuation and to >400 ng/L; or 4) clinical evidence of HF."
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "of GDMT for patients with improved HFrEF and Treatment was withdrawn successfully in only 50%"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "HFmrEF is important to reduce risk of recrudescent of patients.1 Secondary analyses showed worsening"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "HF.4 Meta-analyses report diverse findings with neu- Kansas City Cardiomyopathy Questionnaire scores,"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "rohormonal antagonism in patients with HFmrEF, a substantial reduction in LVEF, and nonsignificant"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "specifying benefit in certain subgroups, underlining increases in NT-proBNP and LV volumes with with-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "the heterogeneity of this phenotype.2,9 Patients with drawal of HF medications."
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "HFmrEF should have repeat evaluation of LVEF to"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "determine the trajectory of their disease process"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "and should undergo testing as clinically indicated 7.7. Preserved EF (HFpEF)"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "to diagnose conditions warranting disease-specific"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "7.7.1. HF With Preserved Ejection Fraction"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "therapy (eg, CAD, sarcoidosis, amyloidosis)."
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "Recommendations for HF With Preserved Ejection Fraction*"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "7.6.2. HF With Improved Ejection Fraction Referenced studies that support the recommendations are"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "summarized in the Online Data Supplements."
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "Recommendation for HF With Improved Ejection Fraction"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendation are summarized COR LOE Recommendations"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "in the Online Data Supplements. 1. Patients with HFpEF and hypertension should"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation 1 C-LD have medication titrated to attain blood pres-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "sure targets in accordance with published clini-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "1. In patients with HFimpEF after treatment, cal practice guidelines to prevent morbidity.1–3"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "GDMT should be continued to prevent relapse"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "1 B-R of HF and LV dysfunction, even in patients who 2. In patients with HFpEF, SGLT2i can be ben-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "may become asymptomatic.1 2a B-R eficial in decreasing HF hospitalizations and"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "cardiovascular mortality.4"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "3. In patients with HFpEF, management of AF can 2a C-EO"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "Synopsis be useful to improve symptoms."
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "4. In selected patients with HFpEF, MRAs may be"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "Although GDMT can result in improvement in symptoms,"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "considered to decrease hospitalizations, par-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "functional capacity, LVEF, and reverse remodeling in 2b B-R ticularly among patients with LVEF on the lower"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "patients with HFrEF,2 in most patients, LV function and end of this spectrum.5–7"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "structural abnormalities do not fully normalize, and symp- 5. In selected patients with HFpEF, the use of"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "toms and biomarker abnormalities may persist or reoc- 2b B-R ARB may be considered to decrease hospital-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "izations, particularly among patients with LVEF"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "cur. Many patients deemed to have recovered from HF"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "on the lower end of this spectrum.8,9"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "with resolution of symptoms and improvement of LVEF"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "6. In selected patients with HFpEF, ARNi may be"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "and natriuretic peptide levels will relapse after withdrawal considered to decrease hospitalizations, par-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "2b B-R"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "of GDMT.1 Resolution of symptoms and improvement in ticularly among patients with LVEF on the lower"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "end of this spectrum.10,11"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "cardiac function and biomarkers after treatment does not"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "reflect full and sustained recovery but, rather, remission, 7. In patients with HFpEF, routine use of nitrates"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "3: No-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "B-R or phosphodiesterase-5 inhibitors to increase"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "which requires treatment to be maintained.3 Stage C HF Benefit"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "activity or QOL is ineffective.12,13"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "patients are defined as patients with structural heart dis-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "*See Section 7.2, “Diuretics and Decongestion Strategies in Patients with"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "ease with previous or current symptoms of HF. In those"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "HF,” and Section 10.2, “Management of Atrial Fibrillation (AF) in HF” for recom-"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "patients who do not improve (ie, patients who remain mendations for use of diuretics and management of AF in HF."
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 55,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "e950 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "1. The role of blood pressure control is well established"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "for the prevention of HF, as well as for reduction"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "of other cardiovascular events and HF mortality in"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "patients without prevalent baseline HF.1–3,21–24 The"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "SPRINT (Systolic Blood Pressure Intervention)"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "trial and meta-analyses established that more"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "intensive blood pressure control in patients with"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "high cardiovascular risk significantly reduces HF"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "and other cardiovascular outcomes.2,3,25 In recent"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "clinical practice guidelines for hypertension, blood"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "pressure targets in HFpEF are extrapolated from"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "those for treatment of patients with hypertension"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "in general.26 However, the optimal blood pressure"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "goal and antihypertensive regimens are not known"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "for patients with HFpEF. RAAS antagonists includ-"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "ing ACEi, ARB, MRA, and possibly ARNi, could be"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "first-line agents given experience with their use in"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "HFpEF trials.8,10,16,20,27,28 Beta blockers may be used"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "to treat hypertension in patients with a history of"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "MI,27 symptomatic CAD, or AF with rapid ventricular"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "Figure 12. Recommendations for Patients With Preserved"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "LVEF (≥50%). response. These effects need to be balanced with"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "Colors correspond to COR in Table 2. Medication recommendations the potential contribution of chronotropic incompe-"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "for HFpEF are displayed. ARB indicates angiotensin receptor tence to exercise intolerance in some patients.29"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "blocker; ARNi, angiotensin receptor-neprilysin inhibitor; HF, heart"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "2. EMPEROR-Preserved (Empagliflozin Outcome"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "failure; HFpEF, heart failure with preserved ejection fraction; LVEF,"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "Trial in Patients with Chronic Heart Failure with"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "left ventricular ejection fraction; MRA, mineralocorticoid receptor"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "antagonist; and SGLT2i, sodium-glucose cotransporter-2 inhibitor. Preserved Ejection Fraction) showed a significant"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "*Greater benefit in patients with LVEF closer to 50%. benefit of the SGLT2i, empagliflozin, in symptom-"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "atic patients with HF with LVEF >40% and ele-"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "Synopsis vated natriuretic peptides.30 The 21% reduction"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "HFpEF (LVEF ≥50%) is highly prevalent, accounting in the primary composite endpoint of time to HF"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "for up to 50% of all patients with HF, and is associ- hospitalization or cardiovascular death was driven"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "ated with significant morbidity and mortality.14 HFpEF mostly by a significant 29% reduction in time to HF"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "is a heterogenous disorder, contributed to by comor- hospitalization (nonsignificant lower cardiovascular"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "bidities that include hypertension, diabetes, obesity, death [HR, 0.91; 95% CI, 0.76-1.0]), with no benefit"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "CAD, CKD, and specific causes such as cardiac amy- on all-cause mortality. Empagliflozin also resulted in"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "loidosis.15–17 Clinical trials have used variable defini- a significant reduction in total HF hospitalizations,"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "tions of HFpEF (eg, LVEF ≥40%, 45%, or 50%, and decrease in the slope of the eGFR decline, and a"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "the varying need for accompanying evidence of struc- modest improvement in QOL at 52 weeks. Of note,"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "tural heart disease or elevated levels of natriuretic the benefit was similar irrespective of the pres-"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "peptides).18 Until recently, clinical trials had been ence or absence of diabetes at baseline. Although"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "generally disappointing, with no benefit on mortality the benefit in the primary endpoint did not have a"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "and marginal benefits on HF hospitalizations.5,8,11,19,20 significant interaction by LVEF subgroups (<50%,"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "Currently, recommended management is that used 50%–<60%, and >60%),30 in a subgroup analysis"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "for HF in general with use of diuretics to reduce by EF, there was a signal for lower benefit on the"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "congestion and improve symptoms (see Section primary composite endpoint, first and recurrent HF"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "7.1.1 for recommendations for nonpharmacological hospitalizations at higher LVEFs >62.5%.31"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "management and Section 7.2 for recommendations 3. Large, randomized clinical trial data are unavail-"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "for diuretics), identification and treatment of spe- able to specifically guide therapy in patients with"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "cific causes such as amyloidosis, and management HFpEF and AF. Currently, the comprehensive care"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "of contributing comorbidities such as hypertension, of AF can be extrapolated from the clinical practice"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "CAD, and AF (see Section 10.2 for recommendations guidelines for AF, with individualization of strategies"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "on management of AF). Figure 12 summarizes COR for rate or rhythm control in patients with HFpEF"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "1, 2a, and 2b for HFpEF. (see also Section 10.2, “Management of Atrial"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 56,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e951"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "Fibrillation (AF) in HF,” for HF specific recommen- HF hospitalization) was not significantly differ-"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "dations for AF). Although beta blockers and nondi- ent between the 2 groups (HR, 0.89; 95% CI,"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "hydropyridine calcium channel blockers are often 0.77–1.03, P=0.118; covariate-adjusted HR, 0.86;"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "considered as first-line agents for heart rate con- P=0.051). Cardiovascular mortality was identical in"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "trol in patients with HFpEF, a recent smaller open- the 2 groups; HF hospitalizations were lower in the"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "label trial, RATE-AF in elderly patients with AF candesartan arm, with borderline statistical signifi-"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "and symptoms of HF (most with preserved LVEF), cance on the covariate-adjusted analysis only (HR,"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "compared the use of the beta blocker, bisoprolol, to 0.84; 95% CI, 0.70–1.00; P=0.047; unadjusted"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "digoxin.32 At 6 months, the primary endpoint of QOL P=0.072). The number of individuals hospitalized"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "was similar between the 2 groups. However, sev- for HF (reported by the investigator) was lower in"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "eral secondary QOL endpoints, functional capacity, the candesartan group than placebo (230 versus"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "and reduction in NT-proBNP favored digoxin at 12 279; P=0.017). A post hoc analysis of the CHARM"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "months. There was a similar heart rate reduction trials showed that improvement in outcomes with"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "in both groups. Of note, more adverse events such candesartan was greater at the lower end the LVEF"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "as higher rates of dizziness, lethargy, and hypoten- spectrum.39 In a meta-analysis of 7694 patients"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "sion occurred with beta blockers than digoxin. The with HFpEF in 4 trials evaluating ARB, there was"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "comprehensive care of AF is beyond the scope of no signal for benefit on cardiovascular mortality"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "these guidelines. AF-specific care recommenda- (HR, 1.02), all-cause mortality (HR, 1.02), or HF"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "tions can be found in separate ACC/AHA clinical hospitalization (HR, 0.92; 95% CI, 0.83–1.02).40,41"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "practice guidelines.33,34 6. In the PARAMOUNT-HF (Prospective Comparison"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "4. MRAs improve diastolic function in patients with of ARNi With ARB on Management of Heart"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "HFpEF.35 The TOPCAT trial investigated the Failure With Preserved Ejection Fraction) trial, a"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "effects of spironolactone in patients with HFpEF. phase II RCT in patients with HFpEF (LVEF ≥45%),"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "The small reduction (HR, 0.89) in the composite of sacubitril-valsartan resulted in a lower level of"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "death, aborted cardiac death, and HF hospitaliza- NT-proBNP after 12 weeks of treatment compared"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "tion was not statistically significant, although HF with the ARB, valsartan.42 In the PARAGON-HF"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "hospitalization was reduced (HR, 0.83); adverse (Prospective Comparison of Angiotensin Receptor"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "effects of hyperkalemia and increasing creati- Neprilysin Inhibitor With Angiotensin Receptor"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "nine levels were more common in the treatment Blocker Global Outcomes in Heart Failure and"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "group.5 A post hoc analysis6 showed efficacy in Preserved Left Ventricular Ejection Fraction)"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "the Americas (HR 0.83) but not in Russia-Georgia trial, in 4822 patients with HFpEF (LVEF ≥45%,"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "(HR 1.10). A sample of the Russia-Georgia popu- HF admission within 9 months or elevated natri-"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "lation in the active treatment arm had nondetect- uretic peptide levels, and eGFR ≥30 mL/min/m2),"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "able levels of a spironolactone metabolite. Post hoc sacubitril-valsartan compared with valsartan did"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "analyses have limitations, but they suggest a pos- not achieve a significant reduction in the primary"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "sibility of benefit in appropriately selected patients composite endpoint of cardiovascular death or"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "with symptomatic HFpEF (LVEF ≥45%, elevated total (first and recurrent) HF hospitalizations (rate"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "BNP level or HF admission within 1 year, eGFR ratio, 0.87; 95% CI, 0.75-1.01; P=0.06).10 Given"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": ">30 mL/min/1.73 m2, creatinine <2.5 mg/dL, and the primary outcome was not met, other analyses"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "potassium <5.0 mEq/L). Furthermore, another are exploratory. There was no benefit of sacubitril-"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "post hoc analysis suggested that the potential effi- valsartan on cardiovascular death (HR, 0.95) or"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "cacy of spironolactone was greatest at the lower total mortality (HR, 0.97). There was a signal of"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "end of the LVEF spectrum.7 Careful monitoring of benefit for the ARNi for HF hospitalizations (rate"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "potassium, renal function, and diuretic dosing at ratio, 0.85; 95% CI, 0.72–1.00; P=0.056). The"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "initiation and follow-up are key to minimizing the occurrence of hyperkalemia and the composite"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "risk of hyperkalemia and worsening renal function. outcome of decline in renal function favored sacu-"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "5. Although RAAS inhibition strategies have been bitril-valsartan, but it was associated with a higher"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "successful in the treatment of HFrEF, and RAAS incidence of hypotension and angioedema. In pre-"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "activation is suggested in HFpEF,36,37 clinical tri- specified subgroup analyses, a differential effect"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "als with RAAS inhibition have not showed much by LVEF and sex was noted. A benefit of sacubitril-"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "benefit in patients HFpEF. In the CHARM- valsartan compared with valsartan was observed in"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "Preserved (Candesartan in patients with chronic patients with LVEF below the median (45%–57%;"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "HF and preserved left-ventricular ejection frac- rate ratio, 0.78; 95% CI, 0.64–0.95), and in women"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "tion) trial, patients with LVEF >40% were ran- (rate ratio, 0.73; 95% CI, 0.59–0.90).10,43,44"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "domized to an ARB, candesartan, or to placebo.38 7. Nitrate therapy can reduce pulmonary conges-"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "The primary endpoint (cardiovascular death or tion and improve exercise tolerance in patients"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 57,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "e952 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "with HFrEF. However, the NEAT-HFpEF (Nitrate’s cardiomyopathy [AL-CM]) or transthyretin amyloidosis"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "Effect on Activity Tolerance in Heart Failure With (ATTR-CM). ATTR can be caused by pathogenic vari-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "Preserved Ejection Fraction) trial45 randomized ants in the transthyretin gene TTR (variant transthyretin"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "110 patients with EF ≥50% on stable HF therapy, amyloidosis, ATTRv) or wild-type transthyretin (wild-type"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "not including nitrates, and with activity limited by transthyretin amyloidosis, ATTRwt). A diagnostic ap-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "dyspnea, fatigue, or chest pain, to either isosorbide proach is outlined in Figure 13.9"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "mononitrate or placebo and found no beneficial"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "effects on activity levels, QOL, exercise tolerance,"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "or NT-proBNP levels. Although the routine use of"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "nitrates in patients with HFpEF does not appear 1. Diagnosis of ATTR-CM requires a high index of"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "beneficial, patients with HFpEF and symptom- suspicion. LV thickening (wall thickness ≥14 mm)"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "atic CAD may still receive symptomatic relief with along with fatigue, dyspnea, or edema should trigger"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "nitrates. Phosphodiesterase-5 inhibition augments consideration of ATTR-CM, especially with discor-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "the nitric oxide system by upregulating cGMP activ- dance between wall thickness on echocardiogram"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "ity. The RELAX (Phosphodiesterase-5 Inhibition and QRS voltage on ECG,10 or other findings such"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "to Improve Clinical Status and Exercise Capacity as apical sparing of LV longitudinal strain impair-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "in Heart Failure with Preserved Ejection Fraction) ment on echocardiography and diffuse late-gado-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "trial13 randomized 216 patients with EF ≥50% on linium enhancement on cardiac MRI. ATTR-CM is"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "stable HF therapy and with reduced exercise tol- prevalent in severe aortic stenosis,1 HFpEF,2 car-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "erance (peak observed VO , <60% of predicted) pal tunnel syndrome,3 lumbar spinal stenosis,4 and"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "to phosphodiesterase-5 inhibition with sildenafil or autonomic or sensory polyneuropathy.5 Practically,"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "placebo. This study did not show improvement in screening for the presence of a monoclonal light"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "oxygen consumption or exercise tolerance. chain and technetium pyrophosphate (99mTc-PYP)"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "scan can be ordered at the same time for con-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "venience, but the results of the 99mTc-PYP scan"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "7.8. Cardiac Amyloidosis"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "are interpreted only on the context of a nega-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "7.8.1. Diagnosis of Cardiac Amyloidosis tive monoclonal light chain screen. 99mTc-PYP"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "Recommendations for Diagnosis of Cardiac Amyloidosis scans may be positive even in AL amyloidosis7 and,"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa- thus, a bone scintigraphy scan alone, without con-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "comitant testing for light chains, cannot distinguish"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations ATTR-CM from AL-CM. Serum free light chain"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "1. Patients for whom there is a clinical suspi- (FLC) concentration and serum and urine immu-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "cion for cardiac amyloidosis*1–5 should have nofixation electrophoresis (IFE) are assessed to"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "screening for serum and urine monoclonal"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "1 B-NR rule out AL-CM. IFE is preferred because serum"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "light chains with serum and urine immuno-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "fixation electrophoresis and serum free light plasma electrophoresis and urine plasma electro-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "chains.6 phoresis are less sensitive. Together, measurement"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "2. In patients with high clinical suspicion for car- of serum IFE, urine IFE, and serum FLC is >99%"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "diac amyloidosis, without evidence of serum or"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "sensitive for AL amyloidosis.6,11"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "1 B-NR urine monoclonal light chains, bone scintigra-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "phy should be performed to confirm the pres- 2. The use of 99mTc bone-avid compounds for bone"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "ence of transthyretin cardiac amyloidosis.7 scintigraphy allows for noninvasive diagnosis"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "3. In patients for whom a diagnosis of transthyre- of ATTR-CM.7 99mTc compounds include PYP,"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "tin cardiac amyloidosis is made, genetic testing 3,3-diphosphono-1,2-propanodicarboxylic acid,"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "1 B-NR with TTR gene sequencing is recommended to and hydromethylene diphosphonate, and PYP"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "differentiate hereditary variant from wild-type"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "transthyretin cardiac amyloidosis.8 is used in the United States. In the absence of a"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "light-chain abnormality, the 99mTc-PYP scan is diag-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "*LV wall thickness ≥14 mm in conjunction with fatigue, dyspnea, or"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "edema, especially in the context of discordance between wall thickness on nostic of ATTR-CM if there is grade 2/3 cardiac"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "echocardiogram and QRS voltage on ECG, and in the context of aortic ste- uptake or an H/CL ratio of >1.5. In fact, the pres-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "nosis, HFpEF, carpal tunnel syndrome, spinal stenosis, and autonomic or"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "ence of grade 2/3 cardiac uptake in the absence"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "sensory polyneuropathy."
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "of a monoclonal protein in serum or urine has a"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "very high specificity and positive predictive value"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "for ATTR-CM.7 SPECT is assessed in all positive"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "Cardiac amyloidosis is a restrictive cardiomyopathy with scans to confirm that uptake represents myocar-"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "extracellular myocardial protein deposition, most com- dial retention of the tracer and not blood pool or rib"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "monly monoclonal immunoglobulin light chains (amyloid uptake signal.12"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 58,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e953"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "Figure 13. Diagnostic and Treatment of Transthyretin Cardiac Amyloidosis Algorithm."
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "Colors correspond to COR in Table 2. AF indicates atrial fibrillation; AL-CM, amyloid cardiomyopathy; ATTR-CM, transthyretin amyloid"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "cardiomyopathy; ATTRv, variant transthyretin amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; CHADS-VASc, congestive heart failure,"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "2 2"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category; ECG,"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "electrocardiogram; H/CL, heart to contralateral chest; HFrEF, heart failure with reduced ejection fraction; IFE, immunofixation electrophoresis;"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "MRI, magnetic resonance imaging; NYHA, New York Heart Association; PYP, pyrophosphate; Tc, technetium; and TTR, transthyretin."
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "3. If ATTR-CM is identified, then genetic sequenc- of ATTRv would trigger genetic counseling"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "ing of the TTR gene will determine if the patient and potential screening of family members"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "has a pathological variant (ATTRv) or wild-type and therapies, inotersen and patisiran, which"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "(ATTRwt) disease.12 Differentiating ATTRv from are presently approved only for ATTRv with"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "ATTRwt is important because confirmation polyneuropathy.13,14"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 59,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "e954 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "7.8.2. Treatment of Cardiac Amyloidosis Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "Recommendations for Treatment of Cardiac Amyloidosis 1. Tafamidis is currently the only therapy to improve"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "cardiovascular outcomes in ATTR-CM.1 Tafamidis"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "binds the thyroxin-binding site of TTR. In the"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "ATTR-ACT (Safety and Efficacy of Tafamidis in"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "1. In select patients with wild-type or variant trans-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "Patients With Transthyretin Cardiomyopathy)"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "thyretin cardiac amyloidosis and NYHA class I"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "1 B-R to III HF symptoms, transthyretin tetramer sta- clinical trial, a randomized trial of patients with"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "bilizer therapy (tafamidis) is indicated to reduce ATTRwt-CM or ATTRv-CM and NYHA class I to"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "cardiovascular morbidity and mortality.1"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "III symptoms, tafamidis had lower all-cause mor-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "2. At 2020 list prices, tafamidis provides low tality (29.5% versus 42.9%) and lower cardio-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "Value Statement: economic value (>$180 000 per QALY gained)"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "vascular-related hospitalization (0.48 versus 0.70"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "Low Value (B-NR) in patients with HF with wild-type or variant"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "transthyretin cardiac amyloidosis.2 per year) after 30 months.1 There was a higher"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "rate of cardiovascular-related hospitalizations in"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "3. In patients with cardiac amyloidosis and AF,"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "anticoagulation is reasonable to reduce the patients with NYHA class III HF, potentially attrib-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "risk of stroke regardless of the CHA 2 DS 2 -VASc utable to longer survival during a more severe"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "2a C-LD (congestive heart failure, hypertension, age"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "≥75 years, diabetes mellitus, stroke or transient period of disease. Given that tafamidis prevents"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "ischemic attack [TIA], vascular disease, age 65 but does not reverse amyloid deposition, tafami-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "to 74 years, sex category) score.3,4 dis is expected to have greater benefit when"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "administered early in the disease course. As the"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "survival curves separate after 18 months, patients"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "for whom noncardiac disease is not expected to"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "For patients with ATTR-CM and EF ≤40%, GDMT may limit survival should be selected. Benefit has not"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "be poorly tolerated. The vasodilating effects of ARNi, been observed in patients with class IV symp-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "ACEi, and ARB may exacerbate hypotension, especially toms, severe aortic stenosis, or impaired renal"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "with amyloid-associated autonomic dysfunction. Beta function (eGFR <25 mL·min−1·1.73 m−2 body"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "blockers may worsen HF symptoms as patients with AT- surface area). Tafamidis is available in 2 formula-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "TR-CM rely on heart rate response to maintain cardiac tions: tafamidis meglumine is available in 20-mg"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "output. The benefit of ICDs in ATTR-CM has not been capsules; and the FDA-approved dose is 80 mg"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "studied in randomized trials, and a case-control study (4 capsules) once daily. Tafamidis is also avail-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "showed unclear benefit.5 CRT has not been studied in able in 61-mg capsules; the FDA-approved dose"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "ATTR-CM with HFrEF. Disease-modifying therapies in- for this new formulation is 61 mg once daily."
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "clude TTR silencers (disrupt hepatic synthesis via mRNA 2. One model-based analyses used the results of"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "inhibition/degradation: inotersen and patisiran), TTR the ATTR-ACT study1 to evaluate the cost-effec-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "stabilizers (prevent misfolding/deposition: diflunisal and tiveness of chronic tafamidis compared with no"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "tafamidis), and TTR disruptors (target tissue clearance: amyloidosis-specific therapy among patients with"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "doxycycline, tauroursodeoxycholic acid [TUDCA], and wild-type or variant transthyretin amyloidosis and"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "epigallocatechin-3-gallate [EGCG] in green tea). Light NYHA class I to III HF.2 With assumptions that"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "chain cardiac amyloidosis is managed by hematology- tafamidis remained effective beyond the clinical"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "oncology specialists and beyond the scope of cardiolo- trial duration, they estimated tafamidis increased"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "gists, but diagnosis is often made by cardiologists when average survival by 1.97 years and QALY by 1.29."
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "cardiac amyloid becomes manifest (Figure 13). AL amy- Despite these large clinical benefits, tafamidis"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "loidosis is treatable, and patients with AL amyloidosis (with an annual cost of $225 000) had an incre-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "with cardiac involvement should promptly be referred to mental cost-effectiveness ratio >$180 000 per"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "hematology-oncology for timely treatment. Inotersen and QALY gained, the benchmark used by this guide-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "patisiran are associated with slower progression of am- line for low value. The cost of tafamidis would"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "yloidosis-related polyneuropathy in ATTRv-CM.6,7 There need to decrease by approximately 80% for it"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "are ongoing trials of the impact of inotersen and pati- to be intermediate value with a cost per QALY"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "siran and newer generation mRNA inhibitors-degraders <$180 000."
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "on cardiovascular morbidity or mortality. There is limited 3. Intracardiac thrombosis occurs in approximately"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "benefit of diflunisal,8 doxycycline plus TUDCA,9,10 and one-third of patients with cardiac amyloidosis, in"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "EGCG,11 on surrogate endpoints such as LV mass, but some cases in the absence of diagnosed AF3,4,12"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "the impact of these agents on cardiovascular morbid- and regardless of CHA DS -VASc score.13 The"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "2 2"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "ity and mortality has not been assessed. Evaluation and use of anticoagulation reduced the risk of intra-"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "management of autonomic dysfunction, volume status, cardiac thrombi in a retrospective study.4 The"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "and arrhythmia are important. choice of direct oral anticoagulants (DOAC)"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 60,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e955"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Table 16. ESC Definition of Advanced HF used to describe this population, including “end-stage,”"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "“advanced,” and “refractory” HF. In 2018, the European"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "All these criteria must be present despite optimal guideline-directed treatment:"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Society of Cardiology updated its definition of advanced"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "1. Severe and persistent symptoms of HF (NYHA class III [advanced] or IV)"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "HF (Table 16), which now includes 4 distinct criteria.1"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "2. Severe cardiac dysfunction defined by ≥1 of these:"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "The revised definition focuses on refractory symptoms"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "LVEF ≤30% rather than cardiac function and more clearly acknowl-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Isolated RV failure edges that advanced HF can occur in patients without"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Nonoperable severe valve abnormalities severely reduced EF, including those with isolated RV"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Nonoperable severe congenital heart disease"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "dysfunction, uncorrectable valvular or congenital heart"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "EF ≥40%, elevated natriuretic peptide levels and evidence of significant"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "disease, and in patients with preserved and mildly re-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "diastolic dysfunction"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "duced EF.1,3 The INTERMACS (Interagency Registry"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "3. Hospitalizations or unplanned visits in the past 12 mo for episodes of:"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "for Mechanically Assisted Circulatory Support) has"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Congestion requiring high-dose intravenous diuretics or diuretic com-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "developed 7 profiles that further stratify patients with"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "binations"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "advanced HF (Table 17).7"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Low output requiring inotropes or vasoactive medications"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Determining that HF and not a concomitant pulmonary"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Malignant arrhythmias"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "disorder is the basis of dyspnea is important. Severely"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "4. Severe impairment of exercise capacity with inability to exercise or low"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "6-minute walk test distance (<300 m) or peak VO (<12–14 mL/kg/min) symptomatic patients presenting with a new diagnosis"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "estimated to be of cardiac origin of HF can often improve substantially if they are initially"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Criteria 1 and 4 can be met in patients with cardiac dysfunction (as stabilized. Patients should also be evaluated for nonad-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "described in criterion 2) but who also have substantial limitations as a herence to medications.8–11 Finally, a careful review of"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "result of other conditions (eg, severe pulmonary disease, noncardiac"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "medical management should be conducted to verify that"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "cirrhosis, renal disease). The therapeutic options for these patients may"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "be more limited. all therapies likely to improve clinical status have been"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "considered."
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "EF indicates ejection fraction; ESC, European Society of Cardiology; HF,"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart As-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "sociation; RV, right ventricular; and VO, oxygen consumption/oxygen uptake."
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Adapted with permission from Crespo-Leiro et al.1 Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "1. Clinical indicators of advanced HF that should trig-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "versus warfarin has not been studied in patients ger possible referral to an advanced HF special-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "with ATTR, nor has the role of left atrial append- ist are shown in Table 18.1,2,12–14 Timely referral for"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "age closure devices. The risk of anticoagulation review and consideration of advanced HF therapies"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "on bleeding risk in patients with ATTR-CM and is crucial to achieve optimal patient outcomes.15–17"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "AF has not been established. However, although Acronyms such as I-Need-Help…"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "patients with AL amyloidosis may have acquired I, Intravenous inotropes"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "hemostatic abnormalities, including coagulation N, New York Heart Association (NYHA) class IIIB"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "factor deficiencies, hyperfibrinolysis, and platelet to IV or persistently elevated natriuretic peptides"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "dysfunction, TTR amyloidosis is not associated E, End-organ dysfunction"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "with hemostatic defects. E, EF ≤35%"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "D, Defibrillator shocks"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "H, Hospitalizations >1"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "8. STAGE D (ADVANCED) HF E, Edema despite escalating diuretics"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "L, Low systolic BP ≤90, high heart rate"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "8.1. Specialty Referral for Advanced HF"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "P, Prognostic medication; progressive intolerance"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "or down-titration of GDMT"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Recommendation for Specialty Referral for Advanced HF"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "…have been developed to assist in decision-making"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "for referral to advanced HF.18 Indications and contra-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "1. In patients with advanced HF, when consistent"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "indications to durable mechanical support are listed in"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "with the patient’s goals of care, timely refer-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "ral for HF specialty care is recommended to Table 19. After patients develop end-organ dysfunc-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "1 C-LD review HF management and assess suitability tion or cardiogenic shock, they may no longer qualify"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "for advanced HF therapies (eg, LVAD, cardiac"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "for advanced therapies.19,20 A complete assessment"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "transplantation, palliative care, and palliative"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "inotropes).1–6 of the patient is not required before referral, because"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "comprehensive, multidisciplinary assessment of car-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "diac disease and comorbid conditions is routinely"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "performed when evaluating patients for advanced"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "A subset of patients with chronic HF will continue to therapies.19,20 Decisions around evaluation and use"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "progress and develop persistently severe symptoms of advanced therapies should be informed by the pa-"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "despite maximum GDMT. Several terms have been tient’s values, goals, and preferences. Discussion with"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 61,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 61,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "All these criteria must be present despite optimal guideline-directed treatment:": "1. Severe and persistent symptoms of HF (NYHA class III [advanced] or IV)"
            },
            {
                "All these criteria must be present despite optimal guideline-directed treatment:": "2. Severe cardiac dysfunction defined by ≥1 of these:"
            },
            {
                "All these criteria must be present despite optimal guideline-directed treatment:": "LVEF ≤30% Isolated RV failure Nonoperable severe valve abnormalities Nonoperable severe congenital heart disease EF ≥40%, elevated natriuretic peptide levels and evidence of significant diastolic dysfunction"
            },
            {
                "All these criteria must be present despite optimal guideline-directed treatment:": "3. Hospitalizations or unplanned visits in the past 12 mo for episodes of:"
            },
            {
                "All these criteria must be present despite optimal guideline-directed treatment:": "Congestion requiring high-dose intravenous diuretics or diuretic com- binations Low output requiring inotropes or vasoactive medications Malignant arrhythmias"
            },
            {
                "All these criteria must be present despite optimal guideline-directed treatment:": "4. Severe impairment of exercise capacity with inability to exercise or low 6-minute walk test distance (<300 m) or peak VO (<12–14 mL/kg/min) 2 estimated to be of cardiac origin"
            },
            {
                "All these criteria must be present despite optimal guideline-directed treatment:": "Criteria 1 and 4 can be met in patients with cardiac dysfunction (as described in criterion 2) but who also have substantial limitations as a result of other conditions (eg, severe pulmonary disease, noncardiac cirrhosis, renal disease). The therapeutic options for these patients may be more limited."
            }
        ],
        "conteudo_texto": "1. Severe and persistent symptoms of HF (NYHA class III [advanced] or IV) | 2. Severe cardiac dysfunction defined by ≥1 of these: | LVEF ≤30% Isolated RV failure Nonoperable severe valve abnormalities Nonoperable severe congenital heart disease EF ≥40%, elevated natriuretic peptide levels and evidence of significant diastolic dysfunction | 3. Hospitalizations or unplanned visits in the past 12 mo for episodes of: | Congestion requiring high-dose intravenous diuretics or diuretic com- binations Low output requiring inotropes or vasoactive medications Malignant arrhythmias | 4. Severe impairment of exercise capacity with inability to exercise or low 6-minute walk test distance (<300 m) or peak VO (<12–14 mL/kg/min) 2 estimated to be of cardiac origin | Criteria 1 and 4 can be met in patients with cardiac dysfunction (as described in criterion 2) but who also have substantial limitations as a result of other conditions (eg, severe pulmonary disease, noncardiac cirrhosis, renal disease). The therapeutic options for these patients may be more limited."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "e956 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Table 17. INTERMACS Profiles"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Profile* Profile Description Features"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "1 Critical cardiogenic shock Life-threatening hypotension and rapidly escalating inotropic/pressor support, with critical organ hypoperfusion"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "often confirmed by worsening acidosis and lactate levels."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "2 Progressive decline “Dependent” on inotropic support but nonetheless shows signs of continuing deterioration in nutrition, renal"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "function, fluid retention, or other major status indicator. Can also apply to a patient with refractory volume over-"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "load, perhaps with evidence of impaired perfusion, in whom inotropic infusions cannot be maintained because"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "of tachyarrhythmias, clinical ischemia, or other intolerance."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "3 Stable but inotrope dependent Clinically stable on mild-moderate doses of intravenous inotropes (or has a temporary circulatory support de-"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "vice) after repeated documentation of failure to wean without symptomatic hypotension, worsening symptoms,"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "or progressive organ dysfunction (usually renal)."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "4 Resting symptoms on oral Patient who is at home on oral therapy but frequently has symptoms of congestion at rest or with activities of"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "therapy at home daily living (dressing or bathing). He or she may have orthopnea, shortness of breath during dressing or bath-"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "ing, gastrointestinal symptoms (abdominal discomfort, nausea, poor appetite), disabling ascites, or severe"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "lower extremity edema."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "5 Exertion intolerant Patient who is comfortable at rest but unable to engage in any activity, living predominantly within the house or"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "housebound."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "6 Exertion limited Patient who is comfortable at rest without evidence of fluid overload but who is able to do some mild ac-"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "tivity. Activities of daily living are comfortable, and minor activities outside the home such as visiting friends"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "or going to a restaurant can be performed, but fatigue results within a few minutes or with any meaningful"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "physical exertion."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "7 Advanced NYHA class III Patient who is clinically stable with a reasonable level of comfortable activity, despite a history of previous"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "decompensation that is not recent. This patient is usually able to walk more than a block. Any decompensation"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "requiring intravenous diuretics or hospitalization within the previous month should make this person a Patient"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Profile 6 or lower."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "ICD indicates implantable cardioverter-defibrillator; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; and NYHA, New York Heart"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Association."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Adapted from Stevenson et al,7 with permission from the International Society for Heart and Lung Transplantation."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "*Modifier options: Profiles 3 to 6 can be modified for patients with recurrent decompensations leading to frequent (generally at least 2 in past 3 mo or 3 in past 6"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "mo) emergency department visits or hospitalizations for intravenous diuretics, ultrafiltration, or brief inotropic therapy. Profile 3 can be modified in this manner if the"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "patient is usually at home. If a Profile 7 patient meets the modification of frequent hospitalizations, the patient should be moved to Profile 6 or worse. Other modifier"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "options include arrhythmia, which should be used in the presence of recurrent ventricular tachyarrhythmias contributing to the overall clinical course (eg, frequent ICD"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "shocks or requirement of external defibrillation, usually more than twice weekly); or temporary circulatory support for hospitalized patients Profiles 1 to 3."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "HF specialists and other members of the multidisci- tion has limited-to-no effect on clinical outcomes or"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "plinary team may help ensure that the patient has ad- diuretic use.4 Although HF nutritional counseling typi-"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "equate information to make an informed decision. cally focuses on restricting sodium and fluid, patients"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "with advanced HF have the greatest risk of developing"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "cachexia or malnutrition.11 Hence, dietary restrictions"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "8.2. Nonpharmacological Management:"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "and recommendation should be both evidence-based"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Advanced HF"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "and comprehensive."
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Recommendation for Nonpharmacological Management: Advanced HF"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "1. For patients with advanced HF and hypona-"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "1. In a registry study of hyponatremia in acute decom-"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "2b C-LD tremia, the benefit of fluid restriction to reduce"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "congestive symptoms is uncertain.1–4 pensated HF, fluid restriction only improved hypo-"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "natremia marginally.1 A registered dietitian-guided"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "fluid and sodium restriction intervention improved"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "NYHA functional classification and leg edema in"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Hyponatremia and diuretic-refractory congestion is patients with HFrEF who were not in stage D HF,2"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "common in advanced HF and is associated with poor and fluid restriction improved QOL in a pilot RCT of"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "clinical5,6 and patient-reported outcomes.7 Moreover, patients with HFrEF and HFpEF (NYHA class I to"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "improvement in hyponatremia has been shown to IV).3 In a meta-analysis of RCTs on fluid restriction"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "improve clinical outcomes.8,9 Fluid restriction is com- in HF in general, restricted fluid intake compared"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "monly prescribed for patients with hyponatremia in with free fluid consumption did not result in reduced"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "acute HF but only improves hyponatremia modestly.1 hospitalization or mortality rates, changes in thirst,"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Although restricting fluid is a common recommenda- the duration of intravenous diuretic use, serum cre-"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "tion for patients with HF, evidence in this area is of low atinine, or serum sodium levels.4 The validity of a"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "quality,10 and many studies have not included patients previous trial supporting clinical benefits of fluid"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "with advanced HF specifically. Moreover, fluid restric- restriction in HF is in serious question.12"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 62,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 62,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Profile*": "1",
                "Profile Description": "Critical cardiogenic shock",
                "Features": "Life-threatening hypotension and rapidly escalating inotropic/pressor support, with critical organ hypoperfusion often confirmed by worsening acidosis and lactate levels."
            },
            {
                "Profile*": "2",
                "Profile Description": "Progressive decline",
                "Features": "“Dependent” on inotropic support but nonetheless shows signs of continuing deterioration in nutrition, renal function, fluid retention, or other major status indicator. Can also apply to a patient with refractory volume over- load, perhaps with evidence of impaired perfusion, in whom inotropic infusions cannot be maintained because of tachyarrhythmias, clinical ischemia, or other intolerance."
            },
            {
                "Profile*": "3",
                "Profile Description": "Stable but inotrope dependent",
                "Features": "Clinically stable on mild-moderate doses of intravenous inotropes (or has a temporary circulatory support de- vice) after repeated documentation of failure to wean without symptomatic hypotension, worsening symptoms, or progressive organ dysfunction (usually renal)."
            },
            {
                "Profile*": "4",
                "Profile Description": "Resting symptoms on oral therapy at home",
                "Features": "Patient who is at home on oral therapy but frequently has symptoms of congestion at rest or with activities of daily living (dressing or bathing). He or she may have orthopnea, shortness of breath during dressing or bath- ing, gastrointestinal symptoms (abdominal discomfort, nausea, poor appetite), disabling ascites, or severe lower extremity edema."
            },
            {
                "Profile*": "5",
                "Profile Description": "Exertion intolerant",
                "Features": "Patient who is comfortable at rest but unable to engage in any activity, living predominantly within the house or housebound."
            },
            {
                "Profile*": "6",
                "Profile Description": "Exertion limited",
                "Features": "Patient who is comfortable at rest without evidence of fluid overload but who is able to do some mild ac- tivity. Activities of daily living are comfortable, and minor activities outside the home such as visiting friends or going to a restaurant can be performed, but fatigue results within a few minutes or with any meaningful physical exertion."
            },
            {
                "Profile*": "7",
                "Profile Description": "Advanced NYHA class III",
                "Features": "Patient who is clinically stable with a reasonable level of comfortable activity, despite a history of previous decompensation that is not recent. This patient is usually able to walk more than a block. Any decompensation requiring intravenous diuretics or hospitalization within the previous month should make this person a Patient Profile 6 or lower."
            }
        ],
        "conteudo_texto": "1, Critical cardiogenic shock, Life-threatening hypotension and rapidly escalating inotropic/pressor support, with critical organ hypoperfusion often confirmed by worsening acidosis and lactate levels. | 2, Progressive decline, “Dependent” on inotropic support but nonetheless shows signs of continuing deterioration in nutrition, renal function, fluid retention, or other major status indicator. Can also apply to a patient with refractory volume over- load, perhaps with evidence of impaired perfusion, in whom inotropic infusions cannot be maintained because of tachyarrhythmias, clinical ischemia, or other intolerance. | 3, Stable but inotrope dependent, Clinically stable on mild-moderate doses of intravenous inotropes (or has a temporary circulatory support de- vice) after repeated documentation of failure to wean without symptomatic hypotension, worsening symptoms, or progressive organ dysfunction (usually renal). | 4, Resting symptoms on oral therapy at home, Patient who is at home on oral therapy but frequently has symptoms of congestion at rest or with activities of daily living (dressing or bathing). He or she may have orthopnea, shortness of breath during dressing or bath- ing, gastrointestinal symptoms (abdominal discomfort, nausea, poor appetite), disabling ascites, or severe lower extremity edema. | 5, Exertion intolerant, Patient who is comfortable at rest but unable to engage in any activity, living predominantly within the house or housebound. | 6, Exertion limited, Patient who is comfortable at rest without evidence of fluid overload but who is able to do some mild ac- tivity. Activities of daily living are comfortable, and minor activities outside the home such as visiting friends or going to a restaurant can be performed, but fatigue results within a few minutes or with any meaningful physical exertion. | 7, Advanced NYHA class III, Patient who is clinically stable with a reasonable level of comfortable activity, despite a history of previous decompensation that is not recent. This patient is usually able to walk more than a block. Any decompensation requiring intravenous diuretics or hospitalization within the previous month should make this person a Patient Profile 6 or lower."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e957"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Table 18. Clinical Indicators of Advanced HF1,2,12,13,23–37 Table 19. Indications and Contraindications to Durable Me-"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "chanical Support37"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Repeated hospitalizations or emergency department visits for HF in the past"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "12 mo. Indications (combination of these):"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Need for intravenous inotropic therapy. Frequent hospitalizations for HF"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Persistent NYHA functional class III to IV symptoms despite therapy. NYHA class IIIb to IV functional limitations despite maximal therapy"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Severely reduced exercise capacity (peak VO, <14 mL/kg/min or <50% Intolerance of neurohormonal antagonists"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "predicted, 6-min walk test distance <300 m, or inability to walk 1 block on"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Increasing diuretic requirement"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "level ground because of dyspnea or fatigue)."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Symptomatic despite CRT"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Intolerance to RAASi because of hypotension or worsening renal function."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Inotrope dependence"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Intolerance to beta blockers as a result of worsening HF or hypotension."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Low peak VO (<14–16)"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Recent need to escalate diuretics to maintain volume status, often reaching 2"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "daily furosemide equivalent dose >160 mg/d or use of supplemental meto- End-organ dysfunction attributable to low cardiac output"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "lazone therapy."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Contraindications:"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Refractory clinical congestion."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Absolute"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Progressive deterioration in renal or hepatic function."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Irreversible hepatic disease"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Worsening right HF or secondary pulmonary hypertension."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Irreversible renal disease"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Frequent SBP ≤90 mm Hg."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Irreversible neurological disease"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Cardiac cachexia."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Medical nonadherence"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Persistent hyponatremia (serum sodium, <134 mEq/L)."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Severe psychosocial limitations"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Refractory or recurrent ventricular arrhythmias; frequent ICD shocks."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Relative"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Increased predicted 1-year mortality (eg, >20%) according to HF survival"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "models (eg, MAGGIC,21 SHFM22). Age >80 y for destination therapy"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Obesity or malnutrition"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "HF indicates heart failure; ICD, implantable cardioverter-defibrillator; MAG-"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "GIC, Meta-analysis Global Group in Chronic Heart Failure; NYHA, New York Musculoskeletal disease that impairs rehabilitation"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Heart Association; RAASi, renin-angiotensin-aldosterone system inhibitors;"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Active systemic infection or prolonged intubation"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "SBP, systolic blood pressure; SHFM, Seattle Heart Failure model; and VO,"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "2"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "oxygen consumption/oxygen uptake. Untreated malignancy"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Severe PVD"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "8.3. Inotropic Support Active substance abuse"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Impaired cognitive function"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Recommendations for Inotropic Support"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are Unmanaged psychiatric disorder"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "summarized in the Online Data Supplements."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Lack of social support"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "CRT indicates cardiac resynchronization therapy; HF, heart failure; NYHA,"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "1. In patients with advanced (stage D) HF refrac- New York Heart Association; VO oxygen consumption; and PVD, peripheral"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "2,"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "tory to GDMT and device therapy who are vascular disease."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "2a B-NR eligible for and awaiting MCS or cardiac trans-"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "plantation, continuous intravenous inotropic"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "support is reasonable as “bridge therapy.”1–4 or dopaminergic receptors, calcium sensitization), paren-"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "teral inotropes remain an option to help the subset of"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "2. In select patients with stage D HF, despite"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "optimal GDMT and device therapy who are patients with HF who are refractory to other therapies"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "ineligible for either MCS or cardiac transplan- and are suffering consequences from end-organ hypo-"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "2b B-NR tation, continuous intravenous inotropic sup-"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "perfusion. In hospitalized patients presenting with doc-"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "port may be considered as palliative therapy"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "for symptom control and improvement in func- umented severe systolic dysfunction who present with"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "tional status.5–7 low blood pressure and significantly low cardiac index,"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "3. In patients with HF, long-term use of either short-term, continuous intravenous inotropic support"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "continuous or intermittent intravenous inotropic may be reasonable to maintain systemic perfusion and"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "3: Harm B-R agents, for reasons other than palliative care or"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "preserve end-organ performance.8,11,12 There continues"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "as a bridge to advanced therapies, is potentially"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "harmful.5,6,8–11 to be lack of robust evidence to suggest the clear benefit"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "of 1 inotrope over another.13 To minimize adverse effects,"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "lower doses of parenteral inotropic drugs are preferred,"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "although the development of tachyphylaxis should be ac-"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Despite improving hemodynamic compromise, positive knowledged, and the choice of agent may need to be"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "inotropic agents have not shown improved survival in changed during longer periods of support. Similarly, the"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "patients with HF in either the hospital or the outpatient ongoing need for inotropic support and the possibility of"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "setting.6 Regardless of their mechanism of action (eg, in- discontinuation should be regularly assessed. Table 20"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "hibition of phosphodiesterase, stimulation of adrenergic compares commonly used inotropes."
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 63,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 63,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Need for intravenous inotropic therapy."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Persistent NYHA functional class III to IV symptoms despite therapy."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Severely reduced exercise capacity (peak VO, <14 mL/kg/min or <50% 2 predicted, 6-min walk test distance <300 m, or inability to walk 1 block on level ground because of dyspnea or fatigue)."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Intolerance to RAASi because of hypotension or worsening renal function."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Intolerance to beta blockers as a result of worsening HF or hypotension."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Recent need to escalate diuretics to maintain volume status, often reaching daily furosemide equivalent dose >160 mg/d or use of supplemental meto- lazone therapy."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Refractory clinical congestion."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Progressive deterioration in renal or hepatic function."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Worsening right HF or secondary pulmonary hypertension."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Frequent SBP ≤90 mm Hg."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Cardiac cachexia."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Persistent hyponatremia (serum sodium, <134 mEq/L)."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Refractory or recurrent ventricular arrhythmias; frequent ICD shocks."
            },
            {
                "Repeated hospitalizations or emergency department visits for HF in the past 12 mo.": "Increased predicted 1-year mortality (eg, >20%) according to HF survival models (eg, MAGGIC,21 SHFM22)."
            }
        ],
        "conteudo_texto": "Need for intravenous inotropic therapy. | Persistent NYHA functional class III to IV symptoms despite therapy. | Severely reduced exercise capacity (peak VO, <14 mL/kg/min or <50% 2 predicted, 6-min walk test distance <300 m, or inability to walk 1 block on level ground because of dyspnea or fatigue). | Intolerance to RAASi because of hypotension or worsening renal function. | Intolerance to beta blockers as a result of worsening HF or hypotension. | Recent need to escalate diuretics to maintain volume status, often reaching daily furosemide equivalent dose >160 mg/d or use of supplemental meto- lazone therapy. | Refractory clinical congestion. | Progressive deterioration in renal or hepatic function. | Worsening right HF or secondary pulmonary hypertension. | Frequent SBP ≤90 mm Hg. | Cardiac cachexia. | Persistent hyponatremia (serum sodium, <134 mEq/L). | Refractory or recurrent ventricular arrhythmias; frequent ICD shocks. | Increased predicted 1-year mortality (eg, >20%) according to HF survival models (eg, MAGGIC,21 SHFM22)."
    },
    {
        "pagina": 63,
        "tipo": "tabela",
        "indice_tabela": 2,
        "conteudo_dict": [
            {
                "Indications (combination of these):": "Frequent hospitalizations for HF"
            },
            {
                "Indications (combination of these):": "NYHA class IIIb to IV functional limitations despite maximal therapy"
            },
            {
                "Indications (combination of these):": "Intolerance of neurohormonal antagonists"
            },
            {
                "Indications (combination of these):": "Increasing diuretic requirement"
            },
            {
                "Indications (combination of these):": "Symptomatic despite CRT"
            },
            {
                "Indications (combination of these):": "Inotrope dependence"
            },
            {
                "Indications (combination of these):": "Low peak VO (<14–16) 2"
            },
            {
                "Indications (combination of these):": "End-organ dysfunction attributable to low cardiac output"
            },
            {
                "Indications (combination of these):": "Contraindications:"
            },
            {
                "Indications (combination of these):": "Absolute"
            },
            {
                "Indications (combination of these):": "Irreversible hepatic disease"
            },
            {
                "Indications (combination of these):": "Irreversible renal disease"
            },
            {
                "Indications (combination of these):": "Irreversible neurological disease"
            },
            {
                "Indications (combination of these):": "Medical nonadherence"
            },
            {
                "Indications (combination of these):": "Severe psychosocial limitations"
            },
            {
                "Indications (combination of these):": "Relative"
            },
            {
                "Indications (combination of these):": "Age >80 y for destination therapy"
            },
            {
                "Indications (combination of these):": "Obesity or malnutrition"
            },
            {
                "Indications (combination of these):": "Musculoskeletal disease that impairs rehabilitation"
            },
            {
                "Indications (combination of these):": "Active systemic infection or prolonged intubation"
            },
            {
                "Indications (combination of these):": "Untreated malignancy"
            },
            {
                "Indications (combination of these):": "Severe PVD"
            },
            {
                "Indications (combination of these):": "Active substance abuse"
            },
            {
                "Indications (combination of these):": "Impaired cognitive function"
            },
            {
                "Indications (combination of these):": "Unmanaged psychiatric disorder"
            },
            {
                "Indications (combination of these):": "Lack of social support"
            }
        ],
        "conteudo_texto": "Frequent hospitalizations for HF | NYHA class IIIb to IV functional limitations despite maximal therapy | Intolerance of neurohormonal antagonists | Increasing diuretic requirement | Symptomatic despite CRT | Inotrope dependence | Low peak VO (<14–16) 2 | End-organ dysfunction attributable to low cardiac output | Contraindications: | Absolute | Irreversible hepatic disease | Irreversible renal disease | Irreversible neurological disease | Medical nonadherence | Severe psychosocial limitations | Relative | Age >80 y for destination therapy | Obesity or malnutrition | Musculoskeletal disease that impairs rehabilitation | Active systemic infection or prolonged intubation | Untreated malignancy | Severe PVD | Active substance abuse | Impaired cognitive function | Unmanaged psychiatric disorder | Lack of social support"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "e958 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Table 20. Intravenous Inotropic Agents Used in the Management of HF"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Dose (mcg/kg) Effects"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Drug Kinetics Adverse"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Inotropic Agent Bolus Infusion (/min) and Metabolism CO HR SVR PVR Effects Special Considerations"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Adrenergic agonists"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Dopamine NA 5–10 t : 2–20 min ↑ ↑ ↔ ↔ T, HA, N, Caution: MAO-I"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "1/2"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "tissue necrosis"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "NA 10–15 R, H, P ↑ ↑ ↑ ↔"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Dobutamine NA 2.5–20 t : 2–3 min H ↑ ↑ ↔ ↔ ↑/↓BP, HA, T, Caution: MAO-I; CI: sulfite"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "1/2"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "N, F, allergy"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "hypersensitivity"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "PDE 3 inhibitor"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Milrinone NR 0.125–0.75 t : 2.5 h H ↑ ↑ ↓ ↓ T, ↓BP Accumulation may occur in"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "1/2"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "setting of renal failure; monitor"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "kidney function and LFTs"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Vasopressors"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Epinephrine NR 5–15 mcg/min t : 2–3 min ↑ ↑ ↑ (↓) ↔ HA, T Caution: MAO-I"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "1/2"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "15–20 mcg/min t : 2–3 min ↑ ↑↑ ↑↑ ↔ HA, T Caution: MAO-I"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "1/2"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Norepinephrine NR 0.5–30 mcg/min t : 2.5 min ↔ ↑ ↑↑ ↔ ↓ HR, tissue Caution: MAO-I"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "1/2"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "necrosis"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "BP indicates blood pressure; CI, contraindication; CO, cardiac output; F, fever; H, hepatic; HA, headache; HF, heart failure; HR, heart rate; LFT, liver function"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "test; MAO-I, monoamine oxidase inhibitor; N, nausea; NA, not applicable; NR, not recommended; P, plasma; PDE, phosphodiesterase; PVR, pulmonary vascular"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "resistance; R, renal; SVR, systemic vascular resistance; T, tachyarrhythmias; and t , elimination half-life."
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "1/2"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Up arrow means increase. Side arrow means no change. Down arrow means decrease. Up/down arrow means either increase or decrease."
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text 8.4. Mechanical Circulatory Support"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "1. More prolonged use of inotropes as “bridge” ther-"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Recommendations for Mechanical Circulatory Support"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "apy for those awaiting either heart transplantation Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "or MCS may have benefit in reducing pulmonary rized in the Online Data Supplements."
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "hypertension and maintaining end-organ perfusion COR LOE Recommendations"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "beyond initial stabilization of patients.1–4 1. In select patients with advanced HFrEF with"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "2. The use of inotropes for palliation does carry NYHA class IV symptoms who are deemed"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "to be dependent on continuous intravenous"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "with it risks for arrhythmias and catheter-related 1 A"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "inotropes or temporary MCS, durable LVAD"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "infections, although the presence of an ICD implantation is effective to improve functional"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "does decrease the mortality associated with status, QOL, and survival.1–18"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "arrhythmias. This risk should be shared with 2. In select patients with advanced HFrEF who"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "patients if there is planned use of inotropes have NYHA class IV symptoms despite GDMT,"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "2a B-R durable MCS can be beneficial to improve"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "in a patient without an ICD, or in whom the"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "symptoms, improve functional class, and"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "preference is to deactivate the ICD for pallia- reduce mortality.2,4,7,10,12–17,19"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "tive purposes. The rate of inappropriate shocks"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "3. In patients with advanced HFrEF who have"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "for sinus tachycardia is relatively low, and the Value Statement: NYHA class IV symptoms despite GDMT,"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "concomitant use of beta blockers may help in Uncertain Value durable MCS devices provide low to intermedi-"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "(B-NR) ate economic value based on current costs and"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "these patients. Patients may elect to have their outcomes.20–24"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "shocking devices deactivated, especially if they"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "4. In patients with advanced HFrEF and hemody-"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "receive numerous shocks.14,15 namic compromise and shock, temporary MCS,"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "3. With the currently available inotropic agents, 2a B-NR including percutaneous and extracorporeal"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "ventricular assist devices, are reasonable as a"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "the benefit of hemodynamic support and sta-"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "“bridge to recovery” or “bridge to decision.”25–29"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "bilization may be compromised by increased"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "myocardial oxygen demand and increased"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "arrhythmic burden. As newer agents are devel-"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "oped, more options may not have these known MCS is a therapeutic option for patients with advanced"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "risks. There are investigational inotropic agents HFrEF to prolong life and improve functional capacity. Over"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "that may provide more options for the manage- the past 10 years, evolution and refinement of temporary"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "ment of patients with HF and represent differ- and durable options has continued. MCS is differentiated"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "ent classes of agents.16 by the implant location, approach, flow characteristics,"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 64,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e959"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "pump mechanisms, and ventricle(s) supported. It can be ef- to assess patient risk for complications, but fac-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "fective for short-term support (hours to days) and for long- tors such as elevated central venous pressure,"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "term management (months to years). There are anatomic pulmonary hypertension, and coagulopathy have"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "and physiologic criteria that make durable MCS inappropri- been linked to poorer outcomes.15,34–36 In patients"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "ate for some patients; it is most appropriate for those with who are unable to tolerate anticoagulation after"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "HFrEF and a dilated ventricle. With any form of MCS, the repeated challenges, implantation of a durable"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "device will eventually be turned off, whether at the time of MCS is associated with excess morbidity; incidents"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "explant for transplantation or recovery, or to stop support in of pump thrombosis, hemolysis, and ischemic neu-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "a patient who either no longer wishes to continue support, rologic events have been linked to subtherapeu-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "or in whom the continued functioning of an MCS prevents tic international normalized ratios.37–41 In addition,"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "their death from other causes, such as a catastrophic neu- implantation of MCS in patients with INTERMACS"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "rologic event, or metastatic malignancy.30 This topic should profile of 1 has been associated with poorer out-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "be addressed a priori with patients before discussions come, while those ambulatory patients with profiles"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "about MCS. Particularly with temporary devices, the poten- 5 to 7 might be too well to have large significant"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "tial need to either discontinue or to escalate support should benefit, depending on their symptom burden.19 For"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "be addressed at time of implantation. patients who are initially considered to be trans-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "plant ineligible because of pulmonary hyperten-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "sion, obesity, overall frailty, or other reasons, MCS"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "can provide time to reverse or modify these con-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "1. Durable LVADs should be considered in selected ditions.35,42–44 Continuing and uptitrating GDMT in"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "patients with NHYA class IV symptoms who are patients with durable MCS is recommended.45"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "deemed dependent on IV inotropes or tempo- 3. Multiple studies evaluated the cost-effectiveness of"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "rary MCS. The magnitude of the survival ben- ventricular assist device implantation for advanced"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "efit for durable LVAD support in advanced NYHA HF between 2012 and 2017.20,21,23 They consis-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "class IV patients has progressively improved, tently found device implantation was of low eco-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "with a 2-year survival >80% in recent trials with nomic value, with incremental cost-effectiveness"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "newer generation LVADs, which approaches ratios of $200 000 per QALY gained compared"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "the early survival after cardiac transplantation.2 with medical therapy alone among patients who"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "The 2020 INTERMACS (Interagency Registry potentially underwent subsequent heart transplant"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "for Mechanically Assisted Circulatory Support) and those who were ineligible for heart transplant."
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "report showed that 87.6% of recent durable LVAD In these studies, costs after implantation remained"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "recipients were categorized as INTERMACS 1 to high given high rates of complication and rehos-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "3 before their implant surgery.10 It also showed pitalization. However, these studies used earlier"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "improved mean survival, >4 years for the desti- estimates of post-implant outcomes and compli-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "nation LVAD cohort, and >5 years for bridge-to- cation-related costs that have generally improved"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "transplant patients. Durable LVAD support has also over time with better care and newer devices.46–48"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "achieved impressive functional improvement and Additionally, limited recent data suggest improve-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "QOL improvement in multiple trials,2,7,31 although ment in health care costs and intermediate eco-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "patients remain tethered to external electrical nomic value with LVAD among patients with"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "power supplies via a percutaneous lead can limit advanced HF who are either eligible or ineligible"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "this improvement. Most patients require rehospi- for subsequent heart transplant.22,24 The improve-"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "talization within the first year post-implant. These ment may result from lower complication rates,"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "factors emphasize the need for a thorough evalu- increased survival, lower implant costs, and higher"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "ation and patient education before the decision to estimated QOL. However, given the conflicting"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "proceed with the treatment. Appropriate patient data and limited analyses of contemporary data,"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "selection benefits from review by a multidisci- the current value of LVAD therapy is uncertain."
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "plinary team that typically includes an HF cardi- 4. Temporary MCS can help stabilize patients and"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "ologist, surgeon, social worker, nurse, pharmacist, allow time for decisions about the appropriateness"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "dietician, and a palliative medicine specialist. of transitions to definitive management, such as"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "2. Durable MCS should be considered in patients durable MCS as a bridge or destination therapy,"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "with NHYA class IV symptoms despite optimal stabilization until cardiac transplantation or, in the"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "medical therapy or those deemed dependent case of improvement and recovery, suitability for"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "on IV inotropes. Destination therapy MCS pro- device removal.45 These patients often present in"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "vides considerable survival advantage in addition cardiogenic shock that cannot be managed solely"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "to improvement in functional status and health- with IV inotropes and in whom other organ function"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "related QOL.1,7,12,32,33 There is no clear 1-risk model is at risk. Temporary MCS is also appropriate for"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 65,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "e960 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "use to allow patients to engage in decision-making years.1 Cardiac transplantation also improves"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "for durable MCS or transplantation and for deter- functional status and health-related QOL.12–15"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "mination of recovery of neurologic status. Good outcomes can be achieved in patients not"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "only with HF that is primarily cardiovascular in"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "origin, including reversible pulmonary hyperten-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "8.5. Cardiac Transplantation"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "sion,16 congenital heart disease,17 and hypertro-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "phic cardiomyopathy,18 but also in patients with"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Recommendation for Cardiac Transplantation"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "systemic conditions complicated by HF, such as"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "muscular dystrophy,19 sarcoidosis,20 and amyloi-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "1. For selected patients with advanced HF"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "dosis.21 CPET can refine candidate prognosis"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "1 C-LD despite GDMT, cardiac transplantation is indi-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "cated to improve survival and QOL.1–3 and selection.22–28 Appropriate patient selection"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "should include integration of comorbidity burden,"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Value Statement: 2. In patients with stage D (advanced) HF despite"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Intermediate Value GDMT, cardiac transplantation provides inter- caretaker status, and goals of care. The listing"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "(C-LD) mediate economic value.4 criteria, evaluation, and management of patients"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "undergoing cardiac transplantation are described"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Synopsis by the International Society for Heart and Lung"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Transplantation.29 The United Network of Organ"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "The evidence that cardiac transplantation provides a"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Sharing Heart Transplant Allocation Policy was"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "mortality and morbidity benefit to selected patients"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "revised in 2018 with a broader geographic shar-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "with stage D HF (refractory, advanced) is derived from"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "ing policy and a 6-tiered system to better priori-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "observational cohorts. Datasets from the International"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "tize more unstable patients and minimize waitlist"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Society for Heart and Lung Transplantation1 and Unit-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "mortality.5–11"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "ed Network of Organ Sharing2 document the median"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "2. One study evaluated the cost-effectiveness of"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "survival of adult transplant recipients to be now >12"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "heart transplantation compared with medical"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "years; the median survival of patients with stage D HF"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "therapy among patients with inotrope-dependent"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "without advanced therapies is <2 years. For compari-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "advanced HF.30 This analysis found transplanta-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "son, the risk of death becomes greater than survival"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "tion was of intermediate value. The results were"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "between 3 and 4 years on an LVAD, regardless of im-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "similar across a broad range of patient age, wait-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "plant strategy (eg, bridge-to-transplant, bridge-to-de- list duration, and monthly mortality risk with medi-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "cision, destination therapy).3 Improvements in pre- and"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "cal therapy."
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "posttransplant management have also increased more"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "patients to be eligible for transplant, and treated rejec-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "tion rates in the first year after transplantation are now 9. PATIENTS HOSPITALIZED WITH ACUTE"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "<15%.1 Minimizing waitlist mortality while maximizing"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "DECOMPENSATED HF"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "posttransplant outcomes continues to be a priority in"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "heart transplantation and was addressed with the re- 9.1. Assessment of Patients Hospitalized With"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "cent changes in donor allocation policy instituted in Decompensated HF"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "2018.5 Several analyses6–11 have confirmed a decrease"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "in waitlist mortality as well as an increase in the use of Recommendations for Assessment of Patients Hospitalized With"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Decompensated HF"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "temporary circulatory support devices, graft ischemic"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "times, and distances between donor and recipient hos-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "pitals. The impact on posttransplant survival remains 1. In patients hospitalized with HF, severity of con-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "1 C-LD gestion and adequacy of perfusion should be"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "uncertain. Multiorgan transplantation remains uncom- assessed to guide triage and initial therapy.1–5"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "mon and reserved for highly selected candidates. In"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "2. In patients hospitalized with HF, the common"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "2018, 7% of all heart transplants involved another or-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "precipitating factors and the overall patient"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "1 C-LD"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "gan, in addition to the heart.1 trajectory should be assessed to guide appro-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "priate therapy.5,6"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Goals for Optimization and Continuation of GDMT"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text 3. For patients admitted with HF, treatment should"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "address reversible factors, establish optimal"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "1. Cardiac transplantation is the established treat- 1 C-LD volume status, and advance GDMT toward"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "ment for eligible patients with stage D HF refrac- targets for outpatient therapy.6"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "tory to GDMT, device, and surgical optimization."
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "The survival of adult recipients who received a"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "transplantation between 2011 and 2013 at 1, 3,"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "and 5 years is 90.3%, 84.7%, and 79.6%, respec- Initial triage includes clinical assessment of the hemo-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "tively.2 Conditional survival now approaches 15 dynamic profile for severity of congestion and adequa-"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 66,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e961"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Table 21. Common Factors Precipitating HF Hospitalization of right-sided pressures, particularly with TR,"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "With Acute Decompensated HF hinders effective decongestion. Disproportionate"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "elevation of left-sided filling pressures may be"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "ACS"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "underrecognized as the cause of dyspnea in the"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Uncontrolled hypertension"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "absence of jugular venous distention and edema."
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "AF and other arrhythmias"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Elevated natriuretic peptides can help identify"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Additional cardiac disease (eg, endocarditis)"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "HF in the urgent care setting but with less utility"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Acute infections (eg, pneumonia, urinary tract) in certain situations, including decreased sen-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Nonadherence with medication regimen or dietary intake sitivity with obesity and HFpEF and decreased"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Anemia specificity in the setting of sepsis. Resting hypo-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "perfusion is often underappreciated in patients"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Hyper- or hypothyroidism"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "with chronic HF but can be suspected from nar-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Medications that increase sodium retention (eg, NSAID)"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "row pulse pressure and cool extremities1,9 and"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Medications with negative inotropic effect (eg, verapamil)"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "by intolerance to neurohormonal antagonists."
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "ACS indicates acute coronary syndrome; AF, atrial fibrillation; HF, heart fail- Elevated serum lactate levels may indicate hypo-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "ure; and NSAID, nonsteroidal anti-inflammatory drug."
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "perfusion and impending cardiogenic shock.12"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "When initial clinical assessment does not sug-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "cy of perfusion.1–5 The diagnosis of cardiogenic shock"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "gest congestion or hypoperfusion, symptoms"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "warrants consideration of recommendations in Sec-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "of HF may be a result of transient ischemia,"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "tion 9.5, “Evaluation and Management of Cardiogenic"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "arrhythmias, or noncardiac disease such as"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Shock,” but any concern for worsening hypoperfusion"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "chronic pulmonary disease or pneumonia, and"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "should also trigger involvement of the multidisciplinary"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "more focused hemodynamic assessment may"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "team for hemodynamic assessment and intervention."
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "be warranted. Assessment of arrhythmia, device"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Initial triage includes recognition of patients with ACS"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "profiles such as percent LV pacing versus RV"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "for whom urgent revascularization may be indicated."
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "pacing in patients with CRT, and device therapy"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "In the absence of ischemic disease, recent onset with"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "and shocks in patients with ICD can provide"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "accelerating hemodynamic decompensation may rep-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "important information."
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "resent inflammatory heart disease, particularly when"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "3. Hospitalization for HF is a sentinel event that"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "accompanied by conduction block or ventricular ar-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "signals worse prognosis and the need to restore"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "rhythmias.7,8 However, most HF hospitalizations for de-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "hemodynamic compensation but also provides"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "compensation are not truly “acute” but follow a gradual"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "key opportunities to redirect the disease trajec-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "increase of cardiac filling pressures on preexisting"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "tory. During the HF hospitalization, the approach"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "structural heart disease, often with precipitating fac-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "to management should include and address"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "tors that can be identified3,6 (Table 21). Some patients"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "precipitating factors, comorbidities, and previ-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "present with pulmonary edema and severe hyperten-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "ous limitations to ongoing disease manage-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "sion, which require urgent treatment to reduce blood"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "ment related to social determinants of health.1"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "pressure, more commonly in patients with preserved"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Patients require assessment and management"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "LVEF. Patients require assessment and management"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "of ischemia, arrhythmia, and other precipitat-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "of ischemia, arrhythmia and other precipitating factors"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "ing factors and comorbidities. The presenting"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "and comorbidities. The presenting profile, reversible"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "profile, reversible factors, appropriate work-up"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "factors, appropriate workup for the cause of HF includ-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "for cause of HF including ischemic and non-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "ing ischemic and nonischemic causes, comorbidities,"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "ischemic causes, comorbidities, disease trajec-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "and potential for GDMT titration inform the plan of care"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "tory, and goals of care should be addressed."
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "to optimize the disease trajectory.5"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Establishment of optimal volume status is a"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "major goal, and patients with residual conges-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "tion merit careful consideration for further inter-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "1. and 2. Most patients admitted with HF have vention before and after discharge, because"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "clinical evidence of congestion without appar- they face higher risk for rehospitalization and"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "ent hypoperfusion.1–5,9,10 Although elevations of death.2–5 The disease trajectory for patients hos-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "right- and left-sided cardiac filling pressures pitalized with reduced EF is markedly improved"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "are usually proportional in decompensation of by optimization of recommended medical ther-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "chronic HF with low EF, up to 1 in 4 patients apies, which should be initiated or increased"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "have a mismatch between right- and left-sided toward target doses once the efficacy of diure-"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "filling pressures.9–11 Disproportionate elevation sis has been shown.13,14"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 67,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 67,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "ACS": "Uncontrolled hypertension"
            },
            {
                "ACS": "AF and other arrhythmias"
            },
            {
                "ACS": "Additional cardiac disease (eg, endocarditis)"
            },
            {
                "ACS": "Acute infections (eg, pneumonia, urinary tract)"
            },
            {
                "ACS": "Nonadherence with medication regimen or dietary intake"
            },
            {
                "ACS": "Anemia"
            },
            {
                "ACS": "Hyper- or hypothyroidism"
            },
            {
                "ACS": "Medications that increase sodium retention (eg, NSAID)"
            },
            {
                "ACS": "Medications with negative inotropic effect (eg, verapamil)"
            }
        ],
        "conteudo_texto": "Uncontrolled hypertension | AF and other arrhythmias | Additional cardiac disease (eg, endocarditis) | Acute infections (eg, pneumonia, urinary tract) | Nonadherence with medication regimen or dietary intake | Anemia | Hyper- or hypothyroidism | Medications that increase sodium retention (eg, NSAID) | Medications with negative inotropic effect (eg, verapamil)"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "e962 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "9.2. Maintenance or Optimization of GDMT blockers.1 In a meta-analysis of observational"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "During Hospitalization and trial data, discontinuation of beta blockers in"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "hospitalized patients with HFrEF also was asso-"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Recommendations for Maintenance or Optimization of GDMT During ciated with a higher risk of in-hospital mortality,"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Hospitalization short-term mortality, and the combined endpoint"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "of short-term rehospitalization or mortality.4"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Withholding or reducing beta-blocker therapy"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "should be considered in patients with marked"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "1. In patients with HFrEF requiring hospitalization,"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "volume overload or marginal low cardiac output."
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "preexisting GDMT should be continued and"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "1 B-NR"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "optimized to improve outcomes, unless contra- In the Get With The Guidelines-Heart Failure"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "indicated.1–5 (GWTG-HF) registry, withdrawal of ACEi-ARB"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "2. In patients experiencing mild decrease of renal among patients hospitalized with HFrEF was"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "function or asymptomatic reduction of blood associated with higher rates of postdischarge"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "1 B-NR pressure during HF hospitalization, diuresis and"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "mortality and readmission.2 In the COACH"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "other GDMT should not routinely be discontin-"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "ued.6–11 (Coordinating study evaluating Outcomes of"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "3. In patients with HFrEF, GDMT should be initi- Advising and Counselling in Heart failure) study,"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "1 B-NR ated during hospitalization after clinical stability continuation of spironolactone among hospital-"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "is achieved.2,3,5,12–18"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "ized patients with HFrEF was associated with"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "4. In patients with HFrEF, if discontinuation of lower 30-day mortality and HF rehospitaliza-"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "GDMT is necessary during hospitalization, it"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "1 B-NR tion.3 From the ARIC (Atherosclerosis Risk in"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "should be reinitiated and further optimized as"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "soon as possible.19–22 Communities) study, discontinuation of any oral"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "GDMT among patients hospitalized with HFrEF"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "was associated with higher mortality risk.5 Oral"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "GDMT should not be withheld for mild or tran-"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Hospitalization for HFrEF is a critical opportunity to sient reductions in blood pressure6–9 or mild"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "continue, initiate, and further optimize GDMT.23–25 deteriorations in renal function.10,11 True contra-"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Continuation of oral GDMT during hospitalization indications are rare, such as advanced degree"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "for HF has been shown in registries to lower risk of atrioventricular block for beta blockers in the"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "postdischarge death and readmission compared with absence of pacemakers; cardiogenic shock that"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "discontinuation.1–5 Initiation of oral GDMT during hos- may preclude use of certain medications until"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "pitalization for HF is associated with numerous clini- resolution of shock state; or angioedema for"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "cal outcome benefits.2,5,12,16,17 Based on data from the ACEi or ARNi."
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "CHAMP-HF (Change the Management of Patients with 2. In CHAMP-HF, very few patients with HF and"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Heart Failure) registry, however, only 73%, 66%, and SBP <110 mm Hg received target doses of beta"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "33% of eligible patients with HFrEF were prescribed blockers (17.5%) ACEi-ARB (6.2 %), or ARNi"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "ACEi-ARB-ARNi, beta blockers, and MRA therapy, (1.8%).6 In PARADIGM-HF, patients with HF and"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "respectively.19 Furthermore, based on information ob- lower SBP on sacubitril-valsartan had the same"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "tained from claims data, roughly 42% of patients are tolerance and relative benefit over enalapril"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "not prescribed any GDMT within 30 days postindex compared with patients with higher SBP.7 From"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "hospitalization,20 and 45% are prescribed either no oral the SENIORS (Study of Effects of Nebivolol"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "GDMT or monotherapy within 1-year post-hospitaliza- Intervention on Outcomes and Rehospitalization"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "tion.21 In the management of patients with HFrEF in in Seniors With Heart Failure) trial, nebivolol had"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "the community, very few receive target doses of oral equivalent tolerance and benefits irrespective of"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "GDMT.6 Moreover, most patients with HFrEF have no SBP.8 In Val-HeFT (Valsartan Heart Failure Trial),"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "changes made to oral GDMT over 12 months,21 despite decreases in SBP did not offset the beneficial"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "being discharged on suboptimal doses or no GDMT.22 It effects of valsartan on HF morbidity.9 In patients"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "cannot be assumed that oral GDMT will be initiated or with HF on oral GDMT, small to moderate"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "optimized after hospitalization for HFrEF. worsening of renal function (defined as ≥20%"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "decrease in eGFR in that study) was not asso-"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "ciated with AKI.10 Moreover, it has been shown"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "that spironolactone and beta blockers might be"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "1. In OPTIMIZE-HF (Organized Program to Initiate protective in patients with HF and worsening"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Lifesaving Treatment in Hospitalized Patients renal function.11"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "with Heart Failure), discontinuation of beta 3. In OPTIMIZE-HF, discharge use of carvedilol"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "blockers was associated with a higher risk for was associated with a reduction in 60- to"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "mortality compared with those continued on beta 90-day mortality and composite risk of mortality"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 68,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e963"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "or rehospitalization compared with no carvedilol 9.3. Diuretics in Hospitalized Patients:"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "use.12,13 Discharge use of beta blockers is also Decongestion Strategy"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "associated with lower 30-day all-cause mortality"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "and 4-year all-cause mortality/all-cause read- Recommendations for Diuretics in Hospitalized Patients: Decongestion"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "mission.14 Caution should be used when initiating Strategy"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "beta blockers in patients who have required ino-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "tropes during hospitalization. In GWTG-HF, initia-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "tion of ACEi-ARB in patients hospitalized with"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "1. Patients with HF admitted with evidence of"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "HFrEF reduced 30-day and 1-year mortality.2"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "significant fluid overload should be promptly"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "1 B-NR"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "Among patients hospitalized with HFrEF, initia- treated with intravenous loop diuretics to"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "tion of ACEi-ARB also is associated with lower improve symptoms and reduce morbidity.1"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "risk of 30-day all-cause readmission and all- 2. For patients hospitalized with HF, therapy with"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "cause mortality.15 In a claims study, initiation of diuretics and other guideline-directed medica-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "1 B-NR tions should be titrated with a goal to resolve"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "MRA therapy at hospital discharge was associ-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "clinical evidence of congestion to reduce symp-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "ated with improved HF readmission but not mor- toms and rehospitalizations.1–6"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "tality or cardiovascular readmission among older 3. For patients requiring diuretic treatment during"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "adults hospitalized with HFrEF.16 In COACH, hospitalization for HF, the discharge regimen"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "1 B-NR"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "should include a plan for adjustment of diuret-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "initiating spironolactone among patients hospi-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "ics to decrease rehospitalizations.7"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "talized with HFrEF was associated with lower"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "4. In patients hospitalized with HF when diuresis"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "30-day mortality and HF rehospitalization.3 In"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "is inadequate to relieve symptoms and signs"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "the PIONEER-HF trial, ARNi use was associ- of congestion, it is reasonable to intensify the"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "2a B-NR"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "ated with reduced NT-proBNP levels in patients diuretic regimen using either: a. higher doses of"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "intravenous loop diuretics.1,3); or b. addition of"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "hospitalized for acute decompensated HF with-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "a second diuretic.3"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "out increased rates of adverse events (worsen-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "ing renal function, hyperkalemia, symptomatic"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "hypotension, angioedema) when compared with Synopsis"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "enalapril.18 In the ARIC study, initiation of any oral"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "Intravenous loop diuretic therapy provides the most"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "GDMT was associated with reduced 1-year mor-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "rapid and effective treatment for signs and symptoms of"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "tality among patients hospitalized with HFrEF.5 In"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "congestion leading to hospitalization for HF. Titration to"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "SOLOIST-WHF, initiation of sotagliflozin before"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "achieve effective diuresis may require doubling of initial"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "or shortly after discharge reduced cardiovascular"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "doses, adding a thiazide diuretic, or adding an MRA that"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "mortality and hospitalization.17"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "has diuretic effects in addition to its cardiovascular bene-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "4. Nearly half (46%) of patients with HFrEF have"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "fits. A major goal of therapy is resolution of the signs and"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "no changes made to oral GDMT in the 12"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "symptoms of congestion before discharge, as persistent"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "months after hospitalization despite many being"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "congestion scored at discharge has been associated"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "discharged on suboptimal doses.21 From claims-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "with higher rates of rehospitalizations and mortality. Most"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "based studies, 42% of patients with HFrEF"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "patients who have required intravenous diuretic therapy"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "are not prescribed any GDMT within 30 days"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "during hospitalization for HF will require prescription of"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "post-index hospitalization,20 and 45% are pre-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "loop diuretics at discharge to decrease recurrence of"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "scribed either no oral GDMT or monotherapy"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "symptoms and hospitalization."
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "within 1-year post-index hospitalization.21 From"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "CHAMP-HF, initiation or dose increases of beta"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "blockers, ACEi-ARB-ARNi, and MRA occur in"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "≤10% of patients with HFrEF within 1 year of 1. Diuretic therapy with oral furosemide was the"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "hospitalization.22 Very few eligible patients with cornerstone of HF therapy for >20 years before"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "HFrEF receive target doses of beta blockers construction of the modern bases of evidence"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "(18.7%), ACEi-ARB (10.8%), or ARNi (2.0%).6 for HF therapies. The pivotal RCTs showing ben-"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "Less than 1% of patients with HFrEF are on tar- efit in ambulatory HFrEF have been conducted"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "get doses of ACEi-ARB-ARNi, beta blockers, and on the background of diuretic therapy to treat"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "MRA within 12 months of an index hospitaliza- and prevent recurrence of fluid retention. An RCT"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "tion.22 For patients with HFrEF, there is a graded compared intravenous diuretic doses and infusion"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "improvement in the risk of death or rehospitaliza- to bolus dosing during hospitalization for HF but"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "tion with monotherapy, dual therapy, and triple without a placebo arm.1 Protocols for recent trials"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "therapy compared with no GDMT after an index of other medications in patients hospitalized with"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "hospitalization in Medicare claims data.21 HF have all included intravenous diuretic therapy"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 69,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "e964 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "as background therapy.1–6,8,9 There are no RCTs for symptoms or in the change in renal function when"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "hospitalized patients comparing intravenous loop diuretic therapy was administered by bolus, com-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "diuretics to placebo, for which equipoise is consid- pared with continuous infusion or at a high dose"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "ered unlikely.10 compared with a low dose. Patients in the low-dose"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "2. Monitoring HF treatment includes careful measure- group were more likely to require a 50% increase in"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "ment of fluid intake and output, vital signs, standing the dose at 48 hours than were those in the high-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "body weight at the same time each day, and clinical dose group, and all treatment groups had higher"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "signs and symptoms of congestion and hypoperfu- doses of diuretics compared with baseline pread-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "sion. Daily laboratory tests during active medication mission doses, underlining the necessity to inten-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "adjustment include serum electrolytes, urea nitrogen, sify and individualize diuretic regimen.1 MRAs have"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "and creatinine concentrations. Signs and symptoms mild diuretics properties and addition of MRAs can"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "of congestion have been specified as inclusion cri- help with diuresis in addition to significant cardio-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "teria in recent trials of patients hospitalized for HF, in vascular benefits in patients with HF. Addition of"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "which resolution of these signs and symptoms has low-dose dopamine to diuretic therapy in the set-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "been defined as a goal to be achieved by hospital dis- ting of reduced eGFR did not improve outcomes"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "charge,1–6,8,9 as it has in the recent HF hospitalization in a study that included patients with all EFs, but"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "pathway consensus document.11 Evidence of persis- a subset analysis showed increased urine output"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "tent congestion at discharge has been reported in and weight loss in patients with LVEF <0.40,9 with"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "25% to 50% of patients,4,5,12 who have higher rates of significant interaction of effect with LVEF. Bedside"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "mortality and readmission and are more likely to have ultrafiltration initiated early after admission"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "elevated right atrial pressures, TR, and renal dysfunc- increased fluid loss, with decreased rehospitaliza-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "tion. Diuresis should not be discontinued prematurely tions in some studies when compared with use"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "because of small changes in serum creatinine,13,14 of diuretics without systematic escalation.15,16and"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "because elevations in the range of 0.3 mg/dL do not was also associated with adverse events related to"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "predict worse outcomes except when patients are the intravenous catheters required.3 Many aspects"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "discharged with persistent congestion. Decongestion of ultrafiltration including patient selection, fluid"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "often requires not only diuresis but also adjustment of removal rates, venous access, prevention of ther-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "other guideline-directed therapies, because elevated apy-related complications, and cost require further"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "volume status and vasoconstriction can contribute to investigation."
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "elevated filling pressures."
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "3. After discharge, ACEi-ARB, MRAs, and beta block-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "9.4a. Parenteral Vasodilation Therapy in"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "ers all may decrease recurrent congestion leading"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "Patients Hospitalized With HF"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "to hospitalization in HFrEF. Despite these therapies,"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "most patients with recent HF hospitalization require"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "Recommendation for Parenteral Vasodilation Therapy in Patients Hos-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "continued use of diuretics after discharge to pre-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "pitalized With HF"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "vent recurrent fluid retention and hospitalization, Referenced studies that support the recommendation are summarized"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "as shown in a recent large observational analysis.7 in the Online Data Supplements."
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "Increases in diuretic doses are frequently required COR LOE Recommendation"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "early after discharge even in patients on all other 1. In patients who are admitted with decompen-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "currently recommended therapies for HFrEF.8 It sated HF, in the absence of systemic hypoten-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "2b B-NR sion, intravenous nitroglycerin or nitroprusside"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "is unknown how increased penetration of therapy"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "may be considered as an adjuvant to diuretic"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "with ARNi and SGLT2i will, in the future, affect the therapy for relief of dyspnea.1,2"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "dosing of diuretics after discharge with HFrEF."
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "4. Titration of diuretics has been described in mul-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "tiple recent trials of patients hospitalized with HF,"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "often initiated with at least 2 times the daily home Vasodilators can be used in acute HF to acutely relieve"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "diuretic dose (mg to mg) administered intrave- symptoms of pulmonary congestion in selected patients."
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "nously.1 Escalating attempts to achieve net diuresis Although they may mitigate dyspnea and relieve pulmo-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "include serial doubling of intravenous loop diuretic nary congestion, their benefits have not been shown to"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "doses, which can be done by bolus or infusion, and have durable effects for either rehospitalization or mor-"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "sequential nephron blockade with addition of a tality benefit. In select patients who present with signs"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "thiazide diuretic, as detailed specifically in the pro- of hypoperfusion such as worsening renal function, even"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "tocol for the diuretic arms of the CARRESS and in the absence of hypotension, other escalation of care"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "ROSE trials.3,9 In the DOSE (Diuretic Optimization may need to be considered (see Section 8.3, “Inotropic"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "Strategies Evaluation) trial, there were no signifi- Support,” and Section 9.5, “Evaluation and Management"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "cant differences in patients’ global assessment of of Cardiogenic Shock”)."
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 70,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e965"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text patients with acute illnesses, severe respiratory dis-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "eases, or simply a broad spectrum of hospitalized"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "1. The role for directed vasodilators in acute decom-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "medical patients.9–12 All included trials excluded"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "pensated HF remains uncertain. Part of the rationale"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "patients perceived to have an elevated risk of"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "for their use is targeting pulmonary congestion, while"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "bleeding complications or of toxicity from the spe-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "trying to avoid some potential adverse consequences"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "cific agent tested (eg, enoxaparin in patients with"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "of loop diuretics. Patients with hypertension, coronary"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "compromised renal function). In some trials, aspirin"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "ischemia, or significant MR may be suitable candidates"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "was allowed but not controlled for as a confounding"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "for the use of intravenous nitroglycerin. However,"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "variable. Despite the increased risk for the develop-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "tachyphylaxis may develop within 24 hours, and up"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "ment of VTE in the 30 days after hospitalization,"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "to 20% of those with HF may develop resistance to"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "the data for extending prophylaxis to the immediate"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "even high doses.3,4 Because of sodium nitroprusside’s"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "post-hospital period have shown decreased devel-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "potential for producing marked hypotension, invasive"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "opment of VTE but were associated with increased"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "hemodynamic blood pressure monitoring (eg, an arte-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "bleeding events and overall do not appear to pro-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "rial line) is typically required, and nitroprusside is usu-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "vide additional benefit.2,3,11 For patients admitted"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "ally used in the intensive care setting; longer infusions"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "specifically for decompensated HF and with ade-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "of the drug have been associated, albeit rarely, with"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "quate renal function (creatinine clearance, >30"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "thiocyanate and cyanide toxicity, particularly in the set-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "mL/min), randomized trials suggest that enoxaparin"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "ting of renal insufficiency and significant hepatic dis-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "40 mg subcutaneously once daily,1,13 unfraction-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "ease. Nitroprusside is potentially of value in severely"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "ated heparin 5000 units subcutaneously every 8"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "congested patients with hypertension or severe MV"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "or 12 hours,14–17 or rivaroxaban 10 mg once daily11"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "regurgitation complicating LV dysfunction.5 Overall,"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "will radiographically reduce demonstrable venous"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "there are no data that suggest that intravenous vaso-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "thrombosis. Effects on mortality or clinically sig-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "dilators improve outcomes in the patient hospitalized"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "nificant pulmonary embolism rates are unclear. For"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "with HF; as such, use of intravenous vasodilators is"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "obese patients, a higher dose of enoxaparin 60 mg"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "limited to the relief of dyspnea in the hospitalized HF"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "once daily achieved target range of thromboprophy-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "patient with intact or high blood pressure.6,7"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "laxis without increased bleeding.12"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "9.4b. VTE Prophylaxis in Hospitalized Patients 9.5. Evaluation and Management of Cardiogenic"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Shock"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Recommendation for VTE Prophylaxis in Hospitalized Patients"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendation are summarized"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "in the Online Data Supplements. Recommendations for Evaluation and Management of Cardiogenic Shock"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation rized in the Online Data Supplements."
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "1. In patients hospitalized with HF, prophylaxis for"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "1 B-R VTE is recommended to prevent venous throm-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "boembolic disease.1–3 1. In patients with cardiogenic shock, intravenous"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "inotropic support should be used to maintain"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "1 B-NR"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "systemic perfusion and preserve end-organ"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "performance.1–8"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "2. In patients with cardiogenic shock, temporary"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "HF has long been recognized as affording additional risk MCS is reasonable when end-organ function"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "2a B-NR for venous thromboembolic disease. When patients are cannot be maintained by pharmacologic means"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "to support cardiac function.9–17"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "hospitalized for decompensated HF, or when patients with"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "chronic stable HF are hospitalized for other reasons, they 3. In patients with cardiogenic shock, manage-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "2a B-NR ment by a multidisciplinary team experienced in"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "are at increased risk for venous thromboembolic disease."
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "shock is reasonable.17–22"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "The risk may be associated with higher HF symptom bur-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "4. In patients presenting with cardiogenic shock,"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "den.4 This risk may extend for up to 2 years after hospi- placement of a PA line may be considered to"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "2b B-NR"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "talization but is greatest in the first 30 days.5,6 The use of define hemodynamic subsets and appropriate"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "management strategies.23–27"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "anticoagulation with subcutaneous low-molecular-weight"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "heparin, unfractionated heparin, fondaparinux, or approved 5. For patients who are not rapidly responding to"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "initial shock measures, triage to centers that"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "DOAC are used for the prevention of clinically symptomatic 2b C-LD"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "can provide temporary MCS may be consid-"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "deep vein thrombosis and pulmonary embolism.7,8 ered to optimize management.17–22"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supporting Text Synopsis"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "1. Trials using available antithrombotic drugs often Cardiogenic shock is a commonly encountered clinical"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "were not limited to patients with HF but included challenge with a high mortality and is characterized by"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 71,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "e966 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Table 22. Suggested Shock Clinical Criteria*29 Table 23. Suggested Shock Hemodynamic Criteria*29"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "SBP <90 mm Hg for >30 min: 1. SBP <90 mm Hg or mean BP <60 mm Hg"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "a. Or mean BP <60 mm Hg for >30 min 2. Cardiac index <2.2 L/min/m2"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "b. Or requirement of vasopressors to maintain systolic BP ≥90 mm Hg or 3. Pulmonary capillary wedge pressure >15 mm Hg"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "mean BP ≥60 mm Hg"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "4. Other hemodynamic considerations"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Hypoperfusion defined by: a. Cardiac power output ([CO x MAP]/451) <0.6 W"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "b. Shock index (HR/systolic BP) >1.0"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "c. Decreased mentation"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "c. RV shock"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "d. Cold extremities, livedo reticularis i. Pulmonary artery pulse index [(PASP-PADP)/CVP] <1.0"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "ii. CVP >15 mm Hg"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "e. Urine output <30 mL/h"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "iii. CVP-PCW >0.6"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "f. Lactate >2 mmol/L"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "BP indicates blood pressure; CO, cardiac output; CVP, central venous pres-"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "BP indicates blood pressure; and SBP, systolic blood pressure. sure; HR, heart rate; MAP, mean arterial pressure; PADP, pulmonary artery"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "*Systolic BP and hypoperfusion criteria need to be met for the shock diag- diastolic pressure; PASP, pulmonary artery systolic pressure; PCW, pulmonary"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "nosis. capillary wedge; RV, right ventricular; and SBP, systolic blood pressure."
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "*Diagnosis of shock requires ≥1 criteria to be present along with cardiac"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "index <2.0 L/min/m2 and SBP <90 mm Hg."
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "a critical reduction in cardiac output manifest by end-"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "organ dysfunction.28 Hypotension (eg, SBP <90 mm recognition, invasive hemodynamic assessment when"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Hg) is the primary clinical manifestation of shock but is there is insufficient clinical improvement to initial mea-"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "not sufficient for the diagnosis. Additionally, end-organ sures and providing appropriate pharmacological and"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "hypoperfusion should be present as a consequence of MCS to optimize end-organ perfusion and prevent meta-"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "cardiac dysfunction (Tables 22, 23, 24).29 Causes can bolic complications. The evidence that supports the use"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "be broadly separated into acute decompensations of of specific pharmacologic therapies and the nature of"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "chronic HF, acute myocardial dysfunction without prec- temporary MCS is primarily gleaned from observational"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "edent HF, and survivors of cardiac arrest. In the case retrospective datasets. Only a few randomized trials have"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "of acute MI, urgent revascularization is paramount. The been conducted to assess the most appropriate circula-"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "approach to cardiogenic shock should include its early tory support device, and they have been limited by small"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Table 24. Society for Cardiovascular Angiography and Interventions (SCAI) Cardiogenic Shock Criteria29"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Stage Bedside Findings Selected Laboratory Markers Hemodynamics"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "A: At risk Normal venous pressure Normal renal function SBP >100 mm Hg"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Normotensive Clear lungs Normal lactate Hemodynamics: Normal"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Normal perfusion Warm extremities"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Cause for risk for shock such as Strong palpable pulses"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "large myocardial infarction or HF Normal mentation"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "B: Beginning shock (“pre-shock”) Elevated venous pressure Preserved renal function SBP <90 mm Hg, MAP <60 mm Hg, or >30"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Hypotension Rales present Normal lactate mm Hg decrease from baseline SBP"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Normal perfusion Warm extremities Elevated BNP HR >100 bpm"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Strong pulses Hemodynamics: CI ≥2.2 L/min/m2"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Normal mentation"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "C: Classic cardiogenic shock Elevated venous pressure Impaired renal function SBP <90 mm Hg; MAP <60 mm Hg; >30"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Hypotension Rales present Increased lactate mm Hg from baseline SBP despite drugs"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "and temporary MCS"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Hypoperfusion Cold, ashen, livedo Elevated BNP"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "HR >100 bpm"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Weak or nonpalpable pulses Increased LFTs"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Hemodynamics: CI ≤2.2 L/min/m2; PCW"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Altered mentation Acidosis"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": ">15 mm Hg; CPO <0.6 W; PAPi <2.0;"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Decreased urine output CVP-PCW >1.0"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Respiratory distress"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "D: Deteriorating Same as stage C Persistent or worsening values Escalating use of pressors or MCS to main-"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Worsening hypotension of stage C tain SBP and end-organ perfusion in setting"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "of stage C hemodynamics"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Worsening hypoperfusion"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "E: Extremis Cardiac arrest Worsening values of stage C SBP only with resuscitation"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Refractory hypotension CPR laboratories PEA"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Refractory hypoperfusion Recurrent VT/VF"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "BNP indicates brain natriuretic peptide; CI, cardiac index; CPO, cardiac power output; CPR, cardiopulmonary resuscitation; CVP, central venous pressure; HR,"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "heart rate; LFT, liver function test; MAP, mean arterial blood pressure; MCS, mechanical circulatory support; PAPi, pulmonary artery pulsatility index; PCW, pulmonary"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "capillary wedge pressures; PEA, pulseless electrical activity; SBP, systolic blood pressure; VF, ventricular fibrillation; and VT, ventricular tachycardia."
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Adapted from Baran D et al,29 with permission from Wiley Periodicals, Inc."
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 72,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 72,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "SBP <90 mm Hg for >30 min:": "a. Or mean BP <60 mm Hg for >30 min"
            },
            {
                "SBP <90 mm Hg for >30 min:": "b. Or requirement of vasopressors to maintain systolic BP ≥90 mm Hg or mean BP ≥60 mm Hg"
            },
            {
                "SBP <90 mm Hg for >30 min:": "Hypoperfusion defined by:"
            },
            {
                "SBP <90 mm Hg for >30 min:": "c. Decreased mentation"
            },
            {
                "SBP <90 mm Hg for >30 min:": "d. Cold extremities, livedo reticularis"
            },
            {
                "SBP <90 mm Hg for >30 min:": "e. Urine output <30 mL/h"
            },
            {
                "SBP <90 mm Hg for >30 min:": "f. Lactate >2 mmol/L"
            }
        ],
        "conteudo_texto": "a. Or mean BP <60 mm Hg for >30 min | b. Or requirement of vasopressors to maintain systolic BP ≥90 mm Hg or mean BP ≥60 mm Hg | Hypoperfusion defined by: | c. Decreased mentation | d. Cold extremities, livedo reticularis | e. Urine output <30 mL/h | f. Lactate >2 mmol/L"
    },
    {
        "pagina": 72,
        "tipo": "tabela",
        "indice_tabela": 2,
        "conteudo_dict": [
            {
                "1. SBP <90 mm Hg or mean BP <60 mm Hg": "2. Cardiac index <2.2 L/min/m2"
            },
            {
                "1. SBP <90 mm Hg or mean BP <60 mm Hg": "3. Pulmonary capillary wedge pressure >15 mm Hg"
            },
            {
                "1. SBP <90 mm Hg or mean BP <60 mm Hg": "4. Other hemodynamic considerations a. Cardiac power output ([CO x MAP]/451) <0.6 W b. Shock index (HR/systolic BP) >1.0 c. RV shock i. Pulmonary artery pulse index [(PASP-PADP)/CVP] <1.0 ii. CVP >15 mm Hg iii. CVP-PCW >0.6"
            }
        ],
        "conteudo_texto": "2. Cardiac index <2.2 L/min/m2 | 3. Pulmonary capillary wedge pressure >15 mm Hg | 4. Other hemodynamic considerations a. Cardiac power output ([CO x MAP]/451) <0.6 W b. Shock index (HR/systolic BP) >1.0 c. RV shock i. Pulmonary artery pulse index [(PASP-PADP)/CVP] <1.0 ii. CVP >15 mm Hg iii. CVP-PCW >0.6"
    },
    {
        "pagina": 72,
        "tipo": "tabela",
        "indice_tabela": 3,
        "conteudo_dict": [
            {
                "Stage": "A: At risk Normotensive Normal perfusion Cause for risk for shock such as large myocardial infarction or HF",
                "Bedside Findings": "Normal venous pressure Clear lungs Warm extremities Strong palpable pulses Normal mentation",
                "Selected Laboratory Markers": "Normal renal function Normal lactate",
                "Hemodynamics": "SBP >100 mm Hg Hemodynamics: Normal"
            },
            {
                "Stage": "B: Beginning shock (“pre-shock”) Hypotension Normal perfusion",
                "Bedside Findings": "Elevated venous pressure Rales present Warm extremities Strong pulses Normal mentation",
                "Selected Laboratory Markers": "Preserved renal function Normal lactate Elevated BNP",
                "Hemodynamics": "SBP <90 mm Hg, MAP <60 mm Hg, or >30 mm Hg decrease from baseline SBP HR >100 bpm Hemodynamics: CI ≥2.2 L/min/m2"
            },
            {
                "Stage": "C: Classic cardiogenic shock Hypotension Hypoperfusion",
                "Bedside Findings": "Elevated venous pressure Rales present Cold, ashen, livedo Weak or nonpalpable pulses Altered mentation Decreased urine output Respiratory distress",
                "Selected Laboratory Markers": "Impaired renal function Increased lactate Elevated BNP Increased LFTs Acidosis",
                "Hemodynamics": "SBP <90 mm Hg; MAP <60 mm Hg; >30 mm Hg from baseline SBP despite drugs and temporary MCS HR >100 bpm Hemodynamics: CI ≤2.2 L/min/m2; PCW >15 mm Hg; CPO <0.6 W; PAPi <2.0; CVP-PCW >1.0"
            },
            {
                "Stage": "D: Deteriorating Worsening hypotension Worsening hypoperfusion",
                "Bedside Findings": "Same as stage C",
                "Selected Laboratory Markers": "Persistent or worsening values of stage C",
                "Hemodynamics": "Escalating use of pressors or MCS to main- tain SBP and end-organ perfusion in setting of stage C hemodynamics"
            },
            {
                "Stage": "E: Extremis Refractory hypotension Refractory hypoperfusion",
                "Bedside Findings": "Cardiac arrest CPR",
                "Selected Laboratory Markers": "Worsening values of stage C laboratories",
                "Hemodynamics": "SBP only with resuscitation PEA Recurrent VT/VF"
            }
        ],
        "conteudo_texto": "A: At risk Normotensive Normal perfusion Cause for risk for shock such as large myocardial infarction or HF, Normal venous pressure Clear lungs Warm extremities Strong palpable pulses Normal mentation, Normal renal function Normal lactate, SBP >100 mm Hg Hemodynamics: Normal | B: Beginning shock (“pre-shock”) Hypotension Normal perfusion, Elevated venous pressure Rales present Warm extremities Strong pulses Normal mentation, Preserved renal function Normal lactate Elevated BNP, SBP <90 mm Hg, MAP <60 mm Hg, or >30 mm Hg decrease from baseline SBP HR >100 bpm Hemodynamics: CI ≥2.2 L/min/m2 | C: Classic cardiogenic shock Hypotension Hypoperfusion, Elevated venous pressure Rales present Cold, ashen, livedo Weak or nonpalpable pulses Altered mentation Decreased urine output Respiratory distress, Impaired renal function Increased lactate Elevated BNP Increased LFTs Acidosis, SBP <90 mm Hg; MAP <60 mm Hg; >30 mm Hg from baseline SBP despite drugs and temporary MCS HR >100 bpm Hemodynamics: CI ≤2.2 L/min/m2; PCW >15 mm Hg; CPO <0.6 W; PAPi <2.0; CVP-PCW >1.0 | D: Deteriorating Worsening hypotension Worsening hypoperfusion, Same as stage C, Persistent or worsening values of stage C, Escalating use of pressors or MCS to main- tain SBP and end-organ perfusion in setting of stage C hemodynamics | E: Extremis Refractory hypotension Refractory hypoperfusion, Cardiac arrest CPR, Worsening values of stage C laboratories, SBP only with resuscitation PEA Recurrent VT/VF"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e967"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "sample size, the inherent open-label study design, short have associated PA catheterization use with"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "follow-up, and surrogate endpoints. improved outcomes, particularly in conjunction with"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "short-term MCS.23–27,41 PA catheterization may also"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "be useful when there is diagnostic uncertainty as"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "to the cause of hypotension or end-organ dysfunc-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "1. Intravenous inotropic support can increase tion, particularly when a patient in shock is not"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "cardiac output and improve hemodynamics in responding to empiric initial shock measures.42"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "patients presenting with cardiogenic shock. 5. Transfer to centers capable of providing such sup-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Despite their ubiquitous use for initial manage- port should be considered early in the assessment"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "ment of cardiogenic shock, there are few pro- of a patient with cardiogenic shock and a trajec-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "spective data and a paucity of randomized trials tory of worsening end-organ malperfusion.17–22,43"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "to guide their use.1–8 However, their broad avail- The treatment of shock should be recognized as"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "ability, ease of administration, and clinician famil- a temporizing strategy to support end-organ per-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "iarity favor such agents as the first therapeutic fusion and blood pressure until the cause of the"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "consideration when signs of organ hypoperfu- cardiac failure has either been treated (eg, revas-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "sion persist despite empiric volume replacement cularization in ST-elevation MI) or recovery (eg,"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "and vasopressors. There is a lack of robust evi- myocarditis) or a definitive solution to the cardiac"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "dence to suggest the clear benefit of one inotro- failure can be accomplished (eg, durable LVAD"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "pic agent over another in cardiogenic shock.30 In or transplant). In many cases, pharmacological or"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "general, the choice of a specific inotropic agent MCS can provide sufficient time to address the"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "is guided by blood pressure, concurrent arrhyth- appropriateness of more definitive therapies (eg,"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "mias, and availability of drug. bridge-to-decision) with the patient, family, and the"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "2. Despite the lack of direct comparative data, multidisciplinary shock team."
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "the use of short-term MCS has dramatically"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "increased.9–16,31,32 The hemodynamic benefits of"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "9.6. Integration of Care: Transitions and"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "the specific devices vary, and few head-to-head"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Team-Based Approaches"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "randomized comparisons exist.33–39 Randomized"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "clinical trials are underway that will address the"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Recommendations for Integration of Care: Transitions and Team-Based"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "risks and benefits of one modality over another. Approaches"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Vascular, bleeding, and neurologic complications Referenced studies that support the recommendations are"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "are common to MCS devices, and the risk of such summarized in the Online Data Supplements."
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "complications should generally be considered in COR LOE Recommendations"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "the calculation to proceed with such support.40 As 1. In patients with high-risk HF, particularly those"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "much as possible, an understanding of a patient’s with recurrent hospitalizations for HFrEF, refer-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "1 B-R ral to multidisciplinary HF disease management"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "wishes, overall prognosis and trajectory, and"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "programs is recommended to reduce the risk of"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "assessment of therapeutic risk should precede the hospitalization.1–4"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "use of invasive temporary MCS."
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "2. In patients hospitalized with worsening HF,"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "3. Team-based cardiogenic shock management pro- patient-centered discharge instructions with a"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "1 B-NR"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "vides the opportunity for various clinicians to pro- clear plan for transitional care should be pro-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "vided before hospital discharge.5,6"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "vide their perspective and input to the patient’s"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "3. In patients hospitalized with worsening HF, management.17–22 The escalation of either phar-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "participation in systems that allow benchmark-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "macological and mechanical therapies should 2a B-NR ing to performance measures is reasonable to"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "be considered in the context of multidisciplinary increase use of evidence-based therapy, and to"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "improve quality of care.7–10"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "teams of HF and critical care specialists, inter-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "ventional cardiologists, and cardiac surgeons. 4. In patients being discharged after hospital-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "ization for worsening HF, an early follow-up,"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Such teams should also be capable of provid-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "2a B-NR generally within 7 days of hospital discharge, is"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "ing appropriate palliative care. Most documented reasonable to optimize care and reduce rehos-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "experiences have suggested outcomes improve pitalization.11,12"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "after shock teams are instituted.17–22 In 1 such"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "experience, the use of a shock team was asso-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "ciated with improved 30-day all-cause mortality"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "(HR, 0.61; 95% CI, 0.41–0.93) and reduced in- For patients with HF, the transition from inpatient to"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "hospital mortality (61.0% vs. 47.9%; P=0.041).19 outpatient care can be an especially vulnerable period"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "4. If time allows, escalation to MCS should be guided because of the progressive nature of the disease state,"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "by invasively obtained hemodynamic data (eg, PA complex medical regimens, the large number of comor-"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "catheterization). Several observational experiences bid conditions, and the multiple clinicians who may be"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 73,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "e968 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Table 25. Important Components of a Transitional Care Plan management programs coordinated by HF special-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "ists, including HF nurses, may be best suited for"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "A transitional care plan, communicated with the patient and their outpatient"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "clinicians before hospital discharge, should clearly outline plans for: patients with HFrEF; however, there are far fewer"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "data on the effectiveness of disease management"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Addressing any precipitating causes of worsening HF identified in the hos-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "pital; programs in patients with HFpEF.2"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Adjusting diuretics based on volume status (including weight) and electro- 2. Although hospitalizations for worsening HF are"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "lytes; often characterized by rapid changes in medical,"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Coordination of safety laboratory checks (eg, electrolytes after initiation or surgical, and device therapy to optimize a patient’s"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "intensification of GDMT); clinical status, the patient’s journey with achieving"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Further changes to optimize GDMT, including: optimal HF care continues beyond hospital dis-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Plans for resuming medications held in the hospital; charge. Written discharge instructions or educa-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Plans for initiating new medications;"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "tional material given to the patient, family members,"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Plans for titration of GDMT to goal doses as tolerated;"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "or caregiver during the hospital stay or at discharge"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Reinforcing HF education and assessing compliance with medical ther-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "apy and lifestyle modifications, including dietary restrictions and physical to home should address all of these: activity level,"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "activity; diet, discharge medications, follow-up appoint-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Addressing high-risk characteristics that may be associated with poor post- ment, weight monitoring, cardiac rehabilitation, and"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "discharge clinical outcomes, such as: what to do if symptoms worsen.14 Thorough dis-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Comorbid conditions (eg, renal dysfunction, pulmonary disease, diabetes,"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "charge planning that includes special emphasis on"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "mental health, and substance use disorders);"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Limitations in psychosocial support; ensuring adherence to an evidence-based medica-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Impaired health literacy, cognitive impairment; tion regimen is associated with improved patient"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Additional surgical or device therapy, referral to cardiac rehabilitation in the outcomes.15,16 Details of the hospital course and"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "future, where appropriate; the transitional plan of care, with special attention"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Referral to palliative care specialists and/or enrollment in hospice in to changes in medications and new medical diag-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "selected patients."
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "noses, must be transmitted in a timely and clearly"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "GDMT indicates guideline-directed medical therapy; and HF, heart failure. understandable form to all of the patient’s clini-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "cians who will be delivering follow-up care (Table"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "involved. Patients are at highest risk for decompensation 25). Any changes in prognosis that will require"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "requiring readmission in the days and weeks post-hospi- appropriate care coordination and follow-up post-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "tal discharge.13 Optimal transitions of care can decrease discharge should be noted."
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "avoidable readmissions and improve patient satisfac- 3. Systems of care designed to support patients with"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "tion.14 Multidisciplinary systems of care that promote im- HF as they move through the continuum of care"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "proved communication between health care profession- can improve outcomes.7,14,17,18 Real-time feedback"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "als, systematic use and monitoring of GDMT, medication on performance measure benchmarks can improve"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "reconciliation, and consistent documentation are exam- use of evidence-based therapy and quality of"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "ples of patient safety standards that should be ensured care.8 Quality improvement programs designed to"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "for all patients with HF transitioning out of the hospital. increase the prescription of appropriate discharge"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "medications can increase GDMT prescription at"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "discharge and decrease readmissions and mortal-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "ity.9 Electronic point-of-care reminders to prescribe"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "1. HF disease management programs can help GDMT in patients with HFrEF can improve use.10,19"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "to organize the patient’s care across settings. Leveraging transparent health care analytics plat-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Potential team members may include cardiologists, forms for benchmarking and performance improve-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "primary care clinicians, HF nurses, pharmacists, ment may be helpful. There are ongoing studies to"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "dieticians, social workers, and community health determine the most effective strategies to improve"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "workers. A Cochrane systematic review of 47 RCTs evidence-based care.20"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "of disease management interventions after hospi- 4. Early outpatient follow-up, a central element of"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "tal discharge found that interventions that use case transitional care, varies significantly across US"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "management (case manager or nurse coordinates hospitals.11 Early postdischarge follow-up may help"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "care for high-risk patients) or multidisciplinary minimize gaps in understanding of changes to the"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "approach may decrease all-cause mortality and care plan or knowledge of test results and has been"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "rehospitalization.3 Disease management programs associated with a lower risk of subsequent rehos-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "may comprise education, self-management, medi- pitalization.11,12 Transition of care interventions"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "cation optimization, device management, weight have often bundled timely clinical follow-up with"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "monitoring, exercise and dietary advice, facilitated other interventions, making it challenging to iso-"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "access to care during episodes of decompensation, late any unique intervention effects.21 A structured"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "and social and psychological support.14 Disease contact with the patient within 7 days of hospital"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 74,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 74,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "A transitional care plan, communicated with the patient and their outpatient clinicians before hospital discharge, should clearly outline plans for:": "Addressing any precipitating causes of worsening HF identified in the hos- pital;"
            },
            {
                "A transitional care plan, communicated with the patient and their outpatient clinicians before hospital discharge, should clearly outline plans for:": "Adjusting diuretics based on volume status (including weight) and electro- lytes;"
            },
            {
                "A transitional care plan, communicated with the patient and their outpatient clinicians before hospital discharge, should clearly outline plans for:": "Coordination of safety laboratory checks (eg, electrolytes after initiation or intensification of GDMT);"
            },
            {
                "A transitional care plan, communicated with the patient and their outpatient clinicians before hospital discharge, should clearly outline plans for:": "Further changes to optimize GDMT, including: Plans for resuming medications held in the hospital; Plans for initiating new medications; Plans for titration of GDMT to goal doses as tolerated;"
            },
            {
                "A transitional care plan, communicated with the patient and their outpatient clinicians before hospital discharge, should clearly outline plans for:": "Reinforcing HF education and assessing compliance with medical ther- apy and lifestyle modifications, including dietary restrictions and physical activity;"
            },
            {
                "A transitional care plan, communicated with the patient and their outpatient clinicians before hospital discharge, should clearly outline plans for:": "Addressing high-risk characteristics that may be associated with poor post- discharge clinical outcomes, such as: Comorbid conditions (eg, renal dysfunction, pulmonary disease, diabetes, mental health, and substance use disorders); Limitations in psychosocial support; Impaired health literacy, cognitive impairment;"
            },
            {
                "A transitional care plan, communicated with the patient and their outpatient clinicians before hospital discharge, should clearly outline plans for:": "Additional surgical or device therapy, referral to cardiac rehabilitation in the future, where appropriate;"
            },
            {
                "A transitional care plan, communicated with the patient and their outpatient clinicians before hospital discharge, should clearly outline plans for:": "Referral to palliative care specialists and/or enrollment in hospice in selected patients."
            }
        ],
        "conteudo_texto": "Addressing any precipitating causes of worsening HF identified in the hos- pital; | Adjusting diuretics based on volume status (including weight) and electro- lytes; | Coordination of safety laboratory checks (eg, electrolytes after initiation or intensification of GDMT); | Further changes to optimize GDMT, including: Plans for resuming medications held in the hospital; Plans for initiating new medications; Plans for titration of GDMT to goal doses as tolerated; | Reinforcing HF education and assessing compliance with medical ther- apy and lifestyle modifications, including dietary restrictions and physical activity; | Addressing high-risk characteristics that may be associated with poor post- discharge clinical outcomes, such as: Comorbid conditions (eg, renal dysfunction, pulmonary disease, diabetes, mental health, and substance use disorders); Limitations in psychosocial support; Impaired health literacy, cognitive impairment; | Additional surgical or device therapy, referral to cardiac rehabilitation in the future, where appropriate; | Referral to palliative care specialists and/or enrollment in hospice in selected patients."
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e969"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Table 26. Most Common Co-Occurring Chronic Conditions Among Medicare Beneficiaries With HF (N=4 947 918), 2011"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Beneficiaries Age ≥65 y (n=4 376 150)* Beneficiaries Age <65 y (n=571 768)†"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "n % n %"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Hypertension 3 685 373 84.2 Hypertension 461 235 80.7"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Ischemic heart disease 3 145 718 71.9 Ischemic heart disease 365 889 64.0"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Hyperlipidemia 2 623 601 60.0 Diabetes 338 687 59.2"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Anemia 2 200 674 50.3 Hyperlipidemia 325 498 56.9"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Diabetes 2 027 875 46.3 Anemia 284 102 49.7"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Arthritis 1 901 447 43.5 CKD 257 015 45.0"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "CKD 1 851 812 42.3 Depression 207 082 36.2"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "COPD 1 311 118 30.0 Arthritis 201 964 35.3"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "AF 1 247 748 28.5 COPD 191 016 33.4"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Alzheimer’s disease or dementia 1 207 704 27.6 Asthma 88 816 15.5"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Data source: Centers for Medicare & Medicaid Services administrative claims data, January 2011 to December 2011, from the Chronic Condition Warehouse"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "(CCW), ccwdata.org.50"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "AF indicates atrial fibrillation; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; and HF, heart failure."
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "*Mean No. of conditions is 6.1; median is 6."
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "†Mean No. of conditions is 5.5; median is 5."
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "discharge is a desired goal. Although historically"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Recommendations for the Management of Comorbidities in Patients"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "this has been an in-person visit, telemedicine is With HF (Continued)"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "being increasingly used for chronic management."
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "A pragmatic randomized trial found that an initial"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Management of Sleep Disorders"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "telephone visit with a nurse or pharmacist to guide"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "4. In patients with HF and suspicion of sleep-dis-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "follow-up may reduce the need for in-person vis-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "ordered breathing, a formal sleep assessment"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "its if they are constrained.22 Overall, the timing and 2a C-LD is reasonable to confirm the diagnosis and"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "method of delivery (in-person clinic versus virtual differentiate between obstructive and central"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "sleep apnea.9,10"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "visit by video or telephone) should be individualized"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "based on patient risk and available care delivery 5. In patients with HF and obstructive sleep"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "apnea, continuous positive airway pressure"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "options. Clinical risk prediction tools may help to 2a B-R"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "may be reasonable to improve sleep quality and"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "identify patients at highest risk of postdischarge decrease daytime sleepiness.9,11–13"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "adverse outcomes.23–25 6. In patients with NYHA class II to IV HFrEF and"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "3: Harm B-R central sleep apnea, adaptive servo-ventilation"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "causes harm.11,12"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "10. COMORBIDITIES IN PATIENTS WITH HF Management of Diabetes"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "7. In patients with HF and type 2 diabetes, the"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "10.1. Management of Comorbidities in Patients use of SGLT2i is recommended for the man-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "1 A"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "With HF agement of hyperglycemia and to reduce HF-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "related morbidity and mortality.14–17"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Recommendations for the Management of Comorbidities in Patients"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "With HF"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Multimorbidity is common in patients with HF, with >85%"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations of patients having ≥2 additional chronic conditions.18,19 Hy-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Management of Anemia or Iron Deficiency pertension, ischemic heart disease, diabetes, anemia, CKD,"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "1. In patients with HFrEF and iron deficiency with morbid obesity, frailty, and malnutrition are among the most"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "2a B-R or without anemia, intravenous iron replace- common comorbid conditions in patients with HF (Table"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "ment is reasonable to improve functional status"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "26). These chronic conditions complicate the manage-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "and QOL.1–4"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "ment of HF and have a significant impact on its prognosis."
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "2. In patients with HF and anemia, erythropoietin-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "3: Harm B-R stimulating agents should not be used to How to generate specific recommendations addressing"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "improve morbidity and mortality.5,6 many of these conditions in the setting of HF is challeng-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Management of Hypertension ing given the current state of the evidence. For example,"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "although depression is common in patients with HF and"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "3. In patients with HFrEF and hypertension,"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "1 C-LD uptitration of GDMT to the maximally tolerated strongly impacts QOL and mortality, conventional thera-"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "target dose is recommended.7,8 pies such as antidepressants have not been effective in"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 75,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "e970 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "Figure 14. Recommendations for Treatment of Patients With HF and Selected Comorbidities."
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "Colors correspond to COR in Table 2. Recommendations for treatment of patients with HF and select comorbidities are displayed. ACEi indicates"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; AV, atrioventricular; CHADS-VASc, congestive"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "2 2"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack [TIA], vascular disease, age 65 to 74 years, sex"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "category; CPAP, continuous positive airway pressure; CRT, cardiac resynchronization therapy; EF, ejection fraction; GDMT, guideline-directed"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; IV, intravenous; LVEF, left ventricular ejection fraction; NYHA,"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "New York Heart Association; SGLT2i, sodium-glucose cotransporter-2 inhibitor; and VHD, valvular heart disease. *Patients with chronic HF"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "with permanent-persistent-paroxysmal AF and a CHADS-VASc score of ≥2 (for men) and ≥3 (for women)."
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "2 2"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "improving outcomes.20–22 CKD and HF are closely inter- Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "twined in pathophysiology and have a complex and bidirec-"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "Anemia"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "tional relationship.23 Renal dysfunction increases the risk of"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "toxicities of HF therapies and impairs response to diuret- 1. Routine baseline assessment of all patients with"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "ics.23 The effectiveness of GDMT in patients with HF and HF includes an evaluation for anemia. Anemia is"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "concomitant kidney disease is uncertain, because data for independently associated with HF disease sever-"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "treatment outcomes in this patient population are sparse.24 ity and mortality,25 and iron deficiency appears"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "Recommendations surrounding the management of ane- to be uniquely associated with reduced exercise"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "mia, hypertension, diabetes, and sleep disorders that are capacity.26 Iron deficiency is usually defined as"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "attributable to the presence of evolving evidence for spe- ferritin level <100 μg /L or 100 to 300 μg/L, if"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "cific treatment strategies in HF are discussed next. Other the transferrin saturation is <20%. Intravenous"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "comorbidities not addressed in the recommendations are, repletion of iron has been shown to improve exer-"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "of course, also important and warrant attention but, be- cise capacity and QOL.1–3,27 The FAIR-HF (Ferric"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "cause of lack of large-scale trial data, are not addressed as Carboxymaltose Assessment in Patients With Iron"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "specific recommendations. Figure 14 summarizes COR 1 Deficiency and Chronic Heart Failure) trial showed"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "and 2a for management of select HF comorbidities. significant improvement in NYHA classification,"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 76,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e971"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "the 6-minute walk test, and QOL of 459 outpa- Nevertheless, hypertension in patients with HFrEF"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "tients with chronic HF who received weekly intra- represents an opportunity to maximize GDMT to"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "venous ferric carboxymaltose until iron repletion.1 goal blood pressures defined by the ACC/AHA"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "The improvement was independent of the pres- hypertension guidelines.36"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "ence of anemia. These findings were confirmed"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "in 2 more recent trials.2,3 The IRONOUT HF (Iron"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "Sleep Disorders"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "Repletion Effects on Oxygen Uptake in Heart"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "Failure) trial, however, showed no such improve- 4. In patients with HF, daytime sleepiness—typically"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "ment with oral iron supplementation.28 This is a feature of obstructive sleep apnea—may not"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "attributed to the poor absorption of oral iron and reflect the degree of underlying sleep-disordered"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "inadequacy of oral iron to replete the iron stores breathing.37 Hence, the decision to refer a patient"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "in patients with HF. Therefore, oral iron is not ade- for a sleep study should be based on clinical judg-"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "quate to treat iron deficiency anemia in patients ment. Because the treatment of obstructive sleep"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "with HF. Although these trials were underpowered apnea and central sleep apnea differ, and because"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "to detect reductions in hard clinical endpoints, 2 obstructive sleep apnea and central sleep apnea"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "meta-analyses have suggested intravenous iron can co-occur,9,11,12 sleep studies can inform clinical"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "is associated with a reduction in cardiovascular decision-making in patients with HF."
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "death and hospitalizations.27,29 Most recently, the 5. In patients with HF and central sleep apnea, con-"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "AFFIRM-AHF multicenter trial, which included tinuous positive airway pressure is associated"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "1132 patients with EF <50% hospitalized for with better sleep quality and nocturnal oxygen-"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "HF, showed a decrease in hospitalization for HF ation9 but has not been shown to affect sur-"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "with intravenous ferric carboxymaltose compared vival.38 In adults with HFrEF and sleep-disordered"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "to placebo (RR, 0.74; 95% CI, 0.58–0.94) but no breathing, meta-analyses of RCTs have shown"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "reduction in cardiovascular death.4 that positive airway pressure therapy results in a"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "2. Anemia in patients with HF is associated with moderate reduction in BNP39 and improvement in"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "impaired erythropoietin production, with low lev- blood pressure and LVEF.40"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "els found to be associated with worse long-term 6. Adaptive servo-ventilation was associated with"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "outcomes.30,31 Although small studies examining increased mortality in 2 RCTs involving patients"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "the use of erythropoietin-stimulating agents for with HFrEF and central sleep apnea.11,12 Meta-"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "the treatment of anemia in patients with HF have analyses have supported these results.41,42 The"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "suggested a trend toward improvement in func- weight of evidence does not support the use"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "tional capacity and reduction in hospitalization, of adaptive servo-ventilation for central sleep"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "a high-quality randomized trial of darbepoetin apnea in HFrEF."
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "alpha in 2278 patients showed no benefit and an"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "increase in thrombotic events, including stroke.5,6,32"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "Diabetes"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "A meta-analysis of 13 trials supports these find-"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "ings.6 Accordingly, erythropoietin-stimulating agent 7. The American Diabetes Association guidelines"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "therapy is not recommended for the treatment of recommend the use of SGLT2i as first-line agent"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "anemia in patients with HF. for the treatment of hyperglycemia in patients with"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "diabetes with HF or at high risk of HF.43 SGLT2i"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "are the first class of glucose-lowering agents to"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "Hypertension"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "receive approval from the FDA for the treatment of"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "3. Clinical trials assessing the impact of goal blood HFrEF. Treatment of patients with type 2 diabetes"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "pressure reduction on outcomes in patients with with SGLT2i, including canagliflozin, dapagliflozin,"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "HFrEF and concomitant hypertension are lacking. empagliflozin, and sotagliflozin, is associated with"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "The optimal blood pressure goal and antihyper- a reduction in major adverse cardiovascular events,"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "tensive regimen are not known. Antihypertensive including hospitalization for HF and cardiovascular"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "therapy is associated with a decrease in the risk death.44 The mechanisms underlying the improve-"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "of incident HF in the general population,33,34 nota- ment in cardiovascular outcomes attributed to"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "bly with the more stringent SBP target <120 mm SGLT2i are, however, unknown but appear to be"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "Hg.35 However, low blood pressure, not as a part of only partially related to the glucosuric effect.45 Two"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "an antihypertensive treatment, has been associated RCTs totaling 8474 patients with NYHA class II,"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "with poor outcomes in patients with HFrEF.7,8 This III, or IV HF and EF ≤40%—DAPA-HF assessing"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "observation may reflect the association between dapagliflozin and EMPEROR-Reduced assessing"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "low cardiac output and low blood pressure, rather empagliflozin—showed significant reductions in the"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "than the effects of treatment for hypertension. relative risk of all-cause death (13%), cardiovascular"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 77,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "e972 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "death (14%), hospitalization for HF (26%), and atrioventricular nodal ablation with placement of a CRT"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "renal outcomes (38%) with SGLT2i treatment.14–17 device can be considered. Patients with HF, and difficult"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "Benefits were consistent across age, sex, and in to control rates, may benefit from atrioventricular node"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "patients with or without diabetes. Whether dapa- ablation and implantation of a permanent pacemaker if"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "gliflozin or empagliflozin improves outcomes spe- other rate and rhythm control measures fail. If their LVEF"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "cifically in patients with HFpEF is being studied.46,47 is >50%, there is no current evidence that CRT is ben-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "The SOLOIST-WHF trial extends the benefits eficial compared with RV pacing.15,21"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "of SGLT2i to patients with diabetes and acutely"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "decompensated HF.48 Patients on SGLT2i should"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "be closely monitored for potential risks, including"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "severe genitourinary infections and, less commonly, 1. The efficacy of long-term warfarin for the preven-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "diabetic ketoacidosis.49 tion of stroke in patients with AF is well established;"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "randomized trials have shown reduced embolic"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "rates and mortality. The AHA/ACC/Heart Rhythm"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "10.2. Management of AF in HF"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "Society guidelines for AF recommend use of the"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "CHA DS -VASc score (history of hypertension,"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "Recommendations for Management of AF in HF 2 2"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa- age ≥75 [doubled weight], diabetes mellitus, previ-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements. ous stroke or transient ischemic attack or thrombo-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations embolism [doubled weight], vascular disease, age"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "1. Patients with chronic HF with permanent-per- 65 to 74 years, sex category) to assess patient risk"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "sistent-paroxysmal AF and a CHADS-VASc for adverse outcomes before initiating anticoagu-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "1 A 2 2"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "score of ≥2 (for men) and ≥3 (for women)"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "lation therapy.1,27,28 Regardless of whether patients"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "should receive chronic anticoagulant therapy.1–5"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "receive rhythm or rate control, anticoagulation is"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "2. For patients with chronic HF with permanent-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "recommended for patients with HF and AF for"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "1 A persistent-paroxysmal AF, DOAC is recom-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "mended over warfarin in eligible patients.2–10 stroke prevention with a CHA DS -VASc score of"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "2 2"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "3. For patients with HF and symptoms caused by ≥2 (for men) and ≥3 (for women).2–5"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "2a B-R AF, AF ablation is reasonable to improve symp- 2. Trials of DOAC have compared the efficacy and"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "toms and QOL.11–14"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "safety with warfarin therapy rather than placebo."
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "4. For patients with AF and LVEF ≤50%, if a Several DOAC are available, including the factor"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "rhythm control strategy fails or is not desired,"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "Xa inhibitors apixaban, rivaroxaban, edoxaban, and"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "2a B-R and ventricular rates remain rapid despite medi-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "cal therapy, atrioventricular nodal ablation with the direct thrombin inhibitor dabigatran.2–5 These"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "implantation of a CRT device is reasonable.15–22 drugs do not need routine anticoagulation monitor-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "5. For patients with chronic HF and permanent- ing or dose adjustment. The fixed dosing together"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "2a B-NR persistent-paroxysmal AF, chronic anticoagulant with fewer interactions may simplify patient man-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "therapy is reasonable for men and women with-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "agement, particularly with the polypharmacy com-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "out additional risk factors.23–26"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "monly seen in HF, but cost for some patients can"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "be prohibitive when not covered by insurance."
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "These drugs have a potential for an improved ben-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "The interplay between AF and HF is complex. It is clear efit–risk profile compared with warfarin, which may"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "that AF may worsen HF but also that HF increases the increase their use in practice, especially in those"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "risk of AF. Data from randomized trials support the use at increased bleeding risk.6–9 In a meta-analysis of"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "of anticoagulation among those with HF and AF but not 4 trials examining efficacy and safety of DOAC in"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "in patients with HF without AF. Anticoagulation may be patients with and without HF, DOAC more effec-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "accomplished with DOAC or with warfarin when favored tively reduced the rate of stroke or systemic embo-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "because of other indications, cost or drug-drug interac- lism, major bleeding, and intracranial bleeding"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "tions (the DOAC are generally preferred). The choice compared with warfarin, with no treatment hetero-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "between rate or rhythm control strategy reflects both geneity by HF status.10"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "patient symptoms and the likelihood of better ventricular 3. The 2 largest RCTs of AF ablation in HF showed"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "function with sinus rhythm. RCTs of rhythm control with a benefit in hospitalizations and mortality with"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "antiarrhythmic agents versus rate control have not shown ablation.11,12although other smaller trials did"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "a benefit of rhythm control. More recent RCTs with abla- not. In the AATAC (Ablation Versus Amiodarone"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "tion show that ablation may be preferable to antiarrhyth- for Treatment of Persistent Atrial Fibrillation in"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "mic drugs for a rhythm control strategy. Patients thought Patients with Congestive Heart Failure and an"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "to have a cardiomyopathy resulting from rapid AF despite Implanted Device) trial, 203 patients with persis-"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "attempts at rate control should be aggressively treated tent AF, LVEF <40%, and NYHA class II to III HF,"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "to maintain sinus rhythm and, if that is not successful, ablation improved the likelihood of maintaining"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 78,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e973"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "normal sinus rhythm at 24 months compared 11. SPECIAL POPULATIONS"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "with amiodarone and, in addition, had a 45%"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "11.1. Disparities and Vulnerable Populations*"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "decrease in hospitalization and decrease in mor-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "tality (8% vs. 18%).11 The CASTLE AF (Catheter"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "Recommendations for Disparities and Vulnerable Populations"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "Ablation for Atrial Fibrillation with Heart Failure) Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "trial randomized 363 patients with paroxysmal or rized in the Online Data Supplements."
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "persistent AF, LVEF <35%, NYHA class II to IV COR LOE Recommendations"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "HF, and ICD to ablation versus standard medi-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "1. In vulnerable patient populations at risk for"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "cal care.12 The composite endpoint of death or health disparities, HF risk assessments and"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "rehospitalization was lower in ablation (28.5%) 1 C-LD multidisciplinary management strategies should"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "target both known risks for CVD and social"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "compared with standard care (44.6%). In addi-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "determinants of health, as a means toward"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "tion, there was a lower mortality in the ablation elimination of disparate HF outcomes.1–6"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "group. In a meta-analysis of 11 RCTs comparing 2. Evidence of health disparities should be moni-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "rhythm versus rate control, patients undergoing 1 C-LD tored and addressed at the clinical practice"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "and the health care system levels.7–13"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "catheter ablation had improved survival (49%"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "relative risk reduction) and reduced hospitaliza- *This section crosslinks to Section 7.1.1, “Stage C Nonpharmacological In-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "terventions and Self-Care Support in HF,” where screening and interventions for"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "tions (56% relative risk reduction).13"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "social determinants of health are now addressed."
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "4. If a rhythm control strategy fails or is undesired,"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "and ventricular rates remain rapid despite medi-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "cal therapy after all other options are exhausted,"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "atrioventricular nodal ablation with implantation of There are important differences in HF incidence, risk"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "a CRT device can be considered as a treatment factors, clinical care needs, and outcomes between spe-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "option. Ablate and pace is an old strategy for diffi- cific patient populations2,3,14,15 (Table 27). It is essential"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "cult to rate control AF. Early studies with RV pacing that HF clinicians be aware of the biological factors,"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "showed benefit.15,16 However, when RV pacing was social determinants of health, and implicit biases that"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "compared with cardiac resynchronization in more impact the burden of disease, clinical decision-making,"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "recent trials, especially in those with reduced LVEFs, and effective delivery of GDMT.9,16–18 Women generally"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "CRT generally produced more benefit than RV pac- present with HF later in life, with more comorbidities and"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "ing.17–21 The PAVE (Left Ventricular-Based Cardiac lower patient-reported health status than men.10,19 Sur-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "Stimulation post AV Nodal Ablation Evaluation) vival for women with HF is generally more favorable,20"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "and the BLOCK-HF (Biventricular versus Right although access to specialty care may be lower.21–24"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "Ventricular Pacing in Patients with AV block) trials The highest incident of HF is consistently observed in"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "included patients with LVEF >35%, with mean EF self-identified Black patients.25,26 HF hospitalization and"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "46%22 in PAVE and 40% in BLOCK-HF (enrolled mortality rates for Black patients are also higher than"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "≤50%). In both of these trials, patients undergoing for White patients, with the gap increasing over time for"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "CRT had improved outcomes. young men.2,4,27 These differences are driven mostly by"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "5. HF is a hypercoagulable state and serves as social circumstances; a biological premise or genetic ex-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "an independent risk factor for stroke, systemic planation for disease or disease severity should not be"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "embolism, and mortality in the setting of AF.23,24 inferred by race or ethnicity.28 Older patients with HF"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "There are compelling data to support the use of are especially vulnerable to polypharmacy, multimorbid-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "anticoagulation in most patients with HF and con- ity, cognitive decline, and frailty.29,30 Important strate-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "comitant AF, barring contraindications. In patients gies to remove biases within health care professionals"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "with HF and a CHA DS -VASc score of 1, those and systems impacting minority and socioeconomically"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "2 2"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "with AF had a 3-fold higher risk compared with disadvantaged patient populations include implicit bias"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "individuals without concomitant AF.25 In a post training, recruiting a diverse workforce, and promoting"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "hoc analysis of 2 contemporary HF trials, parox- broad access to HF care.28,31–35"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "ysmal and new onset AF were associated with"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "a greater risk for hospitalization caused by HF"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "or stroke.26 In a recent registry study, the risk of"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "stroke was particularly higher in the initial period 1. Hypertension is significantly more prevalent in"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "after diagnosis of HF among patients with preva- Black patients, compared with White patients, pop-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "lent AF.29 Because HF is a risk factor, additional ulations in the United States, with a younger age"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "risk factors may not be required to support the of onset and greater attributable cardiovascular"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "use of anticoagulation in patients with HF, and risks.36,37 An estimated 50 000 to 350 000 immi-"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "the decision to anticoagulate can be individual- grants to the United States from Mexico and Central"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "ized according to risk versus benefit. America may have asymptomatic Trypanosoma"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 79,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "e974 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Table 27. Risk of HF and Outcomes in Special Populations"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Vulnerable Population Risk of HF HF Outcomes"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Women The lifetime risk of HF is equivalent between sexes, but HFpEF risk Overall, more favorable survival with HF than men. In the OPTI-"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "is higher in women—in FHS participants with new-onset HF, odds MIZE-HF registry, women with acute HF had a lower 1-y mortality"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "of HFpEF (EF >45%) are 2.8-fold higher in women than in men.66 (HR, 0.93; 95% CI, 0.89–0.97), although women are more likely"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Sex-specific differences in the predictive value of cardiac bio- not to receive optimal GDMT.20,69–71"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "markers for incident HF.67 Lower patient-reported quality of life for women with HFrEF, com-"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Nontraditional cardiovascular risk factors, including anxiety, de- pared with men.10,71"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "pression, caregiver stress, and low household income may contrib- Greater transplant waitlist mortality for women but equivalent sur-"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "ute more toward incident heart disease in women than men.68 vival after heart transplantation or LVAD implantation.24,52"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Older adults Per FHS, at 40 y of age, the lifetime risk of incident HF is 20% Among 1233 patients with HF aged ≥80 y, 40% mortality during"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "for both sexes; at 80 y of age, the risk remains 20% for men mean 27-mo follow-up; survival associated with prescription of"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "and women despite the shorter life expectancy.72 GDMT.74"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "LVEF is preserved in at least two-thirds of older adults with the"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "diagnosis of HF.73"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Lower socioeconomic Among 27 078 White and Black adults of low income (70% Age-adjusted 1999–2018 HF mortality (deaths/100 000; mean"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "status populations earned <$15 000/y) participating from 2002–2009 in the and 95% CI) was higher with increasing quartiles of ADI, which is"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Southern Community Cohort Study, a 1 interquartile increase in based on 17 indicators of employment, poverty, and education:"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "neighborhood deprivation index was associated with a 12% in- Quartile 1, 20.0 (19.4–20.5);"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "crease in risk of HF (adjusted HR, 1.12; 95% CI, 1.07–1.18).46"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Quartile 2, 23.3 (22.6–24.0);"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Quartile 3, 26.4 (25.5–27.3);"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Quartile 4, 33.1 (31.8–34.4).6"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Black populations In MESA, patients of Black race had highest risk of incident HF CDC data show race-based differences in HF mortality over time:"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "(4.6/1000 person-years) and highest proportion of nonisch- Black men had a 1.16-fold versus 1.43-fold higher age-adjusted"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "emic incident HF.26 HF-related CVD death rate compared with White men in 1999 ver-"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Higher prevalence of HF risk factors including hypertension, sus 2017; Black women had a 1.35-fold versus 1.54-fold higher"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "obesity, and diabetes, compared with White populations.75 age-adjusted HF-related CVD death rate compared with White"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "women in 1999 versus 2017.27"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Gap in outcomes is more pronounced among younger adults (35–"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "64 y of age) versus older adults (65–84 y of age); age-adjusted"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "HF-related CVD death rates were 2.60-fold and 2.97-fold higher in"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "young Black versus White men and women, respectively.27"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Higher rates of hospitalization3 and mortality among patients with"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "HFpEF.76"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Lower 5-year survival after heart transplant.77–79"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Hispanic populations MESA study showed higher HF incidence in Hispanic com- Despite higher rates of hospitalization for HF compared with non-"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "pared with non-Hispanic White groups (3.5 versus 2.4 per Hispanic Whites, Hispanic patients with HF have shown lower"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "1000 person-years) but lower than for African Americans short-term mortality rates.81"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "(4.6/1000 person-years).7,26,80 In GWTG, Hispanic patients with HFpEF had lower mortality (OR,"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "0.50; 95% CI, 0.31–0.81) than non-Hispanic Whites, but this was"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "not the case for Hispanic patients with HFrEF (OR, 0.94; 95% CI,"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "0.62–1.43).82"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Lower risk of developing AF in the setting of HF, compared with"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "White patients.83"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Asian and Pacific Islander Limited population-specific data for Asian and Pacific Islander High rates of preventable HF hospitalization observed in some"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "populations subgroups in the United States.84,85 Asian and Pacific Islander populations.13"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Lower mortality rates from HF for Asian subgroups when listed as the"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "primary cause of death, compared with non-Hispanic White groups.86"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Native American and Limited population-specific data, with cardiovascular risk fac- Limited data suggest HF mortality rates in American Indians and"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Alaskan Native tor trends best characterized by the Strong Heart Study and Alaska Natives are similar to those in White populations.88"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "populations Strong Heart Family Study, demonstrating high rates of hyper-"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "tension and diabetes.11,87"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "CDC indicates Centers for Disease Control and Prevention; CVD, cardiovascular disease; FHS, Framingham Heart Study; GDMT, guideline-directed medical"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "therapy; GWTG, Get With The Guidelines registry; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "fraction; HR, hazard ratio; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; MESA, Multi-Ethnic Study of Atherosclerosis; OPTMIZE-HF,"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure; and OR, odds ratio."
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "cruzi, with 20% progressing to Chagas cardiomy- delivery of GDMT and are associated with poorer"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "opathy.38 Diabetes is highly prevalent in Southeast outcomes.5,41 Among older adults, low income,"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Asian and Pacific Islander populations and more social isolation, and lack of caregiver support"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "strongly associated with poor HF outcomes.39,40 increase HF mortality and low QOL.9,18,42 Nursing"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Among patients with established HF, social and home residents, and elderly inpatients with acute"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "medical vulnerabilities can impede successful HF, are at risk of inadequate GDMT prescription,"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 80,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 80,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Vulnerable Population": "Women",
                "Risk of HF": "The lifetime risk of HF is equivalent between sexes, but HFpEF risk is higher in women—in FHS participants with new-onset HF, odds of HFpEF (EF >45%) are 2.8-fold higher in women than in men.66 Sex-specific differences in the predictive value of cardiac bio- markers for incident HF.67 Nontraditional cardiovascular risk factors, including anxiety, de- pression, caregiver stress, and low household income may contrib- ute more toward incident heart disease in women than men.68",
                "HF Outcomes": "Overall, more favorable survival with HF than men. In the OPTI- MIZE-HF registry, women with acute HF had a lower 1-y mortality (HR, 0.93; 95% CI, 0.89–0.97), although women are more likely not to receive optimal GDMT.20,69–71 Lower patient-reported quality of life for women with HFrEF, com- pared with men.10,71 Greater transplant waitlist mortality for women but equivalent sur- vival after heart transplantation or LVAD implantation.24,52"
            },
            {
                "Vulnerable Population": "Older adults",
                "Risk of HF": "Per FHS, at 40 y of age, the lifetime risk of incident HF is 20% for both sexes; at 80 y of age, the risk remains 20% for men and women despite the shorter life expectancy.72 LVEF is preserved in at least two-thirds of older adults with the diagnosis of HF.73",
                "HF Outcomes": "Among 1233 patients with HF aged ≥80 y, 40% mortality during mean 27-mo follow-up; survival associated with prescription of GDMT.74"
            },
            {
                "Vulnerable Population": "Lower socioeconomic status populations",
                "Risk of HF": "Among 27 078 White and Black adults of low income (70% earned <$15 000/y) participating from 2002–2009 in the Southern Community Cohort Study, a 1 interquartile increase in neighborhood deprivation index was associated with a 12% in- crease in risk of HF (adjusted HR, 1.12; 95% CI, 1.07–1.18).46",
                "HF Outcomes": "Age-adjusted 1999–2018 HF mortality (deaths/100 000; mean and 95% CI) was higher with increasing quartiles of ADI, which is based on 17 indicators of employment, poverty, and education: Quartile 1, 20.0 (19.4–20.5); Quartile 2, 23.3 (22.6–24.0); Quartile 3, 26.4 (25.5–27.3); Quartile 4, 33.1 (31.8–34.4).6"
            },
            {
                "Vulnerable Population": "Black populations",
                "Risk of HF": "In MESA, patients of Black race had highest risk of incident HF (4.6/1000 person-years) and highest proportion of nonisch- emic incident HF.26 Higher prevalence of HF risk factors including hypertension, obesity, and diabetes, compared with White populations.75",
                "HF Outcomes": "CDC data show race-based differences in HF mortality over time: Black men had a 1.16-fold versus 1.43-fold higher age-adjusted HF-related CVD death rate compared with White men in 1999 ver- sus 2017; Black women had a 1.35-fold versus 1.54-fold higher age-adjusted HF-related CVD death rate compared with White women in 1999 versus 2017.27 Gap in outcomes is more pronounced among younger adults (35– 64 y of age) versus older adults (65–84 y of age); age-adjusted HF-related CVD death rates were 2.60-fold and 2.97-fold higher in young Black versus White men and women, respectively.27 Higher rates of hospitalization3 and mortality among patients with HFpEF.76 Lower 5-year survival after heart transplant.77–79"
            },
            {
                "Vulnerable Population": "Hispanic populations",
                "Risk of HF": "MESA study showed higher HF incidence in Hispanic com- pared with non-Hispanic White groups (3.5 versus 2.4 per 1000 person-years) but lower than for African Americans (4.6/1000 person-years).7,26,80",
                "HF Outcomes": "Despite higher rates of hospitalization for HF compared with non- Hispanic Whites, Hispanic patients with HF have shown lower short-term mortality rates.81 In GWTG, Hispanic patients with HFpEF had lower mortality (OR, 0.50; 95% CI, 0.31–0.81) than non-Hispanic Whites, but this was not the case for Hispanic patients with HFrEF (OR, 0.94; 95% CI, 0.62–1.43).82 Lower risk of developing AF in the setting of HF, compared with White patients.83"
            },
            {
                "Vulnerable Population": "Asian and Pacific Islander populations",
                "Risk of HF": "Limited population-specific data for Asian and Pacific Islander subgroups in the United States.84,85",
                "HF Outcomes": "High rates of preventable HF hospitalization observed in some Asian and Pacific Islander populations.13 Lower mortality rates from HF for Asian subgroups when listed as the primary cause of death, compared with non-Hispanic White groups.86"
            },
            {
                "Vulnerable Population": "Native American and Alaskan Native populations",
                "Risk of HF": "Limited population-specific data, with cardiovascular risk fac- tor trends best characterized by the Strong Heart Study and Strong Heart Family Study, demonstrating high rates of hyper- tension and diabetes.11,87",
                "HF Outcomes": "Limited data suggest HF mortality rates in American Indians and Alaska Natives are similar to those in White populations.88"
            }
        ],
        "conteudo_texto": "Women, The lifetime risk of HF is equivalent between sexes, but HFpEF risk is higher in women—in FHS participants with new-onset HF, odds of HFpEF (EF >45%) are 2.8-fold higher in women than in men.66 Sex-specific differences in the predictive value of cardiac bio- markers for incident HF.67 Nontraditional cardiovascular risk factors, including anxiety, de- pression, caregiver stress, and low household income may contrib- ute more toward incident heart disease in women than men.68, Overall, more favorable survival with HF than men. In the OPTI- MIZE-HF registry, women with acute HF had a lower 1-y mortality (HR, 0.93; 95% CI, 0.89–0.97), although women are more likely not to receive optimal GDMT.20,69–71 Lower patient-reported quality of life for women with HFrEF, com- pared with men.10,71 Greater transplant waitlist mortality for women but equivalent sur- vival after heart transplantation or LVAD implantation.24,52 | Older adults, Per FHS, at 40 y of age, the lifetime risk of incident HF is 20% for both sexes; at 80 y of age, the risk remains 20% for men and women despite the shorter life expectancy.72 LVEF is preserved in at least two-thirds of older adults with the diagnosis of HF.73, Among 1233 patients with HF aged ≥80 y, 40% mortality during mean 27-mo follow-up; survival associated with prescription of GDMT.74 | Lower socioeconomic status populations, Among 27 078 White and Black adults of low income (70% earned <$15 000/y) participating from 2002–2009 in the Southern Community Cohort Study, a 1 interquartile increase in neighborhood deprivation index was associated with a 12% in- crease in risk of HF (adjusted HR, 1.12; 95% CI, 1.07–1.18).46, Age-adjusted 1999–2018 HF mortality (deaths/100 000; mean and 95% CI) was higher with increasing quartiles of ADI, which is based on 17 indicators of employment, poverty, and education: Quartile 1, 20.0 (19.4–20.5); Quartile 2, 23.3 (22.6–24.0); Quartile 3, 26.4 (25.5–27.3); Quartile 4, 33.1 (31.8–34.4).6 | Black populations, In MESA, patients of Black race had highest risk of incident HF (4.6/1000 person-years) and highest proportion of nonisch- emic incident HF.26 Higher prevalence of HF risk factors including hypertension, obesity, and diabetes, compared with White populations.75, CDC data show race-based differences in HF mortality over time: Black men had a 1.16-fold versus 1.43-fold higher age-adjusted HF-related CVD death rate compared with White men in 1999 ver- sus 2017; Black women had a 1.35-fold versus 1.54-fold higher age-adjusted HF-related CVD death rate compared with White women in 1999 versus 2017.27 Gap in outcomes is more pronounced among younger adults (35– 64 y of age) versus older adults (65–84 y of age); age-adjusted HF-related CVD death rates were 2.60-fold and 2.97-fold higher in young Black versus White men and women, respectively.27 Higher rates of hospitalization3 and mortality among patients with HFpEF.76 Lower 5-year survival after heart transplant.77–79 | Hispanic populations, MESA study showed higher HF incidence in Hispanic com- pared with non-Hispanic White groups (3.5 versus 2.4 per 1000 person-years) but lower than for African Americans (4.6/1000 person-years).7,26,80, Despite higher rates of hospitalization for HF compared with non- Hispanic Whites, Hispanic patients with HF have shown lower short-term mortality rates.81 In GWTG, Hispanic patients with HFpEF had lower mortality (OR, 0.50; 95% CI, 0.31–0.81) than non-Hispanic Whites, but this was not the case for Hispanic patients with HFrEF (OR, 0.94; 95% CI, 0.62–1.43).82 Lower risk of developing AF in the setting of HF, compared with White patients.83 | Asian and Pacific Islander populations, Limited population-specific data for Asian and Pacific Islander subgroups in the United States.84,85, High rates of preventable HF hospitalization observed in some Asian and Pacific Islander populations.13 Lower mortality rates from HF for Asian subgroups when listed as the primary cause of death, compared with non-Hispanic White groups.86 | Native American and Alaskan Native populations, Limited population-specific data, with cardiovascular risk fac- tor trends best characterized by the Strong Heart Study and Strong Heart Family Study, demonstrating high rates of hyper- tension and diabetes.11,87, Limited data suggest HF mortality rates in American Indians and Alaska Natives are similar to those in White populations.88"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e975"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "although interventions in nursing facilities can"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Recommendations for Cardio-Oncology (Continued)"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "improve care delivery for HF.30,43–45 Lower socio-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "economic status is associated with HF incidence"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "3. In patients with cardiovascular risk factors or"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "and HF mortality.6,46,47 Homelessness,48 substance"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "known cardiac disease being considered for"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "use, food insecurity, and lack of transportation potentially cardiotoxic anticancer therapies,"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "2a B-NR"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "each represent potential barriers to optimal dis- pretherapy evaluation of cardiac function is rea-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "sonable to establish baseline cardiac function"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "ease management.49 Case management and social"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "and guide the choice of cancer therapy.2,5–16"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "work services are essential to the comprehensive"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "4. In patients with cardiovascular risk factors or"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "multidisciplinary HF team approach for coordinat-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "known cardiac disease receiving potentially"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "ing complex medical, psychiatric, and social needs 2a B-NR cardiotoxic anticancer therapies, monitoring of"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "across multiple sectors. cardiac function is reasonable for the early iden-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "tification of drug-induced cardiomyopathy.2,4,6,8"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "2. Health care system factors are a potential source"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "of disparate HF care delivery and outcomes. 5. In patients at risk of cancer therapy–related"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "cardiomyopathy, initiation of beta blockers"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Women are less likely to receive discharge"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "2b B-R and ACEi/ARB for the primary prevention of"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "instructions for HF,50 less likely to be referred to drug-induced cardiomyopathy is of uncertain"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "specialty care,21,22 and less likely to receive a heart benefit.17–28"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "transplantation,51–54 compared with men. Patients 6. In patients being considered for potentially car-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "diotoxic therapies, serial measurement of car-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "with HF of Black race have been identified as less 2b C-LD"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "diac troponin might be reasonable for further"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "likely to receive care from a cardiologist during risk stratification.29–32"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "an ICU admission for HF,55 have less access to"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "specialized inpatient HF care,12 and may be vul-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "nerable to clinician biases during evaluation for Synopsis"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "advanced HF therapies.11,53 Hispanic patients"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Advances in cancer therapy and an aging population"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "are disproportionately noninsured in the United"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "have led to a growing number of cancer patients with"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "States,56 may experience language barriers to"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "comorbid CVD receiving treatment for cancer.33,34 Car-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "quality care,7,57 and also have less access to spe-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "diovascular complications of cancer therapy, notably"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "cialized inpatient HF care.12 Native American and"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "cardiomyopathy and HF, can result in significant mor-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Alaskan Native populations experience particu-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "bidity and interruption of treatment, impacting both"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "lar challenges in specialty care access because"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "short- and long-term survival.35,36 Because drug devel-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Indian Health Service facilities are often small and"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "opment in cancer therapeutics grows at an exponential"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "rural.11 Engaging patients in medical care within"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "pace, establishing a unified framework for the man-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "culturally tailored environments has proven suc-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "agement of cancer therapy–related cardiomyopathy—"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "cessful.58,59 HF written educational materials for"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "commonly defined as a decrease in LVEF of at least"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "patients and caregivers should be delivered at or"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "10% to <50%—is necessary to mitigate the cardio-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "below the sixth grade reading level.60 Workplace"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "vascular risks of established novel therapies. Cardio-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "interventions that improve cultural competency"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "oncology is the practice of precancer therapy cardio-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "and address implicit biases are increasingly avail-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "vascular risk stratification, prevention, early detection,"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "able. Many aspects of GDMT have been inade-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "and treatment of cardiovascular complications.36,37"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "quately studied by population subgroups, largely"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "The evidence from which guideline recommendations"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "as a result of clinical trial underrepresentation.61–65"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "in cardio-oncology have emerged has been based on"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "studies of anthracycline and trastuzumab-induced car-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "11.2. Cardio-Oncology diomyopathy. Cancer therapy–related cardiomyopathy"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "is, however, a heterogeneous disease, with a wide"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Recommendations for Cardio-Oncology range of presentations—from asymptomatic LV dys-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "function to cardiogenic shock—and drug-dependent"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "pathophysiologic mechanisms that are often poorly"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "understood. Until sufficient high-quality, drug-specific"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "1. In patients who develop cancer therapy–related evidence and cost-effectiveness analyses for screen-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "cardiomyopathy or HF, a multidisciplinary"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "ing and monitoring are available, these recommen-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "discussion involving the patient about the risk-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "1 B-NR"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "benefit ratio of cancer therapy interruption, dis- dations are applicable across potentially cardiotoxic"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "continuation, or continuation is recommended therapies (Table 28)."
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "to improve management.1,2"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "2. In asymptomatic patients with cancer therapy–"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "related cardiomyopathy (EF <50%), ARB, Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "2a B-NR ACEi, and beta blockers are reasonable to"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "prevent progression to HF and improve cardiac 1. HF secondary to cancer therapy–related cardio-"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "function.2–4 myopathy is associated with significantly worse"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 81,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "e976 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Table 28. Cancer Therapies Known to Be Associated With Cardiomyopathy"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Cardiac Function Monitoring Often"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Performed in Clinical Practice"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Class Agent(s) Pretherapy Serial"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Anthracyclines55–57 Doxorubicin, epirubicin X X"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Alkylating agents58–60 Cyclophosphamide, ifosfamide, melphalan X"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Antimicrotubule agents.61,62 Docetaxel"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Antimetabolites63–72 Fluorouracil, capecitabine, fludarabine, decitabine"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Anti-HER2 agents73–76 Trastuzumab, pertuzumab X X"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Monoclonal antibodies77 Rituximab"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Tyrosine-kinase inhibitors78–100 Dabrafenib, dasatinib, lapatinib, pazopanib, ponatinib, sorafenib,"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "trametinib, sunitinib, vandetanib, imatinib, vandetanib"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Immune checkpoint inhibitors39,40,101 Nivolumab, ipilimumab, pembrolizumab"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Protease inhibitors102–106 Bortezomib, carfilzomib"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Endocrine therapy107–111 Goserelin, leuprolide, flutamide, bicalutamide, nilutamide"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Chimeric antigen receptor T-cell therapy.112,113 Tisagenlecleucel, axicabtagene ciloleucel X"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Hematopoietic stem cell transplantation7,44,114–119 Hematopoietic stem cell transplantation X"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Radiation7,44,114–119 Chest"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "outcomes.1,2,38 Patients who develop HF while overlap with comorbid CVD. Available data in"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "receiving potentially cardiotoxic therapies patients with anthracycline and trastuzumab-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "should have these therapies discontinued while induced cardiomyopathy suggest beta blockers"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "a diagnostic workup is undertaken to ascertain and ACEi are effective in improving LV dysfunc-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "the cause of HF and initiate GDMT. The com- tion.2–4 Given the dearth of data specific to can-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "plex decision to resume, modify, or permanently cer therapy–related cardiomyopathy for other"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "discontinue therapy by the primary oncologist GDMT, their use should align with the HFrEF"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "should be done in a patient-centered approach management guidelines. Initiation and uptitration"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "in concert with a cardiovascular specialist in of standard HF therapies remains the mainstay of"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "cardio-oncology. Factors impacting the decision treatment in patients with cancer therapy–related"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "include the severity of cancer therapy–related cardiomyopathy or LVEF <50%, with close moni-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "cardiomyopathy and the response to neurohor- toring of cardiac function to guide discussions"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "monal blockade, the offending agent’s specific with oncology on the resumption of, or choice of,"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "mechanism of injury, the patient’s comorbid con- subsequent cancer therapies.2"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "ditions and cancer-related prognosis and, lastly, 3. Pretherapy quantification of LVEF in patients"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "the availability of alternative noncardiotoxic receiving potentially cardiotoxic cancer thera-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "treatment options. However, the clinical signifi- pies serves 4 purposes: 1) pretherapy risk"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "cance of asymptomatic cancer therapy–related stratification and diagnosis of preexisting car-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "cardiomyopathy that is identified on routine diomyopathy, 2) establish a reference baseline"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "monitoring is less clear. This is most apparent in to which reevaluations can be compared, 3) initi-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "patients receiving trastuzumab in whom asymp- ate cardioprotective medications before cancer"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "tomatic decreases in LVEF can occur in >10% of therapy, and 4) guide choice of cancer therapy."
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "patients yet result in a high recovery rate and low Echocardiography is recommended as the first-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "rate of discontinuation of therapy.1,2 Accordingly, line modality for LVEF assessment given its"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "trastuzumab is often continued in patients availability, safety, relatively low cost, and its abil-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "deemed low risk while neurohormonal blockade ity to provide structural and functional informa-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "is initiated. Conversely, patients diagnosed with tion beyond LVEF.2,5–16,41–47 The risk of cancer"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "immune checkpoint-related myocarditis typically therapy–related cardiomyopathy varies greatly"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "have the offending agents discontinued indefi- across cancer therapies and is modified by pre-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "nitely, given the associated high mortality.39,40 existing cardiovascular risk factors (Table 29)."
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "2. Studying the effectiveness of neurohormonal Pretherapy LVEF is a strong predictor of major"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "therapies specifically in patients with the CTRC adverse cardiovascular events in patients receiv-"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "gene is challenging given the relative infrequency ing potentially cardiotoxic therapies.2,5–10,42–47 The"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "of events, heterogeneity of offending agents, clinical use and cost-effectiveness of systematic"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "the poorly understood pathophysiology, and the screening in all patients, however, is unclear.11–16"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 82,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e977"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Table 29. Risk Factors for Cancer Therapy–Related has been investigated in a number of small"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Cardiomyopathy clinic trials, with conflicting findings.17–27,49 The"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Age ≥60 y most supportive of this practice is a study that"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "randomized 114 patients receiving high-dose"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Black race"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "chemotherapy and having a posttreatment tropo-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "CAD"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "nin rise >0.07 ng/mL to enalapril or placebo.20"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Hypertension"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "None of the patients in the enalapril arm met the"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Diabetes primary endpoint (>10% decrease in LVEF to"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Preexisting cardiomyopathy below 50%), while 43% of patients in the stan-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Previous exposure to anthracyclines dard of care group had a significant decrease"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "in LVEF.20 Although other studies have shown"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Previous chest radiation"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "similar findings, the magnitude of the difference"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Elevated troponin pretherapy"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "in LVEF between arms was often small (<5%)"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "CAD indicates coronary artery disease. and of questionable clinical significance.19,22 Not"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "all studies have replicated these findings.18,21,24,26"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Patients with cancer and preexisting cardio-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Most importantly, none of the studies have"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "vascular risk factors are at significantly higher"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "assessed whether preemptive use of HF thera-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "risk of cancer therapy–related cardiomyopathy,"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "pies in patients at risk for cancer therapy–related"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "representing a population in which pretherapy"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "cardiomyopathy improves clinical outcomes, such"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "evaluation would have a significantly higher"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "as mortality or hospitalization for HF. Additional"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "yield.2,5–10,42–47"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "studies are needed to define the appropriate cri-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "4. The purpose of serial monitoring of LVEF in"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "teria and patient population in whom to initiate"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "patients receiving potentially cardiotoxic anti-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "medical therapies for the primary prevention of"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "cancer agents is to identify subclinical cardiac"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "cancer therapy–related cardiomyopathy."
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "injury, initiate cardioprotective agents, and con-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "6. Cardiovascular biomarkers, notably troponin, have"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "sider temporary or permanent interruption of"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "been studied for cardiovascular risk stratifica-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "the offending agent.2,4,6,8,48 The practice of LVEF"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "tion in patients undergoing potentially cardiotoxic"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "monitoring has mostly been implemented in"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "therapies.29–32 A study of 452 patients with breast"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "patients receiving anthracyclines, trastuzumab,"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "cancer showed that an elevated pretreatment"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "or both (Table 28). In a study of 2625 patients"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "level (>14 ng/L) was associated with a 4-fold"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "receiving anthracyclines for breast cancer or"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "increase in the risk of cancer therapy–related car-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "lymphoma who underwent serial LVEF moni-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "diomyopathy.32 Other smaller studies have found"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "toring, cancer therapy–related cardiomyopathy"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "no advantage in measuring troponin or natriuretic"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "occurred in 9% of patients, of whom 81% had"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "mild symptoms (NYHA class I to II).4 Beta block- peptides pretherapy.50–53 Overall, these biomarker"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "ers and ACEi-ARB were initiated in all patients, studies were observational and small in sample"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "with 86% having at least partial recovery of size and number of events.54 Serial biomarkers"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "LVEF.4 Patients with recovered LVEF had a lower may be more useful in risk stratification. For exam-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "incidence of cardiac events than those that ple, in a study of 703 patients receiving anthra-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "did not.4 The clinical significance of an asymp- cyclines, an increase in troponin within 72 hours"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "tomatic decrease in LVEF and the optimal fre- of chemotherapy and 1 month after the comple-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "quency and duration of monitoring is less clear tion of treatment course were associated with a"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "and likely depend on patient risk, the anticancer greater risk of cancer therapy–related cardiomy-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "agent used, and its cumulative dose. Although opathy.29 The clinical use of measuring biomark-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "a one-size-fits-all approach to monitoring for ers was assessed in 1 trial in which 114 patients"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "cancer therapy–related cardiomyopathy may be with posttreatment increase in troponin to >0.07"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "easier to implement systematically, it may not be ng/mL were randomized to enalapril or standard"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "the most cost-effective. Until additional data are of care.20 None of the patients in the enalapril"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "available, limiting the monitoring to patients at group had a decrease in LVEF, compared with"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "higher risk of cancer therapy–related cardiomy- 43% in the standard of care group.20 Data for the"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "opathy (Table 29) is a reasonable strategy. use of natriuretic peptides are limited. In practice,"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "5. Whether the preemptive use of ACEi-ARB, spi- biomarkers could provide rapid risk stratification"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "ronolactone, or selected beta blockers such as in patients for which echocardiographic findings"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "carvedilol and nebivolol is effective in reducing the are equivocal and help determine whether symp-"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "risk of cancer therapy–related cardiomyopathy toms are cardiovascular in origin."
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 83,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 83,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Age ≥60 y": "Black race"
            },
            {
                "Age ≥60 y": "CAD"
            },
            {
                "Age ≥60 y": "Hypertension"
            },
            {
                "Age ≥60 y": "Diabetes"
            },
            {
                "Age ≥60 y": "Preexisting cardiomyopathy"
            },
            {
                "Age ≥60 y": "Previous exposure to anthracyclines"
            },
            {
                "Age ≥60 y": "Previous chest radiation"
            },
            {
                "Age ≥60 y": "Elevated troponin pretherapy"
            }
        ],
        "conteudo_texto": "Black race | CAD | Hypertension | Diabetes | Preexisting cardiomyopathy | Previous exposure to anthracyclines | Previous chest radiation | Elevated troponin pretherapy"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "e978 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "11.3. HF and Pregnancy are essential.1,3,50 Among women with non–peri-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "partum cardiomyopathy, major cardiovascular"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "Recommendations for HF and Pregnancy events occurred in 39% (United States) and 35%"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "(Canada) of pregnancies, with 1% and 7% mortal-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "ity, respectively.51,52 Previous cardiac events, NYHA"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "class III to IV, or LVEF <40% markedly increased"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "1. In women with a history of HF or cardiomyopathy,"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "maternal and fetal risks.51–55 The ROPAC (Registry"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "including previous peripartum cardiomyopathy,"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "1 C-LD patient-centered counseling regarding contra- of Pregnancy and Cardiac disease) study describes"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "ception and the risks of cardiovascular deteriora- pregnancy outcomes for 1321 women with struc-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "tion during pregnancy should be provided.1–8"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "tural heart disease: Women with prepregnancy or"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "2. In women with acute HF caused by peripartum peripartum cardiomyopathy had the highest mortal-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "cardiomyopathy and LVEF <30%, anticoagula-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "ity rate (2.4%).2,22 ROPAC was used to validate the"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "2b C-LD tion may be reasonable at diagnosis, until 6 to"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "8 weeks postpartum, although the efficacy and modified WHO risk classification56; the ZAHARA I"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "safety are uncertain.9–12 (Zwangerschap bij Aangeboren Hartafwijkingen I)"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "3. In women with HF or cardiomyopathy who are and CARPREG II (CARdiac disease in PREGnancy)"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "pregnant or currently planning for pregnancy, scores also support shared decision-making.51,57,58"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "3: Harm C-LD ACEi, ARB, ARNi, MRA, SGLT2i, ivabradine,"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "Subsequent pregnancies for women with previous"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "and vericiguat should not be administered"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "because of significant risks of fetal harm.13–15 peripartum cardiomyopathy have been associated"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "with further decreases in LV function, maternal"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "death, and adverse fetal outcomes.43,58 The stron-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "gest prognostic determinant is LVEF <50% before"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "HF may complicate pregnancy either secondary to an ex- a subsequent pregnancy.6–8 An international sys-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "isting prepregnancy cardiomyopathy, or as a result of peri- tematic review that included 93 subsequent preg-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "partum cardiomyopathy.16–18 Peripartum cardiomyopathy is nancies with persistent LV dysfunction reported"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "defined as systolic dysfunction, typically LVEF <45%, often 48% further LVEF deterioration, 49% HF symp-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "with LV dilation, occurring in late pregnancy or early postpar- toms, and 16% mortality, whereas among 98 with"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "tum with no other identifiable cardiomyopathy cause.14,19–21 recovered LV function presubsequent pregnancy,"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "Peripartum cardiomyopathy occurs globally,22,23 with the these rates were 27%, 32%, and 0%, respectively.5"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "highest incidences in Nigeria, Haiti, and South Africa. Inci- 2. Pregnancy is a hypercoagulable state even in the"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "dence in the United States is 1 in 1000 to 8000 deliver- absence of cardiovascular complications. In the set-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "ies and has risen over time.24,25 Peripartum cardiomyopathy ting of acute HF, particularly when there is LV blood"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "risk factors include maternal age >30 years, African an- stasis because of severely reduced systolic function,"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "cestry, multiparity, multigestation, preeclampsia/eclampsia, the risk of intracardiac thrombus formation is sig-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "anemia, diabetes, obesity, and prolonged tocolysis.22,23,26–30 nificant. The incidence of intracardiac thrombi dur-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "A genetic contribution is recognized,31–33 particularly titan ing acute HF caused by peripartum cardiomyopathy"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "gene mutations.34,35 Most women present with HF within has been reported to be around 16% to 17%.9,10"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "1 month postpartum; cardiogenic shock, arrhythmias, or with 9% thromboembolic events in 2 separate"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "venous-arterial thromboembolism are all possible. Treat- cohorts11,12 Women with an intracardiac thrombus"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "ment includes GDMT adjusted for pregnancy or breast- or a thromboembolic event receive anticoagula-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "feeding status and anticoagulation consideration16; iden- tion as per standard of care. Women with severely"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "tification of a pathogenic 16-kDa prolactin led to trials of depressed LVEF (<30%) in the setting of acute"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "the dopamine-agonist bromocriptine.36–41 Patient-centered HF caused by peripartum cardiomyopathy can be"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "multidisciplinary planning is essential, including early insti- considered for anticoagulation, especially in the first"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "tution of mechanical support for shock42 (Table 30). Prog- 6 to 8 weeks postpartum, when hypercoagulabil-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "nosis is related to initial LVEF, LV thrombosis, RV involve- ity is most pronounced. If bromocriptine is used for"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "ment, preeclampsia, geographic region, and race.7,43–48 LV postpartum women with severe acute HF caused"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "recovery and survival is generally favorable in developed by peripartum cardiomyopathy and LVEF <35%, it"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "countries11,25,49; a 100-patient US registry showed 93% should be accompanied by at least prophylactic-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "transplant/LVAD-free 1-year survival.46 dosed anticoagulation, because of the potential"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "association with thromboembolic events.6 However,"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "the efficacy and safety of bromocriptine for acute"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "peripartum cardiomyopathy treatment currently"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "1. Pregnancy is generally well-tolerated in women with remains uncertain, and further randomized placebo-"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "cardiomyopathy and NYHA class I prepregnancy. controlled trials are required to define the role of this"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "However, clinical deterioration can occur, so pre- therapy, particularly in the setting of contemporary"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "pregnancy counseling and shared decision-making HF GDMT and cardiogenic shock management."
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 84,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e979"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Table 30. HF Management Strategies Across the Pregnancy Continuum"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Preconception During Pregnancy Postpartum"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Nonpharmacological Preconception genetic counseling and testing Close maternal monitoring for HF signs or symp- Multidisciplinary recommendations from ob-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "strategies for potentially heritable cardiac conditions. toms or other cardiovascular instability by cardiol- stetrics and neonatology and pediatrics teams"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Use of pregnancy cardiovascular risk ogy and obstetric and maternal-fetal medicine and shared decision-making regarding the"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "tools,51,56–58 and echocardiography for myo- teams; close fetal monitoring by the obstetric and maternal and neonatal risks and benefits of"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "cardial structure and function assessment, to maternal-fetal medicine teams. breastfeeding."
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "provide information that facilitates informed Consideration of routine echocardiographic For women presenting with decompensated"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "counseling. screening in the third trimester for reassess- HF or cardiogenic shock, HF management"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "For women planning a pregnancy, provide per- ment of myocardial structure and function should include hemodynamic monitoring and"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "sonalized counseling that promotes the auton- before labor; echocardiography for any signifi- mechanical circulatory support as appropriate"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "omy and goals of the patient (and her partner, cant changes in HF symptoms or signs during"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "as applicable), the patient’s ability for self-care pregnancy, or if HF medications are reduced"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "and risk awareness, and ensures adequate or discontinued.18"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "psychosocial support for decision-making.3 BNP or NT-proBNP monitoring during preg-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "For women not currently planning a pregnancy nancy may have some value for prediction of"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "but who might conceive, discuss HF-specific cardiovascular events.73,74"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "considerations regarding pregnancy and refer Close maternal monitoring by obstetrics and"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "to gynecology or primary care for contracep- maternal-fetal medicine teams for preeclamp-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "tive counseling. sia, which has shared risk factors and patho-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "genesis with PPCM.47,75"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "For women presenting with decompensated"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "HF or cardiogenic shock, hemodynamic moni-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "toring and MCS, as appropriate, within a mul-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "tidisciplinary collaborative approach that sup-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "ports prompt decision-making about the timing"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "and mechanism of delivery."
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Pharmacological strat- Review of all current medications. Close monitoring of maternal blood pressure, For women with acute HF caused by PPCM"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "egies For women planning pregnancy imminently, heart rate, and volume status, with adjustment and LVEF <30%, consideration of anticoagula-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "modification of HF pharmacotherapy includ- of the modified HF regimen as appropriate tion until 6–8 wk postpartum, although the ef-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "ing. discontinuation of any ACEi, ARB, ARNi, to avoid hypotension (systemic vasodilation ficacy and safety remain uncertain at this time."
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "MRA, or SGLT2i or ivabradine medications; peaks in the second trimester) and placental For postpartum women with severe acute HF"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "within a construct of multidisciplinary shared hypoperfusion. caused by PPCM and LVEF <35%, in GDMT"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "decision-making, continuation of a beta block- For women with HF or cardiomyopathy pharmacotherapy and prophylactic anticoagula-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "er (most commonly metoprolol), hydralazine, presenting during pregnancy without precon- tion, to improve LVEF recovery6,31,3641,76; the"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "and nitrates; adjustment of diuretic dosing ception counseling and assessment, urgent efficacy and safety of bromocriptine for acute"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "to minimize the risk of placental hypoperfu- discontinuation of any GDMT pharmacothera- PPCM treatment remains uncertain at this time,"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "sion.13–15 pies with fetal toxicities; within a construct particularly in the setting of contemporary HF"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Ideally, repeat echocardiography approximately of multidisciplinary shared decision-making, GDMT and cardiogenic shock management.*"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "3 mo after preconception HF medication continuation of a beta blocker (most com- For women who choose to breastfeed, review"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "adjustments to ensure stability of myocardial monly metoprolol succinate), hydralazine, and medications with neonatology and pediatrics"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "structure and function before conception. nitrates; adjustment of diuretic dosing to mini- teams for neonatal safety during lactation, ideally"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "mize the risk of placental hypoperfusion. with pharmacist consultation if available."
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Within a construct of multidisciplinary shared"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "decision-making, medications that may be ap-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "propriate during breastfeeding include ACEi"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "(enalapril or captopril preferred, monitor neona-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "tal weight), beta blockers (metoprolol preferred,"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "monitor neonatal heart rate).15"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Diuretics can suppress lactation, but with neo-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "natal follow-up the use of furosemide may be"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "appropriate.15"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Multidisciplinary care Consultation with genetics, gynecology, and Multidisciplinary management with obstetrics Multidisciplinary management with obstetrics,"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "beyond the cardiology maternal-fetal medicine teams, as appropriate and maternal-fetal medicine teams during maternal-fetal medicine, neonatology, and pe-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "team to the outcome of shared decision-making. pregnancy. diatrics teams, especially for multidisciplinary"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "For women with decompensated HF or evi- recommendations regarding lactation."
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "dence of hemodynamic instability antepartum, Consultation with gynecology team for ongoing"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "delivery planning will include obstetrics and contraceptive planning."
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "maternal-fetal medicine, anesthesia, and neo-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "natology teams."
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; BNP, B-natriuretic peptide; GDMT,"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "guideline-directed medical therapy; HF, heart failure; LVEF, left ventricular ejection fraction; MCS, mechanical circulatory support; MRA, mineralocorticoid receptor antagonist;"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PPCM, peripartum cardiomyopathy; RCT, randomized controlled trial; RV, right ventricular; and SGLT2i, sodium-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "glucose cotransporter-2 inhibitor."
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "*An initial open-label pilot RCT in South Africa suggested addition of bromocriptine to GDMT was associated with greater LVEF improvement and a lower rate of the composite"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "endpoint at 6 mo.37 Among 96 women with acute PPCM in a Burkina Faso RCT, 4 wk of bromocriptine was associated with LVEF recovery and lower mortality (16.6% versus"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "29.1%; P<0.001).39 A multicenter German study randomized 63 patients to 1 versus 8 wk of bromocriptine (no placebo, as deemed unethical),38 with LVEF recovery ≥50% in"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "52% and 68% of the 1- and 8-wk groups, respectively, and no deaths. A substudy also showed high rates of RV recovery.41 Two retrospective cohorts (Germany, Canada) and a"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "multicenter cohort of subsequent pregnancies also suggested greater LVEF recovery with bromocriptine.31,38,40 Bromocriptine may currently be most justified in women with LVEF"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "<25% or cardiogenic shock. The downsides of prohibiting breastfeeding should be considered. Bromocriptine should be accompanied by at least prophylactic-dosed anticoagula-"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "tion, because of potential hypercoagulability.38 The European Society of Cardiology endorses “BOARD” (Bromocriptine, Oral HF therapy, Anticoagulation, vasoRelaxing agents,"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Diuretics) for acute PPCM management.13,14"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 85,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 85,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "": "Nonpharmacological strategies",
                "Preconception": "Preconception genetic counseling and testing for potentially heritable cardiac conditions. Use of pregnancy cardiovascular risk tools,51,56–58 and echocardiography for myo- cardial structure and function assessment, to provide information that facilitates informed counseling. For women planning a pregnancy, provide per- sonalized counseling that promotes the auton- omy and goals of the patient (and her partner, as applicable), the patient’s ability for self-care and risk awareness, and ensures adequate psychosocial support for decision-making.3 For women not currently planning a pregnancy but who might conceive, discuss HF-specific considerations regarding pregnancy and refer to gynecology or primary care for contracep- tive counseling.",
                "During Pregnancy": "Close maternal monitoring for HF signs or symp- toms or other cardiovascular instability by cardiol- ogy and obstetric and maternal-fetal medicine teams; close fetal monitoring by the obstetric and maternal-fetal medicine teams. Consideration of routine echocardiographic screening in the third trimester for reassess- ment of myocardial structure and function before labor; echocardiography for any signifi- cant changes in HF symptoms or signs during pregnancy, or if HF medications are reduced or discontinued.18 BNP or NT-proBNP monitoring during preg- nancy may have some value for prediction of cardiovascular events.73,74 Close maternal monitoring by obstetrics and maternal-fetal medicine teams for preeclamp- sia, which has shared risk factors and patho- genesis with PPCM.47,75 For women presenting with decompensated HF or cardiogenic shock, hemodynamic moni- toring and MCS, as appropriate, within a mul- tidisciplinary collaborative approach that sup- ports prompt decision-making about the timing and mechanism of delivery.",
                "Postpartum": "Multidisciplinary recommendations from ob- stetrics and neonatology and pediatrics teams and shared decision-making regarding the maternal and neonatal risks and benefits of breastfeeding. For women presenting with decompensated HF or cardiogenic shock, HF management should include hemodynamic monitoring and mechanical circulatory support as appropriate"
            },
            {
                "": "Pharmacological strat- egies",
                "Preconception": "Review of all current medications. For women planning pregnancy imminently, modification of HF pharmacotherapy includ- ing. discontinuation of any ACEi, ARB, ARNi, MRA, or SGLT2i or ivabradine medications; within a construct of multidisciplinary shared decision-making, continuation of a beta block- er (most commonly metoprolol), hydralazine, and nitrates; adjustment of diuretic dosing to minimize the risk of placental hypoperfu- sion.13–15 Ideally, repeat echocardiography approximately 3 mo after preconception HF medication adjustments to ensure stability of myocardial structure and function before conception.",
                "During Pregnancy": "Close monitoring of maternal blood pressure, heart rate, and volume status, with adjustment of the modified HF regimen as appropriate to avoid hypotension (systemic vasodilation peaks in the second trimester) and placental hypoperfusion. For women with HF or cardiomyopathy presenting during pregnancy without precon- ception counseling and assessment, urgent discontinuation of any GDMT pharmacothera- pies with fetal toxicities; within a construct of multidisciplinary shared decision-making, continuation of a beta blocker (most com- monly metoprolol succinate), hydralazine, and nitrates; adjustment of diuretic dosing to mini- mize the risk of placental hypoperfusion.",
                "Postpartum": "For women with acute HF caused by PPCM and LVEF <30%, consideration of anticoagula- tion until 6–8 wk postpartum, although the ef- ficacy and safety remain uncertain at this time. For postpartum women with severe acute HF caused by PPCM and LVEF <35%, in GDMT pharmacotherapy and prophylactic anticoagula- tion, to improve LVEF recovery6,31,3641,76; the efficacy and safety of bromocriptine for acute PPCM treatment remains uncertain at this time, particularly in the setting of contemporary HF GDMT and cardiogenic shock management.* For women who choose to breastfeed, review medications with neonatology and pediatrics teams for neonatal safety during lactation, ideally with pharmacist consultation if available. Within a construct of multidisciplinary shared decision-making, medications that may be ap- propriate during breastfeeding include ACEi (enalapril or captopril preferred, monitor neona- tal weight), beta blockers (metoprolol preferred, monitor neonatal heart rate).15 Diuretics can suppress lactation, but with neo- natal follow-up the use of furosemide may be appropriate.15"
            },
            {
                "": "Multidisciplinary care beyond the cardiology team",
                "Preconception": "Consultation with genetics, gynecology, and maternal-fetal medicine teams, as appropriate to the outcome of shared decision-making.",
                "During Pregnancy": "Multidisciplinary management with obstetrics and maternal-fetal medicine teams during pregnancy. For women with decompensated HF or evi- dence of hemodynamic instability antepartum, delivery planning will include obstetrics and maternal-fetal medicine, anesthesia, and neo- natology teams.",
                "Postpartum": "Multidisciplinary management with obstetrics, maternal-fetal medicine, neonatology, and pe- diatrics teams, especially for multidisciplinary recommendations regarding lactation. Consultation with gynecology team for ongoing contraceptive planning."
            }
        ],
        "conteudo_texto": "Nonpharmacological strategies, Preconception genetic counseling and testing for potentially heritable cardiac conditions. Use of pregnancy cardiovascular risk tools,51,56–58 and echocardiography for myo- cardial structure and function assessment, to provide information that facilitates informed counseling. For women planning a pregnancy, provide per- sonalized counseling that promotes the auton- omy and goals of the patient (and her partner, as applicable), the patient’s ability for self-care and risk awareness, and ensures adequate psychosocial support for decision-making.3 For women not currently planning a pregnancy but who might conceive, discuss HF-specific considerations regarding pregnancy and refer to gynecology or primary care for contracep- tive counseling., Close maternal monitoring for HF signs or symp- toms or other cardiovascular instability by cardiol- ogy and obstetric and maternal-fetal medicine teams; close fetal monitoring by the obstetric and maternal-fetal medicine teams. Consideration of routine echocardiographic screening in the third trimester for reassess- ment of myocardial structure and function before labor; echocardiography for any signifi- cant changes in HF symptoms or signs during pregnancy, or if HF medications are reduced or discontinued.18 BNP or NT-proBNP monitoring during preg- nancy may have some value for prediction of cardiovascular events.73,74 Close maternal monitoring by obstetrics and maternal-fetal medicine teams for preeclamp- sia, which has shared risk factors and patho- genesis with PPCM.47,75 For women presenting with decompensated HF or cardiogenic shock, hemodynamic moni- toring and MCS, as appropriate, within a mul- tidisciplinary collaborative approach that sup- ports prompt decision-making about the timing and mechanism of delivery., Multidisciplinary recommendations from ob- stetrics and neonatology and pediatrics teams and shared decision-making regarding the maternal and neonatal risks and benefits of breastfeeding. For women presenting with decompensated HF or cardiogenic shock, HF management should include hemodynamic monitoring and mechanical circulatory support as appropriate | Pharmacological strat- egies, Review of all current medications. For women planning pregnancy imminently, modification of HF pharmacotherapy includ- ing. discontinuation of any ACEi, ARB, ARNi, MRA, or SGLT2i or ivabradine medications; within a construct of multidisciplinary shared decision-making, continuation of a beta block- er (most commonly metoprolol), hydralazine, and nitrates; adjustment of diuretic dosing to minimize the risk of placental hypoperfu- sion.13–15 Ideally, repeat echocardiography approximately 3 mo after preconception HF medication adjustments to ensure stability of myocardial structure and function before conception., Close monitoring of maternal blood pressure, heart rate, and volume status, with adjustment of the modified HF regimen as appropriate to avoid hypotension (systemic vasodilation peaks in the second trimester) and placental hypoperfusion. For women with HF or cardiomyopathy presenting during pregnancy without precon- ception counseling and assessment, urgent discontinuation of any GDMT pharmacothera- pies with fetal toxicities; within a construct of multidisciplinary shared decision-making, continuation of a beta blocker (most com- monly metoprolol succinate), hydralazine, and nitrates; adjustment of diuretic dosing to mini- mize the risk of placental hypoperfusion., For women with acute HF caused by PPCM and LVEF <30%, consideration of anticoagula- tion until 6–8 wk postpartum, although the ef- ficacy and safety remain uncertain at this time. For postpartum women with severe acute HF caused by PPCM and LVEF <35%, in GDMT pharmacotherapy and prophylactic anticoagula- tion, to improve LVEF recovery6,31,3641,76; the efficacy and safety of bromocriptine for acute PPCM treatment remains uncertain at this time, particularly in the setting of contemporary HF GDMT and cardiogenic shock management.* For women who choose to breastfeed, review medications with neonatology and pediatrics teams for neonatal safety during lactation, ideally with pharmacist consultation if available. Within a construct of multidisciplinary shared decision-making, medications that may be ap- propriate during breastfeeding include ACEi (enalapril or captopril preferred, monitor neona- tal weight), beta blockers (metoprolol preferred, monitor neonatal heart rate).15 Diuretics can suppress lactation, but with neo- natal follow-up the use of furosemide may be appropriate.15 | Multidisciplinary care beyond the cardiology team, Consultation with genetics, gynecology, and maternal-fetal medicine teams, as appropriate to the outcome of shared decision-making., Multidisciplinary management with obstetrics and maternal-fetal medicine teams during pregnancy. For women with decompensated HF or evi- dence of hemodynamic instability antepartum, delivery planning will include obstetrics and maternal-fetal medicine, anesthesia, and neo- natology teams., Multidisciplinary management with obstetrics, maternal-fetal medicine, neonatology, and pe- diatrics teams, especially for multidisciplinary recommendations regarding lactation. Consultation with gynecology team for ongoing contraceptive planning."
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "e980 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "3. In 2015, the FDA adopted the Pregnancy and reach the performance measure standard. Performance"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Lactation Labeling Rule, which retired the previous measures of the ACC/AHA focus on process of care"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "pregnancy risk categories A through X and, instead, measures that measure the quality of care by the clini-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "assigned a descriptive risk summary to aid medication cian, facility, and health system. Patient registries that"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "counseling for pregnant and breastfeeding women. track such measures can provide feedback to partici-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "ACEi and ARB are associated with second- and third- pants, which may help with improvement in quality."
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "trimester renal and tubular dysplasia, oligohydramnios,"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "fetal growth restriction, ossification disorders of the"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "skull, lung hypoplasia, contractures, large joints, ane-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "mia, and intrauterine fetal death and are, therefore, 1. The current ACC/AHA performance and qual-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "strictly contraindicated.59–61 There are no specific ity measures (based on the 2013 ACC/AHA HF"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "data for ARNi or ivabradine. For spironolactone, there guideline and the 2017 ACC/AHA/HFSA guideline"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "is sufficient information regarding dose-dependent supplement) are displayed in Table 31.8 The perfor-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "feminization of male rabbit and rat offspring to raise mance measures are derived from the most defini-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "concern62; data are limited for eplerenone. HFrEF tive guideline recommendations (ie, NYHA class I"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "medications considered acceptable during preg- and class III recommendations). Observational data"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "nancy,15 within a construct of multidisciplinary shared suggest that hospitals that receive feedback on"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "decision-making regarding benefits and potential their HF care improve over time.1–7"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "2. Hospitals that perform well on medication-related"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "risks, are furosemide, beta blockers (most com-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "monly metoprolol),63–65 hydralazine, and nitrates.13,14,19 performance measures have better HF mortality"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Women with peripartum cardiomyopathy were his- rates than hospitals with poorer performance.3,4 Other"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "torically counseled against breastfeeding because observational data suggest that hospitals that par-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "of metabolic demands and prolactin stimulation, but ticipate in registries have better process of care and"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "breastfeeding may even be associated with LV recov- outcomes compared with hospitals that do not partic-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "ery.66–70 Postpartum women who breastfeed can start ipate.5,6 Randomized studies of audit and feedback of"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "ACEi (enalapril or captopril preferred), and metoprolol performance, in many different patient groups, have,"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "remains the preferred beta blocker.66,71 The National in general, showed improvement in care.7 However,"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Library of Medicine hosts LactMed (https://www.ncbi. public reporting of HF measures in Ontario, Canada,"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "nlm.nih.gov/books/NBK501922/).72 did not clearly improve care during a randomized trial.9"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "12. QUALITY METRICS AND REPORTING 13. GOALS OF CARE"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "12.1. Performance Measurement 13.1. Palliative and Supportive Care, Shared"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Decision-Making, and End-of-Life"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Recommendations for Performance Measurement"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Referenced studies that support the recommendations are summa- Recommendations for Palliative and Supportive Care, Shared Decision-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements. Making, and End-of-Life"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations Referenced studies that support the recommendations are summa-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "rized in the Online Data Supplements."
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "1. Performance measures based on professionally"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "developed clinical practice guidelines should COR LOE Recommendations"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "1 B-NR"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "be used with the goal of improving quality of"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "1. For all patients with HF, palliative and supportive"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "care for patients with HF.1–7"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "care—including high-quality communication,"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "2. Participation in quality improvement programs, 1 C-LD conveyance of prognosis, clarifying goals of"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "including patient registries that provide bench- care, shared decision-making, symptom man-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "mark feedback on nationally endorsed, clinical agement, and caregiver support—should be"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "2a B-NR practice guideline–based quality and perfor- provided to improve QOL and relieve suffering.1"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "mance measures can be beneficial in improving 2. For patients with HF being considered for, or"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "the quality of care for patients with HF.1,2,5,6 treated with, life-extending therapies, the option"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "for discontinuation should be anticipated and dis-"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "1 C-LD"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "cussed through the continuum of care, including at"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "the time of initiation, and reassessed with changing"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "medical conditions and shifting goals of care.2,3"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "The ACC/AHA Task Force on Performance Measures"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "(Task Force) distinguishes quality measures from perfor- 3. For patients with HF—particularly stage D"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "HF patients being evaluated for advanced"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "mance measures. Performance measures are selected"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "therapies, patients requiring inotropic support"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "from the most important ACC/AHA clinical practice or temporary mechanical support, patients"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "guideline recommendations with the strongest evidence. 2a B-R experiencing uncontrolled symptoms, major"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "medical decisions, or multimorbidity, frailty, and"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "These measures are suitable for public reporting or pay"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "cognitive impairment—specialist palliative care"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "for performance. Quality measures are those metrics that consultation can be useful to improve QOL"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "may be useful for local quality improvement but do not and relieve suffering.4–6"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 86,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e981"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Table 31. ACC/AHA 2020 HF Clinical Performance, Quality, and Structural Measures8"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Measure No. Measure Title Care Setting Attribution Measure Domain"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-1 LVEF assessment Outpatient Individual practitioner Diagnostic"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-2 Symptom and activity assessment Outpatient Individual practitioner Monitoring"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-3 Symptom management Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-4 Beta-blocker therapy for HFrEF Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Inpatient Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-5 ACEi, ARB, or ARNi therapy for HFrEF Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Inpatient Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-6 ARNi therapy for HFrEF Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Inpatient Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-7 Dose of beta blocker therapy for HFrEF Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-8 Dose of ACEi, ARB, or ARNi therapy for HFrEF Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-9 MRA therapy for HFrEF Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Inpatient Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-10 Laboratory monitoring in new MRA therapy Outpatient Individual practitioner Monitoring"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Inpatient Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-11 Hydralazine and isosorbide dinitrate therapy for HFrEF in Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "those patients self-identified as Black or African American Inpatient Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-12 Counseling regarding ICD placement for patients with Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "HFrEF on GDMT Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "PM-13 CRT implantation for patients with HFrEF on GDMT Outpatient Individual practitioner Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "QM-1 Patient self-care education Outpatient Individual practitioner Self-care"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "QM-2 Measurement of patient-reported outcome-health status Outpatient Individual practitioner Monitoring"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "QM-3 Sustained or improved health status in HF Outpatient Individual practitioner Outcome"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "QM-4 Post-discharge appointment for patients with HF Inpatient Individual practitioner, Treatment"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "SM-1 HF registry participation Outpatient Facility Structure"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Inpatient"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Rehabilitation PMs Related to HF (From the 2018 ACC/AHA performance measures for cardiac rehabilitation10"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Rehab PM-2 Exercise training referral for HF from inpatient setting Inpatient Facility Process"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Rehab PM-4 Exercise training referral for HF from outpatient setting Outpatient Individual practitioner Process"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Facility"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "ACEi indicates angiotensin-converting enzyme inhibitor; ACC, American College of Cardiology; AHA, American Heart Association; ARB, angiotensin receptor"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "blocker; ARNi, angiotensin receptor-neprilysin inhibitor; CRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, heart failure; HFrEF,"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "heart failure with reduced ejection fraction; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antago-"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "nist; PM, performance measure; QM, quality measure; and SM, structural measure."
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Recommendations for Palliative and Supportive Care, Shared Decision-"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Making, and End-of-Life (Continued) Palliative care—defined as patient- and family-cen-"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendations tered care that optimizes health-related QOL by an-"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "4. For patients with HF, execution of advance ticipating, preventing, and treating suffering—should"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "care directives can be useful to improve docu- be integrated into the care of all patients with HF.9"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "2a C-LD mentation of treatment preferences, delivery of"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Palliative care includes high-quality communication,"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "patient-centered care, and dying in preferred"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "place.7 estimation of prognosis, anticipatory guidance, ad-"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "dressing uncertainty; shared decision-making about"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "5. In patients with advanced HF with expected"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "2a C-LD survival <6 months, timely referral to hospice medically reasonable treatment options; advance care"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "can be useful to improve QOL.8 planning; attention to physical, emotional, spiritual, and"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 87,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 87,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Measure No.": "PM-1",
                "Measure Title": "LVEF assessment",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Diagnostic"
            },
            {
                "Measure No.": "PM-2",
                "Measure Title": "Symptom and activity assessment",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Monitoring"
            },
            {
                "Measure No.": "PM-3",
                "Measure Title": "Symptom management",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "PM-4",
                "Measure Title": "Beta-blocker therapy for HFrEF",
                "Care Setting": "Outpatient Inpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "PM-5",
                "Measure Title": "ACEi, ARB, or ARNi therapy for HFrEF",
                "Care Setting": "Outpatient Inpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "PM-6",
                "Measure Title": "ARNi therapy for HFrEF",
                "Care Setting": "Outpatient Inpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "PM-7",
                "Measure Title": "Dose of beta blocker therapy for HFrEF",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "PM-8",
                "Measure Title": "Dose of ACEi, ARB, or ARNi therapy for HFrEF",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "PM-9",
                "Measure Title": "MRA therapy for HFrEF",
                "Care Setting": "Outpatient Inpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "PM-10",
                "Measure Title": "Laboratory monitoring in new MRA therapy",
                "Care Setting": "Outpatient Inpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Monitoring"
            },
            {
                "Measure No.": "PM-11",
                "Measure Title": "Hydralazine and isosorbide dinitrate therapy for HFrEF in those patients self-identified as Black or African American",
                "Care Setting": "Outpatient Inpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "PM-12",
                "Measure Title": "Counseling regarding ICD placement for patients with HFrEF on GDMT",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "PM-13",
                "Measure Title": "CRT implantation for patients with HFrEF on GDMT",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "QM-1",
                "Measure Title": "Patient self-care education",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Self-care"
            },
            {
                "Measure No.": "QM-2",
                "Measure Title": "Measurement of patient-reported outcome-health status",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Monitoring"
            },
            {
                "Measure No.": "QM-3",
                "Measure Title": "Sustained or improved health status in HF",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Outcome"
            },
            {
                "Measure No.": "QM-4",
                "Measure Title": "Post-discharge appointment for patients with HF",
                "Care Setting": "Inpatient",
                "Attribution": "Individual practitioner, facility",
                "Measure Domain": "Treatment"
            },
            {
                "Measure No.": "SM-1",
                "Measure Title": "HF registry participation",
                "Care Setting": "Outpatient Inpatient",
                "Attribution": "Facility",
                "Measure Domain": "Structure"
            },
            {
                "Measure No.": "Rehabilitation PMs Related to HF (From the 2018 ACC/AHA performance measures for cardiac rehabilitation10",
                "Measure Title": "",
                "Care Setting": "",
                "Attribution": "",
                "Measure Domain": ""
            },
            {
                "Measure No.": "Rehab PM-2",
                "Measure Title": "Exercise training referral for HF from inpatient setting",
                "Care Setting": "Inpatient",
                "Attribution": "Facility",
                "Measure Domain": "Process"
            },
            {
                "Measure No.": "Rehab PM-4",
                "Measure Title": "Exercise training referral for HF from outpatient setting",
                "Care Setting": "Outpatient",
                "Attribution": "Individual practitioner Facility",
                "Measure Domain": "Process"
            }
        ],
        "conteudo_texto": "PM-1, LVEF assessment, Outpatient, Individual practitioner Facility, Diagnostic | PM-2, Symptom and activity assessment, Outpatient, Individual practitioner Facility, Monitoring | PM-3, Symptom management, Outpatient, Individual practitioner Facility, Treatment | PM-4, Beta-blocker therapy for HFrEF, Outpatient Inpatient, Individual practitioner Facility, Treatment | PM-5, ACEi, ARB, or ARNi therapy for HFrEF, Outpatient Inpatient, Individual practitioner Facility, Treatment | PM-6, ARNi therapy for HFrEF, Outpatient Inpatient, Individual practitioner Facility, Treatment | PM-7, Dose of beta blocker therapy for HFrEF, Outpatient, Individual practitioner Facility, Treatment | PM-8, Dose of ACEi, ARB, or ARNi therapy for HFrEF, Outpatient, Individual practitioner Facility, Treatment | PM-9, MRA therapy for HFrEF, Outpatient Inpatient, Individual practitioner Facility, Treatment | PM-10, Laboratory monitoring in new MRA therapy, Outpatient Inpatient, Individual practitioner Facility, Monitoring | PM-11, Hydralazine and isosorbide dinitrate therapy for HFrEF in those patients self-identified as Black or African American, Outpatient Inpatient, Individual practitioner Facility, Treatment | PM-12, Counseling regarding ICD placement for patients with HFrEF on GDMT, Outpatient, Individual practitioner Facility, Treatment | PM-13, CRT implantation for patients with HFrEF on GDMT, Outpatient, Individual practitioner Facility, Treatment | QM-1, Patient self-care education, Outpatient, Individual practitioner Facility, Self-care | QM-2, Measurement of patient-reported outcome-health status, Outpatient, Individual practitioner Facility, Monitoring | QM-3, Sustained or improved health status in HF, Outpatient, Individual practitioner Facility, Outcome | QM-4, Post-discharge appointment for patients with HF, Inpatient, Individual practitioner, facility, Treatment | SM-1, HF registry participation, Outpatient Inpatient, Facility, Structure | Rehabilitation PMs Related to HF (From the 2018 ACC/AHA performance measures for cardiac rehabilitation10, , , ,  | Rehab PM-2, Exercise training referral for HF from inpatient setting, Inpatient, Facility, Process | Rehab PM-4, Exercise training referral for HF from outpatient setting, Outpatient, Individual practitioner Facility, Process"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "e982 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "Figure 15. A Depiction of the Clinical Course of HF With Associated Types and Intensities of Available Therapies Over Time.12"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "CHF indicates congestive heart failure; HF, heart failure; and MCS, mechanical circulatory support. Adapted with permission of the American"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "Thoracic Society. Copyright © 2021 American Thoracic Society. All rights reserved. The American Journal of Respiratory and Critical Care"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "Medicine is an official journal of the American Thoracic Society.13 Readers are encouraged to read the entire article for the correct context"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "at https://www.atsjournals.org/doi/abs/10.1164/rccm.200605-587ST. The authors, editors, and The American Thoracic Society are not"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "responsible for errors or omissions in adaptations. Adapted with permission from the World Health Organization.14 Copyright 1990 World"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "Health Organization."
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "psychological distress; relief of suffering; and inclu- Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "sion of family caregivers in patient care and attention"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "1. Palliative and supportive approaches to the care of"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "to their needs during bereavement.10 Other support-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "patients with HF is inherent to their overall care and"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "ive needs include home and case management assis-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "should be incorporated throughout the course of ill-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "tance, transportation, and care coordination.11 Pallia-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "ness by all health care professionals.9 The applica-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "tive and supportive care has a role across the stages"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "tion of the principles embraced have been shown"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "of HF, starting early in the course of illness, intensify-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "to improve various processes of care and patient"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "ing in end-stage disease, and extending into caregiver"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "outcomes (Table 32). Palliative and supportive care"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "bereavement (Figure 15).12 Many palliative care needs"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "discussions do not imply that a formal palliative care"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "can and should be addressed by the patient’s interdis-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "consultation is needed for each patient but that"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "ciplinary care team (primary palliative care), including"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "team members should integrate palliative and sup-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "clarifying their core values, health outcome goals, and"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "therapeutic preferences.1 Specialty palliative care cli- portive considerations into routine care."
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "nicians (secondary palliative care) may be consulted 2. As overall illness progresses, major decisions are"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "to collaboratively care for patients and their families increasingly made regarding the initiation, con-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "with more challenging needs.7 Barriers to the receipt tinued use, and discontinuation of potentially"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "of palliative care include reluctance of health care pro- life-sustaining therapies, including intravenous ino-"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "fessionals to address death and dying and a propen- tropes, ICDs, MCS, and renal replacement therapy."
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "sity for patients and caregivers to equate palliation and Dependence on, and deactivation of, potentially"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "hospice as hastening death.15 life-sustaining therapies should be anticipated and"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 88,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e983"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Table 32. Palliative and Supportive Care Domains to Improve Processes of Care and Patient Outcomes"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Palliative and Supportive"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Domains of Care What Palliative Care Adds to Overall HF Management"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "High-quality communication Central to palliative care approaches are communication and patient-caregiver engagement techniques.16"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Conveyance of prognosis Palliative care specifically addresses patient and caregiver understanding of disease, treatment, and prognosis. Research"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "suggests that patients tend to overestimate their survival17 and overestimate the potential benefits of treatment.18 Objective"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "risk models can calibrate expectations, but discussion of uncertainty should accompany prognostic conversations, often sum-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "marized as “hope for the best, plan for the worst.”"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Clarifying goals of care Management of patients with HF as their disease becomes end-stage and death seems near includes decisions about"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "when to discontinue treatments designed primarily to prolong life (eg, ICD, hospitalization, tube feeding), decisions on"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "when to initiate treatments to reduce pain and suffering that may hasten death (eg, narcotics), and decisions about the"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "location of death, home services, and hospice care. Exploring patients’ expressed preferences, values, needs, concerns,"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "means and desires through clinician-led discussion can clarify values-treatment concordance and improve medical deci-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "sion-making.12"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Shared decision-making Shared decision-making is a process by which patients and clinicians work together to make optimal health care"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "decisions from medically reasonable options that align with what matters most to patients. Shared decision-making re-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "quires: unbiased medical evidence about the risks, benefits, and burdens of each alternative, including no intervention;"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "clinician expertise in communication and tailoring that evidence for individual patients; and patient goals and informed"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "preferences.12"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Symptom management Dyspnea, fatigue, pain, nausea, depression, anxiety, and other symptoms of HF refractory to cardiovascular therapies can be"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "partially remediated through palliative and supportive approaches in addition to GDMT.5"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Caregiver support Care of the patient with heart failure should extend to their loved ones, including beyond their death, to offer support to fami-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "lies and help them cope with loss."
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "GDMT indicates guideline-directed medical therapy; HF, heart failure; and ICD, implantable cardioverter-defibrillator."
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "discussed at the time of initiation and reconsidered 4. Advance care planning is a process that sup-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "serially with changing medical realities and evolv- ports understanding and sharing of patients’ per-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "ing goals of care.12 Patients have a right to decline sonal values, life goals, and preferences regarding"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "or withdraw care at any time, consistent with the future medical care. Key domains include discuss-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "principle of respect for autonomy.19 Failure to pro- ing patients’ values, documenting plans for medi-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "actively address topics such as deactivation of ICD cal treatments, designating a surrogate decision"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "and LVAD therapies can lead to suffering at the maker, and revisiting this process over time.24"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "end of life.2,3 Familiarity with local and state laws is needed relat-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "ing to advance care planning, decisions regarding"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "3. Although a range of clinicians caring for patients"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "life-sustaining treatments, and evolving treatments"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "with HF are able to manage many palliative care"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "with legal ramifications, especially when caring for"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "needs, formal palliative care consultation may"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "vulnerable populations.19 Few patients with HF"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "be particularly helpful for patients with these: 1)"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "have formally defined their care goals and desig-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "refractory symptoms; 2) major medical decisions"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "nated a surrogate decision maker.25"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "(eg, in the United States, inclusion of a palliative"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "5. Hospice is a specific model of subspecialty pallia-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "care specialist on the team is mandatory for pay-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "tive care that is offered to patients with a terminal"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "ment from Medicare for LVAD implantation); and 3)"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "disease who are at the end of life when curative"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "multimorbidity, frailty, or cognitive impairment (mul-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "or life-prolonging therapy is no longer the focus"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "tiple validated frailty and cognitive measures are"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "of treatment.10 Historically, hospice use has been"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "available). A growing body of evidence supports"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "low among patients dying with HF and, among"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "the inclusion of specialty palliative care into the"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "those engaging in hospice, the duration of time in"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "management of patients diagnosed with a range"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "hospice was short, suggesting late referral. Low"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "of advanced diseases,20 including HF. An interdis-"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "hospice referral rates and high-intensity care at"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "ciplinary palliative care intervention in patients with"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "end of life often reflects health care professional"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "advanced HF showed greater benefits in QOL, biases and limitations in models of care rather than"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "anxiety, depression, and spiritual well-being com- patient values.26 This appears to be changing in"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "pared with usual care alone (PAL-HF [Palliative the United States, where CDC data from 2003 to"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Care in Heart Failure]).4 However, other trials have 2017 on US site of death show that the proportion"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "been mixed,5,6 and many negative,21–23 such that of cardiovascular deaths related to HF occurring"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "formal palliative care interventions should be tai- in hospice facilities rose from 0.2% to 8.2% and"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "lored to patient and caregiver wants and needs. deaths at home rose from 20.6% to 30.7%.27"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 89,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 89,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Palliative and Supportive Domains of Care": "High-quality communication",
                "What Palliative Care Adds to Overall HF Management": "Central to palliative care approaches are communication and patient-caregiver engagement techniques.16"
            },
            {
                "Palliative and Supportive Domains of Care": "Conveyance of prognosis",
                "What Palliative Care Adds to Overall HF Management": "Palliative care specifically addresses patient and caregiver understanding of disease, treatment, and prognosis. Research suggests that patients tend to overestimate their survival17 and overestimate the potential benefits of treatment.18 Objective risk models can calibrate expectations, but discussion of uncertainty should accompany prognostic conversations, often sum- marized as “hope for the best, plan for the worst.”"
            },
            {
                "Palliative and Supportive Domains of Care": "Clarifying goals of care",
                "What Palliative Care Adds to Overall HF Management": "Management of patients with HF as their disease becomes end-stage and death seems near includes decisions about when to discontinue treatments designed primarily to prolong life (eg, ICD, hospitalization, tube feeding), decisions on when to initiate treatments to reduce pain and suffering that may hasten death (eg, narcotics), and decisions about the location of death, home services, and hospice care. Exploring patients’ expressed preferences, values, needs, concerns, means and desires through clinician-led discussion can clarify values-treatment concordance and improve medical deci- sion-making.12"
            },
            {
                "Palliative and Supportive Domains of Care": "Shared decision-making",
                "What Palliative Care Adds to Overall HF Management": "Shared decision-making is a process by which patients and clinicians work together to make optimal health care decisions from medically reasonable options that align with what matters most to patients. Shared decision-making re- quires: unbiased medical evidence about the risks, benefits, and burdens of each alternative, including no intervention; clinician expertise in communication and tailoring that evidence for individual patients; and patient goals and informed preferences.12"
            },
            {
                "Palliative and Supportive Domains of Care": "Symptom management",
                "What Palliative Care Adds to Overall HF Management": "Dyspnea, fatigue, pain, nausea, depression, anxiety, and other symptoms of HF refractory to cardiovascular therapies can be partially remediated through palliative and supportive approaches in addition to GDMT.5"
            },
            {
                "Palliative and Supportive Domains of Care": "Caregiver support",
                "What Palliative Care Adds to Overall HF Management": "Care of the patient with heart failure should extend to their loved ones, including beyond their death, to offer support to fami- lies and help them cope with loss."
            }
        ],
        "conteudo_texto": "High-quality communication, Central to palliative care approaches are communication and patient-caregiver engagement techniques.16 | Conveyance of prognosis, Palliative care specifically addresses patient and caregiver understanding of disease, treatment, and prognosis. Research suggests that patients tend to overestimate their survival17 and overestimate the potential benefits of treatment.18 Objective risk models can calibrate expectations, but discussion of uncertainty should accompany prognostic conversations, often sum- marized as “hope for the best, plan for the worst.” | Clarifying goals of care, Management of patients with HF as their disease becomes end-stage and death seems near includes decisions about when to discontinue treatments designed primarily to prolong life (eg, ICD, hospitalization, tube feeding), decisions on when to initiate treatments to reduce pain and suffering that may hasten death (eg, narcotics), and decisions about the location of death, home services, and hospice care. Exploring patients’ expressed preferences, values, needs, concerns, means and desires through clinician-led discussion can clarify values-treatment concordance and improve medical deci- sion-making.12 | Shared decision-making, Shared decision-making is a process by which patients and clinicians work together to make optimal health care decisions from medically reasonable options that align with what matters most to patients. Shared decision-making re- quires: unbiased medical evidence about the risks, benefits, and burdens of each alternative, including no intervention; clinician expertise in communication and tailoring that evidence for individual patients; and patient goals and informed preferences.12 | Symptom management, Dyspnea, fatigue, pain, nausea, depression, anxiety, and other symptoms of HF refractory to cardiovascular therapies can be partially remediated through palliative and supportive approaches in addition to GDMT.5 | Caregiver support, Care of the patient with heart failure should extend to their loved ones, including beyond their death, to offer support to fami- lies and help them cope with loss."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "e984 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Table 33. Evidence Gaps and Future Research Directions"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Definition"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Consensus on specific classifications of HFrEF, HFpEF, HFmrEF, and HFimpEF or whether a 2-category definition of HFrEF and HF with normal EF, or an addi-"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "tional category of HFimpEF is needed separately for HFpEF; and whether these approaches can be uniformly applied to clinical trials and practice."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Definitions, detection, and management of myocarditis and myocardial injury, especially in the context of rapidly evolving concepts, such as COVID-19 infection"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "and cardiotoxicity."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Definition and classification of cardiomyopathies."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Screening"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Cost-effectiveness of different strategies to screen for HF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Prediction of higher risk for HF among patients with traditional risk factors (eg, which patients with diabetes would be at a higher risk HF, warranting preventive"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "treatment for HF)."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Diagnostics and monitoring"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Individualized treatment targeting specific causes."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Advanced role of precision medicine with incorporation of genetic, personalized, and individualized factors in medical management of HF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "High-value methods to use biomarkers in the optimization of medical therapy."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Ability to use integrated systems biology models, including biomarkers, molecular markers, omics, diagnostic modalities, and genetic variables for diagnosis,"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "prognosis, and targeting therapies."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Ability to monitor and adjust therapy to individual changes over time."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Nonmedical strategies"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of specific dietary interventions, sodium restriction, and fluid restriction to prevent and treat HF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of cardiac rehabilitation in patients with HFpEF and HFmrEF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Medical therapies"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Effective management strategies for patients with HFpEF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Evidence for specific treatment strategies for HFmrEF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Research on causes and targeted therapies for cardiomyopathies such as peripartum cardiomyopathy."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Treatment of asymptomatic LV dysfunction to prevent transition to symptomatic HF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Therapies targeting different phenotypes of HF; patients with advanced HF, persistent congestion, patients with profiles excluded from clinical trials such as"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "those with advanced kidney failure or hypotension."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Studies on targets for optimal decongestion; treatment and prevention of cardiorenal syndrome and diuretic resistance."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Diagnostic and management strategies of RV failure."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of hydralazine isosorbide in non–African American patients with HF and also in African American patients on GDMT including SGLT2i and ARNi."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of vericiguat in patients with HFrEF and markedly elevated natriuretic peptide levels."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of omecamtiv mecarbil in patients with stage D (advanced HF) HFrEF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Additional efficacy and safety of SGLT2i therapies in patients with HFpEF or patients with HFmrEF, efficacy and safety of combined SGLT2i and SGLT1i in"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "HFrEF, HFmrEF, or HFpEF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Additional efficacy and safety of SGLT2i studies in hospitalized patients with acute decompensated HF with and without diabetes."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of nonsteroidal, selective MRA in patients with HF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of ARNi in pre-HF stage (stage B)."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Effective management strategies for combined post- and precapillary pulmonary hypertension."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Novel treatments for ATTR cardiomyopathy."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Treatment strategies targeting downstream processes such as fibrosis, cardiac metabolism or contractile performance in dilated cardiomyopathies and HFpEF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Comparative effectiveness and safety of different initiation and titration of GDMT at the same time or in different sequences, optimal strategies for sequencing"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "and titration of therapies for HFrEF and HFpEF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Studies on prediction of patient response; studies on how to incorporate patient preferences."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of optimal BP target in patients with established HF and hypertension."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Optimal BP target while optimizing GDMT in patients with HFrEF and HFpEF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Appropriate management of electrolyte abnormalities in HF (eg, hyperkalemia or hypokalemia)."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Role of potassium binders in optimization of GDMT and clinical outcomes in patients with HF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of pirfenidone and other targeted treatment strategies for maladaptive fibrosis in patients with HFpEF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "AF risk in patients treated with PUFA for patients at risk for HF or with HF."
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "(Continued )"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 90,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 90,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Definition": "Consensus on specific classifications of HFrEF, HFpEF, HFmrEF, and HFimpEF or whether a 2-category definition of HFrEF and HF with normal EF, or an addi- tional category of HFimpEF is needed separately for HFpEF; and whether these approaches can be uniformly applied to clinical trials and practice."
            },
            {
                "Definition": "Definitions, detection, and management of myocarditis and myocardial injury, especially in the context of rapidly evolving concepts, such as COVID-19 infection and cardiotoxicity."
            },
            {
                "Definition": "Definition and classification of cardiomyopathies."
            },
            {
                "Definition": "Screening"
            },
            {
                "Definition": "Cost-effectiveness of different strategies to screen for HF."
            },
            {
                "Definition": "Prediction of higher risk for HF among patients with traditional risk factors (eg, which patients with diabetes would be at a higher risk HF, warranting preventive treatment for HF)."
            },
            {
                "Definition": "Diagnostics and monitoring"
            },
            {
                "Definition": "Individualized treatment targeting specific causes."
            },
            {
                "Definition": "Advanced role of precision medicine with incorporation of genetic, personalized, and individualized factors in medical management of HF."
            },
            {
                "Definition": "High-value methods to use biomarkers in the optimization of medical therapy."
            },
            {
                "Definition": "Ability to use integrated systems biology models, including biomarkers, molecular markers, omics, diagnostic modalities, and genetic variables for diagnosis, prognosis, and targeting therapies."
            },
            {
                "Definition": "Ability to monitor and adjust therapy to individual changes over time."
            },
            {
                "Definition": "Nonmedical strategies"
            },
            {
                "Definition": "Efficacy and safety of specific dietary interventions, sodium restriction, and fluid restriction to prevent and treat HF."
            },
            {
                "Definition": "Efficacy and safety of cardiac rehabilitation in patients with HFpEF and HFmrEF."
            },
            {
                "Definition": "Medical therapies"
            },
            {
                "Definition": "Effective management strategies for patients with HFpEF."
            },
            {
                "Definition": "Evidence for specific treatment strategies for HFmrEF."
            },
            {
                "Definition": "Research on causes and targeted therapies for cardiomyopathies such as peripartum cardiomyopathy."
            },
            {
                "Definition": "Treatment of asymptomatic LV dysfunction to prevent transition to symptomatic HF."
            },
            {
                "Definition": "Therapies targeting different phenotypes of HF; patients with advanced HF, persistent congestion, patients with profiles excluded from clinical trials such as those with advanced kidney failure or hypotension."
            },
            {
                "Definition": "Studies on targets for optimal decongestion; treatment and prevention of cardiorenal syndrome and diuretic resistance."
            },
            {
                "Definition": "Diagnostic and management strategies of RV failure."
            },
            {
                "Definition": "Efficacy and safety of hydralazine isosorbide in non–African American patients with HF and also in African American patients on GDMT including SGLT2i and ARNi."
            },
            {
                "Definition": "Efficacy and safety of vericiguat in patients with HFrEF and markedly elevated natriuretic peptide levels."
            },
            {
                "Definition": "Efficacy and safety of omecamtiv mecarbil in patients with stage D (advanced HF) HFrEF."
            },
            {
                "Definition": "Additional efficacy and safety of SGLT2i therapies in patients with HFpEF or patients with HFmrEF, efficacy and safety of combined SGLT2i and SGLT1i in HFrEF, HFmrEF, or HFpEF."
            },
            {
                "Definition": "Additional efficacy and safety of SGLT2i studies in hospitalized patients with acute decompensated HF with and without diabetes."
            },
            {
                "Definition": "Efficacy and safety of nonsteroidal, selective MRA in patients with HF."
            },
            {
                "Definition": "Efficacy and safety of ARNi in pre-HF stage (stage B)."
            },
            {
                "Definition": "Effective management strategies for combined post- and precapillary pulmonary hypertension."
            },
            {
                "Definition": "Novel treatments for ATTR cardiomyopathy."
            },
            {
                "Definition": "Treatment strategies targeting downstream processes such as fibrosis, cardiac metabolism or contractile performance in dilated cardiomyopathies and HFpEF."
            },
            {
                "Definition": "Comparative effectiveness and safety of different initiation and titration of GDMT at the same time or in different sequences, optimal strategies for sequencing and titration of therapies for HFrEF and HFpEF."
            },
            {
                "Definition": "Studies on prediction of patient response; studies on how to incorporate patient preferences."
            },
            {
                "Definition": "Efficacy and safety of optimal BP target in patients with established HF and hypertension."
            },
            {
                "Definition": "Optimal BP target while optimizing GDMT in patients with HFrEF and HFpEF."
            },
            {
                "Definition": "Appropriate management of electrolyte abnormalities in HF (eg, hyperkalemia or hypokalemia)."
            },
            {
                "Definition": "Role of potassium binders in optimization of GDMT and clinical outcomes in patients with HF."
            },
            {
                "Definition": "Efficacy and safety of pirfenidone and other targeted treatment strategies for maladaptive fibrosis in patients with HFpEF."
            },
            {
                "Definition": "AF risk in patients treated with PUFA for patients at risk for HF or with HF."
            }
        ],
        "conteudo_texto": "Consensus on specific classifications of HFrEF, HFpEF, HFmrEF, and HFimpEF or whether a 2-category definition of HFrEF and HF with normal EF, or an addi- tional category of HFimpEF is needed separately for HFpEF; and whether these approaches can be uniformly applied to clinical trials and practice. | Definitions, detection, and management of myocarditis and myocardial injury, especially in the context of rapidly evolving concepts, such as COVID-19 infection and cardiotoxicity. | Definition and classification of cardiomyopathies. | Screening | Cost-effectiveness of different strategies to screen for HF. | Prediction of higher risk for HF among patients with traditional risk factors (eg, which patients with diabetes would be at a higher risk HF, warranting preventive treatment for HF). | Diagnostics and monitoring | Individualized treatment targeting specific causes. | Advanced role of precision medicine with incorporation of genetic, personalized, and individualized factors in medical management of HF. | High-value methods to use biomarkers in the optimization of medical therapy. | Ability to use integrated systems biology models, including biomarkers, molecular markers, omics, diagnostic modalities, and genetic variables for diagnosis, prognosis, and targeting therapies. | Ability to monitor and adjust therapy to individual changes over time. | Nonmedical strategies | Efficacy and safety of specific dietary interventions, sodium restriction, and fluid restriction to prevent and treat HF. | Efficacy and safety of cardiac rehabilitation in patients with HFpEF and HFmrEF. | Medical therapies | Effective management strategies for patients with HFpEF. | Evidence for specific treatment strategies for HFmrEF. | Research on causes and targeted therapies for cardiomyopathies such as peripartum cardiomyopathy. | Treatment of asymptomatic LV dysfunction to prevent transition to symptomatic HF. | Therapies targeting different phenotypes of HF; patients with advanced HF, persistent congestion, patients with profiles excluded from clinical trials such as those with advanced kidney failure or hypotension. | Studies on targets for optimal decongestion; treatment and prevention of cardiorenal syndrome and diuretic resistance. | Diagnostic and management strategies of RV failure. | Efficacy and safety of hydralazine isosorbide in non–African American patients with HF and also in African American patients on GDMT including SGLT2i and ARNi. | Efficacy and safety of vericiguat in patients with HFrEF and markedly elevated natriuretic peptide levels. | Efficacy and safety of omecamtiv mecarbil in patients with stage D (advanced HF) HFrEF. | Additional efficacy and safety of SGLT2i therapies in patients with HFpEF or patients with HFmrEF, efficacy and safety of combined SGLT2i and SGLT1i in HFrEF, HFmrEF, or HFpEF. | Additional efficacy and safety of SGLT2i studies in hospitalized patients with acute decompensated HF with and without diabetes. | Efficacy and safety of nonsteroidal, selective MRA in patients with HF. | Efficacy and safety of ARNi in pre-HF stage (stage B). | Effective management strategies for combined post- and precapillary pulmonary hypertension. | Novel treatments for ATTR cardiomyopathy. | Treatment strategies targeting downstream processes such as fibrosis, cardiac metabolism or contractile performance in dilated cardiomyopathies and HFpEF. | Comparative effectiveness and safety of different initiation and titration of GDMT at the same time or in different sequences, optimal strategies for sequencing and titration of therapies for HFrEF and HFpEF. | Studies on prediction of patient response; studies on how to incorporate patient preferences. | Efficacy and safety of optimal BP target in patients with established HF and hypertension. | Optimal BP target while optimizing GDMT in patients with HFrEF and HFpEF. | Appropriate management of electrolyte abnormalities in HF (eg, hyperkalemia or hypokalemia). | Role of potassium binders in optimization of GDMT and clinical outcomes in patients with HF. | Efficacy and safety of pirfenidone and other targeted treatment strategies for maladaptive fibrosis in patients with HFpEF. | AF risk in patients treated with PUFA for patients at risk for HF or with HF."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e985"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Table 33. Continued"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Device management and advanced therapies"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Optimal and timely selection of candidates for percutaneous interventions, MCS, or cardiac transplantation."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Interventional approaches to recurrent, life-threatening ventricular tachyarrhythmias."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Comparative effectiveness of His-bundle pacing or multisite pacing to prevent progression of HF."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Safety and efficacy of cardiac contractility modulation, vagal nerve stimulation, autonomic modulation, and renal denervation in patients with HF."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Safety and efficacy of splanchnic nerve ablation splanchnic nerve ablation to reduce splanchnic vasoconstriction and volume redistribution in HF."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Safety and efficacy of interatrial shunt, pericardiectomy, baroreceptor and neuromodulation, and renal denervation in HFpEF."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Safety and efficacy of percutaneous or surgical interventions for tricuspid regurgitation."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Clinical outcomes"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Impact of therapies in patient-reported outcomes, including symptoms and QOL."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Studies addressing patient goals about care and care intensity as it intersects with disease trajectory."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Real-world evidence data to characterize generalization of therapies in HF populations who may not have been represented in trials."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Systems of care and social determinants of health"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Implementation studies on how to develop a structured approach to patient participation in informed decision-making and goal setting through the continuum of"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "HF care."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Implementation science for adoption and optimization of GDMT by clinicians on how to initiate multiple or sequenced GDMT, how to integrate these into learning"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "health systems and networks, and how to increase patient education and adherence."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Pragmatic studies on multidisciplinary new care models (eg, cardiac teams for structural and valve management, shock teams, cardiometabolic clinics, telemedi-"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "cine, digital health, cardiac rehabilitation at home or postdischarge, and palliative care)."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Studies on strategies to eliminate structural racism, disparities, and health inequities in HF care."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Studies addressing evidence gaps in women, racial, and ethnic populations."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Management strategies for palliative care."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Identification of factors that lead to unwarranted variations in HF care."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Identify characteristics of systems of care (eg, disciplines and staffing, electronic health records, and models of care) that optimize GDMT before and after the"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "discharge of hospitalized patients."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Comorbidities"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Further studies on rhythm control versus ablation in AF."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Appropriate patient selection in evolving percutaneous approaches in VHD (eg, timing and appropriate patient selection for TAVI, Mitraclip, tricuspid valve inter-"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "ventions)."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Effective and safe treatment options in CKD, sleep-disordered breathing, chronic lung disease, diabetes, depression, cognitive disorders, and iron deficiency."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of transvenous stimulation of the phrenic nerve or role of nocturnal supplemental oxygen for treatment of central sleep apnea in"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "patients with HF."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of weight loss management and treatment strategies in patients with HF and obesity."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of nutritional and food supplementation in patients with HF and frailty and malnutrition."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Efficacy and safety of GDMT in end-stage renal disease or in patients with eGFR <30 mL/min/1.73 m2."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Future/novel strategies"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Pharmacological therapies targeting novel pathways and endophenotypes."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "New device therapies, including percutaneous and durable mechanical support devices."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Invasive (eg, pulmonary artery pressure monitoring catheter) or noninvasive remote monitoring."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Studies on telehealth, digital health, apps, wearables technology, and artificial intelligence."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Role of enrichment trials, adaptive trials, umbrella trials, basket trials, and machine learning–based trials."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Therapies targeting multiple cardiovascular, cardiometabolic, renovascular, and pathobiological mechanisms."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Novel dissemination and implementation techniques to identify patients with HF (eg, natural language processing of electronic health records and automated"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "analysis of cardiac imaging data) and to test and monitor proven interventions."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "AF indicates atrial fibrillation; ARNi, angiotensin receptor-neprilysin inhibitor; ATTR, transthyretin amyloidosis; BP, blood pressure; CKD, chronic kidney disease;"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; GDMT, guideline-directed medical therapy; HF, heart failure; HFimpEF, heart failure"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "with improved ejection fraction; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "with reduced ejection fraction; LV, left ventricular; MCS, mechanical circulatory support; MRA, mineralocorticoid receptor antagonist; PUFA, polyunsaturated fatty"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "acid; QOL, quality of life; RV, right ventricular; SGLT1i, sodium-glucose cotransporter-1 inhibitors; SGLT2i, sodium-glucose cotransporter-2 inhibitors; TAVI, transcath-"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "eter aortic valve implantation; and VHD, valvular heart disease."
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 91,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 91,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Device management and advanced therapies": "Optimal and timely selection of candidates for percutaneous interventions, MCS, or cardiac transplantation."
            },
            {
                "Device management and advanced therapies": "Interventional approaches to recurrent, life-threatening ventricular tachyarrhythmias."
            },
            {
                "Device management and advanced therapies": "Comparative effectiveness of His-bundle pacing or multisite pacing to prevent progression of HF."
            },
            {
                "Device management and advanced therapies": "Safety and efficacy of cardiac contractility modulation, vagal nerve stimulation, autonomic modulation, and renal denervation in patients with HF."
            },
            {
                "Device management and advanced therapies": "Safety and efficacy of splanchnic nerve ablation splanchnic nerve ablation to reduce splanchnic vasoconstriction and volume redistribution in HF."
            },
            {
                "Device management and advanced therapies": "Safety and efficacy of interatrial shunt, pericardiectomy, baroreceptor and neuromodulation, and renal denervation in HFpEF."
            },
            {
                "Device management and advanced therapies": "Safety and efficacy of percutaneous or surgical interventions for tricuspid regurgitation."
            },
            {
                "Device management and advanced therapies": "Clinical outcomes"
            },
            {
                "Device management and advanced therapies": "Impact of therapies in patient-reported outcomes, including symptoms and QOL."
            },
            {
                "Device management and advanced therapies": "Studies addressing patient goals about care and care intensity as it intersects with disease trajectory."
            },
            {
                "Device management and advanced therapies": "Real-world evidence data to characterize generalization of therapies in HF populations who may not have been represented in trials."
            },
            {
                "Device management and advanced therapies": "Systems of care and social determinants of health"
            },
            {
                "Device management and advanced therapies": "Implementation studies on how to develop a structured approach to patient participation in informed decision-making and goal setting through the continuum of HF care."
            },
            {
                "Device management and advanced therapies": "Implementation science for adoption and optimization of GDMT by clinicians on how to initiate multiple or sequenced GDMT, how to integrate these into learning health systems and networks, and how to increase patient education and adherence."
            },
            {
                "Device management and advanced therapies": "Pragmatic studies on multidisciplinary new care models (eg, cardiac teams for structural and valve management, shock teams, cardiometabolic clinics, telemedi- cine, digital health, cardiac rehabilitation at home or postdischarge, and palliative care)."
            },
            {
                "Device management and advanced therapies": "Studies on strategies to eliminate structural racism, disparities, and health inequities in HF care."
            },
            {
                "Device management and advanced therapies": "Studies addressing evidence gaps in women, racial, and ethnic populations."
            },
            {
                "Device management and advanced therapies": "Management strategies for palliative care."
            },
            {
                "Device management and advanced therapies": "Identification of factors that lead to unwarranted variations in HF care."
            },
            {
                "Device management and advanced therapies": "Identify characteristics of systems of care (eg, disciplines and staffing, electronic health records, and models of care) that optimize GDMT before and after the discharge of hospitalized patients."
            },
            {
                "Device management and advanced therapies": "Comorbidities"
            },
            {
                "Device management and advanced therapies": "Further studies on rhythm control versus ablation in AF."
            },
            {
                "Device management and advanced therapies": "Appropriate patient selection in evolving percutaneous approaches in VHD (eg, timing and appropriate patient selection for TAVI, Mitraclip, tricuspid valve inter- ventions)."
            },
            {
                "Device management and advanced therapies": "Effective and safe treatment options in CKD, sleep-disordered breathing, chronic lung disease, diabetes, depression, cognitive disorders, and iron deficiency."
            },
            {
                "Device management and advanced therapies": "Efficacy and safety of transvenous stimulation of the phrenic nerve or role of nocturnal supplemental oxygen for treatment of central sleep apnea in patients with HF."
            },
            {
                "Device management and advanced therapies": "Efficacy and safety of weight loss management and treatment strategies in patients with HF and obesity."
            },
            {
                "Device management and advanced therapies": "Efficacy and safety of nutritional and food supplementation in patients with HF and frailty and malnutrition."
            },
            {
                "Device management and advanced therapies": "Efficacy and safety of GDMT in end-stage renal disease or in patients with eGFR <30 mL/min/1.73 m2."
            },
            {
                "Device management and advanced therapies": "Future/novel strategies"
            },
            {
                "Device management and advanced therapies": "Pharmacological therapies targeting novel pathways and endophenotypes."
            },
            {
                "Device management and advanced therapies": "New device therapies, including percutaneous and durable mechanical support devices."
            },
            {
                "Device management and advanced therapies": "Invasive (eg, pulmonary artery pressure monitoring catheter) or noninvasive remote monitoring."
            },
            {
                "Device management and advanced therapies": "Studies on telehealth, digital health, apps, wearables technology, and artificial intelligence."
            },
            {
                "Device management and advanced therapies": "Role of enrichment trials, adaptive trials, umbrella trials, basket trials, and machine learning–based trials."
            },
            {
                "Device management and advanced therapies": "Therapies targeting multiple cardiovascular, cardiometabolic, renovascular, and pathobiological mechanisms."
            },
            {
                "Device management and advanced therapies": "Novel dissemination and implementation techniques to identify patients with HF (eg, natural language processing of electronic health records and automated analysis of cardiac imaging data) and to test and monitor proven interventions."
            }
        ],
        "conteudo_texto": "Optimal and timely selection of candidates for percutaneous interventions, MCS, or cardiac transplantation. | Interventional approaches to recurrent, life-threatening ventricular tachyarrhythmias. | Comparative effectiveness of His-bundle pacing or multisite pacing to prevent progression of HF. | Safety and efficacy of cardiac contractility modulation, vagal nerve stimulation, autonomic modulation, and renal denervation in patients with HF. | Safety and efficacy of splanchnic nerve ablation splanchnic nerve ablation to reduce splanchnic vasoconstriction and volume redistribution in HF. | Safety and efficacy of interatrial shunt, pericardiectomy, baroreceptor and neuromodulation, and renal denervation in HFpEF. | Safety and efficacy of percutaneous or surgical interventions for tricuspid regurgitation. | Clinical outcomes | Impact of therapies in patient-reported outcomes, including symptoms and QOL. | Studies addressing patient goals about care and care intensity as it intersects with disease trajectory. | Real-world evidence data to characterize generalization of therapies in HF populations who may not have been represented in trials. | Systems of care and social determinants of health | Implementation studies on how to develop a structured approach to patient participation in informed decision-making and goal setting through the continuum of HF care. | Implementation science for adoption and optimization of GDMT by clinicians on how to initiate multiple or sequenced GDMT, how to integrate these into learning health systems and networks, and how to increase patient education and adherence. | Pragmatic studies on multidisciplinary new care models (eg, cardiac teams for structural and valve management, shock teams, cardiometabolic clinics, telemedi- cine, digital health, cardiac rehabilitation at home or postdischarge, and palliative care). | Studies on strategies to eliminate structural racism, disparities, and health inequities in HF care. | Studies addressing evidence gaps in women, racial, and ethnic populations. | Management strategies for palliative care. | Identification of factors that lead to unwarranted variations in HF care. | Identify characteristics of systems of care (eg, disciplines and staffing, electronic health records, and models of care) that optimize GDMT before and after the discharge of hospitalized patients. | Comorbidities | Further studies on rhythm control versus ablation in AF. | Appropriate patient selection in evolving percutaneous approaches in VHD (eg, timing and appropriate patient selection for TAVI, Mitraclip, tricuspid valve inter- ventions). | Effective and safe treatment options in CKD, sleep-disordered breathing, chronic lung disease, diabetes, depression, cognitive disorders, and iron deficiency. | Efficacy and safety of transvenous stimulation of the phrenic nerve or role of nocturnal supplemental oxygen for treatment of central sleep apnea in patients with HF. | Efficacy and safety of weight loss management and treatment strategies in patients with HF and obesity. | Efficacy and safety of nutritional and food supplementation in patients with HF and frailty and malnutrition. | Efficacy and safety of GDMT in end-stage renal disease or in patients with eGFR <30 mL/min/1.73 m2. | Future/novel strategies | Pharmacological therapies targeting novel pathways and endophenotypes. | New device therapies, including percutaneous and durable mechanical support devices. | Invasive (eg, pulmonary artery pressure monitoring catheter) or noninvasive remote monitoring. | Studies on telehealth, digital health, apps, wearables technology, and artificial intelligence. | Role of enrichment trials, adaptive trials, umbrella trials, basket trials, and machine learning–based trials. | Therapies targeting multiple cardiovascular, cardiometabolic, renovascular, and pathobiological mechanisms. | Novel dissemination and implementation techniques to identify patients with HF (eg, natural language processing of electronic health records and automated analysis of cardiac imaging data) and to test and monitor proven interventions."
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "e986 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "14. RECOMMENDATION FOR PATIENT- disease status and more responsive to HF therapy"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "than generic health status measures.1 Although"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "REPORTED OUTCOMES AND EVIDENCE"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "select clinics have successfully implemented"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "GAPS AND FUTURE RESEARCH"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "patient-reported health status in clinical practice,23"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "DIRECTIONS there are minimal data regarding the impact of such"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "efforts. However, there are potential advantages to"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "14.1. Patient-Reported Outcomes"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "routine assessment. First, better understanding of"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Recommendation for Patient-Reported Outcomes symptom burden and prognosis may improve the"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "quality of treatment decisions and, subsequently,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "COR LOE Recommendation"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "QOL. Health status can be improved via guide-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "1. In patients with HF, standardized assessment"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "of patient-reported health status using a vali- line-recommended therapies.24–31 Although some"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "2a C-LD dated questionnaire can be useful to provide therapies are recommended for mortality benefit,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "incremental information for patient functional"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "symptom assessment can identify patients need-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "status, symptom burden, and prognosis.1–19"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "ing additional interventions (eg, diuretic escala-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "tion). Second, routine assessment can facilitate"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Synopsis"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "population health management by identifying high-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Health status encapsulates symptoms, functional status, risk patients needing closer monitoring or refer-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "and health-related QOL. Understanding health status is ral to specialized centers. Third, patient-reported"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "important for treatment decisions and counseling. Clini- health status assessment increases the patient’s"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "cians traditionally evaluate health status based on the role, which can motivate initiation and uptitration"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "clinical interview and exam, summarizing it as the NYHA of medical therapy. However, routine assessment"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "functional classification. Additionally, patient-reported of patient-reported status increases the burden"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "health status can be ascertained using standardized of data collection for patients and health systems"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "questionnaires, such as the Kansas City Cardiomyopathy and underscores the need for future studies evalu-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Questionnaire or the Minnesota Living with Heart Fail- ating the impact of assessment."
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "ure Questionnaire. Previous studies found discordance"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "between patient-reported health status and clinician as- 14.2. Evidence Gaps and Future Research"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "sessment using NYHA classification.20,21 Patient-reported Directions"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "health status may have higher reliability and better sensi-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Significant gaps exist despite evolving evidence and"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "tivity for clinical changes than NYHA classification and is"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "treatment strategies in patients with HF. Table 33 pro-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "moderately correlated with CPET and the 6-minute walk"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "vides selected, common issues that should be addressed"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "test.1–8 Patient-reported health status is an independent"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "in future clinical research."
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "predictor of hospitalization and mortality.9–19 There are"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "minimal data regarding the effect of incorporating patient-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "reported health status assessment into routine care. How- ACC/AHA JOINT COMMITTEE MEMBERS"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "ever, these assessments provide valuable incremental"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Joshua A. Beckman, MD, MS, FAHA, FACC, Chair; Pat-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "information beyond the standard evaluation. Increasing"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "rick T. O’Gara, MD, MACC, FAHA, Immediate Past Chair*;"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "the patient’s voice in clinical assessment and decision-"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Sana M. Al-Khatib, MD, MHS, FACC, FAHA*; Anastasia"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "making is important in its own right. Additionally, there is"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "L. Armbruster, PharmD, FACC; Kim K. Birtcher, PharmD,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "substantial variation in risk-adjusted health status across"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "MS, AACC*; Joaquin E. Cigarroa, MD, FACC*; Lisa de las"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "practices.22 Future efforts should focus on expanding the"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Fuentes, MD, MS, FAHA; Anita Deswal, MD, MPH, FACC,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "use of patient-reported health status in routine care while"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "FAHA; Dave L. Dixon, PharmD, FACC*; Lee A. Fleisher,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "researching its implementation and impact."
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "MD, FACC, FAHA*; Federico Gentile, MD, FACC*; Zachary"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "D. Goldberger, MD, FACC, FAHA*; Bulent Gorenek, MD,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Recommendation-Specific Supportive Text"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "FACC; Norrisa Haynes, MD, MPH; Adrian F. Hernandez,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "1. Standardized patient-reported health status ques- MD, MHS; Mark A. Hlatky, MD, FACC, FAHA*; José A."
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "tionnaires provide reliable measures of health Joglar, MD, FACC, FAHA; W. Schuyler Jones, MD, FACC;"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "status correlated to other functional status mea- Joseph E. Marine, MD, FACC*; Daniel B. Mark, MD, MPH,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "sures1–8 and independently associated with FACC, FAHA; Debabrata Mukherjee, MD, FACC, FAHA;"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "clinical outcomes.9–19 HF-specific health status Latha P. Palaniappan, MD, MS, FACC, FAHA; Mariann R."
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "assessments (eg, Kansas City Cardiomyopathy Piano, RN, PhD, FAHA; Tanveer Rab, MD, FACC; Erica S."
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Questionnaire, Minnesota Living with Heart Spatz, MD, MS, FACC; Jacqueline E. Tamis-Holland, MD,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Failure Questionnaire, PROMIS-Plus-HF [Patient- FAHA, FACC; Duminda N. Wijeysundera, MD, PhD*; Y."
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Reported Outcomes Measurement Information Joseph Woo, MD, FACC, FAHA"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "System-Plus-Heart Failure]) are preferable"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "because they are more sensitive to changes in *Former Task Force member; current member during the writing effort."
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 92,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e987"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "PRESIDENTS AND STAFF REFERENCES"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "American College of Cardiology PREAMBLE"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "1. Committee on Standards for Developing Trustworthy Clinical Practice"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Dipti N. Itchhaporia, MD, FACC, President"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Cathleen C. Gates, Chief Executive Officer Trust. National Academies Press; 2011."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "MaryAnne Elma, MPH, Senior Director, Enterprise Content 2. Committee on Standards for Systematic Reviews of Comparative Effective-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "ness Research, Institute of Medicine (US). Finding What Works in Health"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "and Digital Strategy"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Care: Standards for Systematic Reviews. National Academies Press; 2011."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Grace D. Ronan, Team Leader, Clinical Policy Publications 3. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Timothy W. Schutt, MA, Clinical Practice Guidelines cost/value methodology in clinical practice guidelines and performance"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "measures: a report of the American College of Cardiology/American Heart"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Analyst"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Association Task Force on Performance Measures and Task Force on Prac-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "tice Guidelines. Circulation. 2014;129:2329–2345."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "4. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "American College of Cardiology/American Policies From the ACCF/AHA Task Force on Practice Guidelines. American"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "College of Cardiology and American Heart Association; 2010. Accessed"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Heart Association"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "June 3, 2020. https://www.acc.org/Guidelines/About-Guidelines-and-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Clinical-Documents/Methodology and https://professional.heart.org/-/"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Thomas S.D. Getchius, Director, Guideline Strategy and"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "media/phd-files/guidelines-and-statements/methodology_manual_and_"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Operations policies_ucm_319826.pdf"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Abdul R. Abdullah, MD, Director, Guideline Science and 5. Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "AHA clinical practice guideline recommendation classification system: a re-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Methodology"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "port of the American College of Cardiology/American Heart Association"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Task Force on Clinical Practice Guidelines. Circulation. 2016;133:1426–"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "1428."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "American Heart Association 6. Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "enhance application of clinical practice guidelines in patients with cardio-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Donald M. Lloyd-Jones, MD, ScM, FAHA, President vascular disease and comorbid conditions: from the American Heart As-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Nancy Brown, Chief Executive Officer sociation, American College of Cardiology, and U.S. Department of Health"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "and Human Services. Circulation. 2014;130:1662–1667."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Mariell Jessup, MD, FAHA, Chief Science and Medical"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "7. Levine GN, O’Gara PT, Beckman JA, et al. Recent innovations, modifications,"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Officer and evolution of ACC/AHA clinical practice guidelines: an update for our"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Radhika Rajgopal Singh, PhD, Senior Vice President, constituencies: a report of the American College of Cardiology/American"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Heart Association Task Force on Clinical Practice Guidelines. Circulation."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Office of Science and Medicine"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "2019;139:e879–e886."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Paul St. Laurent, DNP, RN, Senior Science and Medicine"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Advisor, Office of Science, Medicine and Health"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "1.4. Scope of the Guideline"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Jody Hundley, Production and Operations Manager,"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Scientific Publications, Office of Science Operations 1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "management of heart failure: a report of the American College of Cardiol-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "ogy Foundation/American Heart Association Task Force on Practice Guide-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "lines. Circulation. 2013;128:e240–e327."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "ARTICLE INFORMATION 2. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "update of the 2013 ACCF/AHA guideline for the management of heart"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "This document was approved by the American College of Cardiology Clinical failure: a report of the American College of Cardiology/American Heart As-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Policy Approval Committee, the American Heart Association Science Advisory sociation Task Force on Clinical Practice Guidelines and the Heart Failure"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "and Coordinating Committee, the American College of Cardiology Science and Society of America. Circulation. 2017;136:e137–e161."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Quality Committee, and the Heart Failure Society of America Executive Commit- 3. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "tee in December 2021 and the American Heart Association Executive Commit- the primary prevention of cardiovascular disease: a report of the American"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "tee in January 2022. College of Cardiology/American Heart Association Task Force on Clinical"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Supplemental materials are available with this article at https://www.ahajournals. Practice Guidelines. Circulation. 2019;140:e596–e646."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "org/doi/suppl/10.1161/CIR.0000000000001063 4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "This article has been copublished in the Journal of the American College of management of patients with valvular heart disease: a report of the Ameri-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Cardiology and the Journal of Cardiac Failure. can College of Cardiology/American Heart Association Joint Committee on"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Copies: This document is available on the websites of the American Heart Clinical Practice Guidelines. Circulation. 2021;143:e72–e227."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Association (professional.heart.org), the American College of Cardiology (www. 5. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "acc.org), and the Heart Failure Society of America (www.hfsa.org). A copy of the guideline for coronary artery revascularization: a report of the American Col-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "document is also available at https://professional.heart.org/statements by se- lege of Cardiology/American Heart Association Joint Committee on Clinical"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "lecting the “Guidelines & Statements” button. To purchase additional reprints, call Practice Guidelines. Circulation. 2022;145:e18–e114."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "215-356-2721 or email Meredith.Edelman@wolterskluwer.com. 6. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "The expert peer review of AHA-commissioned documents (eg, scientific coronary artery bypass graft surgery. a report of the American College of"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "statements, clinical practice guidelines, systematic reviews) is conducted by the Cardiology Foundation/American Heart Association Task Force on Practice"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "AHA Office of Science Operations. For more on AHA statements and guidelines Guidelines. Developed in collaboration with the American Association for"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "development, visit https://professional.heart.org/statements. Select the “Guide- Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "lines & Statements” drop-down menu near the top of the webpage, then click of Thoracic Surgeons. Circulation. 2011;124:e652–e735."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "“Publication Development.” 7. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Permissions: Multiple copies, modification, alteration, enhancement, and/or guideline for percutaneous coronary intervention. a report of the American"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "distribution of this document are not permitted without the express permission of College of Cardiology Foundation/American Heart Association Task Force"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "the American Heart Association. Instructions for obtaining permission are located on Practice Guidelines and the Society for Cardiovascular Angiography and"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "at https://www.heart.org/permissions. A link to the “Copyright Permissions Re- Interventions. Circulation. 2011;124:e574–e651."
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "quest Form” appears in the second paragraph (https://www.heart.org/en/abou- 8. Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI fo-"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "tus/statements-and-policies/copyright-request-form). cused update on primary percutaneous coronary intervention for patients"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 93,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "e988 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "with ST-elevation myocardial infarction: an update of the 2011 ACCF/ 23. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary preven-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "AHA/SCAI guideline for percutaneous coronary intervention and the 2013 tion and risk reduction therapy for patients with coronary and other ath-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "ACCF/AHA guideline for the Management of ST-elevation myocardial in- erosclerotic vascular disease: 2011 update: a guideline from the American"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "farction. Circulation. 2016;133:1135–1147. Heart Association and American College of Cardiology Foundation. Circula-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "9. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diag- tion. 2011;124:2458–2473."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "nosis and treatment of patients with hypertrophic cardiomyopathy: a report 24. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "of the American College of Cardiology/American Heart Association Joint assessment of cardiovascular risk in asymptomatic adults: a report of"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Committee on Clinical Practice Guidelines. Circulation. 2020;142:e558– the American College of Cardiology Foundation/American Heart Asso-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "e631. ciation Task Force on Practice Guidelines. Circulation. 2010;122:e584–"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "10. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused up- e636."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "date of the 2014 AHA/ACC/HRS guideline for the management of pa- 25. Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: post-cardiac ar-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "tients with atrial fibrillation: a report of the American College of Cardiology/ rest care: 2010 American Heart Association guidelines for cardiopul-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "American Heart Association Task Force on Clinical Practice Guidelines and monary resuscitation and emergency cardiovascular care. Circulation."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "the Heart Rhythm Society. Circulation. 2019;140:e125–e151. 2010;122:S768–S786."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "11. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ 26. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint Na-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, tional Committee on prevention, detection, evaluation, and treatment of high"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "detection, evaluation, and management of high blood pressure in adults: a blood pressure. Hypertension. 2003;42:1206–1252."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "report of the American College of Cardiology/American Heart Association 27. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolv-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13– ing diagnosis and management: a scientific statement from the American"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "e115. Heart Association. Circulation. 2020;142:e7–e22."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "12. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused 28. Amsterdam EA, Kirk JD, Bluemke DA, et al. Testing of low-risk pa-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "update on new pharmacological therapy for heart failure: an update of the tients presenting to the emergency department with chest pain: a"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "2013 ACCF/AHA guideline for the management of heart failure: a report scientific statement from the American Heart Association. Circulation."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "of the American College of Cardiology/American Heart Association Task 2010;122:1756–1776."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Force on Clinical Practice Guidelines and the Heart Failure Society of Amer- 29. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovas-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "ica. Circulation. 2016;134:e282–e293. cular diseases in people with diabetes mellitus: a scientific statement from"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "13. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/ the American Heart Association and the American Diabetes Association."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "PCNA/SCAI/STS focused update of the guideline for the diagnosis and Circulation. 2007;115:114–126."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "management of patients with stable ischemic heart disease: a report of the 30. Centers for Disease Control and Prevention. Prevention and control of"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "American College of Cardiology/American Heart Association Task Force influenza: recommendations of the Advisory Committee on Immunization"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "on Practice Guidelines, and the American Association for Thoracic Surgery, Practices (ACIP). Accessed March 24, 2021. https://www.cdc.gov/mmwr/"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Preventive Cardiovascular Nurses Association, Society for Cardiovascular preview/mmwrhtml/rr5510a1.htm"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Angiography and Interventions, and Society of Thoracic Surgeons. Circula-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "tion. 2014;130:1749–1767."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "14. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on life- 1.5. Class of Recommendation and Level of Evidence"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "style management to reduce cardiovascular risk: a report of the American"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "1. ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "College of Cardiology/American Heart Association Task Force on Practice"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Policies From the ACCF/AHA Task Force on Practice Guidelines. American"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Guidelines. Circulation. 2014;129(suppl 2):S76–S99."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "College of Cardiology and American Heart Association; 2010. Accessed"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "15. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "June 3, 2020. https://www.acc.org/Guidelines/About-Guidelines-and-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "for the management of overweight and obesity in adults: a report of the"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Clinical-Documents/Methodology and https://professional.heart.org/-/"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "American College of Cardiology/American Heart Association Task Force on"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "media/phd-files/guidelines-and-statements/methodology_manual_and_"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Practice Guidelines and The Obesity Society. Circulation. 2014;129(suppl"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "policies_ucm_319826.pdf"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "2):s102–s138."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "16. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the man- 2.1. Stages of HF"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "agement of blood cholesterol: a report of the American College of Cardiol-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "ogy/American Heart Association Task Force on Clinical Practice Guidelines. 1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Circulation. 2019;139:e1082–e1143. management of heart failure: a report of the American College of Car-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "17. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guide- diology Foundation/American Heart Association Task Force on Practice"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "line on the treatment of blood cholesterol to reduce atherosclerotic car- Guidelines. Circulation. 2013;128:e240–e327."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "diovascular risk in adults: a report of the American College of Cardiology/ 2. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "American Heart Association Task Force on Practice Guidelines. Circulation. into the ACC/AHA 2005 guidelines for the diagnosis and management"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "2014;129(suppl 2):S1–S45. of heart failure in adults: a report of the American College of Cardiology"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "18. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on Foundation/American Heart Association Task Force on Practice Guidelines."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "the assessment of cardiovascular risk: a report of the American College of Developed in collaboration with the International Society for Heart and Lung"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Cardiology/American Heart Association Task Force on Practice Guidelines. Transplantation. Circulation. 2009;119:e391–e479."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Circulation. 2014;129(suppl 2):S49–S73. 3. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "19. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline significance of heart failure stages: application of the American College of"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "for the management of ST-elevation myocardial infarction: a report of the Cardiology/American Heart Association heart failure staging criteria in the"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "American College of Cardiology Foundation/American Heart Association community. Circulation. 2007;115:1563–1570."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Task Force on Practice Guidelines. Circulation.2013;127:e362–e425. 4. Goldman L, Hashimoto B, Cook EF, et al. Comparative reproducibility"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "20. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused and validity of systems for assessing cardiovascular functional class:"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "update of the 2008 guidelines for device-based therapy of cardiac rhythm advantages of a new specific activity scale. Circulation. 1981;64:1227–"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "abnormalities: a report of the American College of Cardiology Foundation/ 1234."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "American Heart Association Task Force on Practice Guidelines. Circulation. 5. Caraballo C, Desai NR, Mulder H, et al. Clinical implications of the New York"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "2012;126:1784–1800. Heart Association classification. J Am Heart Assoc. 2019;8:e014240."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "21. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ 6. Madsen BK, Hansen JF, Stokholm KH, et al. Chronic congestive heart fail-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "PCNA/SCAI/STS guideline for the diagnosis and management of patients ure: description and survival of 190 consecutive patients with a diagnosis of"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "with stable ischemic heart disease: a report of the American College of chronic congestive heart failure based on clinical signs and symptoms. Eur"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Cardiology Foundation/American Heart Association Task Force on Practice Heart J. 1994;15:303–310."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Guidelines, and the American College of Physicians, American Association 7. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Associa-"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society tion classes and increased mortality and hospitalization in patients"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "for Cardiovascular Angiography and Interventions, and Society of Thoracic with heart failure and preserved left ventricular function. Am Heart J."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Surgeons. Circulation. 2012;126:e354–e471. 2006;151:444–450."
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 94,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e989"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2.2. Classification of HF by Left Ventricular Ejection 8. Savitz ST, Leong T, Sung SH, et al. Contemporary reevaluation of"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "race and ethnicity with outcomes in heart failure. J Am Heart Assoc."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Fraction (LVEF)"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2021;10:e016601."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the 9. Rathore SS, Foody JM, Wang Y, et al. Race, quality of care, and outcomes"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "management of heart failure: a report of the American College of Cardiol- of elderly patients hospitalized with heart failure. JAMA. 2003;289:2517–"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "ogy Foundation/American Heart Association Task Force on Practice Guide- 2524."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "lines. Circulation. 2013;128:e240–e327. 10. Vivo RP, Krim SR, Liang L, et al. Short- and long-term rehospitalization and"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with pre- mortality for heart failure in 4 racial/ethnic populations. J Am Heart Assoc."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "served ejection fraction. Nat Rev Cardiol. 2017;14:591–602. 2014;3:e001134."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "3. Wilcox JE, Fang JC, Margulies KB, et al. Heart failure with recovered left"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "ventricular ejection fraction: JACC Scientific Expert Panel. J Am Coll Cardiol."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2020;76:719–734. 3.2. Cause of HF"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "4. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classifica-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "1. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statis-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "tion of heart failure: a report of the Heart Failure Society of America, Heart"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "tics–2021 update: a report from the American Heart Association. Circula-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Failure Association of the European Society of Cardiology, Japanese Heart"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "tion. 2021;143:e254–e743."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Failure Society and Writing Committee of the Universal Definition of Heart"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Failure. J Card Fail. 2021;27:387–413."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "5. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treat-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "4.1. Clinical Assessment: History and Physical"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "ment for heart failure in patients with recovered dilated cardiomyopathy"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "(TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393:61– Examination"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "73."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "1. Ambrosy AP, Pang P, Khan S, et al. Clinical course and predictive value of"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "congestion during hospitalization in patients admitted for worsening signs"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "and symptoms of heart failure with reduced ejection fraction: findings from"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2.3. Diagnostic Algorithm for Classification of HF"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "the EVEREST trial. Eur Heart J. 2013;34:835–843."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "According to LVEF 2. Selvaraj S, Claggett B, Pozzi A, et al. Prognostic implications of congestion"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "on physical examination among contemporary patients with heart failure and"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diag-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "reduced ejection fraction: PARADIGM-HF. Circulation. 2019;140:1369–"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "nosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "1379."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Ed). 2016;69:1167."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "3. Selvaraj S, Claggett B, Shah SJ, et al. Utility of the cardiovascular physical"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2. Erdei T, Smiseth OA, Marino P, et al. A systematic review of diastolic stress"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "examination and impact of spironolactone in heart failure with preserved"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "tests in heart failure with preserved ejection fraction, with proposals from"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "ejection fraction. Circ Heart Fail. 2019;12:e006125."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "the EU-FP7 MEDIA study group. Eur J Heart Fail. 2014;16:1345–1361."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "4. Caldentey G, Khairy P, Roy D, et al. Prognostic value of the physical exami-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "3. Donal E, Lund LH, Oger E, et al. Value of exercise echocardiography in heart"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "nation in patients with heart failure and atrial fibrillation: insights from the"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "failure with preserved ejection fraction: a substudy from the KaRen study."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "AF-CHF trial (atrial fibrillation and chronic heart failure). J Am Coll Cardiol"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Eur Heart J Cardiovasc Imaging. 2016;17:106–113."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "HF. 2014;2:15–23."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "4. Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics en-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "5. Simonavicius J, Sanders van-Wijk S, Rickenbacher P, et al. Prognostic sig-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "hance diagnosis of early heart failure with preserved ejection fraction. Circ"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "nificance of longitudinal clinical congestion pattern in chronic heart failure:"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Heart Fail. 2010;3:588–595."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "insights from TIME-CHF Trial. Am J Med. 2019;132:e679–e692."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "5. Reddy YNV, Carter RE, Obokata M, et al. A simple, evidence-based ap-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "6. Fudim M, Parikh KS, Dunning A, et al. Relation of volume overload to clini-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "proach to help guide diagnosis of heart failure with preserved ejection frac-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "cal outcomes in acute heart failure (from ASCEND-HF). Am J Cardiol."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "tion. Circulation. 2018;138:861–870."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2018;122:1506–1512."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "6. Sepehrvand N, Alemayehu W, Dyck GJB, et al. External validation of the"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "7. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "H2F-PEF model in diagnosing patients with heart failure and preserved"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "in chronic heart failure and the effect of treatment with angiotensin-con-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "ejection fraction. Circulation. 2019;139:2377–2379."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "verting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077– 7. Selvaraj S, Myhre PL, Vaduganathan M, et al. Application of diagnostic algo-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "1083."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "rithms for heart failure with preserved ejection fraction to the community. J"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "8. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Am Coll Cardiol HF. 2020;8:640–653."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "8. Pieske B, Tschope C, de Boer RA, et al. How to diagnose heart failure with"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "1764."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consen-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "9. Gorodeski EZ, Chu E, Reese JR, et al. Prognosis on chronic dobutamine or"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "sus recommendation from the Heart Failure Association (HFA) of the Euro-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "milrinone infusions for stage D heart failure. Circ Heart Fail. 2009;2:320–"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "pean Society of Cardiology (ESC). Eur Heart J. 2019;40:3297–3317."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "324."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "10. Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-renal lim-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "itations to angiotensin-converting enzyme inhibitors identifies patients with 3.1. Epidemiology of HF"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "severe heart failure and early mortality. J Am Coll Cardiol. 2003;41:2029–"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "1. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart 2035."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "failure in the United States: a policy statement from the American Heart 11. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibril-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Association. Circ Heart Fail. 2013;6:606–619. lator shocks in patients with heart failure. N Engl J Med. 2008;359:1009–"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statis- 1017."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "tics–2021 update: a report from the American Heart Association. Circula- 12. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations pre-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "tion. 2021;143:e254–e743. dict mortality in the community population with heart failure. Am Heart J."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "3. Ni H, Xu J. Recent trends in heart failure-related mortality: United States, 2007;154:260–266."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2000-2014. NCHS Data Brief; 2015:1–8. 13. Marume K, Noguchi T, Tateishi E, et al. Prognosis and clinical characteristics"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "4. Agarwal MA, Fonarow GC, Ziaeian B. National trends in heart failure of dilated cardiomyopathy with family history via pedigree analysis. Circ J."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "hospitalizations and readmissions from 2010 to 2017. JAMA Cardiol. 2020;84:1284–1293."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2021;6:952–956. 14. Waddell-Smith KE, Donoghue T, Oates S, et al. Inpatient detection of car-"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "5. Khera R, Kondamudi N, Zhong L, et al. Temporal trends in heart failure in- diac-inherited disease: the impact of improving family history taking. Open"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "cidence among Medicare beneficiaries across risk factor strata, 2011 to Heart. 2016;3:e000329."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2016. JAMA Netw Open. 2020;3:e2022190. 15. González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "6. Tsao CW, Lyass A, Enserro D, et al. Temporal trends in the incidence of and wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "mortality associated with heart failure with preserved and reduced ejection 2017;38:1895–1904."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "fraction. J Am Coll Cardiol HF. 2018;6:678–685. 16. Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "7. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with pre- experience survey from the Amyloidosis Research Consortium. Adv Ther."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "served ejection fraction. Nat Rev Cardiol. 2017;14:591–602. 2015;32:920–928."
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 95,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "e990 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "17. Drazner MH, Rame JE, Stevenson L, et al. Prognostic importance of el- 4.1.1. Initial Laboratory and Electrocardiographic"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "evated jugular venous pressure and a third heart sound in patients with Testing"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "heart failure. N Engl J Med. 2001;345:574–581."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "1. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracy-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "18. Drazner MH, Hellkamp AS, Leier CV, et al. Value of clinician assessment of"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "cline cardiotoxicity and improvement with heart failure therapy. Circulation."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2015;131:1981–1988."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2008;1:170–177."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "19. Thibodeau JT, Turer AT, Gualano SK, et al. Characterization of a novel"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "cardiac risk stratification of cancer patients undergoing high-dose chemo-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "symptom of advanced heart failure: bendopnea. J Am Coll Cardiol HF."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "therapy. Circulation. 2004;109:2749–2754."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2014;2:24–31."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "3. Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "20. Felker GM, Cuculich PS, Gheorghiade M. The Valsalva maneuver: a bedside"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "amyloidosis and its predictors among elderly patients with severe aortic"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "\"biomarker\" for heart failure. Am J Med. 2006;119:117–122."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "stenosis undergoing transcatheter aortic valve replacement. Eur Heart J."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "21. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolv-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2017;38:2879–2887."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "ing diagnosis and management: a scientific statement from the American"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "4. Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of trans-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "Heart Association. Circulation. 2020;142:e7–e22."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "thyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Sur-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "22. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "vey). J Am Coll Cardiol. 2016;68:161–172."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "Blood. 2020;136:2620–2627."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "5. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "23. Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular toxicity re-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "transthyretin amyloidosis. Circulation. 2016;133:2404–2412."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "lated to cancer treatment: a pragmatic approach to the American"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "6. Brown EE, Lee YZJ, Halushka MK, et al. Genetic testing improves identifi-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "and European Cardio-Oncology Guidelines. J Am Heart Assoc."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "cation of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amy-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2020;9:e018403."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "loid. 2017;24:92–95."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "24. Chang HM, Moudgil R, Scarabelli T, et al. Cardiovascular complications of"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "7. Crawford TC, Okada DR, Magruder JT, et al. A contemporary analysis of"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "cancer therapy: best practices in diagnosis, prevention, and management:"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "heart transplantation and bridge-to-transplant mechanical circulatory sup-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "part 1. J Am Coll Cardiol. 2017;70:2536–2551."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "port outcomes in cardiac sarcoidosis. J Card Fail. 2018;24:384–391."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "25. Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular complications"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "8. Wu RS, Gupta S, Brown RN, et al. Clinical outcomes after cardiac trans-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "of cancer therapy: best practices in diagnosis, prevention, and management:"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "plantation in muscular dystrophy patients. J Heart Lung Transplant."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "part 2. J Am Coll Cardiol. 2017;70:2552–2565."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2010;29:432–438."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "26. Prasad M, Hermann J, Gabriel SE, et al. Cardiorheumatology: cardiac in-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "9. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolv-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "volvement in systemic rheumatic disease. Nat Rev Cardiol. 2015;12:168–"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "ing diagnosis and management: a scientific statement from the American"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "176."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "Heart Association. Circulation. 2020;142:e7–e22."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "27. Jabbar A, Pingitore A, Pearce S, et al. Thyroid hormones and cardiovascular"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "10. Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strate-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "disease. Nat Rev Cardiol. 2017;14:39–55."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "gies for specific dilated cardiomyopathies: a scientific statement from the"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "28. Kenny HC, Abel ED. Heart failure in type 2 diabetes mellitus. Circ Res."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "American Heart Association. Circulation. 2016;134:e579–e646."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2019;124:121–141."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "11. Hendren NS, Drazner MH, Bozkurt B, et al. Description and proposed man-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "29. Zhang R, Gupta D, Albert SG. Pheochromocytoma as a reversible cause"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "agement of the acute COVID-19 cardiovascular syndrome. Circulation."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "of cardiomyopathy: analysis and review of the literature. Int J Cardiol."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2020;141:1903–1914."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2017;249:319–323."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "12. Kouranos V, Sharma R. Cardiac sarcoidosis: state-of-the-art review. Heart."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "30. Colao A, Grasso LFS, Di Somma C, et al. Acromegaly and heart failure. Heart"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2021;107:1591–1599."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "Fail Clin. 2019;15:399–408. 13. Nunes MCP, Beaton A, Acquatella H, et al. Chagas cardiomyopathy: an up-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "31. Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "date of current clinical knowledge and management: a scientific statement"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "heart failure. Prog Cardiovasc Dis. 2018;61:151–156."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "from the American Heart Association. Circulation. 2018;138:e169–e209."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "32. Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomy-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "14. Tschope C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "opathy–a Heart Failure Society of America practice guideline. J Card Fail."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "cardiomyopathy: current evidence and future directions. Nat Rev Cardiol."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2018;24:281–302."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2021;18:169–193."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "33. Huizar JF, Ellenbogen KA, Tan A, et al. Arrhythmia-induced cardiomy-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "15. Davis MB, Arany Z, McNamara D, et al. Peripartum cardiomyopathy: JACC"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "opathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:2328–"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "state-of-the-art review. J Am Coll Cardiol. 2020;75:207–221."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2344."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "34. Drazner MH. The progression of hypertensive heart disease. Circulation."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2011;123:327–334."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "35. Kouranos V, Sharma R. Cardiac sarcoidosis: state-of-the-art review. Heart. 4.2. Use of Biomarkers for Prevention, Initial Diagnosis,"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2021;107:1591–1599. and Risk Stratification"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "36. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics,"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 1. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain na-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2017;121:819–837. triuretic peptide and adrenomedullin: prognostic utility and prediction of ben-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "37. Tschope C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory efit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. New Zealand Heart Failure Group. J Am Coll Cardiol. 2001;37:1781–1787."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2021;18:169–193. 2. Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide levels"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "38. Nunes MCP, Beaton A, Acquatella H, et al. Chagas cardiomyopathy: an in ambulatory patients with established chronic symptomatic systolic heart"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "update of current clinical knowledge and management: a scientific state- failure. Circulation. 2003;108:2964–2966."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "ment from the American Heart Association. Circulation. 2018;138:e169– 3. Zaphiriou A, Robb S, Murray-Thomas T, et al. The diagnostic accuracy of"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "e209. plasma BNP and NTproBNP in patients referred from primary care with"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "39. Davis MB, Arany Z, McNamara D, et al. Peripartum cardiomyopathy: JACC suspected heart failure: results of the UK natriuretic peptide study. Eur J"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "state-of-the-art review. J Am Coll Cardiol. 2020;75:207–221. Heart Fail. 2005;7:537–541."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "40. Napp LC, Bauersachs J. Takotsubo syndrome: between evidence, myths, 4. Son CS, Kim YN, Kim HS, et al. Decision-making model for early diagnosis"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "and misunderstandings. Herz. 2020;45:252–266. of congestive heart failure using rough set and decision tree approaches. J"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "41. Pelliccia F, Kaski JC, Crea F, et al. Pathophysiology of Takotsubo syndrome. Biomed Inform. 2012;45:999–1008."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "Circulation. 2017;135:2426–2441. 5. Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "42. Ware JS, Amor-Salamanca A, Tayal U, et al. Genetic etiology for alcohol- physical examination and additional testing in primary care patients with"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "induced cardiac toxicity. J Am Coll Cardiol. 2018;71:2293–2302. suspected heart failure. Circulation. 2011;124:2865–2873."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "43. Arenas DJ, Beltran S, Zhou S, et al. Cocaine, cardiomyopathy, 6. Booth RA, Hill SA, Don-Wauchope A, et al. Performance of BNP and NT-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "and heart failure: a systematic review and meta-analysis. Sci Rep. proBNP for diagnosis of heart failure in primary care patients: a systematic"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2020;10:19795. review. Heart Fail Rev. 2014;19:439–451."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "44. Reddy PKV, Ng TMH, Oh EE, et al. Clinical characteristics and management 7. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic pep-"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "of methamphetamine-associated cardiomyopathy: state-of-the-art review. J tide in the diagnosis of congestive heart failure in an urgent-care setting. J"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "Am Heart Assoc. 2020;9:e016704. Am Coll Cardiol. 2001;37:379–385."
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 96,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e991"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "8. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in history of cardiac disease): a prospective randomized controlled trial. J Am"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "assessment of acute dyspnoea. Lancet. 1994;343:440–444. Coll Cardiol. 2013;62:1365–1372."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "9. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B- 31. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screen-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "type natriuretic peptide in the emergency diagnosis of heart failure. N Engl ing and collaborative care for heart failure: the STOP-HF randomized trial."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "J Med. 2002;347:161–167. JAMA. 2013;310:66–74."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "10. Januzzi JL Jr, Chen-Tournoux AA, Moe G. Amino-terminal pro-B-type na- 32. Clerico A, Fontana M, Zyw L, et al. Comparison of the diagnostic accuracy of"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "triuretic peptide testing for the diagnosis or exclusion of heart failure in brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "patients with acute symptoms. Am J Cardiol. 2008;101:29–38. BNP immunoassays in chronic and acute heart failure: a systematic review."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "11. Santaguida PL, Don-Wauchope AC, Ali U, et al. Incremental value of natri- Clin Chem. 2007;53:813–822."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "uretic peptide measurement in acute decompensated heart failure (ADHF): 33. Jensen J, Ma LP, Bjurman C, et al. Prognostic values of NTpro BNP/"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "a systematic review. Heart Fail Rev. 2014;19:507–519. BNP ratio in comparison with NTpro BNP or BNP alone in elderly"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "12. Hill SA, Booth RA, Santaguida PL, et al. Use of BNP and NT-proBNP for patients with chronic heart failure in a 2-year follow up. Int J Cardiol."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "the diagnosis of heart failure in the emergency department: a systematic 2012;155:1–5."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "review of the evidence. Heart Fail Rev. 2014;19:421–438. 34. Kristensen SL, Jhund PS, Mogensen UM, et al. Prognostic value of N-ter-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "13. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal minal pro-B-type natriuretic peptide levels in heart failure patients with and"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of pa- without atrial fibrillation. Circ Heart Fail. 2017;10:e004409."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "tients with acute heart failure. J Am Coll Cardiol. 2006;48:1217–1224. 35. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "14. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic obese patients with advanced heart failure. J Am Coll Cardiol. 2006;47:85–"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "peptide predicts outcome after hospital discharge in heart failure patients. 90."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "Circulation. 2004;110:2168–2174. 36. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type na-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "15. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type pep- triuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43:1590–"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "tide predicts treatment outcomes in patients admitted for decompensated 1595."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "heart failure: a pilot study. J Am Coll Cardiol. 2001;37:386–391. 37. Felker GM, Anstrom KJ, Adams KF, et al. Effect of natriuretic peptide-guid-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "16. Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic ed therapy on hospitalization or cardiovascular mortality in high-risk patients"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "peptide levels and in-hospital mortality in acute decompensated heart fail- with heart failure and reduced ejection fraction: a randomized clinical trial."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "ure. J Am Coll Cardiol. 2007;49:1943–1950. JAMA. 2017;318:713–720."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "17. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic pep- 38. Januzzi JL Jr, Ahmad T, Mulder H, et al. Natriuretic peptide response and"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "tide assay for identifying patients at high risk of re-admission after decom- outcomes in chronic heart failure with reduced ejection fraction. J Am Coll"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "pensated heart failure. J Am Coll Cardiol. 2004;43:635–641. Cardiol. 2019;74:1205–1217."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "18. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emer- 39. Mark DB, Cowper PA, Anstrom KJ, et al. Economic and quality-of-life out-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "gency Department Heart Failure Outpatient Trial (REDHOT). A multicenter comes of natriuretic peptide-guided therapy for heart failure. J Am Coll Car-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "study of B-type natriuretic peptide levels, emergency department decision diol. 2018;72:2551–2562."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "making, and outcomes in patients presenting with shortness of breath. J Am 40. Aimo A, Januzzi JL Jr, Vergaro G, et al. Prognostic value of high-sensitivity"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "Coll Cardiol. 2004;44:1328–1333. troponin T in chronic heart failure: an individual patient data meta-analysis."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "19. Zairis MN, Tsiaousis GZ, Georgilas AT, et al. Multimarker strategy for the Circulation. 2018;137:286–297."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "prediction of 31 days cardiac death in patients with acutely decompensated 41. Evans JDW, Dobbin SJH, Pettit SJ, et al. High-sensitivity cardiac troponin"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "chronic heart failure. Int J Cardiol. 2010;141:284–290. and new-onset heart failure: a systematic review and meta-analysis of 67"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "20. Dhaliwal AS, Deswal A, Pritchett A, et al. Reduction in BNP levels with treat- 063 patients with 4 165 incident heart failure events. J Am Coll Cardiol HF."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "ment of decompensated heart failure and future clinical events. J Card Fail. 2018;6:187–197."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "2009;15:293–299. 42. Pang PS, Fermann GJ, Hunter BR, et al. TACIT (High Sensitivity Tro-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "21. O’Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization ponin T Rules Out Acute Cardiac Insufficiency Trial). Circ Heart Fail."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "with advanced heart failure: the ESCAPE (Evaluation Study of Conges- 2019;12:e005931."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "tive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk 43. Ahmad T, Fiuzat M, Neely B, et al. Biomarkers of myocardial stress and"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "model and discharge score. J Am Coll Cardiol. 2010;55:872–878. fibrosis as predictors of mode of death in patients with chronic heart failure."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "22. O’Brien RJ, Squire IB, Demme B, et al. Pre-discharge, but not admission, J Am Coll Cardiol HF. 2014;2:260–268."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J 44. Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "Heart Fail. 2003;5:499–506. incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249–"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "23. Cohen-Solal A, Logeart D, Huang B, et al. Lowered B-type natriuretic pep- 1256."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "tide in response to levosimendan or dobutamine treatment is associated 45. Kosmala W, Przewlocka-Kosmala M, Rojek A, et al. Comparison of the dia-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "with improved survival in patients with severe acutely decompensated heart stolic stress test with a combined resting echocardiography and biomarker"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "failure. J Am Coll Cardiol. 2009;53:2343–2348. approach to patients with exertional dyspnea: diagnostic and prognostic"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "24. Salah K, Kok WE, Eurlings LW, et al. A novel discharge risk model for patients implications. J Am Coll Cardiol Img. 2019;12:771–780."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "hospitalised for acute decompensated heart failure incorporating N-terminal 46. Nymo SH, Aukrust P, Kjekshus J, et al. Limited added value of circulat-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "pro-B-type natriuretic peptide levels: a European coLlaboration on Acute de- ing inflammatory biomarkers in chronic heart failure. J Am Coll Cardiol HF."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "compeNsated Heart Failure: ELAN-HF Score. Heart. 2014;100:115–125. 2017;5:256–264."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "25. Flint KM, Allen LA, Pham M, et al. B-type natriuretic peptide predicts 30-day 47. Emdin M, Aimo A, Vergaro G, et al. sST2 predicts outcome in chronic heart"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "readmission for heart failure but not readmission for other causes. J Am failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "Heart Assoc. 2014;3:e000806. 2018;72:2309–2320."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "26. Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or change 48. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "in B-type natriuretic peptide and long-term outcomes: data from Orga- serial soluble ST2, growth differentiation factor-15, and highly-sensitive"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "nized Program to Initiate Lifesaving Treatment in Hospitalized Patients with troponin T measurements in patients with chronic heart failure. J Am Coll"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail. Cardiol HF. 2014;2:65–72."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "2011;4:628–636. 49. Richards AM. ST2 and prognosis in chronic heart failure. J Am Coll Cardiol."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "27. Kociol RD, McNulty SE, Hernandez AF, et al. Markers of decongestion, dys- 2018;72:2321–2323."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "pnea relief, and clinical outcomes among patients hospitalized with acute 50. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function,"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "heart failure. Circ Heart Fail. 2013;6:240–245. congestive heart failure, and amino-terminal pro-brain natriuretic"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "28. Verdiani V, Ognibene A, Rutili MS, et al. NT-ProBNP reduction percentage peptide measurement: results from the ProBNP Investigation of Dys-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "during hospital stay predicts long-term mortality and readmission in heart pnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "failure patients. J Cardiovasc Med (Hagerstown). 2008;9:694–699. 2006;47:91–97."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "29. Bayes-Genis A, Lopez L, Zapico E, et al. NT-ProBNP reduction percentage 51. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuret-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "during admission for acutely decompensated heart failure predicts long- ic peptide concentration: impact of age and gender. J Am Coll Cardiol."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "term cardiovascular mortality. J Card Fail. 2005;11:S3–S8. 2002;40:976–982."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "30. Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected 52. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natri-"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "prevention of cardiac events in a population of diabetic patients without a uretic peptide levels in healthy adults. Am J Cardiol. 2002;90:254–258."
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 97,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "e992 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "53. Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, es- 12. van Royen N, Jaffe CC, Krumholz HM, et al. Comparison and reproducibil-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "trogens, and natriuretic peptides in young women: observations from the ity of visual echocardiographic and quantitative radionuclide left ventricular"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Dallas Heart Study. J Am Coll Cardiol. 2007;49:109–116. ejection fractions. Am J Cardiol. 1996;77:843–850."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "13. Fu H, Wang X, Diao K, et al. CT compared to MRI for functional evaluation"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "of the right ventricle: a systematic review and meta-analysis. Eur Radiol."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "4.3. Genetic Evaluation and Testing 2019;29:6816–6828."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "14. Kaniewska M, Schuetz GM, Willun S, et al. Noninvasive evaluation of global"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "1. Marume K, Noguchi T, Tateishi E, et al. Prognosis and clinical characteristics and regional left ventricular function using computed tomography and mag-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "of dilated cardiomyopathy with family history via pedigree analysis. Circ J. netic resonance imaging: a meta-analysis. Eur Radiol. 2017;27:1640–1659."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "2020;84:1284–1293. 15. Takx RA, Moscariello A, Schoepf UJ, et al. Quantification of left and right"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "2. Waddell-Smith KE, Donoghue T, Oates S, et al. Inpatient detection of car- ventricular function and myocardial mass: comparison of low-radiation"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "diac-inherited disease: the impact of improving family history taking. Open dose 2nd generation dual-source CT and cardiac MRI. Eur J Radiol."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Heart. 2016;3:e000329. 2012;81:e598–e604."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "3. Pugh TJ, Kelly MA, Gowrisankar S, et al. The landscape of genetic variation 16. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnet-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet ic resonance for the early diagnosis of myocardial iron overload. Eur Heart"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Med. 2014;16:601–608. J. 2001;22:2171–2179."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "4. Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated 17. Bruder O, Schneider S, Nothnagel D, et al. EuroCMR (European Cardiovas-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "cardiomyopathy. Eur Heart J. 2015;36:1123–1135a. cular Magnetic Resonance) registry: results of the German pilot phase. J Am"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "5. Roberts AM, Ware JS, Herman DS, et al. Integrated allelic, transcriptional, Coll Cardiol. 2009;54:1457–1466."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "and phenomic dissection of the cardiac effects of titin truncations in health 18. Bruder O, Wagner A, Lombardi M, et al. European Cardiovascular Magnetic"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "and disease. Sci Transl Med. 2015;7:270ra6. Resonance (EuroCMR) registry--multi national results from 57 centers in"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "6. Gigli M, Merlo M, Graw SL, et al. Genetic risk of arrhythmic phenotypes 15 countries. J Cardiovasc Magn Reson. 2013;15:9."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2019;74:1480– 19. Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "1490. mapping for the diagnosis of cardiac amyloidosis. J Am Coll Cardiol Img."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "7. James CA, Bhonsale A, Tichnell C, et al. Exercise increases age-related 2013;6:488–497."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "penetrance and arrhythmic risk in arrhythmogenic right ventricular dyspla- 20. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, et al. Magnetic resonance in"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "sia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll transthyretin cardiac amyloidosis. J Am Coll Cardiol. 2017;70:466–477."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Cardiol. 2013;62:1290–1297. 21. Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "normal myocardium from diffuse disease in hypertrophic and dilated cardio-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "myopathy. J Am Coll Cardiol Img. 2013;6:475–484."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "4.4. Evaluation With Cardiac Imaging 22. Sado DM, Maestrini V, Piechnik SK, et al. Noncontrast myocardial T1 map-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "ping using cardiovascular magnetic resonance for iron overload. J Magn"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "1. Badgett RG, Mulrow CD, Otto P, et al. How well can the chest radiograph di- Reson Imaging. 2015;41:1505–1511."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "agnose left ventricular dysfunction? J Gen Intern Med. 1996;11:625–634. 23. Sado DM, White SK, Piechnik SK, et al. Identification and assessment of"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "2. Knudsen CW, Omland T, Clopton P, et al. Diagnostic value of B-type natri- Anderson-Fabry disease by cardiovascular magnetic resonance noncon-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "uretic peptide and chest radiographic findings in patients with acute dys- trast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392–398."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "pnea. Am J Med. 2004;116:363–368. 24. Elhendy A, Sozzi F, van Domburg RT, et al. Effect of myocardial ischemia"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "3. Tribouilloy C, Rusinaru D, Mahjoub H, et al. Impact of echocardiography in during dobutamine stress echocardiography on cardiac mortality in patients"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "patients hospitalized for heart failure: a prospective observational study. with heart failure secondary to ischemic cardiomyopathy. Am J Cardiol."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Arch Cardiovasc Dis. 2008;101:465–473. 2005;96:469–473."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "4. Doughty RNWG, Gamble G, et al. Left ventricular remodeling with carvedilol 25. Miller WL, Hodge DO, Tointon SK, et al. Relationship of myocardial perfusion"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "in patients with congestive heart failure due to ischemic heart disease. Aus- imaging findings to outcome of patients with heart failure and suspected"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "tralia-New Zealand Heart Failure Research Collaborative Group. J Am Coll ischemic heart disease. Am Heart J. 2004;147:714–720."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Cardiol. 1997;29:1060–1066. 26. Chow BJW, Coyle D, Hossain A, et al. Computed tomography coronary an-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "5. Duncker D, König T, Hohmann S, et al. Avoiding untimely implantable cardio- giography for patients with heart failure (CTA-HF): a randomized controlled"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "verter/defibrillator implantation by intensified heart failure therapy optimi- trial (IMAGE-HF 1C). Eur Heart J Cardiovasc Imaging. 2021;22:1083–"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "zation supported by the wearable cardioverter/defibrillator-the PROLONG 1090."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "study. J Am Heart Assoc. 2017;6:e004512. 27. Ferreira JP, Rossignol P, Demissei B, et al. Coronary angiography in worsen-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "6. Januzzi JL Jr, Prescott MF, Butler J, et al. Association of change in N-termi- ing heart failure: determinants, findings and prognostic implications. Heart."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "nal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan 2018;104:606–613."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "treatment with cardiac structure and function in patients with heart failure 28. Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "with reduced ejection fraction. JAMA. 2019;322:1–11. impact of revascularization on prognosis in patients with coronary artery"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "7. Solomon SD, Glynn RJ, Greaves S, et al. Recovery of ventricular function disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "after myocardial infarction in the reperfusion era: the healing and early af- 2002;39:1151–1158."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "terload reducing therapy study. Ann Intern Med. 2001;134:451–458. 29. D’Egidio G, Nichol G, Williams KA, et al. PARR-2 Investigators. Increasing"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "8. Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular benefit from revascularization is associated with increasing amounts of"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "ejection fraction and volumes in heart failure by echocardiography, radio- myocardial hibernation: a substudy of the PARR-2 trial. J Am Coll Cardiol"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "nuclide ventriculography and cardiovascular magnetic resonance; are they Img. 2009;2:1060–1068."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "interchangeable? Eur Heart J. 2000;21:1387–1396. 30. Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "9. Grothues F, Smith GC, Moon JC, et al. Comparison of interstudy reproduc- from revascularization in patients with left ventricular systolic dysfunction:"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "ibility of cardiovascular magnetic resonance with two-dimensional echo- inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "cardiography in normal subjects and in patients with heart failure or left 2013;6:363–372."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "ventricular hypertrophy. Am J Cardiol. 2002;90:29–34. 31. Orlandini A, Castellana N, Pascual A, et al. Myocardial viability for decision-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "10. Longmore DB, Klipstein RH, Underwood SR, et al. Dimensional accuracy of making concerning revascularization in patients with left ventricular dys-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "magnetic resonance in studies of the heart. Lancet. 1985;1:1360–1362. function and coronary artery disease: a meta-analysis of non-randomized"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "11. Doherty JU, Kort S, Mehran R, et al. ACC/AATS/AHA/ASE/ASNC/HRS/ and randomized studies. Int J Cardiol. 2015;182:494–499."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "SCAI/SCCT/SCMR/STS 2019 appropriate use criteria for multimodality 32. Desideri A, Cortigiani L, Christen AI, et al. The extent of perfusion-F18-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "imaging in the assessment of cardiac structure and function in nonvalvular fluorodeoxyglucose positron emission tomography mismatch determines"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "heart disease: a report of the American College of Cardiology Appropriate mortality in medically treated patients with chronic ischemic left ventricular"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Use Criteria Task Force, American Association for Thoracic Surgery, Ameri- dysfunction. J Am Coll Cardiol. 2005;46:1264–1269."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "can Heart Association, American Society of Echocardiography, American 33. Collins SP, Lindsell CJ, Storrow AB, et al. Prevalence of negative chest radi-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovas- ography results in the emergency department patient with decompensated"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "cular Angiography and Interventions, Society of Cardiovascular Computed heart failure. Ann Emerg Med. 2006;47:13–18."
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Tomography, Society for Cardiovascular Magnetic Resonance, and the Soci- 34. Echouffo-Tcheugui JB, Erqou S, Butler J, et al. Assessing the risk of pro-"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "ety of Thoracic Surgeons. J Am Coll Cardiol. 2019;73:488–516. gression from asymptomatic left ventricular dysfunction to overt heart"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 98,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e993"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "failure: a systematic overview and meta-analysis. J Am Coll Cardiol HF. 55. St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resyn-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "2016;4:237–248. chronization therapy on left ventricular size and function in chronic heart"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "35. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocar- failure. Circulation. 2003;107:1985–1990."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "diographically determined left ventricular mass in the Framingham Heart 56. Wilcox JE, Fonarow GC, Yancy CW, et al. Factors associated with improve-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "Study. N Engl J Med. 1990;322:1561–1566. ment in ejection fraction in clinical practice among patients with heart fail-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "36. Nauta JF, Hummel YM, van der Meer P, et al. Correlation with invasive left ure: findings from IMPROVE HF. Am Heart J. 2012;163:49–56.e2."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "ventricular filling pressures and prognostic relevance of the echocardio- 57. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angioten-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "graphic diastolic parameters used in the 2016 ESC heart failure guidelines sin converting enzyme inhibitor enalapril on the long-term progression of"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "and in the 2016 ASE/EACVI recommendations: a systematic review in pa- left ventricular dysfunction in patients with heart failure. SOLVD Investiga-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "tients with heart failure with preserved ejection fraction. Eur J Heart Fail. tors. Circulation. 1992;86:431–438."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "2018;20:1303–1311. 58. Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "37. Solomon SD, Anavekar N, Skali H, et al Candesartan in Heart Failure Re- left ventricular volumes in patients with type 2 diabetes, or prediabetes, and"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "duction in Mortality (CHARM) Investigators. Influence of ejection fraction heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "on cardiovascular outcomes in a broad spectrum of heart failure patients. 2021;143:516–525."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "Circulation. 2005;112:3738–3744. 59. Nasser R, Van Assche L, Vorlat A, et al. Evolution of functional mitral re-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "38. Al Saikhan L, Park C, Hardy R, et al. Prognostic implications of left ventricu- gurgitation and prognosis in medically managed heart failure patients with"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "lar strain by speckle-tracking echocardiography in the general population: a reduced ejection fraction. J Am Coll Cardiol HF. 2017;5:652–659."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "meta-analysis. Vasc Health Risk Manag. 2019;15:229–251. 60. Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart failure with recovered"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "39. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al. Burden of systolic and left ventricular ejection fraction: JACC Scientific Expert Panel. J Am Coll"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "diastolic ventricular dysfunction in the community: appreciating the scope of Cardiol. 2020;76:719–734."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "the heart failure epidemic. JAMA. 2003;289:194–202. 61. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "40. Bosch L, Lam CSP, Gong L, et al. Right ventricular dysfunction in left-sided the management of adults with congenital heart disease: a report of the"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "heart failure with preserved versus reduced ejection fraction. Eur J Heart American College of Cardiology/American Heart Association Task Force on"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "Fail. 2017;19:1664–1671. Clinical Practice Guidelines. Circulation. 2019;139:e698–e800."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "41. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac cham- 62. Yoshida A, Ishibashi-Ueda H, Yamada N, et al. Direct comparison of the"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "ber quantification by echocardiography in adults: an update from the Ameri- diagnostic capability of cardiac magnetic resonance and endomyocardial"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "can Society of Echocardiography and the European Association of Cardio- biopsy in patients with heart failure. Eur J Heart Fail. 2013;15:166–175."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "vascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.e14. 63. Kim RJ, Albert TS, Wible JH, et al. Performance of delayed-enhancement"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "42. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the eval- magnetic resonance imaging with gadoversetamide contrast for the detec-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "uation of left ventricular diastolic function by echocardiography: an update tion and assessment of myocardial infarction: an international, multicenter,"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "from the American Society of Echocardiography and the European Associa- double-blinded, randomized trial. Circulation. 2008;117:629–637."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "tion of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29:277–314. 64. Wagner A, Mahrholdt H, Holly TA, et al. Contrast-enhanced MRI and routine"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "43. Biering-Sorensen T, Biering-Sorensen SR, Olsen FJ, et al. Global longitu- single photon emission computed tomography (SPECT) perfusion imaging"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "dinal strain by echocardiography predicts long-term risk of cardiovascular for detection of subendocardial myocardial infarcts: an imaging study. Lan-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "morbidity and mortality in a low-risk general population: the Copenhagen cet. 2003;361:374–379."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "City Heart Study. Circ Cardiovasc Imaging. 2017;10:e005521. 65. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart fail-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "44. Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dys- ure related to dilated cardiomyopathy and coronary artery disease using"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "function: a systematic review and meta-analysis of global longitudinal strain gadolinium-enhanced cardiovascular magnetic resonance. Circulation."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "and ejection fraction. Heart. 2014;100:1673–1680. 2003;108:54–59."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "45. Morris DA, Ma XX, Belyavskiy E, et al. Left ventricular longitudinal sys- 66. Valle-Muñoz A, Estornell-Erill J, Soriano-Navarro CJ, et al. Late gadolinium"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "tolic function analysed by 2D speckle-tracking echocardiography in heart enhancement-cardiovascular magnetic resonance identifies coronary artery"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "failure with preserved ejection fraction: a meta-analysis. Open Heart. disease as the aetiology of left ventricular dysfunction in acute new-onset"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "4;2017:e000630. congestive heart failure. Eur J Echocardiogr. 2009;10:968–974."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "46. Shah AM, Claggett B, Sweitzer NK, et al. Prognostic importance of impaired 67. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "systolic function in heart failure with preserved ejection fraction and the resonance in nonischemic myocardial inflammation: expert recommenda-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "impact of spironolactone. Circulation. 2015;132:402–414. tions. J Am Coll Cardiol. 2018;72:3158–3176."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "47. Lipczynska M, Szymanski P, Klisiewicz A, et al. Hand-carried echocardiog- 68. Wong TC, Piehler K, Meier CG, et al. Association between extracellular ma-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "raphy in heart failure and heart failure risk population: a community based trix expansion quantified by cardiovascular magnetic resonance and short-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "prospective study. J Am Soc Echocardiogr. 2011;24:125–131. term mortality. Circulation. 2012;126:1206–1216."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "48. Martin LD, Howell EE, Ziegelstein RC, et al. Hand-carried ultrasound per- 69. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascu-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "formed by hospitalists: does it improve the cardiac physical examination? lar magnetic resonance for the measurement of diffuse myocardial fibrosis:"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "Am J Med. 2009;122:35–41. preliminary validation in humans. Circulation. 2010;122:138–144."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "49. Maw AM, Hassanin A, Ho PM, et al. Diagnostic accuracy of point-of-care 70. Miller CA, Naish JH, Bishop P, et al. Comprehensive validation of cardio-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "lung ultrasonography and chest radiography in adults with symptoms sug- vascular magnetic resonance techniques for the assessment of myocardial"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "gestive of acute decompensated heart failure: a systematic review and extracellular volume. Circ Cardiovasc Imaging. 2013;6:373–383."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "meta-analysis. JAMA Netw Open. 2019;2:e190703. 71. Vita T, Grani C, Abbasi SA, et al. Comparing CMR mapping methods and"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "50. Platz E, Campbell RT, Claggett B, et al. Lung ultrasound in acute heart myocardial patterns toward heart failure outcomes in nonischemic dilated"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "failure: prevalence of pulmonary congestion and short- and long-term out- cardiomyopathy. J Am Coll Cardiol Img. 2019;12:1659–1669."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "comes. J Am Coll Cardiol HF. 2019;7:849–858. 72. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "51. Pivetta E, Goffi A, Nazerian P, et al. Lung ultrasound integrated with clini- other adverse events in suspected cardiac sarcoidosis. J Am Coll Cardiol"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "cal assessment for the diagnosis of acute decompensated heart failure in Img. 2013;6:501–511."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "the emergency department: a randomized controlled trial. Eur J Heart Fail. 73. Kuruvilla S, Adenaw N, Katwal AB, et al. Late gadolinium enhancement on"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "2019;21:754–766. cardiac magnetic resonance predicts adverse cardiovascular outcomes in"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "52. Palazzuoli A, Ruocco G, Beltrami M, et al. Combined use of lung ultrasound, nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "B-type natriuretic peptide, and echocardiography for outcome prediction in Cardiovasc Imaging. 2014;7:250–258."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "patients with acute HFrEF and HFpEF. Clin Res Cardiol. 2018;107:586– 74. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "596. scar detected by cardiac magnetic resonance imaging on event-free surviv-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "53. Ottervanger JP, van’t Hof AW, Reiffers S, et al. Long-term recovery of left al in patients presenting with signs or symptoms of coronary artery disease."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "ventricular function after primary angioplasty for acute myocardial infarction. Circulation. 2006;113:2733–2743."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "Eur Heart J. 2001;22:785–790. 75. El Aidi H, Adams A, Moons KG, et al. Cardiac magnetic resonance im-"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "54. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo- aging findings and the risk of cardiovascular events in patients with"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "controlled study of the effects of carvedilol in patients with moderate to se- recent myocardial infarction or suspected or known coronary artery"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "vere heart failure. The PRECISE Trial. Prospective Randomized Evaluation disease: a systematic review of prognostic studies. J Am Coll Cardiol."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "of Carvedilol on Symptoms and Exercise. Circulation. 1996;94:2793–2799. 2014;63:1031–1045."
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 99,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "e994 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "76. Lehrke S, Lossnitzer D, Schob M, et al. Use of cardiovascular magnetic reso- 4. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided manage-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "nance for risk stratification in chronic heart failure: prognostic value of late ment of heart failure (GUIDE-HF): a randomised controlled trial. Lancet."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "gadolinium enhancement in patients with non-ischaemic dilated cardiomy- 2021;398:991–1001."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "opathy. Heart. 2011;97:727–732. 5. Martinson M, Bharmi R, Dalal N, et al. Pulmonary artery pressure-guided"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "77. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium en- heart failure management: US cost-effectiveness analyses using the results"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "hancement cardiovascular magnetic resonance in cardiac amyloidosis. Cir- of the CHAMPION clinical trial. Eur J Heart Fail. 2017;19:652–660."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "culation. 2015;132:1570–1579. 6. Sandhu AT, Goldhaber-Fiebert JD, Owens DK, et al. Cost-effectiveness of"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "78. Paterson DI, Wells G, Erthal F, et al. OUTSMART HF: a randomized controlled implantable pulmonary artery pressure monitoring in chronic heart failure. J"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "trial of routine versus selective cardiac magnetic resonance for patients with Am Coll Cardiol HF. 2016;4:368–375."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "nonischemic heart failure (IMAGE-HF 1B). Circulation. 2020;141:818–827. 7. Schmier JK, Ong KL, Fonarow GC. Cost-effectiveness of remote car-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "79. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure diac monitoring with the CardioMEMS heart failure system. Clin Cardiol."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "in US men and women: NHANES I epidemiologic follow-up study. Arch In- 2017;40:430–436."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "tern Med. 2001;161:996–1002. 8. Heywood JT, Jermyn R, Shavelle D, et al. Impact of practice-based manage-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "80. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron ment of pulmonary artery pressures in 2000 patients implanted with the"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "emission tomography imaging-assisted management of patients with se- CardioMEMS sensor. Circulation. 2017;135:1509–1517."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "vere left ventricular dysfunction and suspected coronary disease: a random- 9. Desai AS, Bhimaraj A, Bharmi R, et al. Ambulatory hemodynamic monitoring"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "ized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002–2012. reduces heart failure hospitalizations in \"real-world\" clinical practice. J Am"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "81. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in isch- Coll Cardiol. 2017;69:2357–2365."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "emic left ventricular dysfunction. N Engl J Med. 2011;364:1617–1625. 10. Abraham J, Bharmi R, Jonsson O, et al. Association of ambulatory hemo-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "82. Panza JA, Ellis AM, Al-Khalidi HR, et al. Myocardial viability and long-term dynamic monitoring of heart failure with clinical outcomes in a concurrent"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "outcomes in ischemic cardiomyopathy. N Engl J Med. 2019;381:739–748. matched cohort analysis. JAMA Cardiol. 2019;4:556–563."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "83. Patel MR, White RD, Abbara S, et al. 2013 ACCF/ACR/ASE/ASNC/ 11. Ong MK, Romano PS, Edgington S, et al. Effectiveness of remote patient"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "SCCT/SCMR appropriate utilization of cardiovascular imaging in heart fail- monitoring after discharge of hospitalized patients with heart failure: the"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "ure: a joint report of the American College of Radiology Appropriateness Better Effectiveness After Transition--Heart Failure (BEAT-HF) randomized"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "Criteria Committee and the American College of Cardiology Foundation Ap- clinical trial. JAMA Intern Med. 2016;176:310–318."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "propriate Use Criteria Task Force. J Am Coll Cardiol. 2013;61:2207–2231. 12. Galinier M, Roubille F, Berdague P, et al. Telemonitoring versus standard"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "care in heart failure: a randomised multicentre trial. Eur J Heart Fail."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "2020;22:985–994."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "4.5. Invasive Evaluation 13. Böhm M, Drexler H, Oswald H, et al. Fluid status telemedicine alerts for"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "heart failure: a randomized controlled trial. Eur Heart J. 2016;37:3154–"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "1. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "3363."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "biopsy in the management of cardiovascular disease: a scientific statement"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "14. Boriani G, Da Costa A, Quesada A, et al. Effects of remote monitoring on"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "from the American Heart Association, the American College of Cardiology,"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "clinical outcomes and use of healthcare resources in heart failure patients"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "and the European Society of Cardiology. Circulation. 2007;116:2216–2233."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "with biventricular defibrillators: results of the MORE-CARE multicentre ran-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "2. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "domized controlled trial. Eur J Heart Fail. 2017;19:416–425."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "for patients with transthyretin amyloid cardiomyopathy. N Engl J Med."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "15. Hindricks G, Taborsky M, Glikson M, et al. Implant-based multiparameter"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "2018;379:1007–1016."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "telemonitoring of patients with heart failure (IN-TIME): a randomised con-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "3. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "trolled trial. Lancet. 2014;384:583–590."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "heart failure and pulmonary artery catheterization effectiveness: the ES-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "16. Klersy C, Boriani G, De Silvestri A, et al. Effect of telemonitoring of cardiac"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "CAPE trial. JAMA. 2005;294:1625–1633."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "implantable electronic devices on healthcare utilization: a meta-analysis of"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "4. Shah MRHV, Stevenson LW, et al. Impact of the pulmonary artery catheter"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "randomized controlled trials in patients with heart failure. Eur J Heart Fail."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "in critically ill patients: meta-analysis of randomized clinical trials. JAMA."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "2016;18:195–204."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "2005;294:1664–1670."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "17. Morgan JM, Kitt S, Gill J, et al. Remote management of heart failure using"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "5. Deckers JW, Hare JM, Baughman KL. Complications of transvenous right"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "implantable electronic devices. Eur Heart J. 2017;38:2352–2360."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a 18. Parthiban N, Esterman A, Mahajan R, et al. Remote monitoring of implant-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "seven-year survey of 546 consecutive diagnostic procedures in a tertiary"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "able cardioverter-defibrillators: a systematic review and meta-analysis of"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "referral center. J Am Coll Cardiol. 1992;19:43–47."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "clinical outcomes. J Am Coll Cardiol. 2015;65:2591–2600."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "6. Veress G, Bruce CJ, Kutzke K, et al. Acute thrombus formation as a compli-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "19. Loh JP, Barbash IM, Waksman R. Overview of the 2011 Food and Drug"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "cation of right ventricular biopsy. J Am Soc Echocardiogr. 2010;23:1039–"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "Administration circulatory system devices panel of the medical devices"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "1044."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "advisory committee meeting on the CardioMEMS Champion Heart Failure"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "7. Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "Monitoring System. J Am Coll Cardiol. 2013;61:1571–1576."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascular-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "20. Ollendorf DA, Sandhu AT, Pearson SD. CardioMEMS HF for the man-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "ization in patients with stable ischemic heart disease. J Am Coll Cardiol. agement of heart failure-effectiveness and value. JAMA Intern Med."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "2017;69:2212–2241. 2016;176:1551–1552."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "8. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "21. Krumholz HM, Dhruva SS. Real-world data on heart failure readmission re-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "duction: real or real uncertain? J Am Coll Cardiol. 2017;69:2366–2368."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "1616. 22. Inglis SC, Clark RA, Dierckx R, et al. Structured telephone support or non-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "9. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "invasive telemonitoring for patients with heart failure. Cochrane Database"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511–"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "Syst Rev. 2015:CD007228."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "1520."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "23. Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interven-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "tional management in patients with heart failure (TIM-HF2): a randomised,"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "controlled, parallel-group, unmasked trial. Lancet. 2018;392:1047–1057."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "4.6. Wearables and Remote Monitoring (Including"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "Telemonitoring and Device Monitoring)"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "4.7. Exercise and Functional Capacity Testing"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "1. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "haemodynamic monitoring in chronic heart failure: a randomised controlled 1. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "trial. Lancet. 2011;377:658–666. Vessels. 9th ed. Little, Brown & Co; 1994."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "2. Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery 2. Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Associa-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "pressure monitoring guides management to reduce decompensation in heart tion classes and increased mortality and hospitalization in patients"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "failure with preserved ejection fraction. Circ Heart Fail. 2014;7:935–944. with heart failure and preserved left ventricular function. Am Heart J."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "3. Givertz MM, Stevenson LW, Costanzo MR, et al. Pulmonary artery pressure- 2006;151:444–450."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "guided management of patients with heart failure and reduced ejection 3. Muntwyler J, Abetel G, Gruner C, Follath F. One-year mortality among un-"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "fraction. J Am Coll Cardiol. 2017;70:1875–1886. selected outpatients with heart failure. Eur Heart J. 2002;23:1861–1866."
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 100,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e995"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "4. Brawner CA, Shafiq A, Aldred HA, et al. Comprehensive analysis of car- 27. Rostagno C, Olivo G, Comeglio M, et al. Prognostic value of 6-minute walk"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "diopulmonary exercise testing and mortality in patients with systolic heart corridor test in patients with mild to moderate heart failure: comparison with"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "failure: the Henry Ford Hospital cardiopulmonary exercise testing (FIT-CPX) other methods of functional evaluation. Eur J Heart Fail. 2003;5:247–252."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "project. J Card Fail. 2015;21:710–718. 28. Balady GJ, Arena R, Sietsema K, et al. Clinician’s guide to cardiopulmonary"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "5. Corra U, Giordano A, Mezzani A, et al. Cardiopulmonary exercise testing exercise testing in adults: a scientific statement from the American Heart"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "and prognosis in heart failure due to systolic left ventricular dysfunction: Association. Circulation. 2010;122:191–225."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "a validation study of the European Society of Cardiology Guidelines and"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Recommendations (2008) and further developments. Eur J Prev Cardiol."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "2012;19:32–40. 4.8. Initial and Serial Evaluation: Clinical Assessment: HF"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "6. Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Risk Scoring"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Society for Heart and Lung Transplantation Guidelines for mechanical circu-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "latory support: executive summary. J Heart Lung Transplant. 2013;32:157– 1. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "187. validation of a clinical index to predict survival in ambulatory patients re-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "7. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen con- ferred for cardiac transplant evaluation. Circulation. 1997;95:2660–2667."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "sumption for optimal timing of cardiac transplantation in ambulatory patients 2. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model:"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "with heart failure. Circulation. 1991;83:778–786. prediction of survival in heart failure. Circulation. 2006;113:1424–1433."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "8. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society 3. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart fail-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "for Heart Lung Transplantation listing criteria for heart transplantation: a ure: a risk score based on 39 372 patients from 30 studies. Eur Heart J."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "10-year update. J Heart Lung Transplant. 2016;35:1–23. 2013;34:1404–1413."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "9. Alahdab MT, Mansour IN, Napan S, Stamos TD. Six minute walk test pre- 4. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "dicts long-term all-cause mortality and heart failure rehospitalization in Afri- in patients with chronic heart failure. Eur Heart J. 2006;27:65–75."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "can-American patients hospitalized with acute decompensated heart failure. 5. Wedel H, McMurray JJ, Lindberg M, et al. Predictors of fatal and non-fatal"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "J Card Fail. 2009;15:130–135. outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "10. Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbid- (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "ity with a 6-minute walk test in patients with left ventricular dysfunction. reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "SOLVD Investigators. JAMA. 1993;270:1702–1707. Fail. 2009;11:281–291."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "11. Boxer R, Kleppinger A, Ahmad A, et al. The 6-minute walk is associated with 6. Simpson J, Jhund PS, Lund LH, et al. Prognostic models derived in PARA-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "frailty and predicts mortality in older adults with heart failure. Congest Heart DIGM-HF and validated in ATMOSPHERE and the Swedish Heart Failure"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Fail. 2010;16:208–213. Registry to predict mortality and morbidity in chronic heart failure. JAMA"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "12. Forman DE, Fleg JL, Kitzman DW, et al. 6-min walk test provides prognostic Cardiol. 2020;5:432–441."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "utility comparable to cardiopulmonary exercise testing in ambulatory outpa- 7. O’Connor CM, Whellan DJ, Wojdyla D, et al. Factors related to morbidity and"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "tients with systolic heart failure. J Am Coll Cardiol. 2012;60:2653–2661. mortality in patients with chronic heart failure with systolic dysfunction: the"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "13. Grundtvig M, Eriksen-Volnes T, Orn S, et al. 6 min walk test is a strong inde- HF-ACTION predictive risk score model. Circ Heart Fail. 2012;5:63–71."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "pendent predictor of death in outpatients with heart failure. ESC Heart Fail. 8. O’Connor C, Fiuzat M, Mulder H, et al. Clinical factors related to morbid-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "2020;7:2904–2911. ity and mortality in high-risk heart failure patients: the GUIDE-IT predictive"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "14. Keteyian SJ, Patel M, Kraus WE, et al. Variables measured during cardiopul- model and risk score. Eur J Heart Fail. 2019;21:770–778."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "monary exercise testing as predictors of mortality in chronic systolic heart 9. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "failure. J Am Coll Cardiol. 2016;67:780–789. heart failure with preserved ejection fraction: findings from the Irbesartan in"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "15. McCabe N, Butler J, Dunbar SB, et al. Six-minute walk distance predicts Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "30-day readmission after acute heart failure hospitalization. Heart Lung. Heart Fail. 2011;4:27–35."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "2017;46:287–292. 10. Angraal S, Mortazavi BJ, Gupta A, et al. Machine learning prediction of mor-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "16. Ramalho SHR, Cipriano Junior G, Vieira PJC, et al. Inspiratory muscle tality and hospitalization in heart failure with preserved ejection fraction. J"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "strength and six-minute walking distance in heart failure: prognostic utility Am Coll Cardiol HF. 2020;8:12–21."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "in a 10 years follow up cohort study. PLoS One. 2019;14:e0220638. 11. Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "17. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Tho- hospital mortality in acutely decompensated heart failure: classification and"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "racic Society statement: update on the mechanisms, assessment, and man- regression tree analysis. JAMA. 2005;293:572–580."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "agement of dyspnea. Am J Respir Crit Care Med. 2012;185:435–452. 12. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "18. Reddy YNV, Olson TP, Obokata M, et al. Hemodynamic correlates and di- hospital mortality in patients with heart failure from the American Heart As-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "agnostic role of cardiopulmonary exercise testing in heart failure with pre- sociation Get With The Guidelines program. Circ Cardiovasc Qual Outcomes."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "served ejection fraction. J Am Coll Cardiol HF. 2018;6:665–675. 2010;3:25–32."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "19. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new mea- 13. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "sure of exercise capacity in patients with chronic heart failure. Can Med hospitalized for heart failure: derivation and validation of a clinical model."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Assoc J. 1985;132:919–923. JAMA. 2003;290:2581–2587."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "20. Lans C, Cider A, Nylander E, Brudin L. Test-retest reliability of six-minute 14. O’Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "walk tests over a one-year period in patients with chronic heart failure. Clin with advanced heart failure: the ESCAPE (Evaluation Study of Conges-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Physiol Funct Imaging. 2020;40:284–289. tive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "21. Pollentier B, Irons SL, Benedetto CM, et al. Examination of the six minute model and discharge score. J Am Coll Cardiol. 2010;55:872–878."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "walk test to determine functional capacity in people with chronic heart fail- 15. University of Washington. Seattle Heart Failure Model. 2017. Accessed"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "ure: a systematic review. Cardiopulm Phys Ther J. 2010;21:13–21. September 16, 2020. https://deptswashingtonedu/shfm/?width=1440&h"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "22. Guazzi M, Bandera F, Ozemek C, et al. Cardiopulmonary exercise testing: eight=900"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "what is its value? J Am Coll Cardiol. 2017;70:1618–1636. 16. Meta-AnalysisGlobalGroupinChronicHeartFailure (MAGGIC). Heart Failure Risk"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "23. Raphael C, Briscoe C, Davies J, et al. Limitations of the New York Heart Calculator. Accessed September 16, 2020. http://wwwheartfailureriskorg/"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Association functional classification system and self-reported walking dis- 17. Fonarow GC. GWTG-heart failure risk score. 2021 Accessed September"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "tances in chronic heart failure. Heart. 2007;93:476–482. 29, 2021.https://wwwmdcalccom/gwtg-heart-failure-risk-score"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "24. Parikh MN, Lund LH, Goda A, et al. Usefulness of peak exercise oxygen 18. Canadian Cardiovascular Outcomes Research Team. EFFECT heart failure"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "consumption and the heart failure survival score to predict survival in pa- mortality prediction. 2016. Accessed September 16, 2020. http://wwwc-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "tients >65 years of age with heart failure. Am J Cardiol. 2009;103:998– cortca/Research/CHFRiskModelhtml"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "1002."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "25. Pohwani AL, Murali S, Mathier MM, et al. Impact of beta-blocker therapy on"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "functional capacity criteria for heart transplant listing. J Heart Lung Trans- 5.1. Patients at Risk Factor for HF (Stage A-Primary"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "plant. 2003;22:78–86. Prevention)"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "26. Peterson LR, Schechtman KB, Ewald GA, et al. Timing of cardiac transplan-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "tation in patients with heart failure receiving beta-adrenergic blockers. J 1. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in pa-"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Heart Lung Transplant. 2003;22:1141–1148. tients 80 years of age or older. N Engl J Med. 2008;358:1887–1898."
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 101,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "e996 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "2. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention College of Cardiology/American Heart Association Task Force on Clinical"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "of cardiovascular disease and death: a systematic review and meta-analysis. Practice Guidelines. Circulation. 2019;140:e596–e646."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "Lancet. 2016;387:957–967. 29. Khan SS, Ning H, Shah SJ, et al. 10-year risk equations for incident heart"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "3. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihyper- failure in the general population. J Am Coll Cardiol. 2019;73:2388–2397."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "tensive drug treatment in older persons with isolated systolic hypertension. 30. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "SHEP Cooperative Research Group. JAMA. 1997;278:212–216. ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "4. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison detection, evaluation, and management of high blood pressure in adults: a"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "of placebo and active treatment for older patients with isolated systolic hy- report of the American College of Cardiology/American Heart Association"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "pertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investiga- Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "tors. Lancet. 1997;350:757–764. e115."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "5. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering 31. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and second-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "treatment. 6. Prevention of heart failure and new-onset heart failure--meta- ary prevention of cardiovascular and renal outcomes in type 2 diabetes: a"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "analyses of randomized trials. J Hypertens. 2016;34:373–384. systematic review and meta-analysis of cardiovascular outcome trials. Lan-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "6. Upadhya B, Rocco M, Lewis CE, et al. Effect of intensive blood pressure cet. 2019;393:31–39."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "treatment on heart failure events in the Systolic Blood Pressure Reduction 32. Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "Intervention Trial. Circ Heart Fail. 2017;10:e003613. heart failure: contemporary update. J Am Coll Cardiol HF. 2017;5:543–551."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "7. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A random- 33. Packer M, Anker SD, Butler J, et al. Effects of sodium-glucose cotransporter"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "ized trial of intensive versus standard blood-pressure control. N Engl J Med. 2 inhibitors for the treatment of patients with heart failure: proposal of a"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "2015;373:2103–2116. novel mechanism of action. JAMA Cardiol. 2017;2:1025–1029."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "8. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to 34. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascu-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "congestive heart failure. JAMA. 1996;275:1557–1562. lar benefit: a state-of-the-art review. Diabetologia. 2018;61:2108–2117."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "9. Butler J, Kalogeropoulos AP, Georgiopoulou VV, et al. Systolic blood pres- 35. Vardeny O, Vaduganathan M. Practical guide to prescribing sodium-glu-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "sure and incident heart failure in the elderly. The Cardiovascular Health cose cotransporter 2 inhibitors for cardiologists. J Am Coll Cardiol HF."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "Study and the Health, Ageing and Body Composition Study. Heart. 2019;7:169–172."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "2011;97:1304–1311. 36. Allen LA, Matlock DD, Shetterly SM, et al. Use of risk models to predict"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "10. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and death in the next year among individual ambulatory patients with heart fail-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657. ure. JAMA Cardiol. 2017;2:435–441."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "11. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular out- 37. Liu Y, Chen PC, Krause J, et al. How to read articles that use machine learn-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "comes in type 2 diabetes. N Engl J Med. 2019;380:347–357. ing: users’ guides to the medical literature. JAMA. 2019;322:1806–1816."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "12. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes,"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "13. Del Gobbo LC, Kalantarian S, Imamura F, et al. Contribution of major life- 6.1. Management of Stage B: Preventing the Syndrome of"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "style risk factors for incident heart failure in older adults: the Cardiovascular Clinical HF in Patients With Pre-HF"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "Health Study. J Am Coll Cardiol HF. 2015;3:520–528."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "14. Wang Y, Tuomilehto J, Jousilahti P, et al. Lifestyle factors in relation to heart 1. SOLVD Investigators. Effect of enalapril on mortality and the development of"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "failure among Finnish men and women. Circ Heart Fail. 2011;4:607–612. heart failure in asymptomatic patients with reduced left ventricular ejection"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "15. Young DR, Reynolds K, Sidell M, et al. Effects of physical activity and seden- fractions. N Engl J Med. 1992;327:685–691."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "tary time on the risk of heart failure. Circ Heart Fail. 2014;7:21–27. 2. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "16. Hu G, Jousilahti P, Antikainen R, et al. Joint effects of physical activity, body morbidity in patients with left ventricular dysfunction after myocardial infarc-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "mass index, waist circumference, and waist-to-hip ratio on the risk of heart tion: results of the Survival and Ventricular Enlargement Trial. The SAVE"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "failure. Circulation. 2010;121:237–244. Investigators. N Engl J Med. 1992;327:669–677."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "17. Folsom AR, Shah AM, Lutsey PL, et al. American Heart Association’s Life’s 3. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "Simple 7: avoiding heart failure and preserving cardiac structure and func- and life expectancy in patients with left ventricular systolic dysfunction: a"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "tion. Am J Med. 2015;128:970–976.e2. follow-up study. Lancet. 2003;361:1843–1848."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "18. Tektonidis TG, Åkesson A, Gigante B, et al. Adherence to a Mediterranean 4. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the an-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "diet is associated with reduced risk of heart failure in men. Eur J Heart Fail. giotensin-converting-enzyme inhibitor trandolapril in patients with left"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "2016;18:253–259. ventricular dysfunction after myocardial infarction. Trandolapril Cardiac"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "19. Levitan EB, Wolk A, Mittleman MA. Consistency with the DASH diet and Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670–"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "incidence of heart failure. Arch Intern Med. 2009;169:851–857. 1676."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "20. Levitan EB, Wolk A, Mittleman MA. Relation of consistency with the dietary 5. Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coro-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "approaches to stop hypertension diet and incidence of heart failure in men nary syndromes and stable coronary heart disease: a comparative meta-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "aged 45 to 79 years. Am J Cardiol. 2009;104:1416–1420. analysis of randomised controlled trials. Heart. 2007;93:914–921."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "21. Lara KM, Levitan EB, Gutierrez OM, et al. Dietary patterns and incident 6. Heart Protection Study Collaborative GroupEmberson JR, Ng LL, et al. N-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "heart failure in US adults without known coronary disease. J Am Coll Cardiol. terminal Pro-B-type natriuretic peptide, vascular disease risk, and choles-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "2019;73:2036–2045. terol reduction among 20 536 patients in the MRC/BHF heart protection"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "22. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screen- study. J Am Coll Cardiol. 2007;49:311–319."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "ing and collaborative care for heart failure: the STOP-HF randomized trial. 7. Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "JAMA. 2013;310:66–74. heart failure events: a collaborative meta-analysis of unpublished data from"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "23. Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected major randomized trials. Eur Heart J. 2015;36:1536–1546."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "prevention of cardiac events in a population of diabetic patients without a 8. Scirica BM, Morrow DA, Cannon CP, et al. Intensive statin therapy and the"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "history of cardiac disease): a prospective randomized controlled trial. J Am risk of hospitalization for heart failure after an acute coronary syndrome in"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "Coll Cardiol. 2013;62:1365–1372. the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006;47:2326–2331."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "24. Kannel WB, D’Agostino RB, Silbershatz H, et al. Profile for estimating risk of 9. Strandberg TE, Holme I, Faergeman O, et al. Comparative effect of atorv-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "heart failure. Arch Intern Med. 1999;159:1197–1204. astatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitaliza-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "25. Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Incident heart failure tions for heart failure in patients with previous myocardial infarction. Am J"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "prediction in the elderly: the health ABC heart failure score. Circ Heart Fail. Cardiol. 2009;103:1381–1385."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "2008;1:125–133. 10. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "26. Agarwal SK, Chambless LE, Ballantyne CM, et al. Prediction of incident myocardial infarction complicated by heart failure, left ventricular dysfunc-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "heart failure in general practice: the Atherosclerosis Risk in Communities tion, or both. N Engl J Med. 2003;349:1893–1906."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "(ARIC) Study. Circ Heart Fail. 2012;5:422–429. 11. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "27. Aggarwal M, Bozkurt B, Panjrath G, et al. Lifestyle modifications for prevent- patients with left-ventricular dysfunction: the CAPRICORN randomised trial."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "ing and treating heart failure. J Am Coll Cardiol. 2018;72:2391–2405. Lancet. 2001;357:1385–1390."
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "28. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on 12. Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "the primary prevention of cardiovascular disease: a report of the American use and mortality in patients with asymptomatic and symptomatic left ven-"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 102,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e997"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "tricular systolic dysfunction: a post hoc analysis of the studies of left ven- 35. Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "tricular dysfunction. J Am Coll Cardiol. 1999;33:916–923. trial to DetermIne Superiority in reducing heart failure Events after Myocar-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "13. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of dial Infarction (PARADISE-MI): design and baseline characteristics. Eur J"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "beta-blockers to angiotensin-converting enzyme inhibitors in the Survival Heart Fail. 2021;23:1040–1048."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll 36. Pfeffer MA, Lamas GA, Vaughan DE, et al. Effect of captopril on progres-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Cardiol. 1997;29:229–236. sive ventricular dilatation after anterior myocardial infarction. N Engl J Med."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "14. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator 1988;319:80–86."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "in patients with myocardial infarction and reduced ejection fraction. N Engl 37. Sharpe N, Murphy J, Smith H, et al. Treatment of patients with symptomless"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "J Med. 2002;346:877–883. left ventricular dysfunction after myocardial infarction. Lancet. 1988;1:255–"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "15. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo- 259."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "controlled trial assessing the effects of rosiglitazone on echocardiograph- 38. Velazquez EJ, Pfeffer MA, McMurray JV, et al. VALsartan In Acute myocar-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "ic function and cardiac status in type 2 diabetic patients with New York dial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Heart Association Functional class I or II heart failure. J Am Coll Cardiol. Heart Fail. 2003;5:537–544."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "2007;49:1696–1704. 39. Dickstein K, Kjekshus JOPTIMAAL Steering Committee of the OPTIMAAL"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "16. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of dil- Study Group. Effects of losartan and captopril on mortality and morbidity"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "tiazem on mortality and reinfarction after myocardial infarction. N Engl J in high-risk patients after acute myocardial infarction: the OPTIMAAL ran-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Med. 1988;319:385–392. domised trial. Optimal Trial in Myocardial Infarction with Angiotensin II An-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "17. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset tagonist Losartan. Lancet. 2002;360:752–760."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "congestive heart failure in postinfarction patients with early reduction in 40. Mann DL, Deswal A. Angiotensin-receptor blockade in acute myocardial"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "ejection fraction. Circulation. 1991;83:52–60. infarction--a matter of dose. N Engl J Med. 2003;349:1963–1965."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "18. Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic 41. Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ven-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "significance of heart failure stages: application of the American College of tricular remodeling after acute myocardial infarction: the CAPRICORN Echo"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Cardiology/American Heart Association heart failure staging criteria in the Substudy. Circulation. 2004;109:201–206."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "community. Circulation. 2007;115:1563–1570. 42. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "19. Shah AM, Claggett B, Loehr LR, et al. Heart failure stages among older ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the man-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "adults in the community: the Atherosclerosis Risk in Communities study. agement of blood cholesterol: a report of the American College of Cardiol-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Circulation. 2017;135:224–240. ogy/American Heart Association Task Force on Clinical Practice Guidelines."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "20. Wang Y, Yang H, Huynh Q, et al. Diagnosis of nonischemic stage B heart Circulation. 2019;139:e1082–e1143."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "failure in type 2 diabetes mellitus: optimal parameters for prediction of heart 43. Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "failure. J Am Coll Cardiol Img. 2018;11:1390–1400. remodeling in patients with asymptomatic systolic dysfunction: the REver-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "21. Xanthakis V, Enserro DM, Larson MG, et al. Prevalence, neurohormonal cor- sal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "relates, and prognosis of heart failure stages in the community. J Am Coll 2007;116:49–56."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Cardiol HF. 2016;4:808–815. 44. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart fail-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "22. Al Saikhan L, Park C, Hardy R, et al. Prognostic implications of left ventricu- ure with reduced, mid-range, and preserved ejection fraction: an individ-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "lar strain by speckle-tracking echocardiography in the general population: a ual patient-level analysis of double-blind randomized trials. Eur Heart J."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "meta-analysis. Vasc Health Risk Manag. 2019;15:229–251. 2018;39:26–35."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "23. Biering-Sorensen T, Biering-Sorensen SR, Olsen FJ, et al. Global longitu- 45. Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac func-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "dinal strain by echocardiography predicts long-term risk of cardiovascular tion and exercise capacity in patients with idiopathic dilated cardiomy-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "morbidity and mortality in a low-risk general population: the Copenhagen opathy. Results of the diltiazem in dilated cardiomyopathy trial. Circulation."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "City Heart Study. Circ Cardiovasc Imaging. 2017;10:e005521. 1996;94:346–352."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "24. Echouffo-Tcheugui JB, Erqou S, Butler J, et al. Assessing the risk of pro- 46. Effect of verapamil on mortality and major events after acute myocardial"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "gression from asymptomatic left ventricular dysfunction to overt heart infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "failure: a systematic overview and meta-analysis. J Am Coll Cardiol HF. 1990;66:779–785."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "2016;4:237–248. 47. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "25. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptom- failure in patients with type 2 diabetes and preexisting cardiovascular"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "atic left ventricular systolic dysfunction in the community. Circulation. disease: data from the PROactive study (PROactive 08). Diabetes Care."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "2003;108:977–982. 2007;30:2773–2778."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "26. Yang H, Negishi K, Wang Y, et al. Echocardiographic screening for non- 48. Komajda M, McMurray JJ, Beck-Nielsen H, et al. Heart failure events with"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "ischaemic stage B heart failure in the community. Eur J Heart Fail. rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "2016;18:1331–1339. Heart J. 2010;31:824–831."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "27. Echouffo-Tcheugui JB, Erqou S, Butler J, et al. Assessing the risk of pro- 49. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "gression from asymptomatic left ventricular dysfunction to overt heart death in patients with prediabetes and type 2 diabetes given thiazolidinedio-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "failure: a systematic overview and meta-analysis. J Am Coll Cardiol HF. nes: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129–"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "2016;4:237–248. 1136."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "28. From AM, Scott CG, Chen HH. The development of heart failure in patients 50. Giles TD, Miller AB, Elkayam U, et al. Pioglitazone and heart failure: results"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "with diabetes mellitus and pre-clinical diastolic dysfunction a population- from a controlled study in patients with type 2 diabetes mellitus and systolic"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "based study. J Am Coll Cardiol. 2010;55:300–305. dysfunction. J Card Fail. 2008;14:445–452."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "29. Kane GC, Karon BL, Mahoney DW, et al. Progression of left ventricular dia- 51. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "stolic dysfunction and risk of heart failure. JAMA. 2011;306:856–863. for the management of ST-elevation myocardial infarction: a report of the"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "30. Kosmala W, Sanders P, Marwick TH. Subclinical myocardial impairment in American College of Cardiology Foundation/American Heart Association"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "metabolic diseases. J Am Coll Cardiol Img. 2017;10:692–703. Task Force on Practice Guidelines. Circulation. 2013;127:e362–e42."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "31. Holland DJ, Marwick TH, Haluska BA, et al. Subclinical LV dysfunction and 52. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "10-year outcomes in type 2 diabetes mellitus. Heart. 2015;101:1061– for the management of patients with non-ST-elevation acute coronary syn-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "1066. dromes: a report of the American College of Cardiology/American Heart As-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "32. Beygui F, Cayla G, Roule V, et al. Early aldosterone blockade in acute myo- sociation Task Force on Practice Guidelines. Circulation. 2014;130:e344–"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "cardial infarction: the ALBATROSS randomized clinical trial. J Am Coll Car- e426."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "diol. 2016;67:1917–1927. 53. Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI fo-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "33. Montalescot G, Pitt B, Lopez de Sa E, et al. Early eplerenone treatment in pa- cused update on primary percutaneous coronary intervention for patients"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "tients with acute ST-elevation myocardial infarction without heart failure: the with ST-elevation myocardial infarction: an update of the 2011 ACCF/"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Randomized Double-Blind Reminder Study. Eur Heart J. 2014;35:2295– AHA/SCAI guideline for percutaneous coronary intervention and the 2013"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "2302. ACCF/AHA guideline for the management of ST-elevation myocardial in-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "34. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone block- farction. Circulation. 2016;133:1135–1147."
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "er, in patients with left ventricular dysfunction after myocardial infarction. N 54. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Engl J Med. 2003;348:1309–1321. guideline for coronary artery revascularization: a report of the American Col-"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 103,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "e998 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "lege of Cardiology/American Heart Association Joint Committee on Clinical 16. Ahmed MB, Patel K, Fonarow GC, et al. Higher risk for incident heart fail-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Practice Guidelines. Circulation. 2022;145:e18–e114. ure and cardiovascular mortality among community-dwelling octogenarians"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "55. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/ without pneumococcal vaccination. ESC Heart Fail. 2016;3:11–17."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "PCNA/SCAI/STS focused update of the guideline for the diagnosis and 17. Freedland KE, Carney RM, Rich MW, et al. Depression and multiple rehospi-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "management of patients with stable ischemic heart disease: a report of the talizations in patients with heart failure. Clin Cardiol. 2016;39:257–262."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "American College of Cardiology/American Heart Association Task Force 18. Freedland KE, Hesseler MJ, Carney RM, et al. Major depression and long-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "on Practice Guidelines, and the American Association for Thoracic Surgery, term survival of patients with heart failure. Psychosom Med. 2016;78:896–"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Preventive Cardiovascular Nurses Association, Society for Cardiovascular 903."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Angiography and Interventions, and Society of Thoracic Surgeons. Circula- 19. Murberg TA. Long-term effect of social relationships on mortality in patients"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "tion. 2014;130:1749–1767. with congestive heart failure. Int J Psychiatry Med. 2004;34:207–217."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "56. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for 20. Murberg TA, Bru E. Social relationships and mortality in patients with con-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "coronary artery bypass graft surgery. a report of the American College of gestive heart failure. J Psychosom Res. 2001;51:521–527."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Cardiology Foundation/American Heart Association Task Force on Practice 21. Heidari Gorji MA, Fatahian A, Farsavian A. The impact of perceived and ob-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Guidelines. Developed in collaboration with the American Association for jective social isolation on hospital readmission in patients with heart failure:"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society a systematic review and meta-analysis of observational studies. Gen Hosp"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "of Thoracic Surgeons. Circulation. 2011;124:e652–e735. Psychiatry. 2019;60:27–36."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "57. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update 22. Gallagher R, Luttik ML, Jaarsma T. Social support and self-care in heart"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "of the 2014 AHA/ACC guideline for the management of patients with val- failure. J Cardiovasc Nurs. 2011;26:439–445."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "vular heart disease: a report of the American College of Cardiology/Ameri- 23. Uchmanowicz I, Lee CS, Vitale C, et al. Frailty and the risk of all-cause mor-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "can Heart Association Task Force on Clinical Practice Guidelines. Circula- tality and hospitalization in chronic heart failure: a meta-analysis. ESC Heart"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "tion. 2017;135:e1159–e1195. Fail. 2020;7:3427–3437."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "58. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the 24. Uchmanowicz I, Wleklik M, Gobbens RJ. Frailty syndrome and self-care abil-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "management of patients with valvular heart disease: a report of the Ameri- ity in elderly patients with heart failure. Clin Interv Aging. 2015;10:871–877."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "can College of Cardiology/American Heart Association Joint Committee on 25. Fabbri M, Murad MH, Wennberg AM, et al. Health literacy and outcomes"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Clinical Practice Guidelines. Circulation. 2021;143:e72–e227. among patients with heart failure: a systematic review and meta-analysis. J"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "59. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for Am Coll Cardiol HF. 2020;8:451–460."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "the management of adults with congenital heart disease: a report of the 26. Macabasco-O’Connell A, DeWalt DA, Broucksou KA, et al. Relationship"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "American College of Cardiology/American Heart Association Task Force on between literacy, knowledge, self-care behaviors, and heart failure-re-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Clinical Practice Guidelines. Circulation. 2019;139:e698–e800. lated quality of life among patients with heart failure. J Gen Intern Med."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "2011;26:979–986."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "7.1.1. Self-Care Support in HF"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "27. Bellam N, Kelkar AA, Whellan DJ. Team-based care for managing cardiac"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "1. Holland R, Battersby J, Harvey I, et al. Systematic review of multidisciplinary comorbidities in heart failure. Heart Fail Clin. 2015;11:407–417."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "interventions in heart failure. Heart. 2005;91:899–906. 28. Creaser JW, DePasquale EC, Vandenbogaart E, et al. Team-based care for"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "2. McAlister FA, Stewart S, Ferrua S, et al. Multidisciplinary strategies for the outpatients with heart failure. Heart Fail Clin. 2015;11:379–405."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "management of heart failure patients at high risk for admission: a system- 29. Vader JM, Rich MW. Team-based care for managing noncardiac conditions"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "atic review of randomized trials. J Am Coll Cardiol. 2004;44:810–819. in patients with heart failure. Heart Fail Clin. 2015;11:419–429."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "3. Parajuli DR, Kourbelis C, Franzon J, et al. Effectiveness of the pharmacist- 30. Wever-Pinzon O, Drakos SG, Fang JC. Team-based care for advanced heart"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "involved multidisciplinary management of heart failure to improve hospital- failure. Heart Fail Clin. 2015;11:467–477."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "izations and mortality rates in 4630 patients: a systematic review and meta- 31. Davidson PM, Newton PJ, Tankumpuan T, et al. Multidisciplinary man-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "analysis of randomized controlled trials. J Card Fail. 2019;25:744–756. agement of chronic heart failure: principles and future trends. Clin Ther."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "4. Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions 2015;37:2225–2233."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "for heart failure. Cochrane Database Syst Rev. 2019;1:CD002752. 32. Grady KL, Dracup K, Kennedy G, et al. Team management of patients with"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "5. Jonkman NH, Westland H, Groenwold RH, et al. Do self-management in- heart failure: a statement for healthcare professionals from the Cardio-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "terventions work in patients with heart failure? An individual patient data vascular Nursing Council of the American Heart Association. Circulation."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "meta-analysis. Circulation. 2016;133:1189–1198. 2000;102:2443–2456."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "6. Inglis SC, Clark RA, Dierckx R, et al. Structured telephone support or non- 33. Cooper LB, Hernandez AF. Assessing the quality and comparative effective-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "invasive telemonitoring for patients with heart failure. Cochrane Database ness of team-based care for heart failure: who, what, where, when, and how."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Syst Rev. 2015:CD007228. Heart Fail Clin. 2015;11:499–506."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "7. Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or 34. Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "telemonitoring programmes for patients with chronic heart failure. Cochrane care in persons with heart failure: a scientific statement from the American"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Database Syst Rev. 2010:CD007228. Heart Association. Circulation. 2009;120:1141–1163."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "8. Jovicic A, Holroyd-Leduc JM, Straus SE. Effects of self-management in- 35. Riegel B, Moser DK, Buck HG, et al. Self-care for the prevention and man-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "tervention on health outcomes of patients with heart failure: a systematic agement of cardiovascular disease and stroke: a scientific statement for"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "review of randomized controlled trials. BMC Cardiovasc Disord. 2006;6:43. healthcare professionals from the American Heart Association. J Am Heart"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "9. Ruppar TM, Cooper PS, Mehr DR, et al. Medication adherence interventions Assoc. 2017;6:e006997."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "improve heart failure mortality and readmission rates: systematic review and 36. Moser DK, Dickson V, Jaarsma T, et al. Role of self-care in the patient with"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "meta-analysis of controlled trials. J Am Heart Assoc. 2016;5:e002606. heart failure. Curr Cardiol Rep. 2012;14:265–275."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "10. Butt AA, Omer SB, Yan P, et al. SARS-CoV-2 vaccine effectiveness in 37. Riegel B, Lee CS, Dickson VV, et al. Self care in patients with chronic heart"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "a high-risk national population in a real-world setting. Ann Intern Med. failure. Nat Rev Cardiol. 2011;8:644–654."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "2021;174:1404–1408. 38. Hwang B, Moser DK, Dracup K. Knowledge is insufficient for self-care"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "11. Gotsman I, Shuvy M, Tahiroglu I, et al. Influenza vaccination and outcome in among heart failure patients with psychological distress. Health Psychol."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "heart failure. Am J Cardiol. 2020;128:134–139. 2014;33:588–596."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "12. Modin D, Jorgensen ME, Gislason G, et al. Influenza vaccine in heart failure. 39. Allida S, Du H, Xu X, et al. mHealth education interventions in heart failure."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Circulation. 2019;139:575–586. Cochrane Database Syst Rev. 2020;7:CD011845."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "13. Mohseni H, Kiran A, Khorshidi R, et al. Influenza vaccination and risk of hos- 40. Hwang B, Pelter MM, Moser DK, Dracup K. Effects of an educational inter-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "pitalization in patients with heart failure: a self-controlled case series study. vention on heart failure knowledge, self-care behaviors, and health-related"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Eur Heart J. 2017;38:326–333. quality of life of patients with heart failure: exploring the role of depression."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "14. Vardeny O, Claggett B, Udell JA, et al. Influenza vaccination in patients Patient Educ Couns. 2020;103:1201–1208."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "with chronic heart failure: the PARADIGM-HF trial. J Am Coll Cardiol HF. 41. Dracup K, Moser DK, Pelter MM, et al. Randomized, controlled trial to im-"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "2016;4:152–158. prove self-care in patients with heart failure living in rural areas. Circulation."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "15. Yedlapati SH, Khan SU, Talluri S, et al. Effects of influenza vaccine on 2014;130:256–264."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "mortality and cardiovascular outcomes in patients with cardiovascu- 42. Van Spall HGC, Lee SF, Xie F, et al. Effect of patient-centered transitional"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "lar disease: a systematic review and meta-analysis. J Am Heart Assoc. care services on clinical outcomes in patients hospitalized for heart failure:"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "2021;10:e019636. the PACT-HF randomized clinical trial. JAMA. 2019;321:753–761."
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 104,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e999"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "43. Mohseni Z, Spaanderman MEA, Oben J, et al. Cardiac remodeling and pre- 3. Kalogeropoulos A, Papadimitriou L, Georgiopoulou VV, et al. Low- versus"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "eclampsia: an overview of microRNA expression patterns. Ultrasound Obstet moderate-sodium diet in patients with recent hospitalization for heart fail-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Gynecol. 2018;52:310–317. ure: the PROHIBIT (Prevent Adverse Outcomes in Heart Failure by Limiting"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "44. Bhatt AS, Adler ED, Albert NM, et al. Coronavirus disease-2019 and heart Sodium) pilot study. Circ Heart Fail. 2020;13:e006389."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "failure: a scientific statement from the Heart Failure Society of America. J 4. Colin-Ramirez E, McAlister FA, Zheng Y, et al. The long-term effects of di-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Card Fail. 2021;S1071-9164(21):00354–00357. etary sodium restriction on clinical outcomes in patients with heart failure."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "45. Bhatt AS, Jering KS, Vaduganathan M, et al. Clinical outcomes in pa- The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "tients with heart failure hospitalized with COVID-19. J Am Coll Cardiol HF. Failure): a pilot study. Am Heart J. 2015;169:274–281.e1."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "2021;9:65–73. 5. Colin-Ramirez E, McAlister FA, Zheng Y, et al. Changes in dietary intake and"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "46. Cannata A, Bromage DI, Rind IA, et al. Temporal trends in decompensated nutritional status associated with a significant reduction in sodium intake in"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "heart failure and outcomes during COVID-19: a multisite report from heart patients with heart failure. A sub-analysis of the SODIUM-HF pilot study."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "failure referral centres in London. Eur J Heart Fail. 2020;22:2219–2224. Clin Nutr ESPEN. 2016;11:e26–e32."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "47. Tomasoni D, Inciardi RM, Lombardi CM, et al. Impact of heart failure on 6. Hummel SL, Karmally W, Gillespie BW, et al. Home-delivered meals postdis-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "the clinical course and outcomes of patients hospitalized for COVID-19. charge from heart failure hospitalization. Circ Heart Fail. 11;2018:e004886."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Results of the Cardio-COVID-Italy multicentre study. Eur J Heart Fail. 7. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "2020;22:2238–2247. management of heart failure: a report of the American College of Cardiol-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "48. Patel A, Parikh R, Howell EH, et al. Mini-cog performance: novel marker of ogy Foundation/American Heart Association Task Force on Practice Guide-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "post discharge risk among patients hospitalized for heart failure. Circ Heart lines. Circulation. 2013;128:e240–e327."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Fail. 2015;8:8–16. 8. Yancy CW. The uncertainty of sodium restriction in heart failure: we can do"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "49. Lovell J, Pham T, Noaman SQ, et al. Self-management of heart failure in better than this. J Am Coll Cardiol HF. 2016;4:39–41."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "dementia and cognitive impairment: a systematic review. BMC Cardiovasc 9. Yancy CW. Sodium restriction in heart failure: too much uncertainty-do the"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Disord. 2019;19:99. trials. JAMA Intern Med. 2018;178:1700–1701."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "50. Cannon JA, Moffitt P, Perez-Moreno AC, et al. Cognitive impairment 10. Francis GS. Notice of concern. J Card Fail. 2013;19:523."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "and heart failure: systematic review and meta-analysis. J Card Fail. 11. Alexopoulos D, Moulias A, Koutsogiannis N, et al. Differential effect of ti-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "2017;23:464–475. cagrelor versus prasugrel on coronary blood flow velocity in patients with"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "51. Sbolli M, Fiuzat M, Cani D, et al. Depression and heart failure: the lonely non-ST-elevation acute coronary syndrome undergoing percutaneous coro-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "comorbidity. Eur J Heart Fail. 2020;22:2007–2017. nary intervention: an exploratory study. Circ Cardiovasc Interv. 2013;6:277–"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "52. Zambrano J, Celano CM, Januzzi JL, et al. Psychiatric and psychological 283."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "interventions for depression in patients with heart disease: a scoping review. 12. Van Horn L, Carson JA, Appel LJ, et al. Recommended dietary pattern to"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "J Am Heart Assoc. 2020;9:e018686. achieve adherence to the American Heart Association/American College of"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "53. Nishimura M, Bhatia H, Ma J, et al. The impact of substance abuse on heart Cardiology (AHA/ACC) guidelines: a scientific statement from the Ameri-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "failure hospitalizations. Am J Med. 2020;133:207–213.e1. can Heart Association. Circulation. 2016;134:e505–e529."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "54. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a 13. Mahtani KR, Heneghan C, Onakpoya I, et al. Reduced salt intake for heart"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–M156. failure: a systematic review. JAMA Intern Med. 2018;178:1693–1700."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "55. Smith GH, Shore S, Allen LA, et al. Discussing out-of-pocket costs with 14. Jefferson K, Ahmed M, Choleva M, et al. Effect of a sodium-restricted diet"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "patients: shared decision making for sacubitril-valsartan in heart failure. J on intake of other nutrients in heart failure: implications for research and"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Am Heart Assoc. 2019;8:e010635. clinical practice. J Card Fail. 2015;21:959–962."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "56. Sun Y, Liu B, Rong S, et al. Food insecurity is associated with cardiovascular 15. Lennie TA, Andreae C, Rayens MK, et al. Micronutrient deficiency indepen-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "and all-cause mortality among adults in the United States. J Am Heart As- dently predicts time to event in patients with heart failure. J Am Heart Assoc."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "soc. 2020;9:e014629. 2018;7:e007251."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "57. Makelarski JA, Abramsohn E, Benjamin JH, et al. Diagnostic accuracy of 16. Bonilla-Palomas JL, Gámez-López AL, Castillo-Domínguez JC, et al. Nutri-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "two food insecurity screeners recommended for use in health care settings. tional intervention in malnourished hospitalized patients with heart failure."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Am J Public Health. 2017;107:1812–1817. Arch Med Res. 2016;47:535–540."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "58. Sims M, Kershaw KN, Breathett K, et al. Importance of housing and cardio- 17. Bilgen F, Chen P, Poggi A, et al. Insufficient calorie intake worsens post-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "vascular health and well-being: a scientific statement from the American discharge quality of life and increases readmission burden in heart failure. J"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Heart Association. Circ Cardiovasc Qual Outcomes. 2020;13:e000089. Am Coll Cardiol HF. 2020;8:756–764."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "59. Jayawardana S, Mossialos E. Lives cut short: socioeconomic inequities, 18. Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "homelessness, and cardiovascular disease. Eur Heart J. 2020;41:4021– exercise capacity in patients with heart failure with reduced ejection frac-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "4023. tion and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "60. Baggett TP, Liauw SS, Hwang SW. Cardiovascular disease and homeless- 2017;317:1958–1966."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "ness. J Am Coll Cardiol. 2018;71:2585–2597. 19. Keith M, Quach S, Ahmed M, et al. Thiamin supplementation does not im-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "61. US Preventive Services Task Force. Screening for intimate partner violence, prove left ventricular ejection fraction in ambulatory heart failure patients: a"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "elder abuse, and abuse of vulnerable adults: US Preventive Services Task randomized controlled trial. Am J Clin Nutr. 2019;110:1287–1295."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Force Final Recommendation Statement. JAMA. 2018;320:1678–1687. 20. Rosenblum H, Wessler JD, Gupta A, et al. Zinc deficiency and heart failure:"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "62. Chandan JS, Thomas T, Bradbury-Jones C, et al. Risk of cardiometabolic a systematic review of the current literature. J Card Fail. 2020;26:180–189."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "disease and all-cause mortality in female survivors of domestic abuse. J Am 21. Wang T, Liu Z, Fu J, Min Z. Meta-analysis of vitamin D supplementation in the"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Heart Assoc. 2020;9:e014580. treatment of chronic heart failure. Scand Cardiovasc J. 2019;53:110–116."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "63. Rawal S, Srighanthan J, Vasantharoopan A, et al. Association between lim- 22. McKeag NA, McKinley MC, Harbinson MT, et al. The effect of multiple mi-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "ited English proficiency and revisits and readmissions after hospitalization cronutrient supplementation on left ventricular ejection fraction in patients"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "for patients with acute and chronic conditions in Toronto, Ontario, Canada. with chronic stable heart failure: a randomized, placebo-controlled trial. J Am"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "JAMA. 2019;322:1605–1607. Coll Cardiol HF. 2014;2:308–317."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "64. Magnani JW, Mujahid MS, Aronow HD, et al. Health literacy and cardiovas- 23. Ò Miró, Estruch R, Martín-Sánchez FJ, et al. Adherence to Mediterranean"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "cular disease: fundamental relevance to primary and secondary prevention: diet and all-cause mortality after an episode of acute heart failure: results of"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "a scientific statement from the American Heart Association. Circulation. the MEDIT-AHF study. J Am Coll Cardiol HF. 2018;6:52–62."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "2018;138:e48–e74. 24. Aliti GB, Rabelo ER, Clausell N, et al. Aggressive fluid and sodium restric-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "65. Manemann SM, Chamberlain AM, Roger VL, et al. Perceived social iso- tion in acute decompensated heart failure: a randomized clinical trial. JAMA"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "lation and outcomes in patients with heart failure. J Am Heart Assoc. Intern Med. 2013;173:1058–1064."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "2018;7:e008069. 25. Machado d’Almeida KS, Rabelo-Silva ER, Souza GC, et al. Aggressive"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "fluid and sodium restriction in decompensated heart failure with pre-"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "7.1.2. Dietary Sodium Restriction served ejection fraction: results from a randomized clinical trial. Nutrition."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "1. Philipson H, Ekman I, Forslund HB, et al. Salt and fluid restriction is effective 2018;54:111–117."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "in patients with chronic heart failure. Eur J Heart Fail. 2013;15:1304–1310. 26. Welsh D, Lennie TA, Marcinek R, et al. Low-sodium diet self-management"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "2. Doukky R, Avery E, Mangla A, et al. Impact of dietary sodium restriction on intervention in heart failure: pilot study results. Eur J Cardiovasc Nurs."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "heart failure outcomes. J Am Coll Cardiol HF. 2016;4:24–35. 2013;12:87–95."
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 105,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "e1000 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "7.1.3. Management of Stage C HF: Activity, Exercise 7.2. Diuretics and Decongestion Strategies in Patients"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "Prescription, and Cardiac Rehabilitation With HF"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "1. O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "1. Patterson JH, Adams KF Jr, Applefeld MM, et al. Oral torsemide in pa-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "training in patients with chronic heart failure: HF-ACTION randomized con-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tients with chronic congestive heart failure: effects on body weight, edema,"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "trolled trial. JAMA. 2009;301:1439–1450."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2. Davies EJ, Moxham T, Rees K, et al. Exercise training for systolic heart"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "1994;14:514–521."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "failure: Cochrane systematic review and meta-analysis. Eur J Heart Fail."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2. Goebel KM. Six-week study of torsemide in patients with congestive heart 2010;12:706–715."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "failure. Clin Ther. 1993;15:1051–1059."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "3. Haykowsky MJ, Timmons MP, Kruger C, et al. Meta-analysis of aero-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "3. Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the perfor-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "bic interval training on exercise capacity and systolic function in pa-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "mance of the failing left ventricle in man. Am J Med. 1981;70:234–239."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tients with heart failure and reduced ejection fractions. Am J Cardiol."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "4. Parker JO. The effects of oral ibopamine in patients with mild heart failure—a"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2013;111:1466–1469."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "double blind placebo controlled comparison to furosemide. The Ibopamine"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "4. Santos FV, Chiappa GR, Ramalho SHR, et al. Resistance exercise enhances"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "Study Group. Int J Cardiol. 1993;40:221–227."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "oxygen uptake without worsening cardiac function in patients with sys-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "5. Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of cap-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tolic heart failure: a systematic review and meta-analysis. Heart Fail Rev."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "topril alone against frusemide plus amiloride in mild heart failure. Lancet."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2018;23:73–89."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "1987;2:709–711."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "5. Taylor RS, Walker S, Smart NA, et al. Impact of exercise rehabilitation on"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "6. Grodin JL, Stevens SR, de Las Fuentes L, et al. Intensification of medication"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "exercise capacity and quality-of-life in heart failure: individual participant"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "therapy for cardiorenal syndrome in acute decompensated heart failure. J"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "meta-analysis. J Am Coll Cardiol. 2019;73:1430–1443."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "Card Fail. 2016;22:26–32."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "6. Sagar VA, Davies EJ, Briscoe S, et al. Exercise-based rehabilitation"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "7. Ellison DH, Felker GM. Diuretic treatment in heart failure. N Engl J Med."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "for heart failure: systematic review and meta-analysis. Open Heart."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2017;377:1964–1975."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2015;2:e000163."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "8. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium reten-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "7. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-anal-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tion of congestive heart failure. Arch Intern Med. 1994;154:1905–1914."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "ysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "9. Faselis C, Arundel C, Patel S, et al. Loop diuretic prescription and 30-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2004;328:189."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "day outcomes in older patients with heart failure. J Am Coll Cardiol."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "8. Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2020;76:669–679."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "failure. Cochrane Database Syst Rev. 2014:CD003331."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "10. Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "9. Kitzman DW, Whellan DJ, Duncan P, et al. Physical rehabilita-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "pharmacodynamics of torsemide and furosemide in patients with conges-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tion for older patients hospitalized for heart failure. N Engl J Med."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tive heart failure. Clin Pharmacol Ther. 1995;57:601–609."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2021;385:203–216."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "11. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "10. Pina IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: a statement"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "torsemide compared with furosemide therapy for patients with heart failure."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "from the American Heart Association Committee on Exercise, Rehabilita-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "Am J Med. 2001;111:513–520."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tion, and Prevention. Circulation. 2003;107:1210–1225."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "12. Cosin J, Diez J, TORIC Investigators. Torasemide in chronic heart failure:"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "11. Forman DE, Sanderson BK, Josephson RA, et al. Heart failure as a newly"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "results of the TORIC study. Eur J Heart Fail. 2002;4:507–513."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "approved diagnosis for cardiac rehabilitation: challenges and opportunities."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "13. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states:"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "J Am Coll Cardiol. 2015;65:2652–2659."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "12. McKelvie RS. Exercise training in patients with heart failure: clinical out-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "1996;30:229–249. comes, safety, and indications. Heart Fail Rev. 2008;13:3–11."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "14. Ellison DH. The physiologic basis of diuretic synergism: its role in treating"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "13. Achttien RJ, Staal JB, van der Voort S, et al. Exercise-based cardiac rehabili-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "diuretic resistance. Ann Intern Med. 1991;114:886–894."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tation in patients with chronic heart failure: a Dutch practice guideline. Neth"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "15. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "Heart J. 2015;23:6–17."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527–"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "14. Davies EJ, Moxham T, Rees K, et al. Exercise based rehabilitation for heart"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "1534."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "failure. Cochrane Database Syst Rev. 2010:CD003331."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "16. Cox ZL, Hung R, Lenihan DJ, et al. Diuretic strategies for loop diuretic resis-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "15. Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac reha-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tance in acute heart failure: the 3T trial. J Am Coll Cardiol HF. 2020;8:157–"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "bilitation for adults with heart failure. Cochrane Database Syst Rev."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "168."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2019;1:CD003331."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "17. Brisco-Bacik MA, Ter Maaten JM, Houser SR, et al. Outcomes associated"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "16. Fukuta H, Goto T, Wakami K, et al. Effects of exercise training on cardiac"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "with a strategy of adjuvant metolazone or high-dose loop diuretics in acute"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "function, exercise capacity, and quality of life in heart failure with preserved"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "decompensated heart failure: a propensity analysis. J Am Heart Assoc."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2018;7:e009149."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "Rev. 2019;24:535–547."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "18. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "17. Dieberg G, Ismail H, Giallauria F, et al. Clinical outcomes and cardiovascular"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "decompensated heart failure. N Engl J Med. 2011;364:797–805."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "responses to exercise training in heart failure patients with preserved ejec-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "tion fraction: a systematic review and meta-analysis. J Appl Physiol (1985)."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "7.3.1. Renin-Angiotensin System Inhibition With"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2015;119:726–733."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "18. Kitzman DW, Brubaker PH, Morgan TM, et al. Exercise training in older ACEi or ARB or ARNi"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "patients with heart failure and preserved ejection fraction: a randomized, 1. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "controlled, single-blind trial. Circ Heart Fail. 2010;3:659–667. versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "19. Edelmann F, Gelbrich G, Dungen HD, et al. Exercise training im- 2. Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "proves exercise capacity and diastolic function in patients with heart haemodynamically stabilised heart failure patients in hospital or early af-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "failure with preserved ejection fraction: results of the Ex-DHF (Exer- ter discharge: primary results of the randomised TRANSITION study. Eur J"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "cise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol. Heart Fail. 2019;21:998–1007."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2011;58:1780–1791. 3. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibi-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "20. Fujimoto N, Prasad A, Hastings JL, et al. Cardiovascular effects of 1 year of tion in acute decompensated heart failure. N Engl J Med. 2019;380:539–"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "progressive endurance exercise training in patients with heart failure with 548."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "preserved ejection fraction. Am Heart J. 2012;164:869–877. 4. Desai AS, Solomon SD, Shah AM, et al. Effect of sacubitril-valsartan vs enal-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "21. Kitzman DW, Brubaker PH, Herrington DM, et al. Effect of endurance exer- april on aortic stiffness in patients with heart failure and reduced ejection"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "cise training on endothelial function and arterial stiffness in older patients fraction: a randomized clinical trial. JAMA. 2019;322:1077–1084."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "with heart failure and preserved ejection fraction: a randomized, controlled, 5. Wang Y, Zhou R, Lu C, et al. Effects of the angiotensin-receptor neprilysin"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "single-blind trial. J Am Coll Cardiol. 2013;62:584–592. inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "22. Kitzman DW, Brubaker P, Morgan T, et al. Effect of caloric restriction or 2019;8:e012272."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "aerobic exercise training on peak oxygen consumption and quality of life 6. Consensus Trial Study Group. Effects of enalapril on mortality in severe con-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "in obese older patients with heart failure with preserved ejection fraction: a gestive heart failure. Results of the Cooperative North Scandinavian Enala-"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "randomized clinical trial. JAMA. 2016;315:36–46. pril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435."
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 106,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1001"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "7. SOLVD Investigators. Effect of enalapril on survival in patients with reduced 29. Sandhu AT, Ollendorf DA, Chapman RH, et al. Cost-effectiveness of sacubi-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "left ventricular ejection fractions and congestive heart failure. N Engl J Med. tril-valsartan in patients with heart failure with reduced ejection fraction. Ann"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "1991;325:293–302. Intern Med. 2016;165:681–689."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "8. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low 30. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on enalapril in patients with chronic heart failure: the Omapatrilat Versus Enala-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "morbidity and mortality in chronic heart failure. ATLAS Study Group. Circula- pril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "tion. 1999;100:2312–2318. 2002;106:920–926."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "9. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and 31. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "morbidity in patients with left ventricular dysfunction after myocardial infarc- with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "tion: results of the Survival and Ventricular Enlargement Trial. The SAVE (OCTAVE) trial. Am J Hypertens. 2004;17:103–111."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Investigators. N Engl J Med. 1992;327:669–677. 32. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angioten-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "10. Effect of ramipril on mortality and morbidity of survivors of acute myocar- sin system inhibition for the treatment of heart failure. J Am Coll Cardiol HF."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "dial infarction with clinical evidence of heart failure. The Acute Infarction 2014;2:663–670."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821–828. 33. Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "11. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angio- Lancet. 2000;356:608–609."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "tensin-converting-enzyme inhibitor trandolapril in patients with left ventricu- 34. Braunwald E. The path to an angiotensin receptor antagonist-neprilysin in-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "lar dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation hibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65:1029–"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "(TRACE) Study Group. N Engl J Med. 1995;333:1670–1676. 1041."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "12. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting 35. Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696,"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "enzyme inhibitors on mortality and morbidity in patients with heart failure. a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450–1456. randomised, double-blind, placebo-controlled, active comparator study. Lan-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "13. Woodard-Grice AV, Lucisano AC, Byrd JB, et al. Sex-dependent and race- cet. 2010;375:1255–1266."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "dependent association of XPNPEP2 C-2399A polymorphism with angio- 36. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-as-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "tensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet sociated angioedema. Immunol Allergy Clin North Am. 2006;26:725–737."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Genomics. 2010;20:532–536. 37. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "14. Cohn JN, Tognoni GValsartan Heart Failure Trial Investigators. A randomized associated with the use of drugs that target the renin-angiotensin-aldoste-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N rone system. Arch Intern Med. 2012;172:1582–1589."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Engl J Med. 2001;345:1667–1675. 38. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "15. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in of angioedema as an adverse event of renin-angiotensin system inhibitors."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "myocardial infarction complicated by heart failure, left ventricular dysfunc- Am J Cardiol. 2012;110:383–391."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "tion, or both [published correction appears in N Engl J Med. 2004;350:203]. 39. Rasmussen ER, Pottegard A, Bygum A, et al. Angiotensin II receptor block-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "N Engl J Med. 2003;349:1893–1906. ers are safe in patients with prior angioedema related to angiotensin-con-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "16. Konstam MA, Neaton JD, Dickstein K, et al; HEAAL Investigators. Effects verting enzyme inhibitors - a nationwide registry-based cohort study. J Intern"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "of high-dose versus low-dose losartan on clinical outcomes in patients Med. 2019;285:553–561."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 40. Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "2009;374:1840–1848. trial to DetermIne Superiority in reducing heart failure Events after Myocar-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "17. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in dial Infarction (PARADISE-MI): design and baseline characteristics. Eur J"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559. Heart Fail. 2021;23:1040–1048."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "18. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with 41. Zueger PM, Kumar VM, Harrington RL, et al. Cost-effectiveness analysis of"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, et al. sacubitril/valsartan for the treatment of heart failure with reduced ejection"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Effects of the angiotensin-receptor blocker telmisartan on cardiovascular fraction in the United States. Pharmacotherapy. 2018;38:520–530."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "events in high-risk patients intolerant to angiotensin-converting enzyme in-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "hibitors: a randomised controlled trial. Lancet. 2008;372:1174–1183. 7.3.2. Beta Blockers"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "19. Banka G, Heidenreich PA, Fonarow GC. Incremental cost-effectiveness of 1. Cardiac Insufficiency Authors. The Cardiac Insufficiency Bisoprolol Study II"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "guideline-directed medical therapies for heart failure. J Am Coll Cardiol. (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "2013;61:1440–1446. 2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "20. Dasbach EJ, Rich MW, Segal R, et al. The cost-effectiveness of losartan Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "versus captopril in patients with symptomatic heart failure. Cardiology. Lancet. 1999;353:2001–2007."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "1999;91:189–194. 3. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbid-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "21. Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in ity of patients with severe chronic heart failure: results of the carvedilol pro-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "patients with symptomatic heart failure: an economic analysis of the Stud- spective randomized cumulative survival (COPERNICUS) study. Circulation."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "ies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail. 2002;106:2194–2199."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "1995;1:371–380. 4. Banka G, Heidenreich PA, Fonarow GC. Incremental cost-effectiveness of"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "22. Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin guideline-directed medical therapies for heart failure. J Am Coll Cardiol."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "converting enzyme inhibition in patients with congestive heart failure. Arch 2013;61:1440–1446."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Intern Med. 1994;154:1143–1149. 5. Caro JJ, Migliaccio-Walle K, O’Brien JA, et al. Economic implications of ex-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "23. Reed SD, Friedman JY, Velazquez EJ, et al. Multinational economic evalua- tended-release metoprolol succinate for heart failure in the MERIT-HF trial:"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "tion of valsartan in patients with chronic heart failure: results from the Val- a US perspective of the MERIT-HF trial. J Card Fail. 2005;11:647–656."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "sartan Heart Failure Trial (Val-HeFT). Am Heart J. 2004;148:122–128. 6. Delea TE, Vera-Llonch M, Richner RE, et al. Cost effectiveness of carvedilol"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "24. Shekelle P, Morton S, Atkinson S, et al. Pharmacologic management of heart for heart failure. Am J Cardiol. 1999;83:890–896."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "failure and left ventricular systolic dysfunction: effect in female, black, and 7. Gregory D, Udelson JE, Konstam MA. Economic impact of beta blockade in"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "diabetic patients, and cost-effectiveness. Evid Rep Technol Assess (Summ). heart failure. Am J Med. 2001;110(suppl 7A):74S–80S."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "2003:1–6. 8. Vera-Llonch M, Menzin J, Richner RE, et al. Cost-effectiveness results"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "25. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy from the US Carvedilol Heart Failure Trials Program. Ann Pharmacother."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "after myocardial infarction. J Am Coll Cardiol. 1995;26:914–919. 2001;35:846–851."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "26. Gaziano TA, Fonarow GC, Claggett B, et al. Cost-effectiveness analysis of 9. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "sacubitril/valsartan vs enalapril in patients with heart failure and reduced improvements in left ventricular function and survival in subjects with chronic"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "ejection fraction. JAMA Cardiol. 2016;1:666–672. heart failure. MOCHA Investigators. Circulation. 1996;94:2807–2816."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "27. Gaziano TA, Fonarow GC, Velazquez EJ, et al. Cost-effectiveness of sacu- 10. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart fail-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "bitril-valsartan in hospitalized patients who have heart failure with reduced ure with reduced, mid-range, and preserved ejection fraction: an individ-"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "ejection fraction. JAMA Cardiol. 2020;5:1236–1244. ual patient-level analysis of double-blind randomized trials. Eur Heart J."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "28. King JB, Shah RU, Bress AP, et al. Cost-effectiveness of sacubitril-valsartan 2018;39:26–35."
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "combination therapy compared with enalapril for the treatment of heart fail- 11. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "ure with reduced ejection fraction. J Am Coll Cardiol HF. 2016;4:392–402. metoprolol on total mortality, hospitalizations, and well-being in patients with"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 107,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "e1002 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "heart failure: the Metoprolol CR/XL Randomized Intervention Trial in con- 15. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "gestive heart failure (MERIT-HF). JAMA. 2000;283:1295–1302. of RLY5016, a polymeric potassium binder, in a double-blind, placebo-con-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "12. Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients trolled study in patients with chronic heart failure (the PEARL-HF) trial. Eur"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "with heart failure plus atrial fibrillation: an individual-patient data meta-anal- Heart J. 2011;32:820–828."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "ysis. Lancet. 2014;384:2235–2243. 16. Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "13. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "the effect of nebivolol on mortality and cardiovascular hospital admission in from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215– Heart Fail. 2015;17:1050–1056."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "225."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "14. Beta-Blocker Evaluation of Survival Trial Investigators, Eichhorn EJ, 7.3.4. Sodium-Glucose Cotransporter 2 Inhibitors"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "Domanski MJ, et al. A trial of the beta-blocker bucindolol in patients with (SGLT2i)"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "1. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "15. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "and metoprolol on clinical outcomes in patients with chronic heart failure"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "2008."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "in the Carvedilol Or Metoprolol European Trial (COMET): randomised con-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "2. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "trolled trial. Lancet. 2003;362:7–13."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "16. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "3. Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "hospitalization of initiating treatment for chronic heart failure with bisoprolol"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "dapagliflozin for treatment of patients with heart failure with reduced ejec-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "followed by enalapril, as compared with the opposite sequence: results of"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "tion fraction. JAMA Cardiol. 2021;6:926–935."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circula-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "4. Isaza N, Calvachi P, Raber I, et al. Cost-effectiveness of dapagliflozin for the"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "tion. 2005;112:2426–2435."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "treatment of heart failure with reduced ejection fraction. JAMA Netw Open."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "17. Gattis WA, O’Connor CM. Predischarge initiation of carvedilol in patients"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "2021;4:e2114501."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "hospitalized for decompensated heart failure. Am J Cardiol. 2004;93:74B–"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "76B."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "18. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treat-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "6. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular out-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "ment for heart failure in patients with recovered dilated cardiomyopathy"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "comes in type 2 diabetes. N Engl J Med. 2019;380:347–357."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "(TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393:61–73."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes,"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "19. Waagstein F, Caidahl K, Wallentin I, et al. Long-term beta-blockade in di-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "lated cardiomyopathy: effects of short- and long-term metoprolol treat-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "8. Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "ment followed by withdrawal and readministration of metoprolol. Circulation."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "1989;80:551–563."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "Cardiol. 2020;75:422–434."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "9. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "7.3.3. Mineralocorticoid Receptor Antagonists"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "heart failure with reduced ejection fraction: a meta-analysis of the EMPER-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "(MRAs) OR-Reduced and DAPA-HF trials. Lancet. 2020;396:819–829."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity 10. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "and mortality in patients with severe heart failure. Randomized Aldactone and recent worsening heart failure. N Engl J Med. 2021;384:117–128."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "Evaluation Study Investigators. N Engl J Med. 1999;341:709–717. 11. Vardeny O, Vaduganathan M. Practical guide to prescribing sodium-glu-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "2. Pitt B, Remme W, Zannad F. Eplerenone Post-Acute Myocardial Infarction cose cotransporter 2 inhibitors for cardiologists. J Am Coll Cardiol HF."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selec- 2019;7:169–172."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "tive aldosterone blocker, in patients with left ventricular dysfunction after"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "myocardial infarction. N Engl J Med. 2003;348:1309–1321. 7.3.5. Hydralazine and Isosorbide Dinitrate"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "3. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic (H-ISDN)"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "heart failure and mild symptoms. N Engl J Med. 2011;364:11–21. 1. Carson P, Ziesche S, Johnson G, et al. Racial differences in response to"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "4. Banka G, Heidenreich PA, Fonarow GC. Incremental cost-effectiveness of therapy for heart failure: analysis of the vasodilator-heart failure trials. Vaso-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "guideline-directed medical therapies for heart failure. J Am Coll Cardiol. dilator-Heart Failure Trial Study Group. J Card Fail. 1999;5:178–187."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "2013;61:1440–1446. 2. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "5. Glick HA, Orzol SM, Tooley JF, et al. Economic evaluation of the randomized hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "aldactone evaluation study (RALES): treatment of patients with severe heart 2057."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "failure. Cardiovasc Drugs Ther. 2002;16:53–59. 3. Angus DC, Linde-Zwirble WT, Tam SW, et al. Cost-effectiveness of fixed-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "6. Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effectiveness of dose combination of isosorbide dinitrate and hydralazine therapy for blacks"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "eplerenone compared with placebo in patients with myocardial infarction with heart failure. Circulation. 2005;112:3745–3753."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "complicated by left ventricular dysfunction and heart failure. Circulation. 4. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "2005;111:1106–1113. mortality in chronic congestive heart failure. Results of a Veterans Adminis-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "7. Zhang Z, Mahoney EM, Kolm P, et al. Cost effectiveness of eplerenone in tration Cooperative Study. N Engl J Med. 1986;314:1547–1552."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "patients with heart failure after acute myocardial infarction who were taking 5. Khazanie P, Liang L, Curtis LH, et al. Clinical effectiveness of hydralazine-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Am J isosorbide dinitrate therapy in patients with heart failure and reduced ejec-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "Cardiovasc Drugs. 2010;10:55–63. tion fraction: findings from the Get With The Guidelines-Heart Failure Reg-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "8. Hernandez AF, Mi X, Hammill BG, et al. Associations between aldosterone an- istry. Circ Heart Fail. 2016;9:e002444."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "tagonist therapy and risks of mortality and readmission among patients with 6. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hy-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "heart failure and reduced ejection fraction. JAMA. 2012;308:2097–2107. dralazine-isosorbide dinitrate in the treatment of chronic congestive heart"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "9. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after failure. N Engl J Med. 1991;325:303–310."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 7. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, et al. Effect of direct va-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "2004;351:543–551. sodilation with hydralazine versus angiotensin-converting enzyme inhibition"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "10. FDA Aldactone label 2008. Accessed June 28, 2021. https://www.access- with captopril on mortality in advanced heart failure: the Hy-C trial. J Am Coll"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "data.fda.gov/drugsatfda_docs/label/2008/012151s062lbl.pdf Cardiol. 1992;19:842–850."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "11. FDA INSPRA label 2008. Accessed June 28, 2021. https://www.access-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "data.fda.gov/drugsatfda_docs/label/2008/021437s006lbl.pdf 7.3.6. Other Drug Treatment"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "12. Butler J, Anstrom KJ, Felker GM, et al. Efficacy and safety of spironolactone 1. Macchia A, Levantesi G, Franzosi MG, et al. Left ventricular systolic dysfunc-"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "in acute heart failure: the ATHENA-HF Randomized Clinical Trial. JAMA tion, total mortality, and sudden death in patients with myocardial infarction"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "Cardiol. 2017;2:950–958. treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail. 2005;7:904–"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "13. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition 909."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. 2. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "14. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition acids in patients with chronic heart failure (the GISSI-HF trial): a randomised,"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "in acute decompensated heart failure. N Engl J Med. 2019;380:539–548. double-blind, placebo-controlled trial. Lancet. 2008;372:1223–1230."
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 108,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1003"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "3. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosa- 3. Djoussé L, Cook NR, Kim E, et al. Supplementation with vitamin D and ome-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "pent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. ga-3 fatty acids and incidence of heart failure hospitalization: VITAL-Heart"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "4. Peterson BE, Bhatt DL, Steg PG, et al. Reduction in revascularization with Failure. Circulation. 2020;141:784–786."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "icosapent ethyl: insights from REDUCE-IT revascularization analyses. Cir- 4. Wang T, Liu Z, Fu J, Min Z. Meta-analysis of vitamin D supplementation in"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "culation. 2021;143:33–44. the treatment of chronic heart failure. Scand Cardiovasc J. 2019;53:110–"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "5. Pitt B, Anker SD, Bushinsky DA, et al. Evaluation of the efficacy and safety 116."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "of RLY5016, a polymeric potassium binder, in a double-blind, placebo-con- 5. Zittermann A, Ernst JB, Prokop S, et al. Vitamin D supplementation of 4000"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "trolled study in patients with chronic heart failure (the PEARL-HF) trial. Eur IU daily and cardiac function in patients with advanced heart failure: the"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Heart J. 2011;32:820–828. EVITA trial. Int J Cardiol. 2019;280:117–123."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "6. Anker SD, Kosiborod M, Zannad F, et al. Maintenance of serum potassium 6. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplemen-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results tation on cardiovascular events and cancer: a randomized controlled trial."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "from a phase 3 randomized, double-blind, placebo-controlled trial. Eur J JAMA. 2005;293:1338–1347."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Heart Fail. 2015;17:1050–1056. 7. Marchioli R, Levantesi G, Macchia A, et al. Vitamin E increases the risk of"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "7. Massie BM, Collins JF, Ammon SE, et al. Randomized trial of warfarin, as- developing heart failure after myocardial infarction: results from the GISSI-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "pirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Prevenzione trial. J Cardiovasc Med (Hagerstown). 2006;7:347–350."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation. 8. Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "2009;119:1616–1624. on morbidity and mortality in chronic heart failure: results from Q-SYMBIO:"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "8. Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients a randomized double-blind trial. J Am Coll Cardiol HF. 2014;2:641–649."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859–1869. 9. Madmani ME, Yusuf Solaiman A, Tamr Agha K, et al. Coenzyme Q10 for"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "9. Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart heart failure. Cochrane Database Syst Rev. 2014:CD008684."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379:1332– 10. Effect of verapamil on mortality and major events after acute myocardial"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "1342. infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "10. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden 1990;66:779–785."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "death by n-3 polyunsaturated fatty acids after myocardial infarction: time- 11. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of dil-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "course analysis of the results of the Gruppo Italiano per lo Studio della tiazem on mortality and reinfarction after myocardial infarction. N Engl J"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation. Med. 1988;319:385–392."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "2002;105:1897–1903. 12. Goldstein RE, Boccuzzi SJ, Cruess D, et al. Diltiazem increases late-onset"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "11. Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of potassium in heart congestive heart failure in postinfarction patients with early reduction in"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "failure: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2836– ejection fraction. The Adverse Experience Committee; and the Multicenter"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "2850. Diltiazem Postinfarction Research Group. Circulation. 1991;83:52–60."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "12. Savarese G, Carrero JJ, Pitt B, et al. Factors associated with underuse of 13. Figulla HR, Gietzen F, Zeymer U, et al. Diltiazem improves cardiac func-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "mineralocorticoid receptor antagonists in heart failure with reduced ejection tion and exercise capacity in patients with idiopathic dilated cardiomyop-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "fraction: an analysis of 11 215 patients from the Swedish Heart Failure athy. Results of the Diltiazem in Dilated Cardiomyopathy Trial. Circulation."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Registry. Eur J Heart Fail. 2018;20:1326–1334. 1996;94:346–352."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "13. Kosiborod M, Rasmussen HS, Lavin P, et al. Effect of sodium zirco- 14. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "nium cyclosilicate on potassium lowering for 28 days among outpatients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Sup-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. pression Trial. N Engl J Med. 1991;324:781–788."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "2014;312:2223–2233. 15. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "14. Lavie CJ, Milani RV, Mehra MR, et al. Omega-3 polyunsaturated fatty acids patients with left ventricular dysfunction after recent and remote myocardial"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "and cardiovascular diseases. J Am Coll Cardiol. 2009;54:585–594. infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "15. Malik A, Masson R, Singh S, et al. Digoxin discontinuation and outcomes in 1996;348:7–12."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "patients with heart failure with reduced ejection fraction. J Am Coll Cardiol. 16. Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortal-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "2019;74:617–627. ity after dronedarone therapy for severe heart failure. N Engl J Med."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "16. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fat- 2008;358:2678–2687."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "ty acids vs corn oil on major adverse cardiovascular events in patients at 17. Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardio-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. vascular outcomes in older patients with diabetes. JAMA. 2007;298:2634–"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "2020;324:2268–2280. 2643."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "17. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic 18. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "events in congestive heart failure. The V-HeFT VA Cooperative Studies in patients with prediabetes and type 2 diabetes given thiazolidinediones: a"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Group. Circulation. 876 suppl1993:VI94–VI101. meta-analysis of randomised clinical trials. Lancet. 2007;370:1129–1136."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "18. Dunkman WB. Thromboembolism and antithrombotic therapy in congestive 19. Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "heart failure. J Cardiovasc Risk. 1995;2:107–117. controlled trial assessing the effects of rosiglitazone on echocardiograph-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "19. Cioffi G, Pozzoli M, Forni G, et al. Systemic thromboembolism in chronic heart ic function and cardiac status in type 2 diabetic patients with New York"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "failure. A prospective study in 406 patients. Eur Heart J. 1996;17:1381– Heart Association functional class I or II heart failure. J Am Coll Cardiol."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "1389. 2007;49:1696–1704."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "20. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of 20. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "stroke after myocardial infarction. N Engl J Med. 1997;336:251–257. cardiovascular outcomes in oral agent combination therapy for type 2"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "21. Al-Khadra AS, Salem DN, Rand WM, et al. Warfarin anticoagulation and diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "survival: a cohort analysis from the studies of left ventricular dysfunction. J 2009;373:2125–2135."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Am Coll Cardiol. 1998;31:749–753. 21. Giles TD, Miller AB, Elkayam U, et al. Pioglitazone and heart failure: results"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "22. Dries DL, Domanski MJ, Waclawiw MA, et al. Effect of antithrombotic thera- from a controlled study in patients with type 2 diabetes mellitus and systolic"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "py on risk of sudden coronary death in patients with congestive heart failure. dysfunction. J Card Fail. 2008;14:445–452."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Am J Cardiol. 1997;79:909–913. 22. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "7.3.7. Drugs of Unproven Value or That May Worsen"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "2014;130:1579–1588."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "HF 23. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortal-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "1. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity ity outcomes in patients with type 2 diabetes taking alogliptin versus pla-"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "and mortality in severe chronic heart failure. Prospective Randomized Am- cebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "lodipine Survival Evaluation Study Group. N Engl J Med. 1996;335:1107– 2015;385:2067–2076."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "1114. 24. Verma S, Goldenberg RM, Bhatt DL, et al. Dipeptidyl peptidase-4 inhibitors"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "2. Packer M, Carson P, Elkayam U, et al. Effect of amlodipine on the survival of and the risk of heart failure: a systematic review and meta-analysis. CMAJ"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "patients with severe chronic heart failure due to a nonischemic cardiomy- Open. 2017;5:E152–E177."
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "opathy: results of the PRAISE-2 study (prospective randomized amlodipine 25. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "survival evaluation 2). J Am Coll Cardiol HF. 2013;1:308–314. non-selective non-steroidal anti-inflammatory drugs and congestive heart"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 109,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "e1004 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "failure outcomes in elderly patients: a population-based cohort study. Lan- 49. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "cet. 2004;363:1751–1756. with congestive heart failure and left ventricular dysfunction. Danish Inves-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "26. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with tigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal Med. 1999;341:857–865."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "anti-inflammatory drugs: population based study. BMJ. 2005;330:1370. 50. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syn-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "27. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and drome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "cardiovascular morbidity associated with use of nonsteroidal anti-inflamma- 1335."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "tory drugs in chronic heart failure. Arch Intern Med. 2009;169:141–149. 51. McGuire DK, Van de Werf F, Armstrong PW, et al. Association between si-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "28. Feenstra J, Heerdink ER, Grobbee DE, et al. Association of nonsteroidal tagliptin use and heart failure hospitalization and related outcomes in type"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "anti-inflammatory drugs with first occurrence of heart failure and with re- 2 diabetes mellitus: secondary analysis of a randomized clinical trial. JAMA"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "lapsing heart failure: the Rotterdam Study. Arch Intern Med. 2002;162:265– Cardiol. 2016;1:126–135."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "270. 52. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardio-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "29. Packer M, Carson P, Elkayam U, et al. Effect of amlodipine on the survival of vascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "patients with severe chronic heart failure due to a nonischemic cardiomy- 53. McGuire DK, Alexander JH, Johansen OE, et al. Linagliptin effects on"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "opathy: results of the PRAISE-2 study (prospective randomized amlodipine heart failure and related outcomes in individuals with type 2 diabetes"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "survival evaluation 2). J Am Coll Cardiol HF. 2013;1:308–314. mellitus at high cardiovascular and renal risk in CARMELINA. Circulation."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "30. Salzano A, Marra AM, D’Assante R, et al. Growth hormone therapy in heart 2019;139:351–361."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "failure. Heart Fail Clin. 2018;14:501–515. 54. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "31. Sharma A, Fonarow GC, Butler J, et al. Coenzyme Q10 and heart failure: a on major cardiovascular events in adults with type 2 diabetes and high car-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "state-of-the-art review. Circ Heart Fail. 2016;9:e002639. diovascular and renal risk: the CARMELINA randomized clinical trial. JAMA."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "32. Vest AR, Chan M, Deswal A, et al. Nutrition, obesity, and cachexia in patients 2019;321:69–79."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "with heart failure: a consensus statement from the Heart Failure Society of 55. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiri-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "America Scientific Statements Committee. J Card Fail. 2019;25:380–400. de on major adverse cardiovascular outcomes in patients with type 2 dia-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "33. Hopper I, Connell C, Briffa T, et al. Nutraceuticals in patients with heart betes: the CAROLINA randomized clinical trial. JAMA. 2019;322:1155–"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "failure: a systematic review. J Card Fail. 2020;26:166–179. 1166."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "34. Keith M, Quach S, Ahmed M, et al. Thiamin supplementation does not im- 56. Communication: FDS. FDA adds warnings about heart failure risk to la-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "prove left ventricular ejection fraction in ambulatory heart failure patients: a bels of type 2 diabetes medicines containing saxagliptin and alogliptin."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "randomized controlled trial. Am J Clin Nutr. 2019;110:1287–1295. 2018 Accessed June 5, 2020. https://www.fda.gov/drugs/drug-safety-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "35. Jain A, Mehta R, Al-Ani M, et al. Determining the role of thiamine deficiency and-availability/fda-drug-safety-communication-fda-adds-warnings-about-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "in systolic heart failure: a meta-analysis and systematic review. J Card Fail. heart-failure-risk-labels-type-2-diabetes"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "2015;21:1000–1007. 57. Page RL 2nd, O’Bryant CL, Cheng D, et al. Drugs that may cause or exacer-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "36. DiNicolantonio JJ, Niazi AK, Lavie CJ, et al. Thiamine supplementation for bate heart failure: a scientific statement from the American Heart Associa-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "the treatment of heart failure: a review of the literature. Congest Heart Fail. tion. Circulation. 2016;134:e32–e69."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "2013;19:214–222."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "37. Song X, Qu H, Yang Z, et al. Efficacy and safety of L-carnitine treatment for 7.3.8. Guideline-Directed Medical Therapy (GDMT)"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "chronic heart failure: a meta-analysis of randomized controlled trials. BioMed Dosing, Sequencing, and Uptitration"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "Res Int. 2017;2017:6274854. 1. Cardiac Insufficiency Authors. The Cardiac Insufficiency Bisoprolol Study II"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "38. Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic conges- (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "tive heart failure and its prospective application. Jpn Circ J. 1992;56:95–99. 2. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbid-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "39. Ahmadian M, Dabidi Roshan V, Ashourpore E. Taurine supplementation im- ity of patients with severe chronic heart failure: results of the carvedilol pro-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "proves functional capacity, myocardial oxygen consumption, and electrical spective randomized cumulative survival (COPERNICUS) study. Circulation."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "activity in heart failure. J Diet Suppl. 2017;14:422–432. 2002;106:2194–2199."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "40. Tao J, Liu X, Bai W. Testosterone supplementation in patients with chronic 3. SOLVD Investigators. Effect of enalapril on survival in patients with reduced"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "heart failure: a meta-analysis of randomized controlled trials. Front Endocri- left ventricular ejection fractions and congestive heart failure. N Engl J Med."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "nol (Lausanne). 2020;11:110. 1991;325:293–302."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "41. D’Assante R, Piccioli L, Valente P, et al. Testosterone treatment in chronic 4. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "heart failure. Review of literature and future perspectives. Monaldi Arch enzyme inhibitors on mortality and morbidity in patients with heart fail-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "Chest Dis. 2018;88:976. ure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450–"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "42. Salzano A, D’Assante R, Lander M, et al. Hormonal replacement therapy in 1456."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "heart failure: focus on growth hormone and testosterone. Heart Fail Clin. 5. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "2019;15:377–391. versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "43. Zhang X, Wang WY, Zhang K, et al. Efficacy and safety of levothyroxine 6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "(L-T4) replacement on the exercise capability in chronic systolic heart and mortality in patients with severe heart failure. Randomized Aldactone"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "failure patients with subclinical hypothyroidism: study protocol for a multi- Evaluation Study Investigators. N Engl J Med. 1999;341:709–717."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "center, open label, randomized, parallel group trial (ThyroHeart-CHF). Trials. 7. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "2019;20:143. heart failure and mild symptoms. N Engl J Med. 2011;364:11–21."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "44. Holmager P, Schmidt U, Mark P, et al. Long-term L-Triiodothyronine (T3) 8. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "treatment in stable systolic heart failure patients: a randomised, double- heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "blind, cross-over, placebo-controlled intervention study. Clin Endocrinol. 2008."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "2015;83:931–937. 9. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "45. Einfeldt MN, Olsen AS, Kristensen SL, et al. Long-term outcome in patients empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "with heart failure treated with levothyroxine: an observational nationwide 10. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "cohort study. J Clin Endocrinol Metab. 2019;104:1725–1734. hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "46. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amioda- 2057."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "rone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en 11. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344:493– Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "498. Lancet. 1999;353:2001–2007."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "47. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with con- 12. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in pa-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "gestive heart failure and asymptomatic ventricular arrhythmia. Survival tients with heart failure or left-ventricular dysfunction: a systematic overview"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. of data from individual patients. ACE-inhibitor myocardial infarction collab-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "1995;333:77–82. orative group. Lancet. 2000;355:1575–1581."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "48. Kober L, Bloch Thomsen PE, Moller M, et al. Effect of dofetilide in patients 13. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone block-"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "with recent myocardial infarction and left-ventricular dysfunction: a ran- er, in patients with left ventricular dysfunction after myocardial infarction. N"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "domised trial. Lancet. 2000;356:2052–2058. Engl J Med. 2003;348:1309–1321."
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 110,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1005"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "14. Ezekowitz JA, McAlister FA. Aldosterone blockade and left ventricular 40. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, et al. Effects of cardiac"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "dysfunction: a systematic review of randomized clinical trials. Eur Heart J. resynchronization therapy on overall mortality and mode of death: a meta-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "2009;30:469–477. analysis of randomized controlled trials. Eur Heart J. 2006;27:2682–2688."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "15. Bassi NS, Ziaeian B, Yancy CW, et al. Association of optimal implementa- 41. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the pre-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "tion of sodium-glucose cotransporter 2 inhibitor therapy with outcome for vention of mortality in patients with nonischemic cardiomyopathy: a meta-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "patients with heart failure. JAMA Cardiol. 2020;5:948–951. analysis of randomized controlled trials. JAMA. 2004;292:2874–2879."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "16. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-re- 42. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: implantable"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "lated improvements in left ventricular function and survival in subjects with cardioverter defibrillators for adults with left ventricular systolic dysfunction."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "chronic heart failure. MOCHA Investigators. Circulation. 1996;94:2807– Ann Intern Med. 2007;147:251–262."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "2816."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "17. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low 7.3.9.1. Management of Stage C HF: Ivabradine"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on 1. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chron-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "morbidity and mortality in chronic heart failure. ATLAS Study Group. Circula- ic heart failure (SHIFT): a randomised placebo-controlled study. Lancet."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "tion. 1999;100:2312–2318. 2010;376:875–885."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "18. Konstam MA, Neaton JD, Dickstein K, et al. HEAAL Investigators. Effects 2. Borer JS, Böhm M, Ford I, et al. Effect of ivabradine on recurrent hospitaliza-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "of high-dose versus low-dose losartan on clinical outcomes in patients tion for worsening heart failure in patients with chronic systolic heart failure:"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. the SHIFT Study. Eur Heart J. 2012;33:2813–2820."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "2009;374:1840–1848. 3. Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "19. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality ventricular systolic dysfunction: a pooled analysis of individual patient data"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "and morbidity in patients with left ventricular dysfunction after myocardial from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34:2263–"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "infarction: results of the survival and ventricular enlargement trial. The SAVE 2270."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "Investigators. N Engl J Med. 1992;327:669–677. 4. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "20. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "mortality and morbidity in patients with chronic heart failure: the CHARM- randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "Overall programme. Lancet. 2003;362:759–766. 816."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "21. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A random- 5. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "ized trial of the angiotensin-receptor blocker valsartan in chronic heart fail- ivabradine on cardiovascular outcomes in chronic heart failure: analysis from"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "ure. N Engl J Med. 2001;345:1667–1675. the SHIFT study. Clin Res Cardiol. 2013;102:11–22."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "22. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition 6. Bohm M, Robertson M, Ford I, et al. Influence of cardiovascular and noncar-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. diovascular co-morbidities on outcomes and treatment effect of heart rate"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "23. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in reduction with ivabradine in stable heart failure (from the SHIFT Trial). Am J"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "severe chronic heart failure. N Engl J Med. 2001;344:1651–1658. Cardiol. 2015;116:1890–1897."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "24. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "mortality in chronic congestive heart failure. Results of a Veterans Adminis- 7.3.9.2. Pharmacological Treatment for Stage C Heart"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "tration Cooperative Study. N Engl J Med. 1986;314:1547–1552. Failure With Reduced Ejection Fraction (HFrEF)"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "25. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "(Digoxin)"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a ran-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "domised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816. 1. Digitalis Investigation Group. The effect of digoxin on mortality and morbid-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "26. Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease ity in patients with heart failure. N Engl J Med. 1997;336:525–533."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "without clinical heart failure. N Engl J Med. 2014;371:1091–1099. 2. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "27. Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chron- hospitalization in heart failure: a comprehensive post hoc analysis of the"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "ic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. DIG trial. Eur Heart J. 2006;27:178–186."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "2010;376:875–885. 3. Lader E, Egan D, Hunsberger S, et al. The effect of digoxin on the quality of"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "28. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart life in patients with heart failure. J Card Fail. 2003;9:4–12."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "failure and reduced ejection fraction. N Engl J Med. 2020;382:1883–1893. 4. Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum con-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "29. Rathore SS, Foody JM, Wang Y, et al. Race, quality of care, and outcomes centrations on mortality and hospitalization in heart failure: a propensity-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "of elderly patients hospitalized with heart failure. JAMA. 2003;289:2517– matched study of the DIG trial. Int J Cardiol. 2008;123:138–146."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "2524. 5. Aguirre Dávila L, Weber K, Bavendiek U, et al. Digoxin–mortality: randomized"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "30. Digitalis Investigation Group. The effect of digoxin on mortality and morbid- vs. observational comparison in the DIG trial. Eur Heart J. 2019;40:3336–"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "ity in patients with heart failure. N Engl J Med. 1997;336:525–533. 3341."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "31. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy 6. Ambrosy AP, Butler J, Ahmed A, et al. The use of digoxin in patients with"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "with or without an implantable defibrillator in advanced chronic heart failure. worsening chronic heart failure: reconsidering an old drug to reduce hospi-"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "N Engl J Med. 2004;350:2140–2150. tal admissions. J Am Coll Cardiol. 2014;63:1823–1832."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "32. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resyn- 7. Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "chronization on morbidity and mortality in heart failure. N Engl J Med. heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "2005;352:1539–1549. J Heart Fail. 2013;15:551–559."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "33. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator 8. Adams KF Jr, Butler J, Patterson JH, et al. Dose response characterization"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "in patients with myocardial infarction and reduced ejection fraction. N Engl of the association of serum digoxin concentration with mortality outcomes"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "J Med. 2002;346:877–883. in the Digitalis Investigation Group trial. Eur J Heart Fail. 2016;18:1072–"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "34. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter- 1081."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237. 9. Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "35. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair with atrial fibrillation. J Am Coll Cardiol. 2018;71:1063–1074."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "in patients with heart failure. N Engl J Med. 2018;379:2307–2318. 10. Malik A, Masson R, Singh S, et al. Digoxin discontinuation and outcomes in"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "36. Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of optimal patients with heart failure with reduced ejection fraction. J Am Coll Cardiol."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "implementation of evidence-based heart failure therapies on mortality. Am 2019;74:617–627."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "Heart J. 2011;161:1024–1030. 11. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "37. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in the effect of digoxin withdrawal in patients with mild to moderate chronic"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "patients with heart failure: a meta-analysis of randomized clinical trials. J Am congestive heart failure: results of the PROVED trial. J Am Coll Cardiol."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "Coll Cardiol. 1997;30:27–34. 1993;22:955–962."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "38. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "7.3.9.3. Pharmacological Treatment for Stage C"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "A Bayesian meta-analysis. Ann Intern Med. 2001;134:550–560."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "39. McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization thera- HFrEF: Soluble Guanylyl Cyclase Stimulators"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "py for patients with left ventricular systolic dysfunction: a systematic review. 1. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "JAMA. 2007;297:2502–2514. failure and reduced ejection fraction. N Engl J Med. 2020;382:1883–1893."
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 111,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "e1006 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "2. Arnold WP, Mittal CK, Katsuki S, et al. Nitric oxide activates guanylate cy- 18. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resyn-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "clase and increases guanosine 3’,5’-cyclic monophosphate levels in various chronization on morbidity and mortality in heart failure. N Engl J Med."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "tissue preparations. Proc Natl Acad Sci U S A. 1977;74:3203–3207. 2005;352:1539–1549."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "3. Hardman JG, Davis JW, Sutherland EW. Effects of some hormonal and other 19. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resyn-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "factors on the excretion of guanosine 3’,5’-monophosphate and adenosine chronization in mildly symptomatic heart failure patients and in asymptom-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "3’,5’-monophosphate in rat urine. J Biol Chem. 1969;244:6354–6362. atic patients with left ventricular dysfunction and previous heart failure"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "4. Hardman JG, Sutherland EW. Guanyl cyclase, an enzyme catalyzing the for- symptoms. J Am Coll Cardiol. 2008;52:1834–1843."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "mation of guanosine 3’,5’-monophosphate from guanosine trihosphate. J 20. Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchroniza-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "Biol Chem. 1969;244:6363–6370. tion therapy in mild heart failure. N Engl J Med. 2014;370:1694–1701."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "5. McNamara DB, Kadowitz PJ, Hyman AL, et al. Adenosine 3’,5’-monophos- 21. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "phate formation by preparations of rat liver soluble guanylate cyclase acti- mild-to-moderate heart failure. N Engl J Med. 2010;363:2385–2395."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "vated with nitric oxide, nitrosyl ferroheme, S-nitrosothiols, and other nitroso 22. Feldman AM, de Lissovoy G, Bristow MR, et al. Cost effectiveness of cardiac"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "compounds. Can J Physiol Pharmacol. 1980;58:1446–1456. resynchronization therapy in the Comparison of Medical Therapy, Pacing,"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "6. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "Pharmacol. 2006:213–254. 2005;46:2311–2321."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "7. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the en- 23. Gold MR, Padhiar A, Mealing S, et al. Economic value and cost-effective-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "dogenous nitrovasodilator. Hypertension. 1988;12:365–372. ness of cardiac resynchronization therapy among patients with mild heart"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "failure: projections from the REVERSE long-term follow-up. J Am Coll Car-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "7.4.1. Implantable Cardioverter Defibrillators (ICDs) diol HF. 2017;5:204–212."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "24. Heerey A, Lauer M, Alsolaiman F, et al. Cost effectiveness of biventricular"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "and Cardiac Resynchronization Therapy (CRT)"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "pacemakers in heart failure patients. Am J Cardiovasc Drugs. 2006;6:129–"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "1. Antiarrhythmics versus Implantable Defibrillators Investigators. A com- 137."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "parison of antiarrhythmic-drug therapy with implantable defibrillators in pa- 25. Nichol G, Kaul P, Huszti E, et al. Cost-effectiveness of cardiac resynchro-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "tients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. nization therapy in patients with symptomatic heart failure. Ann Intern Med."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "1997;337:1576–1583. 2004;141:343–351."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "2. Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiar- 26. Noyes K, Veazie P, Hall WJ, et al. Cost-effectiveness of cardiac resyn-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "rhythmic drug therapy with implantable defibrillators in patients resuscitated chronization therapy in the MADIT-CRT trial. J Cardiovasc Electrophysiol."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2013;24:66–74."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "2000;102:748–754. 27. Woo CY, Strandberg EJ, Schmiegelow MD, et al. Cost-effectiveness of"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "3. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator adding cardiac resynchronization therapy to an implantable cardiovert-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "Study (CIDS); a randomized trial of the implantable cardioverter defibrillator er-defibrillator among patients with mild heart failure. Ann Intern Med."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "against amiodarone. Circulation. 2000;101:1297–1302. 2015;163:417–426."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "4. Moss AJ, Hall J, Cannom DS, et al. Improved survival with an implanted 28. Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "defibrillator in patients with coronary disease at high risk for ventricular ar- event reduction with cardiac resynchronization therapy: meta-analysis of"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "rhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. randomized controlled trials. Am Heart J. 2012;163:260–267.e3."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "N Engl J Med. 1996;335:1933–1940. 29. Gervais R, Leclercq C, Shankar A, et al. Surface electrocardiogram to predict"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "5. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention outcome in candidates for cardiac resynchronization therapy: a sub-analysis"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "of sudden death in patients with coronary artery disease. Multicenter Un- of the CARE-HF trial. Eur J Heart Fail. 2009;11:699–705."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "sustained Tachycardia Trial Investigators. N Engl J Med. 1999;341:1882– 30. Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of cardiac resynchro-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "1890. nization therapy by QRS morphology in the Multicenter Automatic Defibril-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "6. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator lator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT)."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "in patients with myocardial infarction and reduced ejection fraction. N Engl Circulation. 2011;123:1061–1072."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "J Med. 2002;346:877–883. 31. Gold MR, Thebault C, Linde C, et al. Effect of QRS duration and morphology"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "7. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implanta- on cardiac resynchronization therapy outcomes in mild heart failure: results"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "tion in patients with nonischemic dilated cardiomyopathy. N Engl J Med. from the Resynchronization Reverses Remodeling in Systolic Left Ventricu-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "2004;350:2151–2158. lar Dysfunction (REVERSE) study. Circulation. 2012;126:822–829."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "8. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter- 32. Birnie DH, Ha A, Higginson L, et al. Impact of QRS morphology and dura-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237. tion on outcomes after cardiac resynchronization therapy: results from the"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "9. Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT)."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221– Circ Heart Fail. 2013;6:1190–1198."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "1230. 33. Nery PB, Ha AC, Keren A, et al. Cardiac resynchronization therapy in pa-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "10. Al-Khatib SM, Anstrom KJ, Eisenstein EL, et al. Clinical and economic im- tients with left ventricular systolic dysfunction and right bundle branch block:"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "plications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann a systematic review. Heart Rhythm. 2011;8:1083–1087."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "Intern Med. 2005;142:593–600. 34. Curtis AB. Biventricular pacing for atrioventricular block and systolic dys-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "11. Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effectiveness function. N Engl J Med. 2013;369:579."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "of prophylactic implantation of a cardioverter defibrillator in patients with 35. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimu-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "reduced left ventricular systolic function: results of Markov modelling in a lation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Elec-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "European population. Europace. 2009;11:716–726. trophysiol. 2005;16:1160–1165."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "12. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrilla- 36. Pugh TJ, Kelly MA, Gowrisankar S, et al. The landscape of genetic variation"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "tor therapy or amiodarone in chronic stable heart failure: results from the in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. Med. 2014;16:601–608."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "2006;114:135–142. 37. Gigli M, Merlo M, Graw SL, et al. Genetic risk of arrhythmic phenotypes"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "13. Mushlin AI, Hall WJ, Zwanziger J, et al. The cost-effectiveness of automatic in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2019;74:1480–"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "implantable cardiac defibrillators: results from MADIT. Multicenter Automat- 1490."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "ic Defibrillator Implantation Trial. Circulation. 1998;97:2129–2135. 38. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "14. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable statement on evaluation, risk stratification, and management of arrhythmo-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "cardioverter-defibrillators. N Engl J Med. 2005;353:1471–1480. genic cardiomyopathy. Heart Rhythm. 2019;16:e301–e372."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "15. Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of implantable 39. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "cardioverter-defibrillators: results from the Multicenter Automatic Defibrilla- for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "tor Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:2310–2318. 1338."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "16. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in 40. Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac-resynchronization therapy in heart"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "chronic heart failure. N Engl J Med. 2002;346:1845–1853. failure with narrow QRS complexes. N Engl J Med. 2007;357:2461–2471."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "17. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy 41. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchroniza-"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "with or without an implantable defibrillator in advanced chronic heart failure. tion therapy in heart failure with a narrow QRS complex. N Engl J Med."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "N Engl J Med. 2004;350:2140–2150. 2013;369:1395–1405."
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 112,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1007"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "42. Smith T, Jordaens L, Theuns DA, et al. The cost-effectiveness of pri- 12. Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "mary prophylactic implantable defibrillator therapy in patients with isch- non-excitatory, cardiac contractility modulation electrical impulses for symp-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "aemic or non-ischaemic heart disease: a European analysis. Eur Heart J. tomatic heart failure. Eur Heart J. 2008;29:1019–1028."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2013;34:211–219. 13. Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "43. Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients evaluating the safety and efficacy of cardiac contractility modulation in ad-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "at high risk for ventricular arrhythmias after coronary-artery bypass graft vanced heart failure. Am Heart J. 2011;161:329–337.e1-2."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N 14. Abraham WT, Kuck KH, Goldsmith RL, et al. A randomized controlled trial"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Engl J Med. 1997;337:1569–1575. to evaluate the safety and efficacy of cardiac contractility modulation. J Am"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "44. Mild therapeutic hypothermia to improve the neurologic outcome after car- Coll Cardiol HF. 2018;6:874–883."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "diac arrest. N Engl J Med. 2002;346:549–556."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "45. Healey JS, Hohnloser SH, Exner DV, et al. Cardiac resynchronization 7.4.3. Revascularization for Coronary Artery Disease"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "therapy in patients with permanent atrial fibrillation: results from the Re- 1. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medi-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "synchronization for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. cal group survival in patients with left main equivalent coronary artery dis-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2012;5:566–570. ease. Long-term CASS experience. Circulation. 1995;91:2335–2344."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "46. Tolosana JM, Hernandez Madrid A, Brugada J, et al. Comparison of ben- 2. Howlett JG, Stebbins A, Petrie MC, et al. CABG improves outcomes in pa-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "efits and mortality in cardiac resynchronization therapy in patients with tients with ischemic cardiomyopathy: 10-year follow-up of the STICH Trial. J"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "atrial fibrillation versus patients in sinus rhythm (results of the Spanish Am Coll Cardiol HF. 2019;7:878–887."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Atrial Fibrillation And Resynchronization [SPARE] study). Am J Cardiol. 3. Mark DB, Knight JD, Velazquez EJ, et al. Quality-of-life outcomes with coro-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2008;102:444–449. nary artery bypass graft surgery in ischemic left ventricular dysfunction: a"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "47. Kalscheur MM, Saxon LA, Lee BK, et al. Outcomes of cardiac resynchroni- randomized trial. Ann Intern Med. 2014;161:392–399."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "zation therapy in patients with intermittent atrial fibrillation or atrial flutter in 4. Park S, Ahn JM, Kim TO, et al. Revascularization in patients with left main"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "the COMPANION trial. Heart Rhythm. 2017;14:858–865. coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "48. Adelstein E, Schwartzman D, Gorcsan J 3rd, et al. Predicting hyperre- 2020;76:1395–1406."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "sponse among pacemaker-dependent nonischemic cardiomyopathy pa- 5. Petrie MC, Jhund PS, She L, et al. Ten-year outcomes after coronary ar-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "tients upgraded to cardiac resynchronization. J Cardiovasc Electrophysiol. tery bypass grafting according to age in patients with heart failure and left"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2011;22:905–911. ventricular systolic dysfunction: an analysis of the extended follow-up of"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "49. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "guideline for management of patients with ventricular arrhythmias and the 2016;134:1314–1324."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "prevention of sudden cardiac death: a report of the American College of 6. Tam DY, Dharma C, Rocha R, et al. Long-term survival after surgical or per-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Cardiology/American Heart Association Task Force on Clinical Practice cutaneous revascularization in patients with diabetes and multivessel coro-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Guidelines and the Heart Rhythm Society. Circulation. 2018;138:e272– nary disease. J Am Coll Cardiol. 2020;76:1153–1164."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "e391. 7. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "50. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchroniza- patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "tion therapy in heart failure with a narrow QRS complex. N Engl J Med. 1616."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2013;369:1395–1405. 8. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "51. Thibault B, Harel F, Ducharme A, et al. Cardiac resynchronization therapy in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374:1511–"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "patients with heart failure and a QRS complex <120 milliseconds: the Eval- 1520."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "uation Of Resynchronization Therapy For Heart Failure (LESSER-EARTH) 9. Perera D, Clayton T, Petrie MC, et al. Percutaneous revascularization for"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "trial. Circulation. 2013;127:873–881. ischemic ventricular dysfunction: rationale and design of the REVIVED-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "52. Muto C, Solimene F, Gallo P, et al. A randomized study of cardiac resynchro- BCIS2 Trial: percutaneous coronary intervention for ischemic cardiomyopa-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "nization therapy defibrillator versus dual-chamber implantable cardioverter- thy. J Am Coll Cardiol HF. 2018;6:517–526."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "defibrillator in ischemic cardiomyopathy with narrow QRS: the NARROW- 10. Nagendran J, Bozso SJ, Norris CM, et al. Coronary artery bypass surgery"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "CRT study. Circ Arrhythm Electrophysiol. 2013;6:538–545. improves outcomes in patients with diabetes and left ventricular dysfunc-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "tion. J Am Coll Cardiol. 2018;71:819–827."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "7.4.2. Other Implantable Electrical Interventions 11. Chaitman BR, Fisher LD, Bourassa MG, et al. Effect of coronary bypass"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "1. Hartupee J, Mann DL. Neurohormonal activation in heart failure with re- surgery on survival patterns in subsets of patients with left main coronary"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "duced ejection fraction. Nat Rev Cardiol. 2017;14:30–38. artery disease. Report of the Collaborative Study in Coronary Artery Surgery"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2. Wagner BR, Frishman WH. Devices for autonomic regulation therapy in (CASS). Am J Cardiol. 1981;48:765–777."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "heart failure with reduced ejection fraction. Cardiol Rev. 2018;26:43–49. 12. Jolicoeur EM, Dunning A, Castelvecchio S, et al. Importance of angina in"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "3. Zile MR, Lindenfeld J, Weaver FA, et al. Baroreflex activation therapy in patients with coronary disease, heart failure, and left ventricular systolic dys-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "patients with heart failure with reduced ejection fraction. J Am Coll Cardiol. function: insights from STICH. J Am Coll Cardiol. 2015;66:2092–2100."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2020;76:1–13. 13. Veterans Administration Coronary Artery Bypass Surgery Cooperative"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "4. Gold MR, Van Veldhuisen DJ, Hauptman PJ, et al. Vagus nerve stimulation Study Group. Eleven-year survival in the Veterans Administration ran-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "for the treatment of heart failure: the INOVATE-HF trial. J Am Coll Cardiol. domized trial of coronary bypass surgery for stable angina. N Engl J Med."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2016;68:149–158. 1984;311:1333–1339."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "5. Leclercq C, Gadler F, Kranig W, et al. A randomized comparison of triple- 14. VA Coronary Artery Bypass Surgery Cooperative Study Group. Eighteen-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "site versus dual-site ventricular stimulation in patients with congestive heart year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "failure. J Am Coll Cardiol. 2008;51:1455–1462. Bypass Surgery for stable angina. Circulation. 1992;86:121–130."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "6. Niazi I, Baker J 2nd, Corbisiero R, et al. Safety and efficacy of multipoint 15. Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "pacing in cardiac resynchronization therapy: the multipoint pacing trial. J Am without surgical ventricular reconstruction. N Engl J Med. 2009;360:1705–"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Coll Cardiol EP. 2017;3:1510–1518. 1717."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "7. LeClercq C. Personal communication about phase 2 trial data. 2020. 16. Dor V, Civaia F, Alexandrescu C, et al. Favorable effects of left ventricular re-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "8. Abdelrahman M, Subzposh FA, Beer D, et al. Clinical outcomes of his construction in patients excluded from the Surgical Treatments for Ischemic"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "bundle pacing compared to right ventricular pacing. J Am Coll Cardiol. Heart Failure (STICH) trial. J Thorac Cardiovasc Surg. 2011;141:905–916,"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2018;71:2319–2330. 916e1-4."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "9. Upadhyay GA, Vijayaraman P, Nayak HM, et al. On-treatment comparison"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "between corrective his bundle pacing and biventricular pacing for cardiac"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "resynchronization: a secondary analysis of the His-SYNC pilot trial. Heart 7.5. Valvular Heart Disease"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Rhythm. 2019;16:1797–1807."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "10. Upadhyay GA, Vijayaraman P, Nayak HM, et al. His corrective pacing or 1. Nasser R, Van Assche L, Vorlat A, et al. Evolution of functional mitral re-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "biventricular pacing for cardiac resynchronization in heart failure. J Am Coll gurgitation and prognosis in medically managed heart failure patients with"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Cardiol. 2019;74:157–159. reduced ejection fraction. J Am Coll Cardiol HF. 2017;5:652–659."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "11. Neelagaru SB, Sanchez JE, Lau SK, et al. Nonexcitatory, cardiac contractility 2. Lowes BD, Gill EA, Abraham WT, et al. Effects of carvedilol on left ventricu-"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "modulation electrical impulses: feasibility study for advanced heart failure in lar mass, chamber geometry, and mitral regurgitation in chronic heart failure."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "patients with normal QRS duration. Heart Rhythm. 2006;3:1140–1147. Am J Cardiol. 1999;83:1201–1205."
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 113,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "e1008 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "3. Capomolla S, Febo O, Gnemmi M, et al. β-Blockade therapy in chronic heart 26. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "failure: diastolic function and mitral regurgitation improvement by carvedilol. the management of patients with valvular heart disease: a report of the"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "Am Heart J. 2000;139:596–608. American College of Cardiology/American Heart Association Task Force on"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "4. Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor Practice Guidelines. Circulation. 2014;129:e521–e643."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "for functional mitral regurgitation. Circulation. 2019;139:1354–1365. 27. Packer M, Grayburn PA. Neurohormonal and transcatheter repair strate-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "5. van Bommel RJ, Marsan NA, Delgado V, et al. Cardiac resynchronization gies for proportionate and disproportionate functional mitral regurgitation in"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "therapy as a therapeutic option in patients with moderate-severe functional heart failure. J Am Coll Cardiol HF. 2019;7:518–521."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "mitral regurgitation and high operative risk. Circulation. 2011;124:912–919. 28. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "6. Obadia J-F, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair in patients with heart failure. N Engl J Med. 2018;379:2307–2318."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "or medical treatment for secondary mitral regurgitation. N Engl J Med. 29. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "2018;379:2297–2306. for aortic stenosis in patients who cannot undergo surgery. N Engl J Med."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "7. Inohara T, Manandhar P, Kosinski AS, et al. Association of renin-angiotensin 2010;363:1597–1607."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "inhibitor treatment with mortality and heart failure readmission in patients 30. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replace-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "with transcatheter aortic valve replacement. JAMA. 2018;320:2231–2241. ment for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696–"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "8. Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter 1704."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "aortic valve replacement compared with standard treatment for patients 31. Tribouilloy C, Levy F, Rusinaru D, et al. Outcome after aortic valve replace-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. ment for low-flow/low-gradient aortic stenosis without contractile reserve"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "Lancet. 2015;385:2485–2491. on dobutamine stress echocardiography. J Am Coll Cardiol. 2009;53:1865–"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "9. Evangelista A, Tornos P, Sambola A, et al. Long-term vasodilator therapy in 1873."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "patients with severe aortic regurgitation. N Engl J Med. 2005;353:1342– 32. Herrmann HC, Pibarot P, Hueter I, et al. Predictors of mortality and outcomes"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "1349. of therapy in low-flow severe aortic stenosis: a Placement of Aortic Trans-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "10. Bhudia SK, McCarthy PM, Kumpati GS, et al. Improved outcomes after aor- catheter Valves (PARTNER) trial analysis. Circulation. 2013;127:2316–"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "tic valve surgery for chronic aortic regurgitation with severe left ventricular 2326."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "dysfunction. J Am Coll Cardiol. 2007;49:1465–1471. 33. Anjan VY, Herrmann HC, Pibarot P, et al. Evaluation of flow after transcath-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "11. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic eter aortic valve replacement in patients with low-flow aortic stenosis: a"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "valve replacement or surgical aortic valve replacement for high surgical risk secondary analysis of the PARTNER randomized clinical trial. JAMA Cardiol."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "patients with aortic stenosis (PARTNER 1): a randomised controlled trial. 2016;1:584–592."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "Lancet. 2015;385:2477–2484. 34. Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Optimizing timing of surgical"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "12. Agricola E, Ielasi A, Oppizzi M, et al. Long-term prognosis of medically treat- correction in patients with severe aortic regurgitation: role of symptoms. J"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "ed patients with functional mitral regurgitation and left ventricular dysfunc- Am Coll Cardiol. 1997;30:746–752."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "tion. Eur J Heart Fail. 2009;11:581–587. 35. Chaliki HP, Mohty D, Avierinos JF, et al. Outcomes after aortic valve replace-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "13. Karaca O, Omaygenc MO, Cakal B, et al. Effect of QRS narrowing after car- ment in patients with severe aortic regurgitation and markedly reduced left"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "diac resynchronization therapy on functional mitral regurgitation in patients ventricular function. Circulation. 2002;106:2687–2693."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "with systolic heart failure. Am J Cardiol. 2016;117:412–419."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "7.6.1. Heart Failure With Mildly Reduced Ejection"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "14. St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resyn-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "chronization therapy on left ventricular size and function in chronic heart Fraction (HFmrEF)"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "failure. Circulation. 2003;107:1985–1990. 1. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "15. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the preserved ejection fraction. N Engl J Med. 2021;385:1451–1461."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "management of patients with valvular heart disease: a report of the Ameri- 2. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart fail-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "can College of Cardiology/American Heart Association Joint Committee on ure with reduced, mid-range, and preserved ejection fraction: an individ-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "Clinical Practice Guidelines. Circulation. 2021;143:e72–e227. ual patient-level analysis of double-blind randomized trials. Eur Heart J."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "16. De la Espriella R, Santas E, Miñana G, et al. Functional mitral regurgitation 2018;39:26–35."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "predicts short-term adverse events in patients with acute heart failure and 3. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin in-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "reduced left ventricular ejection fraction. Am J Cardiol. 2017;120:1344– hibition in heart failure with preserved ejection fraction. N Engl J Med."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "1348. 2019;381:1609–1620."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "17. Breithardt OA, Sinha AM, Schwammenthal E, et al. Acute effects of cardiac 4. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "resynchronization therapy on functional mitral regurgitation in advanced treatment for heart failure in patients with recovered dilated cardio-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "systolic heart failure. J Am Coll Cardiol. 2003;41:765–770. myopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "18. Kheiri B, Zayed Y, Barbarawi M, et al. Interventions for secondary mitral 2019;393:61–73."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "regurgitation in patients with heart failure: a network meta-analysis of ran- 5. Nilsson BB, Lunde P, Grogaard HK, et al. Long-term results of high-intensity"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "domized controlled comparisons of surgery, medical therapy and transcath- exercise-based cardiac rehabilitation in revascularized patients for symp-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "eter intervention. Cardiovasc Revasc Med. 2020;21:155–163. tomatic coronary artery disease. Am J Cardiol. 2018;121:21–26."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "19. Grayburn PA, Sannino A, Packer M. Proportionate and disproportionate 6. Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "functional mitral regurgitation: a new conceptual framework that recon- outcomes and efficacy of sacubitril/valsartan (lcz696) in heart failure with"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "ciles the results of the MITRA-FR and COAPT Trials. J Am Coll Cardiol Img. reduced ejection fraction: the Prospective Comparison of ARNI with ACEI"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "2019;12:353–362. to Determine Impact on Global Mortality and Morbidity in Heart Failure"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "20. Packer M. Disproportionate functional mitral regurgitation: a new therapeu- (PARADIGM-HF) trial. Circ Heart Fail. 2016;9:e002744."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "tic target in patients with heart failure and a reduced ejection fraction. Eur J 7. Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart failure patients"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "Heart Fail. 2020;22:23–25. with mid-range left ventricular ejection fraction-a report from the CHART-2"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "21. Packer M, Grayburn PA. Contrasting effects of pharmacological, procedural, Study. Eur J Heart Fail. 2017;19:1258–1269."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "and surgical interventions on proportionate and disproportionate functional 8. Solomon SD, Vaduganathan M, Claggett BL, et al. Sacubitril/valsar-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "mitral regurgitation in chronic heart failure. Circulation. 2019;140:779–789. tan across the spectrum of ejection fraction in heart failure. Circulation."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "22. Yu C-M, Chan J-S, Zhang Q, et al. Impact of cardiac contractility modulation 2020;141:352–361."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "on left ventricular global and regional function and remodeling. J Am Coll 9. Zheng SL, Chan FT, Nabeebaccus AA, et al. Drug treatment effects on out-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "Cardiol Img. 2009;2:1341–1349. comes in heart failure with preserved ejection fraction: a systematic review"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "23. Clavel MA, Magne J, Pibarot P. Low-gradient aortic stenosis. Eur Heart J. and meta-analysis. Heart. 2018;104:407–415."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "2016;7:2645–2657. 10. Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "24. Vamvakidou A, Jin W, Danylenko O, et al. Low transvalvular flow rate pre- heart failure events in patients with heart failure and a preserved ejection"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "dicts mortality in patients with low-gradient aortic stenosis following aortic fraction: the EMPEROR-Preserved trial. Circulation. 2021;144:1284–"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "valve intervention. J Am Coll Cardiol Img. 2019;12:1715–1724. 1294."
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "25. Spitzer E, Van Mieghem NM, Pibarot P, et al. Rationale and design of the"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "Transcatheter Aortic Valve Replacement to UNload the Left ventricle in 7.6.2. HF With Improved Ejection Fraction"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "patients with ADvanced heart failure (TAVR UNLOAD) trial. Am Heart J. 1. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treat-"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "2016;182:80–88. ment for heart failure in patients with recovered dilated cardiomyopathy"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 114,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1009"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "(TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393:61– 20. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "73. with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2. Wilcox JE, Fang JC, Margulies KB, et al. Heart failure with recovered left 2345."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "ventricular ejection fraction: JACC Scientific Expert Panel. J Am Coll Cardiol. 21. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in pa-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2020;76:719–734. tients 80 years of age or older. N Engl J Med. 2008;358:1887–1898."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "3. Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classifica- 22. Kostis JB, Davis BR, Cutler J, et al. Prevention of heart failure by antihyper-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "tion of heart failure: a report of the Heart Failure Society of America, Heart tensive drug treatment in older persons with isolated systolic hypertension."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "Failure Association of the European Society of Cardiology, Japanese Heart SHEP Cooperative Research Group. JAMA. 1997;278:212–216."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "Failure Society and Writing Committee of the Universal Definition of Heart 23. Piller LB, Baraniuk S, Simpson LM, et al. Long-term follow-up of participants"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "Failure. J Card Fail. 2021;27:387–413. with heart failure in the antihypertensive and lipid-lowering treatment to pre-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "vent heart attack trial (ALLHAT). Circulation. 2011;124:1811–1818."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "7.7.1. HF With Preserved EF (HFpEF) 24. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "1. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering cardiovascular and renal outcomes: updated systematic review and meta-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "treatment in hypertension: 9. Discontinuations for adverse events attributed analysis. Lancet. 2016;387:435–443."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "to different classes of antihypertensive drugs: meta-analyses of randomized 25. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "trials. J Hypertens. 2016;34:1921–1932. prevention of cardiovascular disease: meta-analysis of 147 randomised tri-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2. Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard als in the context of expectations from prospective epidemiological studies."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "blood pressure control and cardiovascular disease outcomes in adults aged BMJ. 2009;338:b1665."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "≥75 years: a randomized clinical trial. JAMA. 2016;315:2673–2682. 26. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "3. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A random- ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "ized trial of intensive versus standard blood-pressure control. N Engl J Med. detection, evaluation, and management of high blood pressure in adults: a"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2015;373:2103–2116. report of the American College of Cardiology/American Heart Association"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "4. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "preserved ejection fraction. N Engl J Med. 2021;385:1451–1461. e115."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "5. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with 27. Aronow WS, Ahn C, Kronzon I. Effect of propranolol versus no propranolol"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "preserved ejection fraction. N Engl J Med. 2014;370:1383–1392. on total mortality plus nonfatal myocardial infarction in older patients with"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "6. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in pa- prior myocardial infarction, congestive heart failure, and left ventricular ejec-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "tients and outcomes in the Treatment of Preserved Cardiac Function tion fraction > or = 40% treated with diuretics plus angiotensin-converting"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. enzyme inhibitors. Am J Cardiol. 1997;80:207–209."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2015;131:34–42. 28. van Veldhuisen DJ, Cohen-Solal A, Böhm M, et al. Beta-blockade with"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "7. Solomon SD, Claggett B, Desai AS, et al. Influence of ejection fraction on nebivolol in elderly heart failure patients with impaired and preserved left"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "outcomes and efficacy of sacubitril/valsartan (lcz696) in heart failure with ventricular ejection fraction: Data From SENIORS (Study of Effects of"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "reduced ejection fraction: the Prospective Comparison of ARNI with ACEI Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "to Determine Impact on Global Mortality and Morbidity in Heart Failure Heart Failure). J Am Coll Cardiol. 2009;53:2150–2158."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "(PARADIGM-HF) trial. Circ Heart Fail. 2016;9:e002744. 29. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dys-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "8. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients function in heart failure with preserved ejection fraction. J Am Coll Cardiol."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "with chronic heart failure and preserved left-ventricular ejection fraction: the 2010;56:845–854."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "CHARM-Preserved Trial. Lancet. 2003;362:777–781. 30. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "9. Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection frac- preserved ejection fraction. N Engl J Med. 2021;385:1451–1461."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "tion in CHARM: characteristics, outcomes and effect of candesartan across 31. Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "the entire ejection fraction spectrum. Eur J Heart Fail. 2018;20:1230– heart failure events in patients with heart failure and a preserved ejection"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "1239. fraction: the EMPEROR-Preserved trial. Circulation. 2021;144:1284–"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "10. Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin in- 1294."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "hibition in heart failure with preserved ejection fraction. N Engl J Med. 32. Kotecha D, Bunting KV, Gill SK, et al. Effect of digoxin vs bisoprolol for heart"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2019;381:1609–1620. rate control in atrial fibrillation on patient-reported quality of life: the RATE-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "11. Solomon SD, Vaduganathan M, B LC, et al. Sacubitril/valsartan across the AF randomized clinical trial. JAMA. 2020;324:2497–2508."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "spectrum of ejection fraction in heart failure. Circulation. 2020;141:352– 33. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "361. the management of patients with atrial fibrillation: a report of the American"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "12. Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart College of Cardiology/American Heart Association Task Force on Practice"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "failure with preserved ejection fraction. N Engl J Med. 2015;373:2314– Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199–"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2324. e267."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "13. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 34. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused up-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "inhibition on exercise capacity and clinical status in heart failure with pre- date of the 2014 AHA/ACC/HRS guideline for the management of pa-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "served ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268– tients with atrial fibrillation: a report of the American College of Cardiology/"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "1277. American Heart Association Task Force on Clinical Practice Guidelines and"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "14. Cincin A, Abul Y, Ozben B, et al. Pleural fluid amino-terminal brain natriuretic the Heart Rhythm Society. Circulation. 2019;140:e125–e151."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "peptide in patients with pleural effusions. Respir Care. 2013;58:313–319. 35. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on dia-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "15. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities stolic function and exercise capacity in patients with heart failure with pre-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "on morbidity and mortality in a predominantly male population with heart served ejection fraction: the Aldo-DHF randomized controlled trial. JAMA."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2013;309:781–791."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2012;59:998–1005. 36. Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "16. Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart increased myocardial collagen turnover linked to diastolic dysfunction. Cir-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. culation. 2007;115:888–895."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2014;64:2281–2293. 37. Yamamoto K, Masuyama T, Sakata Y, et al. Roles of renin-angiotensin and"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "17. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved endothelin systems in development of diastolic heart failure in hypertensive"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "ejection fraction: comorbidities drive myocardial dysfunction and remodeling hearts. Cardiovasc Res. 2000;47:274–283."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 38. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2013;62:263–271. with chronic heart failure and preserved left-ventricular ejection fraction: the"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "18. Ho JE, Zern EK, Wooster L, et al. Differential clinical profiles, exercise re- CHARM-Preserved Trial. Lancet. 2003;362:777–781."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "sponses, and outcomes associated with existing HFpEF definitions. Circula- 39. Nilsson BB, Lunde P, Grogaard HK, et al. Long-term results of high-intensity"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "tion. 2019;140:353–365. exercise-based cardiac rehabilitation in revascularized patients for symp-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "19. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart tomatic coronary artery disease. Am J Cardiol. 2018;121:21–26."
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "failure and preserved ejection fraction. N Engl J Med. 2008;359:2456– 40. Lumbers RT, Martin N, Manoharan K, et al. Do beta-blockers and inhibi-"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2467. tors of the renin-angiotensin aldosterone system improve outcomes in"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 115,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "e1010 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "patients with heart failure and left ventricular ejection fraction >40. Heart. 5. Kim EJ, Holmes BB, Huang S, et al. Outcomes in patients with car-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2019;105:1533–1535. diac amyloidosis and implantable cardioverter-defibrillator. Europace."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "41. Martin N, Manoharan K, Thomas J, et al. Beta-blockers and inhibitors of 2020;22:1216–1223."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "the renin-angiotensin aldosterone system for chronic heart failure with pre- 6. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "served ejection fraction. Cochrane Database Syst Rev. 2018;6:CD012721. for patients with hereditary transthyretin amyloidosis. N Engl J Med."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "42. Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin 2018;379:22–31."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 7. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "double-blind randomised controlled trial. Lancet. 2012;380:1387–1395. therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "43. McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-val- 2018;379:11–21."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "sartan versus valsartan in women compared with men with heart failure 8. Berk JL, Suhr OB, Obici L, et al. Repurposing diflunisal for familial amyloid"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "and preserved ejection fraction: insights from PARAGON-HF. Circulation. polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658–2667."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2020;141:338–351. 9. Wixner J, Pilebro B, Lundgren HE, Olsson M, Anan I. Effect of doxycy-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "44. Solomon SD, Vaduganathan M, Claggett BL, et al. Sacubitril/valsar- cline and ursodeoxycholic acid on transthyretin amyloidosis. Amyloid."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "tan across the spectrum of ejection fraction in heart failure. Circulation. 2017;24:78–79."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2020;141:352–361. 10. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "45. Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart acid for transthyretin amyloidosis: a phase II study. Amyloid. 2012; 19(suppl"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "failure with preserved ejection fraction. N Engl J Med. 2015;373:2314– 1):34–36."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2324. 11. aus dem Siepen F, Bauer R, Aurich M, et al. Green tea extract as a treatment"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "for patients with wild-type transthyretin amyloidosis: an observational study."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "7.8.1. Diagnosis of Cardiac Amyloidosis Drug Des Devel Ther. 2015;9:6319–6325."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "12. Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "1. Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "patients with cardiac amyloidosis. Circulation. 2007;116:2420–2426."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "amyloidosis and its predictors among elderly patients with severe aortic"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "13. Donnellan E, Elshazly MB, Vakamudi S, et al. No association between"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "stenosis undergoing transcatheter aortic valve replacement. Eur Heart J."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "CHADS-VASc score and left atrial appendage thrombus in patients with"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2017;38:2879–2887."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "transthyretin amyloidosis. J Am Coll Cardiol EP. 2019;5:1473–1474."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "transthyretin amyloidosis as a cause of heart failure with preserved ejection"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "fraction. Eur Heart J. 2015;36:2585–2594."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "8.1. Specialty Referral for Advanced HF"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "3. Sperry BW, Reyes BA, Ikram A, et al. Tenosynovial and cardiac amyloi-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "dosis in patients undergoing carpal tunnel release. J Am Coll Cardiol. 1. Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a posi-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2018;72:2040–2050. tion statement of the Heart Failure Association of the European Society of"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "4. Westermark P, Westermark GT, Suhr OB, et al. Transthyretin-derived amyloi- Cardiology. Eur J Heart Fail. 2018;20:1505–1535."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "dosis: probably a common cause of lumbar spinal stenosis. Ups J Med Sci. 2. Fang JC, Ewald GA, Allen LA, et al. Advanced (stage D) heart failure: a"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2014;119:223–228. statement from the Heart Failure Society of America Guidelines Committee."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "5. Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of trans- J Card Fail. 2015;21:519–534."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "thyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Sur- 3. Greenberg B, Fang J, Mehra M, et al. Advanced heart failure: trans-atlantic"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "vey). J Am Coll Cardiol. 2016;68:161–172. perspectives on the heart failure association of the European Society of"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "6. Muchtar E, Gertz MA, Kyle RA, et al. A modern primer on light chain amy- Cardiology position statement. Eur J Heart Fail. 2018;20:1536–1539."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "loidosis in 592 patients with mass spectrometry-verified typing. Mayo Clin 4. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorpo-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "Proc. 2019;94:472–483. rated into the ACC/AHA 2005 guidelines for the diagnosis and manage-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "7. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac ment of heart failure in adults a report of the American College of Car-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "transthyretin amyloidosis. Circulation. 2016;133:2404–2412. diology Foundation/American Heart Association Task Force on Practice"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "8. Brown EE, Lee YZJ, Halushka MK, et al. Genetic testing improves identifi- Guidelines. Circulation. 2009;119:e391–e479."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "cation of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amy- 5. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "loid. 2017;24:92–95. update of the 2013 ACCF/AHA guideline for the management of heart"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "9. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolv- failure: a report of the American College of Cardiology/American Heart As-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "ing diagnosis and management: a scientific statement from the American sociation Task Force on Clinical Practice Guidelines and the Heart Failure"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "Heart Association. Circulation. 2020;142:e7–e22. Society of America. Circulation. 2017;136:e137–e161."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "10. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and func- 6. Thomas R, Huntley A, Mann M, et al. Specialist clinics for reducing emer-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "tion in transthyretin-related versus light-chain cardiac amyloidosis. Circula- gency admissions in patients with heart failure: a systematic review and"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "tion. 2014;129:1840–1849. meta-analysis of randomised controlled trials. Heart. 2013;99:233–239."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "11. Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of 7. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "quantitative kappa and lambda free light chain assays in clinical practice. advanced heart failure: the current picture. J Heart Lung Transplant."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "Clin Chem. 2005;51:878–881. 2009;28:535–541."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "12. Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar techne- 8. Ambardekar AV, Fonarow GC, Hernandez AF, et al. Characteristics and"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "tium 99m pyrophosphate cardiac imaging: predicting survival for patients in-hospital outcomes for nonadherent patients with heart failure: findings"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880–889. from Get With The Guidelines-Heart Failure (GWTG-HF). Am Heart J."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "13. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi 2009;158:644–652."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 9. Andrews AM, Russell CL, Cheng AL. Medication adherence interventions"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2018;379:11–21. for older adults with heart failure: a systematic review. J Gerontol Nurs."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "14. Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment 2017;43:37–45."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "for patients with hereditary transthyretin amyloidosis. N Engl J Med. 10. Fitzgerald AA, Powers JD, Ho PM, et al. Impact of medication nonadherence"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2018;379:22–31. on hospitalizations and mortality in heart failure. J Card Fail. 2011;17:664–"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "669."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "7.8.2. Treatment of Cardiac Amyloidosis 11. Ruppar TM, Cooper PS, Mehr DR, et al. Medication adherence interventions"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "1. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment improve heart failure mortality and readmission rates: systematic review and"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. meta-analysis of controlled trials. J Am Heart Assoc. 2016;5:e002606."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2018;379:1007–1016. 12. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2. Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis therapy management of heart failure: a report of the American College of Car-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "for transthyretin amyloid cardiomyopathy. Circulation. 2020;141:1214–1224. diology Foundation/American Heart Association Task Force on Practice"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "3. El-Am EA, Dispenzieri A, Melduni RM, et al. Direct current cardioversion Guidelines. Circulation. 2013;128:e240–e327."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol. 13. Russell SD, Miller LW, Pagani FD. Advanced heart failure: a call to action."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2019;73:589–597. Congest Heart Fail. 2008;14:316–321."
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "4. Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagula- 14. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC expert consensus deci-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "tion therapy in cardiac amyloidosis. Circulation. 2009;119:2490–2497. sion pathway for optimization of heart failure treatment: answers to 10 piv-"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 116,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1011"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "otal issues about heart failure with reduced ejection fraction: a report of the 8.2. Nonpharmacological Management: Advanced HF"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "American College of Cardiology Task Force on expert consensus decision"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "pathways. J Am Coll Cardiol. 2018;71:201–230. 1. Dunlap ME, Hauptman PJ, Amin AN, et al. Management of hyponatremia"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "15. Guglin M, Zucker MJ, Borlaug BA, et al. Evaluation for heart transplanta- in acute heart failure: a report from the hyponatremia registry for patients"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "tion and LVAD implantation: JACC council perspectives. J Am Coll Cardiol. with euvolemic and hypervolemic hyponatremia (HN Registry). J Am Heart"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "2020;75:1471–1487. Assoc. 2017;6:e005261."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "16. Thorvaldsen T, Benson L, Stahlberg M, et al. Triage of patients with moder- 2. Philipson H, Ekman I, Forslund HB, et al. Salt and fluid restriction is effective"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "ate to severe heart failure: who should be referred to a heart failure center? in patients with chronic heart failure. Eur J Heart Fail. 2013;15:1304–1310."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "J Am Coll Cardiol. 2014;63:661–671. 3. Albert NM, Nutter B, Forney J, et al. A randomized controlled pilot study of"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "17. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device outcomes of strict allowance of fluid therapy in hyponatremic heart failure"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "implantation as destination therapy in the post-REMATCH era: implications (SALT-HF). J Card Fail. 2013;19:1–9."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "for patient selection. Circulation. 2007;116:497–505. 4. De Vecchis R, Baldi C, Cioppa C, et al. Effects of limiting fluid intake on"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "18. Baumwol J. “I Need Help”—A mnemonic to aid timely referral in advanced clinical and laboratory outcomes in patients with heart failure. Results of a"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "heart failure. J Heart Lung Transplant. 2017;36:593–594. meta-analysis of randomized controlled trials. Herz. 2016;41:63–75."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "19. Feldman D, Pamboukian SV, Teuteberg JJ, et al. The 2013 International Soci- 5. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between ad-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "ety for Heart and Lung Transplantation guidelines for mechanical circulatory mission serum sodium concentration and clinical outcomes in patients hos-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "support: executive summary. J Heart Lung Transplant. 2013;32:157–187. pitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "20. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society Heart J. 2007;28:980–988."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "for Heart Lung Transplantation listing criteria for heart transplantation: a 6. Lu DY, Cheng HM, Cheng YL, et al. Hyponatremia and worsening sodium"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "10-year update. J Heart Lung Transplant. 2016;35:1–23. levels are associated with long-term outcome in patients hospitalized for"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "21. Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart fail- acute heart failure. J Am Heart Assoc. 2016;5:e002668."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "ure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 7. Allen LA, Gheorghiade M, Reid KJ, et al. Identifying patients hospitalized"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "2013;34:1404–1413. with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "22. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: Qual Outcomes. 2011;4:389–398."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "prediction of survival in heart failure. Circulation. 2006;113:1424–1433. 8. Wang J, Zhou W, Yin X. Improvement of hyponatremia is associated with"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "23. Ambrosy AP, Pang P, Khan S, et al; Everest Trial Investigators. Clinical lower mortality risk in patients with acute decompensated heart failure: a"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "course and predictive value of congestion during hospitalization in pa- meta-analysis of cohort studies. Heart Fail Rev. 2019;24:209–217."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "tients admitted for worsening signs and symptoms of heart failure with 9. Omar HR, Charnigo R, Guglin M. Prognostic significance of discharge hy-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. ponatremia in heart failure patients with normal admission sodium (from the"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "2013;34:835–843. ESCAPE Trial). Am J Cardiol. 2017;120:607–615."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "24. Caldentey G, Khairy P, Roy D, et al. Prognostic value of the physical exami- 10. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "nation in patients with heart failure and atrial fibrillation: insights from the management of heart failure: a report of the American College of Cardiol-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "AF-CHF trial (atrial fibrillation and chronic heart failure). J Am Coll Cardiol ogy Foundation/American Heart Association Task Force on Practice Guide-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "HF. 2014;2:15–23. lines. Circulation. 2013;128:e240–e327."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "25. Drazner MH, Rame JE, Stevenson L, et al. Prognostic importance of el- 11. Vest AR, Chan M, Deswal A, et al. Nutrition, obesity, and cachexia in patients"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "evated jugular venous pressure and a third heart sound in patients with with heart failure: a consensus statement from the Heart Failure Society of"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "heart failure. N Engl J Med. 2001;345:574–581. America Scientific Statements Committee. J Card Fail. 2019;25:380–400."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "26. Fudim M, Parikh KS, Dunning A, et al. Relation of volume overload to clini- 12. Expression of concern: normal-sodium diet compared with low-sodium diet"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "cal outcomes in acute heart failure (from ASCEND-HF). Am J Cardiol. in compensated congestive heart failure: is sodium an old enemy or a new"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "2018;122:1506–1512. friend? Clin Sci (Lond). 2020;134:1841."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "27. Selvaraj S, Claggett B, Shah SJ, et al. Utility of the cardiovascular physical"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "examination and impact of spironolactone in heart failure with preserved 8.3. Inotropic Support"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "ejection fraction. Circ Heart Fail. 2019;12:e006125."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "28. Selvaraj S, Claggett B, Pozzi A, et al. Prognostic implications of con- 1. Al-Kindi SG, Farhoud M, Zacharias M, et al. Left ventricular assist devic-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "gestion on physical examination among contemporary patients with es or inotropes for decreasing pulmonary vascular resistance in patients"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "heart failure and reduced ejection fraction: PARADIGM-HF. Circulation. with pulmonary hypertension listed for heart transplantation. J Card Fail."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "2019;140:1369–1379. 2017;23:209–215."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "29. Simonavicius J, Sanders van-Wijk S, Rickenbacher P, et al. Prognostic sig- 2. Hübner T, Nickel T, Steinbeck G, et al. A single German center experience"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "nificance of longitudinal clinical congestion pattern in chronic heart failure: with intermittent inotropes for patients on the high-urgent heart transplant"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "insights from TIME-CHF Trial. Am J Med. 2019;132:e679–e692. waiting list. Clin Res Cardiol. 2015;104:929–934."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "30. Gorodeski EZ, Chu E, Reese JR, et al. Prognosis on chronic dobutamine or 3. Aranda JM Jr, Schofield RS, Pauly DF, et al. Comparison of dobutamine"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "milrinone infusions for stage D heart failure. Circ Heart Fail. 2009;2:320– versus milrinone therapy in hospitalized patients awaiting cardiac transplan-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "324. tation: a prospective, randomized trial. Am Heart J. 2003;145:324–329."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "31. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to 4. Brozena SC, Twomey C, Goldberg LR, et al. A prospective study of con-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "mortality in advanced heart failure. Am J Cardiol. 2006;97:1759–1764. tinuous intravenous milrinone therapy for status IB patients awaiting heart"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "32. Poole JE, Johnson GW, Hellkamp AS, et al. Prognostic importance of defibril- transplant at home. J Heart Lung Transplant. 2004;23:1082–1086."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "lator shocks in patients with heart failure. N Engl J Med. 2008;359:1009– 5. Gorodeski EZ, Chu E, Reese JR, et al. Prognosis on chronic dobutamine or"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "1017. milrinone infusions for stage D heart failure. Circ Heart Fail. 2009;2:320–"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "33. Zamora E, Diez-Lopez C, Lupon J, et al. Weight loss in obese patients with 324."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "heart failure. J Am Heart Assoc. 2016;5:e002468. 6. O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobuta-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "34. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight mine is associated with an increased risk of death in patients with advanced"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "loss in chronic heart failure and the effect of treatment with angio- heart failure: insights from the Flolan International Randomized Survival Trial"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "tensin-converting-enzyme inhibitors: an observational study. Lancet. (FIRST). Am Heart J. 1999;138:78–86."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "2003;361:1077–1083. 7. Hershberger RE, Nauman D, Walker TL, et al. Care processes and"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "35. Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-renal limita- clinical outcomes of continuous outpatient support with inotropes"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "tions to angiotensin-converting enzyme inhibitors identifies patients with se- (COSI) in patients with refractory endstage heart failure. J Card Fail."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "vere heart failure and early mortality. J Am Coll Cardiol. 2003;41:2029–2035. 2003;9:180–187."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "36. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations pre- 8. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "dict mortality in the community population with heart failure. Am Heart J. with acute decompensated heart failure requiring intravenous vasoactive"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "2007;154:260–266. medications: an analysis from the Acute Decompensated Heart Failure Na-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "37. Cook JL, Colvin M, Francis GS, et al. Recommendations for the use of tional Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "mechanical circulatory support: ambulatory and community patient care: 9. Nizamic T, Murad MH, Allen LA, et al. Ambulatory inotrope infusions in ad-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "a scientific statement from the American Heart Association. Circulation. vanced heart failure: a systematic review and meta-analysis. J Am Coll Car-"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "2017;135:e1145–e1158. diol HF. 2018;6:757–767."
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 117,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "e1012 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "10. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low-dose dobuta- 17. Nassif ME, Spertus JA, Jones PG, et al. Changes in disease-specific versus"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "mine infusion in severe heart failure: DICE multicenter trial. Am Heart J. generic health status measures after left ventricular assist device implanta-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "1999;138:247–253. tion: insights from INTERMACS. J Heart Lung Transplant. 2017;36:1243–"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "11. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone 1249."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "for acute exacerbation of chronic heart failure: a randomized controlled trial. 18. Rogers JG, Butler J, Lansman SL, et al. Chronic mechanical circulatory sup-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "JAMA. 2002;287:1541–1547. port for inotrope-dependent heart failure patients who are not transplant"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "12. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and va- candidates: results of the INTrEPID Trial. J Am Coll Cardiol. 2007;50:741–"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "sodilator therapy in hospitalized patients with severe heart failure. Am Heart 747."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "J. 2007;153:98–104. 19. Starling RC, Estep JD, Horstmanshof DA, et al. Risk assessment and com-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "13. Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosimendan vs. dobuta- parative effectiveness of left ventricular assist device and medical manage-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "mine: outcomes for acute heart failure patients on beta-blockers in SUR- ment in ambulatory heart failure patients: the ROADMAP study 2-year re-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "VIVE. Eur J Heart Fail. 2009;11:304–311. sults. J Am Coll Cardiol HF. 2017;5:518–527."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "14. Acharya D, Sanam K, Revilla-Martinez M, et al. Infections, arrhythmias, 20. Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, et al. Cost-effective-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "and hospitalizations on home intravenous inotropic therapy. Am J Cardiol. ness of left ventricular assist devices in ambulatory patients with advanced"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "2016;117:952–956. heart failure. J Am Coll Cardiol HF. 2017;5:110–119."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "15. Hashim T, Sanam K, Revilla-Martinez M, et al. Clinical characteristics and 21. Long EF, Swain GW, Mangi AA. Comparative survival and cost-effective-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "outcomes of intravenous inotropic therapy in advanced heart failure. Circ ness of advanced therapies for end-stage heart failure. Circ Heart Fail."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "Heart Fail. 2015;8:880–886. 2014;7:470–478."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "16. Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutane- 22. Mahr C, McGee E Jr, Cheung A, et al. Cost-effectiveness of thoracotomy"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "ous administration of gene therapy in patients with cardiac disease (CUPID approach for the implantation of a centrifugal left ventricular assist device."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "2): a randomised, multinational, double-blind, placebo-controlled, phase 2b ASAIO J. 2020;66:855–861."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "trial. Lancet. 2016;387:1178–1186. 23. Rogers JG, Bostic RR, Tong KB, et al. Cost-effectiveness analysis of con-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "tinuous-flow left ventricular assist devices as destination therapy. Circ Heart"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "Fail. 2012;5:10–16."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "8.4. Mechanical Circulatory Support (MCS) 24. Silvestry SC, Mahr C, Slaughter MS, et al. Cost-effectiveness of a small intra-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "pericardial centrifugal left ventricular assist device. ASAIO J. 2020;66:862–"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "1. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in 870."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "patients awaiting heart transplantation. N Engl J Med. 2007;357:885–896. 25. Garbade J, Gustafsson F, Shaw S, et al. Postmarket experience with Heart-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "2. Mehra MR, Uriel N, Naka Y, et al. A fully magnetically levitated left ventricu- Mate 3 left ventricular assist device: 30-day outcomes from the ELEVATE"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "lar assist device - final report. N Engl J Med. 2019;380:1618–1627. registry. Ann Thorac Surg. 2019;107:33–39."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "3. Jakovljevic DG, Yacoub MH, Schueler S, et al. Left Ventricular assist device 26. Trivedi JR, Cheng A, Singh R, Williams ML, Slaughter MS. Survival on the"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "as a bridge to recovery for patients with advanced heart failure. J Am Coll heart transplant waiting list: impact of continuous flow left ventricular assist"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "Cardiol. 2017;69:1924–1933. device as bridge to transplant. Ann Thorac Surg. 2014;98:830–834."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "4. Grady KL, Naftel D, Stevenson L, et al. Overall quality of life improves to sim- 27. Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term ac-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "ilar levels after mechanical circulatory support regardless of severity of heart tive mechanical support devices in cardiogenic shock: a systematic re-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "failure before implantation. J Heart Lung Transplant. 2014;33:412–421. view and collaborative meta-analysis of randomized trials. Eur Heart J."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "5. Lund LH, Trochu JN, Meyns B, et al. Screening for heart transplantation 2017;38:3523–3531."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "and left ventricular assist system: results from the ScrEEning for advanced 28. den Uil CA, Van Mieghem NM, M BB, et al. Primary intra-aortic balloon sup-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "Heart Failure treatment (SEE-HF) study. Eur J Heart Fail. 2018;20:152– port versus inotropes for decompensated heart failure and low output: a"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "160. randomised trial. EuroIntervention. 2019;15:586–593."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "6. Alba AC, Rao V, Ross HJ, et al. Impact of fixed pulmonary hypertension 29. Ouyang D, Gulati G, Ha R, et al. Incidence of temporary mechanical circu-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "on post-heart transplant outcomes in bridge-to-transplant patients. J Heart latory support before heart transplantation and impact on post-transplant"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "Lung Transplant. 2010;29:1253–1258. outcomes. J Heart Lung Transplant. 2018;37:1060–1066."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "7. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure 30. Arnold SV, Jones PG, Allen LA, et al. Frequency of poor outcome (death or"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "treated with continuous-flow left ventricular assist device. N Engl J Med. poor quality of life) after left ventricular assist device for destination therapy:"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "2009;361:2241–2251. results from the INTERMACS registry. Circ Heart Fail. 2016;9:e002800."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "8. Milano CA, Rogers JG, Tatooles AJ, et al. HVAD: the ENDURANCE supple- 31. Rogers JG, Pagani FD, Tatooles AJ, et al. Intrapericardial left ventricular as-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "mental trials. J Am Coll Cardiol HF. 2018;6:792–802. sist device for advanced heart failure. N Engl J Med. 2017;376:451–460."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "9. Petroni T, D’Alessandro C, Combes A, et al. Long-term outcome of 32. Allen JG, Weiss ES, Schaffer JM, et al. Quality of life and functional status in"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "heart transplantation performed after ventricular assist device com- patients surviving 12 months after left ventricular assist device implantation."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "pared with standard heart transplantation. Arch Cardiovasc Dis. J Heart Lung Transplant. 2010;29:278–285."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "2019;112:485–493. 33. Slaughter MS, Pagani FD, McGee EC, et al. HeartWare ventricular assist"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "10. Molina EJ, Shah P, Kiernan MS, et al. The Society of Thoracic Surgeons system for bridge to transplant: combined results of the bridge to transplant"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "Intermacs 2020 annual report. Ann Thorac Surg. 2021;111:778–792. and continued access protocol trial. J Heart Lung Transplant. 2013;32:675–"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "11. Selim AM, Wadhwani L, Burdorf A, et al. Left ventricular assist devices in 683."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "pulmonary hypertension group 2 with significantly elevated pulmonary vas- 34. Bellavia D, Iacovoni A, Scardulla C, et al. Prediction of right ventricular failure"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "cular resistance: a bridge to cure. Heart Lung Circ. 2019;28:946–952. after ventricular assist device implant: systematic review and meta-analysis"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "12. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular of observational studies. Eur J Heart Fail. 2017;19:926–946."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "assist device for end-stage heart failure. N Engl J Med. 2001;345:1435– 35. Joseph SM, Manghelli JL, Vader JM, et al. Prospective assessment of frailty"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "1443. using the Fried criteria in patients undergoing left ventricular assist device"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "13. Shah KB, Starling RC, Rogers JG, et al. Left ventricular assist devices ver- therapy. Am J Cardiol. 2017;120:1349–1354."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "sus medical management in ambulatory heart failure patients: an analysis of 36. Adamo L, Tang Y, Nassif ME, et al. The HeartMate risk score identifies pa-"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study. J Heart Lung tients with similar mortality risk across all INTERMACS profiles in a large"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "Transplant. 2018;37:706–714. multicenter analysis. J Am Coll Cardiol HF. 2016;4:950–958."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "14. Stewart GC, Kittleson MM, Patel PC, et al. INTERMACS (Interagency Reg- 37. Baumann Kreuziger LM, Kim B, Wieselthaler GM. Antithrombotic therapy"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "istry for Mechanically Assisted Circulatory Support) profiling identifies am- for left ventricular assist devices in adults: a systematic review. J Thromb"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "bulatory patients at high risk on medical therapy after hospitalizations for Haemost. 2015;13:946–955."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "heart failure. Circ Heart Fail. 2016;9:e003032. 38. Goldstein DJ, John R, Salerno C, et al. Algorithm for the diagnosis and"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "15. Kiernan MS, Sundareswaran KS, Pham DT, et al. Preoperative determinants management of suspected pump thrombus. J Heart Lung Transplant."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "of quality of life and functional capacity response to left ventricular assist 2013;32:667–670."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "device therapy. J Card Fail. 2016;22:797–805. 39. Coffin ST, Haglund NA, Davis ME, et al. Adverse neurologic events"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "16. Krabatsch T, Netuka I, Schmitto JD, et al. Heartmate 3 fully magnetically lev- in patients bridged with long-term mechanical circulatory support:"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "itated left ventricular assist device for the treatment of advanced heart fail- a device-specific comparative analysis. J Heart Lung Transplant."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "ure -1 year results from the Ce mark trial. J Cardiothorac Surg. 2017;12:23. 2015;34:1578–1585."
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 118,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1013"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "40. Kato TS, Schulze PC, Yang J, et al. Pre-operative and post-operative risk 15. Grady KL, Naftel DC, Kobashigawa J, et al. Patterns and predictors of qual-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "factors associated with neurologic complications in patients with advanced ity of life at 5 to 10 years after heart transplantation. J Heart Lung Trans-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "heart failure supported by a left ventricular assist device. J Heart Lung plant. 2007;26:535–543."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Transplant. 2012;31:1–8. 16. Kanwar M, Raina A, Aponte MP, et al. Pulmonary hypertension in potential"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "41. Zhigalov K, Mashhour A, Szczechowicz M, et al. Clinical outcome and com- heart transplant recipients: current treatment strategies. Curr Opin Organ"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "parison of three different left ventricular assist devices in a high-risk cohort. Transplant. 2015;20:570–576."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Artif Organs. 2018;42:1035–1042. 17. Givertz MM, DeFilippis EM, Landzberg MJ, et al. Advanced heart failure"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "42. Hawkins RB, Go K, Raymond SL, et al. Laparoscopic sleeve gastrectomy in therapies for adults with congenital heart disease: JACC state-of-the-art"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "patients with heart failure and left ventricular assist devices as a bridge to review. J Am Coll Cardiol. 2019;74:2295–2312."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "transplant. Surg Obes Relat Dis. 2018;14:1269–1273. 18. Maron MS, Kalsmith BM, Udelson JE, et al. Survival after cardiac trans-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "43. Kerrigan DJ, Williams CT, Ehrman JK, et al. Muscular strength and car- plantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "diorespiratory fitness are associated with health status in patients with 2010;3:574–579."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "recently implanted continuous-flow LVADs. J Cardiopulm Rehabil Prev. 19. Wu RS, Gupta S, Brown RN, et al. Clinical outcomes after cardiac trans-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2013;33:396–400. plantation in muscular dystrophy patients. J Heart Lung Transplant."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "44. Kumarasinghe G, Jain P, Jabbour A, et al. Comparison of continuous-flow 2010;29:432–438."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "ventricular assist device therapy with intensive medical therapy in fixed pul- 20. Crawford TC, Okada DR, Magruder JT, et al. A contemporary analysis of"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "monary hypertension secondary to advanced left heart failure. ESC Heart heart transplantation and bridge-to-transplant mechanical circulatory sup-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Fail. 2018;5:695–702. port outcomes in cardiac sarcoidosis. J Card Fail. 2018;24:384–391."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "45. Pham BN, Chaparro SV. Left ventricular assist device recovery: does dura- 21. Barrett CD, Alexander KM, Zhao H, et al. Outcomes in patients with car-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "tion of mechanical support matter? Heart Fail Rev. 2019;24:237–244. diac amyloidosis undergoing heart transplantation. J Am Coll Cardiol HF."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "46. Lampropulos JF, Kim N, Wang Y, et al. Trends in left ventricular assist device 2020;8:461–468."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "use and outcomes among Medicare beneficiaries, 2004-2011. Open Heart. 22. Arena R, Myers J, Aslam SS, et al. Peak VO2 and VE/VCO2 slope in"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "1;2014:e000109. patients with heart failure: a prognostic comparison. Am Heart J."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "47. Mehra MR, Salerno C, Cleveland JC, et al. Healthcare resource use and cost 2004;147:354–360."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "implications in the MOMENTUM 3 long-term outcome study. Circulation. 23. Kato TS, Collado E, Khawaja T, et al. Value of peak exercise oxygen con-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2018;138:1923–1934. sumption combined with B-type natriuretic peptide levels for optimal timing"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "48. Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic Sur- of cardiac transplantation. Circ Heart Fail. 2013;6:6–14."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "geons Intermacs 2019 annual report: the changing landscape of devices 24. Ferreira AM, Tabet JY, Frankenstein L, et al. Ventilatory efficiency and the"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "and indications. Ann Thorac Surg. 2020;109:649–660. selection of patients for heart transplantation. Circ Heart Fail. 2010;3:378–"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "386."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "25. Corra U, Agostoni PG, Anker SD, et al. Role of cardiopulmonary exer-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "8.5. Cardiac Transplantation cise testing in clinical stratification in heart failure. A position paper from"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "the Committee on Exercise Physiology and Training of the Heart Fail-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "1. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "ure Association of the European Society of Cardiology. Eur J Heart Fail."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Organ Transplant Registry of the International Society for Heart and Lung"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2018;20:3–15."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Transplantation: thirty-sixth adult heart transplantation report - 2019; fo-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "26. Peterson LR, Schechtman KB, Ewald GA, et al. The effect of beta-adren-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "cus theme: donor and recipient size match. J Heart Lung Transplant."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "ergic blockers on the prognostic value of peak exercise oxygen uptake in"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2019;38:1056–1066."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "patients with heart failure. J Heart Lung Transplant. 2003;22:70–77."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2. Colvin M, Smith JM, Hadley N, et al. OPTN/SRTR 2018 annual data report:"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "27. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen con-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "heart. Am J Transplant. 2020;20(Suppl 1):340–426."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "sumption for optimal timing of cardiac transplantation in ambulatory patients"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "3. Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic Sur-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "with heart failure. Circulation. 1991;83:778–786."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "geons Intermacs 2019 annual report: the changing landscape of devices"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "28. O’Neill JO, Bott-Silverman CE, McRae AT 3rd, et al. B-type natriuretic"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "and indications. Ann Thorac Surg. 2020;109:649–660."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "peptide levels are not a surrogate marker for invasive hemodynamics"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "4. Long EF, Swain GW, Mangi AA. Comparative survival and cost-effective-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "during management of patients with severe heart failure. Am Heart J."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "ness of advanced therapies for end-stage heart failure. Circ Heart Fail. 2005;149:363–369."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2014;7:470–478."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "29. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "5. US Department of Health and Human Services. Adult heart allocation."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "for Heart Lung Transplantation listing criteria for heart transplantation: a"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2018. Accessed September 15, 2020. https://optn.transplant.hrsa.gov/"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "10-year update. J Heart Lung Transplant. 2016;35:1–23."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "learn/professional-education/adult-heart-allocation/"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "30. Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis ther-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "6. Cogswell R, John R, Estep JD, et al. An early investigation of outcomes with"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "apy for transthyretin amyloid cardiomyopathy. Circulation. 2020;141:1214–"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "the new 2018 donor heart allocation system in the United States. J Heart"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "1224."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Lung Transplant. 2020;39:1–4."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "7. Goff RR, Uccellini K, Lindblad K, et al. A change of heart: preliminary"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "results of the US 2018 adult heart allocation revision. Am J Transplant. 9.1. Assessment of Patients Hospitalized With"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2020;20:2781–2790."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Decompensated HF"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "8. Jawitz OK, Fudim M, Raman V, et al. Reassessing recipient mortality under"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "the new heart allocation system: an updated UNOS registry analysis. J Am 1. Drazner MH, Hellkamp AS, Leier CV, et al. Value of clinician assessment of"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Coll Cardiol HF. 2020;8:548–556. hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "9. Kilic A, Hickey G, Mathier MA, et al. Outcomes of the first 1300 adult heart 2008;1:170–177."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "transplants in the United States after the allocation policy change. Circula- 2. Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure conges-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "tion. 2020;141:1662–1664. tion and perfusion status-impact of the clinical classification on in-hospital"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "10. Trivedi JR, Slaughter MS. “Unintended” consequences of changes in and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "heart transplant allocation policy: impact on practice patterns. ASAIO J. Long-Term Registry. Eur J Heart Fail. 2019;21:1338–1352."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2020;66:125–127. 3. Cleland JG, Chiswell K, Teerlink JR, et al. Predictors of postdischarge out-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "11. Varshney AS, Hirji SA, Givertz MM. Outcomes in the 2018 UNOS donor comes from information acquired shortly after admission for acute heart fail-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "heart allocation system: a perspective on disparate analyses. J Heart Lung ure: a report from the placebo-controlled randomized study of the selective"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Transplant. 2020;39:1191–1194. A1 adenosine receptor antagonist rolofylline for patients hospitalized with"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "12. Habedank D, Ewert R, Hummel M, et al. Changes in exercise capacity, ven- acute decompensated heart failure and volume overload to assess treat-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "tilation, and body weight following heart transplantation. Eur J Heart Fail. ment effect on congestion and renal function (PROTECT) study. Circ Heart"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2007;9:310–316. Fail. 2014;7:76–87."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "13. Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise reha- 4. Ambrosy AP, Pang P, Khan S, et al Everest Trial Investigators. Clinical"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "bilitation after heart transplantation. N Engl J Med. 1999;340:272–277. course and predictive value of congestion during hospitalization in pa-"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "14. Salyer J, Flattery MP, Joyner PL, et al. Lifestyle and quality of life in long- tients admitted for worsening signs and symptoms of heart failure with"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "term cardiac transplant recipients. J Heart Lung Transplant. 2003;22:309– reduced ejection fraction: findings from the EVEREST trial. Eur Heart J."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "321. 2013;34:835–843."
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 119,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "e1014 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "5. Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert 12. Fonarow GC, Abraham WT, Albert NM, et al. Carvedilol use at discharge"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "consensus decision pathway on risk assessment, management, and clinical in patients hospitalized for heart failure is associated with improved sur-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "trajectory of patients hospitalized with heart failure: a report of the American vival: an analysis from Organized Program to Initiate Lifesaving Treatment"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "2019;74:1966–2011. 2007;153:82e1–e11."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "6. Kapoor JR, Kapoor R, Ju C, et al. Precipitating clinical factors, heart failure 13. Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "characterization, and outcomes in patients hospitalized with heart failure beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "with reduced, borderline, and preserved ejection fraction. J Am Coll Cardiol Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "HF. 2016;4:464–472. Failure) Registry. J Am Coll Cardiol. 2009;53:184–192."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "7. Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management 14. Bhatia V, Bajaj NS, Sanam K, et al. Beta-blocker use and 30-day all-cause"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "of fulminant myocarditis: a scientific statement from the American Heart readmission in Medicare beneficiaries with systolic heart failure. Am J Med."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "Association. Circulation. 2020;141:e69–e92. 2015;128:715–721."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "8. Peretto G, Sala S, Rizzo S, et al. Ventricular arrhythmias in myocarditis: char- 15. Sanam K, Bhatia V, Bajaj NS, et al. Renin-angiotensin system inhibition and"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "acterization and relationships with myocardial inflammation. J Am Coll Car- lower 30-day all-cause readmission in Medicare beneficiaries with heart"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "diol. 2020;75:1046–1057. failure. Am J Med. 2016;129:1067–1073."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "9. Thibodeau JT, Drazner MH. The role of the clinical examination in patients 16. Hernandez AF, Mi X, Hammill BG, et al. Associations between aldosterone"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "with heart failure. J Am Coll Cardiol HF. 2018;6:543–551. antagonist therapy and risks of mortality and readmission among patients"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "10. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemody- with heart failure and reduced ejection fraction. JAMA. 2012;308:2097–"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "namic profiles that predict outcomes in patients admitted with heart failure. 2107."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "J Am Coll Cardiol. 2003;41:1797–1804. 17. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "11. Campbell P, Drazner MH, Kato M, et al. Mismatch of right and left-sided fill- and recent worsening heart failure. N Engl J Med. 2021;384:117–128."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "ing pressures in chronic heart failure. J Card Fail. 2011;17:561–568. 18. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibi-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "12. Zymlinski R, Biegus J, Sokolski M, et al. Increased blood lactate is prevalent tion in acute decompensated heart failure. N Engl J Med. 2019;380:539–"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "and identifies poor prognosis in patients with acute heart failure without 548."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "overt peripheral hypoperfusion. Eur J Heart Fail. 2018;20:1011–1018. 19. Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "13. Bhagat AA, Greene SJ, Vaduganathan M, et al. Initiation, continuation, with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "switching and withdrawal of heart failure medical therapies during hospital- 2018;72:351–366."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "ization. J Am Coll Cardiol. 2019;7:1–12. 20. Deschaseaux C, McSharry M, Hudson E, et al. Treatment initiation patterns,"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "14. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker modifications, and medication adherence among newly diagnosed heart"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "continuation or withdrawal on outcomes in patients hospitalized with failure patients: a retrospective claims database analysis. J Manag Care"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. Spec Pharm. 2016;22:561–571."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "2008;52:190–199. 21. Wirtz HS, Sheer R, Honarpour N, et al. Real-world analysis of guideline-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "based therapy after hospitalization for heart failure. J Am Heart Assoc."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "2020;9:e015042."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "9.2. Maintenance or Optimization of GDMT During 22. Greene SJ, Fonarow GC, DeVore AD, et al. Titration of medical ther-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "Hospitalization apy for heart failure with reduced ejection fraction. J Am Coll Cardiol."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "2019;73:2365–2383."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "1. Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker 23. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC expert consensus deci-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "continuation or withdrawal on outcomes in patients hospitalized with sion pathway for optimization of heart failure treatment: answers to 10 piv-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. otal issues about heart failure with reduced ejection fraction: a report of the"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "2008;52:190–199. American College of Cardiology Task Force on Expert Consensus Decision"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "2. Gilstrap LG, Fonarow GC, Desai AS, et al. Initiation, continuation, or with- Pathways. J Am Coll Cardiol. 2018;71:201–230."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "drawal of angiotensin-converting enzyme inhibitors/angiotensin receptor 24. Bhagat AA, Greene SJ, Vaduganathan M, et al. Initiation, continuation,"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "blockers and outcomes in patients hospitalized with heart failure with re- switching and withdrawal of heart failure medical therapies during hospital-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "duced ejection fraction. J Am Heart Assoc. 2017;6:e004675. ization. J Am Coll Cardiol. 2019;7:1–12."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "3. Maisel A, Xue Y, van Veldhuisen DJ, et al. Effect of spironolactone on 30- 25. Curtis LH, Mi X, Qualls LG, et al. Transitional adherence and persistence in"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "day death and heart failure rehospitalization (from the COACH Study). Am J the use of aldosterone antagonist therapy in patients with heart failure. Am"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "Cardiol. 2014;114:737–742. Heart J. 2013;165:979–986.e1."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "4. Prins KW, Neill JM, Tyler JO, et al. Effects of beta-blocker withdrawal in"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "acute decompensated heart failure: a systematic review and meta-analysis."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "J Am Coll Cardiol HF. 2015;3:647–653. 9.3. Diuretics in Hospitalized Patients: Decongestion"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "5. Tran RH, Aldemerdash A, Chang P, et al. Guideline-directed medical therapy Strategy"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "and survival following hospitalization in patients with heart failure. Pharma-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "cotherapy. 2018;38:406–416. 1. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "6. Peri-Okonny PA, Mi X, Khariton Y, et al. Target doses of heart failure medical decompensated heart failure. N Engl J Med. 2011;364:797–805."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "therapy and blood pressure: insights from the CHAMP-HF Registry. J Am 2. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "Coll Cardiol HF. 2019;7:350–358. heart failure and pulmonary artery catheterization effectiveness: the ES-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "7. Bohm M, Young R, Jhund PS, et al. Systolic blood pressure, cardiovascular CAPE trial. JAMA. 2005;294:1625–1633."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in pa- 3. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "tients with chronic heart failure and reduced ejection fraction: results from failure with cardiorenal syndrome. N Engl J Med. 2012;367:2296–2304."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "PARADIGM-HF. Eur Heart J. 2017;38:1132–1143. 4. Rubio-Gracia J, Demissei BG, Ter Maaten JM, et al. Prevalence, predictors"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "8. Montero-Perez-Barquero M, Flather M, Roughton M, et al. Influence of and clinical outcome of residual congestion in acute decompensated heart"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "systolic blood pressure on clinical outcomes in elderly heart failure pa- failure. Int J Cardiol. 2018;258:185–191."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "tients treated with nebivolol: data from the SENIORS trial. Eur J Heart Fail. 5. Ambrosy AP, Pang P, Khan S, et al Everest Trial Investigators. Clinical course"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "2014;16:1009–1015. and predictive value of congestion during hospitalization in patients admit-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "9. Anand IS, Rector TS, Kuskowski M, et al. Effect of baseline and changes ted for worsening signs and symptoms of heart failure with reduced ejection"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "in systolic blood pressure over time on the effectiveness of valsartan in the fraction: findings from the EVEREST trial. Eur Heart J. 2013;34:835–843."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "Valsartan Heart Failure Trial. Circ Heart Fail. 2008;1:34–42. 6. Chioncel O, Mebazaa A, Maggioni AP, et al. Acute heart failure congestion"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "10. Ahmad T, Jackson K, Rao VS, et al. Worsening renal function in patients with and perfusion status-impact of the clinical classification on in-hospital and"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "acute heart failure undergoing aggressive diuresis is not associated with long-term outcomes; insights from the ESC-EORP-HFA heart failure long-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "tubular injury. Circulation. 2018;137:2016–2028. term registry. Eur J Heart Fail. 2019;21:1338–1352."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "11. Brunner-La Rocca HP, Knackstedt C, Eurlings L, et al. Impact of worsen- 7. Faselis C, Arundel C, Patel S, et al. Loop diuretic prescription and 30-"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "ing renal function related to medication in heart failure. Eur J Heart Fail. day outcomes in older patients with heart failure. J Am Coll Cardiol."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "2015;17:159–168. 2020;76:669–679."
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 120,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1015"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "8. Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibi- 5. Fanola CL, Norby FL, Shah AM, et al. Incident heart failure and long-term"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "tion in acute decompensated heart failure. N Engl J Med. 2019;380:539– risk for venous thromboembolism. J Am Coll Cardiol. 2020;75:148–158."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "548. 6. Smilowitz NR, Zhao Q, Wang L, et al. Risk of venous thromboembolism after"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "9. Wan S-H, Stevens SR, Borlaug BA, et al. Differential response to low-dose new onset heart failure. Sci Rep. 2019;9:17415."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "dopamine or low-dose nesiritide in acute heart failure with reduced or pre- 7. Al Yami MS, Silva MA, Donovan JL, et al. Venous thromboembolism prophy-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "served ejection fraction. Circ Heart Fail. 2016;9:1–12. laxis in medically ill patients: a mixed treatment comparison meta-analysis. J"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "10. Cox ZL, Stevenson LW. The weight of evidence for diuretics and parachutes. Thromb Thrombolysis. 2018;45:36–47."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "J Am Coll Cardiol. 2020;76:680–683. 8. Tang L, Wu YY, Lip GY, et al. Heart failure and risk of venous thromboembo-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "11. Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert lism: a systematic review and meta-analysis. Lancet Haematol. 2016;3:e30–"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "consensus decision pathway on risk assessment, management, and clinical e44."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "trajectory of patients hospitalized with heart failure: a report of the American 9. Barba R, Zapatero A, Losa JE, et al. Venous thromboembolism in acutely ill"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. hospitalized medical patients. Thromb Res. 2010;126:276–279."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "2019;74:1966–2011. 10. Riess H, Haas S, Tebbe U, et al. A randomized, double-blind study of cer-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "12. Gilstrap LG, Stevenson LW, Small R, et al. Reasons for guideline nonadher- toparin vs. unfractionated heparin to prevent venous thromboembolic events"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "ence at heart failure discharge. J Am Heart Assoc. 2018;7:e008789. in acutely ill, non-surgical patients: CERTIFY Study. J Thromb Haemost."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "13. Metra M, Cotter G, Senger S, et al. Prognostic significance of creatinine in- 2010;8:1209–1215."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "creases during an acute heart failure admission in patients with and without 11. Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for throm-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "residual congestion: a post hoc analysis of the PROTECT Data. Circ Heart boprophylaxis after hospitalization for medical illness. N Engl J Med."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "Fail. 2018;11:e004644. 2018;379:1118–1127."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "14. Testani JM, Chen J, McCauley BD, et al. Potential effects of aggressive 12. Miranda S, Le Cam-Duchez V, Benichou J, et al. Adjusted value of"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "decongestion during the treatment of decompensated heart failure on renal thromboprophylaxis in hospitalized obese patients: a comparative study"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "function and survival. Circulation. 2010;122:265–272. of two regimens of enoxaparin: the ITOHENOX study. Thromb Res."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "15. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intra- 2017;155:1–5."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "venous diuretics for patients hospitalized for acute decompensated heart 13. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "failure. J Am Coll Cardiol. 2007;49:675–683. placebo for the prevention of venous thromboembolism in acutely ill medical"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "16. Costanzo MR, Negoianu D, Jaski BE, et al. Aquapheresis versus intrave- patients. N Engl J Med. 1999;341:793–800."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "nous diuretics and hospitalizations for heart failure. J Am Coll Cardiol HF. 14. Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "2016;4:95–105. medical patients by low-dose heparin. Scott Med J. 1981;26:115–117."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "15. Tebbe U, Schellong SM, Haas S, et al. Certoparin versus unfractionated"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "heparin to prevent venous thromboembolic events in patients hospitalized"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "9.4a. Parenteral Vasodilation Therapy in Patients because of heart failure: a subgroup analysis of the randomized, controlled"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "CERTIFY study. Am Heart J. 2011;161:322–328."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "Hospitalized With HF"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "16. King CS, Holley AB, Jackson JL, et al. Twice vs three times daily heparin"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "1. Publication Committee for the VMAC Investigators. Intravenous nesiritide dosing for thromboembolism prophylaxis in the general medical population:"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "vs nitroglycerin for treatment of decompensated congestive heart failure: a a metaanalysis. Chest. 2007;131:507–516."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "randomized controlled trial. JAMA. 2002;287:1531–1540. 17. Phung OJ, Kahn SR, Cook DJ, et al. Dosing frequency of unfractionated"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "2. Cioffi G, Stefenelli C, Tarantini L, et al. Hemodynamic response to intensive heparin thromboprophylaxis: a meta-analysis. Chest. 2011;140:374–381."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "unloading therapy (furosemide and nitroprusside) in patients >70 years of"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "age with left ventricular systolic dysfunction and decompensated chronic"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "9.5. Evaluation and Management of Cardiogenic Shock"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "heart failure. Am J Cardiol. 2003;92:1050–1056."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "3. Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance 1. Mathew R, Di Santo P, Jung RG, et al. Milrinone as compared with dobuta-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "to hemodynamic effects of continuous infusion of nitroglycerin in mine in the treatment of cardiogenic shock. N Engl J Med. 2021;385:516–"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "patients with coronary artery disease and heart failure. Circulation. 525."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "1987;76:577–584. 2. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "4. Fung HL, Bauer JA. Mechanisms of nitrate tolerance. Cardiovasc Drugs norepinephrine in the treatment of shock. N Engl J Med. 2010;362:779–"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "Ther. 1994;8:489–499. 789."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "5. Khot UN, Novaro GM, Popovic ZB, et al. Nitroprusside in critically ill pa- 3. Lewis TC, Aberle C, Altshuler D, et al. Comparative effectiveness and safety"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "tients with left ventricular dysfunction and aortic stenosis. N Engl J Med. between milrinone or dobutamine as initial inotrope therapy in cardiogenic"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "2003;348:1756–1763. shock. J Cardiovasc Pharmacol Ther. 2019;24:130–138."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "6. Kozhuharov N, Goudev A, Flores D, et al. Effect of a strategy of comprehen- 4. Levy B, Clere-Jehl R, Legras A, et al. Epinephrine versus norepinephrine"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "sive vasodilation vs usual care on mortality and heart failure rehospitalization for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "among patients with acute heart failure: the GALACTIC randomized clinical 2018;72:173–182."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "trial. JAMA. 2019;322:2292–2302. 5 .Levy B, Perez P, Perny J, et al. Comparison of norepinephrine-dobutamine"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "7. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: to epinephrine for hemodynamics, lactate metabolism, and organ function"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "results of the A Study of Blood Pressure Control in Acute Heart Failure-A variables in cardiogenic shock. A prospective, randomized pilot study. Crit"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "Pilot Study (PRONTO). Am Heart J. 2014;167:529–536. Care Med. 2011;39:450–455."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "6. Pirracchio R, Parenica J, Resche Rigon M, et al. The effectiveness of inodila-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "tors in reducing short term mortality among patient with severe cardiogenic"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "9.4b. Venous Thromboembolism (VTE) Prophylaxis in shock: a propensity-based analysis. PLoS One. 2013;8:e71659."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "7. Schumann J. Cochrane corner: inotropic agents and vasodilator strat-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "Hospitalized Patients"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "egies for cardiogenic shock or low cardiac output syndrome. Heart."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "1. Kleber FX, Witt C, Vogel G, et al. Randomized comparison of enoxaparin 2019;105:178–179."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "with unfractionated heparin for the prevention of venous thromboembolism 8. Belletti A, Castro ML, Silvetti S, et al. The effect of inotropes and vasopres-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "in medical patients with heart failure or severe respiratory disease. Am Heart sors on mortality: A meta-analysis of randomized clinical trials. Br J Anaesth."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "J. 2003;145:614–621. 2015;115:656–675."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "2. Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in 9. Stretch R, Sauer CM, Yuh DD, et al. National trends in the utilization of short-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "acutely ill medical patients. N Engl J Med. 2013;368:513–523. term mechanical circulatory support: incidence, outcomes, and cost analysis."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "3. Mebazaa A, Spiro TE, Buller HR, et al. Predicting the risk of venous J Am Coll Cardiol. 2014;64:1407–1415."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "thromboembolism in patients hospitalized with heart failure. Circulation. 10. Lauten A, Engstrom AE, Jung C, et al. Percutaneous left-ventricular support"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "2014;130:410–418. with the Impella-2.5-assist device in acute cardiogenic shock: results of the"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "4. Aispuru GR, Clavier MM, Cardone AJ, et al. Thrombotic biomarkers and left Impella-EUROSHOCK-registry. Circ Heart Fail. 2013;6:23–30."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "ventricle characteristics as short-term predictors of thrombotic events in 11. Flaherty MP, Khan AR, O’Neill WW. Early initiation of Impella in acute myo-"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "patients hospitalized for acute decompensated heart failure. Eur J Intern cardial infarction complicated by cardiogenic shock improves survival: a"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "Med. 2012;23:545–551. meta-analysis. J Am Coll Cardiol Intv. 2017;10:1805–1806."
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 121,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "e1016 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "12. Basir MB, Schreiber TL, Grines CL, et al. Effect of early initiation of me- 35. Thiele H, Zeymer U, Neumann FJ, et al. Intraaortic balloon support for myo-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "chanical circulatory support on survival in cardiogenic shock. Am J Cardiol. cardial infarction with cardiogenic shock. N Engl J Med. 2012;367:1287–"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "2017;119:845–851. 1296."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "13. Takayama H, Truby L, Koekort M, et al. Clinical outcome of mechanical cir- 36. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "culatory support for refractory cardiogenic shock in the current era. J Heart evaluate the safety and efficacy of a percutaneous left ventricular as-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "Lung Transplant. 2013;32:106–111. sist device versus intra-aortic balloon pumping for treatment of car-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "14. Schrage B, Ibrahim K, Loehn T, et al. Impella support for acute myocardial diogenic shock caused by myocardial infarction. J Am Coll Cardiol."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "infarction complicated by cardiogenic shock. Circulation. 2019;139:1249– 2008;52:1584–1588."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "1258. 37. Ouweneel DM, Eriksen E, Sjauw KD, et al. Percutaneous mechanical circu-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "15. Xie A, Phan K, Tsai YC, et al. Venoarterial extracorporeal membrane oxygen- latory support versus intra-aortic balloon pump in cardiogenic shock after"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "ation for cardiogenic shock and cardiac arrest: a meta-analysis. J Cardiotho- acute myocardial infarction. J Am Coll Cardiol. 2017;69:278–287."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "rac Vasc Anesth. 2015;29:637–645. 38. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "16. Dangers L, Brechot N, Schmidt M, et al. Extracorporeal membrane oxygen- balloon support with a percutaneous left ventricular assist device in patients"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "ation for acute decompensated heart failure. Crit Care Med. 2017;45:1359– with revascularized acute myocardial infarction complicated by cardiogenic"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "1366. shock. Eur Heart J. 2005;26:1276–1283."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "17. Basir MB, Schreiber T, Dixon S, et al. Feasibility of early mechanical cir- 39. Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "culatory support in acute myocardial infarction complicated by cardiogenic study to evaluate the safety and efficacy of the TandemHeart percutaneous"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "shock: the Detroit cardiogenic shock initiative. Catheter Cardiovasc Interv. ventricular assist device versus conventional therapy with intraaortic balloon"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "2018;91:454–461. pumping for treatment of cardiogenic shock. Am Heart J. 2006;152:469."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "18. Basir MB, Kapur NK, Patel K, et al. Improved outcomes associated with the e1–469.e8."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "use of shock protocols: updates from the national cardiogenic shock initia- 40. Thayer KL, Zweck E, Ayouty M, et al. Invasive hemodynamic assessment"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "tive. Catheter Cardiovasc Interv. 2019;93:1173–1183. and classification of in-hospital mortality risk among patients with cardio-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "19. Taleb I, Koliopoulou AG, Tandar A, et al. Shock team approach in refractory genic shock. Circ Heart Fail. 13;2020:e007099."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "cardiogenic shock requiring short-term mechanical circulatory support: a 41. Saxena A, Garan AR, Kapur NK, et al. Value of hemodynamic monitoring in"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "proof of concept. Circulation. 2019;140:98–100. patients with cardiogenic shock undergoing mechanical circulatory support."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "20. Tehrani BN, Truesdell AG, Sherwood MW, et al. Standardized team-based Circulation. 2020;141:1184–1197."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "care for cardiogenic shock. J Am Coll Cardiol. 2019;73:1659–1669. 42. Hernandez-Montfort J, Sinha SS, Thayer KL, et al. Clinical outcomes as-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "21. Lee F, Hutson JH, Boodhwani M, et al. Multidisciplinary code shock team in sociated with acute mechanical circulatory support utilization in heart failure"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "cardiogenic shock: a Canadian centre experience. CJC Open. 2020;2:249– related cardiogenic shock. Circ Heart Fail. 14;2021:e007924."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "257. 43. Rab T, Ratanapo S, Kern KB, et al. Cardiac shock care centers: JACC review"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "22. Shaefi S, O’Gara B, Kociol RD, et al. Effect of cardiogenic shock hospital topic of the week. J Am Coll Cardiol. 2018;72:1972–1980."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "volume on mortality in patients with cardiogenic shock. J Am Heart Assoc."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "2015;4:e001462."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "23. Garan AR, Kanwar M, Thayer KL, et al. Complete hemodynamic profiling 9.6. Integration of Care: Transitions and Team-Based"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "with pulmonary artery catheters in cardiogenic shock is associated with Approaches"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "lower in-hospital mortality. J Am Coll Cardiol HF. 2020;8:903–913."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "24. Vallabhajosyula S, Shankar A, Patlolla SH, et al. Pulmonary artery cathe- 1. Feltner C, Jones CD, Cene CW, et al. Transitional care interventions to pre-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "ter use in acute myocardial infarction-cardiogenic shock. ESC Heart Fail. vent readmissions for persons with heart failure: a systematic review and"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "2020;7:1234–1245. meta-analysis. Ann Intern Med. 2014;160:774–784."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "25. Hernandez GA, Lemor A, Blumer V, et al. Trends in utilization and outcomes 2. Kalogirou F, Forsyth F, Kyriakou M, et al. Heart failure disease management:"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "of pulmonary artery catheterization in heart failure with and without cardio- a systematic review of effectiveness in heart failure with preserved ejection"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "genic shock. J Card Fail. 2019;25:364–371. fraction. ESC Heart Fail. 2020;7:194–212."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "26. Nalluri N, Patel NJ, Atti V, et al. Temporal trends in utilization of right-sided 3. Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "heart catheterization among percutaneous ventricular assist device recipi- for heart failure. Cochrane Database Syst Rev. 2019;1:CD002752."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "ents in acute myocardial infarction complicated by cardiogenic shock. Am J 4. Van Spall HGC, Rahman T, Mytton O, et al. Comparative effectiveness of"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "Cardiol. 2018;122:2014–2017. transitional care services in patients discharged from the hospital with heart"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "27. Rossello X, Vila M, Rivas-Lasarte M, et al. Impact of pulmonary artery cathe- failure: a systematic review and network meta-analysis. Eur J Heart Fail."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "ter use on short- and long-term mortality in patients with cardiogenic shock. 2017;19:1427–1443."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "Cardiology. 2017;136:61–69. 5. Koelling TM, Johnson ML, Cody RJ, et al. Discharge education im-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "28. van Diepen S, Katz JN, Albert NM, et al. Contemporary management of car- proves clinical outcomes in patients with chronic heart failure. Circulation."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "diogenic shock: a scientific statement from the American Heart Association. 2005;111:179–185."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "Circulation. 2017;136:e232–e268. 6. The Joint Commission. Heart failure (HF): specifications manual for Joint"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "29. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus state- Commission National Quality core measures (2010A1). 2010. Accessed"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "ment on the classification of cardiogenic shock. Catheter Cardiovasc Interv. September 27, 2020. https://manual.jointcommission.org/releases/ar-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "2019;94:29–37. chive/TJC2010B/HeartFailure.html"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "30. Kivikko M, Pollesello P, Tarvasmaki T, et al. Effect of baseline characteristics 7. Driscoll A, Meagher S, Kennedy R, et al. What is the impact of systems of"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "on mortality in the SURVIVE trial on the effect of levosimendan vs dobuta- care for heart failure on patients diagnosed with heart failure: a systematic"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "mine in acute heart failure: sub-analysis of the Finnish patients. Int J Cardiol. review. BMC Cardiovasc Disord. 2016;16:195."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "2016;215:26–31. 8. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "31. O’Neill WW, Grines C, Schreiber T, et al. Analysis of outcomes for 15 259 improvement initiative on quality of care for patients hospitalized with heart"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "US patients with acute myocardial infarction cardiogenic shock (AMICS) failure: results of the Organized Program to Initiate Lifesaving Treatment in"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "supported with the Impella device. Am Heart J. 2018;202:33–38. Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "32. Schmidt M, Burrell A, Roberts L, et al. Predicting survival after ECMO for 2007;167:1493–1502."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "refractory cardiogenic shock: the survival after veno-arterial-ECMO (SAVE)- 9. Lappe JM, Muhlestein JB, Lappe DL, et al. Improvements in 1-year car-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "score. Eur Heart J. 2015;36:2246–2256. diovascular clinical outcomes associated with a hospital-based discharge"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "33. Thiele H, Jobs A, Ouweneel DM, et al. Percutaneous short-term active me- medication program. Ann Intern Med. 2004;141:446–453."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "chanical support devices in cardiogenic shock: a systematic review and col- 10. Heidenreich P. Improving heart failure care with a reminder attached to the"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "laborative meta-analysis of randomized trials. Eur Heart J. 2017;38:3523– echocardiography report. Am J Med. 2008;121:853–854."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "3531. 11. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "34. Prondzinsky R, Lemm H, Swyter M, et al. Intra-aortic balloon coun- physician follow-up and 30-day readmission among Medicare beneficiaries"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "terpulsation in patients with acute myocardial infarction complicated hospitalized for heart failure. JAMA. 2010;303:1716–1722."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "by cardiogenic shock: the prospective, randomized IABP SHOCK trial 12. Lee KK, Yang J, Hernandez AF, et al. Post-discharge follow-up characteris-"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "for attenuation of multiorgan dysfunction syndrome. Crit Care Med. tics associated with 30-day readmission after heart failure hospitalization."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "2010;38:152–160. Med Care. 2016;54:365–372."
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 122,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1017"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "13. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day re- 10. Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "admissions after hospitalization for heart failure, acute myocardial infarction, continuous positive airway pressure and transplant-free survival in heart fail-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "or pneumonia. JAMA. 2013;309:355–363. ure: a post hoc analysis of the Canadian Continuous Positive Airway Pres-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "14. Albert NM, Barnason S, Deswal A, et al. Transitions of care in heart failure: sure for Patients with Central Sleep Apnea and Heart Failure Trial (CAN-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "a scientific statement from the American Heart Association. Circ Heart Fail. PAP). Circulation. 2007;115:3173–3180."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "2015;8:384–409. 11. O’Connor CM, Whellan DJ, Fiuzat M, et al. Cardiovascular outcomes with"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "15. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evi- minute ventilation-targeted adaptive servo-ventilation therapy in heart fail-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "dence-based pharmacotherapy in heart failure is associated with improved ure: the CAT-HF trial. J Am Coll Cardiol. 2017;69:1577–1587."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "outcomes. Circulation. 2007;116:737–744. 12. Cowie MR, Woehrle H, Wegscheider K, et al. Adaptive servo-ventilation for"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "16. Naylor MD, Brooten DA, Campbell RL, et al. Transitional care of older adults central sleep apnea in systolic heart failure. N Engl J Med. 2015;373:1095–"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "hospitalized with heart failure: a randomized, controlled trial. J Am Geriatr 1105."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "Soc. 2004;52:675–684. 13. Yamamoto S, Yamaga T, Nishie K, et al. Positive airway pressure therapy"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "17. Chan WV, Pearson TA, Bennett GC, et al. ACC/AHA special report: clini- for the treatment of central sleep apnoea associated with heart failure. Co-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "cal practice guideline implementation strategies: a summary of systematic chrane Database Syst Rev. 2019;12:CD012803."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "reviews by the NHLBI implementation science work group: a report of the 14. Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "American College of Cardiology/American Heart Association task force on heart failure with reduced ejection fraction: a meta-analysis of the EMPER-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "clinical practice guidelines. Circulation. 2017;135:e122–e137. OR-Reduced and DAPA-HF trials. Lancet. 2020;396:819–829."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "18. Ellrodt AG, Fonarow GC, Schwamm LH, et al. Synthesizing lessons learned 15. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "from get with the guidelines: the value of disease-based registries in im- failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139:2528–"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "proving quality and outcomes. Circulation. 2013;128:2447–2460. 2536."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "19. Coma E, Medina M, Mendez L, et al. Effectiveness of electronic point- 16. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "of-care reminders versus monthly feedback to improve adherence to 10 heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "clinical recommendations in primary care: a cluster randomized clinical trial. 2008."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "BMC Med Inform Decis Mak. 2019;19:245. 17. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "20. DeVore AD, Granger BB, Fonarow GC, et al. Care optimization through pa- empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "tient and hospital engagement clinical trial for heart failure: rationale and 18. Chamberlain AM, St Sauver JL, Gerber Y, et al. Multimorbidity in heart fail-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "design of CONNECT-HF. Am Heart J. 2020;220:41–50. ure: a community perspective. Am J Med. 2015;128:38–45."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "21. Hansen LO, Young RS, Hinami K, et al. Interventions to reduce 30-day 19. Wong CY, Chaudhry SI, Desai MM, et al. Trends in comorbidity, disability, and"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "rehospitalization: a systematic review. Ann Intern Med. 2011;155:520– polypharmacy in heart failure. Am J Med. 2011;124:136–143."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "528. 20. Angermann CE, Gelbrich G, Stork S, et al. Effect of escitalopram on all-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "22. Lee KK, Thomas RC, Tan TC, et al. The heart failure readmission intervention cause mortality and hospitalization in patients with heart failure and de-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "by variable early follow-up (THRIVE) study. Circ Cardiovasc Qual Outcomes. pression: the MOOD-HF randomized clinical trial. JAMA. 2016;315:2683–"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "2020;13:e006553. 2693."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "23. O’Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization 21. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "with advanced heart failure: the ESCAPE (Evaluation Study of Conges- analytic review of prevalence, intervention effects, and associations with"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "tive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk clinical outcomes. J Am Coll Cardiol. 2006;48:1527–1537."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "model and discharge score. J Am Coll Cardiol. 2010;55:872–878. 22. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "24. Keenan PS, Normand SL, Lin Z, et al. An administrative claims measure major depression in patients with acute MI or unstable angina. JAMA."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "suitable for profiling hospital performance on the basis of 30-day all-cause 2002;288:701–709."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "readmission rates among patients with heart failure. Circ Cardiovasc Qual 23. Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "Outcomes. 2008;1:29–37. 2017;103:1848–1853."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "25. Win S, Hussain I, Hebl VB, et al. Inpatient mortality risk scores and post- 24. Lunney M, Ruospo M, Natale P, et al. Pharmacological interventions for"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "discharge events in hospitalized heart failure patients: a community-based heart failure in people with chronic kidney disease. Cochrane Database Syst"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "study. Circ Heart Fail. 2017;10:e003926. Rev. 2020;2:CD012466."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "25. Groenveld HF, Januzzi JL, Damman K, et al. Anemia and mortality in heart"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "failure patients a systematic review and meta-analysis. J Am Coll Cardiol."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "10.1. Management of Comorbidities in Patients With HF 2008;52:818–827."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "26. Ebner N, Jankowska EA, Ponikowski P, et al. The impact of iron deficiency"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "1. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in pa- and anaemia on exercise capacity and outcomes in patients with chronic"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "tients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436– heart failure. results from the studies investigating co-morbidities aggravat-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "2448. ing heart failure. Int J Cardiol. 2016;205:6–12."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "2. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects 27. Anker SD, Kirwan BA, van Veldhuisen DJ, et al. Effects of ferric carboxy-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "of long-term intravenous iron therapy with ferric carboxymaltose in patients maltose on hospitalisations and mortality rates in iron-deficient heart"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "with symptomatic heart failure and iron deficiencydagger. Eur Heart J. failure patients: an individual patient data meta-analysis. Eur J Heart Fail."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "2015;36:657–668. 2018;20:125–133."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "3. Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: a randomized 28. Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "trial to assess the effects of iron in heart failure patients with anemia. Int J exercise capacity in patients with heart failure with reduced ejection frac-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "Cardiol. 2013;168:3439–3442. tion and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "4. Ponikowski P, Kirwan BA, Anker SD, et al. Ferric carboxymaltose for iron 2017;317:1958–1966."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "deficiency at discharge after acute heart failure: a multicentre, double-blind, 29. Kapoor M, Schleinitz MD, Gemignani A, et al. Outcomes of patients with"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "randomised, controlled trial. Lancet. 2020;396:1895–1904. chronic heart failure and iron deficiency treated with intravenous iron: a"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "5. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepo- meta-analysis. Cardiovasc Hematol Disord Drug Targets. 2013;13:35–44."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "etin alfa in systolic heart failure. N Engl J Med. 2013;368:1210–1219. 30. Montero D, Haider T, Flammer AJ. Erythropoietin response to anaemia in"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "6. Kang J, Park J, Lee JM, et al. The effects of erythropoiesis stimulating heart failure. Eur J Prev Cardiol. 2019;26:7–17."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "therapy for anemia in chronic heart failure: A meta-analysis of randomized 31. Nagai T, Nishimura K, Honma T, et al. Prognostic significance of endog-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "clinical trials. Int J Cardiol. 2016;218:12–22. enous erythropoietin in long-term outcome of patients with acute decom-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "7. Banach M, Bhatia V, Feller MA, et al. Relation of baseline systolic blood pensated heart failure. Eur J Heart Fail. 2016;18:803–813."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "pressure and long-term outcomes in ambulatory patients with chronic mild 32. Bello NA, Lewis EF, Desai AS, et al. Increased risk of stroke with darbepo-"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "to moderate heart failure. Am J Cardiol. 2011;107:1208–1214. etin alfa in anaemic heart failure patients with diabetes and chronic kidney"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "8. Lee TT, Chen J, Cohen DJ, et al. The association between blood disease. Eur J Heart Fail. 2015;17:1201–1207."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "pressure and mortality in patients with heart failure. Am Heart J. 33. Zhang Y, Liang M, Sun C, et al. Effect of intensive lowering of systolic blood"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "2006;151:76–83. pressure treatment on heart failure events: a meta-analysis of randomized"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "9. Arzt M, Schroll S, Series F, et al. Auto-servoventilation in heart failure with controlled studies. J Hum Hypertens. 2019;33:648–657."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "sleep apnoea: a randomised controlled trial. Eur Respir J. 2013;42:1244– 34. A randomized trial of intensive versus standard blood-pressure control. N"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "1254. Engl J Med. 2017;377:2506."
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 123,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "e1018 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "35. Upadhya B, Rocco M, Lewis CE, et al. Effect of intensive blood pressure 7. McMurray JJ, Ezekowitz JA, Lewis BS, et al. Left ventricular systolic dys-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "treatment on heart failure events in the Systolic Blood Pressure Reduction function, heart failure, and the risk of stroke and systemic embolism in pa-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "Intervention Trial. Circ Heart Fail. 2017;10:e003613. tients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "36. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ Fail. 2013;6:451–460."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, 8. Siller-Matula JM, Pecen L, Patti G, et al. Heart failure subtypes and throm-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "detection, evaluation, and management of high blood pressure in adults: a boembolic risk in patients with atrial fibrillation: the PREFER in AF - HF"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "report of the American College of Cardiology/American Heart Association substudy. Int J Cardiol. 2018;265:141–147."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13– 9. Magnani G, Giugliano RP, Ruff CT, et al. Efficacy and safety of edox-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "e115. aban compared with warfarin in patients with atrial fibrillation and"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "37. Mehra R, Wang L, Andrews N, et al. Dissociation of objective and sub- heart failure: insights from ENGAGE AF-TIMI 48. Eur J Heart Fail."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "jective daytime sleepiness and biomarkers of systemic inflammation in 2016;18:1153–1161."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "sleep-disordered breathing and systolic heart failure. J Clin Sleep Med. 10. Savarese G, Giugliano RP, Rosano GM, et al. Efficacy and safety of novel"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "2017;13:1411–1422. oral anticoagulants in patients with atrial fibrillation and heart failure: a me-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "38. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure ta-analysis. J Am Coll Cardiol HF. 2016;4:870–880."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "for central sleep apnea and heart failure. N Engl J Med. 2005;353:2025– 11. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "2033. treatment of persistent atrial fibrillation in patients with congestive heart"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "39. Zhang XB, Yuan YT, Du YP, et al. Efficacy of positive airway pressure on brain failure and an implanted device: results from the AATAC multicenter ran-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "natriuretic peptide in patients with heart failure and sleep-disorder breathing: domized trial. Circulation. 2016;133:1637–1644."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "a meta-analysis of randomized controlled trials. Lung. 2015;193:255–260. 12. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "40. Aggarwal S, Nadeem R, Loomba RS, et al. The effects of continuous posi- fibrillation with heart failure. N Engl J Med. 2018;378:417–427."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "tive airways pressure therapy on cardiovascular end points in patients with 13. Chen S, Purerfellner H, Meyer C, et al. Rhythm control for patients with"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "sleep-disordered breathing and heart failure: a meta-analysis of randomized atrial fibrillation complicated with heart failure in the contemporary era of"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "controlled trials. Clin Cardiol. 2014;37:57–65. catheter ablation: a stratified pooled analysis of randomized data. Eur Heart"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "41. Voigt J, Emani S, Gupta S, et al. Meta-analysis comparing outcomes of ther- J. 2020;41:2863–2873."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "apies for patients with central sleep apnea and heart failure with reduced 14. Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "ejection fraction. Am J Cardiol. 2020;127:73–83. atrial fibrillation in heart failure: results from the CABANA trial. Circulation."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "42. Yamamoto S, Yamaga T, Nishie K, et al. Positive airway pressure therapy 2021;143:1377–1390."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "for the treatment of central sleep apnoea associated with heart failure. Co- 15. Wood MA, Brown-Mahoney C, Kay GN, et al. Clinical outcomes after abla-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "chrane Database Syst Rev. 2019;12:CD012803. tion and pacing therapy for atrial fibrillation: a meta-analysis. Circulation."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "43. American Diabetes Association. Addendum. 9. Pharmacologic approaches 2000;101:1138–1144."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "to glycemic treatment: standards of medical care in diabetes-2020. Diabe- 16. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "tes Care. 2020; 43( suppl 1):S98–S110. junction ablation and VVIR pacemaker versus pharmacological treatment in"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "44. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors patients with heart failure and chronic atrial fibrillation: a randomized, con-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "with cardiovascular and kidney outcomes in patients with type 2 diabetes: a trolled study. Circulation. 1998;98:953–960."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "meta-analysis. JAMA Cardiol. 2021;6:148–158. 17. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stim-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "45. Li J, Woodward M, Perkovic V, et al. Mediators of the effects of canagliflozin ulation Post AV nodal ablation Evaluation (the PAVE study). J Cardiovasc"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "on heart failure in patients with type 2 diabetes. J Am Coll Cardiol HF. Electrophysiol. 2005;16:1160–1165."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "2020;8:57–66. 18. Brignole M, Gammage M, Puggioni E, et al. Comparative assessment of"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "46. US National Library of Medicine. Clinical Trials.gov. Dapagliflozin Evaluation right, left, and biventricular pacing in patients with permanent atrial fibrilla-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart tion. Eur Heart J. 2005;26:712–722."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "Failure. (DELIVER). 2018. Accessed June 28, 2021. https://clinicaltrials. 19. Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "gov/ct2/show/NCT03619213 patients undergoing atrioventricular junction ablation for permanent atrial"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "47. Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium– fibrillation: a randomized trial. Eur Heart J. 2011;32:2420–2429."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "glucose co-transporter 2 inhibition with empagliflozin on morbidity and mor- 20. Brignole M, Pokushalov E, Pentimalli F, et al. A randomized controlled trial"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "tality in patients with chronic heart failure and a preserved ejection fraction: of atrioventricular junction ablation and cardiac resynchronization therapy"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. in patients with permanent atrial fibrillation and narrow QRS. Eur Heart J."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "2019;21:1279–1287. 2018;39:3999–4008."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "48. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes 21. Chatterjee NA, Upadhyay GA, Ellenbogen KA, et al. Atrioventricular nodal"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "and recent worsening heart failure. N Engl J Med. 2021;384:117–128. ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricu-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "49. Liu D, Chen H, Song F, et al. Adverse drug events observed with the novel lar pacing mode. Eur J Heart Fail. 2012;14:661–667."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "sodium/glucose co-transporter 2 inhibitor ipragliflozin for the treatment of 22. Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "patients with type 2 diabetes mellitus: a systematic review and meta-analy- control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "sis of randomized studies. Adv Ther. 2020;37:4356–4369. J Am Coll Cardiol. 2017;70:1949–1961."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "50. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the 23. Freudenberger RS, Hellkamp AS, Halperin JL, et al. Risk of thromboembo-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "management of heart failure: a report of the American College of Cardiol- lism in heart failure: an analysis from the Sudden Cardiac Death in Heart"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "ogy Foundation/American Heart Association Task Force on Practice Guide- Failure Trial (SCD-HEFT). Circulation. 2007;115:2637–2641."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "lines. Circulation. 2013;128:e240–e327. 24. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "10.2. Management of Atrial Fibrillation (AF) in HF 2429."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "25. Melgaard L, Gorst-Rasmussen A, Lane DA, et al. Assessment of the"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "1. Mason PK, Lake DE, DiMarco JP, et al. Impact of the CHA2DS2-VASc CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism,"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "score on anticoagulation recommendations for atrial fibrillation. Am J Med. and death in patients with heart failure with and without atrial fibrillation."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "2012;125:603e1–603e6. JAMA. 2015;314:1030–1038."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in 26. Mogensen UM, Jhund PS, Abraham WT, et al. Type of atrial fibrillation and"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. outcomes in patients with heart failure and reduced ejection fraction. J Am"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non- Coll Cardiol. 2017;70:2490–2500."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "valvular atrial fibrillation. N Engl J Med. 2011;365:883–891. 27. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "4. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in the management of patients with atrial fibrillation: a report of the American"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "patients with atrial fibrillation. N Engl J Med. 2011;365:981–982. College of Cardiology/American Heart Association Task Force on Practice"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "5. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in pa- Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199–"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "tients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. e267."
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "6. Ferreira J, Ezekowitz MD, Connolly SJ, et al. Dabigatran compared with 28. January CT, Wann LS, Calkins CH, et al. 2019 AHA/ACC/HRS focused"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "warfarin in patients with atrial fibrillation and symptomatic heart failure: a update of the 2014 AHA/ACC/HRS guideline for the management of pa-"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "subgroup analysis of the RE-LY trial. Eur J Heart Fail. 2013;15:1053–1061. tients with atrial fibrillation: a report of the American College of Cardiology/"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 124,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1019"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "American Heart Association Task Force on Clinical Practice Guidelines and failure: have the previously observed sex and racial disparities changed over"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "the Heart Rhythm Society. Circulation. 2019;140:e125–e151. time? Circulation. 2012;125:1094–1101."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "29. Witt BJ, Brown RD Jr, Jacobsen SJ, et al. Ischemic stroke after heart failure: 24. Hsich EM. Sex differences in advanced heart failure therapies. Circulation."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "a community-based study. Am Heart J. 2006;152:102–109. 2019;139:1080–1093."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "25. Rethy L, Petito LC, Vu THT, et al. Trends in the prevalence of self-reported"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "heart failure by race/ethnicity and age from 2001 to 2016. JAMA Cardiol."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "11.1. Disparities and Vulnerable Populations 2020;5:1–5."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "26. Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "1. Colvin M, Sweitzer NK, Albert NM, et al. Heart failure in non-Caucasians, congestive heart failure by ethnicity: the multi-ethnic study of atherosclero-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "women, and older adults: a white paper on special populations from the sis. Arch Intern Med. 2008;168:2138–2145."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Heart Failure Society of America Guideline Committee. J Card Fail. 27. Glynn P, Lloyd-Jones DM, Feinstein MJ, et al. Disparities in cardiovascular"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "2015;21:674–693. mortality related to heart failure in the United States. J Am Coll Cardiol."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "2. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statis- 2019;73:2354–2355."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "tics–2020 update: a report From the American Heart Association. Circula- 28. Churchwell K, Elkind MSV, Benjamin RM, et al. Call to action: structural"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "tion. 2020;141:e139–e596. racism as a fundamental driver of health disparities: a presidential advisory"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "3. Ziaeian B, Kominski GF, Ong MK, et al. National differences in trends for from the American Heart Association. Circulation. 2020;142:e454–e468."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "heart failure hospitalizations by sex and race/ethnicity. Circ Cardiovasc Qual 29. Butrous H, Hummel SL. Heart failure in older adults. Can J Cardiol."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Outcomes. 2017;10:e003552. 2016;32:1140–1147."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "4. Nayak A, Hicks AJ, Morris AA. Understanding the complexity of heart failure 30. Allen LA, Hernandez AF, Peterson ED, et al. Discharge to a skilled nursing"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "risk and treatment in black patients. Circ Heart Fail. 2020. CIRCHEART- facility and subsequent clinical outcomes among older patients hospitalized"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "FAILURE120007264. for heart failure. Circ Heart Fail. 2011;4:293–300."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "5. Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic status and cardiovas- 31. Silver JK, Bean AC, Slocum C, et al. Physician workforce disparities and"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "cular outcomes: challenges and interventions. Circulation. 2018;137:2166– patient care: a narrative review. Health Equity. 2019;3:360–377."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "2178. 32. Mehta LS, Fisher K, Rzeszut AK, et al. Current demographic status of cardi-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "6. Bevan GH, Josephson R, Al-Kindi SG. Socioeconomic deprivation and heart ologists in the United States. JAMA Cardiol. 2019;4:1029–1033."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "failure mortality in the United States. J Card Fail. 2020;26:1106–1167. 33. Hall WJ, Chapman MV, Lee KM, et al. Implicit racial/ethnic bias among"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "7. Rodriguez CJ, Allison M, Daviglus ML, et al. Status of cardiovascular disease health care professionals and its influence on health care outcomes: a sys-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "and stroke in Hispanics/Latinos in the United States: a science advisory tematic review. Am J Public Health. 2015;105:e60–e76."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "from the American Heart Association. Circulation. 2014;130:593–625. 34. Williams JS, Walker RJ, Egede LE. Achieving equity in an evolving health-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "8. Carnethon MR, Pu J, Howard G, et al. Cardiovascular health in African care system: opportunities and challenges. Am J Med Sci. 2016;351:33–"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Americans: a scientific statement from the American Heart Association. 43."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Circulation. 2017;136:e393–e423. 35. Serchen J, Doherty R, Atiq O, Hilden D. Racism and health in the United"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "9. Sterling MR, Ringel JB, Pinheiro LC, et al. Social determinants of health States: a policy statement from the American College of Physicians. Ann"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "and 90-day mortality after hospitalization for heart failure in the REGARDS Intern Med. 2020;173:556–557."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "study. J Am Heart Assoc. 2020;9:e014836. 36. Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, et al. Epidemiology of"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "10. Khariton Y, Nassif ME, Thomas L, et al. Health status disparities by sex, incident heart failure in a contemporary elderly cohort: the health, aging, and"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "race/ethnicity, and socioeconomic status in outpatients with heart failure. J body composition study. Arch Intern Med. 2009;169:708–715."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Am Coll Cardiol HF. 2018;6:465–473. 37. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "11. Breathett K, Sims M, Gross M, et al. Cardiovascular health in American In- ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention,"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "dians and Alaska Natives: a scientific statement from the American Heart detection, evaluation, and management of high blood pressure in adults: a"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Association. Circulation. 2020;141:e948–e959. report of the American College of Cardiology/American Heart Association"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "12. Eberly LA, Richterman A, Beckett AG, et al. Identification of racial inequities Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13–"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "in access to specialized inpatient heart failure care at an academic medical e115."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "center. Circ Heart Fail. 2019;12:e006214. 38. Leiby DA, Rentas FJ, Nelson KE, et al. Evidence of Trypanosoma cruzi infec-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "13. Sentell T, Miyamura J, Ahn HJ, et al. Potentially preventable hospitalizations tion (Chagas’ disease) among patients undergoing cardiac surgery. Circula-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "for congestive heart failure among Asian Americans and Pacific Islanders in tion. 2000;102:2978–2982."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Hawai’i. J Immigr Minor Health. 2015;17:1289–1297. 39. Bank IEM, Gijsberts CM, Teng TK, et al. Prevalence and clinical significance"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "14. Brown AF, Liang LJ, Vassar SD, et al. Trends in racial/ethnic and nativ- of diabetes in Asian versus white patients with heart failure. J Am Coll Car-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "ity disparities in cardiovascular health among adults without prevalent car- diol HF. 2017;5:14–24."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "diovascular disease in the United States, 1988 to 2014. Ann Intern Med. 40. Bitton A, Zaslavsky AM, Ayanian JZ. Health risks, chronic diseases, and ac-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "2018;168:541–549. cess to care among US Pacific Islanders. J Gen Intern Med. 2010;25:435–"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "15. Lawson CA, Zaccardi F, Squire I, et al. Risk factors for heart failure: 20-year 440."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "population-based trends by sex, socioeconomic status, and ethnicity. Circ 41. Sharma A, Zhao X, Hammill BG, et al. Trends in noncardiovascular comorbid-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Heart Fail. 2020;13:e006472. ities among patients hospitalized for heart failure: insights from the Get With"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "16. Brewer LC, Cooper LA. Race, discrimination, and cardiovascular disease. The Guidelines-Heart Failure Registry. Circ Heart Fail. 2018;11:e004646."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Virtual Mentor. 2014;16:455–460. 42. Manemann SM, Chamberlain AM, Roger VL, et al. Perceived social iso-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "17. Cresci S, Pereira NL, Ahmad F, et al. Heart failure in the era of precision lation and outcomes in patients with heart failure. J Am Heart Assoc."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "medicine: a scientific statement from the American Heart Association. Circ 2018;7:e008069."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Genom Precis Med. 2019;12:458–485. 43. Orr NM, Boxer RS, Dolansky MA, et al. Skilled nursing facility care for pa-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "18. White-Williams C, Rossi LP, Bittner VA, et al. Addressing social determi- tients with heart failure: can we make it “heart failure ready? J Card Fail."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "nants of health in the care of patients with heart failure: a scientific state- 2016;22:1004–1014."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "ment from the American Heart Association. Circulation. 2020;141:e841– 44. Gorodeski EZ, Goyal P, Hummel SL, et al. Domain management approach"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "e863. to heart failure in the geriatric patient: present and future. J Am Coll Cardiol."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "19. Lam CSP, Arnott C, Beale AL, et al. Sex differences in heart failure. Eur 2018;71:1921–1936."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Heart J. 2019;40:3859–3868c. 45. Jurgens CY, Goodlin S, Dolansky M, et al. Heart failure management in"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "20. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence skilled nursing facilities: a scientific statement from the American Heart"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "and survival in a community-based population. JAMA. 2004;292:344–350. Association and the Heart Failure Society of America. Circ Heart Fail."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "21. Ehrmann Feldman D, Xiao Y, Bernatsky S, et al. Consultation with cardiolo- 2015;8:655–687."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "gists for persons with new-onset chronic heart failure: a population-based 46. Akwo EA, Kabagambe EK, Harrell FE Jr, et al. Neighborhood depriva-"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "study. Can J Cardiol. 2009;25:690–694. tion predicts heart failure risk in a low-income population of blacks and"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "22. Feldman DE, Huynh T, Des Lauriers J, et al. Gender and other disparities in whites in the Southeastern United States. Circ Cardiovasc Qual Outcomes."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "referral to specialized heart failure clinics following emergency department 2018;11:e004052."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "visits. J Womens Health (Larchmt). 2013;22:526–531. 47. Topel ML, Kim JH, Mujahid MS, et al. Neighborhood socioeconomic status"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "23. Al-Khatib SM, Hellkamp AS, Hernandez AF, et al. Trends in use of implant- and adverse outcomes in patients with cardiovascular disease. Am J Cardiol."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "able cardioverter-defibrillator therapy among patients hospitalized for heart 2019;123:284–290."
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 125,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "e1020 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "48. Baggett TP, Liauw SS, Hwang SW. Cardiovascular disease and homeless- 75. Graham G. Disparities in cardiovascular disease risk in the United States."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "ness. J Am Coll Cardiol. 2018;71:2585–2597. Curr Cardiol Rev. 2015;11:238–245."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "49. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to 76. Lewis EF, Claggett B, Shah AM, et al. Racial differences in characteristics"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "prevent the readmission of elderly patients with congestive heart failure. N and outcomes of patients with heart failure and preserved ejection fraction"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "Engl J Med. 1995;333:1190–1195. in the treatment of preserved cardiac function heart failure trial. Circ Heart"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "50. Fonarow GC, Abraham WT, Albert NM, et al. Age- and gender-related dif- Fail. 11;2018:e004457."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "ferences in quality of care and outcomes of patients hospitalized with heart 77. Lui C, Fraser CD 3rd, Zhou X, et al. Racial disparities in patients bridged to"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "failure (from OPTIMIZE-HF). Am J Cardiol. 2009;104:107–115. heart transplantation with left ventricular assist devices. Ann Thorac Surg."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "51. Steinberg RS, Nayak A, O’Connell C, et al. Sex differences in eligibility for 2019;108:1122–1126."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "advanced heart failure therapies. Clin Transplant. 2020;34:e13839. 78. Morris AA, Kransdorf EP, Coleman BL, et al. Racial and ethnic disparities"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "52. DeFilippis EM, Truby LK, Garan AR, et al. Sex-related differences in use and in outcomes after heart transplantation: a systematic review of contribut-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "outcomes of left ventricular assist devices as bridge to transplantation. J Am ing factors and future directions to close the outcomes gap. J Heart Lung"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "Coll Cardiol HF. 2019;7:250–257. Transplant. 2016;35:953–961."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "53. Breathett K, Yee E, Pool N, et al. Does race influence decision making for 79. Wayda B, Clemons A, Givens RC, et al. Socioeconomic disparities in adher-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "advanced heart failure therapies? J Am Heart Assoc. 2019;8:e013592. ence and outcomes after heart transplant: a UNOS (United Network for"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "54. Breathett K, Yee E, Pool N, et al. Association of gender and race with Organ Sharing) registry analysis. Circ Heart Fail. 2018;11:e004173."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "allocation of advanced heart failure therapies. JAMA Netw Open. 80. Balfour PC Jr, Ruiz JM, Talavera GA, Allison MA, Rodriguez CJ. Cardio-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "3;2020:e2011044. vascular disease in Hispanics/Latinos in the United States. J Lat Psychol."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "55. Breathett K, Liu WG, Allen LA, et al. African Americans are less likely to 2016;4:98–113."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "receive care by a cardiologist during an intensive care unit admission for 81. Alexander M, Grumbach K, Remy L, et al. Congestive heart failure hospital-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "heart failure. J Am Coll Cardiol HF. 2018;6:413–420. izations and survival in California: patterns according to race/ethnicity. Am"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "56. Aviles-Santa ML, Heintzman J, Lindberg NM, et al. Personalized medicine and His- Heart J. 1999;137:919–927."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "panic health: improving health outcomes and reducing health disparities - a Na- 82. Vivo RP, Krim SR, Krim NR, et al. Care and outcomes of Hispanic pa-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "tional Heart, Lung, and Blood Institute workshop report. BMC Proc. 2017;11:11. tients admitted with heart failure with preserved or reduced ejection frac-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "57. Vivo RP, Krim SR, Cevik C, et al. Heart failure in Hispanics. J Am Coll Cardiol. tion: findings from Get With The Guidelines-Heart Failure. Circ Heart Fail."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "2009;53:1167–1175. 2012;5:167–175."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "58. Victor RG, Lynch K, Li N, et al. A cluster-randomized trial of blood-pressure 83. Shulman E, Shah T, Mazori AY, et al. Heart failure and the development of"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "reduction in black barbershops. N Engl J Med. 2018;378:1291–1301. atrial fibrillation in Hispanics, African Americans and non-Hispanic Whites."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "59. Ebinger J, Blyler CA, Brettler J, et al. Barbershop management of hyperten- Int J Cardiol. 2018;271:186–191."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "sion in the African American population: pitfalls and opportunities for exten- 84. Volgman AS, Palaniappan LS, Aggarwal NT, et al. Atherosclerotic cardio-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "sion to other underserved communities. Curr Cardiol Rep. 2020;22:64. vascular disease in South Asians in the United States: epidemiology, risk"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "60. Weiss B. Health Literacy: A Manual for Clinicians. American Medical Associa- factors, and treatments: a scientific statement from the American Heart As-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "tion Foundation; 2003. sociation. Circulation. 2018;138:e1–e34."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "61. Jin X, Chandramouli C, Allocco B, et al. Women’s participation in cardiovas- 85. Palaniappan LP, Araneta MR, Assimes TL, et al. Call to action: cardiovascu-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "cular clinical trials from 2010 to 2017. Circulation. 2020;141:540–548. lar disease in Asian Americans: a science advisory from the American Heart"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "62. Khan MS, Shahid I, Siddiqi TJ, et al. Ten-year trends in enrollment of women Association. Circulation. 2010;122:1242–1252."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "and minorities in pivotal trials supporting recent US Food and Drug Ad- 86. Jose PO, Frank AT, Kapphahn KI, et al. Cardiovascular disease mortality in"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "ministration approval of novel cardiometabolic drugs. J Am Heart Assoc. Asian Americans. J Am Coll Cardiol. 2014;64:2486–2494."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "2020;9:e015594. 87. Muller CJ, Noonan CJ, MacLehose RF, et al. Trends in cardiovascular dis-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "63. Tahhan AS, Vaduganathan M, Greene SJ, et al. Enrollment of older patients, ease morbidity and mortality in American Indians over 25 years: the Strong"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "women, and racial and ethnic minorities in contemporary heart failure clini- Heart study. J Am Heart Assoc. 2019;8:e012289."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "cal trials: a systematic review. JAMA Cardiol. 2018;3:1011–1019. 88. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statis-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "64. Sullivan LT 2nd, Randolph T, Merrill P, et al. Representation of black patients tics–2019 update: a report from the American Heart Association. Circula-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "in randomized clinical trials of heart failure with reduced ejection fraction. tion. 2019;139:e56–e528."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "Am Heart J. 2018;197:43–52."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "65. Ortega RF, Yancy CW, Mehran R, et al. Overcoming lack of diversity in car-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "diovascular clinical trials: a new challenge and strategies for success. Circu- 11.2. Cardio-Oncology"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "lation. 2019;140:1690–1692."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "66. Ho JE, Gona P, Pencina MJ, et al. Discriminating clinical features of heart 1. Wang SY, Long JB, Hurria A, et al. Cardiovascular events, early discontinu-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "failure with preserved vs. reduced ejection fraction in the community. Eur ation of trastuzumab, and their impact on survival. Breast Cancer Res Treat."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "Heart J. 2012;33:1734–1741. 2014;146:411–419."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "67. Suthahar N, Lau ES, Blaha MJ, et al. Sex-specific associations of cardio- 2. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "vascular risk factors and biomarkers with incident heart failure. J Am Coll trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "Cardiol. 2020;76:1455–1465. experience. J Clin Oncol. 2006;24:4107–4115."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "68. Medina-Inojosa JR, Vinnakota S, Garcia M, et al. Role of stress and psycho- 3. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomy-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "social determinants on women’s cardiovascular risk and disease develop- opathy: clinical relevance and response to pharmacologic therapy. J Am Coll"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "ment. J Womens Health (Larchmt). 2019;28:483–489. Cardiol. 2010;55:213–220."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "69. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statis- 4. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracy-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "tics–2020 update: a report from the American Heart Association. Circula- cline cardiotoxicity and improvement with heart failure therapy. Circulation."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "tion. 2020;141:e139–e596. 2015;131:1981–1988."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "70. Motiejunaite J, Akiyama E, Cohen-Solal A, et al. The association of long- 5. Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "term outcome and biological sex in patients with acute heart failure from cardiotoxicity among older patients with breast cancer. J Clin Oncol."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "different geographic regions. Eur Heart J. 2020;41:1357–1364. 2013;31:4222–4228."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "71. Dewan P, Rorth R, Jhund PS, et al. Differential impact of heart failure 6. Goldhar HA, Yan AT, Ko DT, et al. The temporal risk of heart failure associ-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "with reduced ejection fraction on men and women. J Am Coll Cardiol. ated with adjuvant trastuzumab in breast cancer patients: a population study."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "2019;73:29–40. J Natl Cancer Inst. 2016;108:djv301."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "72. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for develop- 7. Armenian SH, Sun CL, Shannon T, et al. Incidence and predictors of conges-"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "ing congestive heart failure: the Framingham Heart Study. Circulation. tive heart failure after autologous hematopoietic cell transplantation. Blood."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "2002;106:3068–3072. 2011;118:6023–6029."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "73. Shah AM, Claggett B, Loehr LR, et al. Heart failure stages among older 8. Henry ML, Niu J, Zhang N, et al. Cardiotoxicity and cardiac monitoring"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "adults in the community: the Atherosclerosis Risk in Communities study. among chemotherapy-treated breast cancer patients. J Am Coll Cardiol Img."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "Circulation. 2017;135:224–240. 2018;11:1084–1093."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "74. Sung SH, Wang TJ, Cheng HM, et al. Clinical characteristics and outcomes 9. Wang L, Tan TC, Halpern EF, et al. Major cardiac events and the value of"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "in the very elderly patients hospitalized for acute heart failure: importance of echocardiographic evaluation in patients receiving anthracycline-based"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "pharmacologic guideline adherence. Sci Rep. 2018;8:14270. chemotherapy. Am J Cardiol. 2015;116:442–446."
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 126,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1021"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "10. Seferina SC, de Boer M, Derksen MW, et al. Cardiotoxicity and cardiac 31. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction pre-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "monitoring during adjuvant trastuzumab in daily Dutch practice: a study dicted by early troponin I release after high-dose chemotherapy. J Am Coll"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "of the Southeast Netherlands Breast Cancer Consortium. Oncologist. Cardiol. 2000;36:517–522."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "2016;21:555–562. 32. Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of troponins I and T"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "11. Abu-Khalaf MM, Safonov A, Stratton J, et al. Examining the cost-effective- and N-terminal prohormone of brain natriuretic peptide in monitoring car-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "ness of baseline left ventricular function assessment among breast cancer diac safety of patients with early-stage human epidermal growth factor re-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "patients undergoing anthracycline-based therapy. Breast Cancer Res Treat. ceptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "2019;176:261–270. study cardiac marker substudy. J Clin Oncol. 2017;35:878–884."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "12. Truong SR, Barry WT, Moslehi JJ, et al. Evaluating the utility of baseline car- 33. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review,"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "diac function screening in early-stage breast cancer treatment. Oncologist. 1975–2014, based on November 2016 SEER data submission, posted to the"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "2016;21:666–670. SEER website, April 2017. National Cancer Institute; 2014."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "13. Jeyakumar A, DiPenta J, Snow S, et al. Routine cardiac evaluation in pa- 34. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018 CA. Cancer J Clin."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "tients with early-stage breast cancer before adjuvant chemotherapy. Clin 2018;68:7–30."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "Breast Cancer. 2012;12:4–9. 35. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “silver tsu-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "14. Steuter J, Bociek R, Loberiza F, et al. Utility of prechemotherapy evaluation nami”: prevalence trajectories and comorbidity burden among older can-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "of left ventricular function for patients with lymphoma. Clin Lymphoma My- cer survivors in the United States. Cancer Epidemiol Biomarkers Prev."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "eloma Leuk. 2015;15:29–34. 2016;25:1029–1036."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "15. Conrad AL, Gundrum JD, McHugh VL, et al. Utility of routine left ventricular 36. Barac A, Murtagh G, Carver JR, et al. Cardiovascular health of patients with"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "ejection fraction measurement before anthracycline-based chemotherapy cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "in patients with diffuse large B-cell lymphoma. J Oncol Pract. 2012;8:336– 2015;65:2739–2746."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "340. 37. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "16. O’Brien PMK, Jeyakumar A, et al. The clinical utility of baseline cardiac need for cardio-oncology and cardio-oncological prevention. J Natl Cancer"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "assessments prior to adjuvant anthracycline chemotherapy in breast can- Inst. 2010;102:14–25."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "cer: a systematic review and meta-analysis. Breast Cancer Res Treat. 38. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "2019;174:357–363. survival in patients with initially unexplained cardiomyopathy. N Engl J Med."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "17. Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolac- 2000;342:1077–1084."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "tone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 39. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "2015;17:81–89. combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "18. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, et al. Carvedilol for 1755."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am 40. Mahmood SS, Fradely MG, Cohen JV, et al. Myocarditis in patients treated"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "Coll Cardiol. 2018;71:2281–2290. with immune checkpoint inhibitors. J Am College Cardiol. 2018;71:1755–"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "19. Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing 1764."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "chemotherapy-induced left ventricular systolic dysfunction in patients with 41. Tarantini L, Gori S, Faggiano P, et al. Adjuvant trastuzumab cardiotoxicity in"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular patients over 60 years of age with early breast cancer: a multicenter cohort"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "dysfunction with Enalapril and caRvedilol in patients submitted to intensive analysis. Ann Oncol. 2012;23:3058–3063."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Car- 42. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "diol. 2013;61:2355–2362. clinical trials experience. J Clin Oncol. 2002;20:1215–1221."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "20. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemo- 43. Hershman DL, McBride RB, Eisenberger A, et al. Doxorubicin, cardiac risk"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "therapy-induced cardiotoxicity in high-risk patients by angiotensin-convert- factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodg-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "ing enzyme inhibition. Circulation. 2006;114:2474–2481. kin’s lymphoma. J Clin Oncol. 2008;26:3159–3165."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "21. Guglin M, Krischer J, Tamura R, et al. Randomized trial of lisinopril versus 44. Chow EJ, Mueller BA, Baker KS, et al. Cardiovascular hospitalizations and"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "carvedilol to prevent trastuzumab cardiotoxicity in patients with breast can- mortality among recipients of hematopoietic stem cell transplantation. Ann"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "cer. J Am Coll Cardiol. 2019;73:2859–2868. Intern Med. 2011;155:21–32."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "22. Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction dur- 45. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "ing adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22:1864–"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "placebo-controlled, double-blind clinical trial of candesartan and metoprolol. 1871."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "Eur Heart J. 2016;37:1671–1680. 46. Doyle JJ, Neugut AI, Jacobson JS, et al. Chemotherapy and cardiotoxic-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "23. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against ity in older breast cancer patients: a population-based study. J Clin Oncol."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258– 2005;23:8597–8605."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "2262. 47. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "24. Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary approach to novel women treated with adjuvant anthracycline chemotherapy for breast cancer."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "therapies in cardio-oncology research (MANTICORE 101-Breast): a ran- J Clin Oncol. 2007;25:3808–3815."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "domized trial for the prevention of trastuzumab-associated cardiotoxicity. J 48. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubi-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "Clin Oncol. 2017;35:870–877. cin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "25. Shah P, Garris R, Abboud R, et al. Meta-analysis comparing usefulness Med. 1979;300:278–283."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "of beta blockers to preserve left ventricular function during anthracycline 49. Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "therapy. Am J Cardiol. 2019;124:789–794. subsequent cardiotoxicity in patients with breast cancer treated with doxo-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "26. Cardinale D, Ciceri F, Latini R, et al. Anthracycline-induced cardiotoxicity: a rubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63:809–816."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "multicenter randomised trial comparing two strategies for guiding preven- 50. van Boxtel W, Bulten BF, Mavinkurve-Groothuis AM, et al. New biomarkers"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "tion with enalapril: the International CardioOncology Society-one trial. Eur J for early detection of cardiotoxicity after treatment with docetaxel, doxorubi-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "Cancer. 2018;94:126–137. cin and cyclophosphamide. Biomarkers. 2015;20:143–148."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "27. Vaduganathan M, Hirji SA, Qamar A, et al. Efficacy of neurohormonal thera- 51. Dodos F, Halbsguth T, Erdmann E, et al. Usefulness of myocardial perfor-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "pies in preventing cardiotoxicity in patients with cancer undergoing chemo- mance index and biochemical markers for early detection of anthracycline-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "therapy. J Am Coll Cardiol CardioOnc. 2019;1:54–65. induced cardiotoxicity in adults. Clin Res Cardiol. 2008;97:318–326."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "28. Wittayanukorn S, Qian J, Westrick SC, et al. Prevention of trastuzumab and 52. Ruggiero A, De Rosa G, Rizzo D, et al. Myocardial performance index and"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "anthracycline-induced cardiotoxicity using angiotensin-converting enzyme biochemical markers for early detection of doxorubicin-induced cardio-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "inhibitors or beta-blockers in older adults with breast cancer. Am J Clin On- toxicity in children with acute lymphoblastic leukaemia. Int J Clin Oncol."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "col. 2018;41:909–918. 2013;18:927–933."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "29. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in 53. Armenian SH, Gelehrter SK, Vase T, et al. Screening for cardiac dysfunc-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "cardiac risk stratification of cancer patients undergoing high-dose chemo- tion in anthracycline-exposed childhood cancer survivors. Clin Cancer Res."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "therapy. Circulation. 2004;109:2749–2754. 2014;20:6314–6323."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "30. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: 54. Hoeger CW, Hayek SS. Role of Cardiovascular biomarkers in the risk strati-"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "clinical and prognostic implications of troponin I evaluation. J Clin Oncol. fication, monitoring, and management of patients with cancer. Cardiol Clin."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "2010;28:3910–3916. 2019;37:505–523."
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 127,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "e1022 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "55. Doxorubicin hydrochloride for injection, USP [package insert]. New York, NY: 88. Ponatinib (Iclusig) [package insert]. Cambridge, MA: ARIAD Pharmaceuticals,"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "Pharmacia & Upjohn Company; 2010. Inc; 2012."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "56. Murbraech K, Wethal T, Smeland KB, et al. Valvular dysfunction in lymphoma 89. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of pona-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "survivors treated with autologous stem cell transplantation: a national cross- tinib in Philadelphia chromosome-positive leukemias. N Engl J Med."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "sectional study. J Am Coll Cardiol Img. 2016;9:230–239. 2013;369:1783–1796."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "57. Epirubicin hydrochloride for injection [package insert]. VIC, Australia: Mayne 90. Sudasena D, Balanescu DV, Donisan T, et al. Fulminant vascular and car-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "Pharma Limited Mulgrave; 2006. diac toxicity associated with tyrosine kinase inhibitor sorafenib. Cardiovasc"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "58. Cyclophosphamide [package insert]. Deerfield, IL: Baxter Healthcare Corpo- Toxicol. 2019;19:382–387."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "ration Deerfield; 2013. 91. Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "59. Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is as- with solid tumors treated with sorafenib: an updated systematic review and"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "sociated with severe, reversible cardiac dysfunction. Ann Intern Med. meta-analysis. Future Oncol. 2014;10:1981–1992."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "1993;118:31–36. 92. Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary ar-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "60. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, tery stenosis in a patient with metastatic renal cell carcinoma treated with"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "treatment and prevention. Drug Saf. 2000;22:263–302. sorafenib. BMC Cancer. 2012;12:231."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "61. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-posi- 93. Sorafenib (Nexavar) [package insert]. Wayne, NJ: Bayer HealthCare"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "tive breast cancer. N Engl J Med. 2005;352:2302–2313. Pharmaceuticals Inc; 2010."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "62. Docetaxel [package insert]. Princeton, NJ:Sandoz;2012. 94. Trametinib (Mekinist) [package insert]. Research Triangle Park, NC:"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "63. Fluorouracil [package insert]. Irvine, CA:Spectrum Pharmaceuticals, Inc; GlaxoSmithKline; 2014."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "2016. 95. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "64. Meyer CC, Calis KA, Burke LB, et al. Symptomatic cardiotoxicity associated in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–114."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "with 5-fluorouracil. Pharmacotherapy. 1997;17:729–736. 96. Sunitinib (Sutent) [package insert]. New York, NY: Pfizer Labs; 2011."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "65. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: in- 97. Li W, Croce K, Steensma DP, et al. Vascular and metabolic implications"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "cidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "2009;53:2231–2247. Cardiol. 2015;66:1160–1178."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "66. Sasson Z, Morgan CD, Wang B, et al. 5-Fluorouracil related toxic myocarditis: 98. Imatinib [package insert]. East Hanover, NJ: Novartis Pharmaceuticals"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "case reports and pathological confirmation. Can J Cardiol. 1994;10:861– Corporation; 2001."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "864. 99. Vandetanib (Caprelsa) [package insert]. Wilmington, DE: AstraZeneca"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "67. Killu A, Madhavan M, Prasad K, et al. 5-fluorouracil induced pericarditis. BMJ Pharmaceuticals LP; 2014."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "Case Rep. 2011;2011:bcr0220113883. 100. Santoni M, Guerra F, Conti A, et al. Incidence and risk of cardiotoxic-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "68. Van Cutsem E, Hoff PM, Blum JL, et al. Incidence of cardiotoxicity with the ity in cancer patients treated with targeted therapies. Cancer Treat Rev."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "oral fluoropyrimidine capecitabine is typical of that reported with 5-fluoro- 2017;59:123–131."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "uracil. Ann Oncol. 2002;13:484–485. 101. Ganatra S, Neilan TG. Immune checkpoint inhibitor associated myocarditis."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "69. Capecitabine (Xeloda) [package insert]. South San Francisco, CA: Genentech Oncologist. 2018;23:879–886."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "USA, Inc; 2015. 102. Bortezomib [package insert]. Cambridge, MA: Millennium Pharmaceuticals"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "70. Fludarabine (Fludara) [package insert]. Montville, NJ: Berlex; 2003. Inc; 2014."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "71. Hussein MA, Gundacker H, Head DR, et al. Cyclophosphamide followed by 103. Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezo-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG mib in multiple myeloma and potential protective effect with thalidomide/lenalid-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "TRIAL 9706. Leukemia. 2005;19:1880–1886. omide-based therapy: review of data from phase 3 trials and studies of novel"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "72. Decitabine (Dacogen) [package insert]. Bloomington, MN: MGI Pharma, Inc; combination regimens. Clin Lymphoma Myeloma Leuk. 2011;11:228–236."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "2006. 104. Carfilzomib [package insert]. Thousand Oaks, CA: Onyx Pharmaceuticals,"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "73. Pertuzumab (Perjeta) [package insert]. South San Francisco, CA: Genentech, Inc; 2016."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "Inc; 2012. 105. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "74. Trastuzuman (Herceptin) [package insert]. South San Francisco, CA: Genen- carfilzomib: experience from 526 patients enrolled in 4 phase II clinical"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "tech, Inc; 2010. studies. Haematologica. 2013;98:1753–1761."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "75. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a 106. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalido-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "monoclonal antibody against HER2 for metastatic breast cancer that over- mide, and dexamethasone for relapsed multiple myeloma. N Engl J Med."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "expresses HER2. N Engl J Med. 2001;344:783–792. 2015;372:142–152."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "76. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associat- 107. Goserelin (Zoladex) [package insert]. Wilmington, DE: AstraZeneca"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "ed cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. Pharmaceuticals LP; 2015."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "2007;25:3859–3865. 108. Leuprolide (Lupron) [package insert]. North Chicago, IL: AbbVie Inc; 2014."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "77. Rituximab [package insert]. South San Francisco, CA: Genentech, Inc; 2010. 109. Flutamide [package insert]. Kenilworth, NJ: Schering Corp; 2001."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "78. Dabrafenib (Tafinlar) [package insert]. Research Triangle Park, NC: 110. Bicalutamide [package insert]. Wilmington, DE: AstraZeneca"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "GlaxoSmithKline; 2014. Pharmaceuticals LP; 2015."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "79. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition 111. Nilutamide [package insert]. Baudette, MN: ANI Pharmaceuticals, Inc; 2015."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694– 112. Tisagenlecleucel (Kymriah) [package insert]. East Hanover, NJ: Novartis"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "1703. Pharmaceuticals Corporation; 2017."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "80. Bronte E, Bronte G, Novo G, et al. What links BRAF to the heart function? 113. Axicabtagene ciloleucel (Yescarta) [package insert]. Santa Monica, CA: Kite"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. Pharma, Inc; 2017."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "Oncotarget. 2015;6:35589–35601. 114. Alblooshi R, Kanfar S, Lord B, et al. Clinical prevalence and outcome of"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "81. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular cardiovascular events in the first 100 days post allogeneic HSCT. Eur J"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210–4218. Haematol. 2021;106:32–39."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "82. Dasatinib (Sprycel) [package insert]. Princeton, NJ: Bristol-Myers Squibb- 115. Gul Z, Bashir Q, Cremer M, et al. Short-term cardiac toxicity of autologous"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "Company; 2010. hematopoietic stem cell transplant for multiple myeloma. Leuk Lymphoma."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "83. Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analy- 2015;56:533–535."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "sis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83:679– 116. Mo XD, Xu LP, Liu DH, et al. Heart failure after allogeneic hematopoietic"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "686. stem cell transplantation. Int J Cardiol. 2013;167:2502–2506."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "84. Battisti NML, Tong D, Ring A, et al. Long-term outcome with targeted ther- 117. Murdych T, Weisdorf DJ. Serious cardiac complications during bone mar-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "apy in advanced/metastatic HER2-positive breast cancer: the Royal Mars- row transplantation at the University of Minnesota, 1977-1997. Bone"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "den experience. Breast Cancer Res Treat. 2019;178:401–408. Marrow Transplant. 2001;28:283–287."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "85. Lapatinib (Tykerb) [package insert]. Research Triangle Park, NC: 118. van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in sur-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "GlaxoSmithKline; 2007. vivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "86. Pazopanib (Votrient) [package insert]. Research Triangle Park, NC: anthracyclines. Blood. 2017;129:2257–2265."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "GlaxoSmithKline; 2009. 119. Nolan MT, Russell DJ, Negishi K, et al. Meta-analysis of association be-"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "87. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in meta- tween mediastinal radiotherapy and long-term heart failure. Am J Cardiol."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "static renal-cell carcinoma. N Engl J Med. 2013;369:722–731. 2016;118:1685–1691."
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 128,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1023"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "11.3. HF and Pregnancy States from the Nationwide Inpatient Sample (NIS) Database. J Card Fail."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "2016;22:512–519."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "1. Cauldwell M, Steer PJ, Swan L, et al. Pre-pregnancy counseling for women 27. Krishnamoorthy P, Garg J, Palaniswamy C, et al. Epidemiology and outcomes"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "with heart disease: a prospective study. Int J Cardiol. 2017;240:374–378. of peripartum cardiomyopathy in the United States: findings from the Na-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "2. Roos-Hesselink JW, Ruys TP, Stein JI, et al. Outcome of pregnancy in pa- tionwide Inpatient Sample. J Cardiovasc Med (Hagerstown). 2016;17:756–"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "tients with structural or ischaemic heart disease: results of a registry of the 761."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "European Society of Cardiology. Eur Heart J. 2013;34:657–665. 28. Nizamuddin J, Gupta A, Patel V, et al. Hypertensive diseases of pregnancy"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "3. Dawson AJ, Krastev Y, Parsonage WA, et al. Experiences of women with increase risk of readmission with heart failure: a national readmissions da-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "cardiac disease in pregnancy: a systematic review and metasynthesis. BMJ tabase study. Mayo Clin Proc. 2019;94:811–819."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Open. 2018;8:e022755. 29. Barasa A, Rosengren A, Sandström TZ, et al. Heart failure in late pregnancy"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "4. Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of sub- and postpartum: incidence and long-term mortality in Sweden from 1997 to"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "sequent pregnancies in women with peripartum cardiomyopathy. N Engl J 2010. J Card Fail. 2017;23:370–378."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Med. 2001;344:1567–1571. 30. Davis MB, Jarvie J, Gambahaya E, et al. Risk prediction for peripartum car-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "5. Elkayam U. Risk of subsequent pregnancy in women with a history of peri- diomyopathy in delivering mothers: a validated risk model: PPCM risk pre-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "partum cardiomyopathy. J Am Coll Cardiol. 2014;64:1629–1636. diction model. J Card Fail. 2021;27:159–167."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "6. Hilfiker-Kleiner D, Haghikia A, Masuko D, et al. Outcome of subsequent 31. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "pregnancies in patients with a history of peripartum cardiomyopathy. Eur J contemporary management in a German cohort of patients with peripartum"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Heart Fail. 2017;19:1723–1728. cardiomyopathy. Basic Res Cardiol. 2013;108:366."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "7. Yameogo NV, Samadoulougou AK, Kagambega LJ, et al. Maternal and fetal 32. Horne BD, Rasmusson KD, Alharethi R, et al. Genome-wide significance"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "prognosis of subsequent pregnancy in black African women with peripartum and replication of the chromosome 12p11.22 locus near the PTHLH gene"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "cardiomyopathy. BMC Cardiovasc Disord. 2018;18:119. for peripartum cardiomyopathy. Circ Cardiovasc Genet. 2011;4:359–366."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "8. Codsi E, Rose CH, Blauwet LA. Subsequent pregnancy outcomes in pa- 33. Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associ-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "tients with peripartum cardiomyopathy. Obstet Gynecol. 2018;131:322– ated or peripartum cardiomyopathy. Circulation. 2010;121:2176–2182."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "327. 34. van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, et al. Titin gene"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "9. Sliwa K, Forster O, Libhaber E, et al. Peripartum cardiomyopathy: inflamma- mutations are common in families with both peripartum cardiomyopathy and"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "tory markers as predictors of outcome in 100 prospectively studied patients. dilated cardiomyopathy. Eur Heart J. 2014;35:2165–2173."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Eur Heart J. 2006;27:441–446. 35. Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "10. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardio- and dilated cardiomyopathies. N Engl J Med. 2016;374:233–241."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "myopathy with contemporary. Am Heart J. 2006;152:509–513. 36. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "11. Moulig V, Pfeffer TJ, Ricke-Hoch M, et al. Long-term follow-up in peripartum 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "cardiomyopathy patients with contemporary treatment: low mortality, high 2007;128:589–600."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "cardiac recovery, but significant cardiovascular co-morbidities. Eur J Heart 37. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Fail. 2019;21:1534–1542. treatment of acute severe peripartum cardiomyopathy: a proof-of-concept"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "12. Laghari AH, Khan AH, Kazmi KA. Peripartum cardiomyopathy: ten year ex- pilot study. Circulation. 2010;121:1465–1473."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "perience at a tertiary care hospital in Pakistan. BMC Res Notes. 2013;6:495. 38. Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treat-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "13. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC ment of peripartum cardiomyopathy: a multicentre randomized study. Eur"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "guidelines for the management of cardiovascular diseases during preg- Heart J. 2017;38:2671–2679."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "nancy. Eur Heart J. 2018;39:3165–3241. 39. Yaméogo NV, Kagambèga LJ, Seghda A, et al. Bromocriptine in manage-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "14. Bauersachs J, Konig T, van der Meer P, et al. Pathophysiology, diagnosis ment of peripartum cardiomyopathy: a randomized study on 96 women in"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "and management of peripartum cardiomyopathy: a position statement from Burkina Faso. J Cardiol Clin Res. 2017;5:1098."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "the Heart Failure Association of the European Society of Cardiology Study 40. Tremblay-Gravel M, Marquis-Gravel G, Avram R, et al. The effect of bro-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21:827–843. mocriptine on left ventricular functional recovery in peripartum cardiomy-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "15. Halpern DG, Weinberg CR, Pinnelas R, et al. Use of medication for cardio- opathy: insights from the BRO-HF retrospective cohort study. ESC Heart"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "vascular disease during pregnancy: JACC state-of-the-art review. J Am Coll Fail. 2019;6:27–36."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Cardiol. 2019;73:457–476. 41. Haghikia A, Schwab J, Vogel-Claussen J, et al. Bromocriptine treatment in"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "16. Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strate- patients with peripartum cardiomyopathy and right ventricular dysfunction."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "gies for specific dilated cardiomyopathies: a scientific statement from the Clin Res Cardiol. 2019;108:290–297."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "American Heart Association. Circulation. 2016;134:e579–e646. 42. Sieweke JT, Pfeffer TJ, Berliner D, et al. Cardiogenic shock complicating pe-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "17. Mehta LS, Warnes CA, Bradley E, et al. Cardiovascular considerations in ripartum cardiomyopathy: importance of early left ventricular unloading and"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "caring for pregnant patients: a scientific statement from the American Heart bromocriptine therapy. Eur Heart J Acute Cardiovasc Care. 2020;9:173–"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Association. Circulation. 2020;141:e884–e903. 182."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "18. Schaufelberger M. Cardiomyopathy and pregnancy. Heart. 2019;105:1543– 43. Sliwa K, Petrie MC, Hilfiker-Kleiner D, et al. Long-term prognosis, subse-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "1551. quent pregnancy, contraception and overall management of peripartum car-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "19. Davis MB, Arany Z, McNamara D, et al. Peripartum cardiomyopathy: JACC diomyopathy: practical guidance paper from the Heart Failure Association"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "state-of-the-art review. J Am Coll Cardiol. 2020;75:207–221. of the European Society of Cardiology Study Group on Peripartum Cardio-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "20. Honigberg MC, Givertz MM. Peripartum cardiomyopathy. BMJ. 2019;364. myopathy. Eur J Heart Fail. 2018;20:951–962."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "k5287–k14. 44. Irizarry OC, Levine LD, Lewey J, et al. Comparison of clinical characteristics"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "21. Lindley KJ. Heart failure and pregnancy: thinking beyond peripartum cardio- and outcomes of peripartum cardiomyopathy between African American"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "myopathy. J Card Fail. 2021;27:153–156. and non-African American women. JAMA Cardiol. 2017;2:1256–1260."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "22. Ruys TP, Roos-Hesselink JW, Hall R, et al. Heart failure in pregnant women 45. Blauwet LA, Delgado-Montero A, Ryo K, et al. Right ventricular function"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "with cardiac disease: data from the ROPAC. Heart. 2014;100:231–238. in peripartum cardiomyopathy at presentation is associated with sub-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "23. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of pa- sequent left ventricular recovery and clinical outcomes. Circ Heart Fail."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "tients from the worldwide registry on peripartum cardiomyopathy (PPCM): 2016;9:e002756."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "EURObservational Research Programme in conjunction with the Heart 46. McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peri-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Failure Association of the European Society of Cardiology Study Group on partum cardiomyopathy in North America: results of the IPAC study (In-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "PPCM. Eur J Heart Fail. 2017;19:1131–1141. vestigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "24. Mogos MF, Piano MR, McFarlin BL, et al. Heart failure in pregnant 2015;66:905–914."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "women: a concern across the pregnancy continuum. Circ Heart Fail. 47. Lindley KJ, Conner SN, Cahill AG, et al. Impact of preeclampsia on clinical"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "11;2018:e004005. and functional outcomes in women with peripartum cardiomyopathy. Circ"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "25. Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and out- Heart Fail. 2017;10:e003797."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "comes of peripartum cardiomyopathy in the United States: a nationwide 48. Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of base-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "population-based study. J Am Heart Assoc. 2014;3:e001056. line left ventricular ejection fraction as a predictor of recovery or persistence"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "26. Afana M, Brinjikji W, Kao D, et al. Characteristics and in-hospital outcomes of severe dysfunction in women in the United States with peripartum cardio-"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "of peripartum cardiomyopathy diagnosed during delivery in the United myopathy. J Card Fail. 2011;17:426–430."
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 129,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "e1024 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "49. Dayoub EJ, Datwani H, Lewey J, et al. One-year cardiovascular outcomes in 12.1. Performance Measurement"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "patients with peripartum cardiomyopathy. J Card Fail. 2018;24:711–715."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "1. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "50. Pfaller B, Sathananthan G, Grewal J, et al. Preventing complications in preg-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "for heart failure in outpatient cardiology practices: primary results of the"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "nant women with cardiac disease. J Am Coll Cardiol. 2020;75:1443–1452."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Registry to Improve the Use of Evidence-Based Heart Failure Therapies in"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "51. Billebeau G, Etienne M, Cheikh-Khelifa R, et al. Pregnancy in women with a"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "the Outpatient Setting (IMPROVE HF). Circulation. 2010;122:585–596."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "cardiomyopathy: outcomes and predictors from a retrospective cohort. Arch"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "2. Nakano A, Vinter N, Egstrup K, et al. Association between process performance"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Cardiovasc Dis. 2018;111:199–209."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "measures and 1-year mortality among patients with incident heart failure: a"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "52. Lima F, Nie L, Yang J, et al. Postpartum cardiovascular outcomes among"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Danish nationwide study. Eur Heart J Qual Care Clin Outcomes. 2019;5:28–34."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "women with heart disease from a nationwide study. Am J Cardiol."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "3. Patel DB, Shah RM, Bhatt DL, et al. Guideline-appropriate care and in-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "2019;123:2006–2014."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "hospital outcomes in patients with heart failure in teaching and nonteaching"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "53. Krul SP, van der Smagt JJ, van den Berg MP, et al. Systematic review of"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "hospitals: findings from Get With The Guidelines-Heart Failure. Circ Cardio-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "pregnancy in women with inherited cardiomyopathies. Eur J Heart Fail."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "vasc Qual Outcomes. 2016;9:757–766."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "2011;13:584–594."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "4. Patel J, Sandhu A, Parizo J, et al. Validity of performance and outcome mea-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "54. Ng AT, Duan L, Win T, et al. Maternal and fetal outcomes in pregnant women"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "sures for heart failure. Circ Heart Fail. 2018;11:e005035."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "with heart failure. Heart. 2018;104:1949–1954."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "5. Heidenreich PA, Hernandez AF, Yancy CW, et al. Get With The Guidelines pro-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "55. Elkayam U, Goland S, Pieper PG, et al. High-risk cardiac disease in preg-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "gram participation, process of care, and outcome for Medicare patients hospi-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "nancy: part I. J Am Coll Cardiol. 2016;68:396–410."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "talized with heart failure. Circ Cardiovasc Qual Outcomes. 2012;5:37–43."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "56. van Hagen IM, Boersma E, Johnson MR, et al. Global cardiac risk assessment"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "6. Heidenreich PA, Lewis WR, LaBresh KA, et al. Hospital performance rec-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "in the Registry Of Pregnancy And Cardiac disease: results of a registry from"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "ognition with the Get With The Guidelines Program and mortality for acute"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "the European Society of Cardiology. Eur J Heart Fail. 2016;18:523–533."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "myocardial infarction and heart failure. Am Heart J. 2009;158:546–553."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "57. Silversides CK, Grewal J, Mason J, et al. Pregnancy outcomes in women with"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "7. Ivers NM, Grimshaw JM, Jamtvedt G, et al. Growing literature, stagnant science?"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "heart disease: the CARPREG II study. J Am Coll Cardiol. 2018;71:2419–2430."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Systematic review, meta-regression and cumulative analysis of audit and feed-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "58. Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complica-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "back interventions in health care. J Gen Intern Med. 2014;29:1534–1541."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "tions in women with congenital heart disease. Eur Heart J. 2010;31:2124–"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "8. Heidenreich PA, Fonarow GC, Breathett K, et al. 2020 ACC/AHA clinical"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "2132."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "performance and quality measures for adults with heart failure: a report of the"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "59. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital mal-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "American College of Cardiology/American Heart Association Task Force on"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "formations after first-trimester exposure to ACE inhibitors. N Engl J Med."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Performance Measures. Circ Cardiovasc Qual Outcomes. 2020;13:e000099."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "2006;354:2443–2451."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "9. Tu JV, Donovan LR, Lee DS, et al. Effectiveness of public report cards for"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "60. Buawangpong N, Teekachunhatean S, Koonrungsesomboon N. Ad-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "improving the quality of cardiac care: the EFFECT study: a randomized trial."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "verse pregnancy outcomes associated with first-trimester exposure to"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "JAMA. 2009;302:2330–2337."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "angiotensin-converting enzyme inhibitors or angiotensin II receptor block-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "10. Thomas RJ, Balady G, Banka G, et al. 2018 ACC/AHA clinical performance"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "ers: a systematic review and meta-analysis. Pharmacol Res Perspect."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "and quality measures for cardiac rehabilitation: a report of the American"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "8;2020:e00644."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "College of Cardiology/American Heart Association Task Force on Perfor-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "61. Bateman BT, Patorno E, Desai RJ, et al. Angiotensin-converting enzyme"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "mance Measures. Circ Cardiovasc Qual Outcomes. 2018;11:e000037."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "inhibitors and the risk of congenital malformations. Obstet Gynecol."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "2017;129:174–184."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "62. Liszewski W, Boull C. Lack of evidence for feminization of males exposed 13.1. Palliative and Supportive Care, Shared Decision-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "to spironolactone in utero: a systematic review. J Am Acad Dermatol. Making, and End-of-Life"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "2019;80:1147–1148."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "63. Tanaka K, Tanaka H, Kamiya C, et al. Beta-blockers and fetal growth restriction in 1. Datla S, Verberkt CA, Hoye A, et al. Multi-disciplinary palliative care is ef-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "pregnant women with cardiovascular disease. Circ J. 2016;80:2221–2226. fective in people with symptomatic heart failure: a systematic review and"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "64. Bateman BT, Heide-Jorgensen U, Einarsdottir K, et al. Beta-blocker use in narrative synthesis. Palliat Med. 2019;33:1003–1016."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "pregnancy and the risk for congenital malformations: an international cohort 2. Goldstein N, Carlson M, Livote E, et al. Brief communication: management"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "study. Ann Intern Med. 2018;169:665–673. of implantable cardioverter-defibrillators in hospice: a nationwide survey."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "65. Bergman JEH, Lutke LR, Gans ROB, et al. Beta-blocker use in pregnancy Ann Intern Med. 2010;152:296–299."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "and risk of specific congenital anomalies: a European case-malformed con- 3. McIlvennan CK, Jones J, Allen LA, et al. Bereaved caregiver perspectives"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "trol study. Drug Saf. 2018;41:415–427. on the end-of-life experience of patients with a left ventricular assist device."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "66. Kearney L, Wright P, Fhadil S, et al. Postpartum cardiomyopathy and consid- JAMA Intern Med. 2016;176:534–539."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "erations for breastfeeding. Card Fail Rev. 2018;4:112–118. 4. Rogers JG, Patel CB, Mentz RJ, et al. Palliative care in heart failure: the PAL-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "67. Koczo A, Marino A, Jeyabalan A, et al. Breastfeeding, cellular immune ac- HF randomized, controlled clinical trial. J Am Coll Cardiol. 2017;70:331–341."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "tivation, and myocardial recovery in peripartum cardiomyopathy. J Am Coll 5. Bekelman DB, Allen LA, McBryde CF, et al. Effect of a collaborative care in-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Cardiol Basic Trans Science. 2019;4:291–300. tervention vs usual care on health status of patients with chronic heart failure:"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "68. Arany Z, Feldman AM. To breastfeed or not to breastfeed with peripartum the CASA randomized clinical trial. JAMA Intern Med. 2018;178:511–519."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "cardiomyopathy. J Am Coll Cardiol Basic Trans Science. 2019;4:301–303. 6. O’Donnell AE, Schaefer KG, Stevenson LW, et al. Social Worker-Aided Pal-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "69. Koenig T, Hilfiker-Kleiner D, Bauersachs J. Breastfeeding in patients with liative Care Intervention in High-risk Patients With Heart Failure (SWAP-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "heart failure: lack of evidence and consensus. J Am Coll Cardiol Basic Trans HF): a pilot randomized clinical trial. JAMA Cardiol. 2018;3:516–519."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Science. 2019;4:866–867. 7. Schichtel M, Wee B, Perera R, et al. The effect of advance care planning"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "70. Safirstein JG, Ro AS, Grandhi S, et al. Predictors of left ventricular recovery on heart failure: a systematic review and meta-analysis. J Gen Intern Med."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "in a cohort of peripartum cardiomyopathy patients recruited via the internet. 2020;35:874–884."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Int J Cardiol. 2012;154:27–31. 8. Candy B, Holman A, Leurent B, et al. Hospice care delivered at home, in"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "71. American Academy of Pediatrics Committee on Drugs. Transfer of drugs nursing homes and in dedicated hospice facilities: a systematic review of"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "and other chemicals into human milk. Pediatrics. 2001;108:776–789. quantitative and qualitative evidence. Int J Nurs Stud. 2011;48:121–133."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "72. National Library of Medicine. Drugs and Lactation Database (LactMed) [In- 9. Braun LT, Grady KL, Kutner JS, et al. Palliative care and cardiovascular dis-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "ternet]. Bethesda (MD). Accessed October 2, 2020. https://wwwncbinlmni- ease and stroke: a policy statement from the American Heart Association/"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "hgov/books/NBK501922/ American Stroke Association. Circulation. 2016;134:e198–e225."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "73. Kampman MA, Balci A, van Veldhuisen DJ, et al. N-terminal pro-B-type na- 10. McIlvennan CK, Allen LA. Palliative care in patients with heart failure. BMJ."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "triuretic peptide predicts cardiovascular complications in pregnant women 2016;353:i1010."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "with congenital heart disease. Eur Heart J. 2014;35:708–715. 11. Casarett D, Fishman J, O’Dwyer PJ, et al. How should we design supportive"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "74. Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant cancer care? The patient’s perspective. J Clin Oncol. 2008;26:1296–1301."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "women with heart disease. J Am Coll Cardiol. 2010;56:1247–1253. 12. Allen LA, Stevenson LW, Grady KL, et al. Decision making in advanced heart"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "75. Gammill HS, Chettier R, Brewer A, et al. Cardiomyopathy and preeclampsia. failure: a scientific statement from the American Heart Association. Circula-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Circulation. 2018;138:2359–2366. tion. 2012;125:1928–1952."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "76. Ersboll AS, Arany Z, Gustafsson F. Bromocriptine for the treatment of peri- 13. Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Soci-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "partum cardiomyopathy: comparison of outcome with a Danish cohort. Eur ety clinical policy statement: palliative care for patients with respiratory dis-"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Heart J. 2018;39:3476–3477. eases and critical illnesses. Am J Respir Crit Care Med. 2008;177:912–927."
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 130,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1025"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "14. World Health Organization Expert Committee on Cancer Pain Relief and 9. Rector TS, Carson PE, Anand IS, et al. Assessment of long-term effects of"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "Active Supportive Care. Cancer pain relief and palliative care. World Health irbesartan on heart failure with preserved ejection fraction as measured by"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "Organization Technical Report Series, No. 804. World Health Organization; the Minnesota Living with Heart Failure Questionnaire in the irbesartan in"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "1990. Accessed December 15, 2020. https://apps.who.int/iris/bitstream/ heart failure with preserved systolic function (I-PRESERVE) trial. Circ Heart"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "handle/10665/39524/WHO_TRS_804.pdf?sequence=1&isAllowed=y Fail. 2012;5:217–225."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "15. Gelfman LP, Kalman J, Goldstein NE. Engaging heart failure clinicians to 10. Carson P, Tam SW, Ghali JK, et al. Relationship of quality of life scores with"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "increase palliative care referrals: overcoming barriers, improving techniques. baseline characteristics and outcomes in the African-American heart failure"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "J Palliat Med. 2014;17:753–760. trial. J Card Fail. 2009;15:835–842."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "16. Tulsky JA, Beach MC, Butow PN, et al. A research agenda for communi- 11. Alla F, Briancon S, Guillemin F, et al. Self-rating of quality of life provides"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "cation between health care professionals and patients living with serious additional prognostic information in heart failure: insights into the EPICAL"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "illness. JAMA Intern Med. 2017;177:1361–1366. study. Eur J Heart Fail. 2002;4:337–343."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "17. Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-predicted 12. Tate CW 3rd, Robertson AD, Zolty R, et al. Quality of life and prognosis in"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "and model-predicted life expectancy among ambulatory patients with heart heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST)."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "failure. JAMA. 2008;299:2533–2542. J Card Fail. 2007;13:732–737."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "18. Matlock DD, Jones J, Nowels CT, et al. Evidence of cognitive bias in decision 13. Moser DK, Yamokoski L, Sun JL, et al. Improvement in health-related qual-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "making around implantable-cardioverter defibrillators: a qualitative frame- ity of life after hospitalization predicts event-free survival in patients with"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "work analysis. J Card Fail. 2017;23:794–799. advanced heart failure. J Card Fail. 2009;15:763–769."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "19. Ferrell BR, Twaddle ML, Melnick A, et al. National consensus project clinical 14. Hoekstra T, Jaarsma T, van Veldhuisen DJ, et al. Quality of life and survival"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "practice guidelines for quality palliative care guidelines, 4th edition. J Palliat in patients with heart failure. Eur J Heart Fail. 2013;15:94–102."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "Med. 2018;21:1684–1689. 15. Soto GE, Jones P, Weintraub WS, et al. Prognostic value of health status"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "20. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients in patients with heart failure after acute myocardial infarction. Circulation."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733– 2004;110:546–551."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "742. 16. Pokharel Y, Khariton Y, Tang Y, et al. Association of serial Kansas City Car-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "21. A controlled trial to improve care for seriously ill hospitalized patients. The diomyopathy Questionnaire assessments with death and hospitalization"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "study to understand prognoses and preferences for outcomes and risks in patients with heart failure with preserved and reduced ejection frac-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA. tion: a secondary analysis of 2 randomized clinical trials. JAMA Cardiol."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "1995;274:1591–1598. 2017;2:1315–1321."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "22. Bakitas MA, Dionne-Odom JN, Ejem DB, et al. Effect of an early pallia- 17. Dunlay SM, Gheorghiade M, Reid KJ, et al. Critical elements of clinical fol-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "tive care telehealth intervention vs usual care on patients with heart fail- low-up after hospital discharge for heart failure: insights from the EVEREST"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "ure: the ENABLE CHF-PC randomized clinical trial. JAMA Intern Med. trial. Eur J Heart Fail. 2010;12:367–374."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "2020;180:1203–1213. 18. Heidenreich PA, Spertus JA, Jones PG, et al. Health status identifies heart"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "23. Carson SS, Cox CE, Wallenstein S, et al. Effect of palliative care-led meet- failure outpatients at risk for hospitalization or death. J Am Coll Cardiol."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "ings for families of patients with chronic critical illness: a randomized clinical 2006;47:752–756."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "trial. JAMA. 2016;316:51–62. 19. Arnold SV, Spertus JA, Vemulapalli S, et al. Association of patient-reported"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "24. Sudore RL, Lum HD, You JJ, et al. Defining advance care planning for health status with long-term mortality after transcatheter aortic valve re-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "adults: a consensus definition from a multidisciplinary Delphi Panel. J Pain placement: report from the STS/ACC TVT Registry. Circ Cardiovasc Interv."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "Symptom Manage. 2017;53:821–832.e1. 2015;8:e002875."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "25. Yadav KN, Gabler NB, Cooney E, et al. Approximately one in three US adults 20. Tran AT, Chan PS, Jones PG, et al. Comparison of patient self-reported"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "completes any type of advance directive for end-of-life care. Health Aff (Mill- health status with clinician-assigned New York Heart Association classifica-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "wood). 2017;36:1244–1251. tion. JAMA Netw Open. 2020;3:e2014319."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "26. Keating NL, Huskamp HA, Kouri E, et al. Factors contributing to geographic 21. Goode KM, Nabb S, Cleland JG, et al. A comparison of patient and physi-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "variation in end-of-life expenditures for cancer patients. Health Aff (Mill- cian-rated New York Heart Association class in a community-based heart"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "wood). 2018;37:1136–1143. failure clinic. J Card Fail. 2008;14:379–387."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "27. Chuzi S, Molsberry R, Ogunseitan A, et al. Trends in place of death for car- 22. Khariton Y, Hernandez AF, Fonarow GC, et al. Health status variation across"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "diovascular mortality related to heart failure in the United States from 2003 practices in outpatients with heart failure: insights from the CHAMP-HF"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "to 2017. Circ Heart Fail. 2020;13:e006587. (Change the Management of Patients With Heart Failure) Registry. Circ Car-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "diovasc Qual Outcomes. 2018;11:e004668."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "23. Stehlik J, Rodriguez-Correa C, Spertus JA, et al. Implementation of real-time"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "14.1. Patient-Reported Outcomes"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "assessment of patient-reported outcomes in a heart failure clinic: a feasibil-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "1. Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of ity study. J Card Fail. 2017;23:813–816."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "the Kansas City Cardiomyopathy Questionnaire: a new health status mea- 24. Turgeon RD, Barry AR, Hawkins NM, et al. Pharmacotherapy for heart fail-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "sure for heart failure. J Am Coll Cardiol. 2000;35:1245–1255. ure with reduced ejection fraction and health-related quality of life: a sys-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "2. Spertus J, Peterson E, Conard MW, et al. Monitoring clinical chang- tematic review and meta-analysis. Eur J Heart Fail. 2021;23:578–589."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "es in patients with heart failure: a comparison of methods. Am Heart J. 25. Chen S, Yin Y, Krucoff MW. Effect of cardiac resynchronization therapy and"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "2005;150:707–715. implantable cardioverter defibrillator on quality of life in patients with heart"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "3. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota failure: a meta-analysis. Europace. 2012;14:1602–1607."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "Living with Heart Failure Questionnaire: reliability and validity during a ran- 26. O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "domized, double-blind, placebo-controlled trial of pimobendan. Am Heart J. training in patients with chronic heart failure: HF-ACTION randomized con-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "1992;124:1017–1025. trolled trial. JAMA. 2009;301:1439–1450."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "4. Demers C, McKelvie RS, Negassa A, et al. Reliability, validity, and respon- 27. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "siveness of the six-minute walk test in patients with heart failure. Am Heart treatment of persistent atrial fibrillation in patients with congestive heart"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "J. 2001;142:698–703. failure and an implanted device: results from the AATAC multicenter ran-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "5. Rector TS, Anand IS, Cohn JN. Relationships between clinical assessments domized trial. Circulation. 2016;133:1637–1644."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "and patients’ perceptions of the effects of heart failure on their quality of life. 28. Khan MN, Jaïs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibril-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "J Card Fail. 2006;12:87–92. lation in patients with heart failure. N Engl J Med. 2008;359:1778–1785."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "6. Gorkin L, Norvell NK, Rosen RC, et al. Assessment of quality of life as ob- 29. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "served from the baseline data of the Studies of Left Ventricular Dysfunction haemodynamic monitoring in chronic heart failure: a randomised controlled"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "(SOLVD) trial quality-of-life substudy. Am J Cardiol. 1993;71:1069–1073. trial. Lancet. 2011;377:658–666."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "7. Quittan M, Wiesinger GF, Crevenna R, et al. Cross-cultural adaptation of 30. Mark DB, Knight JD, Velazquez EJ, et al. Quality-of-life outcomes with coro-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "the Minnesota living with heart failure questionnaire for German-speaking nary artery bypass graft surgery in ischemic left ventricular dysfunction: a"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "patients. J Rehabil Med. 2001;33:182–186. randomized trial. Ann Intern Med. 2014;161:392–399."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "8. van den Berg-Emons RJ, Bussmann JB, Balk AH, et al. Factors associated 31. Arnold SV, Chinnakondepalli KM, Spertus JA, et al. Health status after trans-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "with the level of movement-related everyday activity and quality of life in catheter mitral-valve repair in heart failure and secondary mitral regurgita-"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "people with chronic heart failure. Phys Ther. 2005;85:1340–1348. tion: COAPT trial. J Am Coll Cardiol. 2019;73:2123–2132."
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 131,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "e1026 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2022 AHA/ACC/HFSA Guideline for the"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Management of Heart Failure"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Institutional,"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Ownership/ Organizational,"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Committee Speakers Partnership/ Personal or Other Expert"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Member Employment Consultant Bureau Principal Research Financial Benefit Witness Salary"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Paul A. Stanford University School of Medi- None None None None None None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Heidenreich, cine—Professor and Vice-Chair for"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Chair Quality, Department of Medicine"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Biykem Baylor College of Medicine and De- • Abbott* None None None • Abbott* None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Bozkurt, Bakey VA Medical Center Cardiology • Amgen • Amgen"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Vice Chair Department—Mary and Gordon Cain • Baxter • Relypsa"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Chair; W.A. “Tex” and Deborah Mon- • Bristol-Myers • Respicardia"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "crief, Jr., Chair; Professor of Medicine Squibb* • Sanofi-"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Medical Care Line Executive, DeBakey • E.R. Squibb & Aventis‡"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "VA Medical Center; Director, Winters Sons, L.L.C.* • Past Presi-"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Center for Heart Failure Research; • Relypsa dent, HFSA"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Associate Director, Cardiovascular • Sanofi-aventis* (2019-2020)"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Research Institute; Vice-Chair of Medi- • scPharmaceuticals"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "cine, Baylor College of Medicine • Vifor"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "David Aguilar University of Kentucky—Professor of None None None None None None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Medicine, Department of Medicine,"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Division of Cardiovascular Medicine"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Larry A. Allen University of Colorado School • Abbott None None None • Abbott‡ None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "of Medicine, Anschutz Medical • ACI Clinical* • Amgen"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Campus—Professor of Medicine, • Amgen* • Boston Sci-"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Department of Medicine, Division of • Boston Scientific* entific*‡"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Cardiology • Cytokinetics • Janssen Phar-"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "• Novartis maceuticals"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "• Medtronic"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Vascular Inc."
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "• Novartis‡"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Joni J. Byun Penultimate PR—President None None None None None None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Monica M. University of Michigan—Professor of None None None • CareDX • Abbott‡ None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Colvin Medicine, Department of Medicine,"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Cardiovascular Division;"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Associate Director, Heart Transplant"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Program, Advanced Heart Failure,"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Transplant, and MCS Natera"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Anita Deswal UT MD Anderson Cancer Center— None None None None None None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Ting Tsung and Wei Fong Chao"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Distinguished Chair, Professor of"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Medicine, and Chair of Cardiology"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Mark H. UT Southwestern Medical Cen- None None None None None None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Drazner ter—Professor and Clinical Chief of"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Cardiology, Department of Internal"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Medicine, Cardiology"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Shannon M. Mayo Clinic—Professor of Health None None None None None None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Dunlay Services Research and Medicine, De-"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "partment of Cardiovascular Medicine"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Linda R. Stevens & Lee—Shareholder and Chair None None None None None None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Evers of Stevens & Lee’s Energy, Communi-"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "cations and Public Utility Group"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "James C. University of Utah—Professor of • Boston Scientific† None None None • ACI Clinical None None"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Fang Medicine, Division of Cardiovascular (Adjudication"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Medicine Committee)*"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "• Amgen"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "(Steering"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Committee)"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "• AstraZeneca"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "(Steering"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Committee)"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "• Boston"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Scientific†"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "• Novartis"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "(Executive"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Committee)"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "(Continued )"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 132,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 132,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Committee Member": "Paul A. Heidenreich, Chair",
                "Employment": "Stanford University School of Medi- cine—Professor and Vice-Chair for Quality, Department of Medicine",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Biykem Bozkurt, Vice Chair",
                "Employment": "Baylor College of Medicine and De- Bakey VA Medical Center Cardiology Department—Mary and Gordon Cain Chair; W.A. “Tex” and Deborah Mon- crief, Jr., Chair; Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center; Director, Winters Center for Heart Failure Research; Associate Director, Cardiovascular Research Institute; Vice-Chair of Medi- cine, Baylor College of Medicine",
                "Consultant": "• Abbott* • Amgen • Baxter • Bristol-Myers Squibb* • E.R. Squibb & Sons, L.L.C.* • Relypsa • Sanofi-aventis* • scPharmaceuticals • Vifor",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Abbott* • Amgen • Relypsa • Respicardia • Sanofi- Aventis‡ • Past Presi- dent, HFSA (2019-2020)",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "David Aguilar",
                "Employment": "University of Kentucky—Professor of Medicine, Department of Medicine, Division of Cardiovascular Medicine",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Larry A. Allen",
                "Employment": "University of Colorado School of Medicine, Anschutz Medical Campus—Professor of Medicine, Department of Medicine, Division of Cardiology",
                "Consultant": "• Abbott • ACI Clinical* • Amgen* • Boston Scientific* • Cytokinetics • Novartis",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Abbott‡ • Amgen • Boston Sci- entific*‡ • Janssen Phar- maceuticals • Medtronic Vascular Inc. • Novartis‡",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Joni J. Byun",
                "Employment": "Penultimate PR—President",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Monica M. Colvin",
                "Employment": "University of Michigan—Professor of Medicine, Department of Medicine, Cardiovascular Division; Associate Director, Heart Transplant Program, Advanced Heart Failure, Transplant, and MCS Natera",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• CareDX",
                "Institutional, Organizational, or Other Financial Benefit": "• Abbott‡",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Anita Deswal",
                "Employment": "UT MD Anderson Cancer Center— Ting Tsung and Wei Fong Chao Distinguished Chair, Professor of Medicine, and Chair of Cardiology",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Mark H. Drazner",
                "Employment": "UT Southwestern Medical Cen- ter—Professor and Clinical Chief of Cardiology, Department of Internal Medicine, Cardiology",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Shannon M. Dunlay",
                "Employment": "Mayo Clinic—Professor of Health Services Research and Medicine, De- partment of Cardiovascular Medicine",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Linda R. Evers",
                "Employment": "Stevens & Lee—Shareholder and Chair of Stevens & Lee’s Energy, Communi- cations and Public Utility Group",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "James C. Fang",
                "Employment": "University of Utah—Professor of Medicine, Division of Cardiovascular Medicine",
                "Consultant": "• Boston Scientific†",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• ACI Clinical (Adjudication Committee)* • Amgen (Steering Committee) • AstraZeneca (Steering Committee) • Boston Scientific† • Novartis (Executive Committee)",
                "Expert Witness": "None",
                "Salary": "None"
            }
        ],
        "conteudo_texto": "Paul A. Heidenreich, Chair, Stanford University School of Medi- cine—Professor and Vice-Chair for Quality, Department of Medicine, None, None, None, None, None, None, None | Biykem Bozkurt, Vice Chair, Baylor College of Medicine and De- Bakey VA Medical Center Cardiology Department—Mary and Gordon Cain Chair; W.A. “Tex” and Deborah Mon- crief, Jr., Chair; Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center; Director, Winters Center for Heart Failure Research; Associate Director, Cardiovascular Research Institute; Vice-Chair of Medi- cine, Baylor College of Medicine, • Abbott* • Amgen • Baxter • Bristol-Myers Squibb* • E.R. Squibb & Sons, L.L.C.* • Relypsa • Sanofi-aventis* • scPharmaceuticals • Vifor, None, None, None, • Abbott* • Amgen • Relypsa • Respicardia • Sanofi- Aventis‡ • Past Presi- dent, HFSA (2019-2020), None, None | David Aguilar, University of Kentucky—Professor of Medicine, Department of Medicine, Division of Cardiovascular Medicine, None, None, None, None, None, None, None | Larry A. Allen, University of Colorado School of Medicine, Anschutz Medical Campus—Professor of Medicine, Department of Medicine, Division of Cardiology, • Abbott • ACI Clinical* • Amgen* • Boston Scientific* • Cytokinetics • Novartis, None, None, None, • Abbott‡ • Amgen • Boston Sci- entific*‡ • Janssen Phar- maceuticals • Medtronic Vascular Inc. • Novartis‡, None, None | Joni J. Byun, Penultimate PR—President, None, None, None, None, None, None, None | Monica M. Colvin, University of Michigan—Professor of Medicine, Department of Medicine, Cardiovascular Division; Associate Director, Heart Transplant Program, Advanced Heart Failure, Transplant, and MCS Natera, None, None, None, • CareDX, • Abbott‡, None, None | Anita Deswal, UT MD Anderson Cancer Center— Ting Tsung and Wei Fong Chao Distinguished Chair, Professor of Medicine, and Chair of Cardiology, None, None, None, None, None, None, None | Mark H. Drazner, UT Southwestern Medical Cen- ter—Professor and Clinical Chief of Cardiology, Department of Internal Medicine, Cardiology, None, None, None, None, None, None, None | Shannon M. Dunlay, Mayo Clinic—Professor of Health Services Research and Medicine, De- partment of Cardiovascular Medicine, None, None, None, None, None, None, None | Linda R. Evers, Stevens & Lee—Shareholder and Chair of Stevens & Lee’s Energy, Communi- cations and Public Utility Group, None, None, None, None, None, None, None | James C. Fang, University of Utah—Professor of Medicine, Division of Cardiovascular Medicine, • Boston Scientific†, None, None, None, • ACI Clinical (Adjudication Committee)* • Amgen (Steering Committee) • AstraZeneca (Steering Committee) • Boston Scientific† • Novartis (Executive Committee), None, None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1027"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Appendix 1. Continued"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Institutional,"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Ownership/ Organizational,"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Committee Speakers Partnership/ Personal or Other Expert"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Member Employment Consultant Bureau Principal Research Financial Benefit Witness Salary"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Savitri E. Michael E. DeBakey Medical None None None None None None None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Fedson Center—Professor, Medical Director,"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Advanced Heart Failure and Trans-"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "plantation, Section of Cardiology"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Gregg C. Geffen School of Medicine at • Abbott* None None None • Boston None None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Fonarow UCLA—Professor of Cardiovascular • Amgen Scientific"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Medicine, Chief, UCLA Division of • AstraZeneca • Novartis*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Cardiology, Department of Medicine • CHF Solutions • Medtronic"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Cytokinetics"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Edwards Life-"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "sciences*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Janssen"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Pharmaceuticals"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Medtronic"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Merck*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Novartis*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Regeneron"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Salim S. University of Michigan in Ann Arbor— None None None None None None None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Hayek Assistant Professor, Department of"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Medicine, Division of Cardiology"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Adrian F. Duke University School of Medi- • Amgen None None • American None None None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Hernandez cine—Vice Dean of Clinical Research • AstraZeneca Regent"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Bayer • Amgen"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• BioFourmis • Boston"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Boehringer Scientific"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Ingelheim* • AstraZen-"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Boston Scientific* eca*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Cytokinetics • Boehringer"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Eli Lilly Ingelheim"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Merck* • Daiichi"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Myokardia Sankyo"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Novartis* • Genentech"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Pfizer • GlaxoS-"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Relypsa mithKline*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Sanofi-aventis* • Janssen"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Pharma-"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "ceuticals*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Merck*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Novartis*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Verily*"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Prateeti Kha- University of Colorado—Assistant None None None None None None None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "zanie Professor of Medicine, Department"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "of Medicine, Division of Cardiology"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Michelle M. Smidt Heart Institute Cedars-Sinai— None None None None None None None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Kittleson Professor of Medicine, Cardiology"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Christopher Boston College, William F. Connell None None None None None None None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "S. Lee School of Nursing—Professor and"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Associate Dean for Research"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Mark S. Link UT Southwestern Medical Center, None None None None None None None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Dallas—Professor of Medicine and"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Director, Cardiac Electrophysiology;"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Laurence and Susan Hirsch/Centex"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Distinguished Chair in Heart Dis-"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "ease, Department of Internal Medi-"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "cine, Division of Cardiology"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Carmelo A. Duke University Medical Cen- • Abbott* None None • Abbott* • Abbott* None None"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Milano ter—Professor of Surgery, Surgery • Medtronic* • AbioMed†"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Department • NuPulse† • Allergan†"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• CryoLife†"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• Ethicon†"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "• LivaNova†"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "(Continued )"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 133,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 133,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Committee Member": "Savitri E. Fedson",
                "Employment": "Michael E. DeBakey Medical Center—Professor, Medical Director, Advanced Heart Failure and Trans- plantation, Section of Cardiology",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Gregg C. Fonarow",
                "Employment": "Geffen School of Medicine at UCLA—Professor of Cardiovascular Medicine, Chief, UCLA Division of Cardiology, Department of Medicine",
                "Consultant": "• Abbott* • Amgen • AstraZeneca • CHF Solutions • Cytokinetics • Edwards Life- sciences* • Janssen Pharmaceuticals • Medtronic • Merck* • Novartis* • Regeneron",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Boston Scientific • Novartis* • Medtronic",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Salim S. Hayek",
                "Employment": "University of Michigan in Ann Arbor— Assistant Professor, Department of Medicine, Division of Cardiology",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Adrian F. Hernandez",
                "Employment": "Duke University School of Medi- cine—Vice Dean of Clinical Research",
                "Consultant": "• Amgen • AstraZeneca • Bayer • BioFourmis • Boehringer Ingelheim* • Boston Scientific* • Cytokinetics • Eli Lilly • Merck* • Myokardia • Novartis* • Pfizer • Relypsa • Sanofi-aventis*",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• American Regent • Amgen • Boston Scientific • AstraZen- eca* • Boehringer Ingelheim • Daiichi Sankyo • Genentech • GlaxoS- mithKline* • Janssen Pharma- ceuticals* • Merck* • Novartis* • Verily*",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Prateeti Kha- zanie",
                "Employment": "University of Colorado—Assistant Professor of Medicine, Department of Medicine, Division of Cardiology",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Michelle M. Kittleson",
                "Employment": "Smidt Heart Institute Cedars-Sinai— Professor of Medicine, Cardiology",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Christopher S. Lee",
                "Employment": "Boston College, William F. Connell School of Nursing—Professor and Associate Dean for Research",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Mark S. Link",
                "Employment": "UT Southwestern Medical Center, Dallas—Professor of Medicine and Director, Cardiac Electrophysiology; Laurence and Susan Hirsch/Centex Distinguished Chair in Heart Dis- ease, Department of Internal Medi- cine, Division of Cardiology",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Carmelo A. Milano",
                "Employment": "Duke University Medical Cen- ter—Professor of Surgery, Surgery Department",
                "Consultant": "• Abbott*",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Abbott* • Medtronic* • NuPulse†",
                "Institutional, Organizational, or Other Financial Benefit": "• Abbott* • AbioMed† • Allergan† • CryoLife† • Ethicon† • LivaNova†",
                "Expert Witness": "None",
                "Salary": "None"
            }
        ],
        "conteudo_texto": "Savitri E. Fedson, Michael E. DeBakey Medical Center—Professor, Medical Director, Advanced Heart Failure and Trans- plantation, Section of Cardiology, None, None, None, None, None, None, None | Gregg C. Fonarow, Geffen School of Medicine at UCLA—Professor of Cardiovascular Medicine, Chief, UCLA Division of Cardiology, Department of Medicine, • Abbott* • Amgen • AstraZeneca • CHF Solutions • Cytokinetics • Edwards Life- sciences* • Janssen Pharmaceuticals • Medtronic • Merck* • Novartis* • Regeneron, None, None, None, • Boston Scientific • Novartis* • Medtronic, None, None | Salim S. Hayek, University of Michigan in Ann Arbor— Assistant Professor, Department of Medicine, Division of Cardiology, None, None, None, None, None, None, None | Adrian F. Hernandez, Duke University School of Medi- cine—Vice Dean of Clinical Research, • Amgen • AstraZeneca • Bayer • BioFourmis • Boehringer Ingelheim* • Boston Scientific* • Cytokinetics • Eli Lilly • Merck* • Myokardia • Novartis* • Pfizer • Relypsa • Sanofi-aventis*, None, None, • American Regent • Amgen • Boston Scientific • AstraZen- eca* • Boehringer Ingelheim • Daiichi Sankyo • Genentech • GlaxoS- mithKline* • Janssen Pharma- ceuticals* • Merck* • Novartis* • Verily*, None, None, None | Prateeti Kha- zanie, University of Colorado—Assistant Professor of Medicine, Department of Medicine, Division of Cardiology, None, None, None, None, None, None, None | Michelle M. Kittleson, Smidt Heart Institute Cedars-Sinai— Professor of Medicine, Cardiology, None, None, None, None, None, None, None | Christopher S. Lee, Boston College, William F. Connell School of Nursing—Professor and Associate Dean for Research, None, None, None, None, None, None, None | Mark S. Link, UT Southwestern Medical Center, Dallas—Professor of Medicine and Director, Cardiac Electrophysiology; Laurence and Susan Hirsch/Centex Distinguished Chair in Heart Dis- ease, Department of Internal Medi- cine, Division of Cardiology, None, None, None, None, None, None, None | Carmelo A. Milano, Duke University Medical Cen- ter—Professor of Surgery, Surgery Department, • Abbott*, None, None, • Abbott* • Medtronic* • NuPulse†, • Abbott* • AbioMed† • Allergan† • CryoLife† • Ethicon† • LivaNova†, None, None"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "e1028 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Appendix 1. Continued"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Institutional,"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Ownership/ Organizational,"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Committee Speakers Partnership/ Personal or Other Expert"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Member Employment Consultant Bureau Principal Research Financial Benefit Witness Salary"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Lorraine C. American Heart Association/Ameri- None None None None • AHA/ACC None None"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Nnacheta§ can College of Cardiology—Guide- salaried"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "line Advisor employee"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Alexander T. Stanford University—Instructor of None None None None None None None"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Sandhu Medicine, Division of Cardiology,"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Department of Medicine"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Lynne Vanderbilt University Medical Center, • Novartis None None None • Abbott‡ None None"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Warner Vanderbilt Heart and Vascular Insti- • Biotronik"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Stevenson tute—Director of Cardiomyopathy • Boston"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "and Lisa M. Jacobson Professor of Scientific"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Cardiovascular Medicine • Bristol-Myers"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Squibb‡"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "• Endotronic†"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "• Gore Medical†"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "• Johnson &"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Johnson"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Orly Vardeny Minneapolis VA Health Care System • Amgen None None • AstraZen- • AstraZeneca‡ None None"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "and University of Minnesota— • Novartis eca*"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Associate Professor of Medicine, • Sanofi-Pasteur • Bayer*"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Department of Medicine"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Amanda R. Tufts Medical Center, Cardiovascu- None None None None • Boehringer None None"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Vest lar Center—Assistant Professor of Ingelheim‡*"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Medicine • CareDx‡"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "• Corvia‡"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "• Transmedics‡"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Clyde W. Northwestern University, Feinberg None None None None • Abbott† None None"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Yancy School of Medicine; Northwestern • JAMA"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Memorial Hospital—Professor of Cardiology,"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Medicine (Cardiology); Professor of Deputy Editor"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Medical Social Sciences; Chief of"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Cardiology; Vice-Dean, Diversity &"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Inclusion; Associate Director Car-"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "diovascular Institute Internal Medi-"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "cine/Cardiology & Medical Social"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Sciences"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relation-"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "ships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market value of the business entity; or if funds"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device ad-"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "dressed in the document; or c) the person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "as a result of the issues/content addressed in the document. Writing committee members are required to recuse themselves from voting on sections to which their"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "specific relationships with industry and other entities may apply."
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "*Significant relationship."
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "†No financial benefit."
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "‡This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "there is no direct or institutional relationship with the trial sponsor as defined in the (ACCF or AHA/ACC) Disclosure Policy for Writing Committees."
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "§Lorraine Nnacheta is an AHA/ACC joint staff member and acts as the guideline advisor for the “2022 AHA/ACC/HFSA Guideline for the Management of Heart"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Failure.” No relevant relationships to report. Non-voting author on recommendations and not included/counted in the RWI balance for this committee."
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; HFSA, Heart Failure"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Society of America; RWI, relationships with industry and other entities; UCLA, University of California, Los Angeles; UT, University of Texas; and VA, Veterans Affairs."
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 134,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 134,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Committee Member": "Lorraine C. Nnacheta§",
                "Employment": "American Heart Association/Ameri- can College of Cardiology—Guide- line Advisor",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• AHA/ACC salaried employee",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Alexander T. Sandhu",
                "Employment": "Stanford University—Instructor of Medicine, Division of Cardiology, Department of Medicine",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Lynne Warner Stevenson",
                "Employment": "Vanderbilt University Medical Center, Vanderbilt Heart and Vascular Insti- tute—Director of Cardiomyopathy and Lisa M. Jacobson Professor of Cardiovascular Medicine",
                "Consultant": "• Novartis",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Abbott‡ • Biotronik • Boston Scientific • Bristol-Myers Squibb‡ • Endotronic† • Gore Medical† • Johnson & Johnson",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Orly Vardeny",
                "Employment": "Minneapolis VA Health Care System and University of Minnesota— Associate Professor of Medicine, Department of Medicine",
                "Consultant": "• Amgen • Novartis • Sanofi-Pasteur",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• AstraZen- eca* • Bayer*",
                "Institutional, Organizational, or Other Financial Benefit": "• AstraZeneca‡",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Amanda R. Vest",
                "Employment": "Tufts Medical Center, Cardiovascu- lar Center—Assistant Professor of Medicine",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Boehringer Ingelheim‡* • CareDx‡ • Corvia‡ • Transmedics‡",
                "Expert Witness": "None",
                "Salary": "None"
            },
            {
                "Committee Member": "Clyde W. Yancy",
                "Employment": "Northwestern University, Feinberg School of Medicine; Northwestern Memorial Hospital—Professor of Medicine (Cardiology); Professor of Medical Social Sciences; Chief of Cardiology; Vice-Dean, Diversity & Inclusion; Associate Director Car- diovascular Institute Internal Medi- cine/Cardiology & Medical Social Sciences",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Abbott† • JAMA Cardiology, Deputy Editor",
                "Expert Witness": "None",
                "Salary": "None"
            }
        ],
        "conteudo_texto": "Lorraine C. Nnacheta§, American Heart Association/Ameri- can College of Cardiology—Guide- line Advisor, None, None, None, None, • AHA/ACC salaried employee, None, None | Alexander T. Sandhu, Stanford University—Instructor of Medicine, Division of Cardiology, Department of Medicine, None, None, None, None, None, None, None | Lynne Warner Stevenson, Vanderbilt University Medical Center, Vanderbilt Heart and Vascular Insti- tute—Director of Cardiomyopathy and Lisa M. Jacobson Professor of Cardiovascular Medicine, • Novartis, None, None, None, • Abbott‡ • Biotronik • Boston Scientific • Bristol-Myers Squibb‡ • Endotronic† • Gore Medical† • Johnson & Johnson, None, None | Orly Vardeny, Minneapolis VA Health Care System and University of Minnesota— Associate Professor of Medicine, Department of Medicine, • Amgen • Novartis • Sanofi-Pasteur, None, None, • AstraZen- eca* • Bayer*, • AstraZeneca‡, None, None | Amanda R. Vest, Tufts Medical Center, Cardiovascu- lar Center—Assistant Professor of Medicine, None, None, None, None, • Boehringer Ingelheim‡* • CareDx‡ • Corvia‡ • Transmedics‡, None, None | Clyde W. Yancy, Northwestern University, Feinberg School of Medicine; Northwestern Memorial Hospital—Professor of Medicine (Cardiology); Professor of Medical Social Sciences; Chief of Cardiology; Vice-Dean, Diversity & Inclusion; Associate Director Car- diovascular Institute Internal Medi- cine/Cardiology & Medical Social Sciences, None, None, None, None, • Abbott† • JAMA Cardiology, Deputy Editor, None, None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1029"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2022 AHA/ACC/HFSA Guideline for"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "the Management of Heart Failure (June 2021)"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Institutional,"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Ownership/ Organizational,"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Speakers Partnership/ or Other Financial Expert"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Reviewer Representation Employment Consultant Bureau Principal Personal Research Benefit Witness"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Anastasia Content Reviewer— University of None • AstraZen- None None None None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Armbruster Joint Committee on Health Sciences eca Phar-"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Clinical Practice & Pharmacy in maceuticals"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Guidelines St. Louis"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Alison Content Reviewer— Centennial None None None None • American Society None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Bailey ACC Heart at of Preventive"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Parkridge Cardiology†"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• OptumRx"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Joshua A. Content Reviewer— Vanderbilt • Amgen None • E MX† • Bayer (DSMB) • Vascular Interven- None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Beckman Joint Committee on University • JanOne • JanaCare† • Novartis tional Advances*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Clinical Practice • Janssen • NovoNordisk‡"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Guidelines Pharmaceuticals*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Claudio Content Reviewer— University of None None None None None None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Bravo AHA Washington"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Patricia Content Reviewer— University of None None None None None None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Chang AHA/ACC North Carolina"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Richard Content Reviewer— University of None None None • Eidos‡ None None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Cheng AHA Washington • Ionis‡"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Lisa de las Content Reviewer— Washington • Acceleron • Simply None • Acceleron* • ACC† None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Fuentes Joint Committee on University in St. • Aerovate Speaking* • Bayer • AHA†"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Clinical Practice Louis • Altavant • Complexa* • Circulation Journals"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Guidelines • Arena • Johnson&Johnson* • Foundation for the"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Bayer • Liquidia* NIH†"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Complexa* • Medtronic* • Pulmonary"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Express Scripts • N IH* Hypertension"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Gossamer • Trio Analytics Association*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Johnson&Johnson • United Therapeutics*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Phase Bio • University of Kentucky"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Sommetrics (DSMB)†"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• V-wave • University of Toronto"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Vaderis (DSMB)†"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• WebMD*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Akshay Content Reviewer— Brigham and • Abbott Laboratories* None None • Alnylam* • Baim Clinical None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Desai AHA/ACC Women’s • Alnylam* • AstraZeneca Research Institute*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Hospital • Amgen* Pharmaceuticals* • TIMI Study Group*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• AstraZeneca • Bayer†"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Pharmaceuticals* • Myokardia†"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Biofourmis* • Novartis*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Boehringer"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Ingelheim"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Boston Scientific*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Corvidia"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Therapeutics*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Cytokinetics"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Dalcor Pharma*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Lupin Pharma"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Merck"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Novartis*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Regeneron*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Relypsa*"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Sun Pharma"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Howard Official Reviewer— Penn State None None None None None None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Eisen AHA Health"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Mona Content Reviewer— Duke University • Fire1 None None • Roche* None None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Fiuzat AHA/ACC"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Bulent Content Reviewer— Eskisehir Os- • AstraZeneca None None None None None"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Gorenek Joint Committee on mangazi Pharmaceuticals"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Clinical Practice University • Bayer"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Guidelines • Daiichi Sankyo"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Roche"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Sandoz"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "• Sanofi"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "(Continued )"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 135,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 135,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Reviewer": "Anastasia Armbruster",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "University of Health Sciences & Pharmacy in St. Louis",
                "Consultant": "None",
                "Speakers Bureau": "• AstraZen- eca Phar- maceuticals",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Alison Bailey",
                "Representation": "Content Reviewer— ACC",
                "Employment": "Centennial Heart at Parkridge",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• American Society of Preventive Cardiology† • OptumRx",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Joshua A. Beckman",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Vanderbilt University",
                "Consultant": "• Amgen • JanOne • Janssen Pharmaceuticals*",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "• E MX† • JanaCare†",
                "Personal Research": "• Bayer (DSMB) • Novartis",
                "Institutional, Organizational, or Other Financial Benefit": "• Vascular Interven- tional Advances* • NovoNordisk‡",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Claudio Bravo",
                "Representation": "Content Reviewer— AHA",
                "Employment": "University of Washington",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Patricia Chang",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "University of North Carolina",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Richard Cheng",
                "Representation": "Content Reviewer— AHA",
                "Employment": "University of Washington",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Eidos‡ • Ionis‡",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Lisa de las Fuentes",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Washington University in St. Louis",
                "Consultant": "• Acceleron • Aerovate • Altavant • Arena • Bayer • Complexa* • Express Scripts • Gossamer • Johnson&Johnson • Phase Bio • Sommetrics • V-wave • Vaderis • WebMD*",
                "Speakers Bureau": "• Simply Speaking*",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Acceleron* • Bayer • Complexa* • Johnson&Johnson* • Liquidia* • Medtronic* • N IH* • Trio Analytics • United Therapeutics* • University of Kentucky (DSMB)† • University of Toronto (DSMB)†",
                "Institutional, Organizational, or Other Financial Benefit": "• ACC† • AHA† • Circulation Journals • Foundation for the NIH† • Pulmonary Hypertension Association*",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Akshay Desai",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "Brigham and Women’s Hospital",
                "Consultant": "• Abbott Laboratories* • Alnylam* • Amgen* • AstraZeneca Pharmaceuticals* • Biofourmis* • Boehringer Ingelheim • Boston Scientific* • Corvidia Therapeutics* • Cytokinetics • Dalcor Pharma* • Lupin Pharma • Merck • Novartis* • Regeneron* • Relypsa* • Sun Pharma",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Alnylam* • AstraZeneca Pharmaceuticals* • Bayer† • Myokardia† • Novartis*",
                "Institutional, Organizational, or Other Financial Benefit": "• Baim Clinical Research Institute* • TIMI Study Group*",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Howard Eisen",
                "Representation": "Official Reviewer— AHA",
                "Employment": "Penn State Health",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Mona Fiuzat",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "Duke University",
                "Consultant": "• Fire1",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Roche*",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Bulent Gorenek",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Eskisehir Os- mangazi University",
                "Consultant": "• AstraZeneca Pharmaceuticals • Bayer • Daiichi Sankyo • Roche • Sandoz • Sanofi",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            }
        ],
        "conteudo_texto": "Anastasia Armbruster, Content Reviewer— Joint Committee on Clinical Practice Guidelines, University of Health Sciences & Pharmacy in St. Louis, None, • AstraZen- eca Phar- maceuticals, None, None, None, None | Alison Bailey, Content Reviewer— ACC, Centennial Heart at Parkridge, None, None, None, None, • American Society of Preventive Cardiology† • OptumRx, None | Joshua A. Beckman, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Vanderbilt University, • Amgen • JanOne • Janssen Pharmaceuticals*, None, • E MX† • JanaCare†, • Bayer (DSMB) • Novartis, • Vascular Interven- tional Advances* • NovoNordisk‡, None | Claudio Bravo, Content Reviewer— AHA, University of Washington, None, None, None, None, None, None | Patricia Chang, Content Reviewer— AHA/ACC, University of North Carolina, None, None, None, None, None, None | Richard Cheng, Content Reviewer— AHA, University of Washington, None, None, None, • Eidos‡ • Ionis‡, None, None | Lisa de las Fuentes, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Washington University in St. Louis, • Acceleron • Aerovate • Altavant • Arena • Bayer • Complexa* • Express Scripts • Gossamer • Johnson&Johnson • Phase Bio • Sommetrics • V-wave • Vaderis • WebMD*, • Simply Speaking*, None, • Acceleron* • Bayer • Complexa* • Johnson&Johnson* • Liquidia* • Medtronic* • N IH* • Trio Analytics • United Therapeutics* • University of Kentucky (DSMB)† • University of Toronto (DSMB)†, • ACC† • AHA† • Circulation Journals • Foundation for the NIH† • Pulmonary Hypertension Association*, None | Akshay Desai, Content Reviewer— AHA/ACC, Brigham and Women’s Hospital, • Abbott Laboratories* • Alnylam* • Amgen* • AstraZeneca Pharmaceuticals* • Biofourmis* • Boehringer Ingelheim • Boston Scientific* • Corvidia Therapeutics* • Cytokinetics • Dalcor Pharma* • Lupin Pharma • Merck • Novartis* • Regeneron* • Relypsa* • Sun Pharma, None, None, • Alnylam* • AstraZeneca Pharmaceuticals* • Bayer† • Myokardia† • Novartis*, • Baim Clinical Research Institute* • TIMI Study Group*, None | Howard Eisen, Official Reviewer— AHA, Penn State Health, None, None, None, None, None, None | Mona Fiuzat, Content Reviewer— AHA/ACC, Duke University, • Fire1, None, None, • Roche*, None, None | Bulent Gorenek, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Eskisehir Os- mangazi University, • AstraZeneca Pharmaceuticals • Bayer • Daiichi Sankyo • Roche • Sandoz • Sanofi, None, None, None, None, None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "e1030 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Appendix 2. Continued"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Institutional,"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Ownership/ Organizational,"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Speakers Partnership/ or Other Financial Expert"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Reviewer Representation Employment Consultant Bureau Principal Personal Research Benefit Witness"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "José A. Content Reviewer— UT None None None None None None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Joglar Joint Committee on Southwestern"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Clinical Practice Medical Center"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Guidelines"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "W. Schuyler Content Reviewer— Duke University • Bayer* None None • Boehringer Ingelheim None None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Jones Joint Committee on • Janssen • Bristol Myers Squibb"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Clinical Practice Pharmaceuticals • P CORI"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Guidelines"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Daniel Content Reviewer— The Medical • ADRx None None • Capricor (DSMB) • Array Biopharma‡ None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Judge AHA/ACC University of • Cytokinetics • TRiNDS (DSMB) • Eidos Therapeutics‡"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "South Carolina • Pfizer • Myokardia‡"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "• Tenaya Therapeutics"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Kimberly Lay Reviewer Morris None None None None • Verilogue None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Ketter Cardiovascular"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "& Risk Reduc-"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "tion Center"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Dharam Content Reviewer— UT • ACC* None None None • Circulation, None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Kumbhani AHA/ACC Southwestern Associate Editor*"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Medical Center"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Daniel Content Reviewer— Duke University • Novartis None None None • Elsevier* None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Mark Joint Committee on • Heartflow*"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Clinical Practice • Merck*"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Guidelines • N IH*"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Paul Content Reviewer— University of None None None • Novartis* None None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Mather AHA/ACC Pennsylvania"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Shweta Content Reviewer— Harvard • Baim Institute for None • Relay • Puma Biotechnology* • American Regent‡ None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Motiwala AHA/ACC University Clinical Research* Therapeu- • Relypsa† • Boehringer"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "• Eli Lilly tics* Ingelheim‡"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "• Relay Therapeutics* • Edwards"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Lifesciences‡"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "• NuPulse CV‡"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Debabrata Content Reviewer— Texas Tech • ACC* None None None None None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Mukherjee Joint Committee on University"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Clinical Practice"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Guidelines"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Patrick T. Content Reviewer— Brigham and None None None None • Edwards None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "O’Gara Joint Committee on Women’s Lifesciences†"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Clinical Practice Hospital • Medtronic†"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Guidelines • JAMA*"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "• N IH*"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Francis D. Official Reviewer— University of None None None None None None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Pagani AHA Michigan"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Gurusher Content Reviewer— George • CVRx • Pfizer* None None • Abbott None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Panjrath ACC Washington Laboratories‡"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "University"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Mariann Content Reviewer— Vanderbilt None None None None None None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Piano Joint Committee on University"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Clinical Practice"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Guidelines"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Sean Content Reviewer— University of • Abbott Laboratories None None None None None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Pinney AHA/ACC Chicago • CareDX, Inc."
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "• Medtronic"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "• NuPulse"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "• Procyrion"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "• Transmedics"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Bunny Content Reviewer— University of None None None None None None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Pozehl AHA/ACC Nebraska"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Tanveer Content Reviewer— Emory None None None None • A BIM None"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Rab Joint Committee on University • ACC†"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Clinical Practice • American"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Guidelines Bifurcation Club†"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "(Continued )"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 136,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 136,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Reviewer": "José A. Joglar",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "UT Southwestern Medical Center",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "W. Schuyler Jones",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Duke University",
                "Consultant": "• Bayer* • Janssen Pharmaceuticals",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Boehringer Ingelheim • Bristol Myers Squibb • P CORI",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Daniel Judge",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "The Medical University of South Carolina",
                "Consultant": "• ADRx • Cytokinetics • Pfizer • Tenaya Therapeutics",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Capricor (DSMB) • TRiNDS (DSMB)",
                "Institutional, Organizational, or Other Financial Benefit": "• Array Biopharma‡ • Eidos Therapeutics‡ • Myokardia‡",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Kimberly Ketter",
                "Representation": "Lay Reviewer",
                "Employment": "Morris Cardiovascular & Risk Reduc- tion Center",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Verilogue",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Dharam Kumbhani",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "UT Southwestern Medical Center",
                "Consultant": "• ACC*",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Circulation, Associate Editor*",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Daniel Mark",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Duke University",
                "Consultant": "• Novartis",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Elsevier* • Heartflow* • Merck* • N IH*",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Paul Mather",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "University of Pennsylvania",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Novartis*",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Shweta Motiwala",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "Harvard University",
                "Consultant": "• Baim Institute for Clinical Research* • Eli Lilly • Relay Therapeutics*",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "• Relay Therapeu- tics*",
                "Personal Research": "• Puma Biotechnology* • Relypsa†",
                "Institutional, Organizational, or Other Financial Benefit": "• American Regent‡ • Boehringer Ingelheim‡ • Edwards Lifesciences‡ • NuPulse CV‡",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Debabrata Mukherjee",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Texas Tech University",
                "Consultant": "• ACC*",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Patrick T. O’Gara",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Brigham and Women’s Hospital",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Edwards Lifesciences† • Medtronic† • JAMA* • N IH*",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Francis D. Pagani",
                "Representation": "Official Reviewer— AHA",
                "Employment": "University of Michigan",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Gurusher Panjrath",
                "Representation": "Content Reviewer— ACC",
                "Employment": "George Washington University",
                "Consultant": "• CVRx",
                "Speakers Bureau": "• Pfizer*",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Abbott Laboratories‡",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Mariann Piano",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Vanderbilt University",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Sean Pinney",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "University of Chicago",
                "Consultant": "• Abbott Laboratories • CareDX, Inc. • Medtronic • NuPulse • Procyrion • Transmedics",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Bunny Pozehl",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "University of Nebraska",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Tanveer Rab",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Emory University",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• A BIM • ACC† • American Bifurcation Club†",
                "Expert Witness": "None"
            }
        ],
        "conteudo_texto": "José A. Joglar, Content Reviewer— Joint Committee on Clinical Practice Guidelines, UT Southwestern Medical Center, None, None, None, None, None, None | W. Schuyler Jones, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Duke University, • Bayer* • Janssen Pharmaceuticals, None, None, • Boehringer Ingelheim • Bristol Myers Squibb • P CORI, None, None | Daniel Judge, Content Reviewer— AHA/ACC, The Medical University of South Carolina, • ADRx • Cytokinetics • Pfizer • Tenaya Therapeutics, None, None, • Capricor (DSMB) • TRiNDS (DSMB), • Array Biopharma‡ • Eidos Therapeutics‡ • Myokardia‡, None | Kimberly Ketter, Lay Reviewer, Morris Cardiovascular & Risk Reduc- tion Center, None, None, None, None, • Verilogue, None | Dharam Kumbhani, Content Reviewer— AHA/ACC, UT Southwestern Medical Center, • ACC*, None, None, None, • Circulation, Associate Editor*, None | Daniel Mark, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Duke University, • Novartis, None, None, None, • Elsevier* • Heartflow* • Merck* • N IH*, None | Paul Mather, Content Reviewer— AHA/ACC, University of Pennsylvania, None, None, None, • Novartis*, None, None | Shweta Motiwala, Content Reviewer— AHA/ACC, Harvard University, • Baim Institute for Clinical Research* • Eli Lilly • Relay Therapeutics*, None, • Relay Therapeu- tics*, • Puma Biotechnology* • Relypsa†, • American Regent‡ • Boehringer Ingelheim‡ • Edwards Lifesciences‡ • NuPulse CV‡, None | Debabrata Mukherjee, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Texas Tech University, • ACC*, None, None, None, None, None | Patrick T. O’Gara, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Brigham and Women’s Hospital, None, None, None, None, • Edwards Lifesciences† • Medtronic† • JAMA* • N IH*, None | Francis D. Pagani, Official Reviewer— AHA, University of Michigan, None, None, None, None, None, None | Gurusher Panjrath, Content Reviewer— ACC, George Washington University, • CVRx, • Pfizer*, None, None, • Abbott Laboratories‡, None | Mariann Piano, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Vanderbilt University, None, None, None, None, None, None | Sean Pinney, Content Reviewer— AHA/ACC, University of Chicago, • Abbott Laboratories • CareDX, Inc. • Medtronic • NuPulse • Procyrion • Transmedics, None, None, None, None, None | Bunny Pozehl, Content Reviewer— AHA/ACC, University of Nebraska, None, None, None, None, None, None | Tanveer Rab, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Emory University, None, None, None, None, • A BIM • ACC† • American Bifurcation Club†, None"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063 May 3, 2022 e1031"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "AND"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "GUIDELINES"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "CLINICAL"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "STATEMENTS"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Appendix 2. Continued"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Institutional,"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Ownership/ Organizational,"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Speakers Partnership/ or Other Financial Expert"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Reviewer Representation Employment Consultant Bureau Principal Personal Research Benefit Witness"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Nosheen Content Reviewer— University of None None None None None None"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Reza ACC Pennsylvania"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Jo E. Content Reviewer— University of None None None • Novartis† • Duke Clinical None"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Rodgers AHA North Carolina Research Institute‡"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• GlaxoSmithKline"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Chris Content Reviewer— St. Vincent • Abbott • Medtronic None None • Abbott‡ None"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Salerno ACC Hospital • Medtronic‡"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Sanjiv Shah Official Reviewer— Northwestern • Abbott • Pulmonary None • Actelion* None None"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "HFSA University • A BIM Hypertension • AHA*"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Amgen Association • Covia*"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Aria • N IH*"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• AstraZeneca"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Pharmaceuticals*"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Axon"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Bayer"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Boehringer"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Ingelheim"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Boston Scientific"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Bristol Myers Squibb"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Cardiora"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• CVRx"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Cyclerion"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Cytokinetics"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Eisai"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Ekoi.ai"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• GlaxoSmithKline"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Imara"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Ionis"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Ironwood"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Janssen"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Pharmaceuticals"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Keyto"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Eli Lilly"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Merck"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Myokardia"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Novartis*"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• NovoNordisk"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Pfizer"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Prothena"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Regeneron"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Sanofi"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Shifamed"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Tenax"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• United Therapeutics"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Erica S. Official Reviewer, Yale University None None None None • Centers for Medi- None"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Spatz Joint Committee on care & Medicaid"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Clinical Practice Services*"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Guidelines • US Food and Drug"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Administration*"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Nancy Official Reviewer— University of • Medscape* None None • N IH* • AHA* None"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Sweitzer HFSA Arizona • Myokardia • Merck • Amgen‡"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Novartis† • Array BioPharma‡"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Cellular Logistics†"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• Corvia Medical‡"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• CVRx‡"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• NIH*‡"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• University of"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Arizona*"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Jacqueline Content Reviewer— Mount Sinai • Gaffney Events None None None • AHA† None"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "E. Tamis- Joint Committee on Educational Trust • Bronx Lebanon"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Holland Clinical Practice Hospital, Cardiology"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Guidelines Fellowship Program"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Director†"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• NYS†"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "• The NGS Predict"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Study‡"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "(Continued )"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 137,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 137,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Reviewer": "Nosheen Reza",
                "Representation": "Content Reviewer— ACC",
                "Employment": "University of Pennsylvania",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Jo E. Rodgers",
                "Representation": "Content Reviewer— AHA",
                "Employment": "University of North Carolina",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Novartis†",
                "Institutional, Organizational, or Other Financial Benefit": "• Duke Clinical Research Institute‡ • GlaxoSmithKline",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Chris Salerno",
                "Representation": "Content Reviewer— ACC",
                "Employment": "St. Vincent Hospital",
                "Consultant": "• Abbott",
                "Speakers Bureau": "• Medtronic",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Abbott‡ • Medtronic‡",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Sanjiv Shah",
                "Representation": "Official Reviewer— HFSA",
                "Employment": "Northwestern University",
                "Consultant": "• Abbott • A BIM • Amgen • Aria • AstraZeneca Pharmaceuticals* • Axon • Bayer • Boehringer Ingelheim • Boston Scientific • Bristol Myers Squibb • Cardiora • CVRx • Cyclerion • Cytokinetics • Eisai • Ekoi.ai • GlaxoSmithKline • Imara • Ionis • Ironwood • Janssen Pharmaceuticals • Keyto • Eli Lilly • Merck • Myokardia • Novartis* • NovoNordisk • Pfizer • Prothena • Regeneron • Sanofi • Shifamed • Tenax • United Therapeutics",
                "Speakers Bureau": "• Pulmonary Hypertension Association",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• Actelion* • AHA* • Covia* • N IH*",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Erica S. Spatz",
                "Representation": "Official Reviewer, Joint Committee on Clinical Practice Guidelines",
                "Employment": "Yale University",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Centers for Medi- care & Medicaid Services* • US Food and Drug Administration*",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Nancy Sweitzer",
                "Representation": "Official Reviewer— HFSA",
                "Employment": "University of Arizona",
                "Consultant": "• Medscape* • Myokardia",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "• N IH* • Merck • Novartis†",
                "Institutional, Organizational, or Other Financial Benefit": "• AHA* • Amgen‡ • Array BioPharma‡ • Cellular Logistics† • Corvia Medical‡ • CVRx‡ • NIH*‡ • University of Arizona*",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Jacqueline E. Tamis- Holland",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Mount Sinai",
                "Consultant": "• Gaffney Events Educational Trust",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• AHA† • Bronx Lebanon Hospital, Cardiology Fellowship Program Director† • NYS† • The NGS Predict Study‡",
                "Expert Witness": "None"
            }
        ],
        "conteudo_texto": "Nosheen Reza, Content Reviewer— ACC, University of Pennsylvania, None, None, None, None, None, None | Jo E. Rodgers, Content Reviewer— AHA, University of North Carolina, None, None, None, • Novartis†, • Duke Clinical Research Institute‡ • GlaxoSmithKline, None | Chris Salerno, Content Reviewer— ACC, St. Vincent Hospital, • Abbott, • Medtronic, None, None, • Abbott‡ • Medtronic‡, None | Sanjiv Shah, Official Reviewer— HFSA, Northwestern University, • Abbott • A BIM • Amgen • Aria • AstraZeneca Pharmaceuticals* • Axon • Bayer • Boehringer Ingelheim • Boston Scientific • Bristol Myers Squibb • Cardiora • CVRx • Cyclerion • Cytokinetics • Eisai • Ekoi.ai • GlaxoSmithKline • Imara • Ionis • Ironwood • Janssen Pharmaceuticals • Keyto • Eli Lilly • Merck • Myokardia • Novartis* • NovoNordisk • Pfizer • Prothena • Regeneron • Sanofi • Shifamed • Tenax • United Therapeutics, • Pulmonary Hypertension Association, None, • Actelion* • AHA* • Covia* • N IH*, None, None | Erica S. Spatz, Official Reviewer, Joint Committee on Clinical Practice Guidelines, Yale University, None, None, None, None, • Centers for Medi- care & Medicaid Services* • US Food and Drug Administration*, None | Nancy Sweitzer, Official Reviewer— HFSA, University of Arizona, • Medscape* • Myokardia, None, None, • N IH* • Merck • Novartis†, • AHA* • Amgen‡ • Array BioPharma‡ • Cellular Logistics† • Corvia Medical‡ • CVRx‡ • NIH*‡ • University of Arizona*, None | Jacqueline E. Tamis- Holland, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Mount Sinai, • Gaffney Events Educational Trust, None, None, None, • AHA† • Bronx Lebanon Hospital, Cardiology Fellowship Program Director† • NYS† • The NGS Predict Study‡, None"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "e1032 May 3, 2022 Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "STNEMETATS"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "LACINILC"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "SENILEDIUG"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "DNA"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Heidenreich et al 2022 AHA/ACC/HFSA Heart Failure Guideline"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Appendix 2. Continued"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Institutional,"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Ownership/ Organizational,"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Speakers Partnership/ or Other Financial Expert"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Reviewer Representation Employment Consultant Bureau Principal Personal Research Benefit Witness"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Jennifer Content Reviewer— UT None None None None • CareDX‡ None"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Thibodeau AHA Southwestern • Cytokinetics‡"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Medical Center • Eidos Therapeutics‡"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• N IH‡"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Sanjeev Official Reviewer— Saint Francis None None None None None None"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Trehan ACC (Board of Health System"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Governors)"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Mary Content Reviewer— Ascension None None None None • Amgen‡ None"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Norine AHA/ACC Medical Group • EBR Systems"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Walsh • P CORI‡"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• Thoratec‡"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• Uppsala University‡"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Barbara Content Reviewer— Medical • Lexicomp None None None • ACC† None"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Wiggins ACC University of • American Journal"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "South Carolina of Cardiovascular"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Drugs†"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• PERT Consortium"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Clinical Protocols†"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Y. Joseph Content Reviewer— Stanford None None None None • Associate Editor, None"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Woo Joint Committee on University Journal of Thoracic"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Clinical Practice School of and Cardiovascular"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Guidelines Medicine Disease"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• N IH*"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "This table represents all relationships of reviewers with industry and other entities that were reported at the time of peer review, including those not deemed to be relevant to"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5000 of the fair market"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "each category of review. Please refer to https://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees."
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "*Significant relationship."
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "†No financial benefit."
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "‡This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that there is no"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "direct or institutional relationship with the trial sponsor as defined in the (ACCF or AHA/ACC) Disclosure Policy for Writing Committees."
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "ABIM indicates American Board of Internal Medicine; ACC, American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart As-"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "sociation; DSMB, Data and Safety Monitoring Board; JAMA, Journal of the American Medical Association; NGS, Next-generation sequencing; NIH, National Institutes of Health;"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "NYS, New York State; PCORI, Patient-Centered Outcomes Research Institute; PERT, Pulmonary Embolism Response Team; TIMI, Thrombolysis in Myocardial Infarction; and UT,"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "University of Texas."
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Appendix 3. Appendix for Tables 3 and 4: Suggested Thresholds for Structural Heart Disease and Evidence of Increased"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Filling Pressures"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Morphology • LAVI ≥29 mL/m2"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• LVMI >116/95 g/m2"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• RWT >0.42"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• LV wall thickness ≥12 mm"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Ventricular systolic function • LVEF <50%"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• GLS <16%"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Ventricular diastolic function • Average E/eʹ ≥15 for increased filling pressures"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• Septal eʹ <7 cm/s"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• Lateral eʹ <10 cm/s"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• TR velocity >2.8 m/s"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• Estimated PA systolic pressure >35 mm Hg"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Biomarker • B NP ≥35 pg/mL*"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "• NT-proBNP ≥125 pg/mL*"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "AF indicates atrial fibrillation; BNP, brain natriuretic peptide; CKD, chronic kidney disease; GLS, global longitudinal strain; HF, heart failure; LAVI, left atrial volume"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "index; LV, left ventricular; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; NT-proBNP, natriuretic peptide tests; PA, pulmonary artery; RWT,"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "relative wall thickness; and TR, tricuspid regurgitation."
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "*Cutoffs provided for natriuretic peptide levels may have lower specificity, especially in older patients or in patients with AF or CKD. Usually, higher cutoff values"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "are recommended for the diagnosis of HF in these patients. Natriuretic peptide cutoffs selected for population screening for pre-HF (stage B HF) may be <99%"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "reference limits and need to be defined according to the population at risk."
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "Downloaded"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "from"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "http://ahajournals.org"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "by"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "on"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "June"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "15,"
    },
    {
        "pagina": 138,
        "tipo": "texto",
        "conteudo": "2025"
    },
    {
        "pagina": 138,
        "tipo": "tabela",
        "indice_tabela": 1,
        "conteudo_dict": [
            {
                "Reviewer": "Jennifer Thibodeau",
                "Representation": "Content Reviewer— AHA",
                "Employment": "UT Southwestern Medical Center",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• CareDX‡ • Cytokinetics‡ • Eidos Therapeutics‡ • N IH‡",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Sanjeev Trehan",
                "Representation": "Official Reviewer— ACC (Board of Governors)",
                "Employment": "Saint Francis Health System",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "None",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Mary Norine Walsh",
                "Representation": "Content Reviewer— AHA/ACC",
                "Employment": "Ascension Medical Group",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Amgen‡ • EBR Systems • P CORI‡ • Thoratec‡ • Uppsala University‡",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Barbara Wiggins",
                "Representation": "Content Reviewer— ACC",
                "Employment": "Medical University of South Carolina",
                "Consultant": "• Lexicomp",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• ACC† • American Journal of Cardiovascular Drugs† • PERT Consortium Clinical Protocols†",
                "Expert Witness": "None"
            },
            {
                "Reviewer": "Y. Joseph Woo",
                "Representation": "Content Reviewer— Joint Committee on Clinical Practice Guidelines",
                "Employment": "Stanford University School of Medicine",
                "Consultant": "None",
                "Speakers Bureau": "None",
                "Ownership/ Partnership/ Principal": "None",
                "Personal Research": "None",
                "Institutional, Organizational, or Other Financial Benefit": "• Associate Editor, Journal of Thoracic and Cardiovascular Disease • N IH*",
                "Expert Witness": "None"
            }
        ],
        "conteudo_texto": "Jennifer Thibodeau, Content Reviewer— AHA, UT Southwestern Medical Center, None, None, None, None, • CareDX‡ • Cytokinetics‡ • Eidos Therapeutics‡ • N IH‡, None | Sanjeev Trehan, Official Reviewer— ACC (Board of Governors), Saint Francis Health System, None, None, None, None, None, None | Mary Norine Walsh, Content Reviewer— AHA/ACC, Ascension Medical Group, None, None, None, None, • Amgen‡ • EBR Systems • P CORI‡ • Thoratec‡ • Uppsala University‡, None | Barbara Wiggins, Content Reviewer— ACC, Medical University of South Carolina, • Lexicomp, None, None, None, • ACC† • American Journal of Cardiovascular Drugs† • PERT Consortium Clinical Protocols†, None | Y. Joseph Woo, Content Reviewer— Joint Committee on Clinical Practice Guidelines, Stanford University School of Medicine, None, None, None, None, • Associate Editor, Journal of Thoracic and Cardiovascular Disease • N IH*, None"
    },
    {
        "pagina": 138,
        "tipo": "tabela",
        "indice_tabela": 2,
        "conteudo_dict": [
            {
                "Morphology": "Ventricular systolic function",
                "• LAVI ≥29 mL/m2 • LVMI >116/95 g/m2 • RWT >0.42 • LV wall thickness ≥12 mm": "• LVEF <50% • GLS <16%"
            },
            {
                "Morphology": "Ventricular diastolic function",
                "• LAVI ≥29 mL/m2 • LVMI >116/95 g/m2 • RWT >0.42 • LV wall thickness ≥12 mm": "• Average E/eʹ ≥15 for increased filling pressures • Septal eʹ <7 cm/s • Lateral eʹ <10 cm/s • TR velocity >2.8 m/s • Estimated PA systolic pressure >35 mm Hg"
            },
            {
                "Morphology": "Biomarker",
                "• LAVI ≥29 mL/m2 • LVMI >116/95 g/m2 • RWT >0.42 • LV wall thickness ≥12 mm": "• B NP ≥35 pg/mL* • NT-proBNP ≥125 pg/mL*"
            }
        ],
        "conteudo_texto": "Ventricular systolic function, • LVEF <50% • GLS <16% | Ventricular diastolic function, • Average E/eʹ ≥15 for increased filling pressures • Septal eʹ <7 cm/s • Lateral eʹ <10 cm/s • TR velocity >2.8 m/s • Estimated PA systolic pressure >35 mm Hg | Biomarker, • B NP ≥35 pg/mL* • NT-proBNP ≥125 pg/mL*"
    }
]